{"title": "PDF", "author": "PDF", "url": "ibdigital.uib.es/greenstone/sites/localsite/collect/medicinaBalear/index/assoc/AJHS_Med/icina_Ba/lear_202/3v38n4pd.dir/AJHS_Medicina_Balear_2023v38n4.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "www.medicinabalear.orgVOLUME 38  NUMBER 4 JULY - AUGUST 2023\nMEDICINA BALEARACADEMIC  JOURNAL  \nOF HEALTH  SCIENCES\nPUBLICATION OF THE ROYAL ACADEMY OF MEDICINE OF THE BALEARIC ISLANDSVariables that influence the values of 7 scales that determine the risk \nof nonalcoholic fatty liver disease and liver fibrosis in 219,477 spanish workers\nKnowledge, attitude and practice towards antibiotic use and resistance among\nnon-medical university students: A cross sectional survey in the United Kingdom \nDevelopment of professional skills to prevent aggression \nthrough virtual simulation in nursing students: experimental study  \nChallenges of Adhering to Hand Washing Protocols as a COVID-19 \nPrevention Measure Among Slum Dwellers in Nairobi, Kenya \nComparion between General and Spinal Anesthesia for Lumbar Disc Surgery: A Randomized Clinical Trial \nThe efficiency of artificial neural network (ANN) for diagnosis of obesity and hypertension\nRelationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers\nPrevalence of sacroiliac joint dysfunction in patients with chronic low back pain\nHyperbilirubinemia is a predictor of appendiceal perforation in children: A meta-analysis\nCancer and vaccines. Present and future \nMulticentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience\nConcordance between non-invasive tests for the implementation \nof liver fibrosis screening algorithms in high-risk patients  \nRelationship between nonalcoholic fatty liver disease and liver fibrosis risk scales \nwith overweight and obesity scales in 219,477 spanish workers\nComparing the effect of three trigger methods (human HCG, combination of recombinant HCG \nwith GnRH agonist, and double recombinant HCG) on the fertility outcome of patients \nwith poor ovarian response in ovulation stimulation cycle (IVF/ICSI)\nEvaluation of the Antibacterial Effects of the Various Nanoparticles \nCoated Orthodontic Brackets: A Systematic Review and Meta-analysis\nWhat happens with the health system: Medical mistrust\nSystematic review of the relationship between pain due to herpes zoster \ninfection and the quality of life of subjects living in the community\nEvaluation of dietary habits and nutritional needs in women treated for breast cancer in the Balearic Islands\nVariables influencing the appearance of metabolic syndrome with three different definitions in 418.343 spanish workers\nPrevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving\nanti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nA Quantitative Assessment of Coping Strategies among Jamaican Males 18+ years old: Post-COVID-19\nAssociation between different cardiometabolic risk scales and metabolic syndrome scales in 418.343 Spanish workers\nEffects of a personalized medical educational intervention on the perception\nof the risk of gynecological cancer and attitudes to control it: a healthcare research model\nElimination of cervical cancer\nAcute pancreatitis due to diverticular compression of the gland\nSurgical treatment of a patient with hemangiopericytoma and subsequent abdominoplasty: a clinical case\nPossible benefit of intra- articular ozone in advanced osteonecrosis of the knee: two case reports\nDrug-Induced Stevens Johnson\u2019s Syndrome;  4 case Series in Tertiary Hospital in SomaliaAcademic Journal of Health Sciences Medicina Balear is the organ of the Royal Academy of \nMedicine of the Balearic Island,It was created in 1986 with the aim of following up the scientific \nconcerns and promoting the research spirit of health professionals in the Balearic Islands and with \nthe additional objective of projecting health issues of interest to society.\nCurrently Academic Journal of Health Sciences Medicina Balear publishes in English, Spanish \nor Catalan original papers, review articles, letters to the editor and other writings of interest related \nto health sciences. The journal submits the originals to the anonymous review of at least two external \nexperts (peer review).\nThe scientific material published in AJHS Medicina Balear is protected by copyright. AJHS \nMedicina Balear is not responsible for the information and opinions of the authors.\nThis work-unless otherwise indicated in the text, photographs, or other illustrations-is licensed under \nthe Creative Commons NonCommercial-NoDerivativeWorks 3.0 Spain license.\nCreative Commons; http://creativecommons.org/licenses/by-nc-nd/3.0/es/. In addition, the general \npublic is authorized to reproduce, distribute and communicate the work provided that the authorship \nand the publishing entity are acknowledged and that no commercial use or derivative work is made.\nMedicina Balear is included in the Digital Library of the Balearic Islands, of the University of the \nBalearic Islands, and is included in the following databases: Emerging Sources Citation Index (ESCI), \nSherpa Romeo, Dulcinea, Latindex (cat\u00e0leg), Dialnet, \u00cdndice M\u00e9dico Espa\u00f1ol, DOAJ, Imbiomed, \nREDIB, Google Scholar and Journal Citation Indicator (JCI).\nEDIT\nRoyal Academy of Medicine of the Balearic Islands\nCampaner, 4, 07003 Palma de Mallorca Tel. 971 72 12 30 Email: info@ramib.org  \nP\u00e0gina web: http://www.ramib.org\n \nDip\u00f2sit Legal: PM 486 - 95 \neISSN: 2255 - 0569\nDesign and layout\nIntelagencia Publicitat - www.intelagencia.es - intelagencia@intelagencia.es\nwww.ramib.org \nwww.medicinabalear.org\nEditor \n \nAssistant manager   \nSecretary\nEditor-in -chief\nVowelsWith the \ncollaboration:A. Arturo L\u00f3pez Gonz\u00e1lez, RAMIB, \nReial Acad\u00e8mia de Medicina de les Illes Balears (RAMIB)\nEDITORIAL COUNCIL\nJoan March Noguera, RAMIB\nSebasti\u00e0 Cresp\u00ed Rotger, RAMIB\nPere Riutord Sbert, RAMIB\nJavier Cort\u00e9s Bordoy, RAMIB; Joan Benejam Gual, RAMIB; \nAntonia Barcel\u00f3 Bennasar, RAMIB; Llu\u00eds Masmiquel Comas, RAMIB\nSCIENTIFIC COUNCIL\nMarta Couce Matovelle (Case Western Reserve University), Jos\u00e9 A. Guijarro \nPastor (AEMET), Jaume Rossell\u00f3 Mir ( Universitat de les Illes Balears ), Antoni \nAguil\u00f3 Pons (Universitat de les Illes Balears), Bartolom\u00e9 Burguera Gonz\u00e1lez \n(Cleveland Clinic - Ohio), Amador Calafat Far (Socidrogalcohol ), Valent\u00edn \nEsteban Buedo (Conselleria de Sanitat, Generalitat Valenciana), Carmen \nGonz\u00e1lez Bosch (Universitat de Val\u00e8ncia), Miguel A. Limon Pons (Institut \nMenorqu\u00ed d\u2019Estudis), Jordi Mart\u00ednez Serra (Hospital Son Espases), Virgili \nP\u00e1ez Cervi (Bibliosalut), Lucio Pallar\u00e9s Ferreres (Hospital Son Espases), \nIgnacio Ricci Cabello (University of Oxford), Guillermo S\u00e1ez Tormo (Uni -\nversitat de Val\u00e8ncia), Ma Te\u00f3fila Vicente Herrero (IUNICS), M\u00aa Jos\u00e9 Anad\u00f3n \nBaselga (Universidad Complutense de Madrid), Miquel Cap\u00f3 Mart\u00ed (Universidad \nComplutense de Madrid), Antonio Coca Payeras (Universitat de Barcelona), \nJames Drane (Edinboro University), Leopoldo Forner Navarro (Universitat de \nVal\u00e8ncia), Alexandre Garc\u00eda-Mas, (Universitat de les Illes Balears), Antoni Gela -\nbert Mas (Universitat Aut\u00f2noma de Barcelona), Joan Grimalt Obrador (Consell \nSuperior d\u2019Investigacions Cient\u00edfiques, CSIC), Federico Hawkins Carranza (Uni -\nversitat Complutense de Madrid), Joan Carles March Cerd\u00e0 (Escuela Andaluza \nde Salud P\u00fablica, EASP), Gabriel Mart\u00ed Amengual (Universitat de Barcelona), \nJasone Monasterio Aspiri (Universitat Aut\u00f2noma de Barcelona) Rosa Pulgar En -\ncinas (Universidad de Granada), Ciril Rozman (Universitat de Barcelona), Joan \nBenejam Gual (Hospital de Manacor), Joan Llobera C\u00e0naves (Atenci\u00f3 Prim\u00e0ria \n- Mallorca), Jos\u00e9 Reyes Moreno (Hospital de Inca), Jos\u00e9 Mar\u00eda Vicens Colom \n(Cercle d\u2019Economia de Mallorca), Carmen Tom\u00e1s-Valiente Lanuza (UIB), Anto -\nnio Pareja Bezares (Conselleria de Salut), Farhad Safarpoor Dehkordi (Tehran \nUniversity), Anton Erkoreka Barrena (Director del Museo Vasco de Historia de la \nMedicina y de la Ciencia), Jos\u00e9 Ignacio Ram\u00edrez Manent (Atenci\u00f3n Primaria de \nMallorca-Facultad de Medicina UIB), Colwyn M. Jones (European Association \nof Dental Public Health), P\u00e5l Barkvoll (Universitetet i Oslo), Teresa Szupiany-Ja -\nneczek (Jagiellonian University Medical College Krakow), Yarmukhamedov Be -\nkhzod (Tashkent University), Dr. Pablo Arsenio L\u00f3pez (Director de LA PRENSA \nM\u00c9DICA ARGENTINA), Manuel Luis Mart\u00ed (Academia Nacional de Medicina de \nBuenos Aires), Jes\u00fas Yasoda Endo Mil\u00e1n (Universidad de Ciencias M\u00e9dicas \nde Villa Clara. Cuba), Manel Gen\u00e9 Badia (Universidad de Barcelona), Pedro \nJuan T\u00e1rraga L\u00f3pez (Universidad de Castilla la Mancha), Natalia Tretiak (Poltava \nUkrainian Medical & Stomatological Academy), Petro Tretiak Kravchuk (Poltava \nUkrainian Medical & Stomatological Academy), Hans A Egu\u00eda (Dansk Selskab \nfor Almen Medicin-DSAM), Erjona Abazaj (Institute of Public Health of Albania), \nEmmanuel Ifeanyi Obeagu (Department of Medical Laboratory Science, Kampala \nInternational University, Uganda), Mustafa Azizo\u011flu (Dicle University, Turkey).Bimonthly journal of the Royal Academic of Medicine \nof the Balearic Island\nEditor \n \nAssistant manager   \nSecretary\nEditor-in -chief\nVowelsPREMIOS DE INVESTIGACI\u00d3N\nLa Fundaci\u00f3 Patronat Cient\u00edfic convoca los Premios de Investigaci\u00f3n Mateu Orfila, Dami\u00e0 Carb\u00f3 y \nMetge Matas con la finalidad de premiar la trayectoria de la investigaci\u00f3n en Ciencias de la Salud en \nnuestra comunidad.\nPREMIO FUNDACI\u00d3 MUTUAL M\u00c8DICA  \nAL MEJOR PROYECTO DE TESIS DOCTORAL  \nEl premio tiene como finalidad facilitar a los m\u00e9dicos colegiados en las Illes Balears la obtenci\u00f3n del \nt\u00edtulo de Doctor. Con el patrocinio de la Fundaci\u00f3 Mutual M\u00e9dica.\nBECAS FUNDACI\u00d3N BANCO SABADELL \nDE ROTACI\u00d3N EXTERNA PARA M\u00c9DICOS RESIDENTES  \nFacilitar a los m\u00e9dicos que realicen la residencia en hospitales de Balears la formaci\u00f3n, al menos durante \nun mes, en centros hospitalarios nacionales y extranjeros, en los dos \u00faltimos a\u00f1os de la residencia o al \nterminar la misma. Con la colaboraci\u00f3n de la Fundaci\u00f3 Banc Sabadell.\nBECAS DE INNOVACI\u00d3N  \nTienen como objetivo facilitar a los m\u00e9dicos colegiados en las Illes Balears, excepto MIR, la formaci\u00f3n, durante \nal menos un mes, en centros sanitarios nacionales y extranjeros en t\u00e9cnicas diagn\u00f3sticas o terap\u00e9uticas. \nCERTAMEN DE CASOS CL\u00cdNICOS PARA M\u00c9DICOS RESIDENTES\nPremios a los mejores casos cl\u00ednicos presentados por m\u00e9dicos residentes colegiados en Illes Balears de \ncualquier especialidad m\u00e9dica o quir\u00fargica.\nPREMIO CAMILO JOS\u00c9 CELA DE HUMANIDADES M\u00c9DICAS \nPremio literario de \u00e1mbito nacional destinado a honrar la especial relaci\u00f3n que tuvo el Nobel con los m\u00e9dicos \na lo largo de su vida.https://www.comib.com/premios-y-becas-de-la-fundacio-patronat-cientific-del-comib-convocatoria-2023/PREMIOS Y BECAS 2023\nwww.comib.com2023/38 (3): 76 -83VOLUME 38  NUM. 4\nJULY - AUGUST 2023 CONTENTS\nORIGINALS ARTICLES\nVariables that influence the values of 7 scales that determine the risk of nonalcoholic fatty liver  9-16disease and liver fibrosis in 219,477 spanish workers\nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Katrina Riera Routon, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nKnowledge, attitude and practice towards antibiotic use and resistance among  17-23non-medical university students: A cross sectional survey in the United Kingdom \nShruti Malik\nDevelopment of professional skills to prevent aggression through virtual simulation in nursing students:  24-30experimental study  \nM. Raquel Caballero, Guillermo Moreno, Juan Vicente Beneit, Mercedes G\u00f3mez del Pulgar, Encarnaci\u00f3n Caballero, L. Iv\u00e1n Mayor-Silva\nChallenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure  31-40Among Slum Dwellers in Nairobi, Kenya \nKelly Oluoch, John Muthuka, Francis Wambura, Muthoka Mirrium, Edwin Dede\nComparion between General and Spinal Anesthesia for Lumbar Disc Surgery: A Randomized Clinical Trial  41-46\nMolouk Jaafarpour, Masoud Hatefi, Aminollah Vasigh, Ali Khani, Fatemeh Njafi, Elham Shafiei\nThe efficiency of artificial neural network (ANN) for diagnosis of obesity and hypertension   47-51\nSomayeh Ebrahimi, Farshid Haghi\nRelationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers 52-59\nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Pau Mart\u00ed-Lliteras, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nPrevalence of sacroiliac joint dysfunction in patients with chronic low back pain 60-63\nHossein Karimiyarandi, Khalil Komlakh\nHyperbilirubinemia is a predictor of appendiceal perforation in children: A meta-analysis 64-68\nMustafa Azizo\u011flu, Mehmet Hanifi Okur, Bahattin Aydo\u011fdu, Tu\u011f\u00e7e Merve Orbay, Ayten Ceren Bakir, Sergey Alexandrovich Klyuev, Salim Bilici, Salih Bayram, Fikret Salik, Toni Risteski\nCancer and vaccines. Present and future   69-75\nM\u00aa Te\u00f3fila Vicente-Herrero, Jos\u00e9 Lorenzo Bravo-Grande, M\u00aa Victoria Ram\u00edrez-I\u00f1iguez de la Torre\nMulticentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience  76-84\nMarcos Fern\u00e1ndez-Cuadros, Olga P\u00e9rez-Moro, Mar\u00eda Jes\u00fas Albaladejo-Flor\u00edn, Javier Rodr\u00edguez-de-C\u00eda, Alberto Hern\u00e1ndez, Sandra \u00c1lava-Rabasa, \nMohammed Darraj, Al\u017ebeta Gond\u017e\u00farov\u00e1, Martin Moln\u00e1r, Monika Kulinova, Juraj Vyletelka\nConcordance between non-invasive tests for the implementation of liver fibrosis screening algorithms  85-91in high-risk patients  \nCristina G\u00f3mez Cobo, Daniel Morell Garc\u00eda, Francisco Berga Montaner, Antonia Barcel\u00f3 Bennasar\nRelationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight  92-100and obesity scales in 219,477 spanish workers\nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Pau Mart\u00ed-Lliteras, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nComparing the effect of three trigger methods (human HCG, combination of recombinant HCG with GnRH  101-106agonist, and double recombinant HCG) on the fertility outcome of patients with poor ovarian response in ovulation stimulation cycle (IVF/ICSI)\nHatav Ghasemi Tehrani, Nasrin Heidari, Farahnaz Mardanian, Ferdous Mehrabian, Elham Naghshineh, Narges Motamedi\nEvaluation of the Antibacterial Effects of the Various Nanoparticles Coated Orthodontic Brackets:  107-114A Systematic Review and Meta-analysis\nNavid Kerayechian, Arkia Mardany, Faezeh Bahraini, Fatemeh Teimoori, Maryam Ahmadi, Ali Amiri\nWhat happens with the health system: Medical mistrust 115-118\nSelman K\u0131z\u0131lkaya\nSystematic review of the relationship between pain due to herpes zoster infection and the quality  119-124of life of subjects living in the community\nF\u00e1tima Madrona Marcos, Antonio Moya Moya, Loreto T\u00e1rraga Marcos, Jose Ignacio Ramirez-Manent, Pilar Tom\u00e1s-Gil, Pere Riutord Sbert, Pedro J. Tarraga L\u00f3pez\nEvaluation of dietary habits and nutritional needs in women treated for breast cancer in the Balearic Islands 125-128\nMar Nafr\u00eda, Antoni Aguil\u00f3-Pons, Dora Romaguera, Alice Chaplin, Javier Cort\u00e9s Bordoy\nVariables influencing the appearance of metabolic syndrome with three different definitions in 418.343 spanish workers  129-135\nAndr\u00e9s Mart\u00ednez Jover, \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez, Pilar Tom\u00e1s Gil, Josep Lluis Coll Villalonga, Pau Mart\u00ed Lliteras, Jos\u00e9 Ignacio Ram\u00edrez Manent\nPrevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving  136-144anti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nEmmanuella Chidimma Ofoelo, David Chinaecherem Innocent, Ifeoma Lucy Ofoelo, Advait Vasavada, Stanley Chinedu Eneh\nA Quantitative Assessment of Coping Strategies among Jamaican Males 18+ years old: Post-COVID-19 145-151\nPaul Andrew Bourne, Raveena Blake, Serena Braham, Betonia  Chisholm, Janeil Deer, Patrina Royal, James Fallah, Calvin Campbell, Clifton Foster, Caroline McLean, \nTabitha Muchee, Advella L. Meikle\nAssociation between different cardiometabolic risk scales and metabolic syndrome scales in 418.343 Spanish workers 152-157\nAndr\u00e9s Mart\u00ednez Jover, \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez, Pilar Tom\u00e1s Gil, Josep Lluis Coll Villalonga, Pau Mart\u00ed Lliteras, Jos\u00e9 Ignacio Ram\u00edrez Manent\nEffects of a personalized medical educational intervention on the perception  158-159of the risk of gynecological cancer and attitudes to control it: a healthcare research model\nGabriel Ferret, Gabriela Capllonch, Javier Cort\u00e9s\nSPECIAL ARTICLE\nElimination of cervical cancer 160-162\nJavier Cort\u00e9s, Ana Forteza, Jos\u00e9 Reyes\nCASE REPORT\nAcute pancreatitis due to diverticular compression of the gland 163-165\nAlexey V. Shabunin, David D. Dolidze, Serghei Covantsev, Ivan N. Lebedinsky, Andrei I. Evsikov, Andrei A. Kolotilshchikov\nSurgical treatment of a patient with hemangiopericytoma and subsequent abdominoplasty: a clinical case 166-169\nAlexey V. Shabunin, David D. Dolidze, Ivan N. Lebedinsky, Zurab A. Bagatelia, Anna S. Sukhotko, Maria V. Kovaleva, Serghei Covantsev\nPossible benefit of intra- articular ozone in advanced osteonecrosis of the knee: two case reports 170-174\nMarcos Edgar Fern\u00e1ndez-Cuadros, Olga Susana P\u00e9rez-Moro, Javier Rodr\u00edguez de C\u00eda, Mar\u00eda Jes\u00fas Albaladejo-Flor\u00edn\nDrug-Induced Stevens Johnson\u2019s Syndrome; 4 case Series in Tertiary Hospital in Somalia 175-177\nOznur Sari, Ahmed Muhammad Bashirwww.bancamarch.es\u00bfQu\u00e9 profesional puede\ntener 45 a\u00f1os de edad y\n90 de experiencia?\nLa respuesta es Banca March\nLa experiencia de un profesional no est\u00e1 \n\u00fanicamente en su edad, sino tambi\u00e9n en la edad de \nla firma para la que trabaja.\nY 90 a\u00f1os de experiencia es lo que ofrecen los \nprofesionales de Banca March.\n90 a\u00f1os gestionando patrimonios y demostrando \nentre otras cosas, que la prudencia no est\u00e1 re\u00f1ida \ncon la rentabilidad.2023/38 (3): 76 -83\nwww.bancamarch.es\u00bfQu\u00e9 profesional puede\ntener 45 a\u00f1os de edad y\n90 de experiencia?\nLa respuesta es Banca March\nLa experiencia de un profesional no est\u00e1 \n\u00fanicamente en su edad, sino tambi\u00e9n en la edad de \nla firma para la que trabaja.\nY 90 a\u00f1os de experiencia es lo que ofrecen los \nprofesionales de Banca March.\n90 a\u00f1os gestionando patrimonios y demostrando \nentre otras cosas, que la prudencia no est\u00e1 re\u00f1ida \ncon la rentabilidad.VOLUMEN 38  NUM. 4\nJULIO - AGOSTO 2023 SUMARIO\nORIGINALES\nVariables que influyen en los valores de 7 escalas que determinan el riesgo de h\u00edgado graso  9-16no alcoh\u00f3lico y fibrosis hep\u00e1tica en 219.477 Trabajadores espa\u00f1oles  \nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Katrina Riera Routon, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nConocimiento, actitud y pr\u00e1ctica hacia el uso de antibi\u00f3ticos y la resistencia entre los estudiantes universitarios   17-23no m\u00e9dicos: Una encuesta transversal en el Reino Unido  \nShruti Malik\nDesarrollo de competencias profesionales para prevenir las agresiones a trav\u00e9s de la simulaci\u00f3n virtual  24-30en estudiantes de enfermer\u00eda: estudio experimental \nM. Raquel Caballero, Guillermo Moreno, Juan Vicente Beneit, Mercedes G\u00f3mez del Pulgar, Encarnaci\u00f3n Caballero, L. Iv\u00e1n Mayor-Silva\nDesaf\u00edos de la adhesi\u00f3n a los protocolos de lavado de manos como medida de prevenci\u00f3n del COVID-19  31-40entre los habitantes de los barrios marginales de Nairobi, Kenia  \nKelly Oluoch, John Muthuka, Francis Wambura, Muthoka Mirrium, Edwin Dede\nComparaci\u00f3n entre anestesia general y raqu\u00eddea para la cirug\u00eda discal lumbar: Un ensayo cl\u00ednico aleatorizado   41-46\nMolouk Jaafarpour, Masoud Hatefi, Aminollah Vasigh, Ali Khani, Fatemeh Njafi, Elham Shafiei\nLa eficacia de la red neuronal artificial (RNA) para el diagn\u00f3stico de la obesidad y la hipertensi\u00f3n   47-51\nSomayeh Ebrahimi, Farshid Haghi\nRelaci\u00f3n entre valores de 7 escalas de NAFLD y diferentes escalas de RCV en 219.477 trabajadores espa\u00f1oles 52-59  \nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Pau Mart\u00ed-Lliteras, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nPrevalencia de disfunci\u00f3n de la articulaci\u00f3n sacroil\u00edaca en pacientes con dolor lumbar cr\u00f3nico  60-63\nHossein Karimiyarandi, Khalil Komlakh\nLa hiperbilirrubinemia es un factor predictivo de perforaci\u00f3n apendicular en ni\u00f1os: Un metaan\u00e1lisis  64-68\nMustafa Azizo\u011flu, Mehmet Hanifi Okur, Bahattin Aydo\u011fdu, Tu\u011f\u00e7e Merve Orbay, Ayten Ceren Bakir, Sergey Alexandrovich Klyuev, Salim Bilici, Salih Bayram, Fikret Salik, Toni Risteski\nC\u00e1ncer y vacunas. Presente y futuro  69-75\nM\u00aa Te\u00f3fila Vicente-Herrero, Jos\u00e9 Lorenzo Bravo-Grande, M\u00aa Victoria Ram\u00edrez-I\u00f1iguez de la Torre\nEstudio multic\u00e9ntrico sobre el efecto del Ozono rectal en COVID-19: la experiencia espa\u00f1ola y eslovaca   76-84\nMarcos Fern\u00e1ndez-Cuadros, Olga P\u00e9rez-Moro, Mar\u00eda Jes\u00fas Albaladejo-Flor\u00edn, Javier Rodr\u00edguez-de-C\u00eda, Alberto Hern\u00e1ndez, Sandra \u00c1lava-Rabasa, Mohammed Darraj, \nAl\u017ebeta Gond\u017e\u00farov\u00e1, Martin Moln\u00e1r, Monika Kulinova, Juraj Vyletelka\nConcordancia entre pruebas no invasivas para la implementaci\u00f3n de algoritmos de cribado  85-91de fibrosis hep\u00e1tica en pacientes de alto riesgo \nCristina G\u00f3mez Cobo, Daniel Morell Garc\u00eda, Francisco Berga Montaner, Antonia Barcel\u00f3 Bennasar\nRelaci\u00f3n entre escalas de riesgo de higado graso no alcoh\u00f3lico y fibrosis hep\u00e1tica con escalas  92-100de sobrepeso y obesidad en 219.477 Trabajadores espa\u00f1oles  \nEmilio Mart\u00ednez-Almoyna Rif\u00e1, Pilar Tom\u00e1s-Gil, Josep Lluis Coll Villalonga, Jos\u00e9 Ignacio Ram\u00edrez-Manent, Pau Mart\u00ed-Lliteras, \u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez\nComparaci\u00f3n del efecto de tres m\u00e9todos desencadenantes (HCG humana, combinaci\u00f3n de HCG recombinante  101-106con agonista de GnRH y HCG recombinante doble) en el resultado de la fertilidad de pacientes con respuesta ov\u00e1rica deficiente en el ciclo de estimulaci\u00f3n de la ovulaci\u00f3n (FIV/ICSI)\nHatav Ghasemi Tehrani, Nasrin Heidari, Farahnaz Mardanian, Ferdous Mehrabian, Elham Naghshineh, Narges Motamedi\nEvaluaci\u00f3n de los efectos antibacterianos de los diversos brackets de ortodoncia recubiertos  107-114con nanopart\u00edculas: Una revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis\nNavid Kerayechian, Arkia Mardany, Faezeh Bahraini, Fatemeh Teimoori, Maryam Ahmadi, Ali Amiri\nLo que ocurre con el sistema sanitario: Desconfianza m\u00e9dica 115-118\nSelman K\u0131z\u0131lkaya\nRevisi\u00f3n Sistem\u00e1tica de la relaci\u00f3n entre el dolor por infecci\u00f3n herpes z\u00f3ster  119-124y la calidad de vida de los sujetos que viven en la comunidad\nF\u00e1tima Madrona Marcos, Antonio Moya Moya, Loreto T\u00e1rraga Marcos, Jose Ignacio Ramirez-Manent, Pilar Tom\u00e1s-Gil, Pere Riutord Sbert, Pedro J. Tarraga L\u00f3pez\nEvaluaci\u00f3n de los h\u00e1bitos diet\u00e9ticos y las necesidades nutricionales en mujeres tratadas por c\u00e1ncer de mama   125-128en las Islas Baleares\nMar Nafr\u00eda, Antoni Aguil\u00f3-Pons, Dora Romaguera, Alice Chaplin, Javier Cort\u00e9s Bordoy\nVariables que influyen en la aparici\u00f3n del s\u00edndrome metab\u00f3lico con tres definiciones diferentes  129-135en 418.343 trabajadores espa\u00f1oles  \nAndr\u00e9s Mart\u00ednez Jover, \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez, Pilar Tom\u00e1s Gil, Josep Lluis Coll Villalonga, Pau Mart\u00ed Lliteras, Jos\u00e9 Ignacio Ram\u00edrez Manent\nPrevalencia de los efectos adversos de los medicamentos antirretrovirales en pacientes seropositivos  136-144que reciben tratamiento antirretroviral en el Hospital General de Onitsha, Anambra, Nigeria  \nEmmanuella Chidimma Ofoelo, David Chinaecherem Innocent, Ifeoma Lucy Ofoelo, Advait Vasavada, Stanley Chinedu Eneh\nUna evaluaci\u00f3n cuantitativa de las estrategias de afrontamiento entre los varones jamaicanos  145-151mayores de 18 a\u00f1os: Post-COVID-19  \nPaul Andrew Bourne, Raveena Blake, Serena Braham, Betonia  Chisholm, Janeil Deer, Patrina Royal, James Fallah, Calvin Campbell, Clifton Foster, Caroline McLean, Tabitha Muchee, Advella L. Meikle\nAsociaci\u00f3n entre diferentes escalas de riesgo cardiometab\u00f3lico y escalas de s\u00edndrome metab\u00f3lico  152-157en 418.343 trabajadores espa\u00f1oles  \nAndr\u00e9s Mart\u00ednez Jover, \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez, Pilar Tom\u00e1s Gil, Josep Lluis Coll Villalonga, Pau Mart\u00ed Lliteras, Jos\u00e9 Ignacio Ram\u00edrez Manent\nEfectos de una intervenci\u00f3n educativa m\u00e9dica personalizada sobre la percepci\u00f3n del riesgo de padecer 158-159un c\u00e1ncer ginecol\u00f3gico y de las actitudes para controlarlo: un modelo de investigaci\u00f3n asistencial\nGabriel Ferret, Gabriela Capllonch, Javier Cort\u00e9s\nART\u00cdCULO ESPECIAL\nEliminaci\u00f3n del c\u00e1ncer de c\u00e9rvix 160-162\nJavier Cort\u00e9s, Ana Forteza, Jos\u00e9 Reyes\nESTUDIO DE CASOS\nPancreatitis aguda por compresi\u00f3n diverticular de la gl\u00e1ndula 163-165\nAlexey V. Shabunin, David D. Dolidze, Serghei Covantsev, Ivan N. Lebedinsky, Andrei I. Evsikov, Andrei A. Kolotilshchikov\nTratamiento quir\u00fargico de una paciente con hemangiopericitoma y posterior abdominoplastia: un caso cl\u00ednico  166-169\nAlexey V. Shabunin, David D. Dolidze, Ivan N. Lebedinsky, Zurab A. Bagatelia, Anna S. Sukhotko, Maria V. Kovaleva, Serghei Covantsev\nPosible beneficio del ozono intraarticular en la osteonecrosis avanzada de la rodilla: informe de dos casos   170-174\nMarcos Edgar Fern\u00e1ndez-Cuadros, Olga Susana P\u00e9rez-Moro, Javier Rodr\u00edguez de C\u00eda, Mar\u00eda Jes\u00fas Albaladejo-Flor\u00edn\nS\u00edndrome de Stevens Johnson inducido por f\u00e1rmacos; serie de 4 casos en un hospital terciario de Somalia   175-177\nOznur Sari, Ahmed Muhammad Bashir.com\nHaz algo grande por tu salud\nEn Asisa somos expertos en salud y sabemos \nque el sue\u00f1o es vital para el buen \nfuncionamiento de tu coraz\u00f3n, tu cerebro y \ntodo tu organismo.\nLos especialistas determinan que una \npersona adulta necesita entre 7 y 9 horas \ndiarias de sue\u00f1o para estar bien. \nSin embargo, se estima que el 80% de los \nespa\u00f1oles duermen menos de este tiempo, exponi\u00e9ndose a sufrir hipertensi\u00f3n, \ntaquicardia, depresi\u00f3n, p\u00e9rdida de \nmemoria, sobrepeso y diabetes, entre otros \nproblemas. Y como sabes, en Asisa solo nos \npreocupa tu salud. Por eso invertimos \ntodos nuestros recursos en cuidarte , \nincluido este anuncio en el que te \naconsejamos que duermas una hora m\u00e1s \ntodos los d\u00edas.\nAsisa Palma de Mallorca.\nC/ Pere Dezcallar i Net, 10\nasisa.e s 901 10 10 10Empresa Colaboradora:Nada m\u00e1s que tu salud\nNada menos que tu saludC\nM\nY\nCM\nMY\nCY\nCMY\nK170203 AF PG. PALMA DE MALLORCA generico A4.pdf   1   3/2/17   14:249\n2023/38 (4): 9-16.com\nHaz algo grande por tu salud\nEn Asisa somos expertos en salud y sabemos \nque el sue\u00f1o es vital para el buen \nfuncionamiento de tu coraz\u00f3n, tu cerebro y \ntodo tu organismo.\nLos especialistas determinan que una \npersona adulta necesita entre 7 y 9 horas \ndiarias de sue\u00f1o para estar bien. \nSin embargo, se estima que el 80% de los \nespa\u00f1oles duermen menos de este tiempo, exponi\u00e9ndose a sufrir hipertensi\u00f3n, \ntaquicardia, depresi\u00f3n, p\u00e9rdida de \nmemoria, sobrepeso y diabetes, entre otros \nproblemas. Y como sabes, en Asisa solo nos \npreocupa tu salud. Por eso invertimos \ntodos nuestros recursos en cuidarte , \nincluido este anuncio en el que te \naconsejamos que duermas una hora m\u00e1s \ntodos los d\u00edas.\nAsisa Palma de Mallorca.\nC/ Pere Dezcallar i Net, 10\nasisa.e s 901 10 10 10Empresa Colaboradora:Nada m\u00e1s que tu salud\nNada menos que tu saludC\nM\nY\nCM\nMY\nCY\nCMY\nK170203 AF PG. PALMA DE MALLORCA generico A4.pdf   1   3/2/17   14:24\nORIGINAL\nVariables that influence the values of 7 scales that determine \nthe risk of nonalcoholic fatty liver disease and liver fibrosis \nin 219,477 spanish workers\nVariables que influyen en los valores de 7 escalas que determinan el riesgo de h\u00edgado \ngraso no alcoh\u00f3lico y fibrosis hep\u00e1tica en 219.477 Trabajadores espa\u00f1oles  \nEmilio Mart\u00ednez-Almoyna Rif\u00e11      , Pilar Tom\u00e1s-Gil1      , Josep Lluis Coll Villalonga1      ,\nJos\u00e9 Ignacio Ram\u00edrez-Manent1,2      , Katrina Riera Routon3      , \n\u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez1\n1. Grupo ADEMA-SALUD IUNICS University of the Balearic Islands. Spain.\n2. Mallorca Primary Care    3. Farmac\u00e9uticaeISSN 2255-0569\nReceived: 3 - I - 2023\nAccepted: 4 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.9Corresponding author\nJos\u00e9 Ignacio Ram\u00edrez-Manent \nE-mail: jignacioramirez@telefonica.net  \nAbstract \nIntroduction: Non-alcoholic fatty liver disease (NAFLD) is a very frequent and multifactorial pathology that can lead to liver fibrosis \n(LF). The aim of the present study was to assess the influence of sociodemographic variables such as age, sex, social class and \ntobacco consumption on the increased risk of NASFLD and HF. \nMaterial and methods: Descriptive and cross-sectional study in 219.477 Spanish workers in which the influence of age, sex, \nsocial class and tobacco consumption on the increased risk of presenting NASH and FH determined with 7 different scales was \nassessed. We also assessed the concordance and correlation between the different scales using Pearson\u2019s and Cohen\u2019s kappa \nindices, respectively. \nResults: All the EHGNA and FH risk scales have increased values as age increases and as one moves down the social scale. \nThese values are also higher in men. Smoking does not seem to show any effect on the risk of NASH and FH. The degree of \ncorrelation of the different scales is high. \nConclusions: Age, sex and social class all have an influence on the increased risk of NASH and FH, while smoking has no effect.\nKeywords: non-alcoholic fatty liver disease (NAFLD), sociodemographic variables, tobacco consumption, social class. \nResumen\nIntroducci\u00f3n: La enfermedad del h\u00edgado graso no alcoh\u00f3lico (EHGNA) es una patolog\u00eda muy frecuente y multifactorial que puede \nterminar en fibrosis hep\u00e1tica (FH). El presente estudio tiene como objetivo valorar la influencia de variables sociodemogr\u00e1ficas \ncomo edad, sexo y clase social y el consumo de tabaco en el incremento del riesgo de presentar EHGNA y FH. \nMaterial y m\u00e9todos: Estudio descriptivo y transversal en 219.477 trabajadores espa\u00f1oles en los que se valora la influencia de la \nedad, el sexo, la clase social y el consumo de tabaco en el incremento del riesgo de presentar EHGNA y FH determinadas con 7 \nescalas diferentes. Tambi\u00e9n se valora la concordancia y correlaci\u00f3n entre las diferentes escalas empleando los \u00edndices de Pearson \ny kappa Cohen respectivamente. \nResultados: Todas las escalas de riesgo de EHGNA y FH ven incrementados sus valores a medida que aumenta la edad y a \nmedida que se desciende en la escala social. Estos valores tambi\u00e9n son m\u00e1s elevados en los hombres. El tabaco no parece \nmostrar ning\u00fan efecto en el riesgo de EHGNA y la FH. El grado de correlaci\u00f3n de las diferentes escalas es alto. \nConclusiones: Tanto la edad como el sexo y la clase social influyen en el incremento del riesgo de presentar EHGNA y FH \nmientras el consumo de tabaco no afecta.\nPalabras clave: Enfermedad del h\u00edgado graso no alcoh\u00f3lico (EHGNA), variables sociodemogr\u00e1ficas, consumo de tabaco, clase social .IDID ID ID\nID ID10\n2023/38 (4): 9-16Introduction\nNon-alcoholic fatty liver disease (NAFLD) is a clinical \ndisease that encompasses different liver conditions in \npeople who consume little or no alcohol1. The defining \ncharacteristic of this pathology is the excess fat stored \nin liver cells2. \nNASH is increasing in prevalence worldwide, but \nespecially in more developed countries3 and in the United \nStates it is considered the most common form of chronic \nliver disease, affecting almost 25% of the population4.\nSome people with NASH may eventually develop non-\nalcoholic steatohepatitis, which is one of the most \naggressive forms of the disease and is characterized by \nliver inflammation that can progress to severe scarring \n(cirrhosis) and liver failure. This pathologic picture is very \nsimilar to that caused by excessive alcohol consumption5.\nThere are many known risk factors for NASH, including \ndyslipidemia6, obesity7, especially abdominal obesity8, \npolycystic ovary syndrome9, type 2 diabetes10, \nhypothyroidism11, hypopituitarism12 and advanced age13. \nThere are not too many studies that assess the effect of \nsociodemographic variables and tobacco consumption \non the appearance of NASH, so the aim of this study is \nprecisely to assess this association.\nMaterial and methods\nDescriptive and cross-sectional study in 219,477 \nSpanish workers from different Spanish regions (Balearic \nIslands, Canary Islands, Andalusia, Valencian Community, \nMadrid, Catalonia, Castile and Leon, Castile La Mancha, \nand Basque Country) and belonging mainly to labor \nsectors of public administration, health, construction, and \ncommerce. Participants were selected from occupational \nmedical examinations between the months of January \n2017 and December 2019 from the different companies \nthat participated in the study. Participants were recruited \nwhen they met the following inclusion criteria: age \nbetween 18 and 69 years, belonging to one of the \ncompanies included in the study, not being on temporary \ndisability, giving written consent to participate in the study \nand to use their data for epidemiological purposes.\nFigure 1 shows the flow diagram of the study participants.\nMeasurements and data collection\nAnthropometric measurements and the determination \nof different analytical parameters were performed on \nall the workers who attended the occupational health \ncheck-ups.The anthropometric (height and weight), clinical \nand analytical measurements were taken by health \nprofessionals from the different occupational health units \nparticipating in the study, after standardization of the \nmeasurement techniques.\nWeight (in kg) and height (in cm) were determined \nusing a SECA 700 scale with an attached SECA 220 \ntelescopic measuring rod. Waist circumference (WC) \nwas measured with a SECA measuring tape with the \nperson in a standing position, feet together, trunk straight \nand abdomen relaxed. The tape was placed parallel to \nthe ground at the level of the last floating rib.\nBlood pressure was determined with the person in a \nseated position and after 10 minutes of rest. A calibrated \nOMRON M3 automatic sphygmomanometer was used. \nThree determinations were made at one-minute intervals \nand the mean of the three was obtained. Blood was \nobtained after 12h of fasting. Samples were sent to \nreference laboratories and processed within 2-3 days. \nAutomated enzymatic methods were used to determine \nglucose, total cholesterol and TG. HDL-c was determined \nby precipitation with dextran sulfate-MgCl2. LDL-c was \ncalculated using the Friedewald formula (provided that \nTG was less than 400 mg/dL). The values of all these \nparameters are expressed in mg/dL.Friedewald formula:    \nLDL = colesterol \u2212 HDL \u2212 tryglicerides/5\nThe risk of NAFLD and liver fibrosis were determined by \napplying different scales:\n\u00b7 Fatty liver index (FLI)14\nFLI values above 60 are considered high risk.Figure 1: flow chart of the participants in the study.\n221,218 workers start the study\n326 do not agree to participate\n996 lack any variable \nto calculate scales\n219,477 (2125,403 men and 94,074 \nwomen) finally entered the study419 are under 18 or over 69 years old\nFLI = (e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist circumference  \n- 15.745) / (1 + e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist \ncircumference  - 15.745) x 100Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. 11\n2023/38 (4): 9-16Variables that influence the values of 7 scales that determine the risk of nonalcoholic fatty liver disease and liver fibrosis in 219,477 spanish workers\n\u00b7 Hepatic steatosis index (HSI)15\nHSI= 8 \u00d7 AST/ALT + BMI + 2 if diabetes + 2 if female\nValues above 36 are considered high risk.\n\u00b7 Zhejian University index (ZJU index)16\nZJU= BMI + glycaemia (mmol L) + tryglicerides (mmol L) \n+ 3 AST/ALT + + 2 if female\nValues above 38 are considered high risk.\n\u00b7 Fatty liver disease index (FLD)17\nFLD = BMI + tryglicerides + 3 \u00d7 (AST/ALT) + 2 \u00d7 \nhyperglicaemia (present = 1; absent = 0). \nValues above 37 are considered high risk.\n\u00b7 Framingham steatosis index (FSI)18\nFSI = \u22127.981 + 0.011 \u00d7 age (years) \u2212 0.146 \u00d7 sex \n(woman = 1; man = 0) + 0.173 \u00d7 BMI (kg/m2) + 0.007 \u00d7 \ntryglicerides (mg/dL) + 0.593 \u00d7 hypertension (yes = 1; no \n= 0) + 0.789 \u00d7 diabetes (yes= 1; no = 0) + 1.1 \u00d7 AST/\nALT ratio \u2265 1.33 (yes= 1; no = 0) \n\u00b7 Lipid accumulation product (LAP)19\nMen. (waist (cm) \u2212 65) \u00d7 (tryglicerides (mMol)) \nWomen: (waist (cm) \u2212 58) \u00d7 (tryglicerides (mMol))\nValues above 42,7 are considered high risk.\n\u00b7 BARD score. This is a scale that evaluates the risk of \nhepatic fibrosis in patients with NAFLD20.\nThe presence of a BMI greater than 28 is scored with 1 \npoint, an AST/ALT ratio greater than 0.8 is scored with \n2 points and the presence of diabetes mellitus is also \nscored with 2 points. Values between 2 and 4 points \nindicate a high risk of liver fibrosis.\nA person was considered a smoker if he/she had smoked \nat least one cigarette/day (or its equivalent in other types \nof consumption) in the last 30 days, or had quit smoking \nless than 12 months ago. A person who had not smoked \nin the last year or who had never smoked was considered \na nonsmoker. \nSocial class was determined from the National \nClassification of Occupations 2011 (CNO-11) according \nto the proposal of the social determinants group of the \nSpanish Society of Epidemiology21. Three categories \nwere established:\nClass I: directors/managers, university professionals, \nsportsmen and artists; Class II: intermediate occupations \nand skilled self-employed workers; Class III: unskilled \nworkers.Statistical analysis\nA descriptive analysis of the categorical variables was \nperformed, calculating the frequency and distribution of \nthe responses for each of them. For quantitative variables, \nthe mean and standard deviation were calculated \nfollowing a normal distribution.\nBivariate association analysis was performed using \nthe chi2 test (with correction for Fisher\u2019s exact statistic \nwhen conditions required it) and Student\u2019s t test for \nindependent samples (for comparison of means). \nMultivariate techniques were used to establish the \nvariables associated with the most significant risk factors. \nLogistic regression was used for multivariate analysis, \nwith calculation of the odds ratio and the Hosmer-\nLemeshow goodness-of-fit test. The degree of correlation \nand concordance of the different variables studied was \ndetermined by applying Pearson\u2019s and Cohen\u2019s kappa \ntests, respectively. Statistical analysis was performed \nwith the Statistical Package for the Social Sciences \n(SPSS) version 28.0 (IBM Company, New York, NY, \nUSA) for Windows, with an accepted level of statistical \nsignificance of 0.05.\nEthical considerations and/or aspects\nThe research team undertook at all times to follow \nthe ethical principles of health sciences research \nestablished nationally and internationally (Declaration of \nHelsinki), paying special attention to the anonymity of the \nparticipants and the confidentiality of the data collected. \nApproval was requested from the Ethics and Research \nCommittee of the Balearic Islands (CEI-IB), which was \nobtained with indicator IB 4383/20. Participation in the \nstudy was voluntary, so the participants gave their written \nand oral consent to participate in the study after receiving \nsufficient information about the nature of the study. To \nthis end, they were given an informed consent form, as \nwell as an information sheet explaining the objective of \nthe study.\nThe data collected for the study were identified by a \ncode and only the person responsible for the study can \nrelate these data to the participants. The identity of the \nparticipants will not be disclosed in any report of this study. \nThe investigators will not disseminate any information \nthat could identify them. In any case, the research team \nundertakes to strictly comply with the Organic Law \n3/2018, of December 5, on the protection of personal \ndata and guarantee of digital rights, guaranteeing the \nparticipant in this study that he/she may exercise his/her \nrights of access, rectification, cancellation and opposition \nof the data collected12\n2023/38 (4): 9-16Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nResults\nTable I shows the anthropometric and clinical \ncharacteristics of the workers included in the study. A \ntotal of 125,403 men (57.14%) and 94,074 women \n(42.86%) were included in the analyses. The mean age \nof the sample was 40.5 \u00b1 10.5 years, and the majority \ngroup was between 30 and 49 years. Anthropometric, \nclinical and analytical values were higher among men. The highest percentage of workers (75.5%) belonged to \nsocial class III. A total of 33.3% of the women and 32.5% \nof the men were smokers. The percentage of patients \nwith obesity I was 14.2%, 4.2% of the total sample had \nobesity II, and 1.5% of the population was classified in \nobesity category III.\nTable II shows the mean values of different scales of \nnonalcoholic fatty liver disease and liver fibrosis according Table I: Characteristics of the population.\n  Men n=125,403 Women n=94,074  \n  Mean (SD) Mean (SD) p\nAge 41.8 (10.5) 39.9 (10.5) <0.0001\nHeight 175.2 (6.8) 162.3 (6.3) <0.0001\nWeight 82.6 (15.0) 68.0 (14.7) <0.0001\nSBP 126.1 (15.6) 115.4 (15.5) <0.0001\nDBP 77.3 (11.1) 72.3 (10.5) <0.0001\nCholesterol 195.6 (37.9) 192.1 (35.5) <0.001\nHDL-c 52.1 (9.8) 57.2 (10.3) <0.0001\nLDL-c 118.4 (35.1) 116.3 (33.5) <0.001\nTryglicerides 125.7 (76.0) 93.1 (45.6) <0.0001\nGlycaemia 93.4 (21.5) 88.3 (16.0) <0.0001\nAST 29.0 (17.5) 18.7 (11.6) <0.0001\nALT 24.4 (13.3) 18.2 (7.9) <0.0001\nGGT 32.7 (31.8) 18.8 (16.3) <0.0001\nCreatinine 0.86 (0.17) 0.68 (0.14) <0.0001\n  % % p\n18-29 years 14.4 19.4 <0.0001\n30-39 years 26.6 28.9 \n40-49 years 33.6 32.0 \n50-59 years 21.5 16.8 \n60-69 years 3.9 2.9 \nSocial class I 6.1 7.5 <0.0001\nSocial class II 14.5 20.5 \nSocial class III 79.4 72.0 \nNon smokers 67.5 66.7 <0.001\nSmokers 32.5 33.3  \nSBP systolic blood pressure. DBP diastolic blood pressure. HDL High density lipoprotein.   LDL Low density lipoprotein. AST aspartate transaminase. ALT alanine \ntransaminase.   GGT gamma-glutamyl transferase.\nTable II: Mean values of different risk scales for nonalcoholic fatty liver disease and liver fibrosis according to sociodemographic variables and tobacco consumption.\n    FLI HSI ZJU FLD FSI LAP BARD\nMen n Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)\n18-29 years 18006 26.9 (24.2) 34.5 (6.7) 34.6 (5.3) 29.8 (5.2) 0.12 (0.13) 23.8 (21.2) 0.56 (0.79)\n30-39 years 33411 36.4 (26.4) 36.4 (6.8) 36.5 (5.5) 31.6 (5.3) 0.17 (0.17) 32.0 (29.4) 0.79 (0.90)\n40-49 years 42192 43.3 (26.7) 37.4 (6.8) 37.8 (5.6) 32.6 (5.3) 0.22 (0.19) 36.7 (31.0) 0.98 (0.95)\n50-59 years 26955 45.5 (25.9) 37.6 (6.3) 38.3 (5.6) 32.9 (5.2) 0.26 (0.20) 37.1 (28.9) 2.02 (0.93)\n60-69 years 4839 46.0 (25.2) 37.7 (6.1) 38.8 (5.3) 33.2 (4.9) 0.30 (0.20) 36.4 (26.2) 1.99  (0.89)\nSocial class I 7623 38.1 (25.5) 36.6 (6.6) 36.8 (5.2) 31.7 (4.9) 0.20 (0.17) 32.4 (28.0) 1.10 (1.06)\nSocial class II 18237 39.7 (25.5) 37.1 (6.4) 37.3 (5.3) 32.2 (5.0) 0.20 (0.18) 33.3 (27.2) 1.15 (1.05)\nSocial class III 99543 39.8 (27.1) 36.7 (6.8) 37.1 (5.8) 32.0 (5.5) 0.21 (0.19) 33.8 (29.4) 1.13 (1.05)\nNon smokers* 84642 39.8 (26.8) 36.8 (6.7) 37.2 (5.7) 32.1 (5.4) 0.21 (0.19) 33.8 (28.9) 1.14 (1.05)\nSmokers 40761 39.5 (26.7) 36.7 (6.9) 37.1 (5.7) 32.0 (5.3) 0.20 (0.18) 33.4 (29.3) 1.12 (1.06)\nWomen n Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)\n18-29 years 18270 14.3 (19.7) 34.4 (6.5) 35.1 (5.8) 28.4 (5.7) 0.10 (0.12) 15.9 (15.9) 0.29 (0.53)\n30-39 years 27189 18.0 (22.5) 35.9 (7.1) 36.5 (6.3) 29.7 (6.2) 0.13 (0.15) 18.2 (17.8) 0.39 (0.61)\n40-49 years 30123 20.1 (22.2) 36.7 (6.6) 37.2 (5.8) 30.4 (5.6) 0.15 (0.16) 19.7 (18.1) 0.45 (0.65)\n50-59 years 15774 25.3 (24.1) 38.0 (6.8) 38.7 (6.1) 31.6 (5.7) 0.20 (0.18) 23.5 (20.6) 1.65 (0.78)\n60-69 years 2718 26.9 (23.7) 38.6 (6.6) 39.4 (5.9) 32.1 (5.5) 0.23 (0.19) 24.2 (19.2) 1.69 (0.77)\nSocial class I 7044 13.0 (17.4) 34.2 (5.6) 34.9 (5.0) 28.2 (4.8) 0.11 (0.13) 14.5 (15.8) 0.43 (0.70)\nSocial class II 19284 17.0 (20.9) 35.7 (6.6) 36.2 (5.7) 29.4 (5.5) 0.13 (0.14) 17.2 (16.9) 0.55 (0.78)\nSocial class III 67746 20.8 (23.2) 36.7 (7.0) 37.3 (6.3) 30.4 (6.1) 0.15 (0.17) 20.4 (18.7) 0.68 (0.84)\nNon smokers* 62706 19.6 (22.5) 36.4 (6.9) 37.0 (6.2) 30.1 (5.9) 0.15 (0.16) 19.4 (18.2) 0.64 (0.82)\nSmokers 31368 19.2 (22.4) 36.2 (6.8) 36.8 (6.1) 29.9 (5.9) 0.14 (0.16) 19.1 (18.3) 0.63 (0.82)\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation product. \n(*) No statistically significant differences between smokers and non-smokers on all scales. Age and social class show statistically significant differences in all scales.13\n2023/38 (4): 9-16Variables that influence the values of 7 scales that determine the risk of nonalcoholic fatty liver disease and liver fibrosis in 219,477 spanish workers\nto sociodemographic variables, such as age, sex, social \nclass and tobacco consumption. The mean values of all \nthe aforementioned risk scales increase with increasing \nage in both sexes. The lowest values in all the scales are \nobserved in people belonging to the most favored social \nclass (class I). Smokers present slightly lower values than \nnon-smokers in both sexes, although the differences are \nnot statistically significant. The mean values in all cases \nare lower in women.Table III shows the prevalence of elevated values of \ndifferent risk scales for nonalcoholic fatty liver disease \nand liver fibrosis according to sociodemographic \nvariables such as age, sex and Social class, and tobacco \nconsumption. A trend similar to that already discussed \nwith the mean values is observed, i.e. an increase in \nprevalences as age increases and as one descends in \nthe Social class. In general, prevalences are higher in \nnon-smokers, although without statistical significance. \nPrevalences are higher in males.\nTable IV shows the results of the multivariate analysis \nusing multinomial logistic regression. The risk of \npresenting elevated values for all the nonalcoholic fatty \nliver disease and liver fibrosis scales is higher in men, \nwith odds ratios ranging from 1.03 (95% CI 1.02-1.05) \nfor ZJU and 3.41 (95% CI 3.32-3.50) for FLI. The risk increases with age in all the scales, with the highest \nvalues for the BARD score. The level of risk increased \nas we descended in the Social class with similar odds \nratios for all scales. Tobacco consumption in all scales \ndoes not show any influence in any case.Table III: Prevalence of high values of different risk scales for nonalcoholic fatty liver disease and liver fibrosis according to sociodemographic variables and tobacco \nconsumption.\n    FLI high HSI high ZJU high FLD high LAP high BARD high\nMen n % % % % % %\n18-29 years 18006 12.9 33.9 21.9 48.5 24.3 13.6\n30-39 years 33411 21.5 45.8 32.3 59.9 37.5 21.0\n40-49 years 42192 29.0 53.6 42.7 64.6 45.6 28.9\n50-59 years 26955 31.6 56.3 47.2 65.1 49.2 65.1\n60-69 years 4839 31.4 59.1 52.4 67.3 49.5 65.7\nSocial class I 7623 22.3 49.4 35.9 64.9 38.0 32.4\nSocial class II 18237 23.8 51.2 38.3 66.3 41.9 34.7\nSocial class III 99543 25.8 49.2 38.4 60.1 41.5 33.7\nNon smokers 84642 25.4* 49.6* 38.2* 61.5* 41.6 33.8*\nSmokers 40761 25.1 49.3 38.3 60.9 40.8 33.7\nWomen n % % % % % %\n18-29 years 18270 5.6 32.5 23.9 34.7 20.1 3.4\n30-39 years 27189 8.3 40.6 31.6 39.9 25.6 5.7\n40-49 years 30123 8.7 47.5 37.8 48.2 29.4 7.5\n50-59 years 15774 11.8 57.4 48.0 54.0 37.9 48.6\n60-69 years 2718 12.0 62.9 54.4 60.7 39.8 52.2\nSocial class I 7044 4.1 30.2 21.3 37.2 16.1 7.7\nSocial class II 19284 6.7 40.7 30.2 42.5 23.1 11.8\nSocial class III 67746 9.6 47.4 38.5 45.8 30.9 15.8\nNon smokers 62706 8.6* 45.1 35.8 44.5* 28.4* 14.7\nSmokers 31368 8.6 43.9 34.8 44.5 27.8 13.7\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. LAP Lipid accumulation product. (*) No statistically significant \ndifferences.\nTable IV: Multinomial logistic regression.\n  FLI high HSI high ZJU high FLD high LAP high BARD high\n OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)\nWoman 1 1 1 1 1 1\nMan 3.41 (3.32-3.50) 1.13 (1.11-1.15) 1.03 (1.02-1.05) 1.91 (1.87-1.94) 1.68 (1.65-1.71) 3.18 (3.11-3.26)\n18-29 years 1 1 1 1 1 1\n30-39 years ns 1.17 (1.11-1.23) 1.26 (1.20-1.32) 1.18 (1.12-1.25) ns 1.08 (1.02-1.13)\n40-49 years 1.18 (1.11-1.25) 1.45 (1.38-1.52) 1.64 (1.56-1.72) 1.32 (1.25-1.38) 1.30 (1.24-1.36) 6.59 (6.26-6.94)\n50-59 years 1.64 (1.55-1.74) 1.97 (1.88-2.07) 2.42 (2.30-2.54) 1.71 (1.62-1.80) 1.74 (1.66-1.83) 9.93 (9.41-10.48)\n60-69 years 2.93 (2.75-3.13) 3.10 (2.95-3.27) 3.93 (3.74-4.14) 2.43 (2.31-2.56) 2.91 (2.77-3.07) 17.31 (16.28-18.40)\nSocial class I 1 1 1 1 1 1\nSocial class II 1.30 (1.26-1.35) 1.18 (1.15-1.21) 1.30 (1.27-1.33) ns 1.27 (1.24-1.30) 1.21 (1.18-1.25)\nSocial class III 1.52 (1.44-1.59) 1.46 (1.41-1.52) 1.63 (1.57-1.69) 1.11 (1.07-1.14) 1.60 (1.54-1.67) 1.50 (1.43-1.58)\nNon smokers 1 1 1 1 1 1\nSmokers ns ns ns ns ns ns\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. LAP Lipid accumulation product. 14\n2023/38 (4): 9-16Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nTable V presents the results of the Pearson correlation \ncoefficient between the different scales, showing a \nhigher correlation between FLD with ZJU (0.978) and \nHSI (0.928) and between ZJU and HSI (0.923).Table VI shows the results of Cohen\u2019s Kappa \nconcordance index, whose highest value corresponds \nto ZJU and HSI (0.731).\nDiscussion\nBoth the mean values and the prevalence of high values \nof the nonalcoholic fatty liver disease and liver fibrosis risk \nscales are higher as age increases and as we descend \nin the Social class, and they are also lower in women.\nIn the multivariate analysis, it can be seen that the variable \nthat most increases the risk of presenting highs of the \ndifferent risk scales for nonalcoholic fatty liver disease \nand liver fibrosis is age, followed by sex and social class, \nwithout finding any influence of tobacco consumption.\nThe Pearson correlation index of the different scales is, \nin general, high, especially highlighting the relationship \nbetween FLD with ZJU and HSI and between ZJU and \nHSI. The degree of agreement using Cohen\u2019s kappa \nfound in our study is moderate to insignificant among \nthe scales evaluated, with the exception of ZJU and \nHSI in which there is good (substantial) agreement.\nDifferent studies have assessed the prevalence of \nNASH according to age, with the conclusion that as \nage increases the prevalence of NASH also increases, \na result that agrees with that obtained by us in this \nstudy. Data from the Third National Health and Nutrition \nExamination Survey (NHANES III) carried out in the \nUnited States in 3,270 persons showed very high rates \nof NASH, especially in older persons, even exceeding \n40%22 as in our study. Similar data are found in the \nstudies by Alqahtani et al23 and Bertolotti et al24, the latter also showing a greater number of complications \nderived from NASH in older persons. A study carried out \nin a Spanish working population of more than 30,000 \nworkers also found an increase in the prevalence of \na risk scale, in this case FLI, with age25. The study by \nAbeysekera et al26 conducted in more than 10,000 \npeople in Bristol showed a higher prevalence of liver \nfibrosis determined by FibroScan in older people. \nThe work of Fresneda et al25 found, as we did, a higher \nprevalence of elevated FLI values in males and in people \nfrom the most disadvantaged social classes. Data from \n5,272 middle-aged adults who participated in the 2014-\n2018 Korean National Health and Nutrition Examination \nSurveys (KNHANES)27 also showed a higher prevalence \nof elevated values of an EHGNA risk scale, in this case \nHSI, in people with lower socioeconomic status. A \npaper by Ramirez-Manent et al28 in 15,057 Spanish \nworkers showed that the risk of developing nonalcoholic \nfatty liver disease and liver fibrosis was much higher in \nmen than in women.\nThe role of smoking in the development of NASH \nremains controversial, some authors such as Jung et \nal29 found an increased prevalence in smokers. Other \nauthors such as Zein et al30 observed an increased \nlikelihood of smoking-associated liver fibrosis. A \ncross-sectional study in 160,862 persons showed \nthat smoking was associated with an increased risk Table V: Pearson correlation coefficient of the seven scales.\n  FLI HSI ZJU FLD FSI LAP BARD score\nFLI 1 0,712 0,813 0,864 0,809 0,809 0,731\nHSI   1 0,923 0,928 0,590 0,513 0,587\nZJU     1 0,978 0,768 0,649 0,647\nFLD       1 0,781 0,681 0,669\nFSI         1 0,774 0,649\nLAP           1 0,617\nBARD score             1\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham steatosis index. LAP Lipid accumulation product. \nTable VI: Cohen\u2019s Kappa concordance index of the seven scales.\n  FLI HSI ZJU FLD LAP BARD score\nFLI 1 0,350 0,504 0,130 0,532 0,524\nHSI   1 0,731 0,273 0,458 0,401\nZJU     1 0,098 0,585 0,530\nFLD       1 0,086 0,025\nLAP         1 0,471\nBARD score           1\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. LAP Lipid accumulation product. 15\n2023/38 (4): 9-16Variables that influence the values of 7 scales that determine the risk of nonalcoholic fatty liver disease and liver fibrosis in 219,477 spanish workers\nof NAFLD (adjusted odds ratio 1.10; 95% confidence \ninterval, 1.06-1.14). Furthermore, among Smokers, the \nrisk of NASH increased with the number of cigarettes \n(<10 and \u226510 pack-years vs. never Smokers; odds \nratios 1.04 and 1.11; 95% CI, 1.01-1.08 and 1.05-\n1.16, respectively.\nStrengths and limitations\nAs strengths of the study, we can highlight the large \nsample size (more than 200,000 people) and the large \nnumber of NASH and liver fibrosis risk scales used. \nThe main limitation is that diagnostic techniques for \nNASH or liver fibrosis other than the risk scales were \nnot performed.Conclusions\nTaking into account the results obtained in our study, we \ncan conclude that in this Spanish working population \nthere is a direct relationship between the values of \nthe different NASH risk scales and liver fibrosis when \nconsidering different sociodemographic variables \nsuch as age, sex and social class, and we found no \nrelationship with tobacco consumption. The degree of \ncorrelation of the different scales is good, especially \nbetween FLD with ZJU and HSI and between ZJU and \nHSI. The degree of concordance however is not as \ngood except between ZJU and HSI.\nConflict of Interest\nThe authors declare that no competing interests exist.\nReferences\n1. Dro\u017cd\u017c K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip \nGYH. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, \nand Cardiovascular Disease: Associations with Fructose Metabolism \nand Gut Microbiota. Nutrients. 2021 Dec 27;14(1):103. doi: 10.3390/\nnu14010103.\n2. Xian YX, Weng JP , Xu F. MAFLD vs. NAFLD: shared features and \npotential changes in epidemiology, pathophysiology, diagnosis, and \npharmacotherapy. Chin Med J (Engl). 2020 Dec 14;134(1):8-19. doi: \n10.1097/CM9.0000000000001263. \n3. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-\nrelated HCC: trends, predictions, risk factors and prevention. Nat Rev \nGastroenterol Hepatol. 2021 Apr;18(4):223-38. doi: 10.1038/s41575-\n020-00381-6.\n4. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, \nCaballeria J, et al. Modeling NAFLD disease burden in China, France, \nGermany, Italy, Japan, Spain, United Kingdom, and United States \nfor the period 2016-2030. J Hepatol. 2018 Oct;69(4):896-904. doi: \n10.1016/j.jhep.2018.05.036. \n5. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa \nI, Bugianesi E, et al. Global Perspectives on Nonalcoholic Fatty \nLiver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019 \nJun;69(6):2672-82. doi: 10.1002/hep.30251.\n6. Kasper P , Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. \nNAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. \n2021 Jul;110(7):921-37. doi: 10.1007/s00392-020-01709-7.\n7. Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal \nrelationships between NAFLD, T2D and obesity have implications for \ndisease subphenotyping. J Hepatol. 2020 Aug;73(2):263-76. doi: \n10.1016/j.jhep.2020.03.006. 8. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. \nNon-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, \nclinical management and effects of weight loss. BMC Endocr Disord. \n2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1. \n9. Javed Z, Papageorgiou M, Deshmukh H, Kilpatrick ES, Mann \nV, Corless L, et al. A Randomized, Controlled Trial of Vitamin D \nSupplementation on Cardiovascular Risk Factors, Hormones, and Liver \nMarkers in Women with Polycystic Ovary Syndrome. Nutrients. 2019 \nJan 17;11(1):188. doi: 10.3390/nu11010188.\n10. Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa \nR, et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: \nA Bidirectional Relationship. Can J Gastroenterol Hepatol. 2020 Dec \n28;2020:6638306. doi: 10.1155/2020/6638306.\n11. Mart\u00ednez Escud\u00e9 A, Pera G, Arteaga I, Exp\u00f3sito C, Rodr\u00edguez L, \nTor\u00e1n P , et al. Relationship between hypothyroidism and non-alcoholic \nfatty liver disease in the Spanish population. Med Clin (Barc). 2020 Jan \n10;154(1):1-6. English, Spanish. doi: 10.1016/j.medcli.2019.03.018.\n12. Kang SJ, Kwon A, Jung MK, Chae HW, Kim S, Koh H, et al. High \nPrevalence of Nonalcoholic Fatty Liver Disease Among Adolescents \nand Young Adults With Hypopituitarism due to Growth Hormone \nDeficiency. Endocr Pract. 2021 Nov;27(11):1149-55. doi: 10.1016/j.\neprac.2021.06.003.\n13. Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv \nAging. 2021 Sep 13;16:1633-49. doi: 10.2147/CIA.S295524. \n14. Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH. Fatty Liver \nIndex and Development of Cardiovascular Disease: Findings from the \nUK Biobank. Dig Dis Sci. 2021 Jun;66(6):2092-100. doi: 10.1007/\ns10620-021-06954-y.16\n2023/38 (4): 9-16Variables that influence the values of 7 scales that determine the risk of nonalcoholic fatty liver disease and liver fibrosis in 219,477 spanish workersEmilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \n15. Chang JW, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, et al. \nHepatic Steatosis Index in the Detection of Fatty Liver in Patients with \nChronic Hepatitis B Receiving Antiviral Therapy. Gut Liver. 2021 Jan \n15;15(1):117-27. doi: 10.5009/gnl19301.\n16. Shi M, Liu P , Li J, Su Y, Zhou X, Wu C, et al. The performance \nof noninvasive indexes of adults in identification of nonalcoholic fatty \nliver disease in children. J Diabetes. 2021 Sep;13(9):744-53. doi: \n10.1111/1753-0407.13169.\n17. Lee I, Cho J, Park J, Kang H. Association of hand-grip strength and \nnon-alcoholic fatty liver disease index in older adults. J Exerc Nutrition \nBiochem. 2018 Dec 31;22(4):62-8. doi: 10.20463/jenb.2018.0031. \n18. Jung TY, Kim MS, Hong HP , Kang KA, Jun DW. Comparative \nAssessment and External Validation of Hepatic Steatosis Formulae in \na Community-Based Setting. J Clin Med. 2020 Sep 3;9(9):2851. doi: \n10.3390/jcm9092851\n19. Anoop S S, Dasgupta R, Rebekah G, Jose A, Inbakumari MP , Finney \nG, et al. Lipid accumulation product (LAP) as a potential index to predict \nrisk of insulin resistance in young, non-obese Asian Indian males from \nSouthern India: observations from hyperinsulinemic-euglycemic clamp \nstudies. BMJ Open Diabetes Res Care. 2021 Sep;9(1):e002414. doi: \n10.1136/bmjdrc-2021-002414. \n20. Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, \net al. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients \nand the Reliability of Noninvasive Diagnostic Methods. Biomed Res Int. \n2020 Apr 26;2020:5023157. doi: 10.1155/2020/5023157. \n21. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, \nFerrando J, Borrell C; del Grupo de Determinantes Sociales de \nSociedad Espa\u00f1ola de Epidemiolog\u00eda. Propuestas de Social class \nneoweberiana y neomarxista a partir de la Clasificaci\u00f3n Nacional de \nOcupaciones 2011. Gac Sanit. 2013 May-Jun;27(3):263-72. doi: \n10.1016/j.gaceta.2012.12.009.\n22. Golabi P , Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM. \nPrevalence and long-term outcomes of non-alcoholic fatty liver disease \namong elderly individuals from the United States. BMC Gastroenterol. \n2019 Apr 16;19(1):56. doi: 10.1186/s12876-019-0972-6.23. Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv \nAging. 2021 Sep 13;16:1633-1649. doi: 10.2147/CIA.S295524. \n24. Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri \nS, et al. Nonalcoholic fatty liver disease and aging: epidemiology to \nmanagement. World J Gastroenterol. 2014 Oct 21;20(39):14185-\n204. doi: 10.3748/wjg.v20.i39.14185. PMID: 25339806; PMCID: \nPMC4202348.\n25. Fresneda S, Abbate M, Busquets-Cort\u00e9s C, L\u00f3pez-Gonz\u00e1lez A, \nFuster-Parra P , Bennasar-Veny M, et al. Sex and age differences in the \nassociation of fatty liver index-defined non-alcoholic fatty liver disease \nwith cardiometabolic risk factors: a cross-sectional study. Biol Sex \nDiffer. 2022 Nov 4;13(1):64. doi: 10.1186/s13293-022-00475-7.\n26.Abeysekera KWM, Fernandes GS, Hammerton G, Portal AJ, Gordon \nFH, Heron J, et al. Prevalence of steatosis and fibrosis in young adults in \nthe UK: a population-based study. Lancet Gastroenterol Hepatol. 2020 \nMar;5(3):295-305. doi: 10.1016/S2468-1253(19)30419-4.\n27. Cho J, Lee I, Park DH, Kwak HB, Min K. Relationships between \nSocioeconomic Status, Handgrip Strength, and Non-Alcoholic Fatty \nLiver Disease in Middle-Aged Adults. Int J Environ Res Public Health. \n2021 Feb 16;18(4):1892. doi: 10.3390/ijerph18041892. PMID: \n33669288;\n28. Ram\u00edrez-Manent JI, Altisench Jan\u00e9 B, Arroyo Bote S, L\u00f3pez Roig C, \nGonz\u00e1lez San Miguel H, L\u00f3pez-Gonz\u00e1lez AA. Cardiometabolic profile \nof 15057 elderly Spanish workers: association of sociodemographic \nvariables and tobacco consumption. BMC Geriatr. 2022 Nov \n17;22(1):872. doi: 10.1186/s12877-022-03547-w. \n29. Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, et al. \nSmoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort \nStudy. Am J Gastroenterol. 2019 Mar;114(3):453-463. doi: 10.1038/\ns41395-018-0283-5. \n30. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ; Nonalcoholic \nSteatohepatitis Clinical Research Network. Smoking and severity of \nhepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011 \nApr;54(4):753-9. doi: 10.1016/j.jhep.2010.07.040. 17\n2023/38 (4): 17-23ORIGINAL\nKnowledge, attitude and practice towards antibiotic use \nand resistance among non-medical university students: \nA cross sectional survey in the United Kingdom \nConocimiento, actitud y pr\u00e1ctica hacia el uso de antibi\u00f3ticos y la resistencia entre los \nestudiantes universitarios no m\u00e9dicos: Una encuesta transversal en el Reino Unido  \nShruti Malik\nDepartment of Health and Social Sciences, Frenchay Campus, University of the West of England, Bristol BS16 1QY, United KingdomeISSN 2255-0569\nReceived: 5 - I - 2023\nAccepted: 7 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.17Corresponding author\nDr. Shruti Malik MD, MPH   \nE-mail: malik@iqls.net  / shrutimalik1984@gmail.com  \nAbstract \nObjective: Student surveys conducted in Higher Educational Institutes globally have indicated a dearth of knowledge regarding \nantibiotics and their appropriate usage. The knowledge, attitude, and practices (KAP) of non-medical students towards antibiotics \nis under-researched in the United Kingdom so in this study, we aimed to assess the antibiotic KAP of non-medical students at the \nUniversity of the West of England. \nMethods: A cross-sectional survey was conducted among a diverse group of 602 university students using self-administered \nwritten questionnaires. Descriptive and inferential statistics were carried out using SPSS 24. \nResults: The survey response rate was 99.7%. Knowledge of antibiotics was significantly higher among home (UK) students and \nthose enrolled in Faculty of Health and Applied Sciences (P<0.001). Respondents displayed a good understanding of personal \nuse of antibiotics affecting their own health however the relationship between individual consumption of antibiotics contributing to \nantibiotic resistance in the community was not clear. 71% of the respondents thought antibiotic resistance was a property of human \nbody, rather than bacteria. Over half of the respondents failed to acknowledge it as a serious global and national problem. \nConclusions: This study highlighted the cultural differences in knowledge, attitudes and practices regarding antibiotics among \nstudents. Misconceptions about biological mechanisms of antibiotic resistance and lack of personal responsibility for the issue \nwere clearly demonstrated among respondents. Identification of these misunderstandings could inform targeted interventions \naimed at improving the understanding of causes and consequences of antibiotic resistance along with emphasis on potential social \nbenefit made by rational personal use of antibiotics.\nKeywords: antibiotic resistance, cross sectional survey, university, students, non-medical. \nResumen\nObjetivo: Las encuestas realizadas a estudiantes de centros de ense\u00f1anza superior de todo el mundo han puesto de manifiesto \nla escasez de conocimientos sobre los antibi\u00f3ticos y su uso adecuado. El conocimiento, la actitud y las pr\u00e1cticas (CAP) de los \nestudiantes no m\u00e9dicos con respecto a los antibi\u00f3ticos est\u00e1 poco investigado en el Reino Unido, por lo que en este estudio nos \npropusimos evaluar el CAP sobre antibi\u00f3ticos de los estudiantes no m\u00e9dicos de la Universidad del Oeste de Inglaterra. \nM\u00e9todos: Se realiz\u00f3 una encuesta transversal entre un grupo diverso de 602 estudiantes universitarios utilizando cuestionarios \nescritos autoadministrados. Se realizaron estad\u00edsticas descriptivas e inferenciales con el programa SPSS 24. \nResultados: La tasa de respuesta a la encuesta fue del 99,7%. El conocimiento de los antibi\u00f3ticos fue significativamente mayor \nentre los estudiantes de origen (Reino Unido) y los matriculados en la Facultad de Salud y Ciencias Aplicadas (P<0,001). Los \nencuestados mostraron una buena comprensi\u00f3n del uso personal de los antibi\u00f3ticos que afecta a su propia salud, sin embargo, \nla relaci\u00f3n entre el consumo individual de antibi\u00f3ticos que contribuye a la resistencia a los antibi\u00f3ticos en la comunidad no estaba \nclara. El 71% de los encuestados pensaba que la resistencia a los antibi\u00f3ticos era una propiedad del cuerpo humano, m\u00e1s que \nde las bacterias. M\u00e1s de la mitad de los encuestados no reconocen que se trata de un grave problema mundial y nacional. \nConclusiones: Este estudio puso de manifiesto las diferencias culturales en cuanto a conocimientos, actitudes y pr\u00e1cticas \nen relaci\u00f3n con los antibi\u00f3ticos entre los estudiantes. Los encuestados demostraron claramente sus ideas err\u00f3neas sobre los \nmecanismos biol\u00f3gicos de la resistencia a los antibi\u00f3ticos y su falta de responsabilidad personal en el tema. La identificaci\u00f3n \nde estos malentendidos podr\u00eda servir de base para las intervenciones dirigidas a mejorar la comprensi\u00f3n de las causas y las \nconsecuencias de la resistencia a los antibi\u00f3ticos, junto con el \u00e9nfasis en el potencial beneficio social que supone el uso personal \nracional de los antibi\u00f3ticos.\nPalabras clave: resistencia a los antibi\u00f3ticos, encuesta transversal, universidad, estudiantes, no m\u00e9dicos .ID18\n2023/38 (4): 17-23Shruti Malik \nIntroduction \nAntimicrobial resistance (AMR) is a major public health \nissue presenting a significant threat globally in the 21st \ncentury. The World Health Organization has declared \nAMR as one of the top ten global public health threats \nfacing humanity which requires urgent multisectoral \naction in order to achieve the Sustainable Development \nGoals1.\nThe Global action plan on antimicrobial resistance \nidentifies AMR as a complex problem calling for whole-\nof-society engagement2. University students, being an \naccessible antibiotic user group and influential advisors \nto friends and family, are a potential target to engage with \nfor addressing the problem of AMR. Recent research, \nhowever, has been majorly confined to students with \nmedical backgrounds since they will be future antibiotic \nproviders and trained for appropriate anti-microbial \nprescribing and responsible antibiotic use3-7.\nIn the United Kingdom, knowledge, attitude and practice \n(KAP) relating to antibiotic use and resistance amongst \nstudents in higher educational institutes has not received \nmuch research attention. A literature search revealed \nthree studies exploring antibiotic KAP among health \ncare students8-10 with no published reports on university \nstudents affiliated to non-medical backgrounds in the \ncountry. \nFurthermore, no study so far has attempted to assess \nthese patterns across a wide spectrum of courses in \nan ethnically diverse population of students at the same \ntime using the same survey instrument. The current study \naimed to present a contemporary picture of the antibiotic \nKAP of a varied group of students from non-medical \nbackgrounds in a large UK university. The information \nobtained may provide guidance for the improvement of \nhealth services on the university campus and in initiating \ntargeted health promotion interventions for individuals \nidentified at higher risk. \nMethods \nStudy population \nThe study population consisted of students at the \nUniversity of the West of England (UWE). UWE is the \nlargest provider of higher education in the Southwest \nof England. The student community at UWE is quite \ndiverse in terms of their age groups, ethnic backgrounds \nand study programmes11. \nRaosoft sample size calculator was used to determine \nthe minimum required sample size12. Based on the \ncalculation with a 5% margin of error, a 95% confidence \nlevel and a 50% response distribution, the effective \nsample size estimated was 380. However, a larger sample size of 600 students was eventually included \nin the study, yielding approximately 1.5 times the initial \nsample size projection. \nStudents were approached in public spaces including \npost rooms and cafeterias and questionnaires were \ndistributed to all the participants along with the participant \ninformation sheet. Ethical approval was obtained from the \nUniversity\u2019s Research Ethics Committee. Anonymised \nquestionnaires were used to ensure confidentiality.\nSurvey instruments \nData were collected using a self-administered, pre-\ntested questionnaire containing 26 questions. The \nquestionnaire was developed after undertaking a \nliterature review of comparable studies and was tailored \nto suit the local population13-16. It consisted of three \nsections: the first section recorded the respondent\u2019s \nsocio-demographic characteristics.\nThe second section investigated respondent\u2019s \nknowledge and attitudes relating to antibiotics and their \nuse. It had 12 knowledge statements and 4 attitude \nstatements. A five-point Likert scale was employed to \nevaluate the respondent\u2019s responses. Section three \nconsisted of four questions providing information about \nthe practice of antibiotic use. \nThe questionnaire was pre-tested for content, design, \nreadability, and comprehension on twenty students. \nNecessary modifications were done to make the \nquestionnaire easy to answer and improve the \nacceptability. The pre-test data were discarded in the \nfinal analysis. Cronbach\u2019s alpha was used to assess \nthe reliability of the statements determining knowledge \nand attitude and were calculated to be 0.71 and 0.83, \nrespectively, therefore confirming the adequacy of the \ninternal consistencies of the statements. \nData collection and analysis \nA total of 602 students were approached for the study, \nof which 600 agreed to participate. The study had \nstudents belonging to 74 different countries who were \ngrouped into continents (except the home students) \nfor ease of analysis. The responses for knowledge, \nattitudes, and practice sections were assessed by \ncalculating the percentage of each response selected. \nFurther, the questions relating to knowledge were \nscored using five-point Likert scales (1= Strongly \ndisagree, 2= Disagree, 3= Don\u2019t Know, 4= Agree and \n5= Strongly agree). The total knowledge score for each \nof the respondents was calculated by adding up scores \nfor each of these 12 statements yielding a maximum \nobtainable score of 60.\nData were analysed using the Statistical Packages \nfor Social Sciences (SPSS), version 24.0. Frequency \ntables were used to summarise the data on the socio-19\n2023/38 (4): 17-23Knowledge, attitude and practice towards antibiotic use and resistance among non-medical university students: A cross sectional survey in the United Kingdom \ndemographic variables. To examine the relationship \nbetween knowledge of antibiotics and socio-\ndemographic variables, Mann \u2013Whitney U test and \nKruskal\u2013 Wallis test were employed depending upon \nthe levels of the demographic variables owing to the skewed distribution of data. Groups with number of \ncases <10, were amalgamated with the next category \nwherever appropriate (as in the case of age, level \nof education, and student\u2019s normal residence). In \ndemographic variables for which a significant overall \nassociation with KAP was established, further post hoc \nanalysis was performed to determine the differences \nbetween groups employing Mann-Whitney U tests. \nBonferroni correction was applied to control for inflation \nin Type I error rates. Association between knowledge \nscore and prudent antibiotic use was explored using \nMann-Whitney U test. For all analyses, a p value of < \n0.05 was considered to be statistically significant.\nResults\nA total of 600 UWE students participated and completed \nthe questionnaire survey, generating a response rate \nof 99.7%. The mean age of the participants was 20.4 \nyears. The median antibiotic knowledge score for the \nrespondents was 36 with 55.6% scoring \u2264 median and \nremaining 44.4% scoring > median. Table I summarises \nthe demographic characteristics of the study population.\nKnowledge and perceptions about antibiotics and \nantibiotic resistance \nResponse distributions to knowledge-probing \nstatements are shown in table II.Table I: Demographic characteristics of the study participants.\nDemographic Number of Percentage\ncharacteristics respondents\nGender\n    Male 289 (48.3%)\n    Female 308 (51.2 %)\n    Prefer not to say 3 (0.5%)\nAge\n    Under 18 11 (1.8%)\n    18-22 504 (84.0%)\n    23-29 75 (12.5%)\n    30 or above 10 (1.7%)\nFaculty\n    Health and Applied Sciences 108 (18.0%)\n    Business and Law 275 (45.9%)\n    Environment and Technology 155 (25.8%)\n    Arts, Creative Industries and Education 62 (10.3%)\nLevel of education\n    Foundation 86 (14.3%)\n    Undergraduate 426 (71.1%)\n    Postgraduate 86 (14.3%)\n    Doctoral 2 (0.3%)\nCountry of residence\n    UK (Home) 315 (52.5%)\n    Europe 44 (7.3%)\n    Asia 186 (31.0%)\n    Africa 43 (7.2%)\n    North America 8 (1.3%)\n    South America 4 (0.7%)\n Statements Strongly disagree  Disagree  Don\u2019t know  Agree  Strongly agree   Total\n  N (%) N (%) N(%) N(%) N (%) N (%)\n1 Antibiotics are effective against bacteria   01  17 71 390 121 600\n  (0.2%) (2.8%) (11.8%) (65.0%) (20.2%) -100%\n2 Antibiotics are effective against viruses  43 116 114 294 33 600\n  (7.2%) (19.3%) (19.0%) (49.0%) (5.5%) -100%\n3 Antibiotics work on most colds & coughs 13 153 126 280 28 600\n  (2.2%) (25.5%) (21.0%) (46.7%) (4.7%) -100%\n4 A course of antibiotics should be stopped when  92 228 73 160 47 600\n a person starts feeling better (15.3%) (38.0%) (12.2%) (26.7%) (7.8%) -100%\n5 Humans can become resistant to antibiotics 7 50 116 297 130 600\n  (1.2%) (8.3%) (19.3%) (49.5%) (21.7%) -100%\n6 Viruses can become resistant to antibiotics  21 50 153 307 69 600\n  (3.5%) (8.3%) (25.5%) (51.2%) (11.5%) -100%\n7 Bacteria can become resistant to antibiotics  4 20 159 299 118 600\n  (0.7%) (3.3%) (26.5%) (49.8%) (19.7%) -100%\n8 Antibiotic resistance is an issue that could 6 53 181 294 66 600\n affect me and my family (1.0%) (8.8%) (30.2%) (49.0%) (11.0%) -100%\n9 Resistance to antibiotics is a problem in my country 15 104 295 160 26 600\n  (2.5%) (17.3%) (49.2%) (26.7%) (4.3%) -100%\n10 Antibiotic resistance is a significant global problem 6 30% 261 255 48 600\n  (1.0%) (5.0%) (43.5%) (42.5%) (8.0%) -100%\n11 Inappropriate personal use of antibiotics can contribute  9 21 128 345 97 600\n to the problem of antibiotic resistance for myself (1.5%) (3.5%) (21.3%) (57.5%) (16.2%) -100%\n12 Inappropriate personal use of antibiotics can contribute 3 64 187 288 64 600\n to the problem of antibiotic resistance for the (0.5%) (10.7%) (30.2%) (48.0%) (10.7%) -100%\n whole communityTable II: Overall responses to knowledge assessments statements.20\n2023/38 (4): 17-23Shruti Malik \nConfusion regarding the understanding of the basic \nbiological mechanism behind antibiotic resistance \nwas demonstrated in the study. Almost seven in ten \nrespondents incorrectly agreed that \u201cHumans can \nbecome resistant to antibiotics\u201d. Faculty of Health and \nApplied Sciences (HAAS) had the highest proportion of \nrespondents (81.5%) affirming to the statement. Also, 77% \nof the home students agreed with the statement. Antibiotic \nresistance was not perceived as an important national or \nglobal challenge by a sizeable proportion of students. \nAlmost two \u2013thirds of the respondents (75%) recognised \nthat inappropriate personal use of antibiotics can \ncontribute to the problem of antibiotic resistance for \nthemselves. Whereas the number of respondents \nagreeing to inapt personal antibiotic use contributing \nto the problem of antibiotic resistance for the whole \ncommunity was relatively lower at 59%. \nKnowledge of antibiotics was found to vary significantly \nwith the faculty of enrolment (p<0.001) and country of \nresidence (p<0.001). The respondents from Faculty \nof HAAS and home students had the highest mean \nranks translating into higher antibiotic knowledge when compared to their counterparts (Table III). Further, the \npost hoc analysis performed for the variables of Faculty \nrevealed statistically significant differences between the \nmean ranks of respondents from HAAS & FBL (p<0.001), \nHAAS & FET, (p<0.001), HAAS & ACE (p<0.001) \nrespectively. For the country of normal residence, a \nsignificant difference was found between the mean ranks \nof respondents from UK and Asia (p<0.001). \nAttitudes and beliefs towards antibiotic use \nAlmost one-third of the considered it appropriate to bring \nantibiotics from home to avoid hassles of booking an \nappointment and seeing a doctor at university, of which \n60% were international students (Table IV).\nPractices on antibiotics use among participants \nAlmost three quarters of the students had taken oral \nantibiotics in the past 12 months, with the majority \n(73%) having completed their last antibiotic course. \nApproximately 16% didn\u2019t finish the last antibiotic course, \nmaximum rates reported among respondents from Africa \nand South America (27.7%) followed by Asia (20.0%). \nThe majority of these attributed it to getting better (65%) \nand being forgetful (19%). \nDemographic characteristics N (%) Median Interquartile range  Z score \u03c72\n   knowledge score (P value)* (P value)**\nGender                         \n    Male 289 (48.3) 35.0 32.0 - 39.0 -1.52 \n    Female 308 (51.2) 36.0 33.0 - 40.0  \nAge     \n    Under 18 11 (1.8) 34.0 33.0 - 38.0  0.30\n    18-22 504 (84.0) 36.0 33.0 - 40.0  (0.86)\n    23 and above 85 (12.5) 36.0 33.0 - 40.0  \nFaculty                      \n    Health and Applied Sciences (HAAS) 108 (18.0) 39.0 35.0 - 44.0  46.45\n    Business and Law (FBL) 275 (45.9) 35.0 32.0 - 38.0  (<0.001)\n    Environment and Technology (FET) 155 (25.8) 36.0 33.0 - 40.0   \n    Arts, Creative Industries and Education (ACE) 62 (10.3) 35.0 33.0 - 40.0   \nLevel of education     \n    Foundation 86 (14.3) 35.5 33.0 - 40.0  1.23\n    Undergraduate 426 (71.1) 36.0 33.0 - 40.0  (0.54)\n    Postgrad & Doctoral 88 (14.6) 35.0 32.5 - 38.5  \nStudent\u2019s normal residence     \n    UK (Home) 315 (52.5) 37.0 34.0 - 41.0  32.26\n    Europe+ North America 52 (8.6) 37.0 33.0 - 40.0  (<0.001)\n    Asia 186 (31.0) 34.0 32.0 - 37.0\n    Africa + South America 47 (7.9) 37.0 32.0 - 41.5Table III: Association between knowledge of antibiotics & socio-demographic characteristics of respondents.\n* Mann \u2013Whitney U test  ** Kruskal- Wallis test\n Statements Strongly disagree  Disagree  Don\u2019t know  Agree  Strongly agree  Total\n  N (%) N (%) N (%) N (%) N (%) N (%)\n1 When I get a cold, I should take antibiotics 53 289 73 169 16 600\n to get better quickly (8.8%) (48.1%) (12.2%) (28.2%) (2.7%) -100%\n2 When I have a cold, I should take antibiotics  26 266 101 185 21 600\n to prevent getting worse (4.3%) (44.3%) (12.2%) (30.8%) (3.5%) -100%\n3 It is fine to bring antibiotics from home to avoid hassles 37 214 144 168 37 600\n of booking an appointment and seeing a doctor at university  (6.2%) (35.7%) (24.0%) (28.0%) (6.2%) -100%\n4 It is okay to keep unused antibiotics and use them later  123 293 79 95 10 600\n when needed without the advice of doctor (20.5%) (48.8%) (13.2%) (15.8%) (1.7%) -100%Table IV: Overall responses to attitudes assessments statements.21\n2023/38 (4): 17-23Knowledge, attitude and practice towards antibiotic use and resistance among non-medical university students: A cross sectional survey in the United Kingdom \nMost of the respondents (87%) declared using \nprescribed antibiotics. Of those using unprescribed \nantibiotics, majority either (51%) purchased them from \na pharmacy or obtained them from family and friends \n(25%). The rates of self-medication were highest among \nAfrican and South American students (29.8%) followed \nby Asian respondents (21.5%). Home students reported \nlowest rates of self- medication at 4.4%. Respondents \nwho had finished their last antibiotic course were found \nto be significantly more knowledgeable about antibiotics \nthan those who failed to finish the prescription (p=0.01).\nDiscussion \nTo the best of our knowledge, this is the first study to \nsurvey antibiotic KAP of a diverse population of students \nfrom a range of courses in the UK, all affiliated to non- \nmedical backgrounds. \nKnowledge and perceptions \nThe findings indicate confusion among students regarding \nwhether antibiotics are effective against bacteria or \nviruses and their role in treating coughs and colds as \nobserved in previous student surveys17-20. \nConfusion persists regarding the biological mechanism \nunderlying antibiotic resistance, it seems to be \nconceptualized as some change caused in the human \nbody rendering antibiotics ineffective rather than \ninterpreting it as an intrinsic property of the bacteria. This \nfits with findings published in public surveys21-24.\nMisconception about human body building resistance \nto antibiotics was significantly more prevalent among the \nhome students and those enrolled in Faculty of Health \nand Applied Sciences, both of which were predictors \nof higher knowledge of antibiotics in the study. This is \na unique finding, and no historical studies exist to make \ndirect comparisons. It indicates that although the term \nantibiotic resistance and its severity is firmly instilled \namong students with higher antibiotic knowledge, the \nunderstanding of the biological mechanism and events \nbehind the phenomenon remains largely obscure.\nStudents in our survey didn\u2019t perceive antibiotic resistance \nas a serious global and/or national challenge discordant \nwith the findings reported in student surveys conducted \non medical students3,5,7,18. \nWhen queried about perceptions of relationship between \ninappropriate use of antibiotics and the phenomenon \nof antibiotic resistance, respondents seemed to have \ndemonstrated a good understanding of their personal \nuse of antibiotics affecting their own health. However, \nunderstanding of the relationship between the individual \nconsumption of antibiotics and development of antibiotic \nresistance in the community was limited. The findings are congruent with published reports25-26 and clearly suggests \na lack of understanding of the individual ownership of \nthe cause and calls for development of interventions \nexplaining how antibiotic resistance develops and \nspreads in the first place including a dimension that \nassigns individual responsibility. \n Students from Faculty of Health and Applied Sciences \nseemed to be more knowledgeable about antibiotic use \nand resistance than their peers from other faculties. The \nstudy also revealed a significant relationship between \nknowledge of antibiotics and country of residence with \nthe home students scoring notably better than their \ncounterparts. This difference might be accounted for by \nthe influence of the high-level efforts in the UK, including \nseveral antibiotic awareness campaigns undertaken \nsince 2004, to educate the public about the appropriate \nuse of antibiotics and increase awareness of the issue of \nantibiotic resistance27-30.\nAttitudes and beliefs \nMisbeliefs regarding antibiotics speeding up recovery \nfrom colds and preventing more serious illness were \nfound to be prevalent and were indicative of a lack of \nunderstanding of the efficacy of antibiotics and their role \nin treating viral infections.\nMajority of the international students perceived it \nappropriate to bring antibiotics from home to avoid hassles \nof consulting a doctor at the university. This perception is \nlikely to have been influenced by the apprehensiveness \naccompanying transition and acclimatization in a setting \nvery different from their country of normal residence. \nPractices\nWhen enquired about the practices of antibiotic usage, \nlow level of self-medication and high level of adherence \nto antibiotic prescription was observed. Self -medication \nrates and noncompliance with the course of antibiotics \nwere found to be lowest among the home students \nwhich can in part be associated with the effectiveness \nof antibiotic stewardship programs in UK. Apart from the \nmultiple antibiotic awareness campaigns targeting the \ngeneral public, several regulatory measures including \nsurveillance and legislative actions have been strictly in \nplace to ensure the appropriate use of antibiotics31-33. \nHigh rates of self-medication and non-adherence were \nreported for respondents from Africa and South America \nalong with their Asian peers, suggestive of a lack of \nregulation on antibiotic prescription and sales in these \ncountries. Furthermore, differences in implementation \nof drug regulations affecting the availability of antibiotics \nover counter in different countries has been found to \nplay an important role in promoting higher rates of self \n-medication and inappropriate use34.\nThe more knowledgeable respondents were more \nlikely to have completed their last course of prescribed 22\n2023/38 (4): 17-23Shruti Malik \nantibiotics and was found to be consistent with findings \nreported in previous surveys35-37.\nStrengths and Limitations\nThe strengths of the study include a high response rate \nof 99.7% and a large sample size. Our study has some \nlimitations, it was not possible to carry out a random \nsampling procedure owing to the blanket policy of security \nmeasures in place which might have compromised the \ngeneralizability of the findings, though sincere efforts were \nmade to maintain the representativeness of the sample. \nConclusions\nClear cultural differences in knowledge, attitudes and \npractices regarding antibiotic use were identified among \nrespondents. Misconceptions about the biological \nmechanisms of antibiotic resistance and lack of personal \nresponsibility for the issue was clearly demonstrated \namong the respondents. Antibiotic resistance was \nnot perceived as a serious global or national problem \namong the study subjects. This highlights the need for developing targeted health promotion interventions \nwithin the university strategizing methods to engage \nwith the less knowledgeable groups to improve topic-\nspecific knowledge. Also, campaigns and educational \nefforts applying behavioral insights methodology and \nemphasising on potential social benefit made by \nrational personal use of antibiotics can help facilitate \nthe desired behavioural change and foster responsible \nuse of antibiotics. \nConflict of interest\nThe author has no conflict of interest to declare \nFunding \nThis research did not receive any specific grant from \nfunding agencies in the public, commercial, or not-for-\nprofit sectors. \nAcknowledgments\nThe author would like to acknowledge Dr. Jon Pollock \nfor providing guidance and supervision during the work. \nReferences\n1. World Health Organization (2020) Antimicrobial Resistance \nFactsheet. Available: https://www.who.int/news-room/fact-sheets/\ndetail/antimicrobial-resistance. Accessed 19 September 2021\n2. World Health Organization (2015) Global action plan on antimicrobial \nresistance.Available:https://www.who.int/antimicrobial-resistance/\npublications/global-action-plan/en/. Accessed 19 August 2021\n3. Abbo LM, Cosgrove SE, Pottinger PS, Pereyra M, Sinkowitz-Cochran \nR, Srinivasan A, et al. Medical students\u2019 perceptions and knowledge \nabout antimicrobial stewardship: How are we educating our future \nprescribers? Clin Infect Dis. 2013;57(5):631-8\n4. Minen MT, Duquaine D, Marx MA, Weiss D. A survey of knowledge, \nattitudes, and beliefs of medical students concerning antimicrobial use \nand resistance. Microb Drug Resist. 2010;16(4):285-9\n5. Pulcini C, Williams F, Molinari N, Davey P , Nathwani D. Junior doctors\u2019 \nknowledge and perceptions of antibiotic resistance and prescribing: a \nsurvey in France and Scotland. Clin Microbiol Infect. 2011;17(1):80-7\n6. Scaioli G, Gualano MR, Gili R, Masucci S, Bert F, Siliquini R. Antibiotic \nuse: a cross-sectional survey assessing the knowledge, attitudes and \npractices amongst students of a school of medicine in Italy. PLoS One. \n2015;10(4):e0122476\n7. Yang K, Wu D, Tan F, Shi S, Guo X, Min Q, et al. Attitudes and \nperceptions regarding antimicrobial use and resistance among medical \nstudents in Central China. Springerplus. 2016;5(1):1779.\n8. Dyar OJ, Hills H, Seitz LT, Perry A, Ashiru-Oredope D. Assessing \nthe Knowledge, Attitudes and Behaviors of Human and Animal Health \nStudents towards Antibiotic Use and Resistance: A Pilot Cross-\nSectional Study in the UK. Antibiotics (Basel). 2018;7(1):10. Published \n2018 Jan 30. doi:10.3390/antibiotics70100109. In\u00e1cio J, Barnes L-M, Jeffs S, Castanheira P , Wiseman M, In\u00e1cio \nS, et al. Master of Pharmacy students\u2019 knowledge and awareness of \nantibiotic use, resistance and stewardship. Curr Pharm Teach Learn. \n2017;9(4):551-9.\n10. Wright EP , Jain P . Survey of antibiotic knowledge amongst final year \nmedical students. J Antimicrob Chemother. 2004;53(3):550-1\n11. UWE Bristol (2021) Student and Staff numbers. Available: \nhttps://www.uwe.ac.uk/about/demographic-data/student-and-staff-\nnumbers#a96fa7113-3b62-4ce7-af88-874fcd28c105 Accessed 10 \nNovember 2021\n12. Raosoft Inc (2004) Raosoft Sample Size Calculator. Available: http://\nwww.raosoft.com/samplesize. html. Accessed 10 July 2017 \n13. Andr\u00e9 M, Vernby A, Berg J, Lundborg CS. A survey of public \nknowledge and awareness related to antibiotic use and resistance in \nSweden. J Antimicrob Chemother. 2010;65(6):1292-6.\n14. Carter RR, Sun J, Jump RLP . A survey and analysis of the American \npublic\u2019s perceptions and knowledge about antibiotic resistance. Open \nForum Infect Dis. 2016;3(3):ofw112.\n   \n15. Eng JV, Marcus R, Hadler JL, Imhoff B, Vugia DJ, Cieslak PR, \net al. Consumer attitudes and use of antibiotics. Emerging infectious \ndiseases. 2003;9(9):1128-35\n16. McNulty CA, Boyle P , Nichols T, Clappison P , Davey P . Don\u2019t wear \nme out\u2014the public\u2019s knowledge of and attitudes to antibiotic use. \nJournal of Antimicrobial Chemotherapy. 2007;59(4):727-38\n17. Huang Y, Gu J, Zhang M, Ren Z, Yang W, Chen Y, et al. Knowledge, \nattitude and practice of antibiotics: a questionnaire study among 2500 \nChinese students. BMC Med Educ. 2013;13(1):163.23\n2023/38 (4): 17-23Knowledge, attitude and practice towards antibiotic use and resistance among non-medical university students: A cross sectional survey in the United Kingdom \n18. Khan AK, Banu G, Reshma KK. Antibiotic resistance and usage\u2014a \nsurvey on the knowledge, attitude, perceptions and practices among \nthe medical students of a Southern Indian teaching hospital. Journal of \nclinical and diagnostic research: JCDR. 2013;7(8):1613.\n19. Lv B, Zhou Z, Xu G, Yang D, Wu L, Shen Q, et al. Knowledge, \nattitudes and practices concerning self-medication with antibiotics \namong university students in western China. Trop Med Int Health. \n2014;19(7):769-79.\n20. Shah SJ, Ahmad H, Rehan RB, Najeeb S, Mumtaz M, Jilani MH, \net al. Self-medication with antibiotics among non-medical university \nstudents of Karachi: a cross-sectional study. BMC Pharmacol Toxicol. \n2014;15(1):74\n21. Abu Taha A, Abu-Zaydeh AH, Ardah RA, Al-Jabi SW, Sweileh WM, \nAwang R, et al. Public knowledge and attitudes regarding the use of \nantibiotics and resistance: Findings from a cross-sectional study among \nPalestinian adults. Zoonoses Public Health. 2016;63(6):449\u201357.\n22. Awad AI, Aboud EA. Knowledge, attitude and practice \ntowards antibiotic use among the public in Kuwait. PLoS One. \n2015;10(2):e0117910.\n23. Lim KK, Teh CC. A cross sectional study of public knowledge and \nattitude towards antibiotics in Putrajaya, Malaysia. South Med Rev. \n2012;5(2):26-33.\n24. Oh AL, Hassali MA, Al-Haddad MS, Sulaiman SAS, Shafie AA, \nAwaisu A. Public knowledge and attitudes towards antibiotic usage: \na cross-sectional study among the general public in the state of \nPenang, Malaysia. The Journal of Infection in Developing Countries. \n2010;5(05):338-47.\n25. Brooks L, Shaw A, Sharp D, Hay AD. Towards a better understanding \nof patients\u2019 perspectives of antibiotic resistance and MRSA: a qualitative \nstudy. Fam Pract. 2008;25(5):341- 8.\n26. Hawkings NJ, Wood F, Butler CC. Public attitudes towards \nbacterial resistance: a qualitative study. J Antimicrob Chemother. \n2007;59(6):1155-60.\n27. Bhattacharya A, Hopkins S, Sallis A, Budd EL, Ashiru-Oredope D. \nA process evaluation of the UK-wide Antibiotic Guardian campaign: \ndeveloping engagement on antimicrobial resistance. J Public Health \n(Oxf) [Internet]. 2016; Available from: http://dx.doi.org/10.1093/\npubmed/fdw05928. Chaintarli K, Ingle SM, Bhattacharya A, Ashiru-Oredope D, Oliver \nI, Gobin M. Impact of a United Kingdom-wide campaign to tackle \nantimicrobial resistance on self-reported knowledge and behaviour \nchange. BMC Public Health [Internet]. 2016;16(1). Available from: \nhttp://dx.doi.org/10.1186/s12889-016-3057-2 \n29. Lambert MF, Masters GA, Brent SL. Can mass media campaigns \nchange antimicrobial prescribing? A regional evaluation study. J \nAntimicrob Chemother. 2007;59(3):537-43.\n30. McNulty CAM, Nichols T, Boyle PJ, Woodhead M, Davey P . The \nEnglish antibiotic awareness campaigns: did they change the public\u2019s \nknowledge of and attitudes to antibiotic use? J Antimicrob Chemother. \n2010;65(7):1526-33\n31. Ashiru-Oredope D, Sharland M, Charani E, McNulty C, Cooke J. \nImproving the quality of antibiotic prescribing in the NHS by developing a \nnew Antimicrobial Stewardship Programme: Start Smart\u2014Then Focus. \nJournal of antimicrobial chemotherapy. 2012;67(suppl_1):51-63.\n32. McNulty CAM, Nichols T, French DP , Joshi P , Butler CC. Expectations \nfor consultations and antibiotics for respiratory tract infection in primary \ncare: the RTI clinical iceberg. Br J Gen Pract. 2013;63(612):e429-36.\n33. World Health Organization (2017) Evaluation of antibiotic awareness \ncampaigns. Available:   http://www.who.int/selection_medicines/\ncommittees/expert/21/applications/antibacterials-ccps_rev/en/. \nAccessed 10November 2019\n34. Grigoryan L, Burgerhof JGM, Degener JE, Deschepper R, Lundborg \nCS, Monnet DL, et al. Attitudes, beliefs and knowledge concerning \nantibiotic use and self-medication: a comparative European study. \nPharmacoepidemiol Drug Saf. 2007;16(11):1234-43.\n35. Donkor ES, Tetteh-Quarcoo PB, Nartey P , Agyeman IO. Self-\nmedication practices with antibiotics among tertiary level students in \nAccra, Ghana: a cross-sectional study. Int J Environ Res Public Health. \n2012;9(10):3519-\n36. Fatokun O. Exploring antibiotic use and practices in a Malaysian \ncommunity. Int J Clin Pharm. 2014;36(3):564-9.\n37. Sarahroodi S, Arzi A, Sawalha AF, Ashtarinez A. Antibiotics self-\nmedication among southern Iranian university students. Int J Pharmacol. \n2009;6(1):48-52.24\n2023/38 (4): 24-30ORIGINAL\nDesarrollo de competencias profesionales para prevenir \nlas agresiones a trav\u00e9s de la simulaci\u00f3n virtual \nen estudiantes de enfermer\u00eda: estudio experimental \nDevelopment of professional skills to prevent aggression through \nvirtual simulation in nursing students: experimental study  \nM. Raquel Caballero1      , Guillermo Moreno2      , Juan Vicente Beneit3      , \nMercedes G\u00f3mez del Pulgar3      , Encarnaci\u00f3n Caballero4      , L. Iv\u00e1n Mayor-Silva3\n1. Universidad de Castilla la Mancha, Castilla la Mancha, Espa\u00f1a\n2. Universidad Complutense de Madrid, Facultad de Enfermer\u00eda, Fisioterapia y Podolog\u00eda, Madrid, Espa\u00f1a; Instituto de Investigaci\u00f3n \nimas12, Hospital Universitario 12 de Octubre, Madrid, Espa\u00f1a\n3. Universidad Complutense de Madrid, Facultad de Enfermer\u00eda, Fisioterapia y Podolog\u00eda, Madrid, Espa\u00f1a\n4. Universidad de Castilla la Mancha, Castilla la Mancha, Espa\u00f1aeISSN 2255-0569\nReceived: 8 - I - 2023\nAccepted: 9 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.24Corresponding author\nGuillermo Moreno   \nE-mail: guimoren@ucm.es  \nResumen\nObjetivos: Este estudio tiene como objetivo evaluar los efectos de la simulaci\u00f3n virtual sobre el aprendizaje pr\u00e1ctico y la adquisici\u00f3n \nde competencias de comunicaci\u00f3n, relaci\u00f3n interpersonal, actitudes y trasferencia, para la gesti\u00f3n de conflictos, en estudiantes de \nenfermer\u00eda de \u00faltimo curso, frente al m\u00e9todo tradicional de trabajo con casos cl\u00ednicos escritos. \nM\u00e9todos: Estudio experimental con dos grupos paralelos aleatorizados con 90 estudiantes de enfermer\u00eda. El grupo control \nrecibi\u00f3 una intervenci\u00f3n basada en simulaci\u00f3n tradicional (n = 45) y el grupo experimental recibi\u00f3 una intervenci\u00f3n basada en \nsimulaci\u00f3n virtual (n = 45), ambas orientadas a la adquisici\u00f3n de competencias de comunicaci\u00f3n, relaci\u00f3n interpersonal, actitudes \ny trasferencia, para la gesti\u00f3n de conflictos. La adquisici\u00f3n de estas competencias se evalu\u00f3 mediante la escala ECOEnf con las \nunidades competenciales 6 (UC6) y 7 (UC7). \nResultados: Se compararon las puntuaciones antes y despu\u00e9s de la intervenci\u00f3n, sin observarse diferencias estad\u00edsticamente \nsignificativas en el grupo control, en la UC6 (p=0,54) y en la UC7 (p=0,83), as\u00ed como en el grupo intervenci\u00f3n en la UC6 (p=0,21) \ny en la UC7 (p=0,32). Al ajustar por las variables sociodemogr\u00e1ficas tampoco se encontraron diferencias en cada grupo despu\u00e9s \nde la intervenci\u00f3n. Al comparar las diferencias entre grupos en el momento despu\u00e9s de la intervenci\u00f3n, no se hallaron diferencias \nestad\u00edsticamente significativas ni en la UC6 (p=0,57) ni en la UC7 (p=0,89). \nConclusiones: Con los datos del presente estudio no se puede demostrar que la simulaci\u00f3n mediante realidad virtual sea un \nm\u00e9todo de aprendizaje estrat\u00e9gico.\nPalabras clave: Enfermer\u00eda, habilidades de comunicaci\u00f3n y actitud, agresiones hacia profesiones de la salud, simulaci\u00f3n\nAbstract \nObjectives: This study aims to evaluate the effects of virtual simulation on practical learning and the acquisition of communication \nskills, interpersonal relationships, attitudes and transference, for conflict management, in final year nursing students, compared to \nthe method traditional way of working with written clinical cases. \nMethods: Experimental study with two parallel randomized groups with 90 nursing students. The control group received an \nintervention based on traditional simulation (n = 45) and the experimental group received an intervention based on virtual simulation \n(n = 45), both aimed at the acquisition of communication skills, interpersonal relationships, attitudes and transference, to conflict \nmanagement. The acquisition of these skills was evaluated using the ECOEnf scale with skill units 6 (UC6) and 7 (UC7).\nResults: The scores were compared before and after the intervention, without observing statistically significant differences in the \ncontrol group, in the UC6 (p=0.54) and in the UC7 (p=0.83), as well as in the group intervention in UC6 (p=0.21) and in UC7 \n(p=0.32). When adjusting for sociodemographic variables, no differences were found in each group after the intervention. When \ncomparing the differences between groups at the time after the intervention, no statistically significant differences were found in \neither the UC6 (p=0.57) or the UC7 (p=0.89). \nConclusions: With the data of this study, it cannot be demonstrated that virtual reality simulation is a strategic learning method.\nKeywords: Nursing, communication skills and attitude, aggression towards health professions, simulation. ID\nID ID IDID ID25\n2023/38 (4): 24-30\nDesarrollo de competencias profesionales para prevenir las agresiones a trav\u00e9s de la simulaci\u00f3n virtual en estudiantes de enfermer\u00eda: estudio experimental\nIntroducci\u00f3n\nLa profesi\u00f3n sanitaria es una poblaci\u00f3n expuesta a un alto \nriesgo de violencia, al trabajar en contacto con el p\u00fablico \ny con personas que se encuentran en dificultades. La \nviolencia afecta a la salud de los trabajadores sanitarios \ny tiene consecuencias sociales y psicol\u00f3gicas que \npermanecen frecuentemente escondidas. Adem\u00e1s, los \nprofesionales sanitarios reciben formas de violencia f\u00edsica \ny verbal, esta \u00faltima tan da\u00f1ina y destructiva como el uso \nde la fuerza f\u00edsica1,2. Sin embargo, se puede decir que \neste tipo de violencia ocupacional es predecible y, por \ntanto, evitable. N\u00fameros estudios ponen de manifiesto \nque la percepci\u00f3n de una provocaci\u00f3n es un predictor \nsignificativo de la violencia ocupacional3,4. Aun sabiendo \nesto las agresiones a profesionales sanitarios han ido \naumentando en los \u00faltimos a\u00f1os5. Por ello, los futuros \nprofesionales necesitan aprender a actuar ante estas \nsituaciones. El desarrollo de las habilidades de gesti\u00f3n \nde conflictos debe empezar en el periodo de formaci\u00f3n \nuniversitaria, donde empiezan a darse las primeras \nsituaciones de violencia6,7.\nUna de las posibles metodolog\u00edas para la adquisici\u00f3n de \nestas habilidades es la simulaci\u00f3n a trav\u00e9s de realidad \nvirtual (o simulaci\u00f3n virtual), gracias a la recreaci\u00f3n de \nm\u00faltiples situaciones ficticias8,9. Hay m\u00faltiples estudios \nque demuestran sus beneficios en el desarrollo de \ncompetencias instrumentales10, pero pocos estudios \naleatorizados que demuestren su eficacia en el desarrollo de \nlas competencias de comunicaci\u00f3n, relaci\u00f3n interpersonal, \nactitudes y trasferencia11,12. En este sentido, podr\u00eda ser \n\u00fatil el uso de la simulaci\u00f3n virtual como metodolog\u00eda \npara el aprendizaje de competencias orientadas hacia la \nreducci\u00f3n y prevenci\u00f3n de las agresiones a enfermeras, \nfrente a las simulaciones convencionales basadas en \nlas lecturas y reflexiones sobre casos de situaciones de \nviolencia a profesionales, escritos13.\nPor ello, este estudio tiene como objetivo evaluar los \nefectos de la simulaci\u00f3n virtual sobre el aprendizaje \npr\u00e1ctico y la adquisici\u00f3n de competencias de \ncomunicaci\u00f3n, relaci\u00f3n interpersonal, actitudes y \ntrasferencia, para la gesti\u00f3n de conflictos, en estudiantes \nde enfermer\u00eda de \u00faltimo curso, frente al m\u00e9todo \ntradicional de trabajo con casos cl\u00ednicos escritos.\nMaterial y m\u00e9todos \nDise\u00f1o. Se realiz\u00f3 un estudio experimental con dos \ngrupos paralelos aleatorizados, grupo control, que \nrecibi\u00f3 una intervenci\u00f3n educativa basada en simulaci\u00f3n \ntradicional y grupo experimental, que recibi\u00f3 una \nintervenci\u00f3n educativa basada en simulaci\u00f3n virtual, \nambas orientadas a la adquisici\u00f3n de competencias \nde comunicaci\u00f3n, relaci\u00f3n interpersonal, actitudes y \ntrasferencia, para la gesti\u00f3n de conflictos14,15.Poblaci\u00f3n. Como poblaci\u00f3n del estudio, se consider\u00f3 \nla totalidad de estudiantes de Enfermer\u00eda de cuarto \ncurso (n=116) de la Facultad de Enfermer\u00eda de Castilla \nla Mancha, Espa\u00f1a. Los criterios de inclusi\u00f3n fueron: \nser estudiante de Enfermer\u00eda de cuarto curso de dicha \nfacultad y los criterios de exclusi\u00f3n: no desear participar \nvoluntariamente en el estudio y no cumplimentar el \nconsentimiento informado escrito. De los 116 estudiantes \nde cuarto a\u00f1o del grado de Enfermer\u00eda finalmente \nparticiparon en el estudio 90 (45 en el grupo control y 45 \nen el grupo experimental) (Figura 1). \nVariables del estudio. \n- Adquisici\u00f3n de competencias: como instrumento \nautoadministrado para evaluar la adquisici\u00f3n \nde competencias se utiliz\u00f3 un cuestionario \nautoadministrado, la Escala de Evaluaci\u00f3n de \nCompetencias Enfermeras (ECOEnf)16 que fue \ndise\u00f1ada y validada en espa\u00f1ol para dar respuesta \na la evaluaci\u00f3n de las competencias recogidas \nen la Orden Ministerial CIN 2134/200817. En \nla escala \u201cECOEnf\u201d se determinan 5 Unidades \nCompetenciales (UC), que tienen que ver \ndirectamente con las funciones enfermeras y el \nproceso de atenci\u00f3n de Enfermer\u00eda: UC1.- Valoraci\u00f3n \ny Diagn\u00f3stico; UC2: Planificaci\u00f3n de cuidados; \nUC3: Intervenci\u00f3n de Enfermer\u00eda; UC4: Evaluaci\u00f3n \ny Calidad; UC5: Gesti\u00f3n Cl\u00ednica. Adem\u00e1s de estas \nunidades competenciales, que hacen referencia \nespec\u00edficamente a las funciones del profesional de \nenfermer\u00eda, se incluyen competencias transversales \nde UC6: Comunicaci\u00f3n y Relaci\u00f3n Interpersonal; \nUC7: Actitudes, Valores y Transferencia. Cada \u00edtem Figura 1: Diagrama de flujo para el screening y aleatorizaci\u00f3n de participantes.26\n2023/38 (4): 24-30M. Raquel Caballero et al. \nse valora con una escala tipo Likert con valores \nque van del 1 al 3 en funci\u00f3n de la autopercepci\u00f3n \ndel nivel de logro de adquisici\u00f3n y desempe\u00f1o de \nlas competencias (1 = Avanzado, 2 = Intermedio \ny 3 = B\u00e1sico). Para el estudio solo se emplearon \nla UC6, que consta de 13 \u00edtems, y la UC7, de 14 \n\u00edtems para la UC7. En funci\u00f3n de las puntuaciones \nen cada unidad competencial los sujetos pueden \ncategorizarse en funci\u00f3n de su nivel de competencia \no logro (avanzado, intermedio y b\u00e1sico), dividiendo \nla puntuaci\u00f3n obtenida en cada competencia por la \npuntuaci\u00f3n m\u00e1xima posible: nivel avanzado (13,0-\n42,0%), nivel intermedio (42,1-71,0%) y nivel b\u00e1sico \n(71,1-100,0%) para la UC6, y nivel avanzado (14,0-\n42,7%), nivel intermedio (42,8-71,5%) y nivel b\u00e1sico \n(71,6-100,0%) para la UC7. Esta herramienta es \nv\u00e1lida y fiable, cuenta con un \u00cdndice de validaci\u00f3n de \ncontenido (CVI) superior a 0,85 y un \u00cdndice Kappa \ntotal de 0,8318.\n- Covariables: se recogieron las siguientes variables \npara evaluar su influencia en la intervenci\u00f3n del \nestudio (adquisici\u00f3n de competencias): edad y sexo \nde todos los participantes, medio de acceso a la \nuniversidad (titulaci\u00f3n de acceso al grado, examen \nde acceso a la titulaci\u00f3n o similar), posesi\u00f3n de \notro t\u00edtulo universitario, situaci\u00f3n laboral actual (en el \n\u00e1mbito sanitario) y experiencia profesional previa en \nel \u00e1mbito sanitario. \nIntervenci\u00f3n. Los alumnos de enfermer\u00eda fueron \nreclutados y aleatorizados, tras su aceptaci\u00f3n en la \nparticipaci\u00f3n del estudio, entre noviembre y enero del \n2021. Los estudiantes fueron asignados aleatoriamente a \nun grupo control (simulaci\u00f3n tradicional) y otro grupo de \nintervenci\u00f3n (simulaci\u00f3n virtual) mediante una asignaci\u00f3n \naleatoria simple utilizando el programa SPSS versi\u00f3n 24 para \nWindows. Las covariables del estudio se recogieron antes \nde la intervenci\u00f3n y tras la inclusi\u00f3n de los participantes en \nel estudio. Antes y despu\u00e9s de la intervenci\u00f3n se evaluaron \nlas autopercepciones de competencias espec\u00edficas de \ncomunicaci\u00f3n y relaci\u00f3n interpersonal (UC6), y las de \nactitudes y trasferencia (UC7) mediante la escala ECOEnf. \nLa intervenci\u00f3n (m\u00e9todo de la realidad virtual) consisti\u00f3 en \nla visualizaci\u00f3n de 3 v\u00eddeos de casos de situaciones de \nposible violencia (separados por intervalos de 5 minutos), \na trav\u00e9s de gafas de realidad virtual. Al final del visionado \nde los v\u00eddeos los alumnos deb\u00edan reflexionar y responder \na una pregunta por video, con 3 opciones de respuesta \n(presentadas por los investigadores del estudio), debiendo \nseleccionar la respuesta m\u00e1s correcta de acuerdo con \nlas competencias del profesional ante cada una de las \n3 situaciones. Para la edici\u00f3n y proyecci\u00f3n de los v\u00eddeos \nse utiliz\u00f3 el programa Lumion. Los estudiantes que fueron \naleatorizados al grupo control recibieron los mismos casos \nde los videos, pero a trav\u00e9s de un documento escritos para \nla lectura. Ambas intervenciones abordaban las habilidades \nde comunicaci\u00f3n, relaci\u00f3n personal y actitudes, que deb\u00edan \nadquirir los estudiantes de enfermer\u00eda de cuarto curso.An\u00e1lisis estad\u00edstico\nLos resultados de las variables categ\u00f3ricas se \npresentaron en forma de frecuencias absolutas (n) \ny porcentajes (%). Las variables cuantitativas se \npresentaron como medias y desviaciones t\u00edpicas, o \nsolo medias. Para evaluar la validez del cuestionario \nse calcul\u00f3 el \u00edndice de validez de contenido (IVC) con \nlas respuestas de los alumnos y el \u00edndice Kappa. Las \ncaracter\u00edsticas de los participantes se compararon \nmediante la prueba de chi-cuadrado para las variables \ncateg\u00f3ricas y las pruebas T-Student (pareados e \nindependientes) y ANOVA univariados para las variables \ncuantitativas continuas. Se compararon los resultados \npre y postest por grupo de estudiantes, y entre \ngrupos. Se tomaron las variables sociodemogr\u00e1ficas \ncomo variables control para evaluar su efecto sobre \nlas puntuaciones de la escala ECOEnf despu\u00e9s de la \nintervenci\u00f3n, en cada uno de los grupos. Los resultados \nse consideraron estad\u00edsticamente significativos con un \nnivel de significaci\u00f3n p < 0,05. Todos los an\u00e1lisis de \nlos datos fueron efectuados mediante el programa \nSPSS versi\u00f3n 24 para Windows.\nConsideraciones \u00e9ticas. Este estudio fue aprobado \npor el Comit\u00e9 de \u00c9tica de la Universidad de Castilla \nla Macha. Los estudiantes que fueron voluntarios se \nconvocaron a una reuni\u00f3n de informaci\u00f3n en la que se \nfacilit\u00f3 a cada participante un documento describiendo el \nproyecto. Si los estudiantes deseaban participar, una vez \nque hab\u00edan comprendido la informaci\u00f3n, se les pidi\u00f3 que \nfirmaran un consentimiento por escrito. Este estudio se \nllev\u00f3 a cabo respetando los principios de investigaci\u00f3n \nbiom\u00e9dica de la declaraci\u00f3n de Helsinky. Se respet\u00f3 \nla confidencialidad y privacidad de su informaci\u00f3n en \ncumplimiento de la normativa vigente en materia de \nprotecci\u00f3n de datos personales. Los datos se ingresaron \nen bases de datos seguras y el acceso a los datos se \nrestringi\u00f3 a los investigadores. El an\u00e1lisis de datos fue \nlimitado para los prop\u00f3sitos de este estudio.\nResultados\nDatos sociodemogr\u00e1ficos\nRespecto a los datos sociodemogr\u00e1ficos, dentro del \ngrupo control la mayor\u00eda de los participantes ten\u00eda una \nedad inferior a 21 a\u00f1os (53%), eran mujeres (76%), \nhab\u00edan accedido a la universidad mediante prueba de \nacceso (76%), un 20% ten\u00eda otra titulaci\u00f3n de grado \ny la mayor\u00eda no compatibilizaban sus estudios con \ntrabajo (79%). En el grupo experimental la mayor\u00eda de \nlos estudiantes ten\u00edan menos de 21 a\u00f1os (51%), eran \nmujeres (82%), hab\u00edan accedido al grado a trav\u00e9s de una \nprueba de acceso (80%), no ten\u00edan otra titulaci\u00f3n (72%) \ny no se encontraban trabajando (93%). No se hallaron \ndiferencias estad\u00edsticamente significativas entre ambos \ngrupos en los datos sociodemogr\u00e1ficos (Tabla I).27\n2023/38 (4): 24-30Desarrollo de competencias profesionales para prevenir las agresiones a trav\u00e9s de la simulaci\u00f3n virtual en estudiantes de enfermer\u00eda: estudio experimental\nDiferencias intragrupos en las UC6 y UC7 de la \nescala ECOEnf\nEl presente estudio, realizado con las UC6 y UC7, se \nobtuvieron datos espec\u00edficos de validez de IVC de 0,92 y \n0,84, y de \u00edndice Kappa de 0,92 y 0,83, respectivamente. \nLos grupos fueron homog\u00e9neos en las puntuaciones \nbasales tanto en la UC6 (GC: 19,91\u00b14,93 vs GE: \n20,93\u00b15,67, p=0,36) como en la UC7 (GC: 19,76\u00b15,15 \nvs GE: 20,49\u00b15,15, p=0,50). \nSe compararon las puntuaciones antes y despu\u00e9s \nde la intervenci\u00f3n, sin observarse diferencias \nestad\u00edsticamente significativas en el grupo control, tanto \nen la UC6 (pre: 19,91\u00b14,93 vs post: 19,60\u00b14,91, \np=0,54), como en la UC7 (pre: 19,76\u00b15,15 vs post: \n19,84\u00b15,58, p=0,83). Respecto al grupo intervenci\u00f3n, \ntampoco se observaron diferencias antes-despu\u00e9s \nen la UC6 (pre: 20,93\u00b15,67 vs post: 20,22\u00b15,41, \np=0,21) y en la UC7 (pre: 20,49\u00b15,15 vs post: \n20,00\u00b15,18, p=0,32). Como se puede ver en la tabla \nII, al comparar las diferencias antes y despu\u00e9s de la \nintervenci\u00f3n intragrupo por nivel de logro (avanzado, \nintermedio y b\u00e1sico), solo se observaron diferencias \nestad\u00edsticamente significativas en el grupo control en el \nnivel avanzado (p=0,02). Finalmente, se analizaron las diferencias en las \npuntuaciones en cada una de las unidades \ncompetenciales despu\u00e9s de la intervenci\u00f3n ajustando \npor las variables sociodemogr\u00e1ficas, sin encontrase \ndiferencias estad\u00edsticamente significativas en ninguno de \nlos dos grupos (Tabla III).\nDiferencias entregrupos en las UC6 y UC7 \nde la escala ECOEnf\nAl comparar las diferencias entre grupos en el momento \ndespu\u00e9s de la intervenci\u00f3n, no se hallaron diferencias \nestad\u00edsticamente significativas ni en la UC6 (GC: \n19,60\u00b14,91 vs GI: 20,22\u00b15,41, p=0,57) ni en la UC7 \n(GC: 19,84\u00b15,58 vs GI: 20,00\u00b15,18, p=0,89).\nDiferencias entre grupos a las preguntas \nde los 3 casos cl\u00ednicos\nRespecto a las diferencias entre grupos en las respuestas \ncorrectas de los alumnos a las preguntas planteadas \npara cada uno de los casos, se hallaron diferencias \nentre grupos en el caso 1 (p=0,02), pero no en el caso \n2 (p=0,86) y en el caso 3 (p=0,16). Sin embargo, las \ndiferencias no se correspondieron a un mayor porcentaje \nde respuestas correctas (opci\u00f3n B, Figura 2) \nSubgrupo Grupo control  Grupo experimental  p-valor\n  (n = 45) (n = 45) \nEdad   \n    <21  24 (53%) 23 (51%) p=0,833\n    21-25 15 (32%) 21 (47%) \n    26-30 1 (4%) 0 (0%) \n    31-35 1 (4%) 0 (0%) \n    >40  4 (9%) 1 (2%) \nSexo     \n    Mujer 34 (76%) 37 (82%) p=0,438\n    Hombre 11 (24%) 8 (18%) \nTitulaci\u00f3n de acceso   \n    PAU 34 (76%) 36 (80%) p=0,612\n    FP 8 (18%) 7 (16%) \n    >25 a\u00f1os 2 (4%) 1 (2%) \n    >45 a\u00f1os 1 (2%) 1 (2%) \nPosesi\u00f3n de otro t\u00edtulo  n = 42 n = 44 \n    No   \n    Grado 32 (78%) 32 (72%) p=0,529\n    Diplomado 8 (20%) 10 (23%) \n  1 (2%) 2 (5%) \nTrabajo actual    \n    No 37 (82%) 42 (93%) p=0,108\n    Atenci\u00f3n hospitalaria 4 (10%) 0 \n    Geri\u00e1tricos 2 (4%) 0 \n    Pr\u00e1cticas enfermeria 2 (4%) 3 (7%) \nExperiencia profesional previa    \n    No 32 (71%) 40 (89%) p=0,245\n    <1 a\u00f1o 4 (9%) 4 (9%) \n    1-2 a\u00f1os 0 (0%) 1 (2%) \n    2-3 a\u00f1os 2 (4%) 0 \n    3-4 a\u00f1os 2 (4%) 0\n    5-10 a\u00f1os 2 (4%) 0 \n    >10 a\u00f1os 3 (8%) 0 Tabla I: Diferencias sociodemogr\u00e1ficas entre grupos control y experimental.28\n2023/38 (4): 24-30M. Raquel Caballero et al. \nSubgrupo Grupo control Grupo experimental\n   UC6   UC7   UC6   UC7\n  pre post p-valor pre post p-valor pre post p-valor pre post p-valor\nAvanzado 14,14  15,00  p=0,24  14,40  14,73  p=0,02  14,00  14,25  p= 0,59  15,25  15,31  p=0,79 \nIntermedio 22,33  21,37  p=0,16  21,97  22,03  p=0,91 22,21  21,86  p=0,61  23,04  22,75  p=0,62 \nB\u00e1sico 28*  31* -  36* 33* -  30,40 25,40  p=0,13  33* 18* - Tabla II: Diferencias (medias) antes despu\u00e9s en cada grupo (control y experimental) por nivel de logro.\n* Estos valores son resultado de una sola observaci\u00f3n y por tanto no se analizaron diferencias\nGrupo Grupo control Grupo experimental\nFactor UC6 UC7 UC6 UC7\n  Media\u00b1DT p-valor Media\u00b1DT p-valor Media\u00b1DT p-valor Media\u00b1DT ANOVA\nEdad (a\u00f1os) \n < 21 20,38\u00b14,85 p=0,19 19,96\u00b15,13 p=0,37 20,87\u00b15,23 p=0,34 20,35\u00b14,85 p=0,50\n 21-25 20,13\u00b15,06  21,20\u00b16,65  19,86\u00b15,57  19,90\u00b15,59 \n 26-30 -  -  -  - \n 31-35 -  -  -  - \n > 40 14,25\u00b11,89  15,25\u00b11,89  -  - \nSexo \n Femenino 20,03\u00b14,73 p=0,31 20,03\u00b15,67 p=0,70 20,49\u00b15,21 p=0,487 20,30\u00b15,21 p=0,41\n Masculino 18,27\u00b15,44  19,27\u00b15,58  19,00\u00b16,50  18,63\u00b15,18 \nTitulaci\u00f3n de acceso al grado \n Selectividad/ PAU o similar 20,09\u00b14,72 p=0,43 19,79\u00b15,37 p=0,52 21,25\u00b15,39 p=0,06 20,78\u00b15,30 p=0,09\n Formaci\u00f3n profesional 19,13\u00b15,99  21,50\u00b17,03  16,00\u00b13,01  16,29\u00b12,14 \n Acceso mayor de 25 a\u00f1os 14,50\u00b12,12  -  -  - \n Acceso mayor de 45 a\u00f1os -  -  -  - \nOtro t\u00edtulo universitario \n Diplomatura - p=0,25 - p=0,50 19,00\u00b17,07 p=0,515 19,00\u00b17,07 p=0,49\n Grado 17,29\u00b15,16  19,14\u00b17,58  21,80\u00b15,25  22,10\u00b15,47 \n No 20,09\u00b15,01  19,91\u00b15,40  19,68\u00b15,52  19,35\u00b15,14 \n Bachillerato 23,50\u00b13,54  24,50\u00b14,95  -  - \nTrabajo actual \nen el \u00e1mbito sanitario \n No 19,86\u00b14,91 p=0,08 19,86\u00b15,42 p=0,12 20,40\u00b15,53 p=0,62 20,12\u00b15,29 p=0,59\n S\u00ed, en atenci\u00f3n hospitalaria 16,75\u00b13,10  18,50\u00b16,61  -  - \n S\u00ed, en geri\u00e1tricos 14,50\u00b12,12  14,50\u00b10,71  -  - \n Pr\u00e1cticas de Enfermer\u00eda 25,50\u00b10,71  27,50\u00b10,71  16,50\u00b12,12  16,50\u00b12,12 \nExperiencia profesional previa \nen el \u00e1mbito sanitario (a\u00f1os)\n No tengo experiencia 19,67\u00b14,83 p=0,21 19,69\u00b15,43 p=0,14 20,50\u00b15,53 p=0,62 20,18\u00b15,10 p=0,61\n < 1 23,25\u00b15,56  23,75\u00b16,19  18,25\u00b14,65  19,50\u00b16,81 \n 1-2 -  -  -  - \n 3-4 -  -  -  - \n 5-10 -  -  -  - \n > 10 14,67\u00b12,08  15,33\u00b12,31  -  - Tabla III: Efectos de factores sociodemogr\u00e1ficos sobre las mediciones de UC6 y UC7 postest en el grupo experimental y control (n = 90).\n*Nota: se han eliminado los datos de 1 sola observaci\u00f3n\nFigura 2: Diferencia de la frecuencia de respuestas correctas (respuesta B) e incorrectas (A y C) a los 3 casos entre grupos (n = 90). 29\n2023/38 (4): 24-30Desarrollo de competencias profesionales para prevenir las agresiones a trav\u00e9s de la simulaci\u00f3n virtual en estudiantes de enfermer\u00eda: estudio experimental\nDiscusi\u00f3n \nLos resultados obtenidos a trav\u00e9s del trabajo de campo \nno permiten demostrar que la simulaci\u00f3n virtual utilizada \nen el grupo experimental con respecto al m\u00e9todo \ntradicional de simulaci\u00f3n mejore la adquisici\u00f3n de las UC6 \ny UC7. Aunque se observaron mejoras en los resultados \ndespu\u00e9s de la intervenci\u00f3n en el grupo experimental, \nrelacionados con un nivel de logro avanzado, para las \ndos UC, estas diferencias no fueron estad\u00edsticamente \nsignificativas. Por otro lado, no se observaron mejoras \ncuando se agruparon los datos por niveles, avanzado, \nintermedio y b\u00e1sico. Aunque se encontraron diferencias \nen la frecuencia de respuestas entre grupos en el caso \n1, pero no en el resto, estas diferencias no se debieron \na un mayor porcentaje de respuestas correctas, sino a \ndiferencias entre grupos en las respuestas incorrectas. \nPor tanto, con los datos obtenidos en nuestro estudio, \nno podemos decir que haya diferencias entre grupos en \nla variable independiente y, por tanto, nuestro estudio \nno permite apoyar la hip\u00f3tesis de que la simulaci\u00f3n \nvirtual sea superior a una simulaci\u00f3n basada en el \nuso de casos cl\u00ednicos escritos. En nuestra muestra, \nel hallazgo de equivalencias estad\u00edsticas entre los \ngrupos de intervenci\u00f3n, sobre todo en el momento \npostest, puede corresponderse con las caracter\u00edsticas \nde los participantes, siendo alumnos de cuarto a\u00f1o \nde Enfermer\u00eda, mayormente solo estudiantes y sin \nexperiencia laboral en el \u00e1mbito sanitario. Ello podr\u00eda haber \nobrado como condicionante de las autopercepciones \nacerca de la utilidad de ambos m\u00e9todos de intervenci\u00f3n \nsobre la formaci\u00f3n de competencias comunicacionales \ny actitudinales. \nA diferencia de nuestros resultados, los resultados \nobtenidos hasta el momento, de las evaluaciones \naplicadas, concluyen que existen diferencias \nsignificativas en el aprendizaje de los que usan alg\u00fan tipo \nde modelo simulado con relaci\u00f3n a quienes se les aplica \n\u00fanicamente el m\u00e9todo tradicional19. Estudios como los \nde Cuesta Cambra y Ma\u00f1as Viniegra20 y Levett-Jones \net al.21, la simulaci\u00f3n virtual favorece el desarrollo de las \ncompetencias profesionales, en especial del personal \nde Enfermer\u00eda.\nA pesar de ello, la investigaci\u00f3n en simulaci\u00f3n con \nrealidad virtual puede permitir trabajar aspectos que \nantes solo se pod\u00edan trabajar desde la pr\u00e1ctica con el \npaciente como son la humanizaci\u00f3n de los cuidados, la \nempat\u00eda, los aspectos emocionales etc. que podr\u00edan abrir \nun nuevo paradigma de aprendizaje en un entorno tan \ncambiante como el actual. Las t\u00e9cnicas de aprendizaje \na trav\u00e9s de realidad virtual pueden resultar un m\u00e9todo \nde aprendizaje interesante, ya que la realidad virtual \npermite la recreaci\u00f3n avanzada de un mundo en el que \nlos estudiantes pueden controlar e interactuar. Bajo este \nparadigma, el docente deja de ser la \u00fanica fuente de informaci\u00f3n en el aula, permitiendo un aprendizaje m\u00e1s \nactivo por parte del alumno. Es muy importante se\u00f1alar \nque el uso de recursos tecnol\u00f3gicos podr\u00eda ayudar en la \nmotivaci\u00f3n de los aprendizajes significativos en colegios \ny universidades. Adem\u00e1s, es importante unificar m\u00e9todos \ntradicionales con m\u00e9todos novedosos para avanzar \nmetodol\u00f3gicamente en las t\u00e9cnicas de los profesores y \nen el aprendizaje de los estudiantes.\nLimitaciones\nRespecto a las limitaciones del estudio, la muestra \nestuvo constituida solo por 90 estudiantes de cuarto \ngrado de enfermer\u00eda que, si bien se aproxima al tama\u00f1o \nde la poblaci\u00f3n de estudiantes de enfermer\u00eda, no tiene \nen cuenta el grueso de estudiantes de enfermer\u00eda \nde otros cursos, puede ser poco representativo de \nla poblaci\u00f3n general de estudiantes de enfermer\u00eda, y \npodr\u00eda estar ocultando resultados estad\u00edsticamente \nsignificativos. Por otro lado, el tiempo de seguimiento \nfue demasiado corto para evaluar completamente la \nadquisici\u00f3n de competencias en comunicaci\u00f3n. Por \ntanto, ser\u00eda interesante la implementaci\u00f3n de estudios \ncon un mayor tama\u00f1o muestral y mayor representaci\u00f3n \nde otros cursos del grado, con un tiempo de seguimiento \nde varios meses post-intervenci\u00f3n para ver si aparecen \ndiferencias a largo plazo.\nConclusiones\nCon los datos del presente estudio no se puede \ndemostrar que la simulaci\u00f3n mediante realidad virtual sea \nun m\u00e9todo de aprendizaje estrat\u00e9gico. En este sentido, \nse debe apostar por m\u00e1s estudios con muestras de \nestudiantes de enfermer\u00eda de mayor tama\u00f1o y un tiempo \nde seguimiento mayor. \nAgradecimientos\nagradecemos a los alumnos de la Facultad de \nEnfermer\u00eda de la Universidad de Castilla la Mancha por \nsu participaci\u00f3n en el proyecto.\nConflictos de inter\u00e9s\nNinguno.\nContribuciones de los autores\nLIMS y JVB han contribuido a la conceptualizaci\u00f3n \ndel trabajo y metodolog\u00eda; GM y RC han contribuido \na la escritura inicial del manuscrito; MGP y EC han \ncontribuido a la revisi\u00f3n y edici\u00f3n del manuscrito. Todos \nlos autores han hecho contribuciones sustanciales en \nel trabajo, incluyendo la conceptualizaci\u00f3n y dise\u00f1o del \nestudio, adquisici\u00f3n de datos, o an\u00e1lisis e interpretaci\u00f3n \nde los datos; escritura del manuscrito y revisi\u00f3n cr\u00edtica \nde su contenido y aprobaci\u00f3n final de la versi\u00f3n enviada.\nFinanciaci\u00f3n: Este trabajo de investigaci\u00f3n no ha \nrecibido ning\u00fan tipo de apoyo financiero espec\u00edfico de \ninstituciones p\u00fablicas, privadas o sin \u00e1nimo de lucro.30\n2023/38 (4): 24-30Desarrollo de competencias profesionales para prevenir las agresiones a trav\u00e9s de la simulaci\u00f3n virtual en estudiantes de enfermer\u00eda: estudio experimentalM. Raquel Caballero et al. \nReferencias\n1. Andr\u00e9s MC, Susana S, Andrea S, Luisa P , Raul M, Alberto CJ, et al. \nMaltrato a los profesionales de la salud. Rev M\u00e9dica Univ. 2016;12(2):1-11. \n2. Ministerio de Sanidad C y BS. Informe de agresiones a profesionales \ndel Sistema Nacional de Salud. 2019. \n3. Gabriel E, Acevedo M, L\u00f3pez De Neira J, Nassif LN. Violencia \nocupacional hacia los trabajadores de salud de la ciudad de C\u00f3rdoba \n[Internet]. 2010. Available from: http://lildbi.fcm.unc.edu.ar/lildbi/tesis/\nfaria_maria_alejandra.pdf\n4. Serrano M, Ib\u00e1\u00f1ez M. La prevenci\u00f3n de las situaciones de impacto \nemocional en el ambiente laboral. Estudio te\u00f3rico y an\u00e1lisis de su \nincidencia en el personal sanitario de la comunidad aut\u00f3noma de \nEuskadi-Espa\u00f1a. Trab y Soc. 2015;25:463-92. \n5. Cai J, Qin Z, Wang H, Zhao X, Yu W, Wu S, et al. Trajectories of \nthe current situation and characteristics of workplace violence among \nnurses: a nine-year follow-up study. BMC Health Serv Res. 2021 \nNov;21(1):1220. \n6. (SAP) SA de P . Violencia hacia el Equipo de Salud en el \u00e1mbito \nlaboral. Manual de Prevenci\u00f3n y Procedimientos. 2014. \n7. Arimany-Manso J, Clos-Mas\u00f3 D, G\u00f3mez-Dur\u00e1n EL. [Attacks on \nhealth professionals]. Vol. 48, Atencion primaria. 2016. p. 147-8. \n8. Mart C. Agresiones a profesionales sanitarios. procedimiento de \nprevenci\u00f3n y actuaci\u00f3n. :308-48. \n9. Gimenez C, Marcela V, Martigani I, Dolores M, Marta J, Guillermo LM, \net al. Uso de simuladores en la ense\u00f1anza de las Ciencias de la Salud \nPrograma. 2014. \n10. L\u00f3pez JG, Spirko L V. Simulation, a teaching aid for medical \neducation . Simulaci\u00f3n, Herram para la Educ m\u00e9dica [Internet]. \n2007;23(1):79-95. Available from: http://www.scopus.com/inward/\nrecord.url?eid=2-s2.0-78349288450&partnerID=40&md5=e4ff679e6\n595a67a5f92f70e0a4b3e4a\n11. Komprood SR. Nursing student attitudes toward oncology \nnursing: an evidence-based literature  review. Clin J Oncol Nurs. 2013 \nFeb;17(1):E21-8. \n12. Padilha JM, Machado PP , Ribeiro A, Ramos J, Costa P . Clinical \nVirtual Simulation in Nursing Education: Randomized Controlled Trial. J \nMed Internet Res. 2019 Mar;21(3):e11529. 13. Liaw SY, Ooi SW, Rusli KD Bin, Lau TC, Tam WWS, Chua WL. \nNurse-Physician Communication Team Training in Virtual Reality Versus \nLive  Simulations: Randomized Controlled Trial on Team Communication \nand Teamwork Attitudes. J Med Internet Res. 2020 Apr;22(4):e17279. \n14. P\u00e9rtegas S, Pita Fern\u00e1ndez S. La fiabilidad de las mediciones \ncl\u00ednicas: el an\u00e1lisis de concordancia para variables num\u00e9ricas Pita. Aten \nPrimaria en la Red. 2004;(1995):1-11. \n15. Mukunda S, Shustak RJ, Szyld D, Moral I del, Maestre JM. \nReflexiones sobre una rotaci\u00f3n educativa en simulaci\u00f3n m\u00e9dica. FEM \nRev la Fund Educ M\u00e9dica. 2015;18(3):169-71. \n16. G\u00f3mez del Pulgar Garc\u00eda-Madrid M, Pacheco del Cerro E, Gonz\u00e1lez \nJurado MA, Fern\u00e1ndez Fern\u00e1ndez MP , Beneit Montesinos JV. Dise\u00f1o \ny validaci\u00f3n de contenido de la escala \u201cECOEnf\u201d para la evaluaci\u00f3n \nde competencias enfermeras. Vol. 26, Index de Enfermer\u00eda . scieloes ; \n2017. p. 265-9. \n17. Boletin Oficial del Estado. Orden CIN/2134. Orden CIN/2134/2008, \n3 julio por la que se Establ los requisitos para la Verif los t\u00edtulos \nUniv Of que habiliten para el Ejerc la profesi\u00f3n Enfermero [Internet]. \n2008;174:31680\u20133. Available from: https://www.boe.es/boe/\ndias/2008/07/19/pdfs/A31680-31683.pdf\n18. G\u00f3mez del Pulgar Garc\u00eda Madrid M, Hern\u00e1ndez-Iglesias S, Crespo \nCa\u00f1izares A, P\u00e9rez Mart\u00edn AM, Gonz\u00e1lez Jurado MA, Beneit Montesinos \nJV. Fiabilidad de una escala para la evaluaci\u00f3n de competencias \nenfermeras: estudio de concordancia. Educ M\u00e9dica [Internet]. \n2019;20(4):221-30. Available from: https://www.elsevier.es/es-revista-\neducacion-medica-71-articulo-fiabilidad-una-escala-evaluacion-\ncompetencias-S1575181318303450\n19. Quail M, Brundage SB, Spitalnick J, Allen PJ, Beilby J. Student \nself-reported communication skills, knowledge and confidence across  \nstandardised patient, virtual and traditional clinical learning environments. \nBMC Med Educ. 2016 Feb;16:73. \n20. Cuesta Cambra DU, Ma\u00f1as Viniegra L. Integraci\u00f3n de la realidad \nvirtual inmersiva en los Grados de Comunicaci\u00f3n. Rev ICONO14 Rev \ncient\u00edfica Comun y Tecnol emergentes. 2016;14(2):1. \n21. Levett-Jones T, Bowen L, Morris A. Enhancing nursing students\u2019 \nunderstanding of threshold concepts through the use  of digital stories \nand a virtual community called \u201cWiimali\u201d. Nurse Educ Pract. 2015 \nMar;15(2):91-6. 31\n2023/38 (4): 31-40ORIGINAL\nChallenges of Adhering to Hand Washing Protocols \nas a COVID-19 Prevention Measure Among Slum Dwellers \nin Nairobi, Kenya \nDesaf\u00edos de la adhesi\u00f3n a los protocolos de lavado de manos como medida de \nprevenci\u00f3n del COVID-19 entre los habitantes de los barrios marginales de Nairobi, Kenia  \nKelly Oluoch1      , John Muthuka2      , Francis Wambura3      , Muthoka Mirrium4      , \nEdwin Dede5\n1. Chief Executive Officer, Kenya Medical Training College, Nairobi, Kenya.\n2. Department of Health Education & Promotion, Kenya Medical Training College, Nairobi Campus, Kenya.\n3. Department of Health Education & Promotion, Kenya Medical Training College, Nyahururu Campus, Kenya.\n4. Business and Economics Department, Daystar University, Kenya\n5. Health Services Department, Kenya Medical Training CollegeeISSN 2255-0569\nReceived: 9 - I - 2023\nAccepted: 12 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.31Corresponding author\nJohn Muthuka   \nE-mail: johnmuthuka@gmail.com / koluoch@kmtc.ac.ke  \nAbstract \nIn an effort to mitigate the outbreak of COVID-19, many countries have imposed drastic lockdown, movement control or shelter \nin place orders on their residents. The effectiveness of these mitigation measures is highly dependent on cooperation and \ncompliance of all members of society. The knowledge, attitudes and practices people hold toward the disease play an integral \nrole in determining a society\u2019s readiness to accept behavioral change measures from health authorities. Urban informal settlements \nare characterized by large populations occupying a small land area. Housing in informal settlements is close to each other with \nmost households making do with poor quality and erratic water supply. How challenges of sanitation in slum dwellings in Kenya \naffect spread of COVID 19 is not known. Social distancing, wearing masks and hand washing among other measures are known \nto reduce the spread of COVID 19. Although access to hand-washing facilities with soap and water is near universal in High \nIncome Countries, the same is not true for Low Income Countries. The purpose of this survey was to assess the challenges of \nhand washing as a covid-19 prevention measure among urban slum populations in Kenya. Key information of practices on hand-\nwashing practices among this sub-population will inform the ministry of health, its collaborators and interested health sectors, on \nareas of improvement. A descriptive cross-sectional survey for quantitative data was be used. Solvins formula for calculation of a \nsample size was used. Properly designed data collection tool was used in collecting the primary data on hand washing to prevent \ntransmission of COVID-19 with a combination of face-to-face interviews. A pre-test of the data collection tool prior to pilot data \ncollection was performed to ascertain validity and reliability. Data was analyzed using descriptive statistics such as frequencies, \nmean and standard deviation and displayed using tables and figures. Inferential statistics for predictive associations between \nvariables was performed. In the analysis, data was combined to allow reporting on an array of issues. The results indicate salient \nchallenges on hand-washing and show an acceptable level of knowledge in mitigating COVID-19 through hand-washing and \nhygiene and, highlight the importance of consistent messaging from local health authorities and the government as well as the need \nfor tailored community health education and sensitization programs to improve levels of knowledge, attitudes and practices mostly \non handwashing as this pandemic may be there for some time or there could be possible upsurge in future.\nKeywords: Covid-19, Hand washing, Slum dwellers, Challenges. ID ID ID ID\nID32\n2023/38 (4): 31-40Kelly Oluoch et al. \nResumen\nEn un esfuerzo por mitigar el brote de COVID-19, muchos pa\u00edses han impuesto a sus residentes \u00f3rdenes dr\u00e1sticas de bloqueo, \ncontrol de movimientos o confinamiento. La eficacia de estas medidas de mitigaci\u00f3n depende en gran medida de la cooperaci\u00f3n \ny el cumplimiento de todos los miembros de la sociedad. Los conocimientos, las actitudes y las pr\u00e1cticas que la gente tiene hacia \nla enfermedad desempe\u00f1an un papel integral en la determinaci\u00f3n de la disposici\u00f3n de una sociedad a aceptar las medidas de \ncambio de comportamiento de las autoridades sanitarias. Los asentamientos urbanos informales se caracterizan por tener grandes \npoblaciones que ocupan una peque\u00f1a superficie de terreno. Las viviendas de los asentamientos informales est\u00e1n muy cerca \nunas de otras y la mayor\u00eda de los hogares se conforman con un suministro de agua de mala calidad y err\u00e1tico. No se sabe c\u00f3mo \nafectan los problemas de saneamiento en las viviendas de los barrios marginales de Kenia a la propagaci\u00f3n de COVID 19. Se \nsabe que el distanciamiento social, el uso de mascarillas y el lavado de manos, entre otras medidas, reducen la propagaci\u00f3n del \nCOVID 19. Aunque el acceso a las instalaciones para lavarse las manos con agua y jab\u00f3n es casi universal en los pa\u00edses de renta \nalta, no ocurre lo mismo en los pa\u00edses de renta baja. El objetivo de esta encuesta era evaluar los retos del lavado de manos como \nmedida de prevenci\u00f3n del COVID 19 entre las poblaciones de los barrios marginales urbanos de Kenia. La informaci\u00f3n clave sobre \nlas pr\u00e1cticas de lavado de manos entre esta subpoblaci\u00f3n informar\u00e1 al ministerio de salud, a sus colaboradores y a los sectores \nsanitarios interesados, sobre las \u00e1reas de mejora. Se utiliz\u00f3 una encuesta transversal descriptiva para obtener datos cuantitativos. \nSe utiliz\u00f3 la f\u00f3rmula de Solvins para calcular el tama\u00f1o de la muestra. Se utiliz\u00f3 una herramienta de recopilaci\u00f3n de datos \nadecuadamente dise\u00f1ada para recoger los datos primarios sobre el lavado de manos para prevenir la transmisi\u00f3n del COVID-19 \ncon una combinaci\u00f3n de entrevistas cara a cara. Se realiz\u00f3 una prueba previa de la herramienta de recopilaci\u00f3n de datos antes de \nla recopilaci\u00f3n de datos piloto para determinar la validez y la fiabilidad. Los datos se analizaron mediante estad\u00edsticas descriptivas \ncomo las frecuencias, la media y la desviaci\u00f3n est\u00e1ndar, y se presentaron mediante tablas y figuras. Se realiz\u00f3 una estad\u00edstica \ninferencial para la predicci\u00f3n de asociaciones entre variables. En el an\u00e1lisis se combinaron los datos para poder informar sobre \nuna serie de cuestiones. Los resultados indican los desaf\u00edos m\u00e1s destacados en materia de lavado de manos y muestran un nivel \naceptable de conocimientos para mitigar la COVID-19 mediante el lavado de manos y la higiene, y destacan la importancia de que \nlas autoridades sanitarias locales y el gobierno env\u00eden mensajes coherentes, as\u00ed como la necesidad de programas de educaci\u00f3n \nsanitaria y sensibilizaci\u00f3n de la comunidad adaptados para mejorar los niveles de conocimientos, actitudes y pr\u00e1cticas, sobre todo \nen materia de lavado de manos, ya que esta pandemia puede durar alg\u00fan tiempo o podr\u00eda recrudecerse en el futuro.\nPalabras clave: Covid-19, lavado de manos, habitantes de barrios marginales, desaf\u00edos.\nIntroduction\nThe coronavirus disease 2019 (COVID-19) emerged \nin Wuhan, China at the end of 2019. Since then, it \nhas spread in many countries and has been declared \na global pandemic by the World Health Organization \n(WHO). To date, there are more than 3,343,500 people \nhave died from coronavirus1,2. Lockdown measures were \nperceived as necessary to curb the spread of the virus as \nrapid human-to-human transmission occurred and much \nabout the virus remained unknown3. Due to the obscurity \nof this novel virus, there has been a lot of confusion \nand misunderstanding about the virus itself, how it can \nspread and the necessary precautions that should be \ntaken to prevent infection. This becomes increasingly \nchallenging with the vast amount of misinformation and \ndisinformation shared on social media that is clouding \npeople\u2019s understanding of COVID-194.\nIn Kenyan context, as pertains the Corona Virus \npandemic, from 3 January 2020 to 5:33pm CEST, 7 \nJuly 2021, there have been 186,453 confirmed cases \nof COVID-19 with 3,697 deaths, reported to WHO. As \nof 5 July 2021, a total of 1,417,100 vaccine doses \nhave been administered (WHO, 2021). Generally, \nthe WASH situation in the urban slums is below the \nminimum standard recommended by the World Health \nOrganization (WHO)5. In Kenyan Nairobi slums, only 22 percent of households in Nairobi has water connections, \nwhile 75 percent accesses water through water vendors \nwho overcharge, making slum dwellers pay more for their \nwater than people living in middle- or high-income areas. \nThe provision of sanitary services is also inadequate (UN-\nHabitat & Slum Upgrading Program).\nIn the context of waste management and practices, \nslums and squatter settlements areas are increasingly \nexperiencing difficulties due to ever-increasing gap \nbetween generation, accumulation and removal. \nThe solutions for waste management problems thus \ncontinues to compromise general standards of required \nhygiene. This perceived typical phenomenon in slums \nonly does it not affect health of the dwellers but also, \nother arms of hygiene especially, water and sanitation.\nThe knowledge, attitudes and practices (KAP) toward \nCOVID-19 play an integral role in determining a society\u2019s \nreadiness to accept behavioral change measures \nfrom health authorities. KAP studies provide baseline \ninformation to determine the type of intervention that \nmay be required to change misconceptions about the \nvirus. Assessing the KAP related to hand washing in \nan effort to curb the spread of COVID-19 among the \nperceived vulnerable groups defined by the social 33\n2023/38 (4): 31-40Challenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure Among Slum Dwellers in Nairobi, Kenya\neconomic status, the slum dwellers, this would be \nhelpful to provide better insight to address poor \nknowledge about the disease and the development of \nfurther or harnessing the current preventive strategies \nand health promotion programs. Among the lessons \nlearned from the SARS outbreak is that knowledge and \nattitudes are associated with levels of panic and emotion \nwhich could further complicate measures to contain \nthe spread of the disease6. The survey also gives a \ngeneral picture of informal settlement population\u2019s \nCOVID-19 prevention practices and this can better \nprepare the government to address future health crises \ninvolving infectious diseases using similar approach for \nCOVID-19 prevention. The results of this pilot study are \nimportant to inform future efforts focusing on a broad \nscope approach with an aim of societal readiness to \ncomply with pandemic control measures.\nSurvey Methodology\nThe data tool and collection\nA new data entry form was developed and validated after \nthe first was found to have some missing variables to \ninform the survey objectives. A mixed method of both \nqualitative and quantitative approach was utilized to \nachieve the preliminary objectives of this pilot study. \nA survey was most appropriate as it allowed large \npopulations to be assessed with relative ease7. In this \nstudy, a cross-sectional survey was deemed most \nappropriate to gather information on COVID-19 for \nthe informal settlement context. Data collection was \nperformed face to face for this pilot study using a KAP \nmodel to collect data among slum dwellers in selected \nslums in Nairobi namely; Kibra and Mukuru kwa Njenga. \nEthically, as it should be in a research quest dealing \nwith human subjects, utmost consent to interview the \nparticipants was sought and, considering the fact that \nit was still in COVID-19 era, measures are put in place \nto ensure that there was no risk of compromising the \nparticipants\u2019 health more so, contracting the virus. Masks \nwere provided to all research assistants and the chief \ninvestigators as well as hand sanitizers. It was also \nparamount that, time spent with a specific participant \nwas as minimal as possible.\nThe pilot sample size and the Sampling Procedure\nA cluster stratified sampling technique was used to \ndetermine the sample size convenient for the pilot study \nin the context of the of the chosen study sites\u2019 population \nsize as below, and with a 50% of the proportionate \nallocated population as shown below. Simple random \nsampling was then used to select individual participants\ni. Sample size in Mukurukwa Njenga slum which has \n300,000 slum dwellers: Proportionate Allocation= Number \nof elements selected = 300,000/ 1,250,000*400 = 96ii. Sample size in Kibera slum which has 250,000 slum \ndwellers: Proportionate Allocation= Number of elements \nselected = 250,000/ 1,250,000*400 = 80\nTherefore, we used 162 participants for this pilot study \nafter some 14 questionnaires were found to be improperly \nfilled during data collection. The forms / data collection \ntools were distributed to selected participants for filling \nvia self-administered questionnaire approach with close \nsupervision by research team members to ensure valid \ninformation was completed. Where applicable, face to \nface interviews were also conducted Primary data on \nhand washing was collected using a knowledge, attitude, \nand practices questionnaire tool on their influence on hand \nwashing. This tool was convenient, timely and financially.\nThe thematic areas of pilot data collection\nWith a view of achieving the objectives of this study, \ndata from primary sources was used. The primary data \nconsisted of knowledge, attitude and practices on hand \nwashing, water station services and utilization of the existing \nhand-washing equipment for COVID 19 prevention. Major \nissues to be examined on the set hand washing stations \nimprovised by several organizations including KMTC \nincluded; accessibility, reliability, quality and quantity and \nsustainability of the water and sanitation services.\nThe data collection tool\nThe questionnaire consisted of four main themes: 1) \ndemographics, which surveyed participants\u2019 socio-\ndemographic information, including gender, age, slum \nof residence, religion, marital status, occupation, and \nhousehold size; 2) challenges of hand washing as a \nCOVID-19 prevention measure 3) knowledge about \nCOVID-19; 3) knowledge, attitude and practice of hand \nwashing as a COVID-19 prevention measure. The survey \nwas offered in the English and translation to Kiswahili by \nthe data collection team. This approach was used to \nensure linguistic and conceptual equivalence.\nThe Pilot Data entry and Analysis\nData entry into the SPSS started on 5th April 2021 for one \nweek and this was followed by data analysis and report \ngeneration for the pilot survey.\nThroughout the period of the pilot testing, the approach \nvery little amendments mostly on the timing of data \ncollection and the best way to harmoniously retrieve \ninformation from the study population. The information \ngathered was optimum utilized to address the pertinent \nobjective of the pilot study as well as the preliminary \nresults to inform the broad scope approach for the main \nstudy was successfully backed up.\nData was analyzed using descriptive statistics such as \nfrequencies, mean and standard deviation and displayed \nusing tables and figures. Inferential statistics for predictive \nassociations between variables was conducted. In the 34\n2023/38 (4): 31-40Kelly Oluoch et al. \nanalysis, data from survey was combined to allow reporting \non the objectives of the study. Because questionnaires \nare typically short, analysis was completed quickly after \ndata gathering, and the report was prepared prior to \ndissemination to KMTC and UN-Habitat.\nResults\nPre-testing data collection tool\nPre-testing measured the reaction of the selected group of \nindividuals and helped in establishing whether the priority \naudience would easily provide information using the then \ncurrent components of the data collection tool - usually \nwhether the draft materials understandable, believable \nand appealing. On the same approach, we ascertained \nthe feasibility of using the same tool in it\u2019s the then format. \nWe were able to eliminate some few components which \nwere overlapping especially in collecting a string type \nqualitative data as would be in SPSS analysis. This was \ndone at section 2 and 3 of data collection.  \nThe Pilot study basic report\nDemographic Characteristics\nA total of 162 participants participated in the study. Out of \nthe total, the most of participants were between the ages \nof 25 - 34 years 65 (40.1%), with only 5 (3.1%) being \nover the age of 45 years. The gender of the participants \nwas closely the same at Male, 80 (49.4%) and Female \n82 (50.6%), while most were Christians 123 (75.9%) the \nhousehold size with majority was at 1-5, 93 (57.4%) as \nper the number of family members (Table I).  \nAssessment of Challenges of hand washing as \na COVID-19 prevention measure with selected \ndemographic characteristics using a contingency \ncoefficient With six questions requiring a yes or a no answer, together \nwith five statements on a Likert scale of 1 to 5 ascertaining \nthe possible challenges with respect to specific \ndemographic and related population characteristic, the \npilot study established that, the symmetric measures \ncontingency coefficients generated were far from zero \nindicating a level of dependence.  The frequency table \nbelow (Table II) demonstrate the cumulative responses \nto explain the proportions of specific challenges among \nthe participants. On this note, over 50% of respondents \nindicated that challenges where a norm in the slums with \ngreater percentage reporting \u2018no\u2019 on; lack of access to \nalcohol-based hand rub, 112 (69.6%), lack of sufficient \nwash-stations 10 (64.0%) and, lack of adequate \nwater and soap supply 116 (71.6%) and 110 (67.9%) \nrespectively.\nThe Likert scale of 1-5 defining; 1=very low extent, \n2=Low extent, 3=moderate extent, 4=high extent and \n5=very high extent demonstrated that, challenges\u2019 extent \nwas above 60%, as depicted in table III below with each \nsited challenge demonstrating a mean score of above \n3, equivalent to 60%, this being similar to the responses \ngiven in terms of \u2018yes\u2019 or \u2018no\u2019 above.\nKnowledge, attitude and practices of hand washing \nas a COVID-19 Prevention measure\nKnowledge on Handwashing as a COVID-19 \nControl Measure\nFour broad questions were used to measure knowledge \non the hand washing as a COVID-19 control measure. \nMost participants acknowledged having known of the \nCOVI-19 control measures from government directed \nTV adverts and the normal TV programs 54(33.3%) and \n61(37.7%) respectively with other sources of information \n  Frequency Percent Valid Percent Cumulative Percent\nEducation level\nValid Primary level 26 16.0 16.0 16.0\n Secondary level 78 48.1 48.1 64.2\n Tertiary level 58 35.8 35.8 100.0\n Total 162 100.0 100.0 \nSex of the participant\nValid Male 80 49.4 49.4 49.4\n Female 82 50.6 50.6 100.0\n Total 162 100.0 100.0 \nSize of household\nValid 1-5 93 57.4 57.4 57.4\n 6- 10 62 38.3 38.3 95.7\n 11 and above 7 4.3 4.3 100.0\n Total 162 100.0 100.0 \nAge of participant\nValid 18 \u2013 24 years 57 35.2 35.2 35.2\n 25 \u2013 34 years 65 40.1 40.1 75.3\n 35 \u2013 44 years 35 21.6 21.6 96.9\n 45 + years 5 3.1 3.1 100.0\n Total 162 100.0 100.0 Table I: Key participants\u2019 demographic characteristics.35\n2023/38 (4): 31-40Challenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure Among Slum Dwellers in Nairobi, Kenya\nrecording lower percentages (Table IV). The average \nknowledge score for participants was above average \nbetween 1.0556 and 4.1728 on several knowledge \nscores (Table V), with majority being aware that, poor \nhand washing practices can further enhance the spread \nof corona virus in your community 154 (95.1%) (Table VI). The overall correct answer rate of the knowledge \nquestions was above 60% while the range of correct \nanswer rates for all participants were between 50 to 100%. \nMost participants know that hand washing prevents \ncorona spread 134 (82.7%) (Table VII) representing an \nacceptable level of knowledge on COVID-19.\nN Valid 162 161 162 161 159 161\n Missing 0 1 0 1 3 1\nMean  3.1481 2.9255 3.4074 3.3292 3.5723 3.4783\nSum  510.00 471.00 552.00 536.00 568.00 560.00Distance to \nhand washing \nstation from the \nhouse affects my \nfrequency of hand \nwashingStatistics\nConsistency of \nWater supplyCrowding at hand \nwashing stationLack of soap at \nhand washing \nstationHigh cost of water \nand soapPoor accessibility \nto the water points/\nstationsTable III: Extent of challenges measured on the mean of a Likert scale of 1 to 5.  Frequency Percent Valid Percent Cumulative Percent\nHave you received any training in hand hygiene during this COVID period?\nValid yes 83 51.2 51.2 51.2\n no 78 48.1 48.1 99.4\n 3.00 1 .6 .6 100.0\n Total 162 100.0 100.0 \nDo you easily access alcohol-based hand rub for hand hygiene?\nValid yes 49 30.2 30.4 30.4\n no 112 69.1 69.6 100.0\n Total 161 99.4 100.0 \nIs there sufficient hand washing points where you live?\nValid yes 57 35.2 35.4 35.4\n no 103 63.6 64.0 99.4\n 3.00 1 .6 .6 100.0\n Total 161 99.4 100.0 \nMissing System 1 .6  \nTotal  162 100.0  \nThe hand washing points and are accessible within \u00e0 100 Meters\nValid yes 82 50.6 50.6 50.6\n no 80 49.4 49.4 100.0\n Total 162 100.0 100.0 \nHand Washing stations have adequate water supply\nValid yes 46 28.4 28.4 28.4\n no 116 71.6 71.6 100.0\n Total 162 100.0 100.0 \nHand washing points have adequate supply of soap\nValid yes 51 31.5 31.5 31.5\n no 110 67.9 67.9 99.4\n 3.00 1 .6 .6 100.0\n Total 162 100.0 100.0 Table II: Challenges associated with hand-washing and hygiene in COVI-19 Prevention.\nN Valid 160 162 160 162 162\n Missing 2 0 2 0 0\nMean  1.6125 1.0556 1.9938 3.9321 4.1728\nStd. Error of Mean .06515 .02006 .10877 .08718 .08006\nStd. Deviation .82407 .25538 1.37588 1.10968 1.01895Statistics\nI know that hand \nwashing prevents \ncorona spreadI basically know about \nprinciples of hand \nwashing to prevent \ncorona spreadWhat do you think can \nhappen in future as \nregards corona spread \nwith improper hand \nwashing?Do you think poor hand \nwashing practices can \nfurther enhance the \nspread of corona virus \nin your community?What do you think can \nhappen/happens due to \nimproper hand washing \nin terms of health?Table IV: Source of information on COVID-19 Control protocol.36\n2023/38 (4): 31-40Kelly Oluoch et al. \n  Frequency Percent Valid Percent Cumulative Percent\nDo you think poor hand washing practices can further enhance the spread of corona virus in your community?\nValid yes 154 95.1 95.1 95.1\n no 7 4.3 4.3 99.4\n 3.00 1 .6 .6 100.0\n Total 162 100.0 100.0 \nI know that hand washing prevents corona spread\nValid Strongly Disagree 8 4.9 4.9 4.9\n Disagree 2 1.2 1.2 6.2\n Neutral 18 11.1 11.1 17.3\n Agree 60 37.0 37.0 54.3\n Strongly Agree 74 45.7 45.7 100.0\n Total 162 100.0 100.0Table V: Knowledge assessment by use of Likert scale mean and Proportions on a \u2018yes\u2019 or no and by Likert scale on knowledge score.\n  Frequency Percent Valid Percent Cumulative Percent\nValid Government TV Ads 54 33.3 33.3 33.3\n Government sms 16 9.9 9.9 43.2\n TV programs 61 37.7 37.7 80.9\n Friends 8 4.9 4.9 85.8\n Acquaintances/Neighbors 5 3.1 3.1 88.9\n Other family members 5 3.1 3.1 92.0\n Social media (twitter, text, Facebook etc.)  5 3.1 3.1 95.1\n Internet 1 .6 .6 95.7\n Work colleagues 2 1.2 1.2 96.9\n Church/ Worship Centre 5 3.1 3.1 100.0\n Total 162 100.0 100.0 Table VI: .\n  Frequency Percent Valid Percent Cumulative Percent\nTo what extent are you satisfied about hand washing behavior in your community?\nValid Very dissatisfied 29 17.9 17.9 17.9\n Dissatisfied 78 48.1 48.1 66.0\n Satisfied 37 22.8 22.8 88.9\n Very satisfied 17 10.5 10.5 99.4\n 5.00 1 .6 .6 100.0\n Total 162 100.0 100.0 \nDoes it concern you how hand washing is practiced to prevent corona spread in your community?\nValid yes 138 85.2 85.2 85.2\n no 22 13.6 13.6 98.8\n 5.00 2 1.2 1.2 100.0\n Total 162 100.0 100.0 \nHow interested would you try to mitigate poor hand washing behavior in your community?\nValid Very un-interested 12 7.4 7.4 7.4\n Un-interested 18 11.1 11.1 18.5\n Interested 92 56.8 56.8 75.3\n Very interested 40 24.7 24.7 100.0\n Total 162 100.0 100.0 \nHow important do you regard hand washing?\nValid Not important 8 4.9 4.9 4.9\n Partially Important 20 12.3 12.3 17.3\n Important 127 78.4 78.4 95.7\n Not important 7 4.3 4.3 100.0\nDo you follow the guidelines indicating that you should wash your hand regularly\nValid yes 141 87.0 87.0 87.0\n no 21 13.0 13.0 100.0\n Total 162 100.0 100.0Table VII: Attitude on Handwashing and hygiene as a covid-19 Control Measure.Attitude on Handwashing and hygiene as a covid-19 \nControl Measure\nParticipants were asked a question guided by three \nattitude rating in assessment of attitudes. The question \nasked whether or not it concerns them how hand washing \nis practiced to prevent corona spread in your community \nand the rating of attitude was on; To what extent they were \nsatisfied about hand washing behavior, how interested would they try to mitigate poor hand washing behavior \nand how important they regard hand washing.\nFor the first question, a majority of participants 138 (85.2%) \nwere concerned with how hand washing was being \npracticed. Even so, 66 % of participants were unsatisfied \nwith the handwashing practices, while 81.5 agreed that \nthey would mitigate poor handwashing practices and \n74.8% regarded hand-washing as important (Table VII).37\n2023/38 (4): 31-40Challenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure Among Slum Dwellers in Nairobi, Kenya\n  Frequency Percent Valid Percent Cumulative Percent\nDo you remind other people to properly wash their hands when you see them not doing it properly or not at all?\nValid yes 127 78.4 78.4 78.4\n no 35 21.6 21.6 100.0\n Total 162 100.0 100.0 \nDo you think that there are better practices that could be adopted in ensuring hand sanitation in your community by the government based on the \nnature of your settlement, the slum?\nValid yes 121 74.7 74.7 74.7\n no 41 25.3 25.3 100.0\n Total 162 100.0 100.0 Table VIII: Assessment of Practices of Hand-washing as a covid-19 Control Measure.Assessment of Practices of Hand-washing as a \ncovid-19 Control Measure\nPractices toward COVID-19 were measured using \nthree questions enquiring on: 1) following the guidelines \nindicating that they should wash their hand regularly 141 (87.0%), 2) reminding other people to properly wash their \nhands when not doing it properly or not at all 127 (78.4%) \nand 3) whether there are better practices that could be \nadopted in ensuring hand hygiene in community by the \ngovernment based on the nature settlement, the slum. \n121(74.7%) (Table VIII). \nTable IX: Knowledge as measured by Education level (ANOVA).\nDo you think poor hand washing practices  Between Groups\ncan further enhance the spread of corona virus  Within Groups\nin your community? Total\nI basically know about principles of hand  Between Groups\nwashing to prevent corona spread Within Groups\n Total\nI know that hand washing prevents corona spread Between Groups\n Within Groups\n TotalANOVA\n Sum of Squares df Mean Square F Sig.\n .014 2 .007 .107 .898\n 10.486 159 .066  \n 10.500 161   \n 7.544 2 3.772 3.145 .046\n 190.709 159 1.199  \n 198.253 161   \n 2.705 2 1.353 1.308 .273\n 164.455 159 1.034  \n 167.160 161   \nTable X: Correlation between Education level and the proper hand-washing practices among the participants.\n**. Correlation is significant at the 0.01 level (2-tailed).Education level Pearson Correlation 1 -.105 -.041 -.110\n Sig. (2-tailed)  .186 .600 .163\n N 162 162 162 162\nDo you think that there are better   Pearson Correlation -.105 1 .108 .325**\npractices that could be adopted  Sig. (2-tailed) .186  .170 .000\nin ensuring hand sanitation in your   N 162 162 162 162\ncommunity by the government \nbased on the nature \nof your settlement, the slum? \nDo you remind other people  Pearson Correlation -.041 .108 1 .557**\nto properly wash their hands  Sig. (2-tailed) .600 .170  .000\nwhen you see them not doing  N 162 162 162 162\nit properly or not at all?\nDo you follow the guidelines  Pearson Correlation -.110 .325** .557** 1\nindicating that you should  Sig. (2-tailed) .163 .000 .000 \nwash your hand regularly N 162 162 162 162Correlations\nDo you follow the \nguidelines indicating \nthat you should wash \nyour hand regularlyDo you remind other \npeople to properly wash \ntheir hands when you \nsee them not doing it \nproperly or not at all??Do you think that there \nare better practices that \ncould be adopted in \nensuring hand sanitation \nin your community by \nthe government based \non the nature of your \nsettlement, the slum? Education level38\n2023/38 (4): 31-40Kelly Oluoch et al. \nSpecific demographic characteristics \nand selected key Knowledge, Attitude \nand Practice measures\nKnowledge as measured by Education level (ANOVA)\nThe analysis of variance on specific demographic \ncharacteristics and a key selected knowledge measures \ndemonstrated that, basically most of the participants with \nsecondary education and above knew about principles \nof hand washing to prevent corona spread (significance \nlevel of .046) (Table IX).\nThe association between Education level and the \nproper hand-washing practices among the participants\nThe analysis revealed that, education level positively \npredicted the hand-washing practices among the \nresidents of the slums for this pilot study indicating that the \ngovernment can benchmark better practices guideline, \nthat they remind others of proper practices and that \nthey follow the stipulated guidelines as directed by the \ngovernment with significance levels of p<0.05 (Table X). \nDiscussion\nCOVID-19 is a relatively new virus that has had \ndevastating effects within the short time since it was first \ndetected in December 2019. To date, there has been \nlimited published data on population knowledge, attitudes \nand practices toward COVID-19, specifically in informal \nurban settlements. The novelty of this disease, along \nwith its uncertainties, make it critical for health authorities \nto plan appropriate strategies to prepare and manage \nthe public health in a blanket approach and by focus \non most vulnerable sub-populations in the community. \nIt is therefore of utmost importance that the challenges \nand knowledge, attitudes and practices of the informal \nsettlement population be studied to guide these efforts.\nThe key challenges associated with adhering to \nhandwashing protocols mapped out from this study \nindicated that, over 50% of the population experienced \nchallenges especially, lack of access to alcohol-based \nhand rub, lack of sufficient wash-stations and, lack \nof adequate water and soap supply. Most of these \nchallenges as depicted from Likert scale showed that they \nwere associated with poor demographic characteristics \nranging from education to nature of settlements as \nindicated by other studies8, similar to an Indian survey9.\nMost participants acknowledged having known of the \nCOVI-19 control measures from government directed TV \nadverts and the normal TV programs  with other sources \nof information recording lower percentages, these \npopulations can only get such information in substantial \nmanner as hand technology (advanced cellphones for instance) are consider luxury to them and can\u2019t afford as \nsited by past studies10. The average knowledge score \nfor participants as measured across the Likert scale on \nthe indicators of the same was above average between \n1.0556 and 4.1728 on several knowledge scores. \nThis was seemingly the same in findings from a study \nwhich established the fact that, despite the challenges, \nthe general knowledge of hand-hygiene was universal \nas this is taught even at basic education level11, with \nmajority being aware that, poor hand washing practices \ncan further enhance the spread of corona virus in \nyour community (95.1%), this result replicating similar \nfindings12. The overall rate of the knowledge questions \nwas above 60% while the range of correct answer \nrates for all participants were between 50 to 100% with \nmajority knowing that hand washing prevents corona \nspread (82.7%)13. Also, several studies conducted \namong Syrians have indicated high levels of COVID-19 \nknowledge among the general population14.\nThe present study found that a large majority of \nparticipants held positive attitudes toward overcoming \nCOVID-19 through hand-washing as the most feasible \nway, citing other measures as a little bit expensive and \ndifficult to comply with. The attitude of the participants \ndemonstrated that, majority of participants (85.2%) were \nconcerned with how hand washing was being practiced. \nEven so, 66 % of participants were unsatisfied with the \nhandwashing practices, a greater percentage at 81.5% \nagreed that they would mitigate poor handwashing \npractices and 74.8% regarding the practice of hand \nwashing in preventing covi-19 spread as important. \nThese current collective results are similar to others15. \nGenerally, high levels of positive attitudes were also \ndetected in the KAP study conducted in China16, which \nreplicates this current pilot study.\nPractices of hand washing and hygiene towards \nCOVID-19 prevention  showed that a greater percentage \nover 80% were following the guidelines indicating that \nthey should wash their hand regularly and would remind \nother people to properly wash their hands17,18. They also \nfelt that, based on their presumed \u201cisolated lifestyle\u2019\u2019, \nbetter practices could be adopted in ensuring hand \nhygiene in community by the government as perceived \nbefore in other studies19.\nFrom the general perspective view of the entire KAP \nanalysis, we attributed the positive attitudes and \nseemingly good practices on hand-washing to the \ndrastic measures taken by the Kenyan government in \nmitigating the spread of the virus, but bearing in mind \nthat challenges are bound to compromise these efforts \nin the context of informal urban settlements.\nSpecific demographic characteristics and a key selected \nknowledge measures with ANOVA test demonstrated \nthat, basically participants with secondary education and 39\n2023/38 (4): 31-40Challenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure Among Slum Dwellers in Nairobi, Kenya\nabove knew about principles of hand washing to prevent \ncorona spread with a significance association as well as \npractices on handwashing demonstrating depicting a \npositive correlation at a significant p-value with Pearson \ncorrelation test for association. This is commensurate with \npast studies implicating that education positive predicts \nthe proper handwashing knowledge and practices20.\nCOVID-19 has been a teething public health problem \naround the world. Vaccination programs for the same has \nbeen benchmarked across several countries in the world. \nSocial scientists, especially those in public health and \nhealth communication, are working to identify the levels of \nknowledge, attitudes and practices on COVID-19 among \nthe public in different settings as to design cost-effective \npublic health campaigns and education programs. \nThe current survey, in fact, exposes the need for more \ncomprehensive sensitization, support and improving the \ninfrastructure needed in offering services to mitigate the \nCOVID-19 and focus on consistency of information from \nthe government and related authorities on handwashing \nas a measure to control COVID-19. Due to the levels of \nmedia use with TV messages by the government and \nmessages from TV and evidence from prior research21, \nauthorities would benefit from utilizing both such to reach \nthe presumed marginal areas, the informal settlements in \ndisseminating these messages.Conclusions\nIn summary, the present study was able to provide a \ncomprehensive examination of the challenges and \nknowledge, attitudes and practices among informal \nsettlements population towards hand washing and \nhygiene as a protocol to mitigate the spread of \nCOVID-19. The findings suggest that they possess an \nacceptable level of knowledge on COVID-19 and are \ngenerally positive in their outlook on overcoming the \npandemic. Even so, consistent messaging from the \ngovernment and/ or health authorities are key to aid \npublic knowledge and understanding of COVID-19 \nand the feasibility of hand washing, especially in their \nsettings. Specific health education programs to raise \nCOVID-19 knowledge and improve practices is of \nparamount importance as the pandemic may be here to \nstay for some time and that, such populations are more \nvulnerable due to related demographics.\nConflict of Interest\nThe authors declare that no competing interests exist.\nReferences\n1. Lee ACC, Kozuki N, Cousens S, et al. Estimates of burden and \nconsequences of infants born small for gestational age in low and \nmiddle income countries with INTERGROWTH-21 st standard: Analysis \nof CHERG datasets. BMJ. 2017;358. doi:10.1136/bmj.j3677\n2. Budholiya P , Ali AW, Gunwan D, Sahil S, Tyagi CK, Sharma H. \nCOVID-19: A Global Pandemic of 21st Century. J Drug Deliv Ther.  \n2020;10(3-s). doi:10.22270/jddt.v10i3-s.4088\n3. Azlan AA, Hamzah MR, Sern TJ, Ayub SH, Mohamad E. Public \nknowledge, attitudes and practices towards COVID-19: A cross-\nsectional study in Malaysia. PLoS One . 2020;15(5). doi:10.1371/\njournal.pone.0233668\n4. Heger F, Moshammer H. COVID-19: the Austrian experience. \nAsian Pacific J Environ Cancer . 2020;3(S1). doi:10.31557/\napjec.2020.3.s1.3-45. Kamau N, Njiru H. Water, sanitation and hygiene situation in \nKenya\u2019s urban slums. J Health Care Poor Underserved . 2018;29(1). \ndoi:10.1353/hpu.2018.0022\n6. Taksande A, Panwar RAS, Saqqaf SA, Rao R, Meshram R. Study of \nKnowledge, Attitude and Practice (KAP) towards COVID-19 Pandemic \nin Rural Area. Med Sci. 2020;24(106).\n7. Agadjanian V, Zotova N. Sampling and surveying hard-to-reach \npopulations for demographic research: A study of female labor \nmigrants in Moscow, Russia. Demogr Res. 2012;26. doi:10.4054/\nDemRes.2012.26.5\n8. C.L. M, J. G, S. R, et al. Risk of exposure to fecal contamination for \nadults and children in slum, non-slum, and high-income neighborhoods \nacross Dhaka, Bangladesh using the SaniPath exposure assessment \ntool. Am J Trop Med Hyg. 2018;99(4 Supplement).40\n2023/38 (4): 31-40Challenges of Adhering to Hand Washing Protocols as a COVID-19 Prevention Measure Among Slum Dwellers in Nairobi, KenyaKelly Oluoch et al. \n9. Patel A. Preventing COVID-19 Amid Public Health and Urban Planning \nFailures in Slums of Indian Cities. World Med Heal Policy.  2020;12(3). \ndoi:10.1002/wmh3.351\n10. Subasinghe W. Quality of Life Study on Slum Dwellers (With Special \nReference to Sri Lanka). Int J Sci Res Innov Technol.  2015;2(3).\n11. Ssemugabo C, Halage AA, Namata C, Musoke D, Ssempebwa \nJC. A socio-ecological perspective of the facilitators and barriers to \nuptake of water, sanitation and hygiene interventions in a slum setting \nin kampala, uganda: A qualitative study. J Water Sanit Hyg Dev. \n2020;10(2). doi:10.2166/washdev.2020.124\n12. Brauer M, Zhao JT, Bennitt FB, Stanaway JD. Global access to \nHandwashing: Implications for COVID-19 control in low-income \ncountries. Environ Health Perspect. 2020;128(5). doi:10.1289/\nEHP7200\n13. Mahdi H, Alqahtani A, Barasheed O, et al. Hand hygiene knowledge \nand practices among domestic hajj pilgrims: implications for future \nmass gatherings amidst COVID-19. Trop Med Infect Dis. 2020;5(4). \ndoi:10.3390/tropicalmed5040160\n14. Al ahdab S. A cross-sectional survey of knowledge, attitude \nand practice (KAP) towards COVID-19 pandemic among the Syrian \nresidents. BMC Public Health.  2021;21(1). doi:10.1186/s12889-021-\n10353-315. Singh S, Singh RK. Awareness, Attitude and Practices towards \nCOVID-19 among People of Bihar during Lockdown 1.0: A Cross-\nSectional Study. Int J Sci Healthc Res. 2020;5(2).\n16. Zhong BL, Luo W, Li HM, et al. Knowledge, attitudes, and practices \ntowards COVID-19 among chinese residents during the rapid rise \nperiod of the COVID-19 outbreak: A quick online cross-sectional survey. \nInt J Biol Sci. 2020;16(10). doi:10.7150/ijbs.45221\n17. Kadam S, Pati S, Chauhan AS. A study on knowledge and practice of \nhand washing among slum children and their mothers in Bhubaneswar, \nOdisha. Indian J Public Heal Res Dev. 2014;5(3). doi:10.5958/0976-\n5506.2014.00276.9\n18. Pati S, Kadam SS, Chauhan AS. Hand hygiene behavior among \nurban slum children and their care takers in Odisha, India. J Prev Med \nHyg. 2014;55(2). doi:10.15167/2421-4248/jpmh2014.55.2.431\n19. De Vita MV, Scolfaro C, Santini B, et al. Malnutrition, morbidity and \ninfection in the informal settlements of Nairobi, Kenya: An epidemiological \nstudy. Ital J Pediatr. 2019;45(1). doi:10.1186/s13052-019-0607-0\n20. Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene \non infectious disease risk in the community setting: A meta-analysis. \nAm J Public Health.  2008;98(8). doi:10.2105/AJPH.2007.124610\n21. Cabrera A, Martins C, Cunha IF. Television coverage of the Covid-19 \npandemic in Portugal: An exploratory study. Media J.  2020;20(37). \ndoi:10.14195/2183-5462_37_10\n 41\n2023/38 (4): 41-46ORIGINAL\nComparion between General and Spinal Anesthesia for \nLumbar Disc Surgery: A Randomized Clinical Trial \nComparaci\u00f3n entre anestesia general y raqu\u00eddea para la cirug\u00eda discal lumbar: \nUn ensayo cl\u00ednico aleatorizado  \nMolouk Jaafarpour1      , Masoud Hatefi2, Aminollah Vasigh3      , Ali Khani4      ,\nFatemeh Njafi4, Elham Shafiei5  \n1. Department of Midwifery, School of Nursing and Midwifery Faculty, Ilam University of Medical Sciences, Ilam, Iran. \n2. Department of Neurosurgery, Medicine Faculty, Ilam University of Medical Sciences, Ilam, IR-Iran.\n3. Department of Anaesthesiology, Medicine Faculty, Ilam University of Medical Sciences, Ilam, Iran. \n4. Department of Nursing, Nursing & Midwiferay Faculty, Ilam University of Medical Sciences, Ilam, Iran.   \n5. Department of Epidemiology, School of Health, Ilam University of Medical Sciences, Ilam, Iran.eISSN 2255-0569\nReceived: 11 - I - 2023\nAccepted: 13 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.41Corresponding author\nMasoud Hatefi   \nE-mail: hatefimasoud191@gmail.com  \nAbstract \nIntroduction: Lumbar disc surgery is most often performed under general anesthesia (GA). However, spinal anesthesia (SA) can \nalso be a successful alternative in lumbar disc surgery. The present study was conducted to compare the complications of general \nand spinal anesthesia in patients with lumbar discectomy. \nMaterial and Methods:  Fifty patients were randomly allocated into two groups of general (25 patient) and spinal anesthesia (25 \npatient). The pain severity (based on visual analogue scale [VAS]), the use of analgesics, blood pressure (BP), heart rate (HR), blood \nloss, respiratory rate (RR), patient satisfaction, nausea, vomiting, and shivering in recovery room were recorded. \nResults: The mean pain severity score, postoperative use of analgesics, intraoperative blood loss and recovery time in the \nspinal anesthesia group were significantly lower than general anesthesia group (P<0.001). Intraoperative HR and BP changes, \nnausea, vomiting, and shivering in recovery room were significantly lower in spinal anesthesia group (p<0.05, p<0.001). The patient \nsatisfaction was significantly high in the spinal anesthesia group (p<0.001). \nConclusions: spinal anesthesia is safe and seems to be more effective. Some advantages of SA include lower pain severity score \nand the use of analgesics, reduced amount of blood loss during the surgery and fewer postoperative complications.\nKeywords: Anesthesia, Lumbar Surgery, Pain, Blood Loss. \nResumen\nIntroducci\u00f3n: La cirug\u00eda discal lumbar se realiza con mayor frecuencia bajo anestesia general (AG). Sin embargo, la anestesia \nraqu\u00eddea (AC) tambi\u00e9n puede ser una alternativa satisfactoria en la cirug\u00eda discal lumbar. El presente estudio se realiz\u00f3 para \ncomparar las complicaciones de la anestesia general y espinal en pacientes con discectom\u00eda lumbar. \nMaterial y m\u00e9todos: Cincuenta pacientes fueron asignados aleatoriamente a dos grupos de anestesia general (25 pacientes) \ny raqu\u00eddea (25 pacientes). Se registraron la intensidad del dolor (seg\u00fan la escala anal\u00f3gica visual (EAV), el uso de analg\u00e9sicos, la \npresi\u00f3n arterial (PA), la frecuencia cardiaca (FC), la p\u00e9rdida de sangre, la frecuencia respiratoria (FR), la satisfacci\u00f3n del paciente, \nlas n\u00e1useas, los v\u00f3mitos y los escalofr\u00edos en la sala de recuperaci\u00f3n. \nResultados: La puntuaci\u00f3n media de la gravedad del dolor, el uso postoperatorio de analg\u00e9sicos, la p\u00e9rdida de sangre \nintraoperatoria y el tiempo de recuperaci\u00f3n en el grupo de anestesia raqu\u00eddea fueron significativamente inferiores a los del grupo \nde anestesia general (p<0,001). Los cambios intraoperatorios de la FC y la PA, las n\u00e1useas, los v\u00f3mitos y los escalofr\u00edos en la \nsala de recuperaci\u00f3n fueron significativamente menores en el grupo de anestesia raqu\u00eddea (p<0,05, p<0,001). La satisfacci\u00f3n del \npaciente fue significativamente alta en el grupo de anestesia raqu\u00eddea (p<0,001). \nConclusiones: la anestesia raqu\u00eddea es segura y parece ser m\u00e1s eficaz. Algunas ventajas de la anestesia espinal son una menor \npuntuaci\u00f3n de la intensidad del dolor y del uso de analg\u00e9sicos, una menor p\u00e9rdida de sangre durante la intervenci\u00f3n y menos \ncomplicaciones postoperatorias.\nPalabras clave: anestesia, cirug\u00eda lumbar, dolor, p\u00e9rdida de sangre.ID ID ID\nID42\n2023/38 (4): 41-46Molouk Jaafarpour et al. \nBackground  \nLumbar pain is the second major cause of consultation \nwith physicians in the US and leads to the disability of at \nleast 7 million people. The estimated cost of treatment \nfor back pain is above $50 billion in addition to 93 million \nlost workdays in the year1-5.\nAfter lumbar herniation, lumbar laminectomy and \ndiscectomy with an annual statistics of 300,000 to \n400,000 cases, is one of the most major surgeries with \na prevalence of 10 to 40% in neurosurgery. These figures \nare reported to be about 13000 in the UK and over \n250000 in the US1,6-8. Laminectomy can be performed \nunder general anesthesia (GA) or spinal anesthesia \n(SA)9,10. However, GA is the most common method for \nlumbar disc surgery10,11.\nA safe anesthetic method should have characteristics \nsuch as maintaining stable hemodynamic, both rapid \nonset and reversal of effects, decreasing the length of \nstay in recovery room, reducing the demand for blood \ntransfusion, postoperative pain, nausea, vomiting, and \nopioid use for analgesia9,11. However, recent studies \nshow contradictory results and there is no single \nagreement for the appropriate anesthetic method in the \nlumbar disc surgery12.\nObjectives  \nThe literature review indicated that there are controversial \nresults regarding the effect of GA verses SA on \nlaminectomy outcome13. Evidence shows that patients \nunder spinal anesthesia have fewer complications \nand more satisfied compared to general anesthesia. \nThis issue is consistent with the results of a number of \nconducted studies14. Previous researchers emphasized \nthat further studies must be performed before reaching \na unified conclusion. To the best of our knowledge, this \nstudy aimed to compare the outcomes of spinal versus \ngeneral anesthesia in patients with lumbar laminectomy \nor discectomy. \nMethods\nStudy protocol\nThis is a randomized controlled trial (RCT) performed \nat the one of the teaching hospitals affiliated to Ilam \nUniversity of Medical Sciences (Imam Khomeini hospital). \nPatient characteristics: \nIn this RCT, 50 patients aged 20-60 years with American \nSociety of Anesthesiologist (ASA) physical status I or \nII who were scheduled for elective laminectomy or \ndiscectomy were enrolled in this study. The patients \nunderwent either GA or SA. Patients were randomly divided two groups of general \nor spinal anesthesia with 25 patients in each group \nusing sealed envelopes technique. To avoid the effect of \nconfounding variables, all procedures were performed \nwith the same anesthesiologist and neurosurgeon.\nAnesthesia procedure\nPatients in GA group received 2-3 mg/kg intravenous \npropofol, 1-1.5 mcg/kg intravenous fentanyl, and0.6 mg/\nkg intravenous rocuronium bromide,2-3% sevoflurane \nand 50% N2O in O2 for maintenance of anesthesia. \nVentilation mode: CMV, VT: 10 cc/kg, Breaths per \nminute: 12-14. Patients in SA group received 15 mg \nintrathecal bupivacaine 0.5% at L3 - L4 or L4 - L5 \nspace in a sitting position (To prevent high spinal, we \nused 15 mg intrathecal bupivacaine for all patients \nwith different height and weight). We used the Visual \nAnalogue Scale (VAS) to determine severity of pain. The \npain severity was assessed at 1, 4, 8, 12, and 24 hours \nafter surgery. The patient\u2019s blood loss (during operation), \nmean blood pressure (BP), heart rate (HR), respiratory \nrate (RR), oxygen saturation (SPO2), urinary retention, \nand morphine consumption (IM) were recorded. NSAID \naccording to patients need were administrated. The \ncomplications such as nausea, vomiting, and shivering \nin recovery room were recorded.\nThe exclusion criteria were contraindications to SA \n(such as patient\u2019s refusal, coagulopathy, infection at the \nneedling site, and hypovolemia), severe spinal stenosis, \nhistory of cardiovascular disease, neuromuscular, \nseizure, or intracranial hypertension, renal or metabolic \ndisease, bleeding abnormalities and drug or alcohol \nabuse.\nEthical Consideration \nThis study is approved under the ethical approval code \nof (IR. MEDILAM.RE.1394.39) and informed written \nconsent was obtained from all subjects. Clinical Trial \nCode: (IRCT2015062222870N1) .\nValidity and Reliability\nContent validity was applied to assign the validity of the \nquestionnaire. Cronbach\u2019s alpha test was applied to \nassign the reliability of questionnaire. The reliability of the \nquestionnaire was 0.89.\nStatistical analysis \nAccording to Kolmogorov-Smirnov test, data were \nnormally distributed and therefore, parametric \ntests were used (P > 0.05). Descriptive statistics \n(frequency, percent, mean, and standard deviation \n[SD]), independent t-test, chi-square test, Monte Carlo \ntest, Fishers Exact test, Confidence Interval, Relative \nRisk, and Repeated Measurement were performed to \nanalyze the results. P-Value < 0.05 was considered \nsignificant. Data were analyzed using the statistical \nsoftware SPSS Ver.16.43\n2023/38 (4): 41-46Comparion between General and Spinal Anesthesia for Lumbar Disc Surgery: A Randomized Clinical Trial\nResults\nCharacteristics were presented in table I and showed \nthat demographic information (age and sex) and duration \nof surgical procedure were not different between the two \ngroups (P > 0.5) (Table I).\nPostoperative analgesia, blood loss, BP/S, BP/D and \nPR in the SA group were significantly lower than the GA \ngroup (P < 0.001) (Table II). \nIndependent t-test showed that the pain severity in the \nSA group was significantly lower than the GA group at \ndifferent time intervals (P < 0.001) (Table III). Repeated \nmeasurement analysis showed that the average pain \nintensity in the groups were significantly different at \nvarious intervals (P < 0.001) (Figure 1). At 1, 4, and 8 hours after surgery, the pain severity in \nGA group was significantly higher than the SA group. In \nthe spinal group the postoperative VAS score at 1 hour \nwas lower than one and stayed low (VAS < 2) at 4 and \n8 hours after surgery. This suggests that the SA method \nhas effectively controlled the pain severity (Figure 1).\nIn the SA group, one patient (4%) experienced vomiting, \nwhile eight patients (32%) in the general group experienced \nvomiting. The incidence of vomiting in the GA group was \neight times more than the SA group (RR=8, 95% CI= \n1.08-58.8). Table II shows that the incidence of nausea \nand shivering in the SA group was significantly lower \nthan the GA group, but the incidence of headache after \nsurgery in the GA group was significantly lower than the \nSA group (P < 0.05) (Table IV/ Figure 2).\nPatients Characteristics  Spinal group(n=25) General group (n=25) P- value\nAge / year (mean \u00b1sd)  50\u00b14.7 51\u00b15.3 0.40\nSex M/F n(%)  20 (80%)/5(20%) 19(76%)/6(24%) 0.90\nSurgery duration/min (mean \u00b1sd)  83.6\u00b13.6 85.4\u00b13.3 0.05Table I: Comparison of baseline characteristics and surgery duration of patients in spinal and general groups.\nPatients Characteristics  Spinal group(n=25) General group (n=25) P- value\nAnesthesia duration/ min (mean \u00b1sd)  115.6\u00b111.8 133\u00b19.6 0.000\nRecovery time/ min (mean \u00b1sd)  26\u00b111 38\u00b19 0.000\nMorphine consumption /mg (mean \u00b1sd)  3.7\u00b11.2 8\u00b12.5 0.000\nBlood loos / ml (mean \u00b1sd)  317\u00b110.9 424\u00b15.9 0.000\nBPS/ mm (mean \u00b1sd)  115\u00b128 135\u00b147 0.000\nBPD/ mm (mean \u00b1sd)  68.6\u00b134 87.4\u00b139 0.000\nPR/ per/ min (mean \u00b1sd)  79.6\u00b121 91.8\u00b137 0.000Table II: Postoperative outcomes in the two groups.\nParameter  Groups Test\n  General (25), n(%) Spinal (25), n(%) RR (95% CI) p-value\nVomiting Yes 8 (32) 1 (4) 8 (1.08-58.8)*** 0.012*\n No 17 (68) 24 (96)  \nNausea Yes 12 (48) 3 (12) 4 (1.14-12.5)*** 0.005**\n No 13 (52) 22 (88)  \nShivering Yes 11 (44) 4 (16) 2.75 (1.01-7.46)*** 0.031**\n No 14 (56) 21 (84)  \nHeadache Yes 2 (8) 15 (60) 7.5 (1.9-29)**** 0.001**\n No 23 (92) 10 (40)  \nUrinary retention yes 2 (8) 1 (4) 1.43 (1.09-5.35)*** 0.025**\n No 23 (92) 24 (96) 1.85 (1.01-6.45)*** 0.046**Table III: Adverse effects in patients in spinal and general anesthesia groups.\n*P- value computed using exact test instead of Mont Carlo test ** P- value computed using Chi-square test\n*** Spinal group considered as references group **** General group considered as references group  \nPain score by VAS, h  General group (n=25) Spinal group(n=25) p-value\n [M\u00b1 SD] [M\u00b1 SD]\n1 h after intervention  6.4\u00b10.15 0.8\u00b10.15 0.001\n4 h after intervention  4.4\u00b10.16 1.6\u00b10.16 0.001\n8 h after intervention  3\u00b10.16 1.8\u00b10.16 0.001\n12 h after intervention  2.2\u00b10.09 1.4\u00b10.09 0.001\n24 h after intervention  2.2\u00b110 0.6\u00b110 0.001Table IV: Severity of pain at various intervals in spinal and general anesthesia groups.44\n2023/38 (4): 41-46Molouk Jaafarpour et al. \nFigure 1: Comparison of pain severity between spinal and general group at one, \n4, 8, 12 and 24 hours after anesthesia.\nFigure 2: Comparison of side effects of general and spinal anesthesia.\nDiscussion \nLumbar disc surgery is most commonly performed under \ngeneral anesthesia. Nevertheless, spinal or epidural \nanesthesia is also a safe and successful alternative in \nlumbar surgery15. GA may have complications such as \npostoperative pain, blood loss, nausea, vomiting, and \nincrease in the duration of recovery period11,16.\nThe ability to perform long-term surgery in prone position \nwithout any airway disruption and patient\u2019s satisfaction \nare the main benefits of using GA17. Alternatively, regional \nanesthesia may decrease the amount of intraoperative \nblood loss, incidence of pulmonary and cardiac \ncomplications. It may decrease peripheral venous \npressure to provide appropriate postoperative pain \ncontrol and may decrease the length of inpatient stays \nand the overall costs. It may also lead to appropriate \npostoperative pain control9-12, 18-21.45\n2023/38 (4): 41-46Comparion between General and Spinal Anesthesia for Lumbar Disc Surgery: A Randomized Clinical Trial\nPrevious medical literature indicates inconsistency \nregarding the superiority of GA to SA in lumbar surgery. \nOur results show that patients undergoing lumbar \nsurgery with SA have fewer complications and it has \nmore advantages compared with GA. In addition, the \nsatisfaction of patients and surgeons was significantly \nhigher in SA group compared with GA group, which is \nconsistent with previous studies11,17,22-24, but inconsistent \nwith the study of Sadrolsadat et al.14.\nUsually patients experience severe pain after lumbar \ndisc surgery25,26. The results of previous studies \nindicate that compared to general anesthesia, spinal \nanesthesia had less complications in patients who are \ncandidates for disc surgery11,17,22-24. In their study among \n400 patients undergoing spinal or GA for lumbar disc \nsurgery, McLain et al. (2005) concluded that SA was \nbetter and more effective than GA. They showed that \nSA might lead to reduced incidence of nausea and \nmorphine use, shorter anesthesia duration and fewer \nadverse effects22. Tetzlaff et al. (1998) concluded that \nSA with fewer adverse effects could be determined as \nan effective alternative to GA for lumbar surgery23. Attari \net al. (2011) concluded that SA decreases blood loss, \nBP , HR changes, and postoperative analgesia use. \nFurthermore, the satisfaction of surgeon and patient was \nsignificantly higher in SA group17.\nDemirel et al. (2003) conducted a study among patients \nundergoing discectomy or laminectomy.  They found that \nepidural anesthesia was more successful than GA with \nfewer episodes of hypertension and less blood loss24.\nIn their study, Khajavi et al (2013) compared GA with \ncombined epidural/GA for lumbar disc surgery, and \nconcluded that patients in combined epidural/GA \ngroup had less blood loss, hypotension, lower use of \nanesthetic medications during surgery, lower prevalence \nof tachycardia and hypertension and morphine \nconsumption in the recovery room11.\nIn their prospective study, Sadrolsadat et al. (2009) \nconcluded that as opposed to previous studies that \nshowed spinal anesthesia was better than general \nanesthesia for patients under lumbar surgery, SA does \nnot offer any advantage over general anesthesia, and GA \nhas many advantages over SA14.\nThe mechanism of less blood loss after SA in lumbar \ndisc surgery is due to two factors. The first mechanism \nis vasodilatation due to blockade of the sympathetic \npathway. The second mechanism is spontaneous \nventilation which reduces the intrathoracic pressure \nand resulting in less dilation of the epidural veins. This \nis another important factor for less blood loss after SA17.In our study, the mean arterial BP and HR changes \ncompared to the baseline value were significantly lower \nin SA group compared with GA group. This mechanism \nis due to the better prevention of stress hormones by \nSA than GA27-29. Patients in SA group had less pain and \nmorphine use was significantly lower compared with GA \ngroup. Reduction of pain score and morphine use after \nsurgery can be explained by two mechanisms.  The first \nhypothesis is the preventive effect of spinal anesthesia \nthat reduces the pain severity by blockade of the afferent \nnociceptor sensitization pathway. The second process is \npossibly the remaining sensory block in spinal anesthesia \ngroup. This issue is caused by the delay in sensory \nrecovery following motor recovery17.\nConclusions \nIn conclusion, SA is a safe, effective, and successful \nmethod compared to GA for patients undergoing lumbar \ndisc surgery. Some advantages of SA include decreasing \npain severity score and analgesia use, reduced amount \nof blood loss during the surgery and fewer postoperative \ncomplications.\nLimitations\nThe major limitation of the study was the small sample \nsize, which is tried to be compensated in future studies.\nAcknowledgments \nWe thank Ilam University of Medical Sciences, pa\u00actients \nand all people who participated in this study.\nFunding/Support\nThis study was supported by Ilam University of \nMedical Sciences (IR. MEDILAM.RE.1394.39) and   \nIRCT2015062222870N1. \nConflict of Interest\nThere is no conflict of interest.46\n2023/38 (4): 41-46Molouk Jaafarpour et al. \nComparion between General and Spinal Anesthesia for Lumbar Disc Surgery: A Randomized Clinical Trial\nReferences\n1. Rahimzadeh P , Sharma V, Imani F, Faiz HR, Ghodraty MR, Nikzad-\nJamnani AR , et al . Adjuvant Hyaluronidase to Epidural Steroid \nImproves the Quality of Analgesia in Failed Back Surgery Syndrome: A \nProspective Randomized Clinical Trial. Pain Physician 2014; 17: 75-82.\n2. Amr YM. Effect of Addition of Epidural Ketamine to Steroid in Lumbar \nRadiculitis: One-Year Follow-Up. Pain Physician 2011; 14:475-481.\n3. Manchikanti L, Singh V, Datta S, Cohen SP , Hirsch JA. Comprehensive \nreview of epidemiology, scope, and impact of spinal pain. Pain Physician \n2009; 12:E35- E70\n4. Manchikanti L, Boswell MV, Singh V, Benyamin RM, Fellows B, Abdi \nS, et al . Comprehensive evidence-based guidelines for interventional \ntechniques in the management of chronic spinal pain. Pain Physician \n2009; 12:699-802.\n5. Kim SB, Lee KW, Lee JH, Ah Kim M, Woo An B.  The Effect of \nHyaluronidase in Interlaminar Lumbar Epidural Injection for Failed Back \nSurgery Syndrome. Ann Rehabil Med 2012; 36: 466-473.\n6. Gottschalk A, Freitag M, Tank S, Burmeister MA, Kreil S, Kothe R, \net al. Quality of postoperative pain using an intraoperatively placed \nepidural catheter after major lumbar spinal surgery. Anesthesiology. \n2004 Jul;101(1):175-80. \n7. Raw DA, Beattie JK, Hunter JM. Anaesthesia for spinal surgery in \nadults. Br J Anaesth. 2003;91:886\u2013904.\n8. Gianesello L, Pavoni V, Barboni E, Galeotti I, Nella A. Perioperative \nPregabalin for Postoperative Pain Control and Quality of Life After Major \nSpinal Surgery . J Neurosurg Anesthesiol 2011: 0 (0); 1-6.\n9. Moudgil V, Bajwa BS. Lumbar Spine Surgery Outcome: Effect of \nRegional Anaesthesia Global Journal of Medical Research 2014 ; 14 \n(4): 4-10.\n10. Vural C, Yorukoglu D.Comparison of Patient Satisfaction and Cost in \nSpinal and General Anesthesia for Lumbar Disc Surgery. Turk Neurosurg \n2014, Vol: 24(3);  380-384\n11. Khajavi MR, Asadian MA, Imani F, Etezadi F, Shariat Moharari R, \nAmirjamshidi A. General anesthesia versus combined epidural/general \nanesthesia for elective lumbar spine disc surgery: A randomized clinical \ntrial comparing the impact of the two methods upon the outcome \nvariables. Surgical Neurology International 2015; February 22: IP: \n62.102.131.64\n12. Karaman S,  Karaman T, Dogru S, Sahin A, Arici S, Tapar H. \nRetrospective Evaluation of Anesthesia Approaches for Lumbar Disc \nSurgery. J Anesth Clin Res 2014, 5 (4) :1-3.\n13. Moudgil V, Bajwa BS. Lumbar Spine Surgery Outcome: Effect of \nRegional AnaesthesiaGlobal Journal of Medical Research 2014 ; 14 \n(4): 4-10.\n14. Sadrolsadat SH, Mahdavi AR, Moharari RS, Khajavi MR, Khashayar \nP , Najafi A, et al. A prospective randomized trial comparing the technique \nof spinal and general anesthesia for lumbar disk surgery: a study of 100 \ncases. Surg Neurol 2009 ;71(1):60-5.\n15. Kara I, Celik JB, OC B, Apilliogullari S1, Karabagli H. Comparison \nof Spinal and General Anesthesia in Lumbar Disc Surgery. Journal of \nNeurological Sciences 2011; 28(4):487-96.16. Gulur P , Nishimori M, Ballantyne JC. Regional anaesthesia versus \ngeneral naesthesia, morbidity and mortality.Best Pract Res Clin \nAnaesthesiol. 2006;20:249-63.\n17. Attari M, Mirhosseini A, Honarmand A, Safavi M. Spinal anesthesia \nversus general anesthesia for elective lumbar spine surgery: A \nrandomized clinical trial. J Res Med Sci 2011;16(4):524-9.\n18. Papadopoulos EC, Girardi FP , Sama A, Pappou IP , Urban MK, \nCammisa FP Jr. Lumbar microdiscectomy under epidural anesthesia: A \ncomparison study. Spine J 2006;6:561-4.\n19. Nicassio N, Bobicchio P , Umari M, Tacconi L .Lumbar \nmicrodiscectomy under epidural anaesthesia with the patient in the \nsitting position: a prospective study. J Clin Neurosci , 2010, 17: 1537-\n1540.\n20. De Rojas JO, Syre P , Welch WC .Regional anesthesia versus \ngeneral anesthesia for surgery on the lumbar spine: a review of the \nmodern literature. Clin Neurol Neurosurg, 2014,  119: 39-43.\n21. Weinstein JN, Lurie JD, Tosteson TD, Skinner JS, Hanscom B, \nTosteson AN, et al. Surgical vs nonoperative treatment for lumbar \ndisk herniation: The Spine Patient Outcomes Research Trial (SPORT) \nobservational cohort: JAMA 2006; 296:2451-9\n22. McLain RF, Kalfas I, Bell GR, Tetzlaff JE, Yoon HJ, Rana M. \nComparison of spinal and general anesthesia in lumbar laminectomy \nsurgery: a case-controlled analysis of 400 patients. J Neurosurg Spine \n2005; 2(1): 17-22.\n23. Tetzlaff JE, Dilger JA, Kodsy M, al Bataineh J, Yoon HJ, Bell GR. \nSpinal anesthesia for elective lumbar spine surgery. J Clin Anesth 1998; \n10(8): 666-9.\n24. Demirel CB, Kalayci M, Ozkocak I, Altunkaya H, Ozer Y, Acikgoz \nB. A prospective randomized study comparing perioperative outcome \nvariables after epidural or general anesthesia for lumbar disc surgery. J \nNeurosurg Anesthesiol 2003;15:185-92.\n25. Abrishamkar S, Aminmansour B, Arti H. The effectiveness of \ncomputed tomography scans versus magnetic resonance imaging for \ndecision making in patients with low back pain and radicular leg pain. \nJournal of Research in Medical Sciences, 2006; 11(6): 351-4.\n26. Vasigh A, Najafi F, Jaafarpour M, Khajavikhan J, Khani A.  The \nEffect of Sevoflurane Plus Propofol on Pain and Complications after \nLaminectomy: A Randomized Double Blind Clinical Trial. Journal of \nClinical and Diagnostic Research. 2017 Apr, Vol-11(4): UC05-UC08.\n27. Hebl JR, Horlocker TT, Kopp SL, Schroeder DR. Neuraxial blockade \nin patients with preexisting spinal stenosis, lumbar disk disease, or prior \nspine surgery: efficacy and neurologic complications. Anesth Analg \n2010; 111(6): 1511-9.\n28. Basaranoglu G, Erkalp K, Saidoglu L, Aydas D, Ozdemir H, Teker M. \nSelective spinal anesthesia for limb amputation above knee level. J Clin \nAnesth 2011; 23(2): 169.\n29. Limongi JA, Lins RS. Cardiopulmonary arrest in spinal anesthesia. \nRev Bras Anestesiol 2011; 61(1): 110-20.47\n2023/38 (3): 47-51ORIGINAL\nThe efficiency of artificial neural network (ANN) \nfor diagnosis of obesity and hypertension  \nLa eficacia de la red neuronal artificial (RNA) \npara el diagn\u00f3stico de la obesidad y la hipertensi\u00f3n  \nSomayeh Ebrahimi1      , Farshid Haghi2  \n1. Huazhong University of Science and Technology. Wuhan. China\n2. Dalian Medical University. Dalian. Liaoning. ChinaeISSN 2255-0569\nReceived: 13 - I - 2023\nAccepted: 15 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.47Corresponding author\nSomayeh Ebrahimi   \nE-mail: Somayehebrahimiii6181@gmail.com  \nAbstract \nAim & Background: Obesity and hypertension are health problems in any society. The aim of this study was to evaluate the \nsensitivity, specificity and accuracy of artificial neural network (ANN) for the diagnosis of obesity and hypertension. Material & \nMethods: For this study, demographic information about 500 students aged 7-18 years was recorded in the ANN program. The \nrecorded demographic information consisted of 11 input variables and 3 output variables. Input variables included age, sex, weight, \nheight, waist circumference, body mass index, waist-to-height ratio, abdominal obesity, physical activity, genetics, and unhealthy \neating behaviors, while output variables included obesity, systolic blood pressure, and diastolic blood pressure. In this study, \nLevenberg-Marquardt and Conjugate Gradient algorithms were used to training the network. \nResults: The results showed that the sensitivity, specificity and accuracy of ANN based on experimental data in the diagnosis of \nobesity were equal to 0.941, 1 and 0.990, respectively; for high systolic blood pressure were 0.800, 1 and 0.970 and for high \ndiastolic blood pressure were 0.875, 1 and 0.980, respectively. In addition, it was found that the sensitivity, specificity and accuracy \nof ANN based on the obtained total data in the diagnosis of obesity were equal to 0.945, 0.997 and 0.992, respectively; for high \nsystolic blood pressure were 0.857, 0.993 and 0.970, respectively and for high diastolic blood pressure were 0.810, 0.997 and \n0.900, respectively. \nConclusion: Based on the results of the present study, it can be concluded that ANN designed to diagnose obesity, systolic and \ndiastolic blood pressure has high accuracy, so the use of ANN to diagnose other similar diseases was suggested.\nKeywords: Artificial Neural Network, Health, Obesity, Hypertension, Efficiency, Iran. \nResumen\nObjetivo y antecedentes: La obesidad y la hipertensi\u00f3n son problemas de salud en cualquier sociedad. El objetivo de este \nestudio fue evaluar la sensibilidad, la especificidad y la precisi\u00f3n de la red neuronal artificial (RNA) para el diagn\u00f3stico de la \nobesidad y la hipertensi\u00f3n. \nMaterial y m\u00e9todos: Para este estudio, se registr\u00f3 la informaci\u00f3n demogr\u00e1fica de 500 estudiantes de entre 7 y 18 a\u00f1os en el \nprograma RNA. La informaci\u00f3n demogr\u00e1fica registrada constaba de 11 variables de entrada y 3 de salida. Las variables de entrada \ninclu\u00edan la edad, el sexo, el peso, la altura, el per\u00edmetro de la cintura, el \u00edndice de masa corporal, la relaci\u00f3n cintura-estatura, la \nobesidad abdominal, la actividad f\u00edsica, la gen\u00e9tica y los comportamientos alimentarios poco saludables, mientras que las variables \nde salida inclu\u00edan la obesidad, la presi\u00f3n arterial sist\u00f3lica y la presi\u00f3n arterial diast\u00f3lica. En este estudio, se utilizaron los algoritmos \nde Levenberg-Marquardt y de Gradiente Conjugado para entrenar la red. \nResultados: Los resultados mostraron que la sensibilidad, la especificidad y la precisi\u00f3n de la RNA basada en datos experimentales \nen el diagn\u00f3stico de la obesidad fueron iguales a 0,941, 1 y 0,990, respectivamente; para la presi\u00f3n arterial sist\u00f3lica alta fueron \n0,800, 1 y 0,970 y para la presi\u00f3n arterial diast\u00f3lica alta fueron 0,875, 1 y 0,980, respectivamente. Adem\u00e1s, se comprob\u00f3 que la \nsensibilidad, la especificidad y la precisi\u00f3n de la RNA basada en los datos totales obtenidos en el diagn\u00f3stico de la obesidad eran \niguales a 0,945, 0,997 y 0,992, respectivamente; para la presi\u00f3n arterial sist\u00f3lica alta eran 0,857, 0,993 y 0,970, respectivamente \ny para la presi\u00f3n arterial diast\u00f3lica alta eran 0,810, 0,997 y 0,900, respectivamente.  \nConclusiones: En base a los resultados del presente estudio, se puede concluir que la RNA dise\u00f1ada para diagnosticar la \nobesidad y la presi\u00f3n arterial sist\u00f3lica y diast\u00f3lica tiene una alta precisi\u00f3n, por lo que se sugiri\u00f3 el uso de la RNA para diagnosticar \notras enfermedades similares.\nPalabras clave: Red Neural Artificial, Salud, Obesidad, Hipertensi\u00f3n, Eficiencia, Ir\u00e1n.ID ID48\n2023/38 (3): 47-51Somayeh Ebrahimi et al. \nIntroduction \nObesity is a major public health problem, not only in \ndeveloped countries but also in developing countries \nsuch as Iran, and has many medical and psychological \nconsequences for children and adolescents1. Obesity \nis now so prevalent in the world\u2019s population that it is \nreplacing nutrition and infectious diseases as the most \nimportant cause of disease. In particular, obesity is \nassociated with diseases such as diabetes, heart \ndisease, certain forms of cancer and sleep-disordered \nbreathing and is determined by a body mass index higher \nthan 30 kg/m2 2.\nAccording to the World Health Organization, overweight \nand obesity are the abnormal accumulation of fat in \nthe body that harms human health. In children and \nadolescents, the Body Mass Index (BMI) is used to \nmeasure overweight and obesity3. The BMI of each \nperson is defined as the division of weight per kilogram \nby height squared in meters. Obesity lasts from \nchildhood to adulthood and is significantly associated \nwith increased blood pressure in adulthood. In addition, \nthe level of blood pressure in childhood is the best \npredictor of blood pressure in adulthood4-6. Circulation \nthroughout the body is done by the pressure created in \nthe blood vessels of the body. Blood pressure is mostly \nrelated to heart rate and flexibility in the walls of the \narteries. There are two types of blood pressure, such \nas systolic and diastolic. Systolic is the highest blood \npressure and diastolic is the lowest blood pressure7. \nDespite the great variety in blood pressure, the general \npopulation in children and adolescents is called diastolic \npressure of 80 mmHg or higher and systolic pressure of \n120 mmHg or higher, hypertension8.\nHigh blood pressure is an important risk factor for \nheart and kidney failure. Since the most common sign \nand symptom in patients with high blood pressure is \nasymptomatic in them, its prevention can lead to the \nprevention of complications. There is a direct correlation \nbetween mean systolic and diastolic blood pressure and \nBMI; In other words, body mass index is an important \npredictor of hypertension9,10. In a similar study in Puerto \nRican adolescents, a statistically significant relationship \nwas observed between mean systolic and diastolic \nblood pressure and obesity11. Also, the study of the \nrelationship between BMI, waist size, waist-to-height \nratio and hypertension among Lithuanian adolescents \naged 12-15 years, shows that BMI parameters and \nwaist circumference are more strongly associated with \nhypertension and then the parameter Waist-to-height \nsize more accurately predict hypertension12. Another \nstudy showed that waist size could be an important \nfactor in predicting hypertension in Chinese children and \nadolescents aged 7-17 years. Also, BMI along with waist \nsize had a greater effect on predicting blood pressure in \nchildren and adolescents13.Obtaining an estimate of the prevalence of obesity \namong children is necessary in order to assess the \nneed for preventive measures and identify high-risk \ngroups. Despite the global prevalence of obesity, there \nare limited reports from developing countries on the \nprevalence of obesity among children. In addition, in \nsome studies, abdominal obesity and obesity and the \ncombined effect of both factors in increasing blood \npressure have been identified14-16. A study of Greek \nadolescents aged 6-18 years showed that overweight \nand obesity can be controlled by modifying behavior \nand following the Mediterranean lifestyle, which \nincludes the Mediterranean diet, physical activity and \nactive lifestyle17.\nRecently, many researches have used artificial intelligence \ntools, especially artificial neural network (ANN), to \ndiagnose and predict diseases in the medical field. The \nhigh capacity of ANN, which is inspired by biological \ncomputing networks, has led to their rapid expansion. \nRecently, some attempts to predict the percentage of \nexcess body fat in adults with the approach of artificial \nneural networks have been reported18-20. The aim of \nthis study was to evaluate the sensitivity, specificity \nand accuracy of ANN for the diagnosis of obesity and \nhypertension in students aged 7-18 years.\nMaterial & Methods \nThis study is a descriptive-analytical study that is \npredicted by artificial neural network (ANN). In this study, \nANN predicts and evaluates the status of obesity and \nhypertension in children and adolescents based on input \nvariables. The statistical population of this study was \n500 students aged 7-18 years. The researcher-made \nquestionnaire21 related to the objectives of the present \nstudy was completed by a specialist physician and \nresearchers. \nThe questionnaire included various information such as \nage, gender, weight, height, waist circumference, body \nmass index (BMI), and waist to height ratio, abdominal \nobesity, physical activity, genetics, unhealthy eating \nbehaviors, obesity, systolic blood pressure and diastolic \nblood pressure. Unhealthy eating behaviors include the \ndaily consumption of fast food, cakes, cookies, chips, \npuffs, sugary drinks and soft drinks by children and \nadolescents, which can lead to obesity and high blood \npressure. Unhealthy eating behaviors are scaled at three \nlevels: low, medium and high22,23. Specifications for 11 \ninput variables (including: age, sex, weight, height, waist \ncircumference, abdominal obesity, BMI, waist-to-height \nratio, physical activity, genetics, and unhealthy eating \nbehaviors) and three output variables (including: obesity, \nsystolic blood pressure and diastolic blood pressure) \nare shown in table I.49\n2023/38 (3): 47-51The efficiency of artificial neural network (ANN) for diagnosis of obesity and hypertension \nFinally, using the ANN toolbox in Matlab software, the \nentered data was analyzed. About 80% of the available \ndata, ie 400 students, were used for education and the \nremaining 20% of the data, ie 100 people, were used \nfor ANN testing. Finally, using Sigmolide tangent stimulus \nwarping and two scaled conjugate gradient algorithms \nand Lunberg Marquardt, network training was performed \nand then the results were compared with each other. \nTo determine the network with the best structure, trial \nand error method was used and networks with different \nnumber of neurons were trained.\nResults\nThe results of the network with scaled conjugate gradient \nalgorithm (SCGA) and Levenberg-Marquart algorithm \n(LMA) for output variables including obesity, systolic blood \npressure, and diastolic pressure are presented. Regarding \nthe output variable of obesity, comparison of network results \nshowed that these variables with SCGA and LMA had 17 \nand 15 hidden neurons, respectively. While these values were 18 and 15 for systolic blood pressure output and 17 \nand 17 neurons for diastolic blood pressure, respectively. \nThe accuracy values of the two algorithms (SCGA and LMA) \nfor the designed network with the three output variables \nexamined in table III are presented. In addition, the \nsensitivity, specificity and accuracy of the selected neural \nnetwork are obtained based on the turbulence matrix of \nthe experimental data and the whole data set for obesity \noutcomes, high systolic blood pressure, and high diastolic \nblood pressure, which were shown in tables IV and V. The \nresults showed that the sensitivity, specificity and accuracy \nof ANN based on experimental data in the diagnosis of \nobesity were equal to 0.941, 1 and 0.990, respectively; for \nhigh systolic blood pressure were 0.800, 1 and 0.970 and \nfor high diastolic blood pressure were 0.875, 1 and 0.980, \nrespectively (Table IV). In addition, it was found that the \nsensitivity, specificity and accuracy of ANN based on the \nobtained total data in the diagnosis of obesity were equal \nto 0.945, 0.997 and 0.992, respectively; for high systolic \nblood pressure were 0.857, 0.993 and 0.970, respectively \nand for high diastolic blood pressure were 0.810, 0.997 \nand 0.900, respectively (Table V).Variable name (symbol)  Variable type (Input / Output) Mean Minimum Maximum\nAge (I-1) Input  12.59 7.05 19\nGender (I-2) Input  0.52 0 1\nWeight (I-3) Input  42.06 15.7 103.2\nHeight (I-4) Input  148.2 102 195\nWaist size (I-5) Input  68.5 27.5 111.5\nAbdominal obesity(I-6) Input  0.2 0 1\nBody mass index (BMI) (I-7) Input  18.7 10.45 44.65\nWaist to height ratio (I-8) Input  0.47 0.2 0.76\nPhysical activity (I-9) Input  3.06 0 6.5\nGenetics (I-10) Input  2.09 1 4\nUnhealthy eating behaviors (I-11) Input  0.89 0 2.5\nObesity (I-12) Output 0.11 0 1.1\nSystolic blood pressure (I-13) Output 100.57 61 153\nDiastolic blood pressure (I-14) Output 65.1 35 95Table I: Specifications of input and output variables in the present study.\nVariable name Algorithm type Number of hidden layer neurons Regression Mean Squared Error Gradient\nObesity  SCGA 17 0.98123 0.006148 0.0038214\n LMA 15 0.99435 0.000962 0.0031865\nSystolic blood pressure  SCGA 18 0.87721 0.007804 0.013254\n LMA 15 0.92521 0.0069324 0.013952\nDiastolic blood pressure  SCGA 17 0.90234 0.019251 0.008449\n LMA 17 0.92346 0.019332 0.007825Table II: Network results by SCG and LMA algorithms for output variables.\nANN prediction Control (Healthy) Disease\nDisease (Obesity) 0 16\nControl (Healthy) 83 1\nDisease (Systolic blood pressure) 0 12\nControl (Healthy) 85 3\nDisease (Obesity) 0 14\nControl (Healthy) 84 2Table IV: Designed network accuracy with two algorithms for obesity, systolic \nblood pressure and diastolic blood pressure.\nANN prediction Control (Healthy) Disease\nDisease (Obesity) 1 52\nControl (Healthy) 444 3\nDisease (Systolic blood pressure) 3 70\nControl (Healthy) 415 12\nDisease (Obesity) 1 81\nControl (Healthy) 399 19Table V: Designed network accuracy with two algorithms for obesity, systolic \nblood pressure and diastolic blood pressure.Algorithm type  Output variables\n Obesity Systolic blood pressure  Diastolic blood pressure \nSCGA 0.9916 0.9564 0.9445\nLMA 0.9948 0.9821 0.9674Table III: Designed network accuracy with two algorithms for obesity, systolic blood pressure and diastolic blood pressure.50\n2023/38 (3): 47-51Somayeh Ebrahimi et al. \nDiscussion\nObesity and high blood pressure are the common health \nproblems in Iranian adolescents. In addition, in recent \nyears, the use of ANN in medical sciences with the aim \nof promoting health, has greatly expanded24-28. The main \npurpose of this study was to evaluate the sensitivity, \nspecificity and accuracy by ANN for the diagnosis of \nobesity and hypertension in students aged 7-18 years. \nVarious studies have shown that the input parameters \nused in the design of this network have the greatest \nimpact on the prediction of hypertension and obesity in \nchildren and adolescents. Askary Kachoosangy et al. \n(2015) reported that there was significant association \nbetween increased BMI and hypertension. Maintaining \nnormal weight and BMI is recommended as a priority \nto prevent high blood pressure29. Also the results of the \nstudy of Yuan et al. (2017) showed that BMI and waist \ncircumference variables are directly related to blood \npressure in Chinese adolescents, although according \nto the results of this study, BMI variable is better than \nwaist circumference variable to diagnose pediatric \nhypertension30. Based on the findings of the study Khaji et \nal. (2016) which was performed on fifth grade elementary \nschool children in Tehran, it was found that the prevalence \nof overweight and obesity in them is about 10% and 6%, \nrespectively. In addition, the results of that study showed \nthat different weight groups have significant differences \nin terms of blood pressure, which indicates that blood \npressure has a significant relationship with weight31.\nMany previous studies have demonstrated the effective \nfunction of the Multi-Layer Perceptron (MLP) neural network \nin diagnosing and predicting diseases such as obesity and \nhypertension. In the study of Huang et al. (2010), which \nevaluated the effectiveness of ANN application and logistic \nregression model on residents over 35 years of age in rural \nChina, found that ANN more accurately assesses the risk of \nhypertension32. In a study by Samant and Rao (2010) that \nevaluated the ability of ANN designed with the Lunberg-\nMarquardt algorithm to predict the probability of hypertension \nin a community of healthy and sick people (with a history \nof hypertension) in India, the maximum accuracy of ANN \ndesigned in that study was 92.85%33. A study by Ture et al. \n(2005) were performed to compare classification methods \n(three types of decision trees, four statistical algorithms and \ntwo neural networks) to predict the risk of hypertension. The \nresults of that study showed that the MLP and Radial Basic \nFunction (RBF) neural networks had the best performance \namong the mentioned classification methods with 89.29% \nand 86.36% accuracy, respectively34. Duran et al. (2019) \nused ANN with four input variables including age, height, \nweight and waist circumference to diagnose and predict \nobesity in children, which achieved an accuracy of 92%35, \nwhile in the present study with 11 input variable with 95% \naccuracy, ANN was designed to diagnose and predict \nobesity and hypertension in children and adolescents. This shows that more effective factors are used in determining \nobesity and hypertension, with much more accurate \ndiagnosis and prediction. Considering that in the present \nstudy, 11 effective variables in obesity and hypertension \nwere used, the number of quantitative variables was used in \nthe previous research; therefore, the results of the present \nstudy had a higher accuracy.\nThe results of present study showed that the sensitivity, \nspecificity and accuracy of ANN based on experimental \ndata in the diagnosis of obesity were equal to 0.941, 1 and \n0.990, respectively; for high systolic blood pressure were \n0.800, 1 and 0.970 and for high diastolic blood pressure \nwere 0.875, 1 and 0.980, respectively. In addition, it was \nfound that the sensitivity, specificity and accuracy of ANN \nbased on the obtained total data in the diagnosis of obesity \nwere equal to 0.945, 0.997 and 0.992, respectively; for \nhigh systolic blood pressure were 0.857, 0.993 and \n0.970, respectively and for high diastolic blood pressure \nwere 0.810, 0.997 and 0.900, respectively. \nIn the present study, it was shown that having 11 input \nvariables, a system can be designed to predict obesity \nand blood pressure in students. The system designed in \nthe present study is more accurate than previous studies \nin which they used fewer parameters to predict blood \npressure and obesity. Also, the results of the present \nstudy showed that ANN designed to provide appropriate \nresults for the diagnosis and prognosis of obesity and \nsystolic and diastolic blood pressure in students. The \nresults of the present study showed that this system \npredicts obesity, high systolic blood pressure and high \ndiastolic blood pressure in students with 99, 97 and 98% \naccuracy, respectively.\nIn addition, based on the results of the present study, it was \nfound that high blood pressure and obesity are the common \nhealth problems in children and adolescents. Also, the rate \nof hypertension in obese students is significantly higher \nthan other adolescents with lower weight. According to \nthe results of the present study, about 85% of obese \nadolescents have high blood pressure. In addition, the \nprevalence of risk factors for cardiovascular disease \nis higher in obese individuals with high blood pressure. \nTherefore, the need to design educational programs in the \nfield of lifestyle improvement through social, cultural and \nnutritional effects and provide the correct pattern of food \nconsumption and physical activity can be appropriate \nstrategies to promote community health.\nConclusion \nBased on the results, it can be concluded that the use of \nmore input parameters predicts obesity and hypertension \nin children and adolescents with higher accuracy. \nAlthough using more effective variables complicates the \nanalysis process, this can be done with intelligent tools 51\n2023/38 (3): 47-51The efficiency of artificial neural network (ANN) for diagnosis of obesity and hypertension \nsuch as ANN. Based on the results of the present study, \nit can be concluded that ANN is designed to diagnose \nobesity and hypertension, so the use of ANN to diagnose \nother similar diseases was suggested.Conflict of Interest\nThere is no conflict of interest.\nReferences\n1. Mirmiran P , Sherafat Kazemzadeh R, Jalali Farahani S, Azizi F. Childhood \nobesity in the Middle East: a review. EMHJ-Eastern Mediterranean Health \nJournal, 16 (9), 1009-1017, 2010. \n2. Caprio S. Treating child obesity and associated medical conditions. The \nFuture of Children. 2006: 209-24.\n3. Ferenci T, Kovacs L. Predicting body fat percentage from anthropometric \nand laboratory measurements using artificial neural networks. Applied Soft \nComputing. 2018; 67:834-9.\n4. Weisell RC. Body mass index as an indicator of obesity. Asia Pacific \njournal of clinical nutrition. 2002; 11:S681-4.\n5. Dua S, Bhuker M, Sharma P , Dhall M, Kapoor S. Body mass index \nrelates to blood pressure among adults. North American journal of medical \nsciences. 2014; 6(2):89.\n6. Assadi F. Childhood hypertension: A problem of epidemic proportion. \nInternational Journal of Preventive Medicine. 2014 Mar 7:1-3.\n7. Kaplan NM. Kaplan\u2019s clinical hypertension. Lippincott Williams & Wilkins; 2010.\n8. Kasper DL, Fauci AS, Hauser S, Longo DL, Jameson JL, Loscalzo J. \nParkinson\u2019s disease and other movement disorders. Harrison\u2019s Principles of \nInternal Medicine. 19th ed. New York, NY: McGraw-Hill Education. 2015.\n9. Seravalle G, Grassi G. Obesity and hypertension. Pharmacological \nresearch. 2017; 122:1-7.\n10. Baig M, Gazzaz ZJ, Gari MA, Al-Attallah HG, Al-Jedaani KS, Mesawa \nAT, et al. Prevalence of obesity and hypertension among University \nstudents\u2019 and their knowledge and attitude towards risk factors of \nCardiovascular Disease (CVD) in Jeddah, Saudi Arabia. Pakistan journal of \nmedical sciences. 2015; 31(4):816.\n11. Venegas HL, P\u00e9rez CM, Su\u00e1rez EL, Guzm\u00e1n M. Prevalence of obesity \nand its association with blood pressure, serum lipids and selected lifestyles \nin a Puerto Rican population of adolescents 12-16 years of age. Puerto \nRico Health Sciences Journal. 2003; 22(2).\n12. Kuciene R, Dulskiene V. Associations between body mass index, \nwaist circumference, waist-to-height ratio, and high blood pressure among \nadolescents: a cross-sectional study. Scientific Reports. 2019; 9(1):1-1.\n13. Wang M, Sun J, Ma C, Xi B. A3672 Role of waist circumference in \npredicting elevated blood pressure among children and adolescents with \nnormal body mass index. Journal of Hypertension. 2018; 36:e290.\n14. Golan M, Weizman A. Familial approach to the treatment of childhood \nobesity: conceptual model. Journal of nutrition education. 2001; \n33(2):102-7.\n15. Chhatwal J, Verma M, Riar SK. Obesity among pre-adolescent and \nadolescents of a developing country (India). Asia Pacific journal of clinical \nnutrition. 2004; 13(3).\n16. Mohammadi M, Mirzaei M. The effect of obesity, abdominal obesity \nand joint effect of them on high blood pressure in men of Mazandaran \nProvince, Iran (population attributable fraction study): brief report. Tehran \nUniversity Medical Journal TUMS Publications. 2017; 74(10):735-40.\n17. Katsagoni CN, Psarra G, Georgoulis M, Tambalis K, Panagiotakos \nDB, Sidossis LS, \u0395\u03a5\u0396\u0397\u039d Study Group. High and moderate adherence \nto Mediterranean lifestyle is inversely associated with overweight, general \nand abdominal obesity in children and adolescents: The MediLIFE-index. \nNutrition Research. 2020; 73:38-47.\n18. Ferenci T, Kovacs L. Predicting body fat percentage from anthropometric \nand laboratory measurements using artificial neural networks. Applied Soft \nComputing. 2018; 67: 834-9.19. Kupusinac A, Stoki\u0107 E, Doroslova\u010dki R. Predicting body fat percentage \nbased on gender, age and BMI by using artificial neural networks. \nComputer methods and programs in biomedicine. 2014; 113(2):610-9.\n20. Shao YE. Body fat percentage prediction using intelligent hybrid \napproaches. The Scientific World Journal. 2014; 2014.\n21. Motlagh ME, Ziaodini H, Qorbani M, Taheri M, Aminaei T, Goodarzi A, \net al. Methodology and early findings of the fifth survey of childhood and \nadolescence surveillance and prevention of adult noncommunicable disease: \nthe CASPIAN-V study. International journal of preventive medicine. 2017; 8.\n22. Payab M, Kelishadi R, Qorbani M, Motlagh ME, Ranjbar SH, Ardalan \nG, et al. Association of junk food consumption with high blood pressure \nand obesity in Iranian children and adolescents: the CASPIAN-IV Study. \nJournal de pediatria. 2015; 91:196-205.\n23. Kelishadi R, Poursafa P . A review on the genetic, environmental, and \nlifestyle aspects of the early-life origins of cardiovascular disease. Current \nproblems in pediatric and adolescent health care. 2014; 44(3):54-72.\n24. Amato F, L\u00f3pez A, Pe\u00f1a-M\u00e9ndez EM, Va\u0148hara P , Hampl A, Havel \nJ. Artificial neural networks in medical diagnosis. Journal of applied \nbiomedicine. 2013; 11(2):47-58.\n25. Tajbakhsh N, Shin JY, Gurudu SR, Hurst RT, Kendall CB, Gotway \nMB, et al. Convolutional neural networks for medical image analysis: Full \ntraining or fine tuning?. IEEE transactions on medical imaging. 2016; \n35(5):1299-312.\n26. Brameier M, Banzhaf W. A comparison of linear genetic programming \nand neural networks in medical data mining. IEEE Transactions on \nEvolutionary Computation. 2001; 5(1):17-26.\n27. Hinton GE, Salakhutdinov RR. Reducing the dimensionality of data \nwith neural networks. Science. 2006; 313(5786):504-7.\n28. Lakhani P , Sundaram B. Deep learning at chest radiography: \nautomated classification of pulmonary tuberculosis by using convolutional \nneural networks. Radiology. 2017; 284(2):574-82.\n29. Askary Kachoosangy R, Habibi E, Hosseini L. The Investigation of \nRelationship between Hypertension and High Body Mass Index in 30-60-\nYear Population of Shahid Motahary Hospital, Marvdasht in 1391. Journal \nof Sabzevar University of Medical Sciences. 2015; 22(3):206-12.\n30. Yuan P , Qian ZM, Vaughn M, Huang J, Ward P , Zhu Y, et al. Comparison \nof body mass index with abdominal obesity for identifying elevated blood \npressure in children and adolescents: The SNEC study. Obesity Research \n& Clinical Practice. 2017; 11(4):406-13.\n31. Khaji A, Khodaii S, Faeghi A, Azizi S, Firoozian A, Jafari J. Blood \npressure and obesity in young adolescents in Tehran. Iranian Journal of \nPediatrics 2006; 16(1): 45 \u2013 50.\n32.Huang S, Xu Y, Yue L, Wei S, Liu L, Gan X, et al. Evaluating the risk \nof hypertension using an artificial neural network method in rural residents \nover the age of 35 years in a Chinese area. Hypertension Research. 2010; \n33(7):722-6.\n33. Samant R, Rao S. Evaluation of artificial neural networks in prediction \nof essential hypertension. International Journal of Computer Applications. \n2013; 81(12).\n34. Ture M, Kurt I, Kurum AT, Ozdamar K. Comparing classification \ntechniques for predicting essential hypertension. Expert Systems with \nApplications. 2005; 29(3):583-8.\n35. Duran I, Martakis K, Rehberg M, Semler O, Schoenau E. Diagnostic \nperformance of an artificial neural network to predict excess body fat in \nchildren. Pediatric Obesity. 2019; 14(2):e12494.52\n2023/38 (4): 52-59ORIGINAL\nRelationship between values of 7 NAFLD scales \nand different RCV scales in 219,477 Spanish workers\nRelaci\u00f3n entre valores de 7 escalas de NAFLD y diferentes escalas de RCV \nen 219.477 trabajadores espa\u00f1oles.  \nEmilio Mart\u00ednez-Almoyna Rif\u00e11      , Pilar Tom\u00e1s-Gil1      , Josep Lluis Coll Villalonga1      ,\nJos\u00e9 Ignacio Ram\u00edrez-Manent1,2      , Pau Mart\u00ed-Lliteras1      , \n\u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez1\n1. Grupo ADEMA-SALUD IUNICS University of the Balearic Islands. Spain.\n2. Mallorca Primary Care eISSN 2255-0569\nReceived: 16 - I - 2023\nAccepted: 18 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.52Corresponding author\nJos\u00e9 Ignacio Ram\u00edrez-Manent \nE-mail: jignacioramirez@telefonica.net  \nAbstract \nIntroduction: Cardiometabolic diseases are highly prevalent and constitute the leading cause of morbidity and mortality worldwide. \nNon-alcoholic fatty liver disease (NAFLD) is also very prevalent. The aim of this study is to assess the relationship between different \nNAFLD risk scales and cardiovascular risk (CVR) scales. \nMaterial and methods: Descriptive, cross-sectional study in 219477 Spanish workers in which the relationship between NAFLD and \nliver fibrosis risk scales (FLI, HSI, ZJU, FLD, FSI, LAP and BARD score) and CVR scales (REGICOR, SCORE, DORICA, ERICE and \nvascular age) was assessed. \nResults: In our study there is a direct relationship between the increase in the values of the CVR scales and the increase in the risk \nvalues of NAFLD and hepatic fibrosis. The value of the CVR scales for predicting the presence of high risk values of NAFLD and liver \nfibrosis scales using ROC curves is not very high. \nConclusions: There is a good relationship between the values of both types of scales although the predictive value is not good .\nKeywords: NAFLD, liver fibrosis, cardiovascular risk. \nResumen\nIntroducci\u00f3n: Las enfermedades cardiometab\u00f3licas son muy prevalentes y constituyen la primera causa de morbimortalidad en \ntodo el mundo. La enfermedad del h\u00edgado graso no alcoh\u00f3lico (NAFLD) tambi\u00e9n es muy prevalente. El objetivo de este estudio es \nvalorar la relaci\u00f3n entre diferentes escalas de riesgo de NAFLD y escalas de riesgo cardiovascular (RCV). \nMaterial y m\u00e9todos: Estudio descriptivo y transversal en 219477 trabajadores espa\u00f1oles en el que se valora la relaci\u00f3n entre \nescalas de riesgo de NAFLD y fibrosis hep\u00e1tica (FLI, HSI, ZJU, FLD, FSI, LAP y BARD score) con escalas de RCV (REGICOR, \nSCORE, DORICA, ERICE y edad vascular). \nResultados: En nuestro estudio existe una relaci\u00f3n directa entre el incremento de los valores de las escalas de RCV y el \nincremento de los valores de riesgo de NAFLD y fibrosis hep\u00e1tica. El valor de las escalas de RCV para predecir la presencia de \nvalores de alto riesgo de las escalas de NAFLD y fibrosis hep\u00e1tica empleando las curvas ROC no es muy alto. \nConclusiones: Existe buena relaci\u00f3n entre los valores de ambos tipos de escalas aunque el valor predictivo no es bueno.\nPalabras clave: NAFLD, fibrosis hep\u00e1tica, riesgo cardiovascular.IDID ID\nID IDID53\n2023/38 (4): 52-59 Relationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers\nIntroduction\nThe term non-alcoholic fatty liver disease (NAFLD) is used \nto refer to a broad group of liver disorders ranging from \nan initial phase called simple steatosis to more serious \nconditions such as steatohepatitis and even cirrhosis. \nHistologically, the lesions that appear in NAFLD are similar \nto those caused by alcohol consumption, although by \ndefinition NAFLD develops only in people who do not \ndrink alcohol or only drink alcohol sporadically.\nNAFLD was first described in the 1950s by Zelman1 and \nwas correctly characterized by Ludwig et al2 thirty years \nlater2. Thirty years later, it is currently a clinical condition \nthat attracts the attention of healthcare professionals due \nto its high prevalence, especially in Western countries3. \nRecently, it has been shown that NAFLD can lead \nto death, not only due to the chronic liver disease4 it \ncauses, but also as a consequence of alterations in lipid \nmetabolism and increased cardiovascular risk.\nThe aim of the present study was to assess the \nrelationship between different NAFLD and liver fibrosis \nrisk scales and some cardiovascular risk scales.\nMaterial and methods\nA descriptive, cross-sectional study was carried out in \n219,477 Spanish workers from different regions and \nwork sectors, mostly in public administration, health, \nhospitality, construction and commerce. The workers \nincluded in the study were selected among those who \nattended occupational health checkups carried out \nbetween January 2017 and December 2019. See flow \ndiagram in figure 1.Inclusion criteria:\n- Age between 18 and 69 years.\n- Acceptance to participate in the study.\n- Authorization to use the data obtained for \nepidemiological purposes.\n- Belonging to one of the companies included in the \nstudy and not being on temporary disability at the \ntime of the study.\nThe anthropometric (height, weight and waist \ncircumference), analytical and clinical determinations were \nperformed by the different occupational health professionals \nof the participating companies after standardization of the \nprocesses to avoid interobserver bias.\nWeight (in kilograms) and height (in centimeters) were \ndetermined with a SECA 700 scale-measuring device. \nWaist circumference was measured with the person \nin a standing position, upper extremities hanging, feet \ntogether and abdomen relaxed. It was placed parallel to \nthe ground at the level of the last floating rib.\nBlood pressure was obtained while seated and after \na 10-minute rest at rest. Three measurements were \nobtained one minute apart and the mean was calculated.\nBlood analysis was performed after fasting for no less \nthan 12 hours. Cholesterol, triglycerides and glycemia \nwere obtained using enzymatic techniques while HDL was \nobtained using precipitation techniques. LDL was calculated \nby applying the Friedewald formula (total cholesterol \n-HDL-c- triglycerides/5), which is only applicable when \ntriglycerides do not exceed a value of 400.\nSeven risk scales were calculated for non-alcoholic fatty \nliver disease and liver fibrosis:\n- Fatty Liver Index (FLI)6\nThe cut-off point to consider high risk is 60.\n- Hepatic steatosis index (HSI)7 \nHSI = 8 \u00d7 AST/ALT + BMI + 2 if diabetes, + 2 if female.\nThe cut-off point to consider high risk is 36.\n- Zhejian University index (ZJU index)8  \nZJU = BMI + Blood glucose (mmol L) + Triglycerides \n(mmol L) +3 AST/ALT +2 if female.\nThe cut-off point to consider high risk is 38.\n- Fatty liver disease index (FLD)9 \nFLD = BMI+Triglycerides+3 \u00d7 ( AST/ALT) +2 \u00d7 \nHyperglycemia (present=1; absent=0).\nThe cutoff point to consider high risk is 37.Figure 1: Flow chart of participants in the study.\n221,218 workers start the study\n326 do not agree to participate\n996 lack any variable \nto calculate scales\n219,477 (2125,403 men and 94,074 \nwomen) finally entered the study419 are under 18 or over 69 years oldFLI = (e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist circumference  \n- 15.745) / (1 + e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist \ncircumference  - 15.745) x 10054\n2023/38 (4): 52-59Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \n- Framingham Steatosis Index (FSI)10 \nFSI = -7.981 + 0.011 x age - 0.146 x sex (female =1, \nmale = 0) + 0.173 x BMI + 0.007 x triglycerides + 0.593 \nx hypertension (yes = 1, no =0) + 0.789 x diabetes (yes \n= 1, no =0) + 1.1 x AST/ALT ratio \u22651.33 (yes = 1, no =0).\n- Lipid accumulation product (LCP)11\nMen: (waist (cm) - 65) x (triglycerides (mMol)).\nWomen: (waist (cm) - 58) x (triglycerides (mMol)). \nThe cut-off point to consider high is 42.7.  \n- BARD score12 It is a risk scale for liver fibrosis.\nBMI from 28 (1 point), AST/ALT from 0.8 (2 points), \ndiabetes mellitus (2 points). Values between 2-4 points \nindicate high risk.\nSix cardiovascular risk scales are calculated:\n- Registro Giron\u00ed del Cor (REGICOR)13.\nThis is a scale used to determine the possibility of \nsuffering a cerebrovascular event, fatal or otherwise, \nduring the next decade of life. It is applicable between 35 \nand 74 years of age. Values below 5% are considered \nlow, between 5% and 9% moderate, from 10% to 14% \nhigh, and from 15% and above very high. \n- Systematic Coronary Risk Evaluation (SCORE)14\nEstimates the probability of presenting a fatal \ncerebrovascular event in the next 10 years. It is applicable \nbetween 40 and 65 years of age. Values are considered \nlow up to 3%, moderate between 4% and 5%, and high \nafter 5%.\n- Dyslipidemia Obesity and Cardiovascular Risk in Spain \n(DORICA)15\nEvaluates the risk of presenting a cerebrovascular event \nin the following decade. It is applicable between 20 and \n64 years of age. Risk is considered low if it is less than \n5%, slight between 5% and 9%, moderate between 10% \nand 19%, high between 20% and 39%, and very high \nabove 40%.\n- Spanish Cardiovascular Risk Equation (ERICE)16\nIt also calculates the risk of presenting a cerebrovascular \nevent in the following decade. It is applicable between \n30 and 80 years of age. It is considered low if it is less \nthan 5%, mild between 5% and 9%, moderate between \n10% and 14%, moderate-high between 15%-19%, high \nbetween 20%-29% and very high after 30%.\n- Framingham vascular age and SCORE17.\nBoth are obtained from tables and assess the aging of \nthe vascular tree. A very useful concept is that of ALLY \n(avoidable lost life years), which is the avoidable years \nof life lost, corresponding to the difference between the \nindividual\u2019s biological age and vascular age18.Smoker is any person who has smoked at least one \ncigarette (or its equivalent in another type of consumption) \nin the last 30 days or has quit less than 12 months ago.\nThe social class is determined based on the proposal of \nthe Spanish Society of Epidemiology, which is based on \nthe 2011 National Classification of Occupations19. Three \ngroups are established: class I (directors, managers \nand university professionals), class II (intermediate \noccupations and self-employed workers) and class III \n(manual workers).\nResults\nThe mean age of the sample was over 40 years \n(41.8 years in men and 39.9 years in women), with \nthe majority group being between 30 and 49 years \nof age. The anthropometric, clinical and analytical \nvariables in all cases show more unfavorable values in \nmen. The social class most represented in the study is \nclass III. Approximately one out of every three workers \nincluded in the study was a smoker. All the data can be \nconsulted in table I.\nTable II shows how all the NAFLD and liver fibrosis risk \nscales increase their mean values as the values of the \ndifferent scales that assess cardiovascular risk increase. \nIn all cases, the mean values of the NAFLD and liver \nfibrosis risk scales are higher in men.\nTable III shows that the prevalence of high values of \nthe NAFLD and liver fibrosis risk scales is also higher \nas the values of the cardiovascular risk scales increase. \nAs with the mean values, higher values are observed in \nmen in all cases.\nTable IV shows the results of the multivariate analysis \nby multinomial logistic regression. The risk of presenting \nelevated values for all the nonalcoholic fatty liver \ndisease and liver fibrosis risk scales increases as \nthe cardiovascular risk scales increase. The greatest \nincreases are seen with the DORICA scale.\nFigure 2 and table V show the areas under the curve \nwith their 95% confidence intervals of the cardiovascular \nrisk scales for predicting the presence of high values \nof the nonalcoholic fatty liver disease and liver fibrosis \nrisk scales. In general, the areas under the curve found \nare not high and only DORICA and ALLY Framingham \nvascular age for FLI and BARD score and ERICE for \nBARD score exceed 70%.55\n2023/38 (4): 52-59 Relationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers\nTable I: Characteristics of the population.\n  Men n=125,403 Women n=94,074  \n  Mean (SD) Mean (SD) p\nAge 41.8 (10.5) 39.9 (10.5) <0.0001\nHeight 175.2 (6.8) 162.3 (6.3) <0.0001\nWeight 82.6 (15.0) 68.0 (14.7) <0.0001\nSBP 126.1 (15.6) 115.4 (15.5) <0.0001\nDBP 77.3 (11.1) 72.3 (10.5) <0.0001\nCholesterol 195.6 (37.9) 192.1 (35.5) <0.001\nHDL-c 52.1 (9.8) 57.2 (10.3) <0.0001\nLDL-c 118.4 (35.1) 116.3 (33.5) <0.001\nTryglicerides 125.7 (76.0) 93.1 (45.6) <0.0001\nGlycaemia 93.4 (21.5) 88.3 (16.0) <0.0001\nAST 29.0 (17.5) 18.7 (11.6) <0.0001\nALT 24.4 (13.3) 18.2 (7.9) <0.0001\nGGT 32.7 (31.8) 18.8 (16.3) <0.0001\nCreatinine 0.86 (0.17) 0.68 (0.14) <0.0001\n  % % p\n18-29 years 14.4 19.4 <0.0001\n30-39 years 26.6 28.9 \n40-49 years 33.6 32.0 \n50-59 years 21.5 16.8 \n60-69 years 3.9 2.9 \nSocial class I 6.1 7.5 <0.0001\nSocial class II 14.5 20.5 \nSocial class III 79.4 72.0 \nNon smokers 67.5 66.7 <0.001\nSmokers 32.5 33.3  \nSBP systolic blood pressure. DBP diastolic blood pressure. HDL High density lipoprotein.   LDL Low density lipoprotein. AST aspartate transaminase. ALT  alanine \ntransaminase.   GGT gamma-glutamyl transferase.\nTable II: Mean values of NAFLD and liver fibrosis risk scales according to values of cardiovascular risk scales by sex.\n    FLI HSI ZJU FLD FSI LAP BARD\nMen n mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)\nREGICOR low 85617 41.0 (26.6) 37.1 (6.7) 37.4 (5.6) 32.3 (5.3) 0.21 (0.19) 34.5 (29.0) 1.2 (1.1)\nREGICOR moderate 21321 43.1 (26.8) 37.5 (6.6) 37.9 (5.7) 32.7 (5.3) 0.23 (0.20) 35.8 (29.7) 1.3 (1.1)\nREGICOR high-very high 2103 43.3 (27.6) 37.5 (6.6) 38.0 (5.8) 32.8 (5.4) 0.24 (0.21) 36.5 (31.9) 1.4 (1.1)\nSCORE low 56202 42.8 (26.2) 37.3 (6.6) 37.7 (5.5) 32.5 (5.2) 0.22 (0.19) 35.8 (29.6) 1.2 (1.0)\nSCORE moderate 10860 47.8 (26.4) 38.1 (6.6) 38.9 (5.8) 33.4 (5.3) 0.29 (0.21) 39.3 (31.0) 2.0 (1.0)\nSCORE high 6567 51.5 (25.8) 38.5 (6.4) 39.6 (5.7) 33.9 (5.2) 0.34 (0.21) 41.3 (30.4) 2.2 (0.9)\nERICE low-mild 93513 40.4 (26.4) 36.9 (6.7) 37.2 (5.5) 32.1 (5.3) 0.20 (0.18) 34.4 (29.7) 1.1 (1.0)\nERICE moderate 11280 51.4 (25.9) 39.0 (6.6) 39.8 (5.8) 34.2 (5.3) 0.33 (0.21) 39.8 (26.5) 2.2 (1.0)\nERICE high-very high 2604 52.0 (25.3) 39.3 (6.0) 40.2 (5.5) 34.4 (5.0) 0.36 (0.20) 41.6 (31.1) 2.2 (0.9)\nDORICA low-mild 100614 38.3 (26.1) 36.6 (6.7) 36.8 (5.4) 31.8 (5.2) 0.19 (0.17) 32.1 (26.9) 1.0 (1.0)\nDORICA moderate 15294 53.3 (26.1) 38.9 (6.6) 39.9 (5.9) 34.4 (5.5) 0.33 (0.21) 45.9 (37.7) 2.0 (1.0)\nDORICA high-very high 2187 61.7 (25.0) 39.9 (6.8) 42.0 (6.5) 35.9 (5.5) 0.44 (0.23) 57.4 (41.2) 2.4 (1.0)\nALLY VA Framingham <10 years 74928 36.9 (25.0) 36.2 (6.3) 36.5 (5.1) 31.5 (4.9) 0.18 (0.16) 30.9 (25.1) 1.0 (1.0)\nALLY VA Framingham \u226510 years 32469 53.3 (26.6) 39.4 (7.0) 40.0 (6.0) 34.5 (5.6) 0.32 (0.22) 45.6 (36.7) 1.8 (1.1)\nALLY VA SCORE <10 years 50418 41.7 (25.9) 37.1 (6.4) 37.5 (5.4) 32.3 (5.1) 0.21 (0.18) 34.7 (28.4) 1.2 (1.0)\nALLY VA SCORE \u226510 years 23211 50.0 (26.4) 38.4 (6.9) 39.2 (5.8) 33.7 (5.4) 0.31 (0.21) 41.4 (32.7) 1.8 (1.1)\nWomen n mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)\nREGICOR low 63018 20.0 (22.5) 36.6 (6.9) 37.2 (6.1) 30.3 (5.8) 0.15 (0.16) 19.7 (18.3) 0.7 (0.8)\nREGICOR moderate 13551 21.5 (23.5) 37.0 (6.9) 37.6 (6.3) 30.7 (6.0) 0.17 (0.18) 20.6 (17.8) 0.8 (0.9)\nREGICOR high-very high 1371 22.0 (23.9) 37.1 (7.0) 37.6 (6.4) 30.7 (6.1) 0.17 (0.17) 20.9 (18.7) 0.8 (0.9)\nSCORE low 46626 21.8 (22.8) 37.1 (6.7) 37.7 (5.9) 30.8 (5.7) 0.17 (0.17) 20.9 (18.8) 0.9 (0.9)\nSCORE moderate 1479 32.5 (26.3) 39.8 (7.2) 40.5 (6.2) 33.2 (5.9) 0.28 (0.21) 28.4 (23.1) 1.8 (0.8)\nSCORE high 414 34.8 (28.9) 39.8 (7.6) 40.7 (6.8) 33.3 (6.6) 0.32 (0.22) 29.9 (24.7) 1.9 (0.8)\nERICE low-mild 73515 20.3 (22.7) 36.6 (6.8) 37.2 (6.1) 30.3 (5.9) 1.15 (0.16) 19.8 (18.4) 0.7 (0.8)\nERICE moderate 2136 32.3 (25.4) 41.4 (6.8) 41.0 (6.2) 33.4 (5.7) 0.28 (0.18) 29.6 (17.3) 1.8 (0.8)\nERICE high-very high 153 34.0 (27.5) 40.7 (7.3( 41.3 (6.8) 33.8 (6.3) 0.29 (0.22) 30.1 (24.7) 1.9 (0.8)\nDORICA low-mild 84063 19.3 (22.2) 36.3 (6.8) 36.9 (6.0) 30.1 (5.8) 0.14 (0.16) 19.1 (17.7) 0.6 (0.8)\nDORICA moderate 2586 39.7 (28.4) 41.1 (7.4) 42.4 (7.0) 34.8 (6.5) 0.34 (0.24) 35.8 (29.2) 2.0 (0.9)\nDORICA high-very high 75 60.3 (29.4) 45.3 (8.4) 49.6 (8.1) 39.9 (7.6) 0.52 (0.28) 58.3 (41.0) 2.6 (0.8)\nALLY VA Framingham <10 years 61797 17.4 (20.3) 35.9 (6.5) 36.5 (5.6) 29.7 (5.5) 0.13 (0.14) 17.6 (15.6) 0.6 (0.7)\nALLY VA Framingham \u226510 years 14007 35.1 (27.7) 40.5 (7.3) 41.2 (6.7) 33.9 (6.4) 0.28 (0.22) 31.2 (25.8) 1.4 (1.0)\nALLY VA SCORE <10 years 42006 20.9 (22.2) 36.9 (6.6) 37.5 (5.8) 30.6 (5.6) 0.16 (0.16) 20.2 (18.0) 0.8 (0.9)\nALLY VA SCORE \u226510 years 6513 30.3 (26.8) 39.2 (7.2) 39.9 (6.5) 32.7 (6.2) 0.26 (0.22) 27.5 (24.1) 1.5 (1.0)\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. REGICOR (Registro Gironi del coraz\u00f3n). SCORE Systematic Coronary Risk Evaluation. DORICA Dislipemia Obesidad y Riesgo Cardiovascular en Espa\u00f1a \nERICE  Ecuaci\u00f3n de Riesgo Cardiovascular Espa\u00f1ola. ALLY VA Avoidable lost life a\u00f1os vascular age. Statistically significant differences (p<0.001) in all cases.56\n2023/38 (4): 52-59Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nTable III: Prevalence of high values of NAFLD and liver fibrosis risk scales according to values of cardiovascular risk scales by sex.\n    FLI high HSI high ZJU high FLD high LAP high BARD high\nMen n % % % % % %\nREGICOR low 85617 26.6 51.2 39.7 59.8 43.1 35.5\nREGICOR moderate 21321 28.8 53.5 43.4 63.3 45.5 41.1\nREGICOR high-very high 2103 31.0 54.5 44.3 63.7 46.2 41.2\nSCORE low 56202 27.9 53.0 42.0 65.1 45.3 37.2\nSCORE moderate 10860 34.6 60.4 52.3 63.4 51.1 64.3\nSCORE high 6567 41.0 62.9 58.1 64.8 56.5 72.9\nERICE low-mild 93513 25.6 50.0 38.4 63.5 42.3 31.9\nERICE moderate 11280 39.7 65.7 57.7 62.6 56.0 71.8\nERICE high-very high 2604 40.6 70.2 64.2 65.4 56.9 74.8\nDORICA low-mild 100614 23.1 48.2 35.7 62.4 39.1 29.3\nDORICA moderate 15294 42.2 64.7 59.4 62.5 60.5 65.9\nDORICA high-very high 2187 56.4 69.8 72.0 56.0 72.8 82.6\nALLY VA Framingham <10 years 74928 20.6 45.7 33.1 64.1 37.4 28.1\nALLY VA Framingham \u226510 years 32469 43.1 67.0 59.2 61.7 59.7 58.2\nALLY VA SCORE <10 years 50418 26.5 52.1 40.6 65.7 43.8 37.5\nALLY VA SCORE \u226510 years 23211 38.0 61.2 54.3 63.2 54.5 59.4\nWomen n n % % % % %\nREGICOR low 63018 8.7 46.8 37.3 46.6 29.7 15.7\nREGICOR moderate 13551 10.6 48.9 39.5 46.6 31.2 20.6\nREGICOR high-very high 1371 10.7 51.2 40.9 45.1 31.9 19.5\nSCORE low 46626 9.5 50.9 41.2 50.5 32.0 21.8\nSCORE moderate 1479 17.4 69.8 62.1 60.0 49.3 58.4\nSCORE high 414 24.6 66.7 64.5 45.7 51.4 64.5\nERICE low-mild 73515 9.0 46.8 37.4 46.5 29.5 15.6\nERICE moderate 2136 15.7 73.3 64.7 54.9 50.6 60.8\nERICE high-very high 153 20.2 80.4 68.6 57.4 51.0 61.5\nDORICA low-mild 84063 8.4 44.9 35.4 45.1 28.0 13.5\nDORICA moderate 2586 26.8 75.5 71.9 51.7 59.6 67.3\nDORICA high-very high 75 52.0 88.0 92.0 72.1 88.0 92.0\nALLY VA Framingham <10 years 61797 6.4 42.1 32.4 45.0 24.8 11.1\nALLY VA Framingham \u226510 years 14007 22.3 72.1 64.3 54.9 53.7 43.0\nALLY VA SCORE <10 years 42006 8.7 49.7 39.9 50.1 30.8 19.8\nALLY VA SCORE \u226510 years 6513 17.2 64.2 55.7 54.8 45.0 45.6\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. REGICOR (Registro Gironi del coraz\u00f3n). SCORE Systematic Coronary Risk Evaluation. DORICA Dislipemia Obesidad y Riesgo Cardiovascular en Espa\u00f1a \nERICE  Ecuaci\u00f3n de Riesgo Cardiovascular Espa\u00f1ola. ALLY VA Avoidable lost life a\u00f1os vascular age.  Statistically significant differences (p<0.001) in all cases.\nTable IV: Multinomial logistic regression.\n  FLI high HSI high ZJU high FLD high LAP high BARD high\n  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)\nREGICOR low 1 1 1 1 1 1\nREGICOR moderate 1.08 (1.02-1.17) 1.09 (1.00-1.19) 1,08 (1.02-1.15) 1.09 (1.05-1.15) 1.06 (1.02-1.11) 1.11 (1.06-1.17)\nREGICOR high-very high 1.27 (1.17-1.38) 1.14 (1.07-1.22) 1.17 (1.09-1.25) 1.22 (1.14-1.30) 1.14 (1.07-1.22) 1.30 (1.21-1.40)\nSCORE low 1 1 1 1 1 1\nSCORE moderate 1.21 (1.15-1.26) 1.34 (1.29-1.38) 1.31 (1.26-1.35) 1.05 (1.00-1.10) 1.05 (1.01-1.09) 1.30 (1.25-1.34)\nSCORE high 1.31 (1.26-1.36) 1.47 (1.43-1.51) 1.46 (1.42-1.50) 1.25 (1.16-1.34) 1.35 (1.30-1.40) 1.47 (1.42-1.52)\nERICE low-mild 1 1 1 1 1 1\nERICE moderate 1.09 (1.03-1.116) 1.23 (1.12-1.36) 1.18 (1.08-1.30) 1.14 (1.04-1.25) 1.06 (1.01-1.11) 1.04 (1.00-1.09)\nERICE high-very high 1.27 (1.15-1.40) 1.84 (1.67-2.04) 1.62 (1.47-1.78) 1.17 (1.06-1.28) 2.45 (2.20-2.72) 1.23 (1.12-1.35)\nDORICA low-mild 1 1 1 1 1 1\nDORICA moderate 1.79 (1.63-1.96) 1.16 (1.04-1.28) 1.65 (1.49-1.83) 1.29 (1.22-1.35) 1.63 (1.44-1.84) 1.88 (1.70-2.09)\nDORICA high-very high 3.14 (2.84-3.47) 1.39 (1.25-1.54) 2.53 (2.28-2.82) 1.35 (1.28-1.41) 3.24 (2.87-3.67) 3.37 (3.03-3.76)\nALLY VE Framingham <10 years 1 1 1 1 1 1\nALLY VE Framingham \u226510 years 2.49 (2.41-2.58) 2.41 (2.34-2.49) 2.48 (2.41-2.55) 1.02 (1.00-1.05) 1.99 (1.93-2.05) 2.33 (2.27-2.40)\nALLY VE SCORE <10 years 1 1 1 1 1 1\nALLY VE SCORE \u226510 years 1.08 (1.04-1.13) 1.06 (1.01-1.12) 1.12 (1.05-1.19) 1.05 (1.01-1.09) 1.20 (1.15-1.24) 1.17 (1.08-1.26)\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. REGICOR (Registro Gironi del coraz\u00f3n). SCORE Systematic Coronary Risk Evaluation. DORICA Dislipemia Obesidad y Riesgo Cardiovascular en Espa\u00f1a. \nERICE  Ecuaci\u00f3n de Riesgo Cardiovascular Espa\u00f1ola. ALLY VA Avoidable lost life a\u00f1os vascular age.  Statistically significant differences (p<0.001) in all cases.57\n2023/38 (4): 52-59 Relationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers\nFigure 2: ROC curve.\nTable V: Areas under the curve (ROC curves).\n  FLI high HSI high ZJU high FLD high LAP high BARD high\n  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI) \nREGICOR 0.541 (0.537-0.545) 0.531 (0.527-0.534) 0.534 (0.530-0.537) 0.511 (0.508-0.515) 0.536 (0.533-0.539) 0.554 (0.551-0.557)\nSCORE 0.613 (0.609-0.617) 0.556 (0.553-0.560) 0.572 (0.568-0.575) 0.541 (0.538-0.545) 0.588 (0.585-0.592) 0.695 (0.692-0.698)\nERICE 0.625 (0.622-0.629) 0.571 (0.567-0.574) 0.579 (0.575-0.582) 0.545 (0.542-0.549) 0.590 (0.587-0.593) 0.774 (0.772-0.777)\nDORICA 0.704 (0.701-0.707) 0.610 (0.607-0.613) 0.637 (0.634-0.640) 0.558 (0.555-0.561) 0.665 (0.662-0.668) 0.752 (0.749-0.755)\nALLY VA 0.709 (0.706-0.712) 0.651 (0.648-0.654) 0.674 (0.671-0.677) 0.530 (0.527-0.533) 0.678 (0.675-0.681) 0.715 (0.712-0.718)\nFramingham \nALLY VA 0.626 (0.623-0.630) 0.574 (0.571-0.578) 0.592 (0.589-0.596) 0.529 (0.526-0.533) 0.596 (0.593-0.599) 0.691 (0.688-0.694)\nSCORE\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. REGICOR (Registro Gironi del coraz\u00f3n). SCORE Systematic Coronary Risk Evaluation. DORICA Dislipemia Obesidad y  Riesgo Cardiovascular en Espa\u00f1a ERICE  \nEcuaci\u00f3n de Riesgo Cardiovascular Espa\u00f1ola. ALLY VA Avoidable lost life a\u00f1os vascular age.\nDiscussion\nIn our study, the mean values and the prevalence of \nhigh values for all the NAFLD and liver fibrosis risk \nscales analyzed increase as the cardiovascular risk \nscales increase.\nMultivariate analysis showed that the variable that most \nincreased the risk of presenting elevated values of the \ndifferent non-alcoholic fatty liver disease and liver fibrosis \nrisk scales was the DORICA scale followed by vascular \nage with the Framingham model. The areas under the \ncurve of all the cardiovascular risk scales show low \nvalues that only in some cases exceed 70%.We have not found studies like ours that assess the \nrelationship between NAFLD and liver fibrosis risk scales \nwith cardiovascular risk scales but there is abundant \nliterature showing the relationship between NAFLD and \ncardiovascular disease.\nA review by Targher et al20 concluded that there is \nincreasing evidence that NAFLD is strongly associated \nwith an increased risk of severe cardiovascular disease \nsuch as cardiomyopathy, cardiac valvular calcifications, \nand arrhythmias, independent of traditional \ncardiovascular risk factors.58\n2023/38 (4): 52-59Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nA subsequent review by Kasper et al21 also obtained \nsimilar results, indicating that increasing evidence \nsuggests that individuals with NAFLD are at increased \nrisk of developing hypertension, coronary artery disease, \ncardiomyopathy and cardiac arrhythmias, which will lead \nto increased cardiovascular morbidity and mortality.\nA review by Caussy et al22 provided evidence that \nNAFLD could be considered an independent risk factor \nfor cardiovascular disease based on its relationship with \ndiabetes mellitus. People with diabetes and NAFLD were \nfound to have a higher risk of cardiovascular disease \nthan diabetics without NAFLD, suggesting a possible \nsynergistic effect of both conditions on cardiovascular \nrisk. This synergy could be explained because both \nentities share several pathophysiological pathways.\nStrengths and limitations\nThe strengths of the study include the large sample size, \nmore than 200,000 individuals, and the large number of NAFLD and liver fibrosis risk and cardiovascular risk \nscales used. The main limitation is that no objective \ndiagnostic techniques for NAFLD or liver fibrosis other \nthan the risk scales were used.\nConclusions\nTaking into account the results obtained in our study, we \ncan conclude that in this Spanish working population \nthere is a direct relationship between the values of the \ndifferent NAFLD and liver fibrosis risk scales and the \nvalues of the cardiovascular risk scales. The power of \nthe cardiovascular risk scales to predict the presence of \nelevated values of the different NAFLD and liver fibrosis \nscales is low and only in some cases moderate.\nConflict of Interest\nThe authors declare that no competing interests exist.59\n2023/38 (4): 52-59 Relationship between values of 7 NAFLD scales and different RCV scales in 219,477 Spanish workers\nReferences\n1. Zelman S. The liver in obesity. AMA Arch Intern Med. 1952 \nAug;90(2):141-56. doi: 10.1001/archinte.1952.00240080007002.\n2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: \nMayo Clinic experiences with a hitherto unnamed disease. Mayo Clin \nProc. 1980 Jul;55(7):434-8.\n3. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD \nPrevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol \nHepatol. 2022 Dec;20(12):2809-2817.e28. doi: 10.1016/j.\ncgh.2021.12.002.\n4. Younossi ZM, Paik JM, Al Shabeeb R, Golabi P , Younossi I, Henry \nL. Are there outcome differences between NAFLD and metabolic-\nassociated fatty liver disease? Hepatology. 2022 Nov;76(5):1423-\n1437. doi: 10.1002/hep.32499.\n5. Yi M, Peng W, Feng X, Teng F, Tang Y, Kong Q, et al. Extrahepatic \nmorbidities and mortality of NAFLD: an umbrella review of meta-\nanalyses. Aliment Pharmacol Ther. 2022 Oct;56(7):1119-1130. doi: \n10.1111/apt.17165.\n6. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, \nCastiglione A, et al. The Fatty Liver Index: a simple and accurate predictor \nof hepatic steatosis in the general population. BMC Gastroenterol. 2006 \nNov 2;6:33. doi: 10.1186/1471-230X-6-33. \n7. Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of \nHepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis \nin Type 2 Diabetes. Int J Med Sci. 2021 Jul 23;18(14):3280-3289. doi: \n10.7150/ijms.62010.\n8. Li L, You W, Ren W. The ZJU index is a powerful index for identifying \nNAFLD in the general Chinese population. Acta Diabetol. 2017 \nOct;54(10):905-911. doi: 10.1007/s00592-017-1024-8. \n9. Lee I, Cho J, Park J, Kang H. Association of hand-grip strength and \nnon-alcoholic fatty liver disease index in older adults. J Exerc Nutrition \nBiochem. 2018 Dec 31;22(4):62-68. doi: 10.20463/jenb.2018.0031. \n10. Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann \nU, Muntner P , et al. Development and Validation of the Framingham \nSteatosis Index to Identify Persons With Hepatic Steatosis. Clin \nGastroenterol Hepatol. 2016 Aug;14(8):1172-1180.e2. doi: 10.1016/j.\ncgh.2016.03.034.\n11. Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness \nof obesity and lipid-related indices to predict the presence of Non-\nalcoholic fatty liver disease. Lipids Health Dis. 2021 Oct 10;20(1):134. \ndoi: 10.1186/s12944-021-01561-2. \n12. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of \nlaboratory tests, ultrasound, or magnetic resonance elastography to \ndetect fibrosis in patients with nonalcoholic fatty liver disease: A meta-\nanalysis. Hepatology. 2017 Nov;66(5):1486-1501. doi: 10.1002/\nhep.29302.\n 13. Jan\u00e9 BA, Ram\u00edrez-Manent JI, Bote SA, Sbert PR, Gonz\u00e1lez San \nM\u0131guel HM, Lopez Gonz\u00e1lez \u00c1A. Determination of cardiovascular risk \nin 192,711 underweight and normal weight workers. Turk J Med Sci. \n2022 Aug;52(4):926-933. doi: 10.55730/1300-0144.5392.\n14. Rub\u00edn-Garc\u00eda M, Vitelli-Storelli F, Toledo E, Castro-Barquero S, \nTresserra-Rimbau A, Mart\u00ednez-Gonz\u00e1lez M\u00c1, et al. Polyphenol intake \nand cardiovascular risk in the PREDIMED-Plus trial. A comparison of \ndifferent risk equations. Rev Esp Cardiol (Engl Ed). 2022 May;75(5):401-\n411. doi: 10.1016/j.rec.2021.06.013.\n15. Cinza Sanjurjo S, Prieto D\u00edaz M\u00c1, Llisterri Caro JL, Barquilla Garc\u00eda \nA, Rodr\u00edguez Padial L, Vidal P\u00e9rez R, et al. Prevalencia de obesidad \ny comorbilidad cardiovascular asociada en los pacientes incluidos en \nel estudio IBERICAN. Semergen. 2019 Jul-Aug;45(5):311-322. doi: \n10.1016/j.semerg.2018.11.003. \n16. Mohebbi V, Aramayo A, Morales J. Determination of scales related \nto cardiovascular risk and fatty liver in 5.370 Spanish farmers. Academic \nJournal of Health Sciences  2021;36 (2):26-33. doi: 10.3306/\nAJHS.2021.36.02.26\n17. Cuende JI. Vascular Age Versus Cardiovascular Risk: Clarifying \nConcepts. Rev Esp Cardiol (Engl Ed). 2016 Mar;69(3):243-6. doi: \n10.1016/j.rec.2015.10.019.\n18. Cuende JI. Vascular Age, RR, ALLY, RALLY and Vascular Speed, \nBased on SCORE: Relations Between New Concepts of Cardiovascular \nPrevention. Rev Esp Cardiol (Engl Ed). 2018 May;71(5):399-400. \nEnglish, Spanish. doi: 10.1016/j.rec.2017.02.043.\n19. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, \nFerrando J, Borrell C, et al. Propuestas de clase social neoweberiana \ny neomarxista a partir de la Clasificaci\u00f3n Nacional de Ocupaciones \n2011. Gac Sanit. 2013 May-Jun;27(3):263-72. doi: 10.1016/j.\ngaceta.2012.12.009.\n20. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of \ncardiovascular disease: clinical associations, pathophysiological \nmechanisms and pharmacological implications. Gut. 2020 \nSep;69(9):1691-1705. doi: 10.1136/gutjnl-2020-320622.\n21. Kasper P , Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. \nNAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. \n2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7.\n22. Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 \nDiabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep. 2021 Mar \n19;21(5):15. doi: 10.1007/s11892-021-01383-7.60\n2023/38 (4): 60-63ORIGINAL\nPrevalence of sacroiliac joint dysfunction \nin patients with chronic low back pain\nPrevalencia de disfunci\u00f3n de la articulaci\u00f3n sacroil\u00edaca\nen pacientes con dolor lumbar cr\u00f3nico \nHossein Karimiyarandi1      , Khalil Komlakh2\n1. Assistant Professor of Orthopaedics, School of Medicine, Emam Khomeini Hospital, Ilam University of Medical sciences, Ilam, Iran\n2. Department of Neurosurgery, School of Medicine Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  eISSN 2255-0569\nReceived: 16 - I - 2023\nAccepted: 20 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.60Corresponding author\nKhalil Komlakh \nE-mail: khalil.komlakh@yahoo.com  \nAbstract \nBackground: Sacroiliac joint dysfunction (SIJD) is generally occurring in the event of pain in the sacroiliac region in the form of \nabnormal movement in this region. therefore, the aim of the present study was to determine the prevalence of SIJD in LBP patients.\nMethods: The present study was performed on SIJD patients. A total of 190 patients were included in the present study using \nconvenience sampling method. eligible patients that referred to specialized clinics and offices of orthopedic and neurosurgery \nphysicians were identified and the study objectives were explained to them. After obtaining the patients\u2019 consent, the necessary \ndiagnostic tests were performed to evaluate SIJ-related problems. They were then statistically evaluated if they had this syndrome. \nThe data was analyzed using the SPSS16.\nResults: Results showed that out of 190 LBP patients, 82 (43.2%) had SIJ and 108 (56.8%) did not have such syndrome. Table I \nshowed the demographic characteristics of patients with and without SIJ. The results showed no statistically significant difference \nbetween all demographic characteristics of patients (except for gender, employment and physical activity status). Also, the amount \nof pain in standing is equal to 74 (38.9), in walking is equal to 129 (67.9) and in climbing stairs is equal to 83 (43.7), in getting out \nof a car is equal to 113 (59.5%) and in the state of rising from a chair was also equal to 78 (41.1%).\nConclusions: Due to the high prevalence of the joint in SIJD patients, it is suggested to perform therapeutic interventions and \nrehabilitation in these patients.\nKey words: Sacroiliac joint dysfunction, Chronic low back pain, Pain. \nResumen\nAntecedentes: La disfunci\u00f3n de la articulaci\u00f3n sacroil\u00edaca (DISAS) suele producirse si hay dolor en la regi\u00f3n sacroil\u00edaca \nmanifest\u00e1ndose como movimientos anormales en esta regi\u00f3n.El objetivo del presente estudio es determinar la prevalencia de la \ndisfunci\u00f3n de la articulaci\u00f3n sacroil\u00edaca en pacientes con dolor lumbar.\nM\u00e9todos: El presente estudio se realiz\u00f3 en pacientes con DISAS. Se identific\u00f3 a los pacientes elegibles que acudieron a cl\u00ednicas \nespecializadas y consultas de m\u00e9dicos traumat\u00f3logos y neurocirujanos y se les explicaron los objetivos del estudio. Tras obtener \nel consentimiento de los pacientes, se realizaron las pruebas diagn\u00f3sticas necesarias para evaluar los problemas relacionados \ncon la articulaci\u00f3n sacroil\u00edaca. A continuaci\u00f3n, se evalu\u00f3 estad\u00edsticamente si presentaban este s\u00edndrome. Los datos se analizaron \ncon el programa SPSS 16.0.\nResultados: Los resultados mostraron que de 190 pacientes con dolor lumbar, 82 (43,2%) ten\u00edan DISAS y 108 (56,8%) no \nten\u00edan dicho s\u00edndrome. La tabla I mostr\u00f3 las caracter\u00edsticas demogr\u00e1ficas de los pacientes con y sin DISAS. Los resultados no \nmostraron diferencias estad\u00edsticamente significativas entre todas las caracter\u00edsticas demogr\u00e1ficas de los pacientes (excepto el \nsexo, el empleo y el estado de actividad f\u00edsica). Adem\u00e1s, la cantidad de personas con dolor al estar de pie fue de 74 (38,9%), \nal caminar 129 (67,9%), al subir escaleras 83 (43,7%), al salir de un coche113 (59,5%) y en el estado de levantarse de una silla \ntambi\u00e9n era igual a 78 (41,1%).\nConclusiones: Debido a la alta prevalencia de DISAS, se sugiere realizar intervenciones terap\u00e9uticas y de rehabilitaci\u00f3n en \nestos pacientes .\nPalabras clave: Disfunci\u00f3n de la articulaci\u00f3n sacroil\u00edaca, Lumbalgia cr\u00f3nica, Dolor.ID ID61\n2023/38 (4): 60-63Prevalence of sacroiliac joint dysfunction in patients with chronic low back pain\nBackground\nThe sacroiliac joint (SIJ) is the largest axial joint in the \nbody with an average surface area of about 17.5 \ncm, which supports the upper body when walking or \nstanding and is not very mobile1,2. There are currently no \nspecific computed tomography findings for the diagnosis \nof sacroiliac joint dysfunction (SIJD) and degenerative \nfindings are common in asymptomatic people3. SIJ is \nsupported by a network of muscles that help deliver \nregional muscular forces to the pelvic bones. So that \nsome of these muscles are functionally attached to the \nSIJ ligaments and their function can affect joint mobility. \nAge-related changes in the SIJ begin during puberty and \ncontinue throughout life. These changes are accelerated \nin the third and fourth decades of life and may manifest \nthemselves with superficial irregularities up to and \nincluding joint limitations4,5.\nSIJ is responsible for transferring and distributing \ndistributed loads to the lower limbs, facilitating labor, \nlimiting limb rotation, and providing stability with little \nmovement4. SIJD is generally occurs in the event of pain \nin the sacroiliac region in the form of abnormal movement \nin this region. SIJD symptoms include low-back pain \n(LBP), leg sciatica pain, thigh or hip pain, transient \nnumbness, or foot burning6-8. SIJD is one of the causes \nof chronic pain that may often not be diagnosed properly, \nso, it is estimated that SIJD accounts for about 15-30% \nof chronic LBP , which is due to the prevalence of chronic \nLBP , this number is a very important statistic4,9.\nOne of the major challenges of the health system is chronic \npain, which is very complex and has severe symptoms \nand complications. In fact, experiencing pain is an \nunpleasant experience that can affect other aspects of \nlife10-13. Considering the pain overlapping in different parts \nof the body, physicians may mistakenly diagnose SIJ pain \nin other parts of the body and design the related treatment \naccordingly. Therefore, identifying SIJ pain is so important14. \nThis pain is significantly more common in SIJD patients, \nbut complete statistics and information are not available in \nthis regard. One of these types of pain is LBP pain. LBP \nplays a major role in the burden of social diseases and \nyears lived with disability (YLD). LBP is the main cause of \nretirement and can lead to changes in the patient\u2019s lifestyle, \nmental health disorders and obesity by causing economic \nlosses as well as reducing the quality of life15,16.\nObjectives\nSIJ-related problems are very important and it is \nnecessary to pay attention to this group of people. On \nthe other hand, problems related to patients\u2019 pain are \namong the priorities of the medical staff. Therefore, the \naim of the present study was to determine the prevalence \nof SIJD in LBP patients.Methods\nParticipants and Design \nThe present study was performed on SIJD patients in \nIlam. A total of 190 patients were included in the present \nstudy using convenience sampling method.\nInclusion and Exclusion criteria \nInclusion criteria included participants aged between \n18 and 65 years, consent to participate in the study \nand at least 3 months of chronic LBP according to \nthe opinion of a specialist and clinical examinations. \nExclusion criteria also included disc herniation, structural \nanomaly, history of surgery or tumor in the lumbar region, \npregnant women, traumatic L.B.P , disc herniation, history \nof advanced and professional exercise for at least six \nmonths, joint degenerative disorders, history of chronic \ndiseases affecting pain (including cancer, polyneuropathy, \ndiabetes, osteoporosis and other related diseases), \ninability or lack of cooperation when performing clinical \nexaminations and diagnostic tests, osteoporosis, pelvic \nor spinal fractures.\nSIJD diagnosis method\nSpecific Gillet test, supine to sit test, compression test, \nsitting flexion test, (FABER) patrice test, distraction test, \nGaenslen\u2019s test and Yeoman\u2019s test were used to determine \nthe SIJ involvement16-18. Since the result of one test is not \nsufficient to diagnose SIJ-related problems, therefore, \nseveral diagnostic tests were used and if the result of \nthree tests was positive, SIJD was confirmed18-22. To \ninvestigate the pain states, we used questions that were \nraised Telli et al.\u2019s study. These included five questions \nin the field of pain-causing states, which were answered \nusing Yes-No format23.\nStudy method\nEligible patients that referred to specialized clinics and \noffices of orthopedic and neurosurgery physicians were \nidentified and the study objectives were explained to \nthem. After obtaining the patients\u2019 consent, the necessary \ndiagnostic tests were performed to evaluate SIJ-related \nproblems. They were then statistically evaluated if \nthey had this syndrome. Patients were assured that \ntheir information would be kept confidential and that \ntheir cooperation or non-cooperation would not affect \nprovision of the desired services and the necessary \nmedical services will be provided to them in the best \npossible way.\nData analysis\nThe data was analyzed using the SPSS16.\nResults\nResults showed that out of 190 LBP patients, 82 (43.2%) \nhad SIJ and 108 (56.8%) did not have such syndrome. 62\n2023/38 (4): 60-63Hossein Karimiyarandi et al. \nTable I showed the demographic characteristics of \npatients with and without SIJ. The results showed no \nstatistically significant difference between all demographic \ncharacteristics of patients (except for gender, employment \nand physical activity status).\nResults showed, the amount of pain in standing is equal \nto 74 (38.9), in walking is equal to 129 (67.9) and in \nclimbing stairs is equal to 83 (43.7), in getting out of a car is equal to 113 (59.5%) and in the state of rising from a \nchair was also equal to 78 (41.1%).\nAlso, although level of pain was different in SIJD and non- \nSIJD patients in most items, this level was not statistically \nsignificant. However, this difference was statistically \nsignificant in the case of Item \u2018\u2019getting out of a car\u2019\u2019, and \npain level was higher in SIJD patients than other patients \n(p = 0.000) (Table II).\nDiscussion\nResult showed, out of 190 LBP patients, 82 (43.2%) \nhad SIJD and 108 (56.8%) did not have SIJD. In \nprevious studies, Ramirez et al. showed that the SIJD \nprevalence was 40% among 136 LBP patients in Brazil24. \nWieczorek et al. also observed SIJD prevalence in 51 \npatients (60.7%)25. Similarly, Rawat et al. reported that \nwas 13.3% of LBP patients had SIJD26. Other studies \nalso investigated the prevalence of SIJD in different study \npopulations. The SIJD prevalence was also reported \nto be was 30% among Indian students in a study by \nSivakumar et al.27. Madani et al. also reported that SIJD \nprevalence was 72.3% among patients with lumbar \ndisc hernia (LDH) in Tehran, Iran20, which are consistent \nwith the results of the present study, which confirm the \nsignificant prevalence of SIJD in patients.\nResults of comparing demographic characteristics of \npatients with and without SIJD showed that no significant \ndifference between the two groups of patients in terms of all demographic variables except for gender, occupation \nand physical activity. In fact, the employment rate of SIJD \npatients was reported to be 4.9% compared to patients \nwithout SIJD (16.7%). The daily physical activity of SIJD \npatients was much lower than that of patients without \nSIJD, which is consistent with the results of a study by \nDehghan Manshadi et al. in Hamedan, Iran where the \nlevel of physical activity was 24% and 50% in the SIJD \nand non-SIJD groups, respectively28.\nAccording to the findings, the prevalence of SIJD \nwas higher in women than men. Various studies have \ninvestigated the SIJD status in LBP patients and \nother patients. Wieczorek et al. showed that the LBP \nprevalence was higher in women (67.2%) than men25. Telli \net al.23 also showed that the SIJD prevalence was 63.2% \namong women, which is consistent with the results of the \npresent study. Other relevant studies have investigated \nthe relationship between the SIJD prevalence and Table I: Comparison of Demographic Data Between SJD and No SJD.\n - No N (%) No SJD SJD P-value\nSex Male 93(48.9) 66(61.1) 27(32.9) 0.000\n Female 97(51.1) 42(38.9) 55(67.1) \nOccupation Yes  22(11.6) 18(16.7) 4(4.9) 0.012\n No 168(88.4) 90(83.3) 78(95.1) \nMarital status Marital status 104(54.7) 59(54.6) 45(54.9) 0.97\n Single 86(45.3) 49(45.4) 37(45.1) \nActivity Yes  58(30.5) 39(36.1) 19(23.2) 0.055\n No 132(69.5) 69(63.9) 63(76.8) \nEducation level Reading and writing 51(26.8) 29(26.9) 22(26.8) 0.797\n Diploma 118(62.1) 66(61.1) 52(63.4) \n University 21(11.1) 13(12) 8(9.8) \nAge     \nTable II: Comparison of Pain Characteristics Between SJD and No SJD Groups.\n -  No No SJD SJD\n Prolonged standing Yes  74(38.9) 38(35.2) 36(43.9)\n  No 116(61.1) 70(64.8) 46(56.1)\n Getting out of a car Yes  113(59.5) 52(48.1) 61(74.4)\n  No 77(40.5) 56(51.9) 21(25.6)\nPain on Walking some distance Yes  129(67.9) 72(66.7) 57(69.5)\n  No 61(32.1) 36(33.3) 25(30.5)\n Climbing stairs Yes  83(43.7) 45(41.7) 38(46.3)\n  No 107(56.3) 63(58.3) 44(53.7)\n Rising from a chair Yes  78(41.1) 35(32.4) 43(52.4)\n  No 112(58.9) 73(67.6) 39(47.6)63\n2023/38 (4): 60-63Prevalence of sacroiliac joint dysfunction in patients with chronic low back pain\ngender. For example, Telli et al.23 investigated that the \nSIJD prevalence among LDH women and showed that \nSIJD affects 75.6. % of them, while the same prevalence \nwas 57.1% in the non-SIJD group (P<0.005). Sivakumar \net al. also investigated the SIJD prevalence among 590 \nstudents and found that the prevalence of this disorder \nin female students (n=347, 59%) was higher than male \nstudents (n=243, 41%)27.Conclusions\nDue to the high prevalence of the joint in SIJD patients, \nit is suggested to perform therapeutic interventions and \nrehabilitation in these patients.\nConflict of Interests\nNo conflict of interest.\nEthical Approval\nR.MEDILAM.REC.1401\nReferences\n1. Lee S, Kim S, Lee S: European spine journal: official publication of the \nEuropean Spine Society, the European Spinal Deformity Society, and the \nEuropean Section of the Cervical Spine Research Society. Eur Spine J \n2007, 16(3)):431-7.\n2. Tonosu J, Oka H, Watanabe K, Abe H, Higashikawa A, Kawai T, \nYamada K, Nakarai H, Tanaka S, Matsudaira K: Characteristics of the \nspinopelvic parameters of patients with sacroiliac joint pain. Scientific \nReports 2021, 11(1):1-5.\n3. Eno J-JT, Boone CR, Bellino MJ, Bishop JA: The prevalence of sacroiliac \njoint degeneration in asymptomatic adults. JBJS 2015, 97(11):932-6.\n4. Cohen SP: Sacroiliac joint pain: a comprehensive review of anatomy, \ndiagnosis, and treatment. Anesthesia & Analgesia 2005, 101(5):1440-53.\n5. Joukar A, Elgafy H, Agarwal AK, Duhon B, Goel VK: The Sacroiliac \nJoint: A Review of Anatomy, Biomechanics, Diagnosis, and Treatment \nIncluding Clinical and Biomechanical Studies (In Vitro and In Silico). \nHandbook of Spine Technology 2021:349-74.\n6. Cohen SP , Benzon HT: Pain originating from the buttock: sacroiliac joint \nsyndrome and piriformis syndrome. In: Essentials of Pain Medicine. edn.: \nElsevier Inc.; 2011: 330-9.\n7. Hayden JA, Van Tulder MW, Tomlinson G: Systematic review: strategies \nfor using exercise therapy to improve outcomes in chronic low back pain. \nAnnals of internal medicine 2005, 142(9):776-85.\n8. Arslan A, Ahmad A, Muhammad SB, Asghar M: Prevalence of Sacroiliac \nJoint Dysfunction Among Females In Lahore: A Cross Sectional Study. \nPakistan Journal of Physical Therapy (PJPT) 2021.\n9. Chopp JN, Fischer SL, Dickerson CR: The specificity of fatiguing \nprotocols affects scapular orientation: Implications for subacromial \nimpingement. Clinical Biomechanics 2011, 26(1):40-5.\n10. Hatefi M, KomLakh K: Investigation of the effect of Duloxetine on pain \nstatus of patients with spinal cord injuries: A systematic review of drug \ntherapy. Eurasian Chemical Communications 2022, 4(3):256-62.\n11. Hatefi M, Komlakh K, Nouri L: Investigating the effect of \nmethylprednisolone pulse on the treatment of back pain. Romanian \nJournal of, 125(2):264.\n12. Komlakh K, Karbasfrushan A: The effect of Pregabalin on the pain \nstatus of patients with disc and spinal surgeries: A systematic review \nof drug therapy. EURASIAN CHEMICAL COMMUNICATIONS 2022, \n4(11):1147-55.\n13. Vasigh A, Tarjoman A, Borji M: The effect of spiritual-religious \ninterventions on patients\u2019 pain status: systematic review. Anaesthesia, \nPain & Intensive Care 2018, 22(4).\n14. Deer TR, Rupp A, Budwany R, Bovinet CJ, Chatas JW, Pyles ST, \nAzeem N, Li S, Naidu R, Antony A: Pain relief salvage with a novel minimally \ninvasive posterior sacroiliac joint fusion device in patients with previously \nimplanted pain devices and therapies. Journal of Pain Research 2021, \n14:2709.15. Peck J, Urits I, Peoples S, Foster L, Malla A, Berger AA, Cornett EM, \nKassem H, Herman J, Kaye AD: A comprehensive review of over the \ncounter treatment for chronic low back pain. Pain and Therapy 2021, \n10(1):69-80.\n16. Vickers NJ: Animal communication: when i\u2019m calling you, will you \nanswer too? Current biology 2017, 27(14):R713-R715.\n17. Ribeiro RP , Guerrero FG, Camargo EN, Pivotto LR, Aimi MA, Loss \nJF, Candotti CT: Construct validity and reliability of tests for sacroiliac \ndysfunction: standing flexion test (STFT) and sitting flexion test (SIFT). \nJournal of Osteopathic Medicine 2021, 121(11):849-56.\n18. Laslett M, Young SB, Aprill CN, McDonald B: Diagnosing painful \nsacroiliac joints: A validity study of a McKenzie evaluation and sacroiliac \nprovocation tests. Australian Journal of Physiotherapy 2003, 49(2):89-97.\n19. Young S, Aprill C, Laslett M: Correlation of clinical examination \ncharacteristics with three sources of chronic low back pain. The spine \njournal 2003, 3(6):460-5.\n20. Rezaeian ZS, Alifard F, Goodarzi Z, Karimi A, Asghari-Jafarabadi M: \nPrevalence of sacroiliac dysfunction among patients with Low back pain \nreferring to hospitals in Isfahan (a pilot study). Journal of Research in \nRehabilitation Sciences 2008, 4(1).\n21. McKenzie R, May S: The lumbar spine: mechanical diagnosis and \ntherapy, vol. 1: Orthopedic Physical Therapy; 2003.\n22. Madani SP , Dadian M, Firouznia K, Alalawi S: Sacroiliac joint dysfunction \nin patients with herniated lumbar disc: a cross-sectional study. Journal of \nback and musculoskeletal rehabilitation 2013, 26(3):273-9.\n23. Telli H, H\u00fcner B, Kuru \u00d6: Determination of the prevalence from clinical \ndiagnosis of sacroiliac joint dysfunction in patients with lumbar disc hernia \nand an evaluation of the effect of this combination on pain and quality of \nlife. Spine 2020, 45(8):549.\n24. Ramirez C, Sanchez L, Oliveira B: Prevalence of sacroiliac joint \ndysfunction and sacroiliac pain provocation tests in people with low back \npain. Annals of Physical and Rehabilitation Medicine 2018, 61:e152.\n25. Wieczorek A, Campau E, Pionk E, Gabriel-Champine ME, R\u00edos-\nBedoya CF: A Closer Look into the Association between the Sacroiliac \nJoint and Low Back Pain. Spartan Medical Research Journal 2021, 6(1).\n26. Dr.Sudhir Kumar Rawat DAV, Dr.Arvind Kumar, Dr Munir Upadhyay, \nDr Amit Patel, Dr Mikir Soni, Dr Jainish Patel. A STUDY OF PREVALENCE \nOF SACROILIAC JOINT DISEASE IN CHRONIC IDIOPATHIC LOW BACK \nPAIN PATIENTS.International Journal of Advanced Research (2016), \nVolume 4, Issue 2, 1471-7. In.\n27. Sivakumar S, Kamalakannan M, Arun B, Kalpana A, Prakash J, \nPradeep KV: Prevalence of sacroiliac joint dysfunction in college students. \nBiomedicine 2021, 41(2):293-6.\n28. Dehghan Manshadi F, Haj-valie G, Heydari Moghadam R, Khademi Kalantar \nK, Yavari kia A, Karami M: The relationship between anterior knee pain and \ndysfunction of the sacroiliac joint. Journal of Ergonomics 2015, 3(1):10-6.64\n2023/38 (4): 64-68ORIGINAL\nHyperbilirubinemia is a predictor of \nappendiceal perforation in children: A meta-analysis\nLa hiperbilirrubinemia es un factor predictivo de perforaci\u00f3n apendicular en ni\u00f1os: \nUn metaan\u00e1lisis \nMustafa Azizo\u011flu1,2      , Mehmet Hanifi Okur1,2      , Bahattin Aydo\u011fdu1,2      ,\nTu\u011f\u00e7e Merve Orbay2,3      , Ayten Ceren Bakir2,4      , Sergey Alexandrovich Klyuev2,5      ,\nSalim Bilici2,6      , Salih Bayram2,6      , Fikret Salik2,7      , Toni Risteski2,8\n1. Dicle University Faculty of Medicine, Department of Pediatric Surgery, Diyarbak\u0131r, Turkey    2. PeSMA Study Group\n3. Siirt Traning and Research Hospital Department of Pediatric surgery, Siirt Turkey    4. Marmara University. Department of Pediatric \nSurgery Istambul Turkey    5. Saratov State Medical University named after I.V. Rasumovsky, Department of Pediatric Surgery, \nSaratov, Russian Federation    6. Mardin Artuklu University, Faculty of Medicine, Department of Pediatric Surgery, Mardin, Turkey\n7. Dicle University Faculty of Medicine, Department of Anesthesiology and Reanimation, Diyarbak\u0131r Turkey\n8. University Clinic of Pediatric Surgery, Ss. Cyril and Methodius University of Skopje Medical Faculty, Skopje, North Macedonia.eISSN 2255-0569\nReceived: 20 - I - 2023\nAccepted: 18 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.64Corresponding author\nMustafa Azizoglu \nE-mail: mdmazizoglu@gmail.com  \nAbstract \nObjective: In this meta-analysis, our goal was to examine the diagnostic utility of bilirubin in identifying complicated from \nuncomplicated pediatric appendicitis. \nMaterials and methods: Using the databases Embase, PubMed, Scopus, and Cochrane, we carried out a thorough literature \nsearch up to 2022. Studies comparing complicated appendicitis (CA) and simple appendicitis (SA) in terms of hyperbilirubinemia \nin the pediatric population were included. \nResults: A total of 5 studies with 2740 acute appendicitis patients (1097 complicated appendicitis and 1643 simple appendicitis) \nwere included in this meta-analysis. Five studies have discussed the diagnostic value of total bilirubin (TB). When compared to \nsimple appendicitis, complicated appendicitis had a significantly higher TB count (I2=94%), (WMD=0.18, 95% CI -0.00 to 0.37; \nP=0.05), DB count (I2=0%), (WMD=0.11, 95% CI 0.04 to 0.18; P=0.002), and IB count (I2= not applicable), (WMD=0.04, 95% CI \n0.01 to 0.07; P=0.02). \nConclusions: In conclusion, in this meta-analysis, total bilirubin, direct bilirubin, and indirect bilirubin values were higher in \ncomplicated appendicitis compared to simple appendicitis. Both total bilirubin and direct bilirubin can be used as diagnostic \nparameters in childhood appendicitis to differentiate complicated appendicitis from simple appendicitis.\nKey words: Appendicitis, children, direct hyperbilirubinemia, hyperbilirubinemia. \nResumen\nObjetivo: En este metan\u00e1lisis, nuestro objetivo fue examinar la utilidad diagn\u00f3stica de la bilirrubina para identificar la apendicitis \npedi\u00e1trica complicada frente a la no complicada. \nMateriales y m\u00e9todos: Utilizando las bases de datos Embase, PubMed, Scopus y Cochrane, realizamos una b\u00fasqueda \nbibliogr\u00e1fica exhaustiva hasta 2022. Se incluyeron estudios que compararan apendicitis complicada (AC) y apendicitis simple (AS) \nen t\u00e9rminos de hiperbilirrubinemia en la poblaci\u00f3n pedi\u00e1trica. \nResultados: Se incluyeron en este metan\u00e1lisis un total de 5 estudios con 2740 pacientes con apendicitis aguda (1097 complicada \ny 1643 simple). Cinco estudios han discutido el valor diagn\u00f3stico de la bilirrubina total (TB). En comparaci\u00f3n con la apendicitis \nsimple, la apendicitis complicada tuvo un recuento de TB significativamente mayor (I2=94 %), (DMP=0,18, IC del 95 %: -0,00 a \n0,37; P=0,05), recuento de DB (I2=0 %), (DMP = 0,11, IC del 95 %: 0,04 a 0,18; P = 0,002) y recuento de BI (I2 = no aplicable), \n(DMP = 0,04, IC del 95 %: 0,01 a 0,07; P = 0,02). \nConclusiones: Tanto la bilirrubina total como la directa pueden usarse como par\u00e1metros de diagn\u00f3stico en la apendicitis infantil \npara diferenciar la apendicitis complicada de la apendicitis simple.\nPalabras clave: Apendicitis, ni\u00f1os, hiperbilirrubinemia directa, hiperbilirrubinemia.ID\nID ID ID\nID ID ID IDID ID65\n2023/38 (4): 64-68Hyperbilirubinemia is a predictor of appendiceal perforation in children: A meta-analysis\nIntroduction\nOne of the most typical causes of acute abdomen is \nacute appendicitis1. This disease has a perforation risk \nof up to 20% and a lifetime incidence of about 7%1,2. \nEarly diagnosis can occasionally be difficult, despite \nthe well-known classical signs and clinical features \nof acute appendicitis. Acute appendicitis is primarily \ndiagnosed based on clinical symptoms, with radiological \nexaminations being reserved for specific patients. A \nperforation, which can be linked to considerable morbidity \nand even fatality, may occur if acute appendicitis is not \ndiagnosed at an early stage3,4.\nThe Alvarado score and the RIPASA score are only \ntwo of the several screening and scoring instruments \nthat have been developed to help in the diagnosis \nof acute appendicitis1. However, scoring methods \nlike these have come under fire for lacking sensitivity \nand specificity as well as failing to foretell the severity \nof acute appendicitis. In addition, a number of blood \ntests are utilized to gauge the severity of appendicitis. \nHowever, a raised WBC count has no prognostic \nutility in identifying uncomplicated appendicitis from \ncomplicated appendicitis1-4. Blood cells (WBC) counts \nare typically elevated in patients with appendicitis. \nMany researchers are still interested in finding a method \nor marker that can predict the diagnosis of acute \nappendicitis and distinguish between uncomplicated \nand severe appendicitis with good sensitivity and \nspecificity5-7. A straightforward, affordable, and easily \ncalculable measure of subclinical inflammation is \nbilirubin. Although elevated blood bilirubin has been \nfound to be a possible indicator of appendix perforation, \nits sensitivity and specificity are insufficient8-10.\nIn this meta-analysis, our goal was to examine the \ndiagnostic utility of bilirubin in identifying complicated \nfrom uncomplicated pediatric appendicitis.\nMaterials and Methods\nSearch Strategy\nUsing the databases Embase, PubMed, Scopus, and \nCochrane, we carried out a thorough literature search \nup to 2022. Appendicitis, pediatric appendicitis, \nperforated appendicitis, gangrenous appendicitis, \nhyperbilirubinemia, direct bilirubin, elevated bilirubin, and \nchildren were the search phrases used. Furthermore, \nwe searched also \u201csimple appendicitis, complicated \nappendicitis, un-complicated appendicitis, non-\ncomplicated appendicitis, pediatric appendicitis, \nappendicitis in children, hyperbilirubinemia in \nappendicitis, serum bilirubin, laboratory marker for \nappendicitis\u201d. References and reviews were searched \nmanually for further relevance.Study Selection\nStudies comparing complicated appendicitis (CA) and simple \nappendicitis (SA) in the pediatric population were included . \nInclusion criteria:1 clinical studies comparing CA and \nSA, and2 raw data including some of the following: total \nbilirubin, direct bilirubin, and indirect bilirubin. \nExclusion criteria:1 no comparative case series as a \ncontrol;2 studies could not provide usable raw data or \nduplicate publications.\nData Extraction\nTwo authors independently reviewed the included studies \n(SA and MA). We extracted information on sample size, \nstudy design, and year of publication. Population data \nwere obtained, including the type of appendicitis, and \nbilirubin values.\nRisk of Bias Assessment\nThe risk of bias in the included studies was evaluated \nusing the ROBINS-I (Risk Of Bias in Non-randomized \nStudies\u2014of Interventions) method. The reviewers also \nevaluated the overall risk of bias across all studies \nfor each relevant outcome and considered that \ninformation when making decisions about the \u201cquality \nof evidence.\u201d\nTable I: PRISMA flow diagram of study selection.\nIdentification Screening Eligibility IncludedRecords identified from:\nDatabases:\n(n=5236)\nRecords after the \nremoval of irrelevant \nand duplicates \n(n=81)\nRecords screened\n(n = 81)\nReports assessed for \neligibility\n(n = 42)\nStudies included\nin meta-analysis\n(n = 5)Reports not retrieved for \nreason (n=39)\nFull-text articles did not \nmeet the inclusion \ncriteria (n=37)Studies excluded for \nirrelevancy \nand duplicates \n(n=5155)66\n2023/38 (4): 64-68\nMustafa Azizo\u011flu et al. \nStatistical Analysis\nFor the statistical data analysis, Review Manager \n(RevMan) software version 5.4 was used. Both \ncontinuous and dichotomous variables were evaluated \nusing measured mean differences and risk ratios. The \nI2 statistic was employed to quantify the amount of \nstatistical heterogeneity, and the Chi-square test was \nutilized to determine it. Significance was set at P \u22640.05. \nWe applied a random effect model.\nReporting\nPRISMA (Preferred Reporting Items for Systematic \nreviews and Meta-analysis) was used to report the \nfindings of this systematic review.Results\nUsing a PRISMA flow diagram, table I presents an \noverview of the selection procedure of 42 studies \nidentified during the initial search strategy were retrieved \nfor full-text review, and 5 studies8,9,10,11,12 with 2740 acute \nappendicitis patients (1097 complicated appendicitis \nand 1643 simple appendicitis) who met the inclusion \ncriteria were selected.\nRisk of Bias\nTable II provides a summary of the ROBINS-I tool\u2019s risk \nof bias evaluation. A \u201cmoderate\u201d risk of bias existed in \nthree articles with regard to \u201cBias due to confounding.\u201d \nGiven their retrospective character, all studies had a \n\u201cmoderate\u201d risk of bias in the other categories.\nTable II: Risk of Bias (ROBINS-I Tool).\nAuthor Year Bias due to confounding Bias for other domains\nChen et al. 2021 Moderate: Age under 3 years Moderate\nG\u00fcng\u00f6r et al.  2021 Moderate: Age difference between groups Moderate\nKoirala et al. 2022 Moderate: Difference of number by gender  Moderate\nNoh et al. 2012 Moderate: Age difference between groups Moderate\nYang et al. 2019 Moderate: Age difference between groups Moderate\nFigure 1: The value of total bilirubin. \nFigure 2: The value of direct bilirubin. \nFigure 3: The value of indirect bilirubin. \n67\n2023/38 (4): 64-68Hyperbilirubinemia is a predictor of appendiceal perforation in children: A meta-analysis\nOutcomes\nA total of 5 studies were included in this meta-analysis. All \nof these studies were retrospective comparative studies \nTo be used to distinguish complicated appendicitis from \nsimple appendicitis; 5 studies evaluating total bilirubin, \n2 direct bilirubin, and 1 study of indirect bilirubin were \nincluded in this meta-analysis.\nTotal bilirubin\nFive studies have discussed the diagnostic value of total \nbilirubin (TB). When compared to simple appendicitis, \ncomplicated appendicitis had a significantly higher TB \ncount (I2=94%), (WMD=0.18, 95% CI -0.00 to 0.37; \nP=0.05; Figure 1).\nDirect Bilirubin\nAlthough three studies documented the diagnostic value \nof direct bilirubin (DB), only two studies (111 patients in \nCA group and 52 patients in SA group) were suitable for \nmeta-analysis. However, the CA group had a significantly \nhigher DB when compared to SA group (I2=0%), \n(WMD=0.11, 95% CI 0.04 to 0.18; P=0.002; Figure 2).\nIndirect Bilirubin\nOnly 1 study (93 patients in CA group and 28 patients \nin SA group) was suitable for meta-analysis investigating \nthe effects of indirect bilirubin (IB). It is found that CA \ngroup had a significantly higher IB when compared to the \nSA group (I2= not applicable), (WMD=0.04, 95% CI 0.01 \nto 0.07; P=0.02; Figure 3).\nDiscussion\nSince all studies included in this meta-analysis had a \nmoderate risk of bias, no studies were excluded due to bias.\nIn many previous studies, the effects and results of \nlaboratory blood parameters on the differential diagnosis, \ndiagnostic features, treatment, and complications \nof simple appendicitis and complicated appendicitis \nwere examined11,12. Especially in recent years, relative \nparameters such as neutrophil-lymphocyte ratio and \nplatelet-lymphocyte ratio have come to the fore13-16.\nThe main goal of this study is to establish whether or \nnot hyperbilirubinemia is a valid indicator of appendiceal \nperforation. The meta-analysis of previous studies \nemphasized that hyperbilirubinemia can be used to \npredict perforated appendicitis in adult patients17. There \nare studies suggesting that hyperbilirubinemia in children \ncan be used in the differential diagnosis of complicated \nappendicitis and acute appendicitis, as in adults10-12. But \nthere is no meta-analysis on this subject. However, this \nmeta-analysis is the first meta-analysis suggesting that \nhyperbilirubinemia (both total, indirect and direct) can \nbe used in the differential diagnosis of complicated and \nsimple appendicitis in the pediatric population.According to the study by Koirala et al., it shows that both \ndirect and total bilirubin can be used in the differential \ndiagnosis of complicated and simple appendicitis8. \nSimilar results were found in the study by Chen et al. In \nthe study by Chen et al., the mean of direct bilirubin in the \ncomplicated appendicitis group was almost twice that of \nappendicitis in the simple appendicitis group9. On the \nother hand, according to a study conducted by G\u00fcng\u00f6r \net al. in 2021, the mean total bilirubin in the complicated \nappendicitis group was almost twice as high as the \ntotal bilirubin in the simple appendicitis group12. It is \nnoteworthy that the number of patients in this study is \nconsiderably higher than in equivalent studies. However, \nas a result, when complicated appendicitis and simple \nappendicitis were compared in our study, total bilirubin \n(p=0.05), direct bilirubin (p=0.002), and indirect \nbilirubin (p=0.02) values were higher in the complicated \nappendicitis group.\nConclusions\nIn conclusion, in this meta-analysis, total bilirubin, \ndirect bilirubin, and indirect bilirubin values were higher \nin complicated appendicitis compared to simple \nappendicitis. Both total bilirubin and direct bilirubin can be \nused as diagnostic parameters in childhood appendicitis \nto differentiate complicated appendicitis from simple \nappendicitis.\nConflict of interest\nThe authors declare no conflict of interest\nFunding\nNo68\n2023/38 (4): 64-68Mustafa Azizo\u011flu et al. \nHyperbilirubinemia is a predictor of appendiceal perforation in children: A meta-analysis\nReferences\n1. Krzyzak M, Mulrooney SM. Acute Appendicitis Review: Background, \nEpidemiology, Diagnosis, and Treatment. Cureus. 2020 Jun \n11;12(6):e8562.\n2. Risteski T, Sokolova R, Memeti S, Simeonov R. Laparoscopic versus \nopen appendectomy in pediatric patients: Operative and postoperative \nexperience. J Clin Tri Exp Invest. 2022;1(2):49-55. \n3. Basuguy E, Okur MH, Arslan S, Aydo\u011fdu B, Akdeniz S, Azizo\u011flu M. \n\u00c7ocuklarda torakoport yard\u0131ml\u0131 laparoskopik apendektomi sonu\u00e7lar\u0131m\u0131z. \nDicle Med J. 2020;47(3):727-34.\n4. Falchi D, Bak\u0131r AC, Risteski T, Abu Tziam H, Y\u00fcksel S, Inal Azizo\u011flu \nS. Diagnostic Value of The Ischemia Modified Albumin and Pentraxin \n3 In Pediatric Appendicitis: A Meta Analysis. J Clin Tri Exp Invest. \n2022;1(1):1-9.\n5. Oztan MO, Aksoy Gokmen A, Ozdemir T, M\u00fcderris T, Kaya S, \nKoyluoglu G. Pentraxin-3: A strong novel biochemical marker for \nappendicitis in children. Am J Emerg Med. 2019;37(10):1912-16.\n6. Arslan S, Aydogdu B, Arslan MS, Zeytun H, Okur MH, Basuguy E, \net al. Analysis of Risk Factors for Appendicitis in Children: A Multicenter \nEpidemiological Study. Dicle Med J. 2016;43(4):556-60.\n7. Halaseh SA, Kostalas M, Kopec C, Nimer A. Bilirubin as a Predictor of \nComplicated Appendicitis in a District General Hospital: A Retrospective \nAnalysis. Cureus. 2022;14(9):e29036.\n8. Koirala DP , Gupta AK, Dahal GR, Shrestha BM, Shrestha S, Neupane \nS, et al. Role of hyperbilirubinaemia as a predictor of complicated \nappendicitis in paediatric population. Afr J Paediatr Surg. 2022;19:61-\n4.\n9. Chen Y, Wang Z, Xiao D, Zeng H, Ma X. Predicting the Severity \nof Acute Appendicitis of Young Children (<3 Years Old): Development \nand Assessment of a New Prediction Nomogram. Front Pediatr. \n2021;9:763125.10. Yang J, Liu C, He Y, Cai Z. Laboratory Markers in the Prediction \nof Acute Perforated Appendicitis in Children. Emerg Med Int. \n2019;2019:4608053.\n11. Noh H, Chang SJ, Han A. The diagnostic values of preoperative \nlaboratory markers in children with complicated appendicitis. J Korean \nSurg Soc. 2012;83(4):237-41\n12. G\u00fcng\u00f6r A, G\u00f6ktu\u011f A, G\u00fcneylio\u011flu MM, Yarad\u0131lm\u0131\u015f RM, Bodur \nI, \u00d6zt\u00fcrk B, et al. Utility of biomarkers in predicting complicated \nappendicitis: can immature granulocyte percentage and C-reactive \nprotein be used? Postgrad Med. 2021;133(7):817-21.\n13. Catal O, Ozer B, Sit M, Erkol H. Is appendectomy a simple surgical \nprocedure? Cir Cir. 2021;89(3):303-8\n14. Ozdemir H, Sunamak O. Comparison of the non-absorbable \npolymer clips, knot-tying, and loop ligature appendiceal stump closure \nmethods in laparoscopic appendectomy. Cir Cir. 2022;90(2):193-6.\n15. Esquivel-Esquivel N, Horta-Baas G. Neutrophil-to-lymphocyte ratio \nin the diagnosis of acute appendicitis. Assessment of its diagnostic \naccuracy. Arch Argent Pediatr. 2022;120(5):317-24.\n16. Ayeni A, Mahmood F, Mustafa A, Mcleish B, Kulkarni V, Singhal S, \net al. Predicting the Severity of Acute Appendicitis in Children Using \nNeutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte \nRatio (PLR). Cureus. 2022;14(8):e28619.\n17. Gavriilidis P , de\u2019Angelis N, Evans J, Di Saverio S, Kang P . \nHyperbilirubinemia as a Predictor of Appendiceal Perforation: A \nSystematic Review and Diagnostic Test Meta-Analysis. J Clin Med Res. \n2019;11(3):171-8.69\n2023/38 (4): 69-75ORIGINAL\nC\u00e1ncer y vacunas. Presente y futuro \nCancer and vaccines. Present and future  \nM\u00aa Te\u00f3fila Vicente-Herrero1      , Jos\u00e9 Lorenzo Bravo-Grande2      , \nM\u00aa Victoria Ram\u00edrez-I\u00f1iguez de la Torre3\n1. Grupo C\u00e1ncer y Trabajo y de Gu\u00edas y Protocolos. Asociaci\u00f3n Espa\u00f1ola de Especialistas en Medicina del Trabajo (AEEMT). \nGrupo ADEMA-SALUD del Instituto Universitario de Ciencias de la Salud-IUNICS Illes Balears (Espa\u00f1a)\n2. Grupo C\u00e1ncer y Trabajo y Grupo de Vacunas. Asociaci\u00f3n Espa\u00f1ola de Especialistas en Medicina del Trabajo (AEEMT). Vocal \nde Salud Laboral en la Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda (AEV).\n3. Grupo C\u00e1ncer y Trabajo y de Gu\u00edas y Protocolos. Asociaci\u00f3n Espa\u00f1ola de Especialistas en Medicina del Trabajo (AEEMT). \nResponsable Medicina del Trabajo en SPP Grupo Correos Albacete y Cuenca. Coordinadora de Medicina del Trabajo del SPA \nITEM-prevenci\u00f3n\n eISSN 2255-0569\nReceived: 22 - I - 2023\nAccepted: 23 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.69Corresponding author\nDra. M\u00aa Te\u00f3fila Vicente-Herrero \nE-mail: vicenteherreromt@gmail.com  \nResumen\nIntroducci\u00f3n: En el \u00faltimo siglo, las vacunas han sido la herramienta sanitaria m\u00e1s eficaz en salud p\u00fablica para reducir la mortalidad \ny morbilidad de las enfermedades infecciosas. En la prevenci\u00f3n y tratamiento del c\u00e1ncer, la tendencia actual se orienta hacia un \ntratamiento personalizado en el que se incluyen las vacunas junto con otros tratamientos novedosos, como la inmunoterapia. \nMetodolog\u00eda: Se realiza una revisi\u00f3n bibliogr\u00e1fica, en diciembre de 2022, en las bases de datos de PubMed/Medline, de art\u00edculos \ncient\u00edficos publicados en l\u00ednea hasta la fecha, sin acotar periodo de b\u00fasqueda, utilizando como palabras clave y t\u00e9rminos MeSH: \ncancer and vaccines; Cancer and therapeutic vaccines; colorectal cancer, Skin c\u00e1ncer, Breast cancer, Prostate cancer, Kidney \ncancer, Lung cancer; Cancer and preventive vaccines HPV, Hepatitis B. \nResultados: Los resultados obtenidos en la b\u00fasqueda con el concepto gen\u00e9rico (c\u00e1ncer y vacunas) y, de forma concreta, los \nrelacionados con la utilizaci\u00f3n terap\u00e9utica de las vacunas en c\u00e1ncer, casi duplican los referidos al uso preventivo. Destacan las \nreferencias a c\u00e1ncer de pulm\u00f3n, de piel y de mama y, en uso preventivo, las de virus del papiloma y hepatitis B. \nConclusi\u00f3n: El desarrollo de vacunas para el tratamiento del c\u00e1ncer es un reto, ya que la intervenci\u00f3n vacunal debe combatir \nun sistema inmunitario que ha sido restringido por mecanismos que sostienen la respuesta inmunitaria y frenado por los que \nmantienen la enfermedad en un intento de autotolerancia. Los resultados en curso de este tipo de vacunas son prometedores.\nPalabras clave: c\u00e1ncer, vacunas terap\u00e9uticas, vacunas preventivas, inmunoterapia.\nAbstract \nIntroduction. In the last century, vaccines have been the most effective public health tool to reduce mortality and morbidity from \ninfectious diseases. In cancer prevention and treatment, the current trend is towards personalized treatment, including vaccines \nalong with other novel treatments such as immunotherapy. \nMethodology. A literature review was carried out in December 2022 in the PubMed/Medline databases of scientific articles \npublished online to date, without limiting the search period, using the following keywords and MeSH terms: cancer and vaccines; \nCancer and therapeutic vaccines; colorectal cancer, Skin cancer, Breast cancer, Prostate cancer, Kidney cancer, Lung cancer; \nCancer and preventive vaccines HPV, Hepatitis B. \nResults. The results obtained in the search with the generic concept (cancer and vaccines) and, specifically, those related to the \ntherapeutic use of vaccines in cancer almost double those referring to preventive use. The references to lung, skin and breast \ncancer and, in preventive use, those for papillomavirus and hepatitis B stand out. \nConclusion. The development of vaccines for cancer treatment is challenging, as vaccine intervention must combat an immune \nsystem that has been constrained by mechanisms that sustain the immune response and held back by those that maintain the \ndisease in an attempt at self-tolerance. The expected future results of such vaccines are promising.\nKeywords: cancer, prophylactic cancer vaccine, therapeutic cancer vaccine, immunotherapy. ID ID\nID70\n2023/38 (4): 69-75Introducci\u00f3n\nEn el \u00faltimo siglo, las vacunas han sido la herramienta \nsanitaria m\u00e1s eficaz en salud p\u00fablica para reducir \nla mortalidad y morbilidad de las enfermedades \ninfecciosas. Sin embargo, muchas enfermedades a\u00fan \nno pueden prevenirse mediante vacunaci\u00f3n, dejando un \ncampo abierto a la investigaci\u00f3n. En algunas patolog\u00edas, \nlos ensayos cl\u00ednicos y las nuevas tecnolog\u00edas abren \nnuevas posibilidades para hacer frente, como medidas \npreventivas o terap\u00e9uticas, a m\u00e1s enfermedades en el \nsiglo XXI, con el desarrollo de vacunas, ya sea como \nadyuvantes, vectores, vacunas de \u00e1cidos nucl\u00e9icos o \ndise\u00f1o de ant\u00edgenos1.\nEn el campo del tratamiento del c\u00e1ncer, la tendencia \nactual en las actuaciones sanitarias se orienta de forma \ncreciente hacia un tratamiento personalizado, en el que \nse incluyen las vacunas. Las dificultades asociadas a la \nfalta de potencia y amplitud antig\u00e9nica se reducen con \nel uso de la nanotecnolog\u00eda biomim\u00e9tica, que permitir\u00e1 \nsuperar estos obst\u00e1culos dentro de una perspectiva de \nmedicina personalizada2.\nMetodolog\u00eda\nSe realiza una b\u00fasqueda, en diciembre de 2022, en las \nbases de datos de PubMed/Medline, de art\u00edculos cient\u00edficos \npublicados en l\u00ednea hasta la fecha de la b\u00fasqueda sin \nacotar periodo de tiempo, utilizando como palabras clave y \nt\u00e9rminos MeSH los que se muestran en la tabla.\nSe seleccionaron 46 art\u00edculos originales, revisiones \nsistem\u00e1ticas y art\u00edculos de revisi\u00f3n relacionados con \nla vacunaci\u00f3n preventiva y terap\u00e9utica en c\u00e1ncer. Se \nexcluyeron estudios con informaci\u00f3n no relevante, \ncomentando 27 de estos art\u00edculos por su mayor \ninter\u00e9s para los autores, todos ellos de los \u00faltimos 5 \na\u00f1os (Tabla I). \nResultados \nSon cuantiosos los resultados obtenidos en la b\u00fasqueda \nde la bibliograf\u00eda cient\u00edfica con el concepto gen\u00e9rico (c\u00e1ncer y vacunas) y, de forma concreta, los relacionados \ncon la utilizaci\u00f3n terap\u00e9utica de las vacunas en c\u00e1ncer \ncasi duplican los referidos al uso preventivo. En cuanto \nal tipo de c\u00e1ncer, destacan los que relacionan el uso \nterap\u00e9utico de las vacunas con el c\u00e1ncer de pulm\u00f3n, \nel de piel y el de mama. En el uso preventivo de las \nvacunas en c\u00e1ncer destacan las publicaciones referidas \nal virus del papiloma humano y su relaci\u00f3n con el c\u00e1ncer \nde cuello uterino.\nArt\u00edculos comentados\nEl objetivo de las vacunas contra el c\u00e1ncer es dirigir el \nsistema inmunitario para facilitar la erradicaci\u00f3n de las \nc\u00e9lulas cancerosas. Los recientes avances tecnol\u00f3gicos \nhan puesto de manifiesto una nueva biolog\u00eda que puede \nayudar a lograr un mejor conocimiento en la selecci\u00f3n y \nadministraci\u00f3n de ant\u00edgenos y en el seguimiento de las \nrespuestas humanas tras la vacunaci\u00f3n permitiendo, de \neste modo, enfoques m\u00e1s agresivos y novedosos3.\nLas vacunas contra el c\u00e1ncer se pueden dividir en dos \ntipos: preventivas o terap\u00e9uticas. \n\u00b7 Las vacunas preventivas disponibles comercialmente \nbloquean la infecci\u00f3n de los agentes causantes del virus \ndel papiloma humano, el virus de la hepatitis B o el virus \nde Epstein-Barr y se dirigen a la prevenci\u00f3n del c\u00e1ncer \nde cuello de \u00fatero4, c\u00e1ncer de ano tanto en mujeres \ncomo en hombres5-6, el c\u00e1ncer de h\u00edgado7 y el c\u00e1ncer \nnasofar\u00edngeo y g\u00e1strico8. \n\u00b7 Las vacunas terap\u00e9uticas para el tratamiento del \nc\u00e1ncer se basan en su capacidad para estimular \nla respuesta del sistema inmunitario a las c\u00e9lulas \ncancerosas, que suele ser baja. Este grupo de vacunas \nson de reciente aparici\u00f3n y muchas de ellas se encuentran \nen fase experimental. Es el caso de los ensayos cl\u00ednicos \nen vacunas terap\u00e9uticas contra el c\u00e1ncer de mama, \npulm\u00f3n, colon, piel, ri\u00f1\u00f3n y pr\u00f3stata, entre otros9.\nNos centraremos en estas \u00faltimas por las opciones de \npresente y futuro que plantean de curaci\u00f3n o cronificaci\u00f3n \nde la enfermedad y, con ello, la posibilidad de retorno al \ntrabajo y recuperaci\u00f3n de las actividades de la vida diaria \nperdidas durante la enfermedad. Son estos aspectos de \nespecial relevancia en salud laboral.\nLas vacunas terap\u00e9uticas contra el c\u00e1ncer han supuesto \nun avance en la inmunoterapia contra esta enfermedad y \ncomparten el objetivo de crear y amplificar las respuestas \nde c\u00e9lulas T espec\u00edficas del tumor, pero a\u00fan quedan \nobst\u00e1culos importantes que resaltar\nSe han investigado numerosas estrategias para superar \nlos mecanismos inmunosupresores del microambiente \ntumoral (TME) y contrarrestar el escape del tumor. En \nun esfuerzo por amplificar las respuestas de c\u00e9lulas T \nespec\u00edficas de tumores, se utiliza cada vez m\u00e1s una Tabla I: Resultados de la b\u00fasqueda bibliogr\u00e1fica.\nDescriptor de b\u00fasqueda Resultados obtenidos\nCancer and vaccines 68.516 resultados\nCancer and preventive vaccines 23.292 resultados\nCancer and therapeutic vaccines 48.988 resultados\nColorectal cancer and therapeutic vaccines 1.753 resultados\nSkin cancer and therapeutic vaccines 2.431 resultados\nBreast cancer and therapeutic vaccines 2.384 resultados\nProstate cancer and therapeutic vaccines 1.867 resultados\nKidney cancer and therapeutic vaccines 1.060 resultados\nLung cancer and therapeutic vaccines 3.019 resultados \nHPV and cancer and preventive vaccines 7.910 resultados\nHepatitis B and cancer and preventive vaccines 1.329 resultados\nFuente: https://pubmed.ncbi.nlm.nih.gov/ Fecha de b\u00fasqueda 13/12/2022M\u00aa Te\u00f3fila Vicente-Herrero et al. 71\n2023/38 (4): 69-75C\u00e1ncer y vacunas. Presente y futuro \nestrategia heter\u00f3loga de administraci\u00f3n de ant\u00edgenos \nde inducci\u00f3n y refuerzo para las vacunas basadas en \nvirus. Los sistemas de nanopart\u00edculas se han mostrado \nprometedores como vectores de suministro de vacunas \ncontra el c\u00e1ncer en la investigaci\u00f3n precl\u00ednica. T-win es \notra plataforma dirigida tanto a las c\u00e9lulas tumorales \ncomo al TME, que utiliza vacunas basadas en p\u00e9ptidos \nque se involucran y activan las c\u00e9lulas T para atacar las \nmol\u00e9culas inmunorreguladoras expresadas en las c\u00e9lulas \ninmunosupresoras y malignas. Actualmente est\u00e1n \nsurgiendo algoritmos para la selecci\u00f3n de neoant\u00edgenos \ny para seleccionar objetivos terap\u00e9uticamente relevantes \npara desarrollar terapias personalizadas. En conjunto, \nel campo de las vacunas terap\u00e9uticas contra el c\u00e1ncer \nest\u00e1 evolucionando r\u00e1pidamente, con la promesa de una \nposible sinergia con las inmunoterapias existentes para \nel tratamiento del c\u00e1ncer a largo plazo10.\nEn las vacunas terap\u00e9uticas contra el c\u00e1ncer se trata \ntanto de actuar frente a los tumores existentes como \nde prevenir su reaparici\u00f3n. Predominantemente, \nla investigaci\u00f3n se ha orientado hacia el contexto \nmetast\u00e1sico, bas\u00e1ndose en una inmunoterapia activa en \nla que el sistema inmunitario humano pueda activarse \npara reconocer y destruir las c\u00e9lulas tumorales. Dada las \ndificultades que supone este escenario, se plantea dirigir \nlos estudios a tumores cl\u00ednicamente m\u00e1s accesibles, \nllegar a un consenso sobre los criterios de valoraci\u00f3n \nbiol\u00f3gicos m\u00e1s importantes y probar la capacidad de \nlas vacunas para alcanzarlos para, finalmente, ampliar \nel conocimiento sobre c\u00f3mo manipular el sistema \ninmunitario m\u00e1s all\u00e1 de la estimulaci\u00f3n inicial que \nproporciona una vacuna, comparando los resultados de \ndistintos estudios11.\nEl sistema inmunitario de los pacientes con c\u00e1ncer \nmetast\u00e1sico est\u00e1 considerablemente comprometido, \ntanto por la inmunosupresi\u00f3n mediada por el tumor, \ncomo por el tratamiento. Aun cuando la enfermedad \nresidual es m\u00ednima, las vacunas dirigidas contra ant\u00edgenos \nasociados al tumor no logran erradicarlo en la inmensa \nmayor\u00eda de los casos.\nLa investigaci\u00f3n en animales en relaci\u00f3n con uso \npreventivo de vacunas en la fase m\u00e1s temprana posible \nde la carcinog\u00e9nesis ha demostrado ser m\u00e1s eficaz \npara provocar una respuesta inmunitaria antitumoral con \nmejora en la supervivencia. Esto puede ser de utilidad en \nalgunos c\u00e1nceres humanos, como el adenocarcinoma \nde pr\u00f3stata y el c\u00e1ncer de cuello de \u00fatero, que pueden \ndetectarse en fases muy tempranas y para los que \nse dispone de vacunas terap\u00e9uticas, abriendo la \nposibilidad de administrarlas precozmente a pacientes \ndiagnosticados de lesiones premalignas para detener la \nprogresi\u00f3n de la enfermedad. La capacidad de inmunizar \na los pacientes en las fases m\u00e1s tempranas de la \ncarcinog\u00e9nesis, cuando sus sistemas inmunitarios son \nplenamente competentes, puede provocar un cambio de paradigma en la forma de probar y utilizar cl\u00ednicamente \nestas vacunas terap\u00e9uticas contra el c\u00e1ncer12.\nDurante los \u00faltimos 20 a\u00f1os se han identificado varios \nant\u00edgenos asociados a tumores, algunos de los cuales \nse han utilizado con resultados alentadores como \ninmunoterapia contra diversos tipos de c\u00e1ncer. Sin \nembargo, se ha de tener en consideraci\u00f3n que las \ncaracter\u00edsticas de las c\u00e9lulas tumorales y el estado \ninmunol\u00f3gico frente al c\u00e1ncer difieren mucho de un \npaciente a otro, por lo que el desarrollo de nuevos \ncriterios y biomarcadores fiables para seleccionar a los \npacientes y ant\u00edgenos vacunales adecuados supondr\u00e1 \nun gran avance en el desarrollo de vacunas contra el \nc\u00e1ncer13. \nDe forma general, las vacunas contra el c\u00e1ncer suelen \nderivarse de las c\u00e9lulas tumorales del paciente o de \nlos ant\u00edgenos que se encuentran en su superficie, lo \nque puede ayudar al sistema inmunitario a identificar y \neliminar estas c\u00e9lulas malignas. Muchas investigaciones \nse centran actualmente en el dise\u00f1o de vacunas con \nla esperanza de activar el sistema inmunitario para que \nataque a las c\u00e9lulas cancerosas de forma m\u00e1s eficaz, \nfiable y segura.\nSe analizan a continuaci\u00f3n con m\u00e1s detalle los resultados \nencontrados en el an\u00e1lisis bibliogr\u00e1fico en relaci\u00f3n con el \nuso de vacunas terap\u00e9uticas en algunos de los tipos de \nc\u00e1ncer m\u00e1s prevalentes:\n\u00b7 El c\u00e1ncer de mama se ha convertido en el c\u00e1ncer \nm\u00e1s diagnosticado en todo el mundo y su reca\u00edda y las \nmet\u00e1stasis siguen siendo un gran reto a pesar de los \navances en quimioterapia, terapia endocrina y terapia \ndirigida a HER2 en las \u00faltimas d\u00e9cadas. \nAunque los avances cl\u00ednicos en el campo de la terapia \ndel c\u00e1ncer de mama HER2-positivo han mejorado \ngracias a la comprensi\u00f3n de los mecanismos de \nregulaci\u00f3n inmunitaria del microentorno tumoral, la \nresistencia al tratamiento y la reca\u00edda de la enfermedad \nsiguen consider\u00e1ndose retos importantes en la pr\u00e1ctica \ncl\u00ednica. Cada vez hay m\u00e1s informes sobre la inducci\u00f3n \nde respuestas inmunitarias celulares y humorales en \npacientes con c\u00e1ncer de mama HER2-positivo y se \npresentan otros enfoques inmunoterap\u00e9uticos, como \nlos inhibidores de CTLA-4, los inhibidores del punto de \ncontrol inmunitario y los anticuerpos anti PD-1/PD-L114.\nEl objetivo de las vacunas contra el c\u00e1ncer es inducir \nuna respuesta inmunol\u00f3gica duradera para erradicar las \nc\u00e9lulas tumorales. Se han evaluado diferentes tipos de \nvacunas contra el c\u00e1ncer de mama en ensayos cl\u00ednicos, \npero ninguna ha aportado beneficios significativos. Los \nestudios m\u00e1s recientes indican la posibilidad de aplicar \nvacunas en combinaci\u00f3n con anticuerpos monoclonales \nanti-HER2 o el bloqueo de puntos de control inmunitarios15. 72\n2023/38 (4): 69-75M\u00aa Te\u00f3fila Vicente-Herrero et al. \n\u00b7 El c\u00e1ncer de pulm\u00f3n sigue siendo un reto sanitario. \nLos tres principales tratamientos convencionales, \ncirug\u00eda, quimioterapia y radioterapia, que se utilizan \nhabitualmente para su tratamiento, no han evitado que \nsiga siendo la principal causa de mortalidad relacionada \ncon el c\u00e1ncer. La inmunoterapia ha surgido como una \nterapia eficaz y en la actualidad existe un creciente uso \ncomo herramienta terap\u00e9utica. Comprender los pasos \ndel reconocimiento inmunitario y la erradicaci\u00f3n de las \nc\u00e9lulas cancerosas es vital para entender c\u00f3mo puede \nutilizarse de forma \u00f3ptima en las terapias actuales y \ncon buenas perspectivas de futuro16. Los ensayos \nrealizados con vacunas neoant\u00edgenas ofrecen nuevas \noportunidades terap\u00e9uticas para el tratamiento del \nc\u00e1ncer de pulm\u00f3n17.\nLa combinaci\u00f3n de inmunoterapias, como las vacunas \ncontra el c\u00e1ncer y los inhibidores del punto de control \ninmunitario, as\u00ed como la asociaci\u00f3n con las tres terapias \nconvencionales, puede allanar el camino hacia la \ninmunoterapia personalizada18.\n\u00b7 El c\u00e1ncer colorrectal es una de las principales \ncausas de muerte por c\u00e1ncer. A pesar de los avances \nen la terapia sist\u00e9mica sigue acompa\u00f1\u00e1ndose de una \nelevada mortalidad y son necesarios tratamientos \nm\u00e1s eficaces, especialmente para los pacientes con \nc\u00e1ncer colorrectal metast\u00e1sico. Los datos actuales \napoyan el hecho de que los tumores colorrectales son \ninmunorresponsables y que un subgrupo de pacientes \ncon enfermedad avanzada lograr\u00e1 beneficios a largo \nplazo con la inmunoterapia19.\nEn los \u00faltimos a\u00f1os, se han producido avances \nsignificativos en las estrategias terap\u00e9uticas en este \ntipo de c\u00e1ncer, incluida las vacunas, que en algunos \ncasos han sido aprobadas para uso cl\u00ednico y en otros \nse encuentran en ensayos cl\u00ednicos en fase avanzada. \nEn los ensayos cl\u00ednicos de vacunas contra el c\u00e1ncer \nhay varias consideraciones que deben tenerse en \ncuenta, como la ingenier\u00eda de las c\u00e9lulas presentadoras \nde ant\u00edgenos, la toxicidad potencial de las zonas \nantig\u00e9nicas, la farmacocin\u00e9tica y farmacodin\u00e1mica de las \nvacunas y la monitorizaci\u00f3n de la respuesta inmunitaria \nde los pacientes. Por ello, la necesidad de superar los \nmecanismos de inmunosupresi\u00f3n/tolerancia inmunitaria \nes un paso cr\u00edtico para el \u00e9xito de la introducci\u00f3n \nde vacunas terap\u00e9uticas y se requiere una mejor \ncomprensi\u00f3n de los neoant\u00edgenos, los mecanismos \nde escape de la vigilancia inmunitaria tumoral y las \ninteracciones hu\u00e9sped-tumor para desarrollar vacunas \nm\u00e1s eficaces y seguras en el futuro20.\nLos resultados obtenidos con la inmunoterapia en \nmuchos tipos de tumores s\u00f3lidos avanzados han hecho \nque cada vez sea mayor su utilizaci\u00f3n para el tratamiento \ndel c\u00e1ncer colorrectal como terapia de primera l\u00ednea del \nc\u00e1ncer metast\u00e1sico y en estadios tempranos21.\u00b7 El c\u00e1ncer de pr\u00f3stata es el cuarto c\u00e1ncer m\u00e1s frecuente \nen el mundo y su tratamiento se basa actualmente \nen la extirpaci\u00f3n quir\u00fargica y/o la radioterapia y/o la \nhormonoterapia. En los \u00faltimos a\u00f1os, la inmunoterapia \nse ha convertido en una importante opci\u00f3n terap\u00e9utica \ncontra el c\u00e1ncer22. Las estrategias combinadas son las \nm\u00e1s prometedoras. Varios estudios finalizados y otros en \ncurso han demostrado que la combinaci\u00f3n de vacunas \ncontra el c\u00e1ncer o inhibidores de los puntos de control \ncon diferentes agentes inmunoterap\u00e9uticos, terapia \nhormonal, radioterapia, agentes que act\u00faan frente al \nADN o quimioterapia, pueden potenciar las respuestas \ninmunitarias e inducir respuestas cl\u00ednicas m\u00e1s dr\u00e1sticas \ny duraderas sin toxicidad significativa. El objetivo de la \ninmunoterapia en el c\u00e1ncer de pr\u00f3stata no tiene por \nqu\u00e9 ser la erradicaci\u00f3n completa de la enfermedad \navanzada, sino el retorno a un equilibrio inmunol\u00f3gico \ncon un estado indolente de la enfermedad. Actualmente \nse est\u00e1 trabajando en biomarcadores de la respuesta \ninmunitaria que abren un futuro esperanzador23.\nEl c\u00e1ncer de pr\u00f3stata es un tumor fr\u00edo con una respuesta \ninmunitaria inadecuada al tratamiento. Las vacunas \ncontra el c\u00e1ncer, las citocinas y los inhibidores de los \npuntos de control son agentes inmunoterap\u00e9uticos que \nact\u00faan dentro del ciclo de inmunidad del c\u00e1ncer y el \nc\u00e1ncer de pr\u00f3stata ofrece oportunidades y retos \u00fanicos \npara el desarrollo de f\u00e1rmacos inmunoterap\u00e9uticos \nconvirtiendo un c\u00e1ncer de pr\u00f3stata \u201cfr\u00edo\u201d en \u201ccaliente\u201d y \nhaci\u00e9ndolo as\u00ed m\u00e1s susceptible a la inmunoterapia24.\n\u00b7 El c\u00e1ncer renal y particularmente el carcinoma de \nc\u00e9lulas renales claras, se ha considerado durante \nmucho tiempo que es sensible a las inmunoterapias. \nCon los recientes avances en inmunoterapia para \ntumores s\u00f3lidos se espera que las inmunoterapias \ncombinadas se conviertan en la opci\u00f3n de tratamiento \nde primera l\u00ednea en el c\u00e1ncer de ri\u00f1\u00f3n25. El panorama \nactual del tratamiento se est\u00e1 desplazando hacia los \nagentes inmunooncol\u00f3gicos, que ya han ganado terreno \nen la cl\u00ednica como monoterapia con los inhibidores del \npunto de control inmunitario o es probable que lo hagan \nen un futuro pr\u00f3ximo como combinaci\u00f3n de ellos. El \nfuturo promete nuevas combinaciones u otros agentes \ninmunooncol\u00f3gicos, como vacunas e inhibidores \nmetab\u00f3licos de puntos de control inmunitario, con \nresultados beneficiosos26.\nEl planteamiento actual de tratamiento del carcinoma \nrenal de c\u00e9lulas claras es limitado. Los ant\u00edgenos \nasociados a tumores, especialmente las vacunas \nde ARNm personalizadas basadas en neoant\u00edgenos, \nrepresentan nuevas estrategias y manifiestan \nbeneficios cl\u00ednicos en tumores s\u00f3lidos, pero s\u00f3lo una \npeque\u00f1a proporci\u00f3n de pacientes podr\u00eda beneficiarse \nde ellas, lo que requiere identificar ant\u00edgenos eficaces \ny poblaciones adecuadas para facilitar la aplicaci\u00f3n de \nvacunas de ARNm en la terapia del c\u00e1ncer. Se han 73\n2023/38 (4): 69-75C\u00e1ncer y vacunas. Presente y futuro \nidentificado posibles neoant\u00edgenos eficaces para el \ndesarrollo de vacunas de ARNm contra el carcinoma \nrenal de c\u00e9lulas claras que podr\u00edan beneficiar \nespecialmente a algunos subtipos27.\n\u00b7 Finalmente, en el c\u00e1ncer de piel destaca el aumento \nde la incidencia de melanoma, pero con disminuci\u00f3n de \nla mortalidad. Un manejo mejorado, que parte del an\u00e1lisis \ndel ganglio centinela, ha permitido reducir la morbilidad \nasociada mediante una cirug\u00eda de estadificaci\u00f3n y el \ntratamiento de la enfermedad avanzada con el uso de \nterapia dirigida e inmunoterapia de punto de control28.\nEn las \u00faltimas tres d\u00e9cadas se han llevado a cabo \ninvestigaciones sobre vacunas para el tratamiento del \nmelanoma metast\u00e1sico y la prevenci\u00f3n de recidivas \ntras la resecci\u00f3n, aunque los resultados obtenidos no han \nsido esperanzadores. Las vacunas celulares utilizadas \npueden dividirse en aut\u00f3logas, derivadas del propio tumor \ndel paciente, y alog\u00e9nicas. Las vacunas aut\u00f3logas tienen \nla ventaja de contener todos los ant\u00edgenos asociados al \ntumor potencialmente relevantes para ese paciente en \nparticular. Sin embargo, son dif\u00edciles de obtener de la \nmayor\u00eda de los pacientes con enfermedad avanzada e \nimposibles de conseguir en pacientes tras la resecci\u00f3n \nde toda la enfermedad cl\u00ednicamente evidente. No existe \nconsenso sobre c\u00f3mo deben procesarse, conservarse, \nmodificarse y administrarse los tumores para que sirvan \ncomo vacuna eficaz. La cantidad de tumor aut\u00f3logo \ndisponible rara vez es suficiente para producir m\u00e1s de dos o tres dosis de vacunaci\u00f3n, y el tiempo transcurrido \nentre la extracci\u00f3n inicial del tumor y la disponibilidad final \nde la vacuna puede dar lugar a una progresi\u00f3n tumoral \na intervalos que disminuye la probabilidad de eficacia \nde la vacuna. Todos estos inconvenientes limitan su \naplicabilidad y tambi\u00e9n la capacidad de probar vacunas \naut\u00f3logas en ensayos prospectivos. Las vacunas \nalog\u00e9nicas evitan muchos de estos problemas, pero \npueden no contener todos los ant\u00edgenos asociados \nal tumor presentes en el propio tumor del paciente. \nEn particular, es poco probable que los neoant\u00edgenos \ncreados por mutaciones en el tumor del paciente est\u00e9n \nrepresentados en una vacuna alog\u00e9nica. Aunque las \nvacunas alog\u00e9nicas pueden fabricarse en cantidades \nsuficientes para permitir ensayos a gran escala, siguen \nexistiendo importantes limitaciones en la fabricaci\u00f3n y \nestandarizaci\u00f3n del producto vacunal29.\nConclusiones\nRecogiendo a modo de resumen lo incluido en el \ndocumento de revisi\u00f3n de vacunas Europa, 202230 \npodemos concluir afirmando que, cuando se trata de \neste tipo de opciones inmunizadoras, hay que considerar \ndos enfoques principales.\nEl primero es un enfoque profil\u00e1ctico, orientado a \nla prevenci\u00f3n de c\u00e1nceres relacionados con una \ninfecci\u00f3n, como el c\u00e1ncer de h\u00edgado consecuencia \nTabla II: Revisi\u00f3n de la cartera de vacunas para Europa-2022.\nTipo de c\u00e1ncer Caracter\u00edsticas Situaci\u00f3n vacunal\nGlioblastoma\nC\u00e1ncer de Pulm\u00f3n, \ncolorrectal, \np\u00e1ncreas\nC\u00e1ncer de piel\nTumor s\u00f3lido- Tumor cerebral de crecimiento r\u00e1pido y agresivo que puede provocar la muerte en seis \nmeses o menos, si no se trata.\n- Incidencia de 3,21 por 100.000 habitantes.\n- El GBM presenta retos de tratamiento \u00fanicos debido a la localizaci\u00f3n de los tumores en \nel cerebro.\n- Aproximadamente un 40% de supervivencia en el primer a\u00f1o tras el diagn\u00f3stico y un \n17% en el segundo a\u00f1o.\nC\u00e1ncer de pulm\u00f3n\n- El 2\u00ba c\u00e1ncer m\u00e1s frecuente en todo el mundo\n- M\u00e1s de 2,2 millones de nuevos casos de c\u00e1ncer de pulm\u00f3n en 2020\nC\u00e1ncer colorrectal\n- El 3er c\u00e1ncer m\u00e1s frecuente en todo el mundo\n- M\u00e1s de 1,9 millones de nuevos casos de c\u00e1ncer\ncolorrectal en 2020\nC\u00e1ncer de p\u00e1ncreas\n- El 12\u00ba c\u00e1ncer m\u00e1s frecuente en todo el mundo\n- M\u00e1s de 495.000 nuevos casos de c\u00e1ncer de p\u00e1ncreas en 2020\n- Tipo de c\u00e1ncer m\u00e1s frecuente.\n- Los principales tipos de c\u00e1ncer de piel son el carcinoma de c\u00e9lulas escamosas, el \ncarcinoma basocelular y el melanoma.\nLa mayor\u00eda de las muertes por c\u00e1ncer de piel est\u00e1n causadas por melanoma.\n- M\u00e1s de 150.000 nuevos casos de melanoma en 2020.\n- 8.100 millones de d\u00f3lares de coste anual del tratamiento de los c\u00e1nceres de piel en los \nEstados Unidos. \n- Aproximadamente el 90% de los c\u00e1nceres humanos adultos.\nPueden desarrollarse en muchas partes del cuerpo humano.\n- Los tumores s\u00f3lidos pueden ser no cancerosos (benignos), premalignos (c\u00e9lulas que \ntienen el potencial para volverse malignas) o malignos (cancerosos).Vacunas en proyecto: 1\nPara: Adultos y adultos mayores\nEst\u00e1 en Fase II \nTipo de Vacuna:  Part\u00edcula similar al virus\nVacunas en proyecto: 1\nPara: Adultos \nEst\u00e1 en Fase I \nTipo de Vacuna: mRNA\nVacunas en proyecto: 1\nPara: Adultos y adultos mayores\nEst\u00e1 en Fase II \nTipo de Vacuna:mRNA\nVacunas en proyecto: 2\nPara: Adultos y adultos mayores\nEst\u00e1 en Fase I \nTipo de Vacuna: ARNm \nSubunidad proteica\nFuente: Vaccines Europe pipeline review 2022. Ref31-3674\n2023/38 (4): 69-75M\u00aa Te\u00f3fila Vicente-Herrero et al. \nde la infecci\u00f3n por hepatitis B, los relacionados con la \ninfecci\u00f3n por el VPH (virus del papiloma humano) o el \nvirus de Epstein-Barr.\nEl otro enfoque es curativo. El objetivo de las vacunas \nterap\u00e9uticas contra el c\u00e1ncer es inducir la regresi\u00f3n \ntumoral, erradicar la enfermedad residual m\u00ednima, \nestablecer una memoria antitumoral duradera y evitar \nreacciones inespec\u00edficas o adversas. \nEl desarrollo de vacunas para el tratamiento del c\u00e1ncer \nes un reto, ya que la intervenci\u00f3n vacunal debe combatir \nun sistema inmunitario que ha sido restringido por \nmecanismos que sostienen la respuesta inmunitaria \ny frenado por los mecanismos que mantienen la \nenfermedad en un intento de autotolerancia.\nSin embargo, los resultados recientes de los ensayos \ncl\u00ednicos en curso de este tipo de vacunas son \nprometedores.\nActualmente, los miembros de Vaccines Europe tienen \nen proyecto cinco vacunas contra distintos tipos de \nc\u00e1ncer: glioblastoma, c\u00e1ncer de mama, c\u00e1ncer de \npulm\u00f3n, c\u00e1ncer colorrectal, de p\u00e1ncreas y de piel, as\u00ed \ncomo frente tumores s\u00f3lidos (Tabla II).Se abre as\u00ed una nueva perspectiva en el abordaje del \nc\u00e1ncer, tanto preventiva como curativa, en un marco \nde medicina personalizada que va a requerir adaptar \nlas actuaciones sanitarias, sociales y laborales en \naquellos casos en los que se logre una curaci\u00f3n o \ncronificaci\u00f3n del proceso oncol\u00f3gico que permita el \nretorno al trabajo de las personas que han padecido \nun c\u00e1ncer y lo han superado.\nLos m\u00e9dicos del \u00e1mbito de la salud laboral tendremos \nque participar activamente en la parte que nos concierne, \ntanto en la vacunaci\u00f3n preventiva, como en la valoraci\u00f3n \nde la aptitud laboral de la persona que retorna al trabajo \ncuando el resultado de las terapias administradas, \nentre las que se incluyen las vacunas terap\u00e9uticas as\u00ed \nlo permitan. El objetivo es conseguir que el desempe\u00f1o \nde la actividad laboral sea compatible con las posibles \nsecuelas residuales que hayan podido quedar tras el \nproceso oncol\u00f3gico o por los tratamientos que se hayan \nseguido o que se deban mantener por la persona que \nretorna al trabajo, de forma que no implique riesgos \nde empeoramiento o recidiva del mismo c\u00e1ncer o el \ndesarrollo de otras neoplasias.\nConflicto de intereses\nLos autores declaran no tener ning\u00fan conflicto de \ninereses.\nBibliograf\u00eda\n1. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. \nEMBO Mol Med. 2014 Jun;6(6):708-20.\n2. Zhou J, Kroll AV, Holay M, Fang RH, Zhang L. Biomimetic \nNanotechnology toward Personalized Vaccines. Adv Mater. 2020 \nApr;32(13):e1901255. \n3. Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: Building a bridge \nover troubled waters. Cell. 2022 Jul 21;185(15):2770-88. \n4. Mart\u00ednez-G\u00f3mez X, Curran A, Campins M, Alemany L, Rodrigo-\nPend\u00e1s J\u00c1, Borruel N, Castellsagu\u00e9 X, D\u00edaz-de-Heredia C, Moraga-Llop \nFA, Del Pino M, Torn\u00e9 A. Multidisciplinary, evidence-based consensus \nguidelines for human papillomavirus (HPV) vaccination in high-risk \npopulations, Spain, 2016. Euro Surveill. 2019 Feb;24(7):1700857.\n5. M\u00e9ndez-Mart\u00ednez R, Rivera-Mart\u00ednez NE, Crabtree-Ram\u00edrez B, Sierra-\nMadero JG, Caro-Vega Y, Galv\u00e1n SC, de Le\u00f3n DC, Garc\u00eda-Carranc\u00e1 A. \nMultiple human papillomavirus infections are highly prevalent in the anal \ncanal of human immunodeficiency virus-positive men who have sex with \nmen. BMC Infect Dis. 2014 Dec 16;14:671.\n6. Cort\u00e9s J, Gil A, Martin\u00f3n F, Bosch FX, Ram\u00f3n y Cajal JM. Vaccination \nagainst human papilloma virus in men: situation and proposals\u201c. Acad J \nHealth Sci 2022; 37 (3): 166-70.7. Pattyn J, Hendrickx G, Vorsters A, Van Damme P . Hepatitis B \nVaccines. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351\n8. Shechter O, Sausen DG, Gallo ES, Dahari H, Borenstein R. \nEpstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring \nPathologies and Current Treatments. Int J Mol Sci. 2022 Nov \n19;23(22):14389.\n9. Giarelli E. Cancer vaccines: a new frontier in prevention and \ntreatment. Oncology (Williston Park). 2007 Oct;21(11 Suppl Nurse \nEd):11-7; discussion 18. \n10. Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. \nThe Changing Landscape of Therapeutic Cancer Vaccines-Novel \nPlatforms and Neoantigen Identification. Clin Cancer Res. 2021 Feb \n1;27(3):689-703. \n11. Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent \ndevelopments in therapeutic cancer vaccines. Nat Clin Pract Oncol. \n2005 Feb;2(2):108-13. \n12. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm \nshift in therapeutic vaccination of cancer patients: the need to apply \ntherapeutic vaccination strategies in the preventive setting. Immunol \nRev. 2008 Apr;222:316-27. 75\n2023/38 (4): 69-75C\u00e1ncer y vacunas. Presente y futuro \n13. Sasada T, Itoh K. Current status and future perspective of cancer \nvaccine development. Gan To Kagaku Ryoho. 2011 Apr;38(4):503-8. \n14. Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer \nImmunotherapy: A Focus on Vaccine Development. Arch Immunol Ther \nExp (Warsz). 2020 Jan 9;68(1):2.\n15. Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or \nPromising? Front Immunol. 2022 Jan 28;13:828386.\n16. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. \nRespirology. 2016 Jul;21(5):821-33.\n17. Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized \nneoantigen pulsed dendritic cell vaccine for advanced lung cancer. \nSignal Transduct Target Ther. 2021 Jan 20;6(1):26.\n18. Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future \nProspects of Immunotherapy in Lung Cancer. Life (Basel). 2021 Sep \n30;11(10):1029. \n19. Wrobel P , Ahmed S. Current status of immunotherapy in metastatic \ncolorectal cancer. Int J Colorectal Dis. 2019 Jan;34(1):13-25. \n20. Shahnazari M, Samadi P , Pourjafar M, Jalali A. Therapeutic \nvaccines for colorectal cancer: The progress and future prospect. Int \nImmunopharmacol. 2020 Nov;88:106944. \n21. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy \nin colorectal cancer: current achievements and future perspective. Int J \nBiol Sci. 2021 Sep 3;17(14):3837-49. \n22. Silva D, Abreu-Mendes P , Mourato C, Martins D, Cruz R, Mendes F. \nProstate cancer, new treatment advances - immunotherapy. Actas Urol \nEsp (Engl Ed). 2020 Sep;44(7):458-68.\n23. Bilusic M, Madan RA, Gulley JL. Immunotherapy of Prostate Cancer: \nFacts and Hopes. Clin Cancer Res. 2017 Nov 15;23(22):6764-70. \n24. Patel D, McKay R, Parsons JK. Immunotherapy for Localized \nProstate Cancer: The Next Frontier? Urol Clin North Am. 2020 \nNov;47(4):443-56.\n25. Hammers H. Immunotherapy in kidney cancer: the past, present, \nand future. Curr Opin Urol. 2016 Nov;26(6):543-726. Bedke J, St\u00fchler V, Stenzl A, Brehmer B. Immunotherapy for kidney \ncancer: status quo and the future. Curr Opin Urol. 2018 Jan;28(1):8-14. \n27. Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q, Li H, Ai J. Tumor \nantigens and immune subtypes guided mRNA vaccine development for \nkidney renal clear cell carcinoma. Mol Cancer. 2021 Dec 6;20(1):159. \n28. Curti BD, Faries MB. Recent Advances in the Treatment of \nMelanoma. N Engl J Med. 2021 Jun 10;384(23):2229-40. \n29. Sondak VK, Sabel MS, Mul\u00e9 JJ. Allogeneic and autologous \nmelanoma vaccines: where have we been and where are we going? \nClin Cancer Res. 2006 Apr 1;12(7 Pt 2):2337s-2341s. \n30. Vaccines Europe pipeline review 2022.Disponible en: https://\nisanidad.com/wp-content/uploads/2022/12/Vaccines-Europe-\npipeline-review-2022-1.pdf\n31. American Association of Neurological Surgeons. Glioblastoma \nmultiforme. Disponible en: https://www.aans.org/en/Patients/\nNeurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme \n(consultado el 12 de diciembre de 2022).\n32. World Cancer Research Fund International. Cancer trends. \nDisponible en: https://www.wcrf.org/cancer-trends/ (consultado el 12 \nde diciembre de 2022).\n33.  National Cancer Institute. Skin Cancer (Including melanoma) Patent \nVersion. Disponible en: https://www.cancer.gov/types/skin (consultado \nel 12 de diciembre de 2022).\n34. Skin Cancer Foundation. Skin cancer facts & statistics. Disponible: \nhttps://www.skincancer.org/skin-cancer-information/skin-cancer-facts/ \n(consultado el 12 de diciembre de 2022).\n35. World Cancer Research Fund International. Skin cancer statistics. \nDisponible en: https://www.wcrf.org/cancer-trends/skin-cancer-\nstatistics/ (consultado el 12 de diciembre de 2022).\n36. Thermo Fisher Scientific. Solid Tumor Research. Disponible en: \nhttps://www.thermofisher.com/be/en/home/life-science/cancer-\nresearch/solid-tumor-research.html (consultado el 12 de diciembre \nde 2022).76\n2023/38 (4): 76-84ORIGINAL\nMulticentric study on the effect of rectal Ozone on COVID-19: \nthe Spanish and Slovakian experience \nEstudio multic\u00e9ntrico sobre el efecto del Ozono rectal en COVID-19: \nla experiencia espa\u00f1ola y eslovaca  \nMarcos Fern\u00e1ndez-Cuadros1      , Olga P\u00e9rez-Moro1      ,\nMar\u00eda Jes\u00fas Albaladejo-Flor\u00edn1      , Javier Rodr\u00edguez-de-C\u00eda2      , Alberto Hern\u00e1ndez3,\nSandra \u00c1lava-Rabasa1      , Mohammed Darraj4, Al\u017ebeta Gond\u017e\u00farov\u00e15, Martin Moln\u00e1r6,\nMonika Kulinova7, Juraj Vyletelka4\n1. Rehabilitation Department, Hospital Universitario Santa Cristina, Madrid, Spain    2. Clinical Laboratory Analysis Department, \nHospital Universitario Santa Cristina, Madrid, Spain    3. Anesthesiology and Perioperative Medicine Department, Policlinica Ibiza \nHospital Ibiza, Spain    4. Neurology Department, FNsP \u017dilina, Slovakia    5. COVID-19 Department, FNsP \u017dilina, Slovakia\n6. Radiology Department,  FNsP \u017dlina, Slovakia    7. Internal Medicine Department, FNsP \u017dlina, SlovakiaeISSN 2255-0569\nReceived: 25 - I - 2023\nAccepted: 26 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.76Corresponding author\nMarcos Fern\u00e1ndez-Cuadros \nE-mail: marcosefc@hotmail.com / marcosedgar.fernandez@salud.madrid.org   \nAbstract \nObjective: To evaluate the effect of rectal Ozone (O3) in severe COVID-19 pneumonia in two different cohorts differing in location \n(Madrid vs Zilina), ethnicity (Slovakian vs Spanish cohorts) and age. \nMaterial and Methods: In a multicenter-study, 32 severe bilateral-COVID-19-pneumonia patients and (+) RT-PCR (reverse transcriptase \npolymerase chain reaction) SARS-CoV-2 were evaluated (16 from each cohort). Primary outcomes: a) clinical (O2-saturation); b) biochemical \n(Lymphocyte-count, Fibrinogen, D-Dimer, Urea, Ferritin, LDH [lactate dehydrigenase], IL-6 and CRP [c-reactive protein]); and c) radiological \nimprovement. Secondary outcomes: a) days-of-hospitalization, b) mortality-rate before discharge.The Ozone-protocol consisted of 10 \nsessions of intra-rectal Ozone, total dose 5.25 mg (150 mL volume, 35 \u03bcg/ml concentration). The Standard-of-care protocol included \nO2 supply, antivirals (Remdesivir / Isoprinosine), corticosteroids (Dexamethasone / Metilprednisolone), monoclonal antibodies (Anakinra / \nTocilizumab), antibiotics (Azytromicine), anticoagulants (Enoxaparine / Fraxiparine). \nResults: Patients in Slovakian cohort were younger (53.38 vs 84.69 years). Grade of severity was worse in Spanish-cohort (4.78 \nvs 3.30 points). Length of stay was superior in Spanish-cohort (27.38 vs 10.07 days). Both cohorts improved O2-saturation and \nLymphocyte-count. Inflammation biomarkers (Fibrinogen, D-Dimer, Urea, Ferritin, LDH, CRP and IL-6) decreased in both cohorts. In \nSpanish-cohort, Urea and Ferritin improvement was not significant (p>0.05), while in Slovakian-cohort, Urea, Fibrinogen and LDH were \nnot significant (p>0.05) Radiological signs of bilateral pneumonitis decreased on both cohorts. Mortality was similar between both \ncohorts (12.5%) but inferior if compared to an external control group (23%). \nConclusion: After Standard of care protocol, Rectal Ozone improved O2-saturation, decreased inflammation biomarkers and improved \nTaylor\u2019s radiological scale in both cohorts. Although age, grade of severity and days of hospitalization were inferior in Slovakian cohort, \nmortality was similar in both cohorts, but inferior if compared to an external control cohort.\nKeywords: Ozone, Ozone therapy, Pneumonia, COVID-19, SARS-CoV-2, Rectal insufflation. \nResumen\nObjetivo. Evaluar el efecto del Ozono (O3) rectal en la neumon\u00eda grave por COVID-19 en dos cohortes diferentes en cuanto a \nlocalizaci\u00f3n (Madrid vs Zilina), etnia (cohortes eslovaca vs espa\u00f1ola) y edad. \nMaterial y m\u00e9todos: En un estudio multic\u00e9ntrico, se evaluaron 32 pacientes con neumon\u00eda bilateral grave por COVID-19 y (+) RT-PCR \n(reacci\u00f3n en cadena de la polimerasa con transcriptasa inversa) SARS-CoV-2 (16 de cada cohorte). Resultados primarios: a) cl\u00ednicos \n(saturaci\u00f3n de O2); b) bioqu\u00edmicos (recuento de linfocitos, fibrin\u00f3geno, d\u00edmero D, urea, ferritina, LDH [deshidrogenasa l\u00e1ctica], IL-6 y \nPCR [prote\u00edna c reactiva]); y c) mejor\u00eda radiol\u00f3gica. Resultados secundarios: a) d\u00edas de hospitalizaci\u00f3n, b) tasa de mortalidad antes del \nalta. El protocolo de ozono consisti\u00f3 en 10 sesiones de ozono intra-rectal, dosis total de 5,25 mg (volumen de 150 ml, concentraci\u00f3n \nde 35 \u03bcg/ml). El protocolo de cuidados est\u00e1ndar incluy\u00f3 suministro de O2, antivirales (Remdesivir / Isoprinosina), corticosteroides \n(Dexametasona / Metilprednisolona), anticuerpos monoclonales (Anakinra / Tocilizumab), antibi\u00f3ticos (Azitromicina), anticoagulantes \n(Enoxaparina / Fraxiparina). \nResultados: Los pacientes de la cohorte eslovaca eran m\u00e1s j\u00f3venes (53,38 vs 84,69 a\u00f1os). El grado de gravedad fue peor en la \ncohorte espa\u00f1ola (4,78 frente a 3,30 puntos). La duraci\u00f3n de la estancia fue superior en la cohorte espa\u00f1ola (27,38 frente a 10,07 \nd\u00edas). Ambas cohortes mejoraron la saturaci\u00f3n de O2 y el recuento de linfocitos. Los biomarcadores de inflamaci\u00f3n (fibrin\u00f3geno, d\u00edmero \nD, urea, ferritina, LDH, PCR e IL-6) disminuyeron en ambas cohortes. En la cohorte espa\u00f1ola, la mejor\u00eda de la Urea y la Ferritina no \nfue significativa (p>0,05), mientras que en la cohorte eslovaca, la Urea, el Fibrin\u00f3geno y la LDH no fueron significativos (p>0,05) Los \nsignos radiol\u00f3gicos de neumonitis bilateral disminuyeron en ambas cohortes. La mortalidad fue similar en ambas cohortes (12,5%), \npero inferior si se compara con un grupo de control externo (23%). \nConclusiones: Tras el protocolo de cuidados est\u00e1ndar, el ozono rectal mejor\u00f3 la saturaci\u00f3n de O2, disminuy\u00f3 los biomarcadores \nde inflamaci\u00f3n y mejor\u00f3 la escala radiol\u00f3gica de Taylor en ambas cohortes. Aunque la edad, el grado de gravedad y los d\u00edas de \nhospitalizaci\u00f3n fueron inferiores en la cohorte eslovaca, la mortalidad fue similar en ambas cohortes, pero inferior si se compara con \nuna cohorte de control externa.\nPalabras clave: Ozono, Ozonoterapia, Neumon\u00eda, COVID-19, SARS-CoV-2, Insuflaci\u00f3n rectal.ID ID\nID\nID\nIDID77\n2023/38 (4): 76-84Multicentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience\nIntroduction\nSince the discovery of a new coronavirus on Wuhan, \nprovince of China, by December 2019, this new \npandemic due to the new SARS-CoV-2 or COVID-19 \nvirus has hit the economies and Sanitary Health Systems \nall over the world to an extent that the World Health \nOrganization (WHO) has declared an exceptional situation \nof pandemic by the 3rd of March 20201.\nTo date, there is no effective treatment for the \nmanagement of SARS-CoV-2 infection or COVID-19 \ndisease. There are several clinical trials trying to find \nthe most accurate treatment to fight against COVID-19 \ninfection. Unfortunately, there is no evidence from \ncontrolled trials to recommend a specific treatment for \nsuspected/confirmed COVID-19 patients2.\nIn Spain, the pandemic situation in its first and second \nwaves has saturated the Health System extremely that \nMaterial and Human Resources have been reorganized \nbecause of the shortage of them3; therefore, all medical \nactivity has been focused and directed multidisciplinary \nto fight against this new pandemic situation. In that \nscenario, Ozone has been proposed as a complementary \ntreatment to Internal Medicine Staff of our Hospital.\nCurrently, there are 9 clinical trials (CT) that postulate \nthe potential use of Ozonized Autohemotherapy on the \nmanagement of COVID-19 disease (1 CT from Brazil, \n1 from Turkey, 2 CT from Italy, 2 CT from Spain and 3 \nCT from China); only 2 CT considers ozonized saline \nsolution (1 CT from Spain and 1 CT from India); and \n3 CT (2 CT from Cuba and 1 from India) consider \nrectal Ozone as an alternative for the management of \nCOVID-19 infection. The studies from Cuba are still in \nphase of recruiting, and the study from India (Shah et al) \nhas been recently published4-7. \nThe Standard-of-care for COVID-19 is only supportive and \nacute respiratory distress syndrome (ARDS) will cause \nrespiratory failure and finally death in COVID-19 patients. \nAlthough most patients will develop mild symptoms \n(fever, cough, myalgia and dyspnea); a small percentage \nof patients (15%) will develop a hyper inflammation or \n\u201ccytokine storm\u201d syndrome8, and ARDS will constitute \nthe leading cause of mortality, which occurs in 4.9% of \npatients2. Treatment of hyper inflammation will decrease \nthe mortality rate9; therefore, we hypothesize that anti-\ninflammatory drug such as corticosteroids, monoclonal \nantibodies and even ozone could be recommended at \nthis Stage.\nOzone (O3) is capable of modulating pain and \ninflammation and recognized bactericidal, fungicidal, \nvirucidal and anti-parasitic properties are attributed \nto ozone; a fact  that is supported by clinical studies \nthat come from countries where the practice of ozone therapies is well-regulated (Cuba, Italy, Germany, Russia, \nTurkey, India and Spain)10,11. Many water purification \nplants worldwide use ozone because of its germicidal \neffect10. Because of ozone biological properties, \nFern\u00e1ndez-Cuadros et al have postulated ozone as an \nalternative therapy for the management of the present \nSARS-CoV-2 pandemic12. Virucidal, immunomodulatory \nand vasodilator properties that favor O2 transport to \nhypoxemic tissues postulate Ozone as a promising \nalternative in COVID-19 management12.\nDespite the preventive effect of vaccines on COVID-19 \ninfection, there is no drug with anti-viral, anti-inflammatory \nand oxigenatory properties all in one as ozone does. Our \nstudy group postulated and further demonstrated ozone \nas a treatment once COVID-19 disease has started and \nviral spread, inflammation and hypoxia are hallmarks \npresent in COVID-19 patients. In that sense, our \nResearch Group has presented the preliminary results \nof rectal ozone for the management of mild-severe \nCOVID-19, with very promising results13,14. Although our \npatients treated were older (mean age 83 years), there \nis no report of a similar study considering the treatment \nof younger patients, using the same protocol. There is \na need to perform a multicenter study to evaluate our \nprotocol in different groups and with different ages, that \nmeans in different cohorts, considering location, ethnicity \nand age, in order to recommend and to confirm the \nresults observed previously in our country. \nThe objective of this article is to show the updated \nresults of the effectiveness of a rectal ozone (O3) protocol \nin a series of COVID-19 patients with severe bilateral \npneumonia (Spanish cohort), and to compare them with \nanother cohort of patients treated in another country \n(Slovakian cohort), in terms of clinical, biochemical and \nradiological variables. Mortality and Hospitalization time \n(length of stay) were also compared between cohorts. \nCohorts differed on location (Madrid vs Zilina), ethnicity \n(Slovakian vs Spanish cohorts) and age. \nMaterial and methods\nA prospective, before-and-after, multicentric study was \nperformed in 2 Hospitals, one in Hospital Universitario \nSanta Cristina, Madrid-Spain (16 patients), and another \nin FNsP Hospital (Faculty Hospital and Poliklinic), Zilina-\nSlovakia (16 patients). The study included a total of \n32 severe COVID-19 patients, with clinical symptoms \nand RT-PCR (reverse transcriptase polymerase \nchange reaction) positive for SARS-CoV-2. The study \nrun from August 2020 to February 2021. All subjects \ngave their informed consent for inclusion before they \nparticipated in the study. The study was conducted in \naccordance with the Declaration of Helsinki (1975), and \nthe protocol was approved by the Ethics Committee \nof Santa Cristina University Hospital (15/4/20), by 78\n2023/38 (4): 76-84Marcos Fern\u00e1ndez-Cuadros et al. \nEthics Committee for Medical Investigation at Hospital \nUniversitario la Princesa (25-06-20, acta CEIm 14/20, \nRegistry number 4146), and by Zilina\u2019s Ethic Comission \n(17/1/2021). Three Committees authorized the study \nfor ozone treatment for compassionate use in severe \nCOVID-19 pneumonia (Figure 1). \nInclusion criteria: 1) patients 18 years and older; 2) \nwith positive result on RT-PCR SARS-CoV-2; 3) with \nclinical signs of moderate-severe pneumonia (SpO2 \n<93% or PaO2/FiO2<300 mmHg, or moderate/severe \nrespiratory symptoms); 4) with radiological signs of \nCOVID-19 pneumonia [bilateral \u201cground glass image\u201d \n(compatible with  lung lesions) on chest X-ray (according \nto Taylor\u2019s scale)] [15]; 5) who required hospitalization \ndue to moderate or severe respiratory symptoms; 6) \nwho required O2-supply with non-mechanical ventilation; \n7) whose patient/legal representative gave informed \nconsent to participate in the trial. \nExclusion criteria: 1) Pregnancy or breast feeding; 2) \nGlucose 6-phosphate dehydrogenase (G6PD) deficiency \n(favism), rare in Spain; 3) Patients enrolled in other clinical \nstudies. Comorbidities did not constitute a reason for \nexclusion in this study.\nOnce Standard-of-care (SOC) was completed \n(depending of the best available treatment on each \ncountry), no further clinical improvement was observed \nafter Standard-of-care, and at this point, physicians \nconsidered that Ozone could be prescribed as \ncompassionate use in COVID-19 treatment, the initial \nbiochemical evaluation (leucocyte and lymphocyte count \n[Mindray BC-6000 kit], Ferritin [Abbott Alinity I kit], D-Dimer \n[IL ACL TOP 300 CTS kit], Fibrinogen [IL ACL TOP 300 \nCTS kit], CRP [C-reactive protein, Abbott Alinity c kit] and IL-6 [Snibe Maglumi 1000 kit]) and the initial radiography \nof the chest were performed. The procedure, indications \nand contraindications were explained to the patient and/\nor legal representative, and informed consent was signed \nprior to patient evaluation and treatment.\nThe Standard-of-care protocol in Spanish cohort \nincluded O2-supply, antivirals (Remdesivir [200 \nmg/1day, the first day and 100 mg/day for 4 days]), \ncorticosteroids [Dexamethasone 6 mg/day por 7 \ndays] or Metilprednisolone [40 mg/day for 7 days]), \nantibiotics (Azytromicine [500 mg/day per 5 days]) and \nanticoagulants (Enoxaparine [40 mg SC [subcutaneous]/\nday, all hospitalization period], anti-IL-6 (Tocilizumab \n8 mg/kg IV [intravenous] twice with an interval of 12 h, \nand up to a maximum of 800 mg per dose]) or anti-IL-1 \n(Anakinra 100 mg, single dose) and hyper immune serum \n(1 dose) if necessary.\nThe Standard-of-care protocol In Slovakian cohort \nincluded O2-supply, antivirals (Remdesivir [200 mg \nIV/1 day, the first day and 100 mg/day for 4 days]; \nIsoprinosine 500 mg, 2 tablets/3 time/day in the case of \nlymphocytopenia), corticosteroids [Dexamethasone 8-24 \nmg IV/ 10-24 days], antibiotics [Azytromicine 500 mg/day \nfor 6 days], anticoagulants [Fraxiparine, 1 dose per day \nif D Dimer > 1.0, 2 doses per day if D Dimer>2.0], and \nanti-IL-1 (Anakinra 100 mg, single dose in some cases).\nThe ozone protocol consisted in administering intra rectally \na dose of 5,25 mg of ozone (rectal insufflation of 150 mL \nof Ozone at a 35 \u03bcg/mL concentration for 5 to 10 days), \naccording to the severity of the patients. The supplies \nneeded for ozone insufflation were: a) Ozonosan \u03b1-Plus\u00ae \n[Ozone Generator for Spanish cohort], or Ozofutura\u00ae \n[Ozone Generator for Slovakian cohort] ; b) Rectal probe; \nFigure 1: Study protocol, enrollment, initial/final evaluation and follow-up in COVID-19 patients including both Spanish and Slovakian cohorts. SOC, Standard of care..79\n2023/38 (4): 76-84Multicentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience\nc) three silicone syringes of 50 mL capacity; and d) gel \nfor lubrication of probe.\nPrior to ozone administration, the patient was placed in \nthe supine position (sedated patients) or lateral decubitus \nposition (collaborative patients) with the lower limbs flexed. \nThree 50-mL silicone syringes of ozone were loaded with \nthe corresponding concentration (35 \u03bcg/mL), and were \nslowly injected rectally through a 14 French rectal probe. \nThe probe was previously lubricated with medical gel-\ntype solution. The insufflation rate was of 1 mL / second.\nThe final evaluation was performed after of ozone protocol \nwas completed. Clinical, biochemical analysis and chest \nradiographies were evaluated, and any adverse effects \nwere recorded. Mortality and Hospitalization time were \ncompared between both cohorts.\nChest Radiography was used to confirm diagnosis \nand to grade severity. Taylor Scale for Severe Acute \nRespiratory Infection grades severity (SARS), ranging \nfrom 1 to 5 degrees. Grade 1 is normal. Grade 2 shows \npatchy atelectasis, hyper inflammation or bronchial wall \nthickening. Grade 3 denotes focal alveolar consolidation \nbut with no more than one segment or lobe involved. \nGrade 4 depicts multifocal consolidation and grade 5 \nshows diffuse alveolar consolidation15. \nFor determination of sample size, the a priori power \ncalculation was based on Taylor Scale, with an expected \neffect size of 0.2 between Groups at 10-days follow-up, a \n2-time point of measurement (pretest-posttest evaluation) \nand a level of significance of 0.05 and a desired power of \n0.80; all of which gave us a total sample size estimation \nof 30 patients. With an expected dropout of 10% during \nthe study, a total of 32 patients were finally calculated (16 \npatients in each group).\nStatistical analysis was performed using Statistical \nPackage for Social Sciences (SPSS\u00ae), Illinois, USA \nversion 20.0. Frequencies and percentages were used \nto evaluate qualitative variables; while for the evaluation \nof quantitative variables, means/median and standard \ndeviation were used. For evaluation of Taylor\u2019s Scale, \nmedian and Interquartile range (IQR) were used. The \nWilcoxon test was the statistical tool used to evaluate \na change before-and-after treatment in quantitative variables. The level of significance was 95% (p <0.05).\nResults\nThis is a multicenter study where two cohorts of 16 \npatients each who were treated using homogeneous \nozone protocol (Total dose 5.25 mg, 150 ml at a 35 \u03bcg/\nml concentration, every day for up to 10 days.\nDemographic Variables\nIn table I, we observe that the Slovakian cohort was \nyounger than the Spanish cohort (53.38 vs 84.69 years, \np=0.0001). Regarding COVID-19 severity, using Taylor \nscale as a radiological grading system, the Spanish \ncohort was more severe than the Slovakian cohort (4.78 \nvs 3.30, p=0.0001). No significant differences regarding \nsex were observed in both cohorts. The Length of Stay \n(LOS) was superior in the Spanish cohort (27.38 vs \n10.07 days, p=0.0038). Number of Ozone sessions was \nsimilar in both cohorts (7.5 vs 6.43). No adverse events \nwere observed in both cohorts. Mortality was similar in \nboth cohorts (12.5%, p=0.7642). Table I.\nPrimary Outcomes \n(clinical, biochemical and radiological variables)\nIn table II, in the Spanish cohort, all variables improved \non an overall view. The improvement was significant for \nSaturation of O2, Lymphocytes, Fibrinogen, D-Dimer, LDH, \nCRP , IL-6 and Taylor Scale (p<0.05). On the contrary, the \nimprovement was not significant for Leucocytes, Urea \nand Ferritin (p>0.05). Table II.\nIn table III, in the Slovakian cohort, all variables improved \non an overall view. The improvement was significant \nfor Saturation of O2, Lymphocytes, D-Dimer, Ferritin, \nCRP , IL-6 and Taylor Scale (p<0.05). On the contrary, \nthe improvement was not significant for Leucocytes, \nFibrinogen, Urea and LDH (p>0.05). Table III.\nIn table IV, when both the Spanish and the Slovakian \ncohort were evaluated together, all variables improved \non an overall view. The improvement was significant for \nSaturation of O2, Lymphocytes, Fibrinogen, D-Dimer, \nCRP , IL-6 and Taylor Scale (p<0.05). On the contrary, the \nimprovement was not significant for Leucocytes, Urea \nand Ferritin (p>0.05). Table IV. Figures 2 and 3.\nTable I: Demographic and clinical Variables in patients treated in Spain and Slovakia, after rectal Ozone insufflation (n=32).\n*, p<0.05. %, percentage. **, p<0.01. IQR, Interquartile range. SD, standard deviation.Variable Spanish Cohort Slovakian Cohort p\nTaylor, median [IQR] 4.78 [0.3] 3.30 [0.82] 0,0001**\nAge (years) mean \u00b1 SD 84,69 \u00b1 12.23 53,38 \u00b1 11.88 0,0001**\nMale Sex n (%) 12(75%) 10(62.5%) 0.3342\nFemale Sex n (%) 4(25%) 6(37.5%) 0.2982\nLength of Stay  (days) mean \u00b1 SD 27,38 \u00b1 15.96 10,07 \u00b1 3.81 0,0038**\nNumber of Ozone sessions mean \u00b1 SD 7.5 \u00b1 2.80 6.43 \u00b1 1.71 0.1187\nAdverse events 0 0 1\nMortality (%) 12.5 12.5 0.764280\n2023/38 (4): 76-84Marcos Fern\u00e1ndez-Cuadros et al. \nTable II: Main Variables in patients treated in Spain, after rectal Ozone insufflation (n=16).\n*, p<0.05. **, p<0.01. Sat O2, Saturation of Oxygen. LDH, lactate dehydrogenase. CRP , C-reactive protein. IL-6, interleukin 6. . IQR, Interquartile range.  SD, standard deviation.VARIABLES PRE-O3 POST-O3 P\nCLINICAL\nSat O2 mean \u00b1 SD 89 \u00b1 4.1 94.5 \u00b1 3.4 0.0002**\nBIOCHEMICAL\nLeucocytes cells/mL mean \u00b1 SD 8602 \u00b1 3676 7823 \u00b1 2568 0.4165\nLymphocytes cells/mL mean \u00b1 SD 985 \u00b1 484 1278 \u00b1 583 0.0403*\nFibrinogen mg/dL mean \u00b1 SD 713 \u00b1 112 572 \u00b1 163 0.0107*\nD-Dimer ng/mL mean \u00b1 SD 3240 \u00b1 2484 1343 v 1320 0.0110*\nUrea mg/dL mean \u00b1 SD 67 \u00b1 41 55 \u00b1 24 0.1089\nFerritin ng/mL mean \u00b1 SD 989 \u00b1 799 840 \u00b1 1060 0.6043\nLDH U/L mean \u00b1 SD 329 \u00b1 111 241 \u00b1 89 0.0209*\nCRP mg/mL mean \u00b1 SD 8.9 \u00b1 6.1 2.46 \u00b1 3.7 0.0040**\nIL6 pg/mL mean \u00b1 SD 85.07 \u00b1 50.53 30.48 \u00b1 38.10 0.0048**\nRADIOLOGICAL\nTaylor median [IQR] 4.78[0.3] 3.0[0.0] 0.0001**\nTable III: Main Variables in patients treated in Slovakia, after rectal Ozone insufflation (n=16).\n*, p<0.05. **, p<0.01. Sat O2, Saturation of Oxygen. LDH, lactate dehydrogenase. CRP , C-reactive protein. IL-6, interleukin 6. . IQR, Interquartile range. SD, standard deviation.VARIABLES PRE-O3 POST-O3 P\nCLINICAL\nSat O2 mean \u00b1 SD 86 \u00b1 6.99 94 \u00b1 2.47 0.0001**\nBIOCHEMICAL\nLeucocytes cells/mL mean \u00b1 SD 9200 \u00b1 4239 8826 \u00b1 1713 0.7763\nLymphocytes cells/mL mean \u00b1 SD 1300 \u00b1 564 2473 \u00b1 897 0.0001**\nFibrinogen mg/dL mean \u00b1 SD 289 \u00b1 142 271 \u00b1 127 0.4334\nD-Dimer ng/mL mean \u00b1 SD 1389 \u00b1 1106 622 \u00b1 428 0.0172*\nUrea mg/dL mean \u00b1 SD 31 \u00b1 12 32\u00b1 9 0.6655\nFerritin ng/mL mean \u00b1 SD 730 \u00b1 531 415 \u00b1 284 0.0173*\nLDH U/L mean \u00b1 SD 231 \u00b1 139 202 \u00b1 121 0.0963\nCRP mg/mL mean \u00b1 SD 19.4 \u00b1 19.4 2.4 \u00b1 3.2 0.0040**\nIL-6 pg/mL mean \u00b1 SD 51.8 \u00b1 42.8 5.8 \u00b1 6.5 0.0026**\nRADIOLOGICAL\nTaylor median [IQR] 3.3 [0.82] 1.9[0.0] 0.0001**\nTable IV: Main Variables in patients treated in Spain and Slovakia, after rectal Ozone insufflation (n=32).\n*, p<0.05. **, p<0.01. Sat O2, Saturation of Oxygen. LDH, lactate dehydrogenase. CRP , C-reactive protein. IL-6, interleukin 6. . IQR, Interquartile range.  SD, standard deviation.VARIABLES PRE-O3 POST-O3 P\nCLINICAL\nSaturation O2 mean \u00b1 SD 88.89 \u00b1 4.39 93.92 \u00b1 2.21 0.0001**\nBIOCHEMICAL\nLeucocytes cells/mL mean \u00b1 SD 88904 \u00b1 3890 83067 \u00b1 2210 0.4551\nLymphocytes cells/mL mean \u00b1 SD 11370 \u00b1 538 18537 \u00b1 955 0.0001**\nFibrinogen mg/dL mean \u00b1 SD 509 \u00b1 250 427 \u00b1 210 0.0089**\nD-Dimer ng/mL mean \u00b1 SD 2349 \u00b1 2130 996 \u00b1 1044 0.0011**\nUrea mg/dL mean \u00b1 SD 50 \u00b1 35 44 \u00b1 22 0.1463\nFerritin ng/mL mean \u00b1 SD 864 \u00b1 683 635 \u00b1 804 0.1478\nLDH U/L mean \u00b1 SD 282,0356 222,3537 0.0052**\nCRP mg/mL mean \u00b1 SD 14.01 \u00b1 14.88 2.43 \u00b1 3.46 0.0002**\nIL-6 pg/mL mean \u00b1 SD 69.04 \u00b1 49.09 18.58 \u00b1 29.57 0.0001**\nRADIOLOGICAL\nTaylor median [IQR] 4.07[2.0] 2.48[1.0] 0.0001**\nFigure 2: Biochemical variables in both Spanish and Slovakian Cohort (n=32). \n*, p<0.05.\nFigure 3: CRP , IL-6 and Radiological Taylor Scale in Spanish and Slovakian \ncohort. *, p<0.05 (n=32). 81\n2023/38 (4): 76-84Multicentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience\nFigure 4: Three cases from Spanish and three cases from Slovakian cohorts are \npresented before/after Ozone (O3).We present six cases of radiological improvement based \non Taylor Scale, three patients from the Spanish cohort \nand three patients from the Slovakian cohort (Figure 4). \nDiscussion\nTo the best of our knowledge, this is the first multicenter \nstudy on the effectiveness of Rectal Ozone insufflation \nprotocol in severe COVID-19 pneumonic patients in the \nlight of SARS-CoV-2 pandemic. After Standard of care \nprotocol was prescribed and no further improvement was \nobserved, Rectal ozone improved clinical, biochemical \nand radiological variables in a significant manner (p<0.05) \nin both Spanish and Slovakian cohorts.\nSince no further improvement was observed after \nstandard of care was administered, ozone was prescribed \nas complementary treatment in both cohorts. Slovakian \ncohort was younger and radiological pneumonia was \nnot as severe as Spanish cohort, as evaluated by Taylor \nScale. This would explain the shorter length of stay in \nSlovakian cohort.\nTo date, almost 1661 clinical trials are in course to \ndetermine the best treatment for COVID-19 infection, \nbut most of the pharmacological therapies investigated \nhave not demonstrated effectivity in the management \nof SARS-CoV-2 pandemic4,16. From the clinical \ntrials evaluating ozone therapy, only 2 of them have \npublished their results7,13. This study presents the use \nof a homogeneous rectal ozone protocol in two different \ncohorts of COVID-19 patients regarding location, \nethnicity and age, and the effects from one population \nwere reproducible in the other one. \nOur study group identified previously four properties \nthat could cope with the complications derived from \nthis COVID-19 infection (anti-viral, anti-oxidant, anti-\ninflammatory and O2 delivery enhancer)12. In the \nmentioned study, it is expected that those properties could cope with the complications derived from this \nCOVID-19 infection12. Our results confirm that those \nproperties are responsible for the clinical, biochemical \nand radiological improvement, as stated by some others \nauthors17-19. Improvement of O2 delivery to tissues \nincluded the lungs, will be the reason why O2 saturation \nimproved in such patients. This comes in line with what \nMenendez-Cepero observed; she mentioned that Ozone \nis capable of modulating interferons and cytokines, \ndecreasing inflammation biomarkers20.\nAyanian et al. have identified that high level of at least \n5 variables such as D-dimer, CRP , IL-6, Ferritin and \nLDH which produce negative outcomes in COVID-19 \npatients (ICU [Intensive Care Unit] admission, intubation \nand death. Reversely, lower levels of such biomarkers \nare related with positive outcomes (survival)21. Moreover, \nLorenz et al. have suggested that severe COVID-19 \npatients have some characteristics features: neutrophilia, \nlymphopenia, hypercoagulability (D Dimer elevation) and \nhyper ferritinemic syndrome22. Copaescu has stated that \nclinical biomarkers (Saturation of Oxygen and respiratory \nrate) and inflammatory biomarkers (IL-6 and CRP [CRP \nas a surrogate of IL-6]) may predict severity in COVID-19, \nand such biomarkers may evaluate response to therapy23. \nTherefore, we intended to demonstrate that ozone was \ncapable of reducing such outcome biomarkers whether \nclinical (Saturation of Oxygen) or biochemical (D-dimer, \nCRP , IL-6, Ferritin and LDH). \nIn a recent review, Cattel has stated that ozone is \nantiviral and might inactivate the virus and inhibit its viral \nreplication. Moreover, ozone could reduce inflammation \nand lung damage and ozone might favor immunity \nand oxygenation, and increase Oxygen saturation and \ndecrease O2 support. As a consequence, an increase in \nlymphocyte count, a decrease of inflammation biomarkers \n(CRP , IL-6, Ferritin, D-Dimer and LDH), an improvement \nin O2 saturation and a decrease in O2 supply; and finally a \nnegativization of RT-PCR SARS-Cov-2 Test is expected \nafter ozone treatment24. We have evaluated similar clinical \nand biochemical variables in both cohorts, the Spanish \nand the Slovakian, and we did observe such positive \neffects in both cohorts.\nChirumbolo et al. have stated that ozone produces \nimprovement in COVID-19 patients whatever the method \nof ozone delivery was used. Major autohemotherapy, \nozonized saline solution and even rectal ozone has \nreduced inflammation in COVID-19 patients25. In our \nstudy, ozone by rectal insufflation was chosen because \nthe technique is very simple, economic and safe12.\nTo date, there are 21 manuscripts that postulate the \nuse of ozone against COVID-1926. There are also 21 \narticles that state the benefit of ozone in treating 682 \npatients with COVID-19 (patients recruited from China, \nSpain, Cuba, Italy, Iran, India and USA). Ozone reduces \n82\n2023/38 (4): 76-84Marcos Fern\u00e1ndez-Cuadros et al. \ninflammation; time of ventilatory support and time to \nnormalize (negativize) RT-PCR for SARS-CoV-226. \nIn our study, an improvement in Saturation of Oxygen \nwas observed (Oxygen Saturation from 88.89 to \n93.92%). Similarly, in another study, Franzini observed \nan improvement of 85 to 95% in Oxygen saturation \n(p<0.001)27. Araimo observed that ozone reduced the \nneed for ventilatory support in COVID-19 disease5. \nOzone improves saturation of Oxygen, as observed by \nFranzini, Araimo and our study5,27.\nIn our multicentric study, an improvement in leucocyte \ncount, in biomarkers of inflammation and in biomarkers \nof coagulation was observed (Fibrinogen, D-Dimer, \nLDH, CRP and IL-6). Similar results have been observed \nby Araimo5, Franzini27, Tascini28, Schwartz29 and \nHern\u00e1ndez30, in different cohorts, in Italy and in Spain.\nFinally, and improvement in radiological severity based on \nTaylor scale was observed in our multicentric study, (change \nin Taylor scale from 4.07 to 2.48 points). This comes in \nline Schwartz et al., who observed an improvement in \nlung affection from 60% to 24%; and the improvement, \noccurred at 3-5 days from ozone treatment29.\nMortality of an external control cohort regarding similar age \nand sex in Spain using Standard of care was 21%14. The \noverall mortality in first and second wave in the Community \nof Madrid was 23% in hospitalized COVID-19 patients29. \nHowever, when mortality was compared to hospitalized \npatients treated by ozone, mortality decreased to 12.5% in \nboth Spanish and Slovakian cohorts. These observations \nwould suggest that ozone could decrease mortality in \nsevere COVID-19 pneumonic patients.\nShah et al. and Hendawy et al. have published a case-\ncontrol study and a case report, respectively; using rectal \nozone insufflation. Shah et al. used a protocol of rectal \nozone insufflation, 150 ml at a 40 \u03bcg/ml concentration, \n2 times/day, for up to 10 days7. They observed clinical \n(oxygen saturation and clinical NEWS Score) and \nbiochemical improvement (LDH, CRP , Ferritin), although \nthe improvement was not statistically significant. Moreover, \non 10th day of treatment, 100% of patients showed RT-\nPCR negativity vs 70% in control group (p=0.01)7. Ozone \nwas superior to negativize SARS-Cov-2 infection7.\nHendawy et al. reported the use of rectal ozone, one \nsingle insufflation, and a total dose of 25.2 mg (2000 \nml at a 12.6 \u03bcg/ml concentration) in two cases, and \nan immediate improvement of oxygen saturation from \n84% to 94-97% was observed31. The observations \nform both authors (Shah and Hendawy) are similar to \nours7,31. Rectal ozone insufflation improved oxygen \nsaturation, and decreased both biomarkers of \ninflammation and coagulation.Pe\u00f1a-Lora and Fernandez-Cuadros have published \nanother case in which, after 5 session of rectal ozone \n(100ml, once a day at a 35 \u03bcg/ml), oxygen saturation \nimproved from 90% to 94%, biochemical variables \nameliorated (IL-6, PCR, D dimer, Fibrinogen and ferritin) \nand radiological improvement was  observed (from 5 to \n3 on Taylor Scale)32.\nIn the present study, we have used a dose of 35 \u03bcg/mL. \nThe dose is similar to the one used in a Cuban protocol \ndirected by Leon-Fernandez et al, which has been lately \npublished33.\nA limitation of this multicentric study is the small sample \nsize analyzed. Moreover, with such a small sample size \n(32 patients, 16 in each cohort), we cannot speculate \nwhy mortality was similar in both cohorts (12.5%). We \nexpected to see some differences since Slovakian \ncohort was younger than the Spanish cohort. Maybe in \na greater sample, these differences would be statistical, \nand could favor the younger cohort, because there is a \nlinear correlation between age and mortality in COVID-19 \npatients12. We did not take into account comorbidities \nin these cohorts, and comorbidities might be related to \nage of population. In any case, the mortality was lower if \ncompared to an external control group (23%). However, \ndespite the number of patients evaluated, the fact that \nozone improved all variables analyzed once standard of \ncare was already finished; a larger sample in a new study \nis needed in order to confirm the effect of rectal ozone \ninsufflation in the management of COVID-19 patients, as \nit was observed in this manuscript. \nConclusions\nIn patients with severe COVID-19 pneumonia, after \nStandard of care protocol was prescribed and no further \nimprovement was observed, rectal Ozone improved \nO2 saturation, decreased inflammation biomarkers \nand improved Taylor\u2019s radiological scale with statistical \nsignificant difference in both Spanish and Slovakian \ncohorts. Although age, grade of severity and days of \nhospitalization were inferior in the Slovakian cohort, \nmortality was similar between both cohorts, but inferior \nif compared to an external control group. It is necessary \nto develop a Randomized Control Trial to confirm these \npromising observations.\nAuthor contributions\nConceptualization; drafting; investigation, project \nadministration, supervision, writing, review, editing and \ntranslation: MEFC. Biochemical Analysis, data-curation \nand validation: JRDC and JV. Patients\u2019 treatment: MEFC, \nOSPM, MJAF, JV. All authors have read and agreed to \nthe published version of the manuscript.83\n2023/38 (4): 76-84Multicentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experience\nFunding\nThis research received no external/internal funding.\nInformed Consent Statement\nAll patients signed informed consent for treatment and \npublication.\nEthics approval\nThis study was approved by Ethics Committee of Hospital \nUniversitario Santa Cristina (15-04-2020), by Hospital \nUniversitario la Princesa (25-06-20, acta CEIm 14/20, Registry number 4146), Madrid-Spain; and by Zilina\u00b4s \nEthic Comission (17/1/2021).\nAcknowledgments\nSaturnino D\u00edaz Trujillo, librarian of the Hospital Universitario \nSanta Cristina, Madrid is acknowledged for the bibliographic \nsearch to carry out this study. Dr. Jose Gabriel Perez \nKarduss is acknowledged for the statistical analysis.\nConflicts of interest\nThe authors declare no conflicts of interest.\nReferences\n1. Alhazzani W, M\u00f8ller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al.  \nSurviving Sepsis Campaign: Guidelines on the Management of Critically \nIll Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. \n2020 Jun;48(6):e440-e469. doi: 10.1097/CCM.0000000000004363.\n2. Uthman AT, Al-Rawi NN, Othman B, Al-Rawi NH. COVID-19: \nUnraveling 10 most significant answers about the current \npandemic. Journal of International Dental and Medical Research \n2021;14(1):394-403.\n3. https://www.eldiario.es/sociedad/coronavirus-sobrecarga-sanidad-\nComunidad-Madrid_0_1004050083.html. Accessed on 15th Dec 2022.\n4. WHO. Coronavirus disease (COVID-2019) situation reports. 2020.\n5. Araimo F, Imperiale C, Tordiglione P , Ceccarelli G, Borrazzo C, \nAlessandri F, et al. Ozone as adjuvant support in the treatment of \nCOVID-19: A preliminary report of probiozovid trial. J Med Virol. 2021 \nApr;93(4):2210-2220. doi: 10.1002/jmv.26636. \n6. https://rpcec.sld.cu/ensayos/RPCEC00000320-Sp. Accessed on \n4th December 2022.\n7. Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair \nPMK, et al. Safety and efficacy of ozone therapy in mild to moderate \nCOVID-19 patients: A phase 1/11 randomized control trial (SEOT \nstudy). Int Immunopharmacol. 2021 Feb;91:107301. doi: 10.1016/j.\nintimp.2020.107301.\n8. Shimabukuro-Vornhagen A, G\u00f6del P , Subklewe M, Stemmler HJ, \nSchl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother \nCancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9.\n9. Mehta P , McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson \nJJ, et al. COVID-19: consider cytokine storm syndromes and \nimmunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. \ndoi: 10.1016/S0140-6736(20)30628-0\n10. Fern\u00e1ndez-Cuadros ME, P\u00e9rez-Moro OS, Albaladejo-Flor\u00edn MJ. \nOzone fundamentals and effectiveness in knee pain: Chondromalacia \nand knee osteoarthritis. Germany: Lambert Academic Publishing; 2016.\n11. Fern\u00e1ndez-Cuadros ME, P\u00e9rez-Moro OS, Albaladejo-Flor\u00edn MJ, \n\u00c1lava-Rabasa S. El ozono intraarticular modula la inflamaci\u00f3n, mejora el \ndolor, la rigidez, la funci\u00f3n y tiene un efecto anab\u00f3lico sobre la artrosis \nde rodilla: estudio cuasi-experimental prospectivo tipo antes-despu\u00e9s, \n115 pacientes. Rev Soc Esp Dolor 2020; 27(2):78-88, https://doi.org/ \n10.20986/resed.2020.3775/2019.12. Fern\u00e1ndez-Cuadros ME, Albaladejo-Flor\u00edn MJ, Pe\u00f1a-Lora D, \n\u00c1lava-Rabasa S, P\u00e9rez-Moro OS. Ozone (O3) and SARS-CoV-2: \nPhysiological Bases and Their Therapeutic Possibilities According to \nCOVID-19 Evolutionary Stage. SN Compr Clin Med. 2020;2(8):1094-\n1102. doi: 10.1007/s42399-020-00328-7. \n13. Fern\u00e1ndez-Cuadros ME, Albaladejo-Flor\u00edn MJ, \u00c1lava-Rabasa \nS, Usandizaga-Elio I, Martinez-Quintanilla Jimenez D, Pe\u00f1a-Lora D, \net al. Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: \nPreliminary Results. SN Compr Clin Med. 2020;2(9):1328-1336. doi: \n10.1007/s42399-020-00374-1.\n14. Fern\u00e1ndez-Cuadros ME, Albaladejo-Flor\u00edn MJ, \u00c1lava-Rabasa \nS, Gallego-Galiana J, P\u00e9rez-Cruz GF, Usandizaga-Elio I, et al. \nCompassionate Use of Rectal Ozone (O3) in Severe COVID-19 \nPneumonia: a Case-Control Study. SN Compr Clin Med. \n2021;3(5):1185-1199. doi: 10.1007/s42399-021-00849-9. \n15. Taylor E, Haven K, Reed P , Bissielo A, Harvey D, McArthur C, et \nal. A chest radiograph scoring system in patients with severe acute \nrespiratory infection: a validation study. BMC Med Imaging. 2015 Dec \n29;15:61. doi: 10.1186/s12880-015-0103-y. \n16. Di Franco S, Alfieri A, Petrou S, Damiani G, Passavanti MB, Pace \nMC, et al. Current status of COVID-19 treatment: An opinion review. \nWorld J Virol. 2020 Sep 25;9(3):27-37. doi: 10.5501/wjv.v9.i3.27. \n17. Mart\u00ednez-S\u00e1nchez G, Schwartz A, Donna VD. Potential Cytoprotective \nActivity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants \n(Basel). 2020 May 6;9(5):389. doi: 10.3390/antiox9050389.\n18. Conti P , Gallenga CE, Tet\u00e8 G, Caraffa A, Ronconi G, Younes A, et \nal. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-\nCoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul \nHomeost Agents. 2020 March-April,;34(2):333-338. doi: 10.23812/\nEditorial-Conti-2. \n19. Marini S, Maggiorotti M, Dardes N, Bonetti M, Martinelli M, Re L, \net al. Oxygen-ozone therapy as adjuvant in the current emergency in \nSARS-COV-2 infection: a clinical study. J Biol Regul Homeost Agents. \n2020 May-Jun;34(3):757-766. doi: 10.23812/20-250-E-56. \n20. Menendez-Cepero S, Marques-Magallanes-Regojo JA, \nHernandez-Martinez A, Tall\u00f3n FJ H, Baeza-Noci J. Therapeutic effects \nof Ozone therapy that justifies its use for the treatment of COVID-19. \nResearch Open J Neurol 2020; 3(1):1-6, https://doi.org/10.31038/\nJNNC.2020314.84\n2023/38 (4): 76-84Multicentric study on the effect of rectal Ozone on COVID-19: the Spanish and Slovakian experienceMarcos Fern\u00e1ndez-Cuadros et al. \n21. Ayanian S, Reyes J, Lynn L, Teufel K. The association between \nbiomarkers and clinical outcomes in novel coronavirus pneumonia in a \nUS cohort. Biomark Med. 2020 Aug;14(12):1091-1097. doi: 10.2217/\nbmm-2020-0309. \n22. Lorenz G, Moog P , Bachmann Q, La Ros\u00e9e P , Schneider H, Schlegl \nM, et al. Cytokine release syndrome is not usually caused by secondary \nhemophagocytic lymphohistiocytosis in a cohort of 19 critically ill \nCOVID-19 patients. Sci Rep. 2020 Oct 26;10(1):18277. doi: 10.1038/\ns41598-020-75260-w.\n23. Copaescu A, James F, Mouhtouris E, Vogrin S, Smibert OC, Gordon \nCL, et al. The Role of Immunological and Clinical Biomarkers to Predict \nClinical COVID-19 Severity and Response to Therapy-A Prospective \nLongitudinal Study. Front Immunol. 2021 Mar 17;12:646095. doi: \n10.3389/fimmu.2021.646095.\n24. Cattel F, Giordano S, Bertiond C, Lupia T, Corcione S, Scaldaferri \nM, et al. Ozone therapy in COVID-19: A narrative review. Virus Res. \n2021 Jan 2;291:198207. doi: 10.1016/j.virusres.2020.198207.\n25. Chirumbolo S, Valdenassi L, Simonetti V, Bertossi D, Ricevuti G, \nFranzini M, et al. Insights on the mechanisms of action of ozone in \nthe medical therapy against COVID-19. Int Immunopharmacol. 2021 \nJul;96:107777. doi: 10.1016/j.intimp.2021.107777.\n26. Martinez-Sanchez G. La ozonoterapia como terapia complementaria \nen el enfrentamiento a la COVID-19. Revista Cubana de Farmacia \n2021; 54(1).\n27. Franzini M, Valdenassi L, Ricevuti G, Chirumbolo S, Depfenhart \nM, Bertossi D, et al. Oxygen-ozone (O2-O3) immunoceutical \ntherapy for patients with COVID-19. Preliminary evidence reported. \nInt Immunopharmacol. 2020 Nov;88:106879. doi: 10.1016/j.\nintimp.2020.106879.28. Tascini C, Sermann G, Pagotto A, Sozio E, De Carlo C, Giacinta \nA, et al. Blood ozonization in patients with mild to moderate COVID-19 \npneumonia: a single centre experience. Intern Emerg Med. 2021 \nApr;16(3):669-675. doi: 10.1007/s11739-020-02542-6.\n29. Schwartz A, Mart\u00ednez-S\u00e1nchez G, de Luc\u00eda AM, Viana SM, Mita \nCA. Complementary application of the ozonized saline solution in mild \nand severe patients with pneumonia COVID-19: A non-randomized \npilot study. Journal of Pharmacy and Pharmacognosy Research \n2021;9(2):126-42, https://jppres.com/jppres.\n30. Hern\u00e1ndez A, Vi\u00f1als M, Pablos A, Vil\u00e1s F, Papadakos PJ, \nWijeysundera DN, et al. Ozone therapy for patients with COVID-19 \npneumonia: Preliminary report of a prospective case-control study. \nInt Immunopharmacol. 2021 Jan;90:107261. doi: 10.1016/j.\nintimp.2020.107261.\n31. Hendawy HA, Mosallam W, Abuelnaga ME, Sabry AM. Old \nTreatment for a New Disease: Can Rectal Ozone Insufflation Be Used \nfor COVID-19 Management? A Case Report. SN Compr Clin Med. \n2021;3(6):1424-1427. doi: 10.1007/s42399-021-00895-3.\n32. Pe\u00f1a-Lora D, Albaladejo-Flor\u00edn MJ, Fern\u00e1ndez-Cuadros ME. Uso de \nozonoterapia en paciente anciana con neumon\u00eda grave por COVID-19. \nRevista Espanola de Geriatria y Gerontologia 2020; 55(6):362-4, \nhttps://doi.org/10.1016/j.regg.2020.07.005.\n33. Le\u00f3n Fern\u00e1ndez OS, Oru GT, Hansler RV. Medical Ozone: The \nPharmacological Mechanisms Accounting for its Effectiveness against \nCOVID-19.  J Med-Clin Res & Rev 2021;5(3):1-1085\n2023/38 (4): 85-91ORIGINAL\nConcordancia entre pruebas no invasivas\npara la implementaci\u00f3n de algoritmos de cribado\nde fibrosis hep\u00e1tica en pacientes de alto riesgo \nConcordance between non-invasive tests for the implementation \nof liver fibrosis screening algorithms in high-risk patients  \nCristina G\u00f3mez Cobo1,2      , Daniel Morell Garc\u00eda1,2      , Francisco Berga Montaner1      ,\nAntonia Barcel\u00f3 Bennasar1,2\n1. Servicio An\u00e1lisis Cl\u00ednicos Hospital Son Espases. Palma de Mallorca\n2. Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa)eISSN 2255-0569\nReceived: 29 - I - 2023\nAccepted: 30 - III - 2023\ndoi: 10.3306/AJHS.2023.38.04.85Corresponding author\nAnt\u00f2nia Barcel\u00f3 \nE-mail: antonia.barcelo@ssib.es   \nResumen \nIntroducci\u00f3n y objetivo: La evaluaci\u00f3n de la fibrosis hep\u00e1tica es de vital importancia para la valoraci\u00f3n de pacientes con \ncualquier enfermedad hep\u00e1tica cr\u00f3nica para la toma de decisiones terap\u00e9uticas, el pron\u00f3stico y la evaluaci\u00f3n de la respuesta al \ntratamiento. La biopsia hep\u00e1tica es actualmente el est\u00e1ndar de referencia para su identificaci\u00f3n y estadificaci\u00f3n, pero presenta  \nvarias limitaciones. Los enfoques con m\u00e9todos no invasivos basados en biomarcadores s\u00e9ricos o la valoraci\u00f3n de la rigidez \nhep\u00e1tica mediante elastograf\u00eda, se est\u00e1n incorporando cada vez m\u00e1s en la pr\u00e1ctica cl\u00ednica reemplazando a la biopsia. Nuestro \nobjetivo es evaluar la concordancia entre algunas de estas pruebas no invasivas: \u00edndice FIB-4, test Enhanced Liver Fibrosis (ELF) \ny elastograf\u00eda transitoria, en pacientes con hepatitis cr\u00f3nica de etiolog\u00eda diversa con alta prevalencia de fibrosis, para determinar su \nutilidad simult\u00e1nea o secuencial en la pr\u00e1ctica cl\u00ednica.\nM\u00e9todos: Estudio retrospecivo en el que se incluyeron 179 pacientes y se comprob\u00f3 la concordancia bivariante entre FIB-4, ELF \nscore  y Fibroscan con los puntos de corte considerados.\nResultados: La concordancia entre el valor de FIB-4 y ELF score se encontr\u00f3 del 29.94%, cuando se compar\u00f3 la concordancia \nentre el valor de FIB-4 y Fibroscan se encontr\u00f3 del 50.46% y la concordancia entre el valor de ELF score y Fibroscan fue del  \n29.38%.\nConclusiones: la concordancia para detectar los puntos de corte considerados entre las pruebas no invasivas estudiadas es \npobre, lo que sugiere la necesidad de utilizar varios marcadores no invasivos con diferentes puntos de corte para varios umbrales \ncl\u00ednicamente relevantes seg\u00fan la mejor tasa de detecci\u00f3n para cada patolog\u00eda. \nPalabras clave: cirrosis, fibrosis hep\u00e1tica, marcadores no invasivos, elastograf\u00eda transitoria, FIB-4, ELF, cribado. \nAbstract\nIntroduction and objective: The evaluation of liver fibrosis is of vital importance in the assessment of patients with any chronic \nliver disease for therapeutic decision making, prognosis and evaluation of response to treatment. Liver biopsy is currently the \ngold standard for identification and staging, but has several limitations. Non-invasive approaches based on serum biomarkers or \nassessment of liver stiffness by elastography are increasingly being incorporated in clinical practice replacing biopsy. Our objective \nis to evaluate the concordance between some of these non-invasive tests: FIB-4 index, Enhanced Liver Fibrosis (ELF) test and \ntransient elastography, in patients with chronic hepatitis of diverse etiology with high prevalence of fibrosis, to determine their \nsimultaneous or sequential usefulness in clinical practice.\nMethods: Retrospective study in which 179 patients were included and the bivariate concordance between FIB-4, ELF score and \nFibroscan with the cut-off points considered was tested.\nResults: The concordance between FIB-4 value and ELF score was found to be 29.94%, when the concordance between FIB-\n4 value and Fibroscan was compared it was found to be 50.46% and the concordance between ELF score and Fibroscan was \n29.38%.\nConclusions: The concordance for detecting the cut-off points considered between the non-invasive tests studied is poor, \nsuggesting the need to use several non-invasive markers with different cut-off points for various clinically relevant thresholds \naccording to the best detection rate for each pathology.\nKey words: cirrhosis, liver fibrosis, non-invasive markers, transient elastography, FIB-4, Enhanced Liver Fibrosis test, screening.ID ID ID\nID86\n2023/38 (4): 85-91Cristina G\u00f3mez Cobo et al. \nIntroducci\u00f3n\nLa enfermedad hep\u00e1tica cr\u00f3nica y la cirrosis suponen \n2 millones de muertes en todo el mundo cada a\u00f1o, \nadem\u00e1s de una alta carga de discapacidad y una \nmayor utilizaci\u00f3n de la atenci\u00f3n m\u00e9dica. La cirrosis es la \nund\u00e9cima causa m\u00e1s com\u00fan de muerte a nivel mundial \ny las muertes por cirrosis han aumentado de 899.000 \na m\u00e1s de 1,32 millones de 1990 a 2017, aunque es \nprobable, que las estimaciones de mortalidad sean \nconservadoras y subestimen su verdadera carga. \nLas etiolog\u00edas m\u00e1s comunes de enfermedad hep\u00e1tica \ncr\u00f3nica y cirrosis son, el virus de la hepatitis B (VHB), \nel virus de la hepatitis C (VHC), la enfermedad hep\u00e1tica \nrelacionada con el alcohol (ALD) y la enfermedad del \nh\u00edgado graso no alcoh\u00f3lico (NAFLD). Las tasas de \nmortalidad est\u00e1n aumentado, lo que es atribuible a la \nhepatitis viral, pero tambi\u00e9n impulsadas por la creciente \nprevalencia de ALD y NAFLD que ahora son las causas \nm\u00e1s comunes de enfermedad hep\u00e1tica cr\u00f3nica en el \nmundo occidental1.\nEn Espa\u00f1a pueden existir m\u00e1s de un mill\u00f3n de personas \n(prevalencia 3.6%) con fibrosis hep\u00e1tica significativa, \nestim\u00e1ndose que 1 de cada 6 de estos pacientes \npresentan cirrosis. Esta poblaci\u00f3n, comparada con la \npoblaci\u00f3n general ajustada por g\u00e9nero y edad, tiene \nm\u00e1s comorbilidad y utiliza m\u00e1s frecuentemente los \nrecursos sanitarios2. \nFibrosis\nLas diferentes causas capaces de generar da\u00f1o \nhep\u00e1tico conducen a hepatocitos da\u00f1ados e \ninfiltraci\u00f3n de c\u00e9lulas inmunitarias que activan la \ntransdiferenciaci\u00f3n de c\u00e9lulas estrelladas hep\u00e1ticas \n(HSC) en miofibroblastos productores de col\u00e1geno. En \nlas enfermedades hep\u00e1ticas cr\u00f3nicas, un desequilibrio \nde los mecanismos profibrog\u00e9nicos y antifibrog\u00e9nicos, \nprovoca una activaci\u00f3n persistente de miofibroblastos \nproliferantes, contr\u00e1ctiles y migratorios que conducen \na una producci\u00f3n excesiva de matriz extracelular, cuya \nacumulaci\u00f3n progresiva es la fibrosis, que favorece la \ndestrucci\u00f3n de la arquitectura fisiol\u00f3gica del h\u00edgado3.\nSe trata de un proceso con un importante per\u00edodo de \nlatencia durante el cual las personas afectadas pueden \ncarecer de signos o s\u00edntomas evidentes de enfermedad. \nEventualmente, la fibrosis puede progresar a cirrosis \ncl\u00ednicamente evidente e insuficiencia hep\u00e1tica4 que, \npueden desembocar en el desarrollo de hipertensi\u00f3n \nportal y complicaciones relacionadas. Adem\u00e1s, los \npacientes que experimentan una progresi\u00f3n fibrog\u00e9nica \ntambi\u00e9n tienen un riesgo significativo de desarrollar \ncarcinoma hepatocelular (CHC)5. El diagn\u00f3stico precoz \npermite iniciar tratamientos espec\u00edficos o medidas \npara prevenir la progresi\u00f3n de la enfermedad y mejorar \nla supervivencia.Los grados de fibrosis (F) en personas con enfermedad \nhep\u00e1tica se dividen en 4 seg\u00fan el sistema METAVIR6:\n\u00b7 F0 (no fibrosis) \n\u00b7 F1 (fibrosis portal sin septos: fibrosis m\u00ednima)\n\u00b7 F2 (fibrosis portal con unos pocos septos: fibrosis \nmoderada o fibrosis cl\u00ednicamente significativa)\n\u00b7 F3 (fibrosis septal con muchos septos, pero no \ncirrosis: fibrosis severa)\n\u00b7 F4 (cirrosis)\nDiferenciar entre estos grados de fibrosis es complicado \ncon pruebas cl\u00ednicas, de laboratorio y de imagen \ncompletas, porque los hallazgos son a menudo \ninespec\u00edficos o insensibles. La biopsia hep\u00e1tica sigue \nsiendo el est\u00e1ndar de referencia para evaluar la fibrosis \nhep\u00e1tica; sin embargo, el uso de m\u00e9todos no invasivos es \ncada vez m\u00e1s com\u00fan en la pr\u00e1ctica cl\u00ednica. Las pruebas \nno invasivas, la biopsia hep\u00e1tica/m\u00e9todos de diagn\u00f3stico \ninvasivos y la evaluaci\u00f3n cl\u00ednica tienen que ser integradas \npara lograr diagn\u00f3sticos correctos y la estratificaci\u00f3n de \nriesgo en enfermedades hep\u00e1ticas cr\u00f3nicas7.\nBiopsia hep\u00e1tica\nA pesar de ser el \u201cest\u00e1ndar de oro\u201d para la evaluaci\u00f3n \nde la fibrosis hep\u00e1tica, tiene varias limitaciones, \nincluida la invasividad, el alto costo, el error de \nmuestreo y la variabilidad entre observadores en \nla interpretaci\u00f3n patol\u00f3gica8. Adem\u00e1s, conlleva un \npeque\u00f1o pero significativo riesgo de complicaciones y \nde contraindicaciones9.\nPruebas no invasivas \npara evaluar la fibrosis hep\u00e1tica\nDurante la \u00faltima d\u00e9cada ha surgido una variedad de \nmetodolog\u00edas no invasivas que incluyen, entre otras, la \nelastograf\u00eda transitoria (ET) y biomarcadores s\u00e9ricos (FIB-\n4, Enhanced Liver Fibrosis\u2026) para la evaluaci\u00f3n de la \nfibrosis10. En condiciones estandarizadas, la precisi\u00f3n \nde estos m\u00e9todos suele ser s\u00f3lida para la fibrosis/\ncirrosis avanzada; sin embargo, las caracter\u00edsticas de \ndiagn\u00f3stico var\u00edan significativamente seg\u00fan el valor de \ncorte y la etiolog\u00eda subyacente de la enfermedad hep\u00e1tica \ncr\u00f3nica11. Sus ventajas incluyen una mejor aceptaci\u00f3n \npor parte de los pacientes, una mayor disponibilidad \npara la detecci\u00f3n de cohortes o basada en la poblaci\u00f3n \ny grados relativamente altos de concordancia con \nlos resultados obtenidos mediante la evaluaci\u00f3n de \nla histolog\u00eda hep\u00e1tica para resultados cl\u00ednicamente \nrelevantes (p. ej., fibrosis/cirrosis avanzada)4. Permiten \nidentificar y estratificar el nivel de fibrosis hep\u00e1tica al \nhacer referencia a puntuaciones histol\u00f3gicas, como la \npuntuaci\u00f3n METAVIR7.\nEl uso de la prueba ELF y otras pruebas no invasivas, se \nrecomienda en las pautas de la European Association for \nthe Study of the Liver (EASL)12 para la estratificaci\u00f3n del \nriesgo de pacientes con enfermedad hep\u00e1tica cr\u00f3nica, \nla gu\u00eda de la British  Society  for  Gastroenterology (BSG) 87\n2023/38 (4): 85-91Concordancia entre pruebas no invasivas para la implementaci\u00f3n de algoritmos de cribado de fibrosis hep\u00e1tica en pacientes de alto riesgo\nsobre la investigaci\u00f3n de la funci\u00f3n hep\u00e1tica anormal13 \ny la gu\u00eda del National Institute for Health and Care \nExcellence (NICE)14 sobre la enfermedad del h\u00edgado \ngraso no alcoh\u00f3lico (NAFLD).\nElastograf\u00eda transitoria\nT\u00e9cnica en la que se eval\u00faa la elasticidad o rigidez \nhep\u00e1tica, es decir, el grado de dureza del tejido hep\u00e1tico \no fibrosis. La ET mide ondas vibratorias, las cuales, \nseg\u00fan su velocidad de propagaci\u00f3n indican el grado de \nrigidez o fibrosis ya que se propagan m\u00e1s r\u00e1pido en el \ntejido hep\u00e1tico duro que en el tejido hep\u00e1tico blando15. \nEntre estas t\u00e9cnicas, la ET con FibroScan\u00ae (Echosens, \nPar\u00eds, Francia) se usa ampliamente para clasificarla \nen la pr\u00e1ctica cl\u00ednica habitual8 y ha demostrado una \ngran utilidad diagn\u00f3stica para la predicci\u00f3n de fibrosis \navanzada/cirrosis hep\u00e1tica. Cuando se utiliza la biopsia \nhep\u00e1tica como est\u00e1ndar de referencia, la ET proporciona \nalta sensibilidad y valores predictivos negativos para la \ndetecci\u00f3n de cirrosis superiores al 95%, para un amplio \nrango de prevalencias y etiolog\u00edas de enfermedad \nhep\u00e1tica subyacente, por lo que resulta m\u00e1s \u00fatil para \ndescartar cirrosis que para confirmarla2. En cuanto a los \npuntos de corte empleados para los diferentes grados \nde fibrosis, en la literatura hay una gran variedad: Castera \net al16: \u22657,1 kPa para F \u2265 2 y \u226512,5 kPa para F4, Ziol \net al.17 \u2265 8,8 kPa para F\u2265 2 y \u226514.6 kPa para F4 o los \npublicados en un meta\u00e1nalisis en el que hab\u00eda varias \ncausas de enfermedad hep\u00e1tica cr\u00f3nica18: \u22657,7 kPa \npara F\u2265 2 y 13,1\u2265 kPa para F4, entre otros.\nEnhanced Liver Fibrosis (ELF)\nLa prueba Enhanced Liver Fibrosis (ELF) es una de las \npruebas que emplea biomarcadores s\u00e9ricos directos. \nEs el resultado de un algoritmo logar\u00edtmico que combina \nmediciones s\u00e9ricas cuantitativas de tres marcadores del \nmetabolismo de la matriz extracelular hep\u00e1tica: \u00e1cido \nhialur\u00f3nico (HA), inhibidor tisular de metaloproteinasa-1 \n(TIMP-1) y p\u00e9ptido N-terminal de procol\u00e1geno III (PIIINP)19.\nLa prueba ELF ha sido validada para la evaluaci\u00f3n \nde la fibrosis hep\u00e1tica en una amplia variedad de \nenfermedades hep\u00e1ticas cr\u00f3nicas y se ha demostrado \nque es un marcador pron\u00f3stico preciso para la mortalidad \npor todas las causas y las complicaciones de la cirrosis \ny puede ser m\u00e1s preciso que la histolog\u00eda hep\u00e1tica para \ndeterminar el pron\u00f3stico20.\nSeg\u00fan los datos del fabricante el ELF debe interpretarse \nde la siguiente manera21:\n\u00b7 <7.7 : sin fibrosis a leve (F0 a F1)\n\u00b7 \u22657.7 a <9.8: fibrosis moderada (\u2265F2)\n\u00b7 \u2265 9.8 a <11.3 fibrosis cl\u00ednicamente significativa (\u2265F3).\n\u00b7 \u2265 11.3 : cirrosis (\u2265F4)\n\u00cdndice FIB-4\nEs una puntuaci\u00f3n basada en par\u00e1metros s\u00e9ricos \nf\u00e1cilmente disponibles que se miden de forma rutinaria (edad, AST, ALT y recuento de plaquetas) y se calcula de \nla siguiente manera (edad en a\u00f1os, ALT y AST en UI/L, y \nrecuento de plaquetas en 109/L):\nNumerosos estudios han evaluado la fibrosis hep\u00e1tica de \nforma no invasiva siguiendo dos pasos: el \u00edndice FIB-4 y \nmodalidades de imagen para descartar y confirmar fibrosis \navanzada, respectivamente, dando lugar a una estrategia \neficaz en la pr\u00e1ctica cl\u00ednica para la detecci\u00f3n de fibrosis \navanzada. FIB-4 tiene un alto valor predictivo negativo y \npodr\u00eda usarse como prueba de cribado de primera l\u00ednea \npara identificar pacientes con bajo riesgo de fibrosis \nhep\u00e1tica avanzada que no requieren evaluaci\u00f3n adicional \n(se evitar\u00edan biopsias o derivaciones innecesarias)22. El \npunto de corte FIB4 \u2265 3,25, es el que originalmente fue \nvalidado para indicar una posible fibrosis avanzada para \nla infecci\u00f3n por VHC, tambi\u00e9n ha sido validado para otras \npatolog\u00edas, como hepatitis B y NAFLD23. Las puntuaciones \nFIB-4 tienen zonas intermedias considerables (~30%), \nlo que, a\u00f1adido a su bajo valor predictivo positivo, ha \noriginado que se hayan propuesto varios algoritmos \nsecuenciales basados en este \u00edndice, especialmente para \nevaluar a pacientes con NASH24.\nMetodolog\u00eda\nDise\u00f1o del estudio\nEste estudio fue dise\u00f1ado como un estudio de un solo \ncentro observacional retrospectivo realizado en pacientes \nque acuden a una consulta especializada de hepatolog\u00eda \nde un hospital de tercer nivel, para evaluar la concordancia \nentre las  pruebas no invasivas de cribado (FIB-4, ELF y \nET) de de fibrosis hep\u00e1tica en pacientes de alto riesgo \ne identificar qu\u00e9 algoritmo o aplicaci\u00f3n secuencial de \npruebas no invasivas podr\u00eda traducirse en una mejor \nestrategia diagn\u00f3stica en estas patolog\u00edas Se ha solicitado \nla aprobaci\u00f3n del estudio a la Comisi\u00f3n de Investigaci\u00f3n \nde nuestro Hospital y al Comit\u00e9 Etico de les Illes Balears.\nPoblaci\u00f3n de estudio\nRegistramos 195 pacientes consecutivos que se \nderivaron a una consulta de hepatolog\u00eda del Hospital \nUniversitario Son Espases entre 2016 y 2020 a los que \nse les solicit\u00f3 ELF y a los que se les calcul\u00f3 el \u00edndice FIB4. \nDe ellos fueron exclu\u00eddos 18 pacientes cuya edad era \ninferior a 18 a\u00f1os, ausencia de datos en las variables a \nestudiar o errores de cuantificaci\u00f3n y registro que impidan \nla obtenci\u00f3n de un resultado de FIB-4 y/o ELF score. A \n179 pacientes se le pudo calcular el FIB-4, siendo la \netiolog\u00eda de su hepatitis, VHC en 77, VHB en 12, ALD \nen 14, NAFLD en 49 y otras causas en 27. Dos de ellos \nno ten\u00edan la determinaci\u00f3n de ELF, mientras que a 114 \u00cdndice FIB4 =  (edad \u00d7 AST)\nrecuento de plaquetas \u00d7 \u221aALT88\n2023/38 (4): 85-91Cristina G\u00f3mez Cobo et al. \npacientes se les hab\u00eda realizado la elastograf\u00eda. El 59% \neran hombres, con una edad media de 56 +/- 12 a\u00f1os).\nRecolecci\u00f3n de datos\nObtuvimos la siguiente informaci\u00f3n de la historia cl\u00ednica \ndel paciente: edad, sexo etiolog\u00eda de la hepatopat\u00eda y \nresultados de la ET.\nPruebas bioqu\u00edmicas/hematologicas\nLos participantes ayunaron durante la noche antes de la \nrecolecci\u00f3n de la muestra de sangre. Examinamos las \nsiguientes pruebas bioqu\u00edmicas: recuento de plaquetas \nen un contador hematol\u00f3gico Alinity HQ de Abbott y AST y \nALT en un autoanalizador Architect ci series de  Abbott. HA \n, TIMP-1 y PIIINP se determinaron mediante inmunoensayo \nen un autoanalizador ADVIACentaur\u00ae (ADVIA CentaurTM, \nSiemensHealthcare Diagnostics, Tarrytown, NY, EE. UU.).\nFIB-4 \nEl \u00edndice FIB-4 se calcul\u00f3 como describimos \nanteriormente: \nSe utiliz\u00f3 el \u00edndice FIB-4 para identificar pacientes de: \nbajo riesgo de fibrosis <1.3; riesgo intermedio de fibrosis \n(\u22651.3 a 3.25); riesgo alto de fibrosis \u2265 3.25.\nELF\nLa prueba ELF se genera como una puntuaci\u00f3n \u00fanica \nque combina las mediciones s\u00e9ricas cuantitativas \nde TIMP-1, PIIINP y HA. El instrumento calcul\u00f3 \nautom\u00e1ticamente la puntuaci\u00f3n ELF empleando la \necuaci\u00f3n recomendada [ELF = 2.278 + 0.851 ln(HA) \n+ 0.751 ln(PIIINP) + 0.394 ln(TIMP-1)] y se expres\u00f3 \ncomo un valor num\u00e9rico sin unidades. Se emplearon los \nvalores de corte recomendados por el fabricante para \nindentificar el grado de fibrosis: <7.7 \u2013 sin fibrosis a leve \n(F0 a F1); \u22657.7 a <9.8: fibrosis moderada (\u2265F2); \u2265 9.8: \nfibrosis cl\u00ednicamente significativa (\u2265F3).\nElastograf\u00eda transitoria\nLas medidas de rigidez hep\u00e1tica se obtuvieron con \nFibroscan (Echosense) M. Los valores de corte que \nempleamos fueron los del metaan\u00e1lisis citado en la \nintroducci\u00f3n que inclu\u00eda varias causas de enfermedad \nhep\u00e1tica cr\u00f3nica como en nuestro caso: \u22657.7 kPa para \nF\u2265 2 y 13.1\u2265 kPa para F4.\nAn\u00e1lisis Estad\u00edstico\nSe comprob\u00f3 la concordancia bivariante entre FIB-4 \n(considerando los puntos de corte para tres estratos de \ngravedad <1.3, \u22651.3-3.25 y \u22653.25), ELF score (considerando \nlos puntos de corte para tres estratos de gravedad <7.7, \n\u22657.7-9.8, \u2265 9.8) y Fibroscan (considerando los puntos de \ncorte para tres estratos de gravedad <7.7 kPa, \u2265 7.7-13 y \n>13 kPa). Se utiliz\u00f3 el grado de concordancia por el \u00edndice \nde Kappa de Cohen ajustado con correcci\u00f3n de Fleiss.Se determin\u00f3 la correlaci\u00f3n de los valores mediante \nc\u00e1lculo del coeficiente de correlaci\u00f3n de Pearson. \nSe consider\u00f3 una significaci\u00f3n estad\u00edstica del 5%. \nSe consider\u00f3 un \u00edndice de Kappa superior a 0.4 una \nfuerza de concordancia moderada y un coeficiente de \ncorrelaci\u00f3n r> 0.5 como moderado.\nSe compararon los porcentajes de pacientes \nclasificados con grado de fibrosis F\u22652 mediante ELF \nversus ET, en el grupo con FIB-4<1.3 mediante la \nprueba de Chi-cuadrado.\nResultados\nLas concordancias que encontramos entre las diferentes \npruebas no invasivas para los tres estratos de gravedad \nconsiderados fueron las siguientes:\nAl comparar la concordancia entre el valor de FIB-4 y \nELF score se encontr\u00f3 del 29.94%, con un \u00edndice Kappa \nde 0.0252 (error standard de 0.0161). El coeficiente de \ncorrelaci\u00f3n de Pearson fue de r=0.4107 (r2= 0.1687; \np<0.00001). Se consider\u00f3 una concordancia pobre, \ncon una correlaci\u00f3n positiva d\u00e9bil significativa.\nCuando se compar\u00f3 la concordancia entre el valor de \nFIB-4 y Fibroscan se encontr\u00f3 del 50.46%, con un \u00edndice \nKappa de 0.029 (error standard de 0.096). El coeficiente \nde correlaci\u00f3n de Pearson fue de r=0.3076 (r2= 0.0946; \np=0.0011). Se consider\u00f3 una concordancia pobre, con \nuna correlaci\u00f3n positiva muy d\u00e9bil significativa.\nLa concordancia entre el valor de ELF score y Fibroscan \nse encontr\u00f3 del 29.38%, con un \u00edndice Kappa de \n0.0585 (error standard de 0.0303). El coeficiente de \ncorrelaci\u00f3n de Pearson fue de r=0.4535 (r2= 0.2057; \np<0.00001). Se consider\u00f3 una concordancia pobre, \ncon una correlaci\u00f3n positiva d\u00e9bil significativa.\nFinalmente se evalu\u00f3 el subgrupo de pacientes con un \ncribado por FIB-4 inferior al grupo de clasificaci\u00f3n de ELF \nscore a los que tambien se habia realizado Fibroscan \n(n=57). Se obtuvo una concordancia para resultado \npositivo de Fibroscan del 29.82% (70.18% para \nresultado negativo), con una concordancia combinada \npara cualquier resultado del 36.30%, p<0.00001. El \n\u00edndice de Kappa fue de 0.29. En este subgrupo: FIB-\n4 correlaciona con Fibroscan con una Rho de 0.327 \n(p=0.012), y ELF score con Fibroscan con Rho 0.357 \n(p=0.0064). Se consider\u00f3 una concordancia pobre, con \nuna correlaci\u00f3n positiva d\u00e9bil significativa.\nLos porcentajes de pacientes clasificados con grado \nde fibrosis F\u22652 mediante ELF versus ET, en el grupo con \nFIB-4 <1.3 fueron de 97.8% y 40.98 % respectivamente \ny las diferencias eran estad\u00edsticamente significativas \n(p<0.00001). edad (a\u00f1os) \u00d7 AST (U/L)\nrecuento de plaquetas (109/L)) \u00d7 ALT (U/L)1/289\n2023/38 (4): 85-91Concordancia entre pruebas no invasivas para la implementaci\u00f3n de algoritmos de cribado de fibrosis hep\u00e1tica en pacientes de alto riesgo\nSi analizamos la concordancia para FIB-4 en un valor \numbral de < 1.3, con el n\u00famero de pacientes con ELF < \n9.8, es decir en los que se descartar\u00eda  grado de fibrosis \ncl\u00ednicamente significativa (F\u22653), encontramos 61 (de 91; \n67.03 %). Mientras que con FIB-4 \u2265 1.3, el n\u00famero de \npacientes con presencia de fibrosis significativa con \nELF ser\u00eda de 43 (de 91; 47.25 %). El \u00edndice de kappa \nfue de 0.17 (error standard de 0.07), que ser\u00eda una \nconcordancia pobre. \nEn las siguientes tablas se expone la evidencia de fibrosis \n(F\u22652) seg\u00fan ELF o ET y la etiolog\u00eda de la enfermedad \nhep\u00e1tica seg\u00fan lo valores de FIB-4:\nTabla I: Con FIB4 <1.3, tabla II: Con FIB4 \u2265 1.3-<3.5 y \ntabla III: Con FIB4 \u22653.25 Discusi\u00f3n\nEn nuestro estudio hemos encontrado concordancias \npobres entre las pruebas no invasivas de cribado de fibrosis \nhep\u00e1tica, en el contexto de etiolog\u00edas de enfermedad \nhep\u00e1tica cr\u00f3nica con alta prevalencia de fibrosis/cirrosis. \nEste hallazgo pone de manifiesto, la dificultad con la que \nnos encontramos a la hora de identificar qu\u00e9 algoritmo \no aplicaci\u00f3n secuencial de pruebas no invasivas podr\u00eda \ntraducirse en una mejor estrategia diagn\u00f3stica en estas \npatolog\u00edas. Las gu\u00edas respaldan un proceso de estratificaci\u00f3n \ndel riesgo de al menos dos niveles, proporcionando como \nejemplo FIB-4 como la primera prueba de elecci\u00f3n dado \nsu aceptable valor predictivo negativo en entornos de baja \nprevalencia, seguida de una ET y/o ELF para identificar a \nlos pacientes con mayor probabilidad de tener una lesi\u00f3n \nsignificativa (\u2265F2) o fibrosis avanzada (F3/4) que requieren \nevaluaci\u00f3n adicional. \nEn la actualidad no existen directrices s\u00f3lidas en las gu\u00edas \nde pr\u00e1ctica cl\u00ednica con respecto a selecci\u00f3n de pacientes \npara la evaluaci\u00f3n del riesgo de fibrosis significativo en la \nenfermedad hep\u00e1tica. NICE recomienda el uso del ELF en \npacientes con evidencia de NAFLD, pero no describe qu\u00e9 \ntipo de estrategia utilizar. La gu\u00eda actual de la British Society \nof Gastroenterology recomienda la evaluaci\u00f3n de la fibrosis \nusando uno de los par\u00e1metros basados en sangre en la \ncomunidad (FIB4 o NAFLD Fibrosis Score) en pacientes \ncon sospecha de NAFLD, pero solo en el contexto de \nenzimas hep\u00e1ticas elevadas. Estas  directrices en gu\u00edas \nprevias, suger\u00edan que estas pruebas se han de realizar en \nel \u00e1mbito de la atenci\u00f3n especializada, sin embargo, dada \nla creciente carga de hepatopat\u00eda, se est\u00e1 defendiendo su \nuso en atenci\u00f3n primaria. \nNo obstante, un punto clave para evaluar el rendimiento \nde una prueba es partir de la base de que este depende \nde la prevalencia de la enfermedad, lo que significa \nque en poblaciones de baja prevalencia la sensibilidad \ny el valor predictivo positivo son menores. Adem\u00e1s, \ncualquier prueba, dependiendo de su naturaleza y el \npunto de corte elegido, se asocia con resultados de \nprueba falsos positivos y falsos negativos, una limitaci\u00f3n \nde la toma de decisiones binaria. Un algoritmo paso \na paso que combine pruebas no invasivas podr\u00eda \nreducir la tasa de pruebas falsas positivas, pero existe \nun n\u00famero limitado de estudios con resultados sobre \nel cribado de la fibrosis hep\u00e1tica usando diferentes \nm\u00e9todos no invasivos y puntos de corte. En ellos las \ntasas de detecci\u00f3n para fibrosis variaron desde 0,7% y \n7,5% en cohortes de poblaci\u00f3n general, frente a 18%-\n27% en poblaciones de alto riesgo25.\nEn nuestro estudio hemos empleado los puntos de corte \nm\u00e1s descritos en la literatura, pero los enfoques basados \nen algoritmos requieren de una validaci\u00f3n de puntos \nde corte basados en la etiolog\u00eda de la enfermedad, \netnicidad y prevalencia, as\u00ed como la consideraci\u00f3n de \nTabla I: FIB-4 <1.3\nTabla II: FIB-4 \u22651.3-<3.25\nTabla III: FIB-4 \u22653.25\n90\n2023/38 (4): 85-91Cristina G\u00f3mez Cobo et al. \nlimitaciones socioecon\u00f3micas regionales y acceso a la \nET y atenci\u00f3n especializada. \nEn cuanto a FIB-4, su principal limitaci\u00f3n es una zona \ngris que no permite definir con precisi\u00f3n si el paciente \ntiene una fibrosis importante o puede necesitar una \nprueba complementaria para estratificar mejor al \npaciente en esta situaci\u00f3n, sin embargo, actualmente, \nla estrategia principal con respecto a la estadificaci\u00f3n \nde la fibrosis en la hepatopat\u00eda por VHC, es identificar \na los pacientes con fibrosis/cirrosis avanzada. En \ngeneral, el rendimiento diagn\u00f3stico de los marcadores \ns\u00e9ricos es mejor para la cirrosis que para la fibrosis \nsignificativa en estos pacientes, ya que esos datos \nson muy relevantes en la era del tratamiento con \nantivirales. La estadificaci\u00f3n precisa de la fibrosis antes \ndel tratamiento es menos crucial desde el punto de \nvista cl\u00ednico que la identificaci\u00f3n de fibrosis avanzada o \ncirrosis, que requiere una vigilancia continua posterior \nal tratamiento. Definir el diagn\u00f3stico de cirrosis antes \ndel tratamiento es de suma importancia, as\u00ed como \nestratificar a aquellos con cirrosis descompensada para \niniciar el tratamiento antes o despu\u00e9s del trasplante \nhep\u00e1tico. Como ya comentamos, el valor de corte para \nFIB-4 \u22653.25 del estudio original, ha sido corroborado \nen estudios adicionales, mostrando su utilidad para \ndiagnosticar fibrosis avanzada. En nuestro estudio solo \nhemos detectado 14 pacientes con ese valor de FIB-\n4, por lo que no podemos valorar el rendimiento de \nlas pruebas evaluadas a ese punto de corte, dada la \nlimitaci\u00f3n de individuos en ese subgrupo.\nDestacamos tambi\u00e9n el elevado porcentaje de \npacientes con FIB-4 < 1.3, que tendr\u00edan un grado de \nfibrosis F\u22652 mediante ELF (97.8%) en comparaci\u00f3n \ncon el 40.98% que se obtuvo por ET, que nos lleva \na plantear la hip\u00f3tesis de que con el punto de corte \ndel fabricante puede que ELF sobreestime el grado \nde fibrosis. De hecho, si seleccionamos como punto \nde corte para ELF \u2265 9.8 (\u2265F3), grado de fibrosis que \ncomo hemos comentado puede ser cl\u00ednicamente m\u00e1s \nrelevante, en el grupo de pacientes con FIB-4 < 1.3, \nel porcentaje de pacientes con fibrosis cl\u00ednicamente \nsignificativa ser\u00eda de 32.96%. Esta situaci\u00f3n tambi\u00e9n \nse reproduce en los otros dos estratos de pacientes, \ndonde considerando este punto de corte de 9.8 \npasar\u00edamos de: 100% a 44.4% en el grupo de \npacientes con FIB-4 en zona intermedia y de 100% a \n78.5% en el grupo con FIB-4 \u22653.25. Aunque hemos de \nse\u00f1alar que a esos puntos de corte, la concordancia \nseguir\u00eda siendo pobre.\nLas principales limitaciones de nuestro estudio es su \ncar\u00e1cter retrospectivo, el n\u00famero relativamente peque\u00f1o \nde pacientes y el hecho de que no hemos podido \ncomparar ninguna de estas pruebas con el m\u00e9todo de \nreferencia que es la biopsia hep\u00e1tica.Creemos que son necesarios m\u00e1s estudios en los se \ndeber\u00edan seleccionar diferentes puntos de corte para \nlas diferentes pruebas no invasivas en funci\u00f3n de la \netiolog\u00eda, posiblemente la edad y el grado de fibrosis que \nse pretenda descartar/confirmar. Para ello necesitamos \nestudios con muestras de gran tama\u00f1o que aborden las \nlagunas de conocimiento m\u00e1s importantes, en particular \ncomparando las pruebas no invasivas existentes de \nfibrosis en t\u00e9rminos de precisi\u00f3n y aplicabilidad en \nentornos espec\u00edficos, evaluando la rentabilidad de la \ndetecci\u00f3n e investigando posibles efectos beneficiosos \na largo plazo.\n 91\n2023/38 (4): 85-91Concordancia entre pruebas no invasivas para la implementaci\u00f3n de algoritmos de cribado de fibrosis hep\u00e1tica en pacientes de alto riesgo\nBibliograf\u00eda\n1. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of \nChronic Liver Disease and Cirrhosis. Vol. 18, Clinical Gastroenterology \nand Hepatology. W.B. Saunders; 2020. p. 2650\u201366. \n2. Romero-G\u00f3mez M, Aller R, Ampuero J, Fern\u00e1ndez Rodr\u00edguez \nC, August\u00edn S, Latorre R, et al. AEEH \u00abConsensus about detection \nand referral of hidden prevalent liver diseases\u00bb. Gastroenterologia y \nHepatologia. Ediciones Doyma, S.L.; 2022. \n3. Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic \nConcepts and Therapeutic Perspectives. Vol. 9, Cells. NLM \n(Medline); 2020. \n4. Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a \nblueprint for the future. Vol. 75, Hepatology. John Wiley and Sons Inc; \n2022. p. 473-88. \n5. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic \ntargets and clinical issues. Vol. 65, Molecular Aspects of Medicine. \nElsevier Ltd; 2019. p. 37-55. \n6. Gheorghe G, Bung\u0103u S, Ceobanu G, Ilie M, Bacalba\u015fa N, Bratu OG, \net al. The non-invasive assessment of hepatic fibrosis. Vol. 120, Journal \nof the Formosan Medical Association. Elsevier B.V.; 2021. p. 794-803. \n7. Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, \nFriedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-\ninvasive tests for evaluation of liver disease severity and prognosis \u2013 \n2021 update. J Hepatol. 2021 Sep 1;75(3):659-89. \n8. Hur M, Park M, Moon HW, Choe WH, Lee CH. Comparison of \nnon-invasive clinical algorithms for liver fibrosis in patients with chronic \nhepatitis B to reduce the need for liver biopsy: Application of enhanced \nliver fibrosis and Mac-2 binding protein glycosylation isomer. Ann Lab \nMed. 2021;42(2):249-57. \n9. Lai M, Afdhal NH. Liver Fibrosis Determination. Vol. 48, \nGastroenterology Clinics of North America. W.B. Saunders; 2019. p. \n281-9. \n10. Sherman KE, Abdel-Hameed EA, Ehman RL, Rouster SD, Campa \nA, Martinez SS, et al. Validation and Refinement of Noninvasive Methods \nto Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus \nEnhanced Liver Fibrosis Index. Dig Dis Sci. 2020 Apr 1;65(4):1252-7. \n11. Loomba R, Adams LA. Advances in non-invasive assessment of \nhepatic fibrosis. Vol. 69, Gut. BMJ Publishing Group; 2020. p. 1343-52. \n12. Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL \nclinical practice guidelines: non-invasive liver tests for evaluation of \nliver disease severity and prognosis. Frontline Gastroenterol. 2022 \nSep;13(5):436-9. \n13. Newsome PN, Cramb R, Davison SM, DIllon JF, Foulerton M, \nGodfrey EM, et al. Guidelines on the management of abnormal liver \nblood tests. Gut. 2018 Jan 1;67(1):6-19. 14. Non-alcoholic fatty liver disease (NAFLD): assessment and \nmanagement NICE guideline [Internet]. 2016. Available from: www.nice.\norg.uk/guidance/ng49\n15. Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. \nDiagnostic accuracy of fibroscan and factors affecting measurements. \nVol. 10, Diagnostics. MDPI AG; 2020. \n16. Cast\u00e9ra L, Vergniol J, Foucher J, le Bail B, Chanteloup E, Haaser \nM, et al. Prospective comparison of transient elastography, Fibrotest, \nAPRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis \nC. Gastroenterology. 2005;128(2):343-50. \n17. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et \nal. Noninvasive assessment of liver fibrosis by measurement of stiffness \nin patients with chronic hepatitis C. Hepatology. 2005 Jan;41(1):48-54.\n \n18. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, \nZeuzem S, et al. Performance of Transient Elastography for the Staging \nof Liver Fibrosis: A Meta-Analysis. Gastroenterology. 2008;134(4). \n19. Patel PJ, Connoley D, Rhodes F, Srivastava A, Rosenberg W. \nA review of the clinical utility of the Enhanced Liver Fibrosis test in \nmultiple aetiologies of chronic liver disease. Vol. 57, Annals of Clinical \nBiochemistry. SAGE Publications Ltd; 2020. p. 36\u201343. \n20. Day J, Patel P , Parkes J, Rosenberg W. Derivation and Performance \nof Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the \nDetection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019 Mar \n1;3(5):815-26. \n21. Day J, Patel P , Parkes J, Rosenberg W. Derivation and Performance \nof Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the \nDetection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019 Mar \n1;3(5):815-26. \n22. Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, \nDoi Y, et al. Profiles of advanced hepatic fibrosis evaluated by FIB-4 \nindex and shear wave elastography in health checkup examinees. \nHepatology Research. 2020 Feb 1;50(2):199-213. \n23. Blanco-Grau A, Gabriel-Medina P , Rodriguez-Algarra F, Villena Y, \nLopez-Mart\u00ednez R, August\u00edn S, et al. Assessing liver fibrosis using the \nfib4 index in the community setting. Diagnostics. 2021 Dec 1;11(12). \n24. Kim M, Jun DW, Park H, Kang BK, Sumida Y. Sequential combination \nof FIB-4 followed by m2bpgi enhanced diagnostic performance for \nadvanced hepatic fibrosis in an average risk population. J Clin Med. \n2020 Apr 1;9(4). \n25. Gin\u00e8s P , Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen \nAM, et al. Population screening for liver fibrosis: Toward early diagnosis \nand intervention for chronic liver diseases. Vol. 75, Hepatology. John \nWiley and Sons Inc; 2022. p. 219-28. 92\n2023/38 (4): 92-100ORIGINAL\nRelationship between nonalcoholic fatty liver disease and \nliver fibrosis risk scales with overweight and obesity scales in \n219,477 spanish workers\nRelaci\u00f3n entre escalas de riesgo de higado graso no alcoh\u00f3lico y fibrosis hep\u00e1tica con \nescalas de sobrepeso y obesidad en 219.477 Trabajadores espa\u00f1oles\nEmilio Mart\u00ednez-Almoyna Rif\u00e11      , Pilar Tom\u00e1s-Gil1      , Josep Lluis Coll Villalonga1      ,\nJos\u00e9 Ignacio Ram\u00edrez-Manent1,2      , Pau Mart\u00ed-Lliteras1      , \n\u00c1ngel Arturo L\u00f3pez-Gonz\u00e1lez1\n1. Grupo ADEMA-SALUD IUNICS University of the Balearic Islands. Spain.\n2. Mallorca Primary Care eISSN 2255-0569\nReceived: 29 - I - 2023\nAccepted: 1 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.92Corresponding author\nJos\u00e9 Ignacio Ram\u00edrez-Manent \nE-mail: jignacioramirez@telefonica.net  \nAbstract \nIntroduction: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent pathology of multifactorial etiology that can lead to liver \nfibrosis. The aim of this study is to assess the association between NASFLD and liver fibrosis risk scales and overweight-obesity scales .\nMaterial and methods: Descriptive and cross-sectional study in 219477 Spanish workers in which the relationship between the \nvalues of different NASH risk scales such as Fatty liver index (FLI), Hepatic steatosis index (HSI), Zhejiang University index (ZJU), \nFatty liver disease index (FLD), Framingham steatosis index (Framingham steatosis index), Zhejiang University index (ZJU) and Fatty \nliver disease index (FLD) was determined, Framingham steatosis index (FSI), Lipid accumulation Product (LAP) and liver fibrosis \n(BARD score) with values of overweight-obesity scales (waist/height index, body mass index, Cl\u00ednica Universitaria de Navarra Body \nFat Estimator (CUN BAE) and Metabolic Score for Visceral Fat (METS-VF).  \nResults: Both the mean values and the prevalence of high-risk values for NASH and liver fibrosis are higher in people with obesity \ndetermined with all the scales. The highest prevalences are obtained when applying the BMI and CUN BAE scales. \nConclusion: The close relationship between the values of different NASH and liver fibrosis risk scales and the values of overweight-\nobesity scales is confirmed.\nKeywords: Non-alcoholic fatty liver disease (NAFLD). Liver fibrosis, overweight, obesity. \nResumen\nIntroducci\u00f3n: La Enfermage del h\u00edgado graso no alcoh\u00f3lico (EHGNA) es una patolog\u00eda altamente prevalente y de etiolog\u00eda \nmultifactorial que puede terminar en fibrosis hep\u00e1tica. El objetivo de este estudio es valorar la asociaci\u00f3n entre escalas de riesgo \nde EHGNA y fibrosis hep\u00e1tica y escalas de sobrepeso-obesidad.\nMaterial y m\u00e9todos:  Estudio descriptivo y transversal en 219477 trabajadores espa\u00f1oles en los que se determina la relaci\u00f3n \nentre los valores de diferentes escalas de riesgo de EHGNA como Fatty liver index (FLI), Hepatic steatosis index (HSI), Zhejian \nUniversity index (ZJU), Fatty liver disease index (FLD), Framingham steatosis index (FSI), Lipid accumulation Product (LAP) y fibrosis \nhep\u00e1tica (BARD score) con valores de escalas de sobrepeso-obesidad (\u00edndice cintura/altura, \u00edndice de masa corporal, Cl\u00ednica \nUniversitaria de Navarra Estimador de grasa corporal (CUN BAE) y Metabolic Score for Visceral Fat (METS-VF).\nResultados: Tanto los valores medios como la prevalencia de valores de alto riesgo de presentar EHGNA y fibrosis hep\u00e1tica son \nm\u00e1s elevados en las personas con obesidad determinados con todas las escalas. Las prevalencias m\u00e1s elevadas se obtienen al \naplicar las escalas de BMI y CUN BAE.\nConclusi\u00f3n: Se confirma la estrecha relaci\u00f3n entre los valores de diferentes escalas de riesgo de EHGNA y fibrosis hep\u00e1tica con \nlos valores de escalas de sobrepeso-obesidad.\nPalabras clave: Enfermedad del h\u00edgado graso no alcoh\u00f3lico (EHGNA). Fibrosis hep\u00e1tica, sobrepeso, obesidad.IDID ID\nID IDID93\n2023/38 (4): 92-100Introduction\nNon-alcoholic fatty liver disease (NAFLD) is a clinical \nentity that brings together various liver conditions in \npeople who do not consume or consume small amounts \nof alcohol1. The most characteristic histological lesion \nof NAFLD is the excessive accumulation of fat at the \nlevel of liver cells2. We know that NASH is increasing \nin prevalence in all countries of the world, but these \nfigures are especially worrying in the most developed \ncountries3, in some cases, such as the United States, \nwhere it affects one in four people4. NAFLD can progress \nto non-alcoholic steatohepatitis, which is considered \none of the most aggressive forms of the disease. This \ncondition presents high levels of liver inflammation that \ncan lead to significant scarring (cirrhosis) and even \nliver failure. Many risk factors have been associated \nwith NAFLD, the most significant being dyslipidemia5, \nobesity6, mainly abdominal obesity7, polycystic ovary \nsyndrome8, diabetes mellitus9, hypothyroidism10, \nhypopituitarism11 and advanced age12. \nThe aim of our study was to determine the relationship \nbetween the values of different scales that assess the \nrisk of NAFLD and liver fibrosis with scales that assess \noverweight and obesity in a group of Spanish workers.\nMaterial and methods\nDescriptive and cross-sectional study conducted in \n219,477 Spanish workers from different regions and \nlabor sectors (public administration, health, hospitality, \nconstruction and commerce mainly). The workers \nincluded in the study were selected from those who \nattended occupational medical examinations performed \nbetween January 2017 and December 2019. See Flow \nchart in Figure 1.Inclusion criteria:\n- Ages between 18 and 69 years.\n- Acceptance to participate in the study.\n- Authorize the use of the data obtained for \nepidemiological purposes.\n- Belonging to one of the companies included in \nthe study and not being on temporary disability at \nthe time of the study.\nAll measurements, whether anthropometric (height, \nweight and waist circumference), analytical or clinical, \nwere performed by the occupational health professionals \nof the participating companies after standardization of \nthe processes to avoid interobserver bias.\nWeight (in kg) and height (in cm) were obtained \nwith a SECA 700 scale-measuring device. Waist \ncircumference was determined with a tape measure \nplaced parallel to the floor at the level of the last floating \nrib while the person was standing upright, with feet \ntogether and abdomen relaxed. \nBlood pressure is determined after 10 minutes of \nrest and with the person in a seated position. Three \nmeasurements are taken at one-minute intervals and \nthe average of the three is obtained. \nThe blood test is obtained after at least 12 hours of \nfasting and processed within 48-72 hours. Automated \nenzymatic techniques are used for blood glucose, total \ncholesterol and triglycerides. For HDL-cholesterol the \nCl2Mg dextran sulfate precipitation technique is used. \nLDL-cholesterol is determined indirectly by applying the \nFriedewald formula which is only valid when triglycerides \ndo not exceed 400. All analytical parameters are \nexpressed in mg/dL.\nLDL= Total colesterol total -HDL-c- triglycerides/5\nAs scales of overweight and obesity were used:\n- Waist/height index. It is obtained by dividing waist \ncircumference by height, both in cm. The cut-off \npoint was 0.5013.\n- Body mass index. It is obtained by dividing weight \n(in kg) by height2 (in m). Underweight < 18.5, \nnormal weight between 18.5 and 24.9, overweight \nbetween 25 and 29.9 and obesity over 30 kg/m2 are \nconsidered.\n- Cl\u00ednica Universitaria de Navarra-Body Fat Estimator \n(CUN BAE)14.\nCUN BAE = -44.988 + (0.503 x age) + (10.689 x sex) \n+ (3.172 x age) - (0.026 x BMI2) + (0.181 x BMI x sex) \n- (0.02 x BMI x age) - (0.005 x BMI2 x sex) + (0.00021 \nx BMI2 x age).\nMan = 0  woman = 1. Figure 1: Flow chart of participants in the study.\n221,218 workers start the study\n326 do not agree to participate\n996 lack any variable \nto calculate scales\n219,477 (2125,403 men and 94,074 \nwomen) finally entered the study419 are under 18 or over 69 years oldRelationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers94\n2023/38 (4): 92-100Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nThe cut-off points are: normal weight (< 30 in women \nand < 20 in men), overweight (30-35 in women and \n20-25 in men) and obesity (> 35 in women and > 25 \nin men).\n- Metabolic score for visceral fat (METS-VF)15\nMETS-VF = 4.466 + 0.011*(Ln(METS-IR))3 + \n3.239*(Ln(WtHR))3 + 0.319*(Sex) + 0.594*(Ln(age)). \nMan = 1 woman = 0\nMETS-IR = Ln [(2*glycaemia) + Triglycerides]*BMI)/\n(Ln[HDLc])16\nHigh risk is considered as from 7,18.\nThe following risk scales for nonalcoholic fatty liver \ndisease and liver fibrosis were used:\n- Fatty liver index (FLI)17\nHigh risk is considered as from 60\n- Hepatic steatosis index (HSI)18 \nHSI = 8 \u00d7 AST/ALT + BMI + 2 if diabetes, + 2 if woman.\nHigh risk is considered as from 36.\n- Zhejian University index (ZJU index)19  \nZJU = BMI + Glycaemia (mmol L) + Triglycerides (mmol L) \n+3 AST/ALT +2 if woman.\nHigh risk is considered as from 38.\n- Fatty liver disease index (FLD)20 \nFLD = BMI+Triglycerides+3 \u00d7 ( AST/ALT) +2 \u00d7 \nHyperglycaemia (present=1; absent=0).\nHigh risk is considered as from 37.\n- Framingham esteatosis index (FSI)21 \nFSI = -7,981 + 0,011 x age \u2013 0,146 x sex (woman =1, \nman = 0) + 0,173 x BMI + 0,007 x triglycerides + 0,593 \nx hypertension (yes = 1, no =0) + 0,789 x diabetes (yes \n= 1, no =0) + 1,1 x AST/ALT ratio \u22651,33 (yes = 1, no =0)\n- Lipid accumulation product (LAP)22\n- Men: (waist (cm) - 65) x (triglycerides (mMol)).\n- Women: (waist (cm) - 58) x (triglycerides (mMol)). \nHigh risk is considered as from 42,7.\n- BARD score23 \nIt is a risk scale for liver fibrosis.\nBMI from 28 (1 point), AST/ALT from 0.8 (2 points), \ndiabetes mellitus (2 points). Values between 2-4 points \nindicate high risk.We considered a smoker to be a person who has \nsmoked at least one cigarette (or its equivalent in other \ntypes of consumption) in the last month or who has quit \nsmoking less than a year ago.\nThe social class is obtained using the proposal of the \nSpanish Society of Epidemiology based on the 2011 \nNational Classification of Occupations24. Three groups are \nconsidered: class I (directors, managers and university \nprofessionals), class II (intermediate occupations and self-\nemployed workers) and class III (manual workers).\nStatistical analysis\nA descriptive analysis of the categorical variables was \nperformed, calculating the frequency and distribution of \nthe responses for each of them. For quantitative variables, \nthe mean and standard deviation were calculated \nfollowing a normal distribution.\nBivariate association analysis was performed using the \nchi2 test (with correction for Fisher\u2019s exact statistic when \nconditions required it) and Student\u2019s t test for independent \nsamples (for comparison of means). Multivariate \ntechniques were used to establish the variables associated \nwith the most significant risk factors. Logistic regression \nwas used for multivariate analysis, with calculation of the \nodds ratio and the Hosmer-Lemeshow goodness-of-fit \ntest. Statistical analysis was performed with the Statistical \nPackage for the Social Sciences (SPSS) version 28.0 \n(IBM Company, New York, NY, USA) for Windows, with an \naccepted statistical significance level of 0.05.\nEthical considerations and/or aspects\nThe research team undertook at all times to follow the \nethical principles of health sciences research established \nnationally and internationally (Declaration of Helsinki), \npaying special attention to the anonymity of the participants \nand the confidentiality of the data collected. Approval was \nrequested from the Ethics and Research Committee of the \nBalearic Islands (CEI-IB), which was obtained with indicator \nIB 4383/20. Participation in the study was voluntary, so \nthe participants gave their written and oral consent to \nparticipate in the study after receiving sufficient information \nabout the nature of the study. To this end, they were given \nan informed consent form, as well as an information sheet \nexplaining the objective of the study.\nThe data collected for the study were identified by a code \nand only the person responsible for the study can relate \nthese data to the participants. The identity of the participants \nwill not be disclosed in any report of this study. The \ninvestigators will not disseminate any information that could \nidentify them. In any case, the research team undertakes to \nstrictly comply with the Organic Law 3/2018, of December \n5, on the protection of personal data and guarantee of \ndigital rights, guaranteeing the participant in this study that \nhe/she may exercise his/her rights of access, rectification, \ncancellation and opposition of the data collectedFLI = (e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist circumference  \n- 15.745) / (1 + e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist \ncircumference  - 15.745) x 10095\n2023/38 (4): 92-100Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers\nThe cut-off points are: normal weight (< 30 in women \nand < 20 in men), overweight (30-35 in women and \n20-25 in men) and obesity (> 35 in women and > 25 \nin men).\n- Metabolic score for visceral fat (METS-VF)15\nMETS-VF = 4.466 + 0.011*(Ln(METS-IR))3 + \n3.239*(Ln(WtHR))3 + 0.319*(Sex) + 0.594*(Ln(age)). \nMan = 1 woman = 0\nMETS-IR = Ln [(2*glycaemia) + Triglycerides]*BMI)/\n(Ln[HDLc])16\nHigh risk is considered as from 7,18.\nThe following risk scales for nonalcoholic fatty liver \ndisease and liver fibrosis were used:\n- Fatty liver index (FLI)17\nHigh risk is considered as from 60\n- Hepatic steatosis index (HSI)18 \nHSI = 8 \u00d7 AST/ALT + BMI + 2 if diabetes, + 2 if woman.\nHigh risk is considered as from 36.\n- Zhejian University index (ZJU index)19  \nZJU = BMI + Glycaemia (mmol L) + Triglycerides (mmol L) \n+3 AST/ALT +2 if woman.\nHigh risk is considered as from 38.\n- Fatty liver disease index (FLD)20 \nFLD = BMI+Triglycerides+3 \u00d7 ( AST/ALT) +2 \u00d7 \nHyperglycaemia (present=1; absent=0).\nHigh risk is considered as from 37.\n- Framingham esteatosis index (FSI)21 \nFSI = -7,981 + 0,011 x age \u2013 0,146 x sex (woman =1, \nman = 0) + 0,173 x BMI + 0,007 x triglycerides + 0,593 \nx hypertension (yes = 1, no =0) + 0,789 x diabetes (yes \n= 1, no =0) + 1,1 x AST/ALT ratio \u22651,33 (yes = 1, no =0)\n- Lipid accumulation product (LAP)22\n- Men: (waist (cm) - 65) x (triglycerides (mMol)).\n- Women: (waist (cm) - 58) x (triglycerides (mMol)). \nHigh risk is considered as from 42,7.\n- BARD score23 \nIt is a risk scale for liver fibrosis.\nBMI from 28 (1 point), AST/ALT from 0.8 (2 points), \ndiabetes mellitus (2 points). Values between 2-4 points \nindicate high risk.We considered a smoker to be a person who has \nsmoked at least one cigarette (or its equivalent in other \ntypes of consumption) in the last month or who has quit \nsmoking less than a year ago.\nThe social class is obtained using the proposal of the \nSpanish Society of Epidemiology based on the 2011 \nNational Classification of Occupations24. Three groups are \nconsidered: class I (directors, managers and university \nprofessionals), class II (intermediate occupations and self-\nemployed workers) and class III (manual workers).\nStatistical analysis\nA descriptive analysis of the categorical variables was \nperformed, calculating the frequency and distribution of \nthe responses for each of them. For quantitative variables, \nthe mean and standard deviation were calculated \nfollowing a normal distribution.\nBivariate association analysis was performed using the \nchi2 test (with correction for Fisher\u2019s exact statistic when \nconditions required it) and Student\u2019s t test for independent \nsamples (for comparison of means). Multivariate \ntechniques were used to establish the variables associated \nwith the most significant risk factors. Logistic regression \nwas used for multivariate analysis, with calculation of the \nodds ratio and the Hosmer-Lemeshow goodness-of-fit \ntest. Statistical analysis was performed with the Statistical \nPackage for the Social Sciences (SPSS) version 28.0 \n(IBM Company, New York, NY, USA) for Windows, with an \naccepted statistical significance level of 0.05.\nEthical considerations and/or aspects\nThe research team undertook at all times to follow the \nethical principles of health sciences research established \nnationally and internationally (Declaration of Helsinki), \npaying special attention to the anonymity of the participants \nand the confidentiality of the data collected. Approval was \nrequested from the Ethics and Research Committee of the \nBalearic Islands (CEI-IB), which was obtained with indicator \nIB 4383/20. Participation in the study was voluntary, so \nthe participants gave their written and oral consent to \nparticipate in the study after receiving sufficient information \nabout the nature of the study. To this end, they were given \nan informed consent form, as well as an information sheet \nexplaining the objective of the study.\nThe data collected for the study were identified by a code \nand only the person responsible for the study can relate \nthese data to the participants. The identity of the participants \nwill not be disclosed in any report of this study. The \ninvestigators will not disseminate any information that could \nidentify them. In any case, the research team undertakes to \nstrictly comply with the Organic Law 3/2018, of December \n5, on the protection of personal data and guarantee of \ndigital rights, guaranteeing the participant in this study that \nhe/she may exercise his/her rights of access, rectification, \ncancellation and opposition of the data collectedFLI = (e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist circumference  \n- 15.745) / (1 + e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist \ncircumference  - 15.745) x 10096\n2023/38 (4): 92-100Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nResults\nThe mean age of the sample is slightly older than 40 \nyears, the majority being between 30 and 49 years of \nage. Anthropometric, clinical and analytical variables \nshow more unfavorable values in men. The majority social \nclass is III. Approximately one third of the patients were \nsmokers. The complete data are presented in table I.Table II shows the mean values of different scales \nof non-alcoholic fatty liver disease and liver fibrosis \naccording to the values of the overweight and obesity \nscales. The mean values of all the aforementioned risk \nscales increase as the value of the overweight-obesity \nscales increases. The mean values in all cases are \nhigher in men. In all cases the differences observed are \nstatistically significant.\nTable I: Characteristics of the population.\n  Men n=125,403 Women n=94,074  \n  Mean (SD) Mean (SD) p\nAge 41.8 (10.5) 39.9 (10.5) <0.0001\nHeight 175.2 (6.8) 162.3 (6.3) <0.0001\nWeight 82.6 (15.0) 68.0 (14.7) <0.0001\nSBP 126.1 (15.6) 115.4 (15.5) <0.0001\nDBP 77.3 (11.1) 72.3 (10.5) <0.0001\nCholesterol 195.6 (37.9) 192.1 (35.5) <0.001\nHDL-c 52.1 (9.8) 57.2 (10.3) <0.0001\nLDL-c 118.4 (35.1) 116.3 (33.5) <0.001\nTryglicerides 125.7 (76.0) 93.1 (45.6) <0.0001\nGlycaemia 93.4 (21.5) 88.3 (16.0) <0.0001\nAST 29.0 (17.5) 18.7 (11.6) <0.0001\nALT 24.4 (13.3) 18.2 (7.9) <0.0001\nGGT 32.7 (31.8) 18.8 (16.3) <0.0001\nCreatinine 0.86 (0.17) 0.68 (0.14) <0.0001\n  % % p\n18-29 years 14.4 19.4 <0.0001\n30-39 years 26.6 28.9 \n40-49 years 33.6 32.0 \n50-59 years 21.5 16.8 \n60-69 years 3.9 2.9 \nSocial class I 6.1 7.5 <0.0001\nSocial class II 14.5 20.5 \nSocial class III 79.4 72.0 \nNon smokers 67.5 66.7 <0.001\nSmokers 32.5 33.3  \nSBP systolic blood pressure. DBP diastolic blood pressure. HDL High density lipoprotein.   LDL Low density lipoprotein. AST aspartate transaminase. ALT alanine \ntransaminase.   GGT gamma-glutamyl transferase.\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation product. \nBMI \u00cdndice de masa corporal. CUN BAE Cl\u00ednica Universitaria de Navarra Body Adiposity Estimator. METS-VF Metabolic Score for Visceral Fat. WtHR Waist to height ratio. \nStatistically significant differences (p<0.001) in all cases.Table II: Mean values of the different risk scales for fatty liver and liver fibrosis according to the values of the overweight and obesity scales by sex.\n    FLI HSI ZJU FLD FSI LAP BARD\nMen n Media (dt) Media (dt) Media (dt) Media (dt) Media (dt) Media (dt) Media (dt)\nWtHR <0.50 68703 23.3 (16.3) 33.7 (5.1) 34.1 (3.7) 29.1 (3.5) 0.12 (0.11) 20.3 (14.7) 0.72 (0.85)\nWtHR \u22650.50 56700 59.6 (23.3) 40.6 (6.5) 40.8 (5.5) 35.6 (5.1) 0.30 (0.21) 49.9 (33.5) 1.64 (1.06)\nUnderweight 936 5.4 (4.6) 25.7 (3.0) 26.6 (2.0) 21.7 (1.4) 0.03 (0.03) 8.1 (8.0) 0.33 (0.54)\nNormalweight BMI 44979 16.8 (11.5) 31.8 (4.2) 32.3 (2.6) 27.4 (2.4) 0.09 (0.08) 17.4 (12.6) 0.50 (0.69)\nOverweight BMI 53751 41.9 (18.5) 37.3 (4.6) 37.6 (2.8) 32.5 (2.5) 0.19 (0.13) 34.6 (23.0) 1.17 (0.98)\nObesity BMI 25737 76.2 (15.7) 44.8 (5.9) 45.0 (4.6) 39.6 (4.3) 0.44 (0.20) 61.2 (38.5) 2.18 (0.86)\nNormalweight CUN BAE 21081 11.6 (7.9) 30.0 (3.9) 30.5 (2.4) 25.7 (2.1) 0.06 (0.05) 14.4 (10.3) 0.30 (0.54)\nOverweight CUNBAE 35814 23.7 (13.8) 33.9 (4.3) 34.2 (2.3) 29.3 (2.2) 0.11 (0.09) 22.0 (15.4) 0.58 (0.71)\nObesity CUN BAE 68508 56.7 (23.0) 40.4 (6.1) 40.7 (4.9) 35.4 (4.6) 0.30 (0.20) 45.7 (32.5) 1.68 (1.00)\nMETS-VF normal 116616 34.1 (22.8) 35.6 (5.9) 35.9 (4.5) 30.9 (4.3) 0.16 (0.14) 28.6 (22.2) 0.97 (0.97)\nMETS-VF high 14787 81.5 (14.1) 45.6 (6.3) 46.2 (5.3) 40.6 (5.0) 0.50 (0.21) 71.4 (43.1) 2.35 (0.87)\nWomen n Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)\nCintura/altura<0.50 72132 9.9 (9.6) 33.9 (5.0) 34.5 (3.9) 27.7 (3.7) 0.09 (0.08) 12.9 (9.8) 0.42 (0.68)\nCintura/altura\u22650.50 21942 50.8 (24.2) 44.2 (6.3) 44.8 (5.6) 37.7 (5.3) 0.33 (0.21) 40.3 (23.2) 1.37 (0.83)\nUnderweight BMI 2844 2.2 (1.3) 27.1 (3.0) 27.9 (1.5) 21.2 (1.4) 0.03 (0.02) 4.7 (4.2) 0.13 (0.38)\nNormalweight BMI 46083 6.0 (4.5) 32.2 (3.9) 32.8 (2.4) 26.1 (2.3) 0.06 (0.05) 10.2 (7.2) 0.24 (0.49)\nOverweight BMI 27090 19.1 (11.3) 37.9 (3.9) 38.5 (2.4) 31.5 (2.1) 0.14 (0.10) 20.7 (12.5) 0.74 (0.82)\nObesity BMI 18057 57.1 (21.6) 45.9 (5.7) 46.4 (4.8) 39.3 (4.5) 0.37 (0.20) 42.6 (23.9) 1.56 (0.75)\nNormalweight CUN BAE 20523 3.8 (2.6) 29.8 (3.4) 30.5 (2.0) 23.9 (1.9) 0.04 (0.03) 8.4 (6.3) 0.09 (0.31)\nOverweight CUNBAE 24492 6.8 (4.7) 33.2 (3.5) 33.8 (1.9) 27.0 (1.8) 0.07 (0.05) 11.0 (7.6) 0.24 (0.48)\nObesity CUN BAE 49059 32.3 (24.7) 40.6 (6.3) 41.1 (5.4) 34.1 (5.2) 0.23 (0.18) 28.0 (20.8) 1.06 (0.87)\nMETS-VF normal 92934 18.6 (21.1) 36.1 (6.6) 36.7 (5.8) 29.8 (5.5) 0.14 (0.15) 18.6 (17.0) 0.62 (0.81)\nMETS-VF high 1140 91.6 (7.9) 55.5 (5.5) 56.2 (5.0) 48.7 (4.7) 0.73 (0.16) 72.5 (34.5) 1.76 (0.85)97\n2023/38 (4): 92-100Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers\nTable III shows the prevalence of elevated values of \ndifferent nonalcoholic fatty liver disease and liver fibrosis \nrisk scales according to the overweight-obesity scales. \nThe same trend that we have seen with the mean \nvalues is observed, i.e. an increase in the prevalences \nas the values of the overweight-obesity scales increase. \nPrevalences are lower in women. In all cases the \ndifferences found are statistically significant.Table IV shows the results of the multivariate analysis \nusing multinomial logistic regression. The risk of presenting \nelevated values of all the nonalcoholic fatty liver disease \nand liver fibrosis scales is greater in those who present \nhigher values of the overweight-obesity scales, with the \ngreatest differences being observed when considering \nBMI and CUN BAE.\nFigure 2 and table V show the areas under the curve \nwith their 95% confidence intervals of the cardiovascular \nrisk scales for predicting the presence of high values of the NASH and liver fibrosis risk scales. The largest areas \nunder the curve were found with high FLI and high ZJU \nwhile the lowest values were found with high FLD.Table III: Prevalence of high values of the different risk scales for fatty liver and liver fibrosis according to values of the overweight and obesity scales by sex.\n    FLI high HSI high ZJU high FLD high LAP high BARD high\nMen n % % % % % %\nWtHR <0.50 68703 3.9 27.0 13.5 60.7 16.3 17.0\nWtHR \u22650.50 56700 51.3 76.7 68.3 62.0 71.6 54.0\nUnderweight BMI 936 0.0 0.3 0.3 0.0 1.0 3.5\nNormalweight BMI 44979 0.9 11.7 1.9 30.8 10.5 9.3\nOverweight BMI 53751 18.4 58.5 39.9 39.5 46.6 34.3\nObesity BMI 25737 83.3 98.6 99.7 95.2 85.6 76.4\nNormalweight CUN BAE 21081 0.1 5.8 0.5 11.7 5.4 3.5\nOverweight CUNBAE 35814 2.4 22.4 4.9 72.6 19.8 11.0\nObesity CUN BAE 68508 45.1 77.1 67.3 70.6 63.6 55.0\nMETS-VF normal 116616 15.6 41.0 28.9 24.5 32.5 25.8\nMETS-VF high 14787 91.4 96.8 97.0 62.8 93.9 83.1\nWomen n % % % % % %\nWtHR <0.50 72132 0.3 30.1 18.9 43.1 12.1 7.9\nWtHR \u22650.50 21942 35.9 92.9 90.2 49.2 81.2 35.6\nUnderweight BMI 2844 0.0 0.8 0.0 0.2 0.1 1.3\nNormalweight BMI 46083 0.01 12.6 1.5 18.9 4.4 2.6\nOverweight BMI 27090 0.7 67.3 54.1 37.4 34.3 17.0\nObesity BMI 18057 43.6 99.7 100.0 97.4 84.3 42.6\nNormalweight CUN BAE 20523 0.0 3.8 0.2 1.7 2.3 0.5\nOverweight CUNBAE 24492 0.02 16.4 1.7 26.5 5.9 2.3\nObesity CUN BAE 49059 16.4 76.0 67.1 71.4 50.2 26.2\nMETS-VF normal 92934 7.5 44.0 34.7 2.1 27.4 13.9\nMETS-VF high 1140 99.2 100.0 100.0 45.3 99.2 53.4\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. BMI \u00cdndice de masa corporal. CUN BAE Cl\u00ednica Universitaria de Navarra Body Adiposity Estimator.  METS-VF Metabolic Score for Visceral Fat.  WtHR Waist to \nheight ratio. Statistically significant differences (p<0.001) in all cases.\nTable IV: Multinomial logistic regression.\n  FLI high HSI high ZJU high FLD high LAP high BARD high\n  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)\nCintura/altura<0.50 1 1 1 1 1 1\nCintura/altura\u22650.50 5.68 (5.43-5.95) 1.39 (1.35-1.43) 1.42 (1.38-1.47) 0.82 (0.78-0.85) 4.63 (4.51-4.76) 1.57 (1.53-1.62)\nBajo-Normalweight BMI 1 1 1 1 1 1\nOverweight BMI 4.30 (4.16-4.45) 3.98 (3.81-4.15) 8.72 (8.51-8.93) 1.45 (1.28-1.63) 2.51 (2.43-2.60) 1.97 (1.91-2.03)\nObesity BMI 16.04 (14.16-18.17) 8.38 (8.22-8.55) 23.11 (22.89-23.33) 3.18 (2.94-3.40) 7.25 (6.86-7.67) 2.53 (2.39-2.68)\nNormalweight CUN BAE 1 1 1 1 1 1\nOverweight CUNBAE 2.88 (2.65-3.13) 3.06 (2.96-3.16) 8.17 (7.77-8.59) 1.92 (1.84-2.01) 1.56 (1.51-1.62) 4.09 (3.91-4.28)\nObesity CUN BAE 26.63 (17.93-39.54) 10.54 (9.96-11.15) 32.42 (27.44-38.32) 19.62 (18.52-20.78) 3.94 (3.69-4.21) 14.62 (13.47-15.87)\nMETS-VF normal 1 1 1 1 1 1\nMETS-VF high 11.19 (10.53-11.90) 1.48 (1.34-1.65) 2.17 (1.95-2.43) 4.02 (3.88-4.17) 4.04 (3.76-4.34) 3.99 (3.82-4.17)\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation \nproduct. \nBMI \u00cdndice de masa corporal. CUN BAE Cl\u00ednica Universitaria de Navarra Body Adiposity Estimator.  METS-VF Metabolic Score for Visceral Fat. Statistically significant \ndifferences (p<0.001) in all cases.98\n2023/38 (4): 92-100Emilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nFigure 1: ROC curve.\nTable V: ROC curve (Area under the curve).\n  FLI high HSI high ZJU high FLD high LAP high BARD high\n  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI)  AUC (95% CI) \nWtHR 0.933 (0.931-0.935) 0.828 (0.826-0.829) 0.875 (0.873-0.876) 0.603 (0.600-0.605) 0.893 (0.891-0.894) 0.788 (0.785-0.790)\nIMC 0.932 (0.931-0.933) 0.914 (0.913-0.916) 0.968 (0.967-0.968) 0.677 (0.674-0.679) 0.868 (0.867-0.870) 0.834 (0.832-0.835)\nCUN BAE 0.749 (0.747-0.751) 0.795 (0.794-0.797) 0.847 (0.845-0.848) 0.535 (0.532-0.537) 0.723 (0.720-0.725) 0.685 (0.682-0.687)\nMETS-VF 0.946 (0.945-0.947) 0.811 (0.809-0.813) 0.854 (0.863-0.856) 0.623 (0.620-0.625) 0.879 (0.878-0.880) 0.835 (0.833-0.837)\nFLI Fatty liver index. HSI  Hepatic steatosis index. ZJU Zhejiang University index. FLD Fatty liver disease. FSI Framingham Steatosis index. LAP Lipid accumulation product. \nWtHR Waist to height ratio. BMI Body mass index. CUN BAE Cl\u00ednica Universitaria de Navarra Body Adiposity Estimator.  METS-VF Metabolic Score for Visceral Fat.99\n2023/38 (4): 92-100Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers\nDiscussion\nIn our study, the mean values and the prevalence of high \nvalues for all the nonalcoholic fatty liver disease and liver \nfibrosis risk scales analyzed were higher in those individuals \nwith higher values for the overweight-obesity scales.\nWhen we performed the analysis using multinomial \nlogistic regression we found that in all cases the level of \nrisk with the scales that assess NAFLD and liver fibrosis \nis higher in the overweight-obese group, with the highest \nvalues in the case of obesity assessed with BMI and \nCUN BAE.\nThe multivariate analysis showed that the variable that \nmost increased the risk of presenting high values of the \ndifferent non-alcoholic fatty liver disease and liver fibrosis \nrisk scales was age, followed by sex and social class, \nwithout finding any influence of tobacco consumption.\nWe have not found any article that simultaneously \nassesses the influence that exists between different \nscales of NAFLD and liver fibrosis risk and scales of \noverweight-obesity, so we will focus our discussion on \nthe relationship between NAFLD and obesity.\nThe relationship between obesity and NAFLD is well \nestablished. Obesity is related not only to the initial \nstages of the disease, the so-called simple steatosis \n(SS), but also to its progression. Epidemiologically, \nboth pathologies have an increasing prevalence \nworldwide. Pathogenically, obesity and its associated \ninsulin resistance favor the initial accumulation of fat in \nhepatocytes (ES) and also the progression of ES to non-\nalcoholic steatohepatitis (NAFLD), cirrhosis and even \nhepatocellular carcinoma.A study performed in transgenic mice showed that NASH \nand obesity are epidemiologically correlated with each \nother25. In the same vein, a study by Mili\u0107 et al26 expressed \nthat up to 80% of NASH patients are obese, defined as \na body mass index (BMI) > 30 kg/m2, although it was \nespecially relevant in those with morbid obesity in whom \nvisceral adipose tissue is very abundant.\nStrengths and limitations\nAs strengths of the study, we can especially highlight the \nlarge sample size, which exceeds 200,000 individuals, and \nthe large number of NASH and liver fibrosis risk scales and \noverweight and obesity scales used. The main limitation is \nthat no objective diagnostic techniques for NAFLD or liver \nfibrosis other than the risk scales were used.\nConclusions\nTaking into account the results obtained in our study, we \ncan conclude that in this Spanish working population \nthere is a direct relationship between the values of the \ndifferent NASH risk scales and liver fibrosis and the \nvalues of the overweight-obesity scales. We found high \npredictive values for the different overweight-obesity \nscales to predict the occurrence of high risk values for \nNAFLD and liver fibrosis except for FLD.\nConflict of Interest\nThe authors declare that no competing interests exist.100\n2023/38 (4): 92-100Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workersEmilio Mart\u00ednez-Almoyna Rif\u00e1 et al. \nReferences\n1. Younossi ZM, Paik JM, Al Shabeeb R, Golabi P , Younossi I, Henry \nL. Are there outcome differences between NAFLD and metabolic-\nassociated fatty liver disease? Hepatology. 2022 Nov;76(5):1423-\n1437. doi: 10.1002/hep.32499.\n2. Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. \nBiomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.\n3. Lazarus JV, Mark HE, Anstee QM, Arab JP , Batterham RL, Castera L, \net al. Advancing the global public health agenda for NAFLD: a consensus \nstatement. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: \n10.1038/s41575-021-00523-4. \n4. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, \nCaballeria J, et al. Modeling NAFLD disease burden in China, France, \nGermany, Italy, Japan, Spain, United Kingdom, and United States \nfor the period 2016-2030. J Hepatol. 2018 Oct;69(4):896-904. doi: \n10.1016/j.jhep.2018.05.036. \n5. Morrow MR, Batchuluun B, Wu J, Ahmadi E, Leroux JM, Mohammadi-\nShemirani P , et al. Inhibition of ATP-citrate lyase improves NASH, liver \nfibrosis, and dyslipidemia. Cell Metab. 2022 Jun 7;34(6):919-936.e8. \ndoi: 10.1016/j.cmet.2022.05.004. \n6. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. \nNon-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, \nclinical management and effects of weight loss. BMC Endocr Disord. \n2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1. \n7. Vilalta A, Guti\u00e9rrez JA, Chaves S, Hern\u00e1ndez M, Urbina S, Hompesch \nM. Adipose tissue measurement in clinical research for obesity, type \n2 diabetes and NAFLD/NASH. Endocrinol Diabetes Metab. 2022 \nMay;5(3):e00335. doi: 10.1002/edm2.335.\n8. Chen Y, Ma L, Ge Z, Pan Y, Xie L. Key Genes Associated With Non-\nAlcoholic Fatty Liver Disease and Polycystic Ovary Syndrome. Front Mol \nBiosci. 2022 May 25;9:888194. doi: 10.3389/fmolb.2022.888194. \n9. Stefan N, Cusi K. A global view of the interplay between non-\nalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. \n2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1. \n10. Hatziagelaki E, Paschou SA, Sch\u00f6n M, Pshighpoulou T, Roden \nM. NAFLD and thyroid function: pathophysiological and therapeutic \nconsiderations. Trends Endocrinol Metab. 2022 Nov;33(11):755-768. \ndoi: 10.1016/j.tem.2022.08.001.\n11. Huang Q, Xu H, Wang X, Mao J, Yu B, Zhu Y, et al. Relationship \nbetween growth hormone deficiency and nonalcoholic fatty liver disease \nin patients with pituitary stalk interruption syndrome. Clin Endocrinol \n(Oxf). 2022 Nov;97(5):612-621. doi: 10.1111/cen.14732.\n12. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, \net al. The prevalence and incidence of NAFLD worldwide: a systematic \nreview and meta-analysis. Lancet Gastroenterol Hepatol. 2022 \nSep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0.\n13. Siwarom S, Pirojsakul K, Aekplakorn W, Paksi W, Kessomboon \nP , Neelapaichit N, et al. Waist-to-Height Ratio Is a Good Predictor of \nMetabolic Syndrome in Adolescents: A Report From the Thai National \nHealth Examination Survey V, 2014. Asia Pac J Public Health. 2022 \nJan;34(1):36-43. doi: 10.1177/10105395211046474. \n14. L\u00f3pez-Gonz\u00e1lez AA, Jover AM, Mart\u00ednez CS, Artal PM, Bote SA, \nJan\u00e9 BA, et al. The CUN-BAE, Deurenberg Fat Mass, and visceral \nadiposity index as confident anthropometric indices for early detection of metabolic syndrome components in adults. Sci Rep. 2022 Sep \n15;12(1):15486. doi: 10.1038/s41598-022-19343-w.\n15. Bello-Chavolla OY, Antonio-Villa NE, Vargas-V\u00e1zquez A, Viveros-\nRuiz TL, Almeda-Valdes P , Gomez-Velasco D, et al. Metabolic Score for \nVisceral Fat (METS-VF), a novel estimator of intra-abdominal fat content \nand cardio-metabolic health. Clin Nutr. 2020 May;39(5):1613-1621. \ndoi: 10.1016/j.clnu.2019.07.012. \n16. Bello-Chavolla OY, Almeda-Valdes P , Gomez-Velasco D, Viveros-\nRuiz T, Cruz-Bautista I, Romo-Romo A, et al. METS-IR, a novel score to \nevaluate insulin sensitivity, is predictive of visceral adiposity and incident \ntype 2 diabetes. Eur J Endocrinol. 2018 May;178(5):533-544. doi: \n10.1530/EJE-17-0883. \n17. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, \nCastiglione A, et al. The Fatty Liver Index: a simple and accurate predictor \nof hepatic steatosis in the general population. BMC Gastroenterol. 2006 \nNov 2;6:33. doi: 10.1186/1471-230X-6-33. \n18. Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of \nHepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis \nin Type 2 Diabetes. Int J Med Sci. 2021 Jul 23;18(14):3280-3289. doi: \n10.7150/ijms.62010.\n19. Li L, You W, Ren W. The ZJU index is a powerful index for identifying \nNAFLD in the general Chinese population. Acta Diabetol. 2017 \nOct;54(10):905-911. doi: 10.1007/s00592-017-1024-8. \n20. Lee I, Cho J, Park J, Kang H. Association of hand-grip strength and \nnon-alcoholic fatty liver disease index in older adults. J Exerc Nutrition \nBiochem. 2018 Dec 31;22(4):62-68. doi: 10.20463/jenb.2018.0031. \n21. Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann \nU, Muntner P , et al. Development and Validation of the Framingham \nSteatosis Index to Identify Persons With Hepatic Steatosis. Clin \nGastroenterol Hepatol. 2016 Aug;14(8):1172-1180.e2. doi: 10.1016/j.\ncgh.2016.03.034.\n22. Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness \nof obesity and lipid-related indices to predict the presence of Non-\nalcoholic fatty liver disease. Lipids Health Dis. 2021 Oct 10;20(1):134. \ndoi: 10.1186/s12944-021-01561-2. \n23. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of \nlaboratory tests, ultrasound, or magnetic resonance elastography to \ndetect fibrosis in patients with nonalcoholic fatty liver disease: A meta-\nanalysis. Hepatology. 2017 Nov;66(5):1486-1501. doi: 10.1002/\nhep.29302.\n24. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, \nFerrando J, Borrell C; del Grupo de Determinantes Sociales de Sociage \nEspa\u00f1ola de Epidemiolog\u00eda. Propuestas de clase social neoweberiana \ny neomarxista a partir de la Clasificaci\u00f3n Nacional de Ocupaciones \n2011. Gac Sanit. 2013 May-Jun;27(3):263-72. doi: 10.1016/j.\ngaceta.2012.12.009.\n25. Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal \nrelationships between NAFLD, T2D and obesity have implications for \ndisease subphenotyping. J Hepatol. 2020 Aug;73(2):263-276. doi: \n10.1016/j.jhep.2020.03.006.\n26. Mili\u0107 S, Luli\u0107 D, \u0160timac D. Non-alcoholic fatty liver disease and \nobesity: biochemical, metabolic and clinical presentations. World J \nGastroenterol. 2014 Jul 28;20(28):9330-7. doi: 10.3748/wjg.v20.\ni28.9330.101\n2023/38 (4): 101-106ORIGINAL\nComparing the effect of three trigger methods (human HCG, \ncombination of recombinant HCG with GnRH agonist, and double \nrecombinant HCG) on the fertility outcome of patients with poor \novarian response in ovulation stimulation cycle (IVF/ICSI)\nComparaci\u00f3n del efecto de tres m\u00e9todos desencadenantes (HCG humana, combinaci\u00f3n \nde HCG recombinante con agonista de GnRH y HCG recombinante doble) en el \nresultado de la fertilidad de pacientes con respuesta ov\u00e1rica deficiente \nen el ciclo de estimulaci\u00f3n de la ovulaci\u00f3n (FIV/ICSI)\nHatav Ghasemi Tehrani1      , Nasrin Heidari2      , Farahnaz Mardanian3      ,\nFerdous Mehrabian2      , Elham Naghshineh3      , Narges Motamedi4\n1. Department of Obstetrics & Gynecology, School of Medicine, Al-Zahra Hospital, Shahid Beheshti Hospital, Isfahan University \nof Medical Sciences, Isfahan, Iran.    2. Department of Obstetrics & Gynecology, School of Medicine, Isfahan University \nof Medical Sciences, Isfahan, Iran.    3. Department of Obstetrics & Gynecology, School of Medicine, Shahid Beheshti Hospital, \nIsfahan University of Medical Sciences, Isfahan, Iran.    4. Isfahan University of Medical Sciences, Isfahan, IraneISSN 2255-0569\nReceived: 30 - I - 2023\nAccepted: 4 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.101Corresponding author\nElham Naghshineh \nE-mail: naghshineh@med.mui.ac.ir  \nAbstract \nAim: The aim of this study is comparing the effect of three trigger methods (human HCG, combination of recombinant HCG \nwith GnRH agonist, and double recombinant HCG) on the fertility outcome of patients with in poor ovarian response in ovulation \nstimulation cycle (IVF/ICSI). \nMethods: In this double-blind randomized clinical trial study, 158 patients with low ovarian reserve were divided to three groups: \nGroup 1: Two doses of recombinant HCG (Ovitrelle) at a dose of 250 \u00b5g at 12 hour intervals, Group 2: HCG trigger (KARMA) \nalone at a dose of 10,000 units, and Group 3: 250 \u00b5g of recombinant HCG+ GNRH agonist. Collected data includes age, BMI, \nAMH, type of transferred embryo (Fresh or Freez), number of embryos, and results of pregnancy (clinical pregnancy rate/ongoing \npregnancy rate/ implantation rate). Three groups is statistically similar in terms of age and BMI, AMH, and AFC. \nResults: In groups 1 and 3, the number of oocytes, the number of M2 oocytes and the number of 2PN embryos was higher \nthan group 2 after ovulation. The percentage of empty follicle syndrome was low in the two groups 1 and 3. Three groups had \nno significant difference in term of fertilization rate, the number of embryos A, B, and C, chemical pregnancy, clinical pregnancy, \nongoing pregnancy, and implantation rate. \nConclusion: Dual trigger treatment with recombinant hCG and GNRH agonist and double recombinant hCG can improve fertility \noutcome patients with poor response in ovulation stimulation cycle. However, there were no significant differences among three \ngroups regarding pregnancy results.\nKeywords: recombinant HCG, GnRH agonist, Fertility, Pregnancy, Ovulation. \nResumen\nObjetivo: El objetivo de este estudio es comparar el efecto de tres m\u00e9todos desencadenantes (HCG humana, combinaci\u00f3n de \nHCG recombinante con agonista de GnRH y HCG recombinante doble) sobre el resultado de fertilidad de pacientes con respuesta \nov\u00e1rica deficiente en el ciclo de estimulaci\u00f3n de la ovulaci\u00f3n (FIV/ ICSI). \nMetodolog\u00eda: En este ensayo cl\u00ednico aleatorio doble ciego, 158 pacientes con baja reserva ov\u00e1rica se dividieron en tres grupos: \nGrupo 1: Dos dosis de HCG recombinante (Ovitrelle) a una dosis de 250 \u00b5g a intervalos de 12 horas, Grupo 2: HCG desencadenante \n(KARMA) solo a una dosis de 10.000 unidades, y Grupo 3: 250 \u00b5g de agonista de HCG+ GNRH recombinante. Los datos \nrecopilados incluyen edad, IMC, AMH, tipo de embri\u00f3n transferido (fresco o congelado), n\u00famero de embriones y resultados del \nembarazo (tasa de embarazo cl\u00ednico/tasa de embarazo en curso/tasa de implantaci\u00f3n). Los tres grupos son estad\u00edsticamente \nsimilares en t\u00e9rminos de edad e IMC, AMH y AFC. \nResultados: En los grupos 1 y 3, el n\u00famero de ovocitos, el n\u00famero de ovocitos M2 y el n\u00famero de embriones 2PN fue mayor \nque el grupo 2 despu\u00e9s de la ovulaci\u00f3n. El porcentaje de s\u00edndrome de fol\u00edculo vac\u00edo fue bajo en los dos grupos 1 y 3. Los tres \ngrupos no tuvieron diferencias significativas en t\u00e9rminos de tasa de fertilizaci\u00f3n, n\u00famero de embriones A, B y C, embarazo qu\u00edmico, \nembarazo cl\u00ednico, embarazo en curso y tasa de implantaci\u00f3n. \nConclusiones: El tratamiento de activaci\u00f3n dual con hCG recombinante y agonista de GNRH y hCG recombinante doble puede \nmejorar los resultados de fertilidad en pacientes con una respuesta deficiente en el ciclo de estimulaci\u00f3n de la ovulaci\u00f3n. Sin \nembargo, no hubo diferencias significativas entre los tres grupos con respecto a los resultados del embarazo.\nPalabras clave: HCG recombinante, agonista de GnRH, Fertilidad, Embarazo, Ovulaci\u00f3n.ID\nID ID IDID ID102\n2023/38 (4): 101-106Hatav Ghasemi Tehrani et al. \nIntroduction\nPeople with poor ovarian response in ovulation stimulation \ncycle are identified according to the Blogna criteria1. \nAccording to these criteria, individuals who meet two \nof the following three criteria may be considered poor \nresponders to ovarian stimulation:\n1. Age over 40 years or risk factors for reducing ovarian \nreserve, such as a history of surgery on the ovary, etc.\n2. History of previous poor response to IVF (less than 3 \noocytes in the previous cycle)\n3. Abnormal ovarian reserve test AFC (antral follicle \ncount) (less than 5 to 7) or AMH (anti-M\u00fcllerian hormone) \nless than 1.11\nDuring various studies, different treatment strategies (such \nas stimulating ovulation, vitamin supplements, various \ntrigger methods, and etc.) have been stated to increase \nthe response of infertile patients in the IVF cycle with poor \nresponse2-6. None of these strategies has been stated as \nthe main protocol yet, due to the sensitivity of these patients \nand the small amount of ovarian reserve6. So, more \nresearch is still needed in this field. In the IVF cycle, when \nthe size of the follicle reaches the appropriate amount, the \nHCG hormone is used to resume meiosis and enter the \noocyte into meiosis II due to its structural similarity with the \nLH hormone. Ovulation is carried out under ultrasound \nguidance after 36 hours. In studies in patients with poor \novulation response in the IVF cycle, changes in this hormone \nhave been applied. In a number of studies, the combination \nof HCG with GNRH agonist has been used in patients with \nlow reserve, and the rate of pregnancy results is higher than \nHCG alone for triggering in the IVF cycle. According to a \nhypothesis, in a study, two injections of newly synthesized \nHCG have been used in the IVF cycle of patients with low \nreserve, with the mechanism that the second dose of HCG \nat an interval of 12 hours can release the cumulus mass \nand attached oocyte to the follicle wall, and prevent from \nthe empty follicle syndrome. Zhang et al. comprised HCG \ntrigger method with or without GNRH in IVF patients with \npoor response. This group showed that there was a higher \nnumber of oocytes in the combined treatment group, but \nthere was no difference between the two groups in terms \nof fertility results7. In similar study, Eftekhar et al. showed no \ndifference in the number of oocytes and fertility results in \nHCG trigger method with or without GNRH in IVF patients \nwith poor response8. Lin et al.9 and Maged et al.10 indicated \nthat HCG trigger method along with GNRH can enhance \nboth number of oocytes and fertility results. Tesarik et al. \nused recombinant HCG in IVF patients with poor response. \nThis groups showed that the follicles had oocytes in the \nnew cycle after treatment11. So, based on limited studies \nwith various results, in our study, we comprised three trigger \nmethods (human HCG, combination of recombinant HCG \nwith GNRH agonist, and double recombinant HCG) on the \nfertility outcome of patients with poor response in ovulation \nstimulation cycle (IVF/ICSI).Materials and methods\nThis is a double-blind randomized clinical trial study. \nPatients under the age of 43 with two bologna criteria \nwere included in study:\n1. Age over 40 years or risk factors for reducing ovarian \nreserve, such as a history of surgery on the ovary, etc.\n2. History of previous poor response to IVF (less than 3 \noocytes in the previous cycle)\n3. Abnormal ovarian reserve test: Antral Follicle Count \n(AFC) less than 5 to 7 or anti-M\u00fcllerian hormone (AMH) \nless than 1.1. \nPatients with azoospermia, history of surgery on the \nuterus, endocrine disorders such as diabetes, history of \nrepeated abortions, repeated failure of implantation more \nthan equal to 3 times in the history, and BMI>30 were not \nentered to study. \nPatients who get infected with corona virus during the \ncycle, patients who did not respond properly to the \novulation stimulation cycle, and patients who have taken \ndrugs incorrectly during the cycle were excluded from \nstudy. In the third day of menstruation cycle day, selected \npatients were administrated with combined 150IU units \nrecombinant FSH (CINALF brand Iran) and 150 UI hMG \n(KARMA brand Iran). When a follicle was seen on TVS \nabove 14 mm, 0.25 mg of GnRH antagonist (Cetrorelix) \nwas given daily up to oocyte triggering. Then, after \nobserving at least two or three follicles, patients were \ndivided to three groups:\nGroup 1: Two doses of recombinant HCG (Ovitrelle) at a \ndose of 250 \u00b5g at 12 hour intervals. \nGroup 2: HCG trigger (KARMA) alone at a dose of \n10,000 units.\nGroup 3: 250 \u00b5g of recombinant HCG+ GNRH agonist\nCOVID-19 polymerase chain reaction (PCR) test were \nchecked for all patients before oocyte reteieval. Oocytes \nwere retrieved under anesthesia and with vaginal \nultrasound guidance (voluson E6 brand) 36 hours after \ntriggering. On the same day, a sperm sample was taken \nfrom the wife and prepared by a laboratory process, and \nmicroinjection was performed by an embryologist. Three \ndays after the preparation of embryos, their quality was \ndetermined by the embryologist based on the degree \nof fragmentation, and embryos with quality a, b were \ncandidates for transfer Then in morula or blastocyst \nstage under sonographic guidance (voluson E6 brand)  \nmaximum two embryos was transferred with LABOTEK \ncatheter. After embryo transfer, luteal phase support \nwith progesterone (50 mg) twice a day intramuscularly \nfrom the day of ovulation and continues until 12 weeks \nof IM pregnancy. \u03b2hCG test was requested two weeks \nafter embryo transfer and vaginal sonography was \nperformed one week later to prove the presence of 103\n2023/38 (4): 101-106Comparing the effect of three trigger methods on the fertility outcome of patients with poor ovarian response in ovulation stimulation cycle (IVF/ICSI)\npregnancy. Collected data includes age, BMI, AMH, \ntype of transferred embryo (Fresh or Freeze), number of \nembryos, and results of pregnancy (clinical pregnancy \nrate/ongoing pregnancy rate/ implantation rate).\nData analysis was done by SPSS version 24. ANOVA test \nwas used to compare the average number of M2 oocytes \nand the number of 2PN, A, B, C obtained embryos after \novulation in the three studied groups. Chi-square test was \nused to compare the frequency of chemical pregnancy, \nthe frequency of implantation rate (the gestational sac in \nultrasound number of embryo transferred), the frequency \nof clinical pregnancy (fetal heart activity in ultrasound \nper transfer), and the frequency of ongoing pregnancy \n(pregnancy continuing until the 12th week of pregnancy \nper transfer) in the three study groups. P<0.05 was \nconsidered significant.  In the statistical analysis, v1 is the \nratio of the number of oocytes to the number of follicles \nabove 14. v2 is the number of gestational sacs, and its \nnumber divided by the number of transferred embryos \nrepresents the implantation rate. W12 is the number of \ngestational sacs with a heart at 12 weeks of pregnancy \ndivided by the number of transferred cycles and is used \nto obtain the ongoing pregnancy rate.\nResults\nIn this study, 158 patients with low ovarian reserve \naccording to Blogna criteria were included. Eight patients \nwere excluded from the study: Two patients due to a \npositive corona test, three patients due to non-acceptance \nof medication, and three patients due to the wrong use \nof medication. Three groups is statistically similar in terms \nof age and BMI, AMH, and AFC. There was no significant \ndifference in term of progesterone and estradiol levels \nbefore the trigger among three groups. Three groups did not differ in terms of the total dose of gonadotropin and \nthe duration of gonadotropin treatment and the number \nof follicles above 14 mm. In groups 1 and 3, the number \nof oocytes, the number of M2 oocytes and the number \nof 2PN embryos was higher than group 2 after ovulation. \nThe percentage of empty follicle syndrome was low in \nthe two groups 1 and 3 (Table I). Three groups had \nno significant difference in term of fertilization rate, the \nnumber of embryos A, B, and C, chemical pregnancy, \nclinical pregnancy, ongoing pregnancy, and implantation \nrate. In the statistical analysis, there is no significant \ndifference among three groups in term of v1, v2, and v3 \nvariables (Table II). \nDiscussion \nIn this study, we compared and evaluated the IVF/ICSI \nresults of three methods, human HCG, combination \nof recombinant HCG with GNRH agonist, and double \nrecombinant HCG. Acquired results showed that in \ngroups with combination of recombinant HCG with \nGNRH agonist, and double recombinant HCG had \nhigher number of oocytes, the number of M2 oocytes \nand the number of 2PN embryos than human HCG. \nThe percentage of empty follicle syndrome was also \nlower in in groups with combination of recombinant \nHCG with GNRH agonist, and double recombinant \nHCG alone. In previous studies, similar results was \nreported. In these studies, dual-trigger using GnRH \nagonist and hCG was introduced as the best strategy. \nHowever, we used recombinant hCG in this dual-trigger \nmethod. More studies showed no significant differences \nbetween dual-trigger and hCG alone. In dual triggering, \nwe used recombinant HCG. Eftekhar et al showed that \nrecombinant HCG is as effective as urine HCG. This \ngroup indicated that the numbers of retrieved oocyte, \nTable I: Comparison of demographic data among three groups.\n Trigger with 12 hour Trigger with 2 hCG Trigger with 2 deka and oitrel p-value\n mean SD mean SD mean SD \nAge 35.74 3.95 34.74 3.53 35.86 4.05 0.283\nBMI 24.60 1.22 24.54 0.64 24.56 1.24 0.961\nAmn 0.77 0.34 0.80 0.29 0.79 0.28 0.887\nAFC 3.76 1.04 3.68 1.11 3.48 1.01 0.397\nBasal fsh 7.39 1.38 7.15 1.46 7.34 1.23 0.654\nFertilizat rat 78.40 27.01 75.30 34.54 79.80 26.47 0.739\nNo_2PN 2.34 1.20 1.86* 1.21 2.56 1.16 0.31\nDuration of stimulate day 10.06 1.83 10.22 1.56 10.16 1.60 0.890\nTotal_Dose_of_gonadotrop 1832.40 278.83 1808.50 240.77 1777.40 242.18 0.557\nSerum_E2 931.90 385.20 883.40 388.28 880.34 427.01 0.771\nSerum_pr 0.88 0.43 0.73 0.37 0.79 0.38 0.187\nNo_Follicle 4.04 1.41 4.00 1.17 4.26 1.44 0.585\nNo_Total_oocyte 3.40 1.47 2.54* 1.72 3.50 1.63 0.006\nNo_Muture_oocyte 2.52 1.35 1.46* 1.31 2.62 1.41 0.001\nEmpty follicle syndrome 17.56 3.08 40.66* 4.82 21.33 3.18 0.001\nTotal embryo 1.86 1.38 1.82 1.56 1.96 1.21 0.875\nEmbryo grade A 0.64 0.13 0.46 0.10 0.56 0.11 0.559\nEmbryo grade B 1.14 0.13 1.14 0.16 1.24 0.14 0.859\nEmbryo grade C 0.42 0.11 0.20 0.08 0.52 0.11 0.085\nTotal No embryo_transfer 1.26 1.02 0.94 0.99 1.36 0.87 0.08104\n2023/38 (4): 101-106Hatav Ghasemi Tehrani et al. \nTable II: Comparison of pregnancy-related data among three groups.\n Trigger with 12 hour Trigger with 2 hCG Trigger with 2 deka and oitrel p-value\n number % number % number % \nPrevius_IVF_attempt       \n         0 35 70 27 54 40 80 0.066\n         1 13 26 18 36 9 18 \n         2 2 4 5 10 1 2 \nIVF_indicator       \n         T 18 36 15 30 14 28 0.066\n         U 27 54 27 54 23 46 \n         M 5 19 8 16 8 16 \n         C 0 0 0 0 5 10 \nCancelation_rate       \n         BAD ANDOMETER 6 12 7 14 7 14 0.403\n         ABSENCE EMBRYO 9 18 11 22 6 12 \n         ABSENCE OVUM 2 4 6 12 2 4 \n         NO CANCEL 33 66 26 52 35 70 \nNo_embryo_grade_A       \n         0 32 64 34 68 32 64 0.499\n         1 6 12 9 18 8 16 \n         2 10 20 7 14 10 20 \n         3 2 4 0 0 0 0 \nNo_embryo_grade_B       \n         0 17 34 22 44 17 34 0.165\n         1 10 20 7 14 7 14 \n         2 22 44 14 28 24 48 \n         3 1 2 6 12 1 2 \n         4 0 0 1 2 1 2 \nNo_embryo_grade_C       \n         0 47 94 44 88 44 88 0.783\n         1 2 4 3 6 4 8 \n         2 1 2 2 4 2 4 \n         4 0 0 1 2 0 0 \nNo_transfer_grade_A       \n         0 38 76 44 88 33 66 0.148\n         1 4 8 2 4 8 16 \n         2 7 14 4 8 9 18 \n         3 1 2 0 0 0 0 \nNo_transfer_grade_B       \n         0 25 50 31 62 27 54 0.794\n         1 9 18 7 14 5 10 \n         2 15 30 11 22 17 34 \n         3 1 2 1 2 1 2 \nNo_transfer_grade_C       \n         0 50 100 47 94 50 100 0.190\n         1 0 0 1 2 0 0 \n         2 0 0 2 4 0 0 \nResult_pregnancy       \n         NO 38 76 39 78 39 78 0.963\n         YES 12 24 11 22 11 22 \n                  V1 0.82 0.21 0.59* 0.34 0.78 0.22 0.001\n                  V2       \n         0 42 84 43 86 42 84 0.950\n         1 8 16 7 14 8 16 \n                  V3       \n         0 44 88 45 90 44 88 0.936\n         1 6 12 5 10 6 12 \n                  W12       \n         0 45 90 45 90 46 92 0.924\n         1 5 10 5 10 4 8 \nImplementation rate       \n 8/63 12.6 7/47 14.89 8/68 11.76 0.884105\n2023/38 (4): 101-106Comparing the effect of three trigger methods on the fertility outcome of patients with poor ovarian response in ovulation stimulation cycle (IVF/ICSI)\nmaturation rates, and fertilization and clinical pregnancy \nrates are similar in both recombinant and urine HCG12. \nBased on similar studies, increases of the number of \noocyte, mature oocytes and the number of zygotes can \nimprove the IVF outcome9,13,14. In current study, these \nincreases is more in dual triggering than HCG alone. \nOn the other hand, these increases is more in triggering \nwith recombinant than urine HCG. Beck-Fruchter et \nal15 and Castillo et al16 mentioned that combination \nof HCG with GNRH agonist can used for treatment of \nrecurrent empty follicle syndrome. Based on our results, \nthe percentage of empty follicle syndrome was lower in \ndual triggering than HCG alone. Based on Humaidan \net al study, administration of hCG either 12 or 35 hours \nafter GnRH agonist trigger can lead to rescue of corpus \nluteum function17. This condition reduce the pregnancy \nloss rate. Lin et al also showed that dual triggering can \nincrease ongoing pregnancy rates and clinical pregnancy \nrate9. In our study, number of oocyte is also better values \nin dual triggering than urine HCG alone group. However, \nthese difference but result of pregnancy is not statistically \nsignificant in our study. Based on a Meta-analysis study \n(2021), seven studies data showed that dual trigger \ntreatment by HCG and GNRH agonist had significant \neffects on clinical pregnancy rate compared with HCG \ntrigger alone18. This data is not compatible with our study. \nWe showed that there is no significant difference among \nthree groups in term of clinical pregnancy rate. Our data is \ncompatible with Eftekhar et al. study8. Similar to our study, \nHu el in Meta-analysis study showed that dual trigger \ntreatment was associated with a significant increase in the \nnumber of oocytes, maturate oocytes, and empty follicle \nsyndrome18. There are conflicting results regarding the \neffect of dual trigger treatment and hCG alone treatment \non implantation and clinical pregnancy rates19-22. These \nconflicting results can be because most of the reported \nstudies are retrospective. In these studies, potential \nconfounding factors can limit data. Our study showed \nthat in some variable (total oocyte, mature oocyte, and \nempty follicle syndrome), dual trigger and double trigger treatment has more significant effect than hCG alone \ntreatment. In another variables, especially implementation \nrate, clinical pregnancy rate, and ongoing pregnancy \nrate, there was no significant difference. In a pilot study, \nTesarik et al. also used double HCG trigger (HCG \novulation trigger 36.5 hours before ovarian puncture and \nsecond HCG trigger 12.5 hours later) in women with a \npaucifollicular response to ovarian stimulation. This group \nshowed that a double HCG trigger appears to improve \nthe rate of oocyte recovery11. Similar to Tesarik et al., we \nshowed similar data by application of same double HCG \ntrigger procedure. Our data also showed that dual trigger \ntreatment can improve the number of oocytes, maturate \noocytes, and empty follicle syndrome. Similar to Tesarik et \nal. suggestion, the addition of a second injection of HCG \nat 12 hour intervals can improve pregnancy in patients \nwith poor ovarian response. Moreover, we showed that \napplication of combination method (recombinant HCG+ \nGnRH agonist) also improve pregnancy rates.\n \nConclusion\nIn conclusion, our study showed that dual trigger \ntreatment with recombinant hCG and GNRH agonist and \ndouble recombinant hCG can improve fertility outcome \npatients with poor response in ovulation stimulation \ncycle. However, there were no significant differences \namong three groups regarding pregnancy results. It\u2019s \nrecommended that a study with larger populations \ndesign and comprise the live birth rates. It is necessary to \nstudy the pregnancy results of frozen embryos in these \npatients. Further studies are also required to identify \nthe specific characteristics of women to help the fertility \nspecialist\u2019s counseling based on patient\u2019s characteristics.\nConflict of Interest\nThe authors declare that no competing interests exist.106\n2023/38 (4): 101-106Comparing the effect of three trigger methods on the fertility outcome of patients with poor ovarian response in ovulation stimulation cycle (IVF/ICSI)Hatav Ghasemi Tehrani et al. \nReferences\n1. Younis JS, Ben-Ami M, Ben-Shlomo I. The Bologna criteria for poor \novarian response: a contemporary critical appraisal. Journal of ovarian \nresearch. 2015;8:76.\n2. Ubaldi F, Vaiarelli A, D\u2019Anna R, Rienzi L. Management of poor \nresponders in IVF: is there anything new? BioMed research international. \n2014;2014:352098.\n3. Drakopoulos P , Bardhi E, Boudry L, Vaiarelli A, Makrigiannakis A, \nEsteves SC. Update on the management of poor ovarian response \nin IVF: the shift from Bologna criteria to the Poseidon concept. \n2020;14:2633494120941480.\n4. Oehninger S. Poor responders in in vitro fertilization (IVF) therapy: the \nchallenge continues. Facts, views & vision in ObGyn. 2011;3(2):101-8.\n5. Ubaldi FM, Rienzi L, Ferrero S, Baroni E, Sapienza F, Cobellis L, et \nal. Management of poor responders in IVF. Reproductive biomedicine \nonline. 2005;10(2):235-46.\n6. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian \nresponse: A systematic review and meta-analysis. Journal of human \nreproductive sciences. 2016;9(2):70-81.\n7. Zhang J, Wang Y, Mao X, Chen Q, Hong Q, Cai R, et al. Dual trigger \nof final oocyte maturation in poor ovarian responders undergoing IVF/\nICSI cycles. Reproductive biomedicine online. 2017;35(6):701-7.\n8. Eftekhar M, Naghshineh E, Neghab N, Hosseinisadat R. A comparison \nof dual triggering (by administration of GnRH agonist plus HCG) versus \nHCG alone in poor ovarian responders in ART outcomes. Middle East \nFertility Society Journal. 2018;23(4):350-3.\n9. Lin MH, Wu FSY, Lee RKK, Li SH, Lin S  Hwu YM. Dual trigger \nwith combination of gonadotropin-releasing hormone agonist and \nhuman chorionic gonadotropin significantly improves the live-birth rate \nfor normal responders in GnRH-antagonist cycles. Fertility and sterility. \n2013;100(5):1296-302.\n10. Maged AM, Ragab MA, Shohayeb A, Saber W, Ekladious S, \nHussein EA, et al. Comparative study between single versus dual trigger \nfor poor responders in GnRH-antagonist ICSI cycles: A randomized \ncontrolled study. International Journal of Gynecology & Obstetrics. \n2021;152(3):395-400.\n11. Tesarik J, Gal\u00e1n-L\u00e1zaro M, Mendoza N, Mendoza-Tesarik R. \nDouble HCG trigger improves recovery of oocytes in women with a \npaucifollicular response to ovarian stimulation: A pilot study. International \nJournal of Gynecology & Obstetrics. 2022;157(1):149-53.\n12. Eftekhar M, Khalili MA, Rahmani E. The efficacy of recombinant \nversus urinary HCG in ART outcome. Iranian journal of reproductive \nmedicine. 2012;10(6):543-8.13. Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or \nboth, when and to whom? Journal of ovarian research. 2015;8(1):1-6.\n14. Haas J, Bassil R, Cadesky K, Casper R. Dual trigger vs. HCG for final \noocyte maturation. A prospective randomized controlled, double blinded \nstudy: preliminary results. Fertility and Sterility. 2017;108(3):e229.\n15. Beck-Fruchter R, Weiss A, Lavee M, Geslevich Y, Shalev E. Empty \nfollicle syndrome: successful treatment in a recurrent case and review of \nthe literature. Human Reproduction. 2012;27(5):1357-67.\n16. Castillo JC, Moreno J, Dolz M, Bonilla-Musoles F. Successful \npregnancy following dual triggering concept (rhCG+ GnRH agonist) \nin a patient showing repetitive inmature oocytes and empty follicle \nsyndrome: case report. Journal of Medical Cases. 2013;4(4):221-6.\n17. Humaidan P , Bungum L, Bungum M, Andersen CY. Rescue of \ncorpus luteum function with peri-ovulatory HCG supplementation \nin IVF/ICSI GnRH antagonist cycles in which ovulation was triggered \nwith a GnRH agonist: a pilot study. Reproductive biomedicine online. \n2006;13(2):173-8.\n18. Hu KL, Wang S, Ye X, Zhang D, Hunt S. GnRH agonist and hCG \n(dual trigger) versus hCG trigger for follicular maturation: a systematic \nreview and meta-analysis of randomized trials. Reproductive biology \nand endocrinology : RB&E. 2021;19(1):78.\n19. Lin M-H, Wu FS-Y, Hwu Y-M, Lee RK-K, Li R-S, Li S-H. Dual trigger \nwith gonadotropin releasing hormone agonist and human chorionic \ngonadotropin significantly improves live birth rate for women with \ndiminished ovarian reserve. Reproductive biology and endocrinology. \n2019;17(1):1-7.\n20. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. \nDual trigger of oocyte maturation with gonadotropin-releasing hormone \nagonist and low-dose human chorionic gonadotropin to optimize live \nbirth rates in high responders. Fertility and sterility. 2012;97(6):1316-20.\n21. Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. \nDual trigger with gonadotropin-releasing hormone agonist and standard \ndose human chorionic gonadotropin to improve oocyte maturity rates. \nFertility and sterility. 2014;102(2):405-9.\n22. Chen C-H, Tzeng C-R, Wang P-H, Liu W-M, Chang H-Y, Chen \nH-H, et al. Dual triggering with GnRH agonist plus hCG versus triggering \nwith hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a \nsystematic review and meta-analysis. Archives of gynecology and \nobstetrics. 2018;298(1):17-26.107\n2023/38 (3): 107-114ORIGINAL\nEvaluation of the Antibacterial Effects of the Various \nNanoparticles Coated Orthodontic Brackets: \nA Systematic Review and Meta-analysis\nEvaluaci\u00f3n de los efectos antibacterianos de los diversos brackets de ortodoncia \nrecubiertos con nanopart\u00edculas: Una revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis\nNavid Kerayechian1      , Arkia Mardany2      , Faezeh Bahraini3      , Fatemeh Teimoori4      ,\nMaryam Ahmadi5      , Ali Amiri6\n1. Biomaterials Division, Department of Molecular Pathobiology, College of Dentistry, New York University, New York, United \nStates    2. Department of Orthodontics, Dental school, Cranio Maxillofacial Research Center, Tehran Medical Sciences, Islamic \nAzad University, Tehran, Iran    3. Orthodontic Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran     \n4. Orthodontist, Private Clinic, Isfahan, Iran    5. Department of Orthodontics, Dental school, Cranio Maxillofacial Research Center, \nTehran Medical Sciences, Islamic Azad University, Tehran, Iran    6. Department of Orthodontics, College of Stomatology, The \nFirst Affiliated Stomatological Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, PR ChinaeISSN 2255-0569\nReceived: 1 - II - 2023\nAccepted: 3 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.107Corresponding author\nAli Amiri \nE-mail: draliamiri2020@gmail.com  /  aliamiri@stu.xjtu.edu.cn\n  \nAbstract \nObjectives: The antibacterial activity of zinc oxide (ZnO) and silver (Ag) nanoparticles (NPs) has been investigated in this study \nto present achievements in this field with the consensus of outcomes. This systematic review and meta-analysis clarified the \nantibacterial potential of silver, zinc-oxide NPs-coated Orthodontic Brackets.\nMethods: PRISMA 2020 Checklist was the basis for performing the current systematic review and meta-analysis. The search \nstrategy was to screen the relevant databases on PubMed, Embase, Web of Science, Scopus, ISI Web of knowledge, and EBSCO \nfrom inception until 1 November 2022. We calculated a 95% confidence interval (95%CI) for the mean difference (MD) based on \nthe fixed effect model and Inverse-variance method. Stata/MP version 17 software was applied to conduct the meta-analysis.\nResults: In the initial search, duplicate studies were removed, and the abstracts of 209 separate relevant articles were presented. \nTwo individual authors reviewed the full text of 32 articles, resulting in the final eight articles. The mean difference (MD) of the \nantibacterial effect of bracket coatings against L. acidophilus between AgNPs coating and the controls was estimated at 2.71 (MD, \n2.71 95%CI 2.05-3.37; p=0.00). The mean difference (MD)  of the antibacterial potential of bracket coatings against S. mutans \nbetween ZnONPs coating and the controls was estimated to be -275.54 (MD, -275.54 95%CI -281.23, -269.85; p=0.00).\nConclusions: The results of our meta-analysis revealed that Ag, ZnO, and Ag/ZnO NPs-coated brackets had antibacterial activity \nagainst L. acidophilus and S. mutans compared to uncoated brackets.\nKeywords: Orthodontic, Orthodontic bracket, Nanoparticles. \nResumen\nObjetivos: En este estudio se investig\u00f3 la actividad antibacteriana de las nanopart\u00edculas (NP) de \u00f3xido de zinc (ZnO) y plata (Ag) \npara presentar los logros en este campo con el consenso de los resultados. Esta revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis aclararon el \npotencial antibacteriano de los brackets de ortodoncia recubiertos con NPs de \u00f3xido de zinc y plata.\nM\u00e9todos: La lista de verificaci\u00f3n PRISMA 2020 fue la base para realizar la revisi\u00f3n sistem\u00e1tica y el metan\u00e1lisis actuales. La \nestrategia de b\u00fasqueda fue examinar las bases de datos relevantes en PubMed, Embase, Web of Science, Scopus, ISI Web of \nKnowledge y EBSCO desde el inicio hasta el 1 de noviembre de 2022. Calculamos un intervalo de confianza del 95% (IC del 95%) \npara la diferencia de medias (MD) basado en el modelo de efectos fijos y el m\u00e9todo de la varianza inversa. Se aplic\u00f3 el software \nStata/MP versi\u00f3n 17 para realizar el metan\u00e1lisis.\nResultados: en la b\u00fasqueda inicial, se eliminaron los estudios duplicados y se presentaron los res\u00famenes de 209 art\u00edculos \nrelevantes separados. Dos autores individuales revisaron el texto completo de 32 art\u00edculos, lo que result\u00f3 en los ocho art\u00edculos \nfinales. La diferencia media (DM) del efecto antibacteriano de los recubrimientos de brackets contra L. acidophilus entre el \nrecubrimiento de AgNP y los controles se estim\u00f3 en 2,71 (DM, 2,71; IC del 95%: 2,05-3,37; p=0,00). La diferencia media (DM) \ndel potencial antibacteriano de los recubrimientos de brackets contra S. mutans entre el recubrimiento de ZnONP y los controles \nse estim\u00f3 en -275,54 (DM, -275,54, IC del 95%: -281,23, -269,85; p = 0,00).\nConclusiones: Los resultados de nuestro metan\u00e1lisis revelaron que los brackets recubiertos con Ag, ZnO y Ag/ZnO NPs ten\u00edan \nactividad antibacteriana contra L. acidophilus y S. mutans en comparaci\u00f3n con los brackets sin recubrimiento.\nPalabras clave: Ortodoncia, bracket de ortodoncia, nanopart\u00edculas.ID ID\nID IDID ID108\n2023/38 (3): 107-114Navid Kerayechian et al. \nIntroduction\nOrthodontic treatment is usually done for cosmetic \npurposes; using fixed appliances in orthodontic \ntreatment is the most common method. However, \nit causes changes in the oral environment1. These \nchanges cause a decrease in Ph and an increase in \nthe microbial load in the tooth cavity, which can be \nthe retention of food particles2. Studies have shown \nthat Lactobacillus acidophilus (L. acidophilus) and \nStreptococcus mutans (S. mutans) are among the \nmicroorganisms that increase in the graft and/or band \nin the oral cavity3,4. Evidence shows that S. mutans \nhas a critical role in the initiation of the decay process5, \nand L. acidophilus plays a more significant role in the \nprocess of caries propagation6. Also, the decrease in \npH results in the demineralization of tooth enamel as \nwhite spot lesions (WSLs), eventually developing more \ncavitation. Accordingly, one of the main concerns of the \npatient and the orthodontist is the appearance of WSLs \nduring bonding7.\nOral hygiene care is recommended and emphasized \nto all patients during orthodontic treatment. However, \nthe increased microbial load is still noted. The use of \nresin materials containing antibacterial agents8, varnish9, \nand modified orthodontic elastomers10 are among \nthe methods that are used to control and prevent the \ndevelopment of WSLs. The addition of nanoparticles \n(NPs) to orthodontic adhesives10,11 has recently been \nof great interest. NPs with a size smaller than 100 \nnm and insoluble materials have been introduced12; \nTherefore, due to their small size, NPs have a greater \nsurface-to-volume ratio and strongly interact with \nmicrobial membranes of microorganisms; which can \nhave antimicrobial activity13. Since the introduction \nof NPs, multiple metals such as silver (Ag), gold (Au), \ncopper (Cu), titanium (Ti), and zinc (Zn) have shown \nantimicrobial activity. Studies have shown that each \nactivity has different properties and scope3,14. Ag, \nAg ions, and Ag compounds are the most common \nantibacterial agents15. Studies have shown that AgNPs \nhave antimicrobial properties by augmenting dental resin \ncomposites and being coated on orthodontics brackets \nand wires16-18. Using zinc oxide (ZnO) NPs can also \naffect the activity of bacteria19. A study has shown that \nusing ZnO on the coating of orthodontic wires can have \nantibacterial activity20. Studies have shown that AgNPs \nhave greater antimicrobial potential than ZnONPs21. \nHowever, studies introduced AgNPs as genotoxic and \ncytotoxic agents for human cells22. Studies show that \nthe cost of using AgNPs is also higher in addition to \nthe cytotoxicity of AgNPs. Therefore, the current study \ninvestigated the antibacterial performance of ZnONPs \nand AgNPs to present achievements in this field with \nthe consensus of outcomes. This systematic review \nand meta-analysis clarified the antibacterial potential of \nAgNPs and ZnONPs-coated Orthodontic Brackets.Method\nThe process of searching for articles\nPRISMA 2020 Checklist was the basis for performing the \ncurrent systematic review and meta-analysis. [23]. The \nsearch strategy was to screen the relevant databases on \nPubMed, Embase, Web of Science, Scopus, ISI Web \nof knowledge, and EBSCO using keywords related to \nthe objectives of the study until 1 November 2022 were \nreviewed. Google Scholar search engine was also used \nto find related articles. MeSH keywords: \n((((((((\u201cOrthodontic Brackets\u201d[Mesh] OR \u201cOrthodontic \nWires\u201d[Mesh] OR \u201cOrthodontic Appliances\u201d[Mesh] OR \n\u201cOrthodontic Appliances, Fixed\u201d[Mesh] OR \u201cDental \nCements\u201d[Mesh] OR  \u201cDental Bonding\u201d[Mesh]) \nAND \u201cNanoparticles\u201d[Mesh]) OR ( \u201cNanoparticles/\nmicrobiology\u201d[Mesh] OR  \u201cNanoparticles/\nstandards\u201d[Mesh] OR  \u201cNanoparticles/statistics \nand numerical data\u201d[Mesh] OR  \u201cNanoparticles/\ntoxicity\u201d[Mesh] )) AND \u201cSilver\u201d[Mesh]) AND \u201cZinc \nOxide\u201d[Mesh]) AND \u201cMetal Nanoparticles\u201d[Mesh]) AND \n( \u201cAnti-Bacterial Agents\u201d[Mesh] OR  \u201cAnti-Bacterial \nAgents\u201d [Pharmacological Action] )) AND \u201cmutacin III, \nStreptococcus mutans\u201d [Supplementary Concept]) \nAND \u201cacidocin D20079, Lactobacillus acidophilus\u201d \n[Supplementary Concept]. \nData items, Data collection, and Selection process\nTable II represents the used checklist, involving the \nname of the first author, year of publication, sample \nsize, study design, control group, intervention group, \nand survival rate extracted and reported. Also, the data \nrequired for meta-analysis, including clinical outcome, \nAntibacterial effect of brackets coating, were extracted \nfrom the studies. All articles were selected based on the \ninclusion criteria, two reviewers independently screened \neach record, and each report was retrieved.\nEligibility criteria\nInclusion criteria: Inclusion criteria were a response \nto PICO, as reported in table I. Articles published in \nEnglish, in-vitro studies, and studies that assessed \nthe antibacterial effect of AgNPs and ZnONPs-coated \nOrthodontic Brackets.\nExclusion criteria: Case studies, case reports, and review \npapers. Studies without full-text access.\nTable I: PICO search strategy.  \nPICO Description\nstrategy\nP Population: orthodontic brackets\nI Intervention: AgNPs and ZnONPs, Ag/ZnO NPs\nC Comparison: brackets as received without modifications\nO Outcome: clinical outcome, Antibacterial activity109\n2023/38 (3): 107-114Evaluation of the Antibacterial Effects of the Various Nanoparticles Coated Orthodontic Brackets: A Systematic Review and Meta-analysis\nStudy risk of bias assessment\nThe quality assessment of searched articles was performed \nby the modified CONSORT (Guidelines for reporting pre-\nclinical in vitro studies on dental materials) criteria24; Each \nstudy was reviewed with 14 items, and the parameters \nwere reported as yes or no. These items were:\nStructured abstract of trial design, methods, findings \nand conclusion, introduction and causes, aims and \nhypotheses, the applied intervention like processes and \nduration, with sufficient detail to allow for replication, well-\ndefined primary and secondary outcomes like when and \nhow evaluated, the estimation process of sample size, the \ngeneration and implementation processes of randomized \nallocation, who created the randomized allocation, the \nblinded participants after assigning the intervention, \nstatistical analysis for group comparison, post-intervention \nfindings and estimated effect size and precision, \nlimitations of the study, assessment of possible bias, lack \nof accuracy, and where the full trial protocol is available in \ncase of multiplicity of analysis, funding and other support.\nThe modified Cochrane risk of bias tool was used, each \nitem of which was given a score of 2, 1, or 0 with the sum \nof scores 0-3, 4-7, and 8-10, meaning low, moderate, \nand high risks of bias, respectively. In this tool, the lowest \nscore was 0, and the highest score was 1025.\nData analysis\nData were analyzed by STATA/MP . V17 software. We \ncalculated a 95% confidence interval (95%CI) for the mean \ndifference (MD) based on the fixed effect model and Inverse-\nvariance method. Random effects were used. I2 showed \npossible heterogeneity, with a value of less than 50% as low \nand above 50% as moderate-to-high heterogeneity.\nResults\nThe selection process of searched articles \nIn the initial search, 209 articles related to the keywords \nwere found. Of these, 5 studies were Duplicate records, \n8 articles were removed due to ineligibility based on \nautomation tools, and 12 articles were deleted for other \nreasons. In the next step, abstracts of 184 articles were \nreviewed, and finally, 152 articles were omitted because \nof exclusion criteria. After reviewing the full text of 32 \narticles according to the inclusion criteria, 24 studies were \nexcluded, and eight studies were selected (Figure 1).\nStudy characteristics\nA total of 566 Orthodontic Brackets were examined; the \ndata from previous attempts are reported in table II. \nRisk of bias in studies\nAccording to the risk of the bias assessment tool, five \nstudies possessed a moderate risk of bias, and three \npossessed a low risk of bias (Tables III and IV).Antibacterial testing\nAntibacterial activity of brackets coating \nagainst L. acidophilus\nThe mean difference (MD) of the antibacterial potential of \nbrackets coating against L. acidophilus between Ag NPs \ncoating and the control group was 2.71 (MD, 2.71 95% CI \n= 2.05, 3.37; p=0.00) with high heterogeneity (I2=99.84%; \nP =0.00). The statistical findings indicated a significantly \nreduced effect on the survival rate of L. acidophilus with \nAg NPs than the control group (Figure 2). \nThe MD of the antibacterial potential of brackets coating \nagainst L. acidophilus between ZnO NPs coating and \ncontrol group was -3.50 (MD, -3.50 95% CI = -4.38, \n-2.63; p=0.00) with high heterogeneity (I2=99.81%; P \n=0.00). The statistical findings indicated a significantly \nreduced effect on the survival rate of L. acidophilus with \nZnO NPs than the control group ( Figure 2 ). \nThe MD of the antibacterial potential of brackets coating \nagainst L. acidophilus between Ag/ZnO NPs coating and \ncontrols was -58.12 (MD, -58.12 95% CI = -68.68, -47.56; \np=0.00). The statistical findings indicated a significantly \nreduced effect on the survival rate of L. acidophilus with \nAg/ZnO NPs than the control group (Figure 3). \nFigures 2, 3, and 4 statistically significantly reduce the \nsurvival rate of L. acidophilus, using Ag/ZnO NPs with \nthe highest impact and then using Ag NPs and ZnO NPs.Figure 1: PRISMA 2020 Checklist.\nIdentification of studies via databases and registers \nArticles detected \nbased on Databases \n(n =209)Records removed \nbefore the screening:\nDeleted duplicates \n(n = 5)\nIneligible articles based \non automation tools \n(n = 8)\nDeleted articles for \nother reasons (n = 12)\nRecords screened\n(n=184)\nRetrieved articles \n(n =32)Not retrieved articles \n(n = 0)\nEligibility of articles \n(n =32)Excluded articles \n(n = 24)Excluded articles**\n(n = 152)\nIncluded articles\n(n =8)Identification Screening Included110\n2023/38 (3): 107-114Navid Kerayechian et al. \nTable II: Summary of data.  \nTable III: Quality of the included studies.\nStudy. Years Item\n 1 2 3 4 5 6 7 8 9 10 11 12 13 14\nZeidan et al., 20223 \u221a \u221a \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u221a \u00d7 \u00d7 \u00d7 \u00d7\nTanbakuchi et al., 202126 \u221a \u221a \u221a \u221a \u221a \u221a \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nKachoei et al., 202127 \u221a \u221a \u221a \u221a \u221a \u221a \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nYassaei et al., 202028 \u221a \u221a \u221a \u221a \u221a \u221a \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nEslamian et al., 202029 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nKambalya et al., 201819 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nRamazanzadeh et al., 201530 \u221a \u221a \u221a \u221a \u00d7 \u221a \u00d7 \u00d7 \u00d7 \u221a \u221a \u221a \u00d7 \u00d7\nMirhashemi et al., 201331 \u221a \u221a \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u00d7 \u221a \u00d7 \u00d7 \u00d7 \u00d7111\n2023/38 (3): 107-114Evaluation of the Antibacterial Effects of the Various Nanoparticles Coated Orthodontic Brackets: A Systematic Review and Meta-analysis\nTable IV: Risk assessment.\n      \n      \nZeidan et al., 20223 1 1 2 0 0 Moderate\nTanbakuchi et al., 202126 1 0 2 0 0 Low\nKachoei et al., 202127 1 0 2 0 0 Low\nYassaei et al., 202028 1 0 2 0 0 Low\nEslamian et al., 202029 1 1 2 0 0 Moderate\nKambalya et al., 201819 1 1 2 0 0 Moderate\nRamazanzadeh et al., 201530 1 1 2 0 0 Moderate\nMirhashemi et al., 201331 1 1 2 0 0 Moderate\nFigure 2: Forest plot showed the Antibacterial potential of Ag NPs-coated Orthodontic Brackets against L. acidophilus.\nAllocation\nconcealment\nSample size\nBlinding\nAssessment\nmethods\nSelective outcome\nreporting\nRisk of biasStudy. Years\nFigure 4: Forest plot showed the antibacterial potential of Ag/ZnO NPs-coated Orthodontic Brackets against L. acidophilus.Figure 3: Forest plot showed the Antibacterial potential of ZnO NPs-coated Orthodontic Brackets against L. acidophilus.112\n2023/38 (3): 107-114\nNavid Kerayechian et al. \nThe MD of the antibacterial performance of brackets \ncoating against S. mutans between Ag NPs coating \nand the controls was -2.87 (MD, -2.87 95% CI = -3.59, \n-2.15; p=0.00) with high heterogeneity (I2=100%; P \n=0.00). The statistical findings indicated a significantly \nreduced effect on the survival rate of S. mutans with Ag \nNPs than control (Figure 5).\nThe MD of the antibacterial performance of brackets \ncoating against S. mutans between ZnO NPs coating and \ncontrols was -275.54 (MD, -275.54 95% CI = -281.23, -269.85; p=0.00) with high heterogeneity (I2=99.99%; \nP =0.00). The statistical findings indicated a significantly \nreduced effect on survival rate of S. mutans with ZnO \nNPs than controls (Figure 6). \nThe MD in the antibacterial performance of brackets \ncoating against S. mutans between Ag/ZnO NPs coating \nand the controls was -574 (MD, -574 95% CI = -580.03, \n-567.97; p=0.00). The statistical findings indicated \na significantly reduced effect on the survival rate of S. \nmutans with Ag/ZnO NPs than controls (Figure 7).\nFigure 5: Forest plot showed the antibacterial potential of Ag NPs-coated Orthodontic Brackets against S. mutans.\nFigure 6: Forest plot showed the antibacterial potential of ZnO NPs-coated Orthodontic Brackets against S. mutans.\nFigure 7: Forest plot showed the antibacterial potential of Ag/ZnO NPs-coated Orthodontic Brackets against S. mutans.113\n2023/38 (3): 107-114Evaluation of the Antibacterial Effects of the Various Nanoparticles Coated Orthodontic Brackets: A Systematic Review and Meta-analysis\nDiscussion\nWe aimed to investigate the antibacterial potential of Ag, \nZnO, and Ag/ZnO NPs-coated orthodontic brackets. \nOne of the problems of orthodontic patients is tooth \ndecay; Therefore, it is very important to use materials that \nhave antibacterial activity during the orthodontic treatment \nprocess, especially in patients who do not brush their \nteeth32. Studies have shown that plaque accumulation, \ntooth surface demineralization, and the formation of white \nspot lesions are very common in orthodontic patients33. \nBased on the present meta-analysis, brackets coated \nwith AgNPs, ZnO NPs, and Ag/ZnO NPs revealed a \nsignificant difference in antibacterial performance versus \nthe two study bacteria. Similarly, it was shown that \nbrackets coated with silver had an antibacterial activity \nversus the two study bacteria34. Another study showed \nthe greater antimicrobial potential of AgNPs compared \nto ZnO NPs. The mentioned study investigated the \nantimicrobial potential of AgNPs and ZnO NPs against S. \nmutans35. A study showed that Ag/ZnO had an enhanced \nantibacterial effect against S. mutans36. The Ag and ZnO \ncombination was synthesized to reduce any possible risk \nfor cytotoxic and genotoxic impacts of AgNPs in humans37 \nand to obtain the merits of its increased antibacterial \nactivity compared to ZnO21. The studies selected in the \npresent study were of medium to high quality. However, \nthe studies had very high heterogeneity, and the reason \nfor this could be related to the cognitive methodology and \nthe use of different concentrations of NPs; therefore, citing \nour findings should be interpreted with caution. Also, the \nduration of the evaluation of the results was different; in some studies, the length of time was not stated. A study \ninvestigating the prolonged antibacterial performance of \ncoated brackets was not found based on the results of \nstudies on the two study bacteria. And then, Ag and ZnO \nthe insignificant difference in the antimicrobial potential of \nthe three groups over time, which means the persistence \nof the antimicrobial effect of the bracket coatings over \ntime. However, the duration of the study may affect \nthe informed results. The cognitive methodology of the \nstudies should be the same in future studies.\nConclusion\nBased on the present meta-analysis, brackets coated \nwith silver, ZnO, and Ag/ZnO NPs had an antibacterial \nperformance against L. acidophilus and S. mutans \ncompared to the uncoated bracket. Further studies \nshould be conducted to evaluate cytotoxicity and other \ncomplications for nanoparticle-coated brackets and their \nefficacy in clinically reducing the incidence of WSLs \nduring orthodontic treatment. Also, more studies should \nbe conducted to investigate the role of abrasion and \nfriction on the NPs coating.\nConflict of Interest\nThe authors declared that there is no conflict of interest.\nAcknowledgments\nThis research received no specific grant from any funding \nagency in the public, commercial, or not-for-profit sectors.\nReferences\n1. Pabari S, Moles DR, Cunningham SJ. Assessment of motivation \nand psychological characteristics of adult orthodontic patients. \nAmerican Journal of Orthodontics and Dentofacial Orthopedics. \n2011;140(6):e263-72. https://doi.org/10.1016/j.ajodo.2011.06.022.\n2. Rosenbloom RG, Tinanoff N. Salivary Streptococcus mutans levels \nin patients before, during, and after orthodontic treatment. American \nJournal of Orthodontics and Dentofacial Orthopedics. 1991;100(1):35-\n7. https://doi.org/10.1016/0889-5406(91)70046-Y.\n3. Zeidan NK, Enany NM, Mohamed GG, Marzouk ES. The antibacterial \neffect of silver, zinc-oxide and combination of silver/zinc oxide \nnanoparticles coating of orthodontic brackets (an in vitro study). BMC \nOral Health. 2022;22(1):1-4. https://doi.org/10.1186/s12903-022-\n02263-6.\n4. Ahn SJ, Lim BS, Lee SJ. Prevalence of cariogenic streptococci on \nincisor brackets detected by polymerase chain reaction. American \nJournal of Orthodontics and Dentofacial Orthopedics. 2007;131(6):736-\n41. https://doi.org/10.1016/j.ajodo.2005.06.036.\n5. Prihastari L, Rizkia S. Streptococcus Mutans Colonies on Plaque \nof Fixed Orthodontic Users after Gargling with Black Tea (Camellia \nSinensis). International Journal of Scientific Research in Dental and \nMedical Sciences. 2022;4(3):97-100. https://doi.org/10.30485/\nijsrdms.2022.349306.1327.6. Ikeda T, Sandham HJ, Bradley Jr EL. Changes in Streptococcus \nmutans and lactobacilli in plaque in relation to the initiation of dental \ncaries in Negro children. Archives of Oral Biology. 1973;18(4):555-66. \nhttps://doi.org/10.1016/0003-9969(73)90076-9.\n7. Gorelick L, Geiger AM, Gwinnett AJ. Incidence of white spot \nformation after bonding and banding. American journal of orthodontics. \n1982;81(2):93-8. https://doi.org/10.1016/0002-9416(82)90032-X.\n8. Caldeira EM, Osorio A, Oberosler EL, Vaitsman DS, Alviano DS, \nNojima MD. Antimicrobial and fluoride release capacity of orthodontic \nbonding materials. Journal of Applied Oral Science. 2013;21:327-34. \nhttps://doi.org/10.1590/1678-775720130010.\n9. Ahn SJ, Lee SJ, Baek SH, Kim TW, Chang YI, Nahm DS, et al. Direct \ndetection of cariogenic streptococci in metal brackets in vivo using \npolymerase chain reaction.2005;35:312-9.\n10. Jeon HS, Choi CH, Kang SM, Kwon HK, Kim BI. Chlorhexidine-\nreleasing orthodontic elastomerics. Dental materials journal. \n2015;34(3):321-6. https://doi.org/10.4012/dmj.2014-216.\n11. Sodagar A, Akhoundi MS, Bahador A, Jalali YF, Behzadi Z, \nElhaminejad F, et al. Effect of TiO 2 nanoparticles incorporation on \nantibacterial properties and shear bond strength of dental composite \nused in Orthodontics. Dental press journal of orthodontics. 2017;22:67-\n74. https://doi.org/10.1590/2177-6709.22.5.067-074.oar.114\n2023/38 (3): 107-114Evaluation of the Antibacterial Effects of the Various Nanoparticles Coated Orthodontic Brackets: A Systematic Review and Meta-analysisNavid Kerayechian et al. \n12. Cushing BL, Kolesnichenko VL, O\u2019connor CJ. Recent advances \nin the liquid-phase syntheses of inorganic nanoparticles. Chemical \nreviews. 2004;104(9):3893-946. https://doi.org/10.1021/cr030027b.\n13. Allaker RP . The use of nanoparticles to control oral biofilm formation. \nJournal of dental research. 2010;89(11):1175-86. https://doi.\norg/10.1177/0022034510377794.\n14. Raeder J, Larson D, Li W, Kepko EL, Fuller-Rowell T. OpenGGCM \nsimulations for the THEMIS mission. Space Science Reviews. \n2008;141(1):535-55. https://doi.org/10.1007/s11214-008-9421-5.\n15. Kumar VA, Augustine D, Panikar D, Nandakumar A, Dinesh KR, \nKarim S, et al. Nocardia farcinica brain abscess: epidemiology, \npathophysiology, and literature review. Surgical infections. \n2014;15(5):640-6. https://doi.org/10.1089/sur.2012.205.\n16. Mhaske AR, Shetty PC, Bhat NS, Ramachandra CS, Laxmikanth \nSM, Nagarahalli K, et al. Antiadherent and antibacterial properties of \nstainless steel and NiTi orthodontic wires coated with silver against \nLactobacillus acidophilus\u2014an in vitro study. Progress in orthodontics. \n2015;16(1):1-6. https://doi.org/10.1186/s40510-015-0110-0.\n17. M\u00fcller LK, Jungbauer G, Jungbauer R, Wolf M, Deschner J. Biofilm \nand orthodontic therapy. Oral Biofilms. 2021;29:201-13. https://doi.\norg/10.1159/000510193.\n18. B\u0105cela J, \u0141abowska MB, Detyna J, Zi\u0119ty A, Michalak I. \nFunctional coatings for orthodontic archwires\u2014A review. Materials. \n2020;13(15):3257. https://doi.org/10.3390/ma13153257.\n19. Kambalyal PB, Shanmugasundaram K, Rajesh V, Donthula S, \nPatil SR. Comparative Evaluation of Antimicrobial Efficacy of Silver, \nTitanium Dioxide and Zinc Oxide Nanoparticles against Streptococcus \nmutans. Pesquisa brasileira em odontopediatria e clinica integrada. \n2018;18(1):4150.\n20. Kachoei M, Nourian A, Divband B, Kachoei Z, Shirazi S. Zinc-oxide \nnanocoating for improvement of the antibacterial and frictional behavior \nof nickel-titanium alloy. Nanomedicine. 2016;11(19):2511-27. https://\ndoi.org/10.2217/nnm-2016-0171.\n21. Vargas-Reus MA, Memarzadeh K, Huang J, Ren GG, Allaker \nRP . Antimicrobial activity of nanoparticulate metal oxides against peri-\nimplantitis pathogens. International journal of antimicrobial agents. \n2012;40(2):135-9. https://doi.org/10.1016/j.ijantimicag.2012.04.012.\n22. Melchels FP , Feijen J, Grijpma DW. A review on stereolithography and its \napplications in biomedical engineering. Biomaterials. 2010;31(24):6121-\n30. https://doi.org/10.1016/j.biomaterials.2010.04.050.\n23. Mardany A, Pornamazeh T, Ahmadvand A, Vatandoust MT, Mirmalek \nSP , Soltanian M. The Comparison of the Bonding Performance between \nthe new Flash-free Orthodontic Bracket Bonding System and the \nTraditional Bracket Bonding System: A Systematic Review and Meta-\nanalysis. International Journal of Scientific Research in Dental and \nMedical Sciences. 2022;4(4):196-200. https://doi.org/10.30485/\nijsrdms.2022.375721.1408.\n24. Tu YK, Needleman I, Chambrone L, Lu HK, Faggion Jr CM. A \nBayesian network meta-analysis on comparisons of enamel matrix \nderivatives, guided tissue regeneration and their combination therapies. \nJournal of clinical periodontology. 2012;39(3):303-14. https://doi.\norg/10.1111/j.1600-051X.2011.01844.x.25. Higgins JP , Altman DG, G\u00f8tzsche PC, J\u00fcni P , Moher D, Oxman \nAD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in \nrandomised trials. Bmj. 2011;343. https://doi.org/10.1136/bmj.d5928.\n26. Tanbakuchi B, Pourhajibagher M, Badiei A, Masaeli R, Bahrami R. \nEvaluation of the cell viability and antimicrobial effects of orthodontic \nbands coated with silver and zinc oxide nanoparticles: an in vitro study. \nThe Korean Journal of Orthodontics.\n27. Kachoei M, Divband B, Rahbar M, Esmaeilzadeh M, Ghanizadeh M, \nAlam M. A novel developed bioactive composite resin containing silver/\nzinc oxide (Ag/ZnO) nanoparticles as an antimicrobial material against \nStreptococcus mutans, lactobacillus, and candida albicans. Evidence-\nBased Complementary and Alternative Medicine. 2021. https://doi.\norg/10.1155/2021/4743411.\n28. Yassaei S, Nasr A, Zandi H, Motallaei MN. Comparison of antibacterial \neffects of orthodontic composites containing different nanoparticles \non Streptococcus mutans at different times. Dental Press Journal \nof Orthodontics. 2020;25:52-60. https://doi.org/10.1590/2177-\n6709.25.2.052-060.oar.\n29. Eslamian L, Borzabadi-Farahani A, Karimi S, Saadat S, Badiee \nMR. Evaluation of the shear bond strength and antibacterial activity \nof orthodontic adhesive containing silver nanoparticle, an in-vitro \nstudy. Nanomaterials. 2020;10(8):1466. https://doi.org/10.3390/\nnano10081466.\n30. Ramazanzadeh B, Jahanbin A, Yaghoubi M, Shahtahmassbi N, \nGhazvini K, Shakeri M, et al. Comparison of antibacterial effects of \nZnO and CuO nanoparticles coated brackets against Streptococcus \nmutans. Journal of Dentistry. 2015;16(3):200-5.\n31. Mirhashemi AH, Bahador A, Kassaee MZ, Daryakenari G, Ahmad-\nAkhoundi MS, Sodagar A. Antimicrobial effect of nano-zinc oxide and \nnano-chitosan particles in dental composite used in orthodontics. \nJournal of Medical Bacteriology. 2013;2(3-4):1-0.\n32. \u00d8gaard B, R\u00f8lla G, Arends J. Orthodontic appliances and enamel \ndemineralization: Part 1. Lesion development. American Journal of \nOrthodontics and Dentofacial Orthopedics. 1988;94(1):68-73. https://\ndoi.org/10.1016/0889-5406(88)90453-2.\n33. Bishara SE, Ostby AW. White spot lesions: formation, prevention, \nand treatment. InSeminars in orthodontics 2008;14(3):174-182).\n \n34. Nalini D. Assessment of Antibacterial Property of Silver Coated \nStainless Steel Orthodontic Brackets against Streptococcus Mutans, \nLactobacillus Acidophilus and Porphyromonas Gingivalis: An In Vitro study: \nTamil Nadu Government Dental College and Hospital, Chennai; 2017 .\n35. Hern\u00e1ndez-Sierra JF, Ruiz F, Pena DC, Mart\u00ednez-Guti\u00e9rrez F, \nMart\u00ednez AE, Guill\u00e9n AD, Tapia-P\u00e9rez H, Casta\u00f1\u00f3n GM. The antimicrobial \nsensitivity of Streptococcus mutans to nanoparticles of silver, zinc oxide, \nand gold. Nanomedicine: Nanotechnology, Biology and Medicine. \n2008;4(3):237-40. https://doi.org/10.1016/j.nano.2008.04.005.\n36. Wang S, Wu J, Yang H, Liu X, Huang Q, Lu Z. Antibacterial \nactivity and mechanism of Ag/ZnO nanocomposite against anaerobic \noral pathogen Streptococcus mutans. Journal of Materials Science: \nMaterials in Medicine. 2017;28(1):1-8. https://doi.org/10.1007/\ns10856-016-5837-8.\n37. AshaRani PV, Low Kah Mun G, Hande MP , Valiyaveettil S. \nCytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS \nnano. 2009;3(2):279-90. https://doi.org/10.1021/nn800596w.115\n2023/38 (4): 115-118ORIGINAL\nWhat happens with the health system: Medical mistrust\nLo que ocurre con el sistema sanitario: Desconfianza m\u00e9dica\nSelman K\u0131z\u0131lkaya\n1. Dicle University, Faculty of Economics and Administrative Sciences, Health Management Department, Diyarbak\u0131r, TurkeyeISSN 2255-0569\nReceived: 3 - II - 2023\nAccepted: 6 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.115Corresponding author\nSelman K\u0131z\u0131lkaya \nE-mail: Selman.kizilkaya@dicle.edu.tr \n  \nAbstract \nAim: This research aims to determine the moderator role of gender in the effect of medical mistrust on the intention to use violence \nagainst healthcare professionals. The data in the study were obtained by the survey method. \nMethods: The obtained data were analyzed with the SPSS program and the process macro software added to the SPSS program. \nResults: The sample of the study consists of 628 people in total. According to the results of the research, a positive and significant \nrelationship was found between medical mistrust and the intention to use violence on healthcare professionals. Gender has been \nfound to have a moderator role in the effect of medical mistrust on the intention to use violence on healthcare professionals. The \neffect of medical mistrust on the intention to use violence on healthcare professionals was \u03b2=2,9054; t=12.8935 in individuals \nwhose physicians were female; while in males \u03b2=1.6301; t=12.2957. \nConclusion: Accordingly, when the doctor\u2019s gender is female, the effect of medical mistrust on the intention to use violence on \nhealthcare professionals becomes more evident.\nKeywords: Medical mistrust, healthcare professionals, violence, gender. \nResumen\nObjetivo: Esta investigaci\u00f3n pretende determinar el papel moderador del g\u00e9nero en el efecto de la desconfianza m\u00e9dica sobre la \nintenci\u00f3n de usar la violencia contra los profesionales sanitarios. \nMetodolog\u00eda: Los datos del estudio se obtuvieron mediante el m\u00e9todo de encuesta. Los datos obtenidos se analizaron con el \nprograma SPSS y el software process macro a\u00f1adido al programa SPSS. \nResults: La muestra del estudio consta de 628 personas en total. Se encontr\u00f3 una relaci\u00f3n positiva y significativa entre la \ndesconfianza m\u00e9dica y la intenci\u00f3n de ejercer violencia sobre los profesionales sanitarios. Se ha observado que el g\u00e9nero tiene un \npapel moderador en el efecto de la desconfianza m\u00e9dica sobre la intenci\u00f3n de ejercer violencia sobre los profesionales sanitarios. \nEl efecto de la desconfianza m\u00e9dica sobre la intenci\u00f3n de ejercer violencia sobre los profesionales sanitarios fue de \u03b2=2,9054; \nt=12,8935 en los individuos cuyos m\u00e9dicos eran mujeres; mientras que en los hombres fue de \u03b2=1,6301; t=12,2957. \nConclusi\u00f3n: En consecuencia, cuando el g\u00e9nero del m\u00e9dico es femenino, el efecto de la desconfianza m\u00e9dica sobre la intenci\u00f3n \nde ejercer violencia sobre los profesionales sanitarios se hace m\u00e1s evidente.\nPalabras clave: Desconfianza m\u00e9dica, profesionales sanitarios, violencia, g\u00e9nero.ID116\n2023/38 (4): 115-118Selman K\u0131z\u0131lkaya et al. \nIntroduction\nDespite the deep and pervasive importance of trust in \nmedical settings, there is no widely shared understanding \nof what trust means, and little is known about what trust \nactually makes, what factors trust influences, and how \ntrust relates to other similar attitudes and behaviors. The \nimportance of trust in medical relationships has been \nknown for a long time1-3, but trust in the system and trust \nin physicians have not been measured or systematically \nanalyzed until recently. However, the doctor-patient \nrelationship has recently attracted more attention (1,4). \nIt is seen as a global feature of patient-doctor-treatment \nrelationships, each of which has important importance \nin its own right, including many ancillary features such \nas trust, satisfaction, communication, competence, and \nprivacy5,6.\nIn this context, it is important to determine how important \nmedical mistrust is in the intention to use violence against \nhealthcare professionals. When the national literature \nis examined, it is seen that there are limited studies \nexamining the effect of medical mistrust on the intention \nto inflict violence on healthcare workers. However, no \narticle was found that examined the role of gender in \nthe effect of medical mistrust on the intention to commit \nviolence against healthcare professionals.\nMaterials and methods\nResearch Model\nThis study\u2019s main purpose is to determine the moderator \nrole of gender in the effect of medical mistrust on the \nintention to inflict violence on healthcare workers. In the \nresearch, the independent variable of medical mistrust; \nIntention to inflict violence on healthcare workers was \nconsidered the dependent variable, and gender was the \nmoderator variable.\nData Collection Tools\nIn this study, the survey method was preferred at the point \nof data collection. The questionnaires were delivered to \nthe participants online. In the questionnaire, there are \nstatements that reveal the opinions of the participants \nabout the intention to use violence against health \nworkers and medical mistrust, as well as descriptive \npersonal characteristics. The medical mistrust scale is a \nscale developed by Thomas et al. The scale, adapted \ninto Turkish by \u015eeng\u00fcl and Bulut (2020), consists of 17 \nstatements7. As a result of the reliability analysis of the \nscale, which was structured as a 4-point Likert scale, \nCronbach\u2019s Alpha coefficient was determined as 0.85. In \nthis study, the said value was determined as 0.85.\nThe other scale included in the questionnaire is the \n\u201cIntention to Inflict Violence Scale on Health Care \nWorkers\u201d developed by \u015eanl\u0131t\u00fcrk and Boy (2020)8. Scale; individuals\u2019 intention to commit violence1, past \nexperiences2, attitude towards behavior3,4,5,6,7,8, subjective \nnorm9,10,11,12,13 and perceived behavioral control14,15 \nconsists of 5 sub-dimensions. The scale, which included \na total of 15 statements, was structured as a 5-point Likert \nscale, ranging from 1: I strongly disagree to 5: I strongly \nagree. As a result of the reliability analysis performed in \nthe study, Cronbach\u2019s Alpha coefficient was determined \nas 0.81. In this study, the said value was determined as \n0.81.\nStatistical Analysis\nThe analysis of the data was made with the SPSS 26.0 \nprogram and it was studied with a confidence level of \n95%. Frequency (n) and percentage (%) statistics for \ncategorical (qualitative) variables, mean (mean), standard \ndeviation (ss), minimum (min.), and maximum (max.) \nstatistics are given for numerical (quantitative) variables. In \nthe study, Cronbach\u2019s Alpha coefficient was used to reveal \nthe reliability of the scales. Skewness and kurtosis values \nwere calculated to examine the conformity of the scores \nobtained from the scales to the normal distribution. The \nkurtosis and skewness values obtained from the scale \nscores between +3 and -3 are considered sufficient for a \nnormal distribution9. Accordingly, it was determined that \nthe scores of Medical mistrust and Intention to Violence \nagainst Health Care Professionals showed a normal \ndistribution. Therefore, parametric methods were used \nin the analyses. Pearson correlation test was used in \nthe relationship between medical mistrust and intention \nto use violence against healthcare professionals, and \nProcess Regression analysis was used in the moderator \neffect model. In the regulatory impact model, the effect of \nthe interaction term should be significant.\nResults\nIt was seen that the average age of the participants was \n31.06 and 61.9% of them were male. In the distribution \nof perceived income level, it was seen that 69.3% of \nthem had medium income. Finally, it was seen that the \ngender of the doctor in the last health institution from \nwhich service was received was male in 40.9% and \nfemale in 59.1% (Table I).\nTable I: Descriptive Characteristics of Research Participants.\n  Mean Std. Deviation\nAge 31,06 7,27\nGender N %\n    Male 389 61,9\n    Female 239 38,1\nIncome rate N %\n    High 97 15,4\n    Middle 435 69,3\n    Low 96 15,3\nGender of the doctor in the last health  N %\ninstitution from which service was received \n    Male 257 40,9\n    Female 371 59,1117\n2023/38 (4): 115-118What happens with the health system: Medical mistrust\nThe mean score of medical mistrust of the respondents \nis 3.1\u00b10.46, the mean score of intention is 2.22\u00b11.56, \nthe mean score of past experience is 4.46\u00b11.13, the \nmean score of attitude towards behavior is 1.69\u00b10.73, \nthe subjective norm means the score was 2.10\u00b10.70, \nand mean perceived behavioral control score was \n2.13\u00b11.12 (Table II).\nIt was observed that there was a positive relationship \nbetween medical mistrust and intention to use violence \nagainst health professionals (r=.551, p<.01), PB (r=.384, \np<.01), ATB (r=.505, p<.01), SN (r=.546, p<.01) and \nPBC (r=.563, p<.01) (Table III).\nIt is seen that the model created for the moderator \neffect of the doctor\u2019s gender on the intention to commit \nviolence against healthcare professionals of medical \nmistrust is significant (F=106,293; p<0.05). While the \nvariables of medical mistrust (B=4.181) and gender \n(B=4.383) have a positive effect on the intention to inflict \nviolence on healthcare workers, the interaction term (B=-\n1.275) has a negative effect (R2=33.8%; p<0.05). When \nthe doctor\u2019s gender is male, the intention to commit \nviolence increases positively in case of medical mistrust \n(B=1,630). This becomes more evident when the gender \nof the doctor is female (B=2.905).(Table IV).\nDiscussion\nMedical mistrust is a multifactorial social phenomenon, \nwhich significantly depends on the type of community, the psychosocial status of a population, and individual beliefs. \nThe predominance of cases of MM happens in diverse \nminorities of the public sector and extremely impacts \nclinical practice. Therefore, the MM linked to gender could \nbe one of the most common and at the same time the \nmost difficult for identification of doctor-patient issues. \nIn different social groups over the world, the rate of MM \nvaries from 20 to 80%10,11. The negative skewness of \nMM with a mean value of 3.11 demonstrates in current \nresearch that 77.5% of questioned experienced MM \nand 44% had an intention of violence toward doctors. \nAccording to some research outcomes12,13 8,3-12.3% \nof represented groups avouched in the use of violence \nagainst medical professionals, mostly in verbal form - \n77,5%12-15. Negative kurtosis of intention shows that the \nnumbers of patients in this study who wished to implicit \nviolence are slightly lower than the mean. \nPast behavior has high mean values (4.46) in this study, \nshowing not only possible experience of previously \ndissatisfactory doctor-patient communication or \nunsuccessful treatment but also a predisposition to further \nmistrust, conflicts, and possible violence. Our study \nrevealed a notable statistical relationship between MM and \nthe intention to use violence, which may indicate mistrust \nas a background of violent behavior attempts. When the \ngender of the doctor is male, the intention to commit \nviolence increases on the background of mistrust and is \nmore pronounced when the gender of the doctor is female.\nThe statistically evident fact of the current investigation, \nthat gender has an impact on the intention to inflict \nviolence towards female doctors (B=2.905) requires \nfurther investigations to rule out or prove discrimination. \nAccording to some studies, discrimination is often related \nto MM10,12. Further populational studies are necessary to \nclarify the causes of MM in the aspect of physician gender \nand should be directed to many aspects - its frequency \nin private and state medical institutions, its distribution \namong different medical specialties (f.i. there are more \ngynecologists women over the world and they have a \npreference among patients14), educational attainment \nof patients, the possible discrepancies in different age \ngroups of patients as well as doctors, who experience \nMM. The role of gender in MM should also be considered \ntogether with other possible factors, which can overlap \neach other and have distinguished meanings alone. \nThus, MM is a complex problem, the roots of which come \nfrom both the doctor and the patient. Meticulous analysis \nof the biased attitude to female doctors could improve \noutcomes of treatment eventually and create better work \nconditions for this group of medical professionals.\nNo Funding\nThe authors declare that they have no conflict of interestTable II: Descriptive Statistics.\n  Min. Max. Mean Std. Devi. Skewness Kurtosis\nMM 1 4 3,11 0,46 -0,41 0,05\nIntention 1 5 2,22 1,56 0,85 -0,91\nPB 1 5 4,46 1,13 -2,13 2,31\nATB 1 4 1,69 0,73 1,02 0,17\nSN 1 4 2,1 0,7 0,39 -0,23\nPBC 1 5 2,13 1,12 0,67 -0,47\nTable IV: The Regulatory Role of Gender in the Effect of Medical Mistrust on \nIntention to Violence against Health Care Professionals.\n  B LLCI-ULCI t p R2 F\nMM 4,181 3,258/5,103 8,899 0,000* 0,338 106,293*\n>Intention \nGender  4,383 2,736/6,030 5,225 0,000*  \n>Intention \nMM* Gender  -1,275 2,347769029 -4,878 0,000*  \n>Intention \nMM*Gender 2,905 2,463/3,348 12,894 0,000*    \n(Female) \nMM* Gender 1,63 1,370/1,891 12,296 0,000*  \n(Male)Table III: Relationships Between Medical Mistrust and Intention to Violence \nAgainst Healthcare Professionals.\n**p<0.01  Intention PB ATB SN PBC\nMM (r) ,551** ,384** ,505** ,546** ,563**ATB: attitude toward behavior; PB: past behavior; PBC: perceived behavioral \ncontrol; SN: subjective norm, MM: Medical Mistrust118\n2023/38 (4): 115-118What happens with the health system: Medical mistrust Selman K\u0131z\u0131lkaya et al. \nReferences\n1. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and \nmedical institutions: what is it, can it be measured, and does it matter? \nMilbank Q. 2001;79(4):613-39, v. doi: 10.1111/1468-0009.00223. \n2. Hall MA. Researching medical trust in the United States. J Health Organ \nManag. 2006;20(5):456-67. doi: 10.1108/14777260610701812. \n3. Zheng B, Hall MA, Dugan E, Kidd KE, Levine D. Development of a \nscale to measure patients\u2019 trust in health insurers. Health Serv Res. \n2002 Feb;37(1):187-202. \n4. Hall MA, Zheng B, Dugan E, Camacho F, Kidd KE, Mishra A, et al. \nMeasuring patients\u2019 trust in their primary care providers. Med Care Res \nRev. 2002 Sep;59(3):293-318. doi: 10.1177/1077558702059003004. \nErratum in: Med Care Res Rev. 2003 Mar;60(1):118. \n5. Lewandowski R, Goncharuk AG, Cirella GT. Restoring patient trust \nin healthcare: medical information impact case study in Poland. BMC \nHealth Serv Res. 2021 Aug 24;21(1):865. doi: 10.1186/s12913-021-\n06879-2. PMID: 34429101; \n6. Vega-Hurtado C. Importancia de las estrategias de comunicaci\u00f3n \nentre m\u00e9dico y paciente [Importance of doctor-patient communication \nstrategies]. Rev Med Inst Mex Seguro Soc. 2020 Apr 13;58(2):197-\n201. Spanish. doi: 10.24875/RMIMSS.M20000017. \n7. \u015eeng\u00fcl H. Bulut A. \u201cT\u0131bbi G\u00fcvensizlik \u00d6l\u00e7e\u011fi ve Doktora G\u00fcven \n\u00d6l\u00e7e\u011finin T\u00fcrk\u00e7e Ge\u00e7erlik G\u00fcvenirlik \u00c7al\u0131\u015fmas\u0131\u201d International Social \nSciences Studies Journal, 2020 (e-ISSN:2587-1587) Vol:6, Issue: 62; \npp:1956-64.\n8. \u015eanl\u0131t\u00fcrk D. Boy Y. Determination of the Society\u2019s Perceptions, \nExperiences, and Intentions to Use Violence Against Health \nProfessionals. Safety and Health at Work 2020. https://doi.\norg/10.1016/j.shaw.2020.12.004.9. Hopkins KD, Weeks DL. \u201cTests for Normality and Measures of \nSkewness and Kurtosis: Their Place in Research Reporting\u201d, Educational \nand Psychological Measurement 1990; 50: 717-29.\n10. Williamson LD, Bigman CA. A systematic review of medical mistrust \nmeasures. Patient Educ Couns. 2018 Oct;101(10):1786-94. doi: \n10.1016/j.pec.2018.05.007. \n11. Armstrong K, Rose A, Peters N, Long JA, McMurphy S, Shea JA. \nDistrust of the health care system and self-reported health in the United \nStates. J Gen Intern Med. 2006 Apr;21(4):292-7. doi: 10.1111/j.1525-\n1497.2006.00396.x. \n12. D\u00f6nd\u00fc \u015e, Yasemin B. Determination of the Society\u2019s Perceptions, \nExperiences, and Intentions to Use Violence Against Health \nProfessionals. Saf Health Work. 2021 Jun;12(2):141-6. doi: 10.1016/j.\nshaw.2020.12.004. \n13. Takak S\u00d6, Artanta\u015f AB. Evaluation of patients\u2019 and their relatives\u2019 \nopinions and attitudes about violence against health care workers. \nAnkara Medical J. 2018;18:103-16. doi: 10.17098/amj.409020.\n14. Riaz B, Sherwani NZF, Inam SHA, Rafiq MY, Tanveer S, Arif A, et al. \nPhysician Gender Preference Amongst Females Attending Obstetrics/\nGynecology Clinics. Cureus. 2021 May 14;13(5):e15028. doi: \n10.7759/cureus.15028. \n15. Baber A. The effect of the COVID-19 pandemic on the psychological \nstate of healthcare workers around the world: A review. The Injector. \n2022;1(1):16-30.119\n2023/38 (4): 119-124ORIGINAL\nRevisi\u00f3n Sistem\u00e1tica de la relaci\u00f3n entre el dolor \npor infecci\u00f3n herpes z\u00f3ster y la calidad de vida \nde los sujetos que viven en la comunidad\nSystematic review of the relationship between pain due to herpes zoster infection \nand the quality of life of subjects living in the community\nF\u00e1tima Madrona Marcos1      , Antonio Moya Moya2, Loreto T\u00e1rraga Marcos3,\nJose Ignacio Ramirez-Manent4,5,6      , Pilar Tom\u00e1s-Gil6,7      , Pere Riutord Sbert6,7      , \nPedro J. Tarraga L\u00f3pez8\n1. Urgencias Hospital General de Albacete\n2. Endocrinolog\u00eda Hospital General de Villarrobledo.\n3.Enfermeria Hospital General Almansa.\n4. Profesor medicina Universidad Islas Baleares.\n5. IdisBa (Institut d\u2019Investigaci\u00f3 Sanitaria Illes Balears). Espa\u00f1a. \n6. ADEMA-SALUD Grupo de IUNICS, Universidad de las Islas Baleares, Palma, Espa\u00f1a.\n7. Escuela Universitaria ADEMA. Palma de Mallorca. Espa\u00f1a.\n8. Profesor Medicina Universidad de Castilla la ManchaeISSN 2255-0569\nReceived: 5 - II - 2023\nAccepted: 6 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.119Corresponding author\nJos\u00e9 Ignacio Ram\u00edrez-Manent \nE-mail: jignacioramirez@telefonica.net\n  \nResumen\nLa prevalencia de la infecci\u00f3n por herpes z\u00f3ster se encuentra en aumento, en parte debido al envejecimiento de la poblaci\u00f3n m\u00e1s \nvulnerable a la misma, ancianos. \nEste hecho, sumado a las diversas modificaciones inmunol\u00f3gicas que determinan la manifestaci\u00f3n de esta enfermedad, obligan \na detectar y analizar los elementos que intervienen en la fisiopatolog\u00eda del dolor producido por herpes, as\u00ed como la necesidad de \nencontrar alternativas terap\u00e9uticas necesarias para el control de este. \nAs\u00ed pues, esta revisi\u00f3n sistem\u00e1tica, cuyo objetivo principal es conocer la relaci\u00f3n existente entre dolor producido tras la infecci\u00f3n \npor herpes z\u00f3ster y el empeoramiento en la calidad de vida de los sujetos que presentan este diagn\u00f3stico para poder establecer \naquellos s\u00edntomas de alarma que perpet\u00faan dicho dolor.\nPalabras clave: Dolor, Neuralgia Postherp\u00e9tica, Calidad de Vida, Alodinia, Polifarmacia.\n \nSummary \nThe prevalence of herpes zoster infection is increasing, in partly due to the aging of the population most vulnerable to it, the elderly. \nThis fact, added to the various immunological modifications that determine the manifestation of this disease, make it necessary \nto detect and analyze the elements that intervene in the pathophysiology of pain caused by herpes, as well as the need to find \ntherapeutic alternatives necessary for its control. \nThus, this systematic review, whose main objective is to know the relationship between pain produced after infection by herpes \nzoster and the deterioration in the quality of life of subjects with this diagnosis in order to establish those alarm symptoms that \nperpetuate said pain.\nKey words: Pain, Postherpetic Neuralgia, Quality of Life, Allodynia, Polypharmacy. ID\nID ID ID\nID120\n2023/38 (4): 119-124F\u00e1tima Madrona et al. \nIntroducci\u00f3n \nAtenci\u00f3n Primaria supone el \u00e1mbito asistencial \ndestacado y predominante donde se detectar\u00e1n casos \nde infecci\u00f3n por herpes z\u00f3ster (HZ). El primer contacto \ndel ser humano con el virus varicela z\u00f3ster, se produce \nhabitualmente durante la infancia, manifestando \nlas lesiones cut\u00e1neas generalizadas que se inician \nsiendo m\u00e1culas, posteriormente se convierten en \np\u00e1pulas y finalizan siendo ves\u00edculas con morfolog\u00eda \ncostrosa, en progresiva resoluci\u00f3n. La caracter\u00edstica \nfundamental de esta primoinfecci\u00f3n es que permite \nque el virus permanezca acantonado en el sistema \nnervioso, es decir, permanece en un ganglio espinal \n(dorsal en su mayor\u00eda) o en un ganglio de los nervios \nde los pares craneales, habitualmente en el ganglio \nde Gasser o ganglio geniculado, dotando de mayor \nvirulencia o gravedad esta segunda reactivaci\u00f3n1. No \nobstante, no son las lesiones cut\u00e1neas las principales \nmanifestaciones de esta patolog\u00eda, si no el dolor su \ns\u00edntoma predominante y m\u00e1s incapacitante en muchos \ncasos. La incidencia de HZ en la poblaci\u00f3n espa\u00f1ola \nes de 2,1 a 5,5/1.000 habitantes a\u00f1o2. En Europa \nes dif\u00edcil concretar su prevalencia por la creciente \ndiversidad de estudios y su deficiencia, sin embargo, \ncabe esperar una incidencia comparable a la espa\u00f1ola, \ny lo que es m\u00e1s llamativo a\u00fan, su aumento con la \nedad y el envejecimiento poblacional, de forma que en \nsujetos con edades superiores a 50 a\u00f1os, represente \n7-8/1.000 casos, increment\u00e1ndose a 10/1.000 casos \na partir de los 80 a\u00f1os2. Los s\u00edntomas de la infecci\u00f3n \npor varicela z\u00f3ster se dividen en 3 fases: 1. Fase \nprodr\u00f3mica: Pueden aparecer s\u00edntomas sist\u00e9micos \ncomo mal estar general, mialgias o fiebre, as\u00ed como \nun dolor urente, alodinia o hiperalgesia del dermatoma \nafecto donde se producir\u00e1 el posterior desarrollo de \nlas lesiones cut\u00e1neas. Esta fase corresponde desde \n2, 3 d\u00edas hasta semanas previas a la aparici\u00f3n de \nlas lesiones cut\u00e1neas. 2. Fase eruptiva: Como su \nnombre indica, corresponde a la presencia de lesiones \npapulosas eritematosas agrupadas que evolucionan a \nves\u00edculas sobre una base eritematosa, finalizando en su \nevoluci\u00f3n a costra al cabo de 3-10 d\u00edas desde su inicio. \nDicha distribuci\u00f3n corresponde a la regi\u00f3n de neuronas \nsensitivas del nervio donde se ha replicado el virus. De \nforma habitual y en sujetos inmunocompetentes, se \nafecta un \u00fanico dermatoma, siendo los m\u00e1s involucrados \ny en este orden descendente: tor\u00e1cicos (53%), cervical \n(20%) y trig\u00e9mino (15%). Lo m\u00e1s habitual es que afecte \na un \u00fanico dermatoma y no cruce la l\u00ednea media. 3. \nFase cr\u00f3nica: Es la fase caracterizada por la presencia \nde dolor persistente tras 4 semanas desde el inicio \ndel cuadro, acompa\u00f1ando al dolor, las parestesias, \ndisestesias y cualquier otra sintomatolog\u00eda que afecte \na la calidad de vida del sujeto y sea la causante del \ns\u00edndrome denominado neuralgia postherp\u00e9tica (NPH, \nsiglas en espa\u00f1ol) persistiendo dichos s\u00edntomas \ndurante meses o a\u00f1os tras la desaparici\u00f3n de las lesiones3. La neuralgia postherp\u00e9tica es la complicaci\u00f3n \nm\u00e1s frecuente del HZ y supone un da\u00f1o neurol\u00f3gico \nsecundario a una respuesta inflamatoria inducida por la \nreplicaci\u00f3n viral en el interior del nervio. Su prevalencia \nsupone el 20% de los pacientes con HZ, especialmente \naquellos con m\u00e1s de 50 a\u00f1os en el momento de la \nprimoinfecci\u00f3n o reactivaci\u00f3n. La definici\u00f3n m\u00e1s \npragm\u00e1tica es la de dolor tipo ardor o descarga \nel\u00e9ctrica en una distribuci\u00f3n dermat\u00f3mica mantenida \ndurante al menos 90 d\u00edas desde la aparici\u00f3n de las \nlesiones cut\u00e1neas4. Los factores de riesgo descritos \nde estas neuralgias son diversos, entre los cuales se \nencuentran, edad avanzada, erupci\u00f3n cut\u00e1nea grave, \ndolor agudo intenso durante la fase prodr\u00f3mica o \nactiva, compromiso oft\u00e1lmico, inmunosupresi\u00f3n o \nenfermedades cr\u00f3nicas como diabetes mellitus y \nlupus. Debido a las caracter\u00edsticas de esta neuralgia, \nsupone una merma considerable en la calidad de vida, \ncon consecuencias f\u00edsicas y psicol\u00f3gicas para el sujeto \nque lo padece5. De esta forma, es considerada una \nenfermedad cr\u00f3nica relevante por la predilecci\u00f3n de \nafectaci\u00f3n por los pacientes con edades superiores \nde 50 a\u00f1os, por las caracter\u00edsticas de cronicidad del \ns\u00edndrome, desde 6 meses hasta a\u00f1os despu\u00e9s de \nla manifestaci\u00f3n inicial y por la variedad de s\u00edntomas \ndel dolor neurop\u00e1tico postherp\u00e9tico que dificulta el \ntratamiento con analg\u00e9sicos disponibles y aumenta \nla morbilidad de los pacientes que se ven obligados \nincluso, a ser valorados en unidades del dolor para \npoder alcanzar un alivio sintom\u00e1tico6. El mecanismo a \npartir del cual, el virus es capaz de da\u00f1ar el sistema \nnervioso, incluye su replicaci\u00f3n en el ganglio dorsal \nque se localice inicialmente, y su posterior migraci\u00f3n \na trav\u00e9s del sistema nervioso perif\u00e9rico, alcanzando \nas\u00ed las ra\u00edces espinales dorsales que en su mayor\u00eda \nafecta. La participaci\u00f3n de sustancias nociceptivas \nas\u00ed como los mecanismos inflamatorios involucrados \nen esta patogenia son los causantes principales del \nda\u00f1o neurol\u00f3gico, en algunos casos irreversible que \nproduce el herpes z\u00f3ster7. En el sistema nervioso \nperif\u00e9rico el virus se manifiesta produciendo el t\u00edpico \nexantema y posteriores ves\u00edculas como muestra de la \ninflamaci\u00f3n de los tejidos y las c\u00e9lulas epiteliales. En la \nregi\u00f3n medular, a nivel de los cordones espinales, el \nvirus afecta a las c\u00e9lulas gliales manifestando distintas \nrespuestas, por un lado, la activaci\u00f3n de Nociceptores \ntipo C como causantes de la neuralgia postherp\u00e9tica; \npor otro lado, las distintas respuestas somatosensoriales \nque producen cambios asociados al desarrollo de \nneuralgias postherp\u00e9tica8. Este complejo entramado \nde manifestaciones cl\u00ednicas diversas, complicaciones \nfisiopatol\u00f3gicas que influyen en distintos niveles de \nla esfera psico-social del paciente y la dificultad en el \ncontrol y tratamiento de las distintas presentaciones \ndel dolor asociado a la infecci\u00f3n por herpes z\u00f3ster, \nnos acomete en la necesidad de aunar toda aquella \nliteratura relacionado con estos elementos. El objetivo \nprincipal de este estudio es analizar la relaci\u00f3n entre la 121\n2023/38 (4): 119-124Revisi\u00f3n Sistem\u00e1tica de la relaci\u00f3n entre el dolor por infecci\u00f3n herpes z\u00f3ster y la calidad de vida de los sujetos que viven en la comunidad\ninfecci\u00f3n por herpes z\u00f3ster y su principal manifestaci\u00f3n \nel dolor, con la afectaci\u00f3n en la calidad de vida de \nlos pacientes, ya sea a trav\u00e9s de manifestaciones \npsicol\u00f3gicas (ansiedad y depresi\u00f3n), como f\u00edsicas (dolor \npersistente, alodinia, dolor urente prolongado) mediante \nla consideraci\u00f3n de la literatura presente hasta la fecha \nactual (septiembre 2022). Con ello se pretende: 1. \nExaminar con exactitud la vinculaci\u00f3n existente entre \nambos conceptos , as\u00ed como las caracter\u00edsticas \ncomunes y distintas que los definen. 2. Indagar en \nla relaci\u00f3n e influencia que representa el conjunto de \ns\u00edntomas (objetivos y subjetivos), todos ellos relevantes \nque se incluyen en el t\u00e9rmino neuralgia postherp\u00e9tica, \nen los \u00e1mbitos f\u00edsicos y psicol\u00f3gicos del paciente con \ninfecci\u00f3n por herpes z\u00f3ster. 3. A partir de la integraci\u00f3n \nde dichos t\u00e9rminos, detectar las \u00e1reas necesarias de \nmayor investigaci\u00f3n que permitan llevar a cabo futuras \ninvestigaciones relacionadas..\nMaterial y M\u00e9todos\nCriterios de Inclusi\u00f3n: \n\u00b7 Textos completos escritos en ingl\u00e9s y castellano. \n\u00b7 Localizaci\u00f3n revisi\u00f3n: Europa, Asia, Am\u00e9rica del Sur, \nAustralia y Estados Unidos. \n\u00b7 Estudios incluidos entre 01/01/1995 y 01/09/2022. \n\u00b7 Esta revisi\u00f3n incluye estudios descriptivos \ntransversales, estudios anal\u00edticos observacionales \nde casos y controles y cohortes (retrospectivos \ny prospectivos). Tambi\u00e9n se incluyen revisiones \nbibliogr\u00e1ficas que recopilan la informaci\u00f3n m\u00e1s \nrelevante en este campo de la ciencia y cartas el \neditor que analizan aspectos de estudios publicados \nrecientemente e incluidos en esta revisi\u00f3n. \n\u00b7 Estudios que incluyeron la asociaci\u00f3n entre infecci\u00f3n \npor herpes z\u00f3ster y neuralgia, psicolog\u00eda y dolor, \nsituaci\u00f3n funcional y alodinia en sujetos que presentan \no han presentado infecci\u00f3n por herpes z\u00f3ster. \n\u00b7 Se incluye solo aquellas b\u00fasquedas sobre las bases \nde datos a nivel de texto principal/completo. \nCriterios de Exclusi\u00f3n: \n\u00b7 Estudios que incluyan sujetos inmunodeprimidos \n(neoplasias activas, uso cr\u00f3nico de glucocorticoides, \nenfermedades inmunes en estadios avanzados). \n\u00b7 Estudios que incluyan sujetos con patolog\u00edas \npsiqui\u00e1tricas o neurol\u00f3gicas, que influyan en el \nconsumo de f\u00e1rmacos o drogas (antidepresivos, \nbenzodiazepinas o abuso de analg\u00e9sicos de forma \ncr\u00f3nica). B\u00fasqueda en la literatura. \nLa presente revisi\u00f3n sistem\u00e1tica se ha llevado a cabo \ndurante los meses de julio de 2022 a septiembre de \n2022. Las principales bases de datos empleadas fueron \nPubMed y Cochrane Library. Las b\u00fasquedas bibliogr\u00e1ficas \nse llevaron a cabo en PubMed utilizando la combinaci\u00f3n \nde los siguientes t\u00e9rminos MeSH: \u201cHerpes Zoster/therapy\u201d y \u201cNeuralgia/psychology\u201d. La b\u00fasqueda comenz\u00f3 acotada \na texto completo obteniendo 12 art\u00edculos. Se excluyeron \naquellos que se encontraban duplicados1. \nA continuaci\u00f3n se limit\u00f3 la revisi\u00f3n a aquellos estudios que \nhab\u00edan sido publicados en el periodo estipulado en los \ncriterios de inclusi\u00f3n, incluyendo 10 art\u00edculos, eliminando \n3 porque inclu\u00edan sujetos en tratamiento glucocorticoide \n(uno de los criterios de exclusi\u00f3n) y otro inclu\u00eda pacientes \ncon enfermedades digestivas autoinmunes (enfermedad \ninflamatoria intestinal). Selecci\u00f3n de estudios Con la \naplicaci\u00f3n de los criterios de inclusi\u00f3n/exclusi\u00f3n se \nobtienen 7 art\u00edculos en esta revisi\u00f3n bibliogr\u00e1fica sobre \nherpes z\u00f3ster y neuralgia. \nResultados  \nEn el global de los 7 estudios incluidos en esta revisi\u00f3n \nbibliogr\u00e1fica, 3 corresponden a estudio de cohortes \nobservacionales, prospectivo en todos ellos, 2 cartas \nal editor, 1 estudio descriptivo transversal y 1 revisi\u00f3n \nbibliogr\u00e1fica (Tabla I). \nDiscusi\u00f3n\nEl principal objetivo de esta revisi\u00f3n sistem\u00e1tica, a \npesar de su corta extensi\u00f3n, se observa en la relaci\u00f3n \nbidireccional que presentan el dolor producido durante la \ninfecci\u00f3n por herpes-z\u00f3ster, incluyendo en este t\u00e9rmino \nel dolor que persiste transcurrida la fase aguda o eruptiva, \ny el empeoramiento o repercusi\u00f3n en la calidad de vida \nde los sujetos de la muestra, de forma que a mayor \nintensidad del dolor, peores puntuaciones obtenidas en \nlos distintos cuestionarios relacionados con la calidad de \nvida, los cuales incluyen, factores psicol\u00f3gicos, sociales \ny h\u00e1bitos diarios, que sufren una merma considerable en \nestos pacientes.\n122\n2023/38 (4): 119-124F\u00e1tima Madrona et al. \nTabla I: Caracter\u00edsticas principales de los estudios incluidos.\nPrimer AutorA\u00f1o \npublicaci\u00f3nPeriodo \nde seguimientoCaracter\u00edsticas \nmuestra Material y M\u00e9todos Resultados\nSybille\nDrolet\nJohnson\nCa\u00f1ada-Merino\nOster2018\n2010\n2010\n2009\n20056 meses\n6 meses\nCartas al Editor\nEncuesta/ \nTransversalEdad:\nGrupo Control: \n55.6\u00b113.0 DE\nGrupo Casos: \n55.1\u00b116.0 DE\nSexo (\u03a6/\u03c3): Grupo \nControl: 13/7 Grupo \nCasos 46/28\nEdad: 65.4\u00b1 10.8 DE\nSexo (\u03c3): 109 (41.8 %)\nEdad 77.0 \u00b1 7.2 DE\nSexo \u03a6 59.2 \u03c3 39.5Las pruebas sensoriales \ncuantitativas se\nel protocolo desarrollado por el \nGerman Research Red de Dolor \nNeurop\u00e1tico (DFNS) Inventario \nde Dolor y\nS\u00edntomas Neurop\u00e1ticos (NPSI)\n\u00cdndice de Discapacidad del Dolor \n(PDI), Encuesta de Salud de \nForma Corta (SF-36), y la escala \nde estado de Spielberger\nInventario de Ansiedad\nEstado-Rasgo (STAI), \nrespectivamente.\nZoster Brief Pain Inventory \n(cuestionario de valoraci\u00f3n \nintensidad del dolor producido \ntras 24 horas de aparici\u00f3n de \nlesiones)\nEuroQol EQ-5D (cuestionario de \ncalidad de vida relacionada con\nla salud).\nExisten dos cuestionarios \nespec\u00edficos para evaluar el dolor \ny el disconfort asociados a HZ y \nNPH: Zoster Brief Pain Inventory\ny Zoster Impact Questionnaire.\nVentajas vacunaci\u00f3n frente a \nherpes z\u00f3ster\nIntensidad de dolor: Brief Pain \nInventory Interferencia calidad de \nvida: Brief Pain Inventory\nCuestionario de calidad de vida \nrelacionada con estado de salud: \nEuroQol EQ-5D Consumo de \nf\u00e1rmacos para control del dolor \nneurop\u00e1tico en la semana previa: \ntipo de medicaci\u00f3nHiperestesia mec\u00e1nica y/o alodinia \ncombinada con modificaciones en \nreceptores de detecci\u00f3n t\u00e9rmica, podr\u00eda\npredecir el desarrollo de NPH.\nD\u00e9ficits en \u00e1mbitos f\u00edsicos, calidad \nde vida o s\u00edntomas ansiosos act\u00faan \ncomo factores de riesgo en el dolor \npersistente asociado a NPH.\nEl herpes z\u00f3ster agudo afect\u00f3 \nsignificativamente la calidad de vida y la \nsituaci\u00f3n funcional de los sujetos. \nLa calidad del sue\u00f1o, estado de\n\u00e1nimo , el disfrute de actividades y \nsituaci\u00f3n laboral fueron los \u00e1mbitos \nm\u00e1s afectados.\nLa alodinia est\u00e1 presente en \u226570% de \nlos pacientes y suele ser considerado \ncomo el m\u00e1s angustioso y debilitante \ncomponente NPH.\nExiste una correlaci\u00f3n positiva entre \nel aumento de la intensidad del dolor \ny el alcance del impacto negativo en \nla calidad de vida relacionada con \nenfermedad.\nPacientes con NPH presentan con \nm\u00e1s frecuencia ansiedad, depresi\u00f3n, \ndificultad en la concentraci\u00f3n, \npolifarmacia y conductas suicidas \nrelacionadas con esta patolog\u00eda.\nVacunaci\u00f3n necesaria\nporque protege a sujetos mayores \nde la infecci\u00f3n y su afectaci\u00f3n a la \ncalidad de vida.\nIndicaciones: inmunizaci\u00f3n individuos \nsanos >50 a\u00f1os, y sujetos con \npatolog\u00edas cr\u00f3nicas (diabetes mellitus, \nasma, EPOC, insuficiencia cardiaca, \ncirrosis hep\u00e1tica o enfermedad renal).\nAl tratarse de una vacuna de \nvirus vivos atenuados est\u00e1 \ncontraindicada en embarazo e \ninmunocomprometidos\n51% sujetos de la muestra hab\u00eda \nconsultado al menos en una \nocasi\u00f3n por dolor relacionado con el \ndiagn\u00f3stico de herpes z\u00f3ster con su \nm\u00e9dico, durante el \u00faltimo mes. 50% \nsujetos hab\u00eda consumido medicaci\u00f3n \npara el control del dolor neurop\u00e1tico \nen semana previa, siendo mayoritarios \nopioides (58%), antiepil\u00e9pticos (46%), y \nantidepresivos (35%).\n40% sujetos refiri\u00f3 que el dolor \ninterfer\u00eda de forma moderada- \nseveramente en sus actividades \ndiarias, 45% inform\u00f3 que el dolor influ\u00eda \nde forma severa\nen su estado de \u00e1nimo.123\n2023/38 (4): 119-124Revisi\u00f3n Sistem\u00e1tica de la relaci\u00f3n entre el dolor por infecci\u00f3n herpes z\u00f3ster y la calidad de vida de los sujetos que viven en la comunidad\nPrimer AutorA\u00f1o \npublicaci\u00f3nPeriodo \nde seguimientoCaracter\u00edsticas \nmuestra Material y M\u00e9todos Resultados\nEdad: 70.6\u00b1 2.3 DE\nSexo: \u03a6 63% \u03c3 37%Hampton\nCoplan2005\n2004Cartas al Editor\n6 mesesCaracter\u00edsticas/Factores de \nriesgo del dolor neurop\u00e1tico \npostherp\u00e9tico\nCaracter\u00edsticas del dolor \n(prurito, alodinia, intensidad\u2026), \ninterferencia del dolor en \nactividades diarias: Zoster Brief \nPain Inventory (modificaci\u00f3n del \ncuestionario Brief Pain Inventory \npara dolor y lesiones de herpes \nz\u00f3ster).\nAfectaci\u00f3n de m\u00faltiples dominios \n( mental, social, econ\u00f3mico) \npor dolor: The McGill Pain \nQuestionnaire.\nInfluencia del dolor en calidad de \nvida: EuroQoL.La intensidad del dolor en la fase \naguda predice la aparici\u00f3n de dolor \nneurop\u00e1tico posteriormente.\nSujetos con dolor neurop\u00e1tico \npresentan un da\u00f1o directo sobre los \nnervios perif\u00e9ricos seg\u00fan localizaci\u00f3n \ndel herpes, en comparaci\u00f3n con \naquellos que no desarrollan dolor \nneurop\u00e1tico, pero si ves\u00edculas.\n40% sujetos que no reciben \ntratamiento antiviral en la fase aguda \ndesarrollan dolor.\nDe forma proporcional, a medida que \nseveras eran las puntuaciones en la \nvaloraci\u00f3n del dolor, empeoraba la \npuntuaci\u00f3n en los cuestionarios de \ncalidad de vida, de forma significativa \n(p<0.005). El uso de un cuestionario \nadaptado a la valoraci\u00f3n del dolor por \nherpes (ej. Zoster Brief Pain) es una \nherramienta con validez adecuada, \nespecialmente cuantos peores son las \npuntuaciones (mayor\nintensidad del dolor).\nLos factores de riesgo involucrados en el desarrollo del \ndolor persistente, el denominado dolor postherp\u00e9tico \no dolor neurop\u00e1tico, descritos en esta revisi\u00f3n, y por \ntanto, necesarios para su detecci\u00f3n precoz por parte del \npersonal m\u00e9dico son:\n\u00b7 A mayor intensidad del dolor presente durante la \nfase aguda, es decir, aquella donde la manifestaci\u00f3n \nprincipal son las lesiones cut\u00e1neas vesiculosas, mayor \nriesgo de desarrollar neuralgia postherp\u00e9tica. Esta \nrelaci\u00f3n se observa en la literatura en otros estudios \n(Katz et al., 2004)16.\n\u00b7 Alodinia, es decir, la percepci\u00f3n anormal del dolor, \nante un est\u00edmulo, generalmente t\u00e1ctil o t\u00e9rmico, que, \nen condiciones de ausencia de alodinia, es indoloro; \nrepresenta el s\u00edntoma m\u00e1s frecuente e incapacitante \nen todos los descritos en la neuralgia postherp\u00e9tica17. \nEsto supone una v\u00eda de detecci\u00f3n precoz de aquellos \nsujetos con infecci\u00f3n por herpes z\u00f3ster cuyo riesgo \nde desarrollar empeoramiento en la calidad de vida \nsea mayor.\n\u00b7 La presencia concomitante de ansiedad, depresi\u00f3n, \nedad, conductas suicidas, polifarmacia (\u2265 5 \nf\u00e1rmacos), dificultad en la concentraci\u00f3n, constituyen \nla base fisiopatol\u00f3gica para perpetuar, y por tanto, \npresentan dificultad en el manejo terap\u00e9utico de \nla neuralgia postherp\u00e9tica18. Estos hallazgos se \nencuentran en concordancia con lo ya descrito \npreviamente en la literatura19,20), los cuales observaron \ns\u00edntomas de ansiedad, depresi\u00f3n y conductas \nsuicidas en aquellos sujetos con mayor intensidad del \ndolor postherp\u00e9tico y peores tasas de respuesta al \ntratamiento m\u00e9dico.\u00b7 Respecto al consumo de f\u00e1rmacos, el 50% de las \npersonas que presentan una infecci\u00f3n por herpes \nz\u00f3ster tomar\u00e1n alguna medicaci\u00f3n relacionada para \nel control del dolor, en la \u00faltima semana. Hallazgos \nen concordancia con estudios previos tales como \nDworkin et al21 y Kost et al22.\nLa fortaleza de esta revisi\u00f3n radica en la inclusi\u00f3n de \nestudios realizados sobre poblaci\u00f3n comunitaria, a \ntrav\u00e9s de los cuales podamos obtener conclusiones \ny hallazgos semejantes a los que alcanzar\u00edamos si \nestudi\u00e1semos una cohorte de individuos pertenecientes \na la poblaci\u00f3n general.\nLa principal debilidad de esta revisi\u00f3n radica en la \nexistencia de m\u00faltiples factores involucrados en la \nfisiopatolog\u00eda del dolor, y en este caso, de la neuralgia \npost-herp\u00e9tica, que pueden actuar en algunos casos \ncomo elementos de confusi\u00f3n, tal es el caso, del \nconsumo de f\u00e1rmacos analg\u00e9sicos que en unos estudios \nse consideraba como criterio de exclusi\u00f3n, pero en \notros no, y que conlleva una diversidad en los resultados \nobservados y que han de tomarse con cautela.\nDe los resultados del estudio se pueden obtener las \nsiguientes utilidades:\nEn primer lugar la importancia de detectar aquellos \ns\u00edntomas objetivos o subjetivos que presenten los \npacientes en el momento del diagn\u00f3stico de la infecci\u00f3n \nherp\u00e9tica para poder incluir a estos pacientes en un \ntratamiento terap\u00e9utico m\u00e1s intensivo desde el inicio, \npor ejemplo, con el comienzo de tratamiento con 124\n2023/38 (4): 119-124Revisi\u00f3n Sistem\u00e1tica de la relaci\u00f3n entre el dolor por infecci\u00f3n herpes z\u00f3ster y la calidad de vida de los sujetos que viven en la comunidadF\u00e1tima Madrona et al. \nf\u00e1rmacos m\u00e1s \u00f3ptimos o favorecedores del control \nde la sintomatolog\u00eda, por ejemplo, amitriptilina, en \ncomparaci\u00f3n con el uso exclusivo de antiinflamatorios \nno esteroideos (AINEs).\nEn segundo lugar, ya que el cribado de estos s\u00edntomas \nfavorecedores de neuralgia postherp\u00e9tica es dif\u00edcil, podr\u00eda \nincluirse el uso de aquellos cuestionarios adaptados y \nque han demostrado validez para considerar de forma \nexitosa a esta poblaci\u00f3n, por ejemplo el cuestionario \nZoster Brief Pain.\nEn \u00faltimo lugar, la atenci\u00f3n del dolor debe considerarse \nde forma multidimensional, intentando la inclusi\u00f3n de \nelementos psicol\u00f3gicos y sociales, necesarios para el \nadecuado abordaje sanitario de esta patolog\u00eda cada vez \nm\u00e1s frecuente.Conclusiones\n1. Dolor persistente tras infecci\u00f3n por herpes z\u00f3ster \n(Neuralgia Post-Herp\u00e9tica) est\u00e1 relacionada de forma \ninversamente proporcional con la calidad de vida, de \nforma que, a mayor intensidad del dolor, peor es la \ncalidad de vida de los sujetos de la muestra.\n2. La alodinia representa el s\u00edntoma m\u00e1s frecuente e \nincapacitante en los sujetos que presentan Neuralgia \nPost-Herp\u00e9tica.\n3. La concordancia de elementos diversos, tales como \nansiedad, depresi\u00f3n, conductas suicidas, en el \u00e1mbito \npsicol\u00f3gico, as\u00ed como dificultad para realizar actividades \ndiarias b\u00e1sicas, dificultad para concentraci\u00f3n en el \n\u00e1mbito social, presentan m\u00e1s riesgo de desarrollar \nneuralgia postherp\u00e9tica y con mayor intensidad.\nConflicto de intereses\nLos autores declaran no tener ning\u00fan conflicto de inereses .\nBibliograf\u00eda\n1. Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical \nManifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: \n10.3390/v14020192. PMID: 35215786; PMCID: PMC8876683.\n2. Mareque M, Oyag\u00fcez I, Morano R, Casado MA. Systematic review \nof the evidence on the epidemiology of herpes zoster: incidence in the \ngeneral population and specific subpopulations in Spain. Public Health. \nfebrero de 2019;167:136-46.\n3. Saguil A, Kane S, Mercado M, Lauters R. Herpes Zoster and \nPostherpetic Neuralgia: Prevention and Management. Am Fam \nPhysician. 15 de noviembre de 2017;96(10):656-63.\n4. Gross GE, Eisert L, Doerr HW, Fickenscher H, Knuf M, Maier P , et \nal. S2k guidelines for the diagnosis and treatment of herpes zoster and \npostherpetic neuralgia. JDDG: Journal der Deutschen Dermatologischen \nGesellschaft. enero de 2020;18(1):55-78\n5. Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F et al. Clinical \nand psychosocial correlates of acute pain in herpes zoster. J Clin Virol. \n2007 Apr;38(4):275-9. doi: 10.1016/j.jcv.2007.01.010. Epub 2007 \nMar 6. PMID: 17339131.\n6. Go\u00dfrau G. Postzosterneuralgie [Postherpetic neuralgia]. Nervenarzt. \n2015 Feb;86(2):219-28; quiz 229-30. German. doi: 10.1007/s00115-\n014-4233-1. PMID: 25659844.\n7. Oaklander AL. The pathology of shingles: Head and Campbell\u2019s 1900 \nmonograph. Arch Neurol. 1999 Oct;56(10):1292-4. doi: 10.1001/\narchneur.56.10.1292. PMID: 10520948.\n8. Petersen KL, Rice FL, Farhadi M, Reda H, Rowbotham MC. \nNatural history of cutaneous innervation following herpes zoster. PAIN \n2010;150: 75-82.\n9. Kramer S, Baeumler P , Geber C, Fleckenstein J, Simang M, Haas L \net al. Somatosensory profiles in acute herpes zoster and predictors of \npostherpetic neuralgia. Pain. 2019 Apr;160(4):882-894. doi: 10.1097/j.\npain.0000000000001467. PMID: 30585985.\n10. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman \nMN et al. The impact of herpes zoster and postherpetic neuralgia on \nhealth-related quality of life: a prospective study. CMAJ. 2010 Nov \n9;182(16):1731-6. doi: 10.1503/cmaj.091711. Epub 2010 Oct 4. \nPMID: 20921251; PMCID: PMC2972323.\n11. Johnson RW, Bouhassira D, Kassianos G, Lepl\u00e8ge A, Schmader \nKE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia \non quality-of-life. BMC Med. 2010 Jun 21;8:37. doi: 10.1186/1741-7015-8-37. PMID: 20565946; PMCID: PMC2905321.\n12. Ca\u00f1ada-Merino JL. Herpes Z\u00f3ster y Neuralgia Post Herp\u00e9tica: \nVentajas de la vacunaci\u00f3n. Rev Esp Quimioter 2009;22(Suppl.1): 19-21\n13. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, \nmedication use, and health-related quality of life in older persons with \npostherpetic neuralgia: results from a population-based survey. J Pain. \n2005 Jun;6(6):356-63. doi: 10.1016/j.jpain.2005.01.359. PMID: \n15943957.\n14. Hampton T. When shingles wanes but pain does not: \nresearchers target chronic postherpetic neuralgia. JAMA. 2005 \nMay 25;293(20):2459-60. doi: 10.1001/jama.293.20.2459. PMID: \n15914732.\n15. Coplan PM, Schmader K, Nikas A, et al. Development of a measure \nof the burden of pain due to herpes zoster and postherpetic neuralgia \nfor prevention trials adaptation of the Brief Pain Inventory. J Pain \n2004;5:344-56.\n16. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute \npain in herpes zoster and its impact on health-related quality of life. Clin \nInfect Dis. 1 de agosto de 2004;39(3):342-8.\n17. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic \npain: clinical manifestations andmechanisms. Lancet Neurol \n2014;13:924-35.\n18. Schlereth T, Heiland A, Breimhorst M, Fe\u00b4 chir M, Kern U, Magerl W, \nBirklein F. Association between pain, central sensitization and anxiety in \npostherpetic neuralgia. Eur J Pain 2015;19:193-201.\n19. Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, \nWhitley RJ. Diagnosis and assessment of pain associated with herpes \nzoster and postherpetic neuralgia. J Pain. enero de 2008;9(1 Suppl \n1):S37-44.\n20. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJM, Stalman WAB, \nvan Essen GA. Herpes zoster and postherpetic neuralgia: incidence \nand risk indicators using a general practice research database. Fam \nPract. octubre de 2002;19(5):471-5.\n21. Dworkin RH, Gnann JW Jr, Oaklander AL, Raja SN, Schmader KE, \nWhitley RJ. Diagnosis and assessment of pain associated with herpes \nzoster and postherpetic neuralgia. J Pain. 2008 Jan;9(1 Suppl 1):S37-\n44. doi: 10.1016/j.jpain.2007.10.008. PMID: 18166464.\n22. Kost RG, Straus SE. Postherpetic neuralgia--pathogenesis, treatment, \nand prevention. N Engl J Med. 4 de julio de 1996;335(1):32-42 .125\n2023/38 (4): 125-128ORIGINAL\nEvaluation of dietary habits and nutritional needs \nin women treated for breast cancer in the Balearic Islands\nEvaluaci\u00f3n de los h\u00e1bitos diet\u00e9ticos y las necesidades nutricionales \nen mujeres tratadas por c\u00e1ncer de mama en las Islas Baleares\nMar Nafr\u00eda1      , Antoni Aguil\u00f3-Pons1,2      , Dora Romaguera1,3      , Alice Chaplin1,3      , \nJavier Cort\u00e9s Bordoy4 \n1. Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR). Health Research Institute of the \nBalearic Islands (IdISBa), University Hospital Son Espases (HUSE). Palma de Mallorca, Spain.\n2. Research Group on Evidence, Lifestyles and Health, Department of Nursing and Physiotherapy, Research Institute of Health \nSciences (IUNICS), University of the Balearic Islands, 07122 Palma, Spain\n3. Consorcio CIBER, M.P. Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain .\n4. Real Academia de Medicina de las Islas Baleares. Carrer de Can Campaner, 4. Palma de Mallorca, Spain.eISSN 2255-0569\nReceived: 7 - II - 2023\nAccepted: 9 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.125Corresponding author\nMar Nafr\u00eda Fern\u00e1ndez \nE-mail: mar.nafria@ssib.es \n  \nAbstract \nBreast cancer is the most common cancer in women, with more than 700 cases diagnosed each year in the Balearic Islands. \nThere is extensive evidence that lifestyle factors, such as diet and physical activity, may be associated with the onset of tumour-\nassociated malnutrition, but also with prognosis, mortality and relapse. At the same time, evidence suggests that nutrition strategies \nare often insufficient or non-existent due to lack of resources or infrastructure. The aim of this protocol is to analyse lifestyle factors, \nsuch as dietary habits, physical activity and quality of life, in women treated for breast cancer in the Balearic Islands, as well as to \nevaluate their need of nutritional support. The project proposed consists of a descriptive cross-sectional study in women treated \nfor breast cancer with chemotherapy. The recruitment procedure will be performed in public and private hospitals (n=200) and will \ncomply with current ethical standards and regulations. The strength of this proposal is to establish an objective perspective of the \ncurrent state of nutritional care for breast cancer patients in the Balearic healthcare system, enabling improved future interventions \nin women treated for breast cancer but also in other oncologic patients.\nKeywords: Breast cancer, Nutrition, Quality of Life, Physical Activity, Clinical practice. \nResumen\nEl c\u00e1ncer de mama es el c\u00e1ncer m\u00e1s com\u00fan entre las mujeres, con m\u00e1s de 700 casos diagnosticados cada a\u00f1o en Baleares. \nExiste amplia evidencia de que los factores del estilo de vida, como la dieta y la actividad f\u00edsica, pueden estar asociados con \nla aparici\u00f3n de desnutrici\u00f3n asociada al c\u00e1ncer, pero tambi\u00e9n con el pron\u00f3stico, la mortalidad y la reca\u00edda. Al mismo tiempo, \nla evidencia sugiere que las estrategias de nutrici\u00f3n a menudo son insuficientes o inexistentes debido a la falta de recursos o \ninfraestructura. El presente protocolo tiene como objetivo analizar los factores relacionados con el estilo de vida, como los h\u00e1bitos \nalimentarios, la actividad f\u00edsica y la calidad de vida, en mujeres tratadas por c\u00e1ncer de mama en Baleares, as\u00ed como evaluar su \nnecesidad de apoyo nutricional. El proyecto propuesto consiste en un estudio descriptivo transversal en mujeres tratadas por \nc\u00e1ncer de mama con quimioterapia. El procedimiento de reclutamiento se realizar\u00e1 en hospitales p\u00fablicos y privados (n=200) y \ncumplir\u00e1 con las normas y est\u00e1ndares \u00e9ticos vigentes. La fuerza de esta propuesta es establecer una perspectiva objetiva del \nestado actual de la nutrici\u00f3n en el sistema sanitario balear, que permita futuras intervenciones en mujeres tratadas por c\u00e1ncer de \nmama, pero tambi\u00e9n en otros pacientes oncol\u00f3gicos.\nPalabras clave: C\u00e1ncer de mama, Nutrici\u00f3n, Calidad de vida, Actividad f\u00edsica, Pr\u00e1ctica cl\u00ednica.ID ID ID ID\nID126\n2023/38 (4): 125-128Background\nCancer is one of the most common causes of death \nworldwide, according to the World Health Organization, \naccounting for one in six deaths. In fact, in 2040, the \nnumber of new cancer diagnoses is estimated to reach \n30.2 million with 16.3 million deaths1. Among all cancers, \nbreast cancer is the most common cancer in women2. \nWhen cancer is diagnosed and treatment starts, many \ndistressing events are usually reported, both physical \nand psychological3. Physical symptoms are classified \naccording whether they are hematological alterations, \nsuch as anemia or lymphopenia, and non-hematological, \nincluding anorexia, myalgia or gastrointestinal disorders4. \nMost importantly, any of these symptoms will promote \nmalnutrition and decrease physical function, which will \nultimately have a deteriorating impact on quality of life.\nWomen with obesity and breast cancer also present \nworse quality of life compared to their non-obese \ncounterparts5. Furthermore, it has also been observed \nthat not only malnutrition, but also the fat gain associated \nto breast cancer, are critical prognostic factors for \nmortality and recurrence6,7. \nThere is extensive evidence that lifestyle factors, such \nas diet and physical activity, may be associated with the \nonset of malnutrition in its different forms8,9. Therefore, \ninterventions which monitor adherence to dietary \nrecommendations and promote an increase in physical \nactivity can have a positive impact on quality of life but \nalso on the prognosis and mortality associated to the \ntumour and recurrence rates10-12. \nAt the same time, it is very well established that in the \nhealth systems of many countries nutritional strategies \nfollowing and/or in conjunction with chemotherapy \nare often insufficient or non-existent, due to a lack of \nresources or infrastructure13-16. Furthermore, studies \nreflecting the current status of this service in Spain are \nscarce and thus it can be assumed that there is a blind \nspot in the clinical practices surrounding this situation.\nIn addition, there is little knowledge regarding the dietary \nhabits of women with cancer in the Balearic Islands and \ntherefore it is unknown whether a nutritional support \nintervention would have an impact on their food habits \nand medic development. Nevertheless, studies in women \nwith breast cancer conducted in other populations have \nshown that patients usually modify their regular diet \nduring the course of chemotherapy treatment17,18.\nThus, the main objective of this study is to perform \na nutritional assessment in women diagnosed and \ntreated for breast cancer in the Balearic Islands and \nexplore their need for nutritional support throughout the \nchemotherapy process. Methodology\nStudy design and participants\nThe project proposed is an observational study, with a \ndescriptive cross-sectional design. Study participants \nare women treated for breast cancer at the time of \nchemotherapy treatment. Sample size was calculated in \norder for it to be representative of the Balearic Islands. \nEvery year, more than 700 women are diagnosed with \nbreast cancer in the Balearic Islands16. Of these women, \nnearly 400 have an age range between 45 and 65 years \nold. Therefore, a representative sample was considered \nto be 50% of this major population, resulting in a sample \nsize of approximately 200 participants. The recruitment \nprocedure will be done in public and private hospitals \nduring the period of 2 years. The type of sampling \nperformed will be opportunistic, whereby all subjects will \nhave the same probability of becoming part of the study \nand will be offered to participate. \nA pilot study will be performed, where comprehension \nof the newly developed survey will be conducted, \nand whether all questions are answered. Changes to \nimprove the survey will be applied if necessary. Ethical \napproval for this research project was obtained from \nthe Ethical Committee of Research from the University \nof Balearic Islands (228CER21). The study will be \ncarried out in accordance with the principles of the \nDeclaration of Helsinki and the International Conference \nfor Harmonization.\nQuestionnaire\nIn order to carry out this nutritional assessment, a new \ncomprehensive survey will be developed based on \npreviously validated and published questionnaires \nwhich consider various dimensions (diet, sleep patterns, \nphysical activity, quality of life, sociodemographic factors). \nThe questionnaires used will be: questionnaire MEDAS \nof Adherence to the Mediterranean Diet19, Mini Nutritional \nAssessment20, Subjective global assessment generated \nby the patient (VGS)21, World Health Organization \nQuality of Life Questionnaire (WHOQOL-Bref)22, Patient \nHealth Quality (PHQ9)23 the MOS-Sleep24 and the \nInternational Questionnaire of Physical Activity (IPAQ)25, \nresulting in around 80 questions with an expected time \nof completion of 30 minutes. Furthermore, 9 questions \nregarding adherence to the World Cancer Research \nFund and the American Institute for Cancer Research, \ndietary and lifestyle recommendations were also \nincluded. Thus, the intention of this survey is to capture Table I: Eligibility criteria.\nInclusion criteria Exclusion criteria\nSign the informed consent Terminal clinical situation\nFemale sex Psychiatric condition\nAn established tumour Previous disease that could have  \nhistochemical subtype affected nutritional status\nAge range \u226518 and \u226480 Receive exclusive feeding \n via parenteral nutritionMar Nafr\u00eda et al. 127\n2023/38 (4): 125-128Evaluation of dietary habits and nutritional needs in women treated for breast cancer in the Balearic Islands\nthe following information: 1. Quality of the diet; 2. Current \nnutritional status; 3. Lifestyle behaviours (eating times, \nsleep); 4. Physical activity levels; 5. Perceived quality of \nlife; 6. Influence of sociodemographic factors; 7. Extent \nto which patients have received nutritional counselling \nas well as the quality of counselling. This survey will be \nimplemented by trained nutritionists. \nStatistical Analysis\nStatistical analysis will be performed using Stata \n(StataCorp. 2019. Stata Statistical Software). Firstly, \nan extensive descriptive analysis will be carried out, \nincluding: labelling and purification of the data. Also, \nnormality tests and scatters plots will be done for all \nvariables of interest. In the case that high deviations \nare found, other measures of central tendency will be \nused, such as medians or modes. Secondly, a bivariate \nanalysis will be carried. Outcomes will be compared with \npublished data, nutritional recommendations and with \nquality diet indexes in literature. \nDiscussion\nThe main limitation of this study relates to the cross-\nsectional nature of our analyses and the potential for \nreverse causality bias, and thus it will not be possible to \nassess the dietary changes that typically occur during \nchemotherapy and that are reflected in the scientific \nliterature. Furthermore, is it highly plausible that subjects \nwho perceive themselves at risk or as overweight/obese \nwill be more likely to adopt favorable changes in their \ndiets. Lastly, answers may be biased by memory and \nexpectations of which is the best possible or \u201cheathier\u201d \nanswer (also known as Social desirability bias) and to try \nto sort this limitation, well trained nutritionist interviewers \nwill be part of the project and different dimensions will be \ninquired by various questions. \nThe advancement in modern medicine has meant earlier \ndiagnosis of cancer and an increase in the amount of \navailable medications, radiation and surgical interventions. \nThus, the number of cancer survivors has increased, and \ntherefore the goal of cancer management is no longer \njust to treat the disease but also to reduce the risk of \nfurther morbidity and mortality. By ensuring survivors \ndevelop healthy lifestyle habits, it will be promoted the \nbest possible quality of life in relation to health. \nThe results of this research will allow the understanding \nof the current practices and knowledge related to \nnutrition and oncology in multidisciplinary cooperation \nand, consequently, enable nutritional interventions in \nthe future. It is expected that this study can provide a \ngeneral overview in order to develop more studies or \nnutritional interventions from the start of chemotherapy \nin future years. Funding statement\nThe authors have no conflicts of interest to declare and \nno financial support has been received to carry out this \nstudy.\nAcknowledgements\nWe would like to thank the following individuals for assisting \nin participant recruitment: all the health personnel from \nthe participating hospitals, particularly Maria Cabrera, \nJosefa Terrassa and Antonia Perell\u00f3. 128\n2023/38 (4): 125-128Mar Nafr\u00eda et al. Evaluation of dietary habits and nutritional needs in women treated for breast cancer in the Balearic Islands\nReferences\n1. Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pi\u00f1eros M, Znaor \nA, et al. Cancer statistics for the year 2020: An overview. Int J cancer . \n2021;149(4):778-89. \n2. Ganesan K, Du B, Chen J. Effects and mechanisms of dietary \nbioactive compounds on breast cancer prevention. Pharmacol Res. \n2022 Apr 1;178:105974. \n3. Salas S, Cottet V, Dossus L, Fassier P , Ginhac J, Latino-Martel P , et \nal. Nutritional Factors during and after Cancer: Impacts on Survival and \nQuality of Life. Nutrients. 2022;14(14).\n4. Cancer Institute N. Common Terminology Criteria for Adverse Events \n(CTCAE) Version 4.0 [Internet]. 2009. Available from: http://www.\nmeddramsso.com\n5. Dev R. Measuring cachexia-diagnostic criteria. Ann Palliat Med. \n2019;8(1):24-32. \n6. Salas S, Cottet V, Dossus L, Fassier P , Ginhac J, Latino-Martel P , et \nal. Nutritional Factors during and after Cancer: Impacts on Survival and \nQuality of Life. Nutrients. 2022;14(14). \n7. De O Santos K, Gomes F, Da Silva S, Da Silva A, Pinho C. \nSarcopenia in oncological patients in chemotherapy treatment. Rev Chil \nNutr. 2019;46(4):375-83. \n8. Guigni B, Callahan D, Tourville T, Miller M, Fiske B, Voigt T, et al. \nSkeletal muscle atrophy and dysfunction in breast cancer patients: Role \nfor chemotherapy-derived oxidant stress. Am J Physiol - Cell Physiol. \n2018 Nov 1;315(5):744-56. \n9. Ballinger TJ, Reddy A, Althouse SK, Nelson EM, Miller KD, Sledge JS. \nImpact of primary breast cancer therapy on energetic capacity and body \ncomposition. Breast Cancer Res Treat. 2018 Nov 1;172(2):445-52 . \n10. Mantzorou M, Tolia M, Poultsidi A, Vasios G, Papandreou D, \nTheocharis S, et al. Adherence to Mediterranean Diet and Nutritional \nStatus in Women with Breast Cancer: What Is Their Impact on Disease \nProgression and Recurrence-Free Patients\u2019 Survival? Curr Oncol. \n2022;29(10):7482-97. \n11. Castro-Espin C, Agudo A. The Role of Diet in Prognosis among \nCancer Survivors: A Systematic Review and Meta-Analysis of Dietary \nPatterns and Diet Interventions. Nutrients. 2022;14(2). \n12. Lach K, Peterson SJ. Nutrition Support for Critically Ill Patients With \nCancer. Nutr Clin Pract. 2017;32(5):578-86. \n13. Keaver L, O\u2019Callaghan N, Douglas P . Nutrition support and \nintervention preferences of cancer survivors. J Hum Nutr Diet. 2022.14. S\u00e1nchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. \nGastrointestinal symptoms and weight loss in cancer patients receiving \nchemotherapy. Br J Nutr. 2013 Mar 14;109(5):894-7. \n15. Smith SL, Singh-Carlson S, Downie L, Payeur N, Wai ES. Survivors \nof breast cancer: Patient perspectives on survivorship care planning. J \nCancer Surviv. 2011 Dec 4;5(4):337-44. \n16. Nutrition in Cancer Care (PDQ\u00ae): Patient Version. www.cancer.gov. \n2022. p. 26389440. \n17. Pedersini R, Di Mauro P , Bosio S, Zanini B, Zanini A, Amoroso V, \net al. Changes in eating habits and food preferences in breast cancer \npatients undergoing adjuvant chemotherapy. Sci Rep. 2021 Jun \n21;11(1):12975. \n18. Carlucci Palazzo C, Cremonezi Japur C, Borges de Ara\u00fajo L, Diez-\nGarcia RW. Eating Experiences, Sweet Preference, and Weight Gain \nin Women During Chemotherapy for Breast Cancer: A Mixed Methods \nStudy. Nutr Cancer. 2019;71(4):594-604. \n19. \u00c1lvarez-\u00c1lvarez I, Mart\u00ednez-Gonz\u00e1lez M\u00c1, S\u00e1nchez-Tainta A, Corella \nD, D\u00edaz-L\u00f3pez A, Fit\u00f3 M, et al. Adherence to an Energy-restricted \nMediterranean Diet Score and Prevalence of Cardiovascular Risk \nFactors in the PREDIMED-Plus: A Cross-sectional Study. Rev Esp \nCardiol (Engl Ed). 2019;72(11):925-34. \n20. Salv\u00e0 Casanovas A. El Mini Nutritional Assessment. Veinte a\u00f1os \nde desarrollo ayudando a la valoraci\u00f3n nutricional. Rev Esp Geriatr \nGerontol. 2012 Nov;47(6):245-6. \n21. De Groot LM, Lee G, Ackerie A, van der Meij BS. Malnutrition \nScreening and Assessment in the Cancer Care Ambulatory Setting: \nMortality Predictability and Validity of the Patient-Generated Subjective \nGlobal Assessment Short form (PG-SGA SF) and the GLIM Criteria. \nNutrients. 2020;12(8):1-13. \n22. Aydin M, Kose E, Odabas I, Bingul BM, Demirci D, Aydin Z. The \nEffect of Exercise on Life Quality and Depression Levels of Breast \nCancer Patients. Asian Pac J Cancer Prev. 2021;22(3):725-32. \n23. Costantini L, Pasquarella C, Odone A, Colucci ME, Costanza A, \nSerafini G, et al. Screening for depression in primary care with Patient \nHealth Questionnaire-9 (PHQ-9): A systematic review. J Affect Disord. \n2021;279:473-83.\n24. Oliva D, Andersson B-\u00c5, Lewin F, Jensen LD. Opposing inflammatory \nbiomarker responses to sleep disruption in cancer patients before and \nduring oncological therapy. Front Neurosci. 2022 Sep 21;16. \n25. Mantilla Toloza SC, G\u00f3mez-Conesa A. El Cuestionario Internacional \nde Actividad F\u00edsica. Un instrumento adecuado en el seguimiento de \nla actividad f\u00edsica poblacional. Vol. 10, Revista Iberoamericana de \nFisioterapia y Kinesiologia. Ediciones Doyma, S.L.; 2007. p. 48-52. 129\n2023/38 (4): 129-135ORIGINAL\nVariables influencing the appearance of metabolic syndrome \nwith three different definitions in 418.343 spanish workers\nVariables que influyen en la aparici\u00f3n del s\u00edndrome metab\u00f3lico \ncon tres definiciones diferentes en 418.343 trabajadores espa\u00f1oles  \nAndr\u00e9s Mart\u00ednez Jover1      , \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez1      , Pilar Tom\u00e1s Gil1      ,\nJosep Lluis Coll Villalonga1      , Pau Mart\u00ed Lliteras1      , Jos\u00e9 Ignacio Ram\u00edrez Manent1,2      \n1. Grupo ADEMA-SALUD IUNICS University of the Balearic Islands. Spain.\n2. Mallorca Primary Care eISSN 2255-0569\nReceived: 9 - II - 2023\nAccepted: 10 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.129Corresponding author\n\u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez \nE-mail: angarturo@gmail.com  \nAbstract \nIntroduction: Metabolic syndrome (MS) is a clinical entity whose prevalence is increasing worldwide. It is a multifactorial condition \nthat increases cardiovascular risk. The aim of this study is to assess the influence of sociodemographic variables and healthy habits \non the appearance of MS. \nMaterial and methods: Descriptive and cross-sectional study in 418.343 Spanish workers in which the influence of sex, age, \nsocial class, educational level, physical activity, adherence to the Mediterranean diet and tobacco consumption on the prevalence \nof metabolic syndrome was assessed by applying three different criteria: NCEP ATPIII, IDF and JIS. \nResults: Multivariate analysis showed that the variables that most increased the risk of presenting MS were sedentary lifestyle, low \nadherence to the Mediterranean diet and age. Of all the variables analyzed, the only one that showed no influence was social class. \nConclusions: In our study, all the variables analyzed except social class increased the risk of MS, of which the most influential were \nlow physical activity, low adherence to the Mediterranean diet, and age.\nKeywords: Metabolic syndrome, physical activity, adherence to the Mediterranean diet. \nResumen\nIntroducci\u00f3n: El s\u00edndrome metab\u00f3lico (SM) es una entidad cl\u00ednica que va aumentando su prevalencia en el mundo. Es un cuadro \nmultifactorial que incrementa el riesgo cardiovascular. El objetivo de este estudio es valorar la influencia de variables sociodemo-\ngr\u00e1ficas y h\u00e1bitos saludables en la aparici\u00f3n de SM. \nMaterial y m\u00e9todos: Estudio descriptivo y transversal en 418.343 trabajadores espa\u00f1oles en los que se valora la influencia del \nsexo, la edad, la clase social, el nivel de estudios, la actividad f\u00edsica, la adherencia a la dieta mediterr\u00e1nea y el consumo de tabaco \nen la prevalencia de s\u00edndrome metab\u00f3lico determinado aplicando tres criterios diferentes: NCEP ATPIII, IDF y JIS. \nResultados: En el an\u00e1lisis multivariante se observa que las variables que m\u00e1s incrementan el riesgo de presentar SM son el \nsedentarismo, la baja adherencia a la dieta mediterr\u00e1nea y la edad. De todas las variables analizadas la \u00fanica que no muestra \ninfluencia es la clase social. \nConclusiones: En nuestro estudio todas las variables analizadas salvo la clase social incrementan el riesgo de SM, de ellas las \nque m\u00e1s influyen son la baja actividad f\u00edsica, la escas adherencia a la dieta mediterr\u00e1nea y la edad.\nPalabras clave: S\u00edndrome metab\u00f3lico, actividad f\u00edsica, adherencia a la dieta mediterr\u00e1nea.ID\nID ID IDID ID130\n2023/38 (4): 129-135Andr\u00e9s Mart\u00ednez Jover et al. \nIntroduction\nMetabolic syndrome (MS) is a clinical entity that \ngroups together in the same person different metabolic \nalterations such as abdominal obesity, elevated \ntriglycerides, lower HDL cholesterol, increased blood \npressure and hyperglycemia1. \nMS is currently considered one of the most important \npublic health problems2. Its presence is five times \nthe prevalence of diabetes mellitus3 and almost three \ntimes the prevalence of cardiovascular disease4, which \ntranslates into a significant increase in health care costs \nworldwide5.\nMS has been known for a century thanks to the studies \nof Kylin in Sweden6. Since this first approach to the \nproblem, which included hypertension, hyperglycemia \nand gout, there have been different definitions. \nCurrently, the most commonly used criteria are those \nof the National Cholesterol Education Program-Adult \nTreatment Panel III (NCEP-ATP-III)7 and those of the \nInternational Diabetes Federation (IDF)7.\nMany risk factors have been associated with the \nappearance of MS, including advanced age8, low \nsocioeconomic level9, family history10, genetics11, \nobesity12, polycystic ovary13, psoriasis14, sleep \ndisorders15, and sarcopenia16, among others.\nThe aim of this study was to assess whether there is \nan association between the appearance of MS (applying \nthree different criteria) and different sociodemographic \nvariables (age, sex, social class, and level of education) \nand healthy habits (physical activity, adherence to the \nMediterranean diet, and tobacco consumption).\nMethods\nA descriptive and cross-sectional study was carried out \nin 418343 workers from different regions of Spain and \nfrom different labor sectors, mostly public administration, \nhealth, construction and commerce. The workers were \nselected from those who attended the periodic medical \nexaminations of the companies January 2017 and \nDecember 2019. \nInclusion criteria:\n- Age between 18 and 67 years. \n- Working in one of the companies included in the \nstudy. \n- Not being in a situation of temporary disability.\n- Sign informed consent to participate in the study \nand to use their data for epidemiological purposes.Measurements and data collection\nDifferent anthropometric and analytical parameters were \nmeasured in the people who participated in the study.\nThe anthropometric, clinical and analytical determinations \nwere performed by the occupational health professionals \nof the companies, after standardization of the different \nmeasurement techniques.\nWeight and height were obtained from the SECA model \nscale-measuring scale. Waist circumference (WC) was \nmeasured while standing upright, feet together, trunk \nstraight and abdomen relaxed. The measuring tape was \nplaced parallel to the floor at the level of the last floating rib.\nBlood pressure was obtained with a calibrated OMRON \nM3 automatic sphygmomanometer while seated and \nafter at least 10 minutes of rest. Three determinations \nwere made at one-minute intervals and the mean of the \nthree was obtained. Blood parameters were obtained \nafter at least 12h of fasting. Samples were processed \nin reference laboratories within 48-72 hours. Glycemia, \ntotal cholesterol and triglycerides were determined by \nautomated enzymatic methods. HDL-c was determined \nby a precipitation process with dextran sulfate-MgCl2. \nLDL-c was calculated indirectly by applying the \nFriedewald formula, which is valid for triglyceride values \nbelow 400 mg/dL. All these parameters are expressed \nin mg/dL.\nFriedewald formula: LDL = cholesterol - HDL - \ntriglycerides/5\nFive age groups were established: 18 to 29 years, 30 to 39 \nyears, 40 to 49 years, 50 to 59 years, and 60 to 67 years.Figure 1: Flow diagram of the study participants.\n421.625 workers start the study\n656 do not agree to participate\n1897 lack any variable \nto calculate the CVR\n418,343 (246,061 men and 172,282 \nwomen) finally entered the study729 are under 18 or over 67 years old131\n2023/38 (4): 129-135Variables influencing the appearance of metabolic syndrome with three different definitions in 418.343 spanish workers \nSocial class was obtained from the proposal of the \nsocial determinants group of the Spanish Society of \nEpidemiology17. Three categories were considered: Class \nI: directors/managers, university professionals, sportsmen \nand artists; Class II: intermediate occupations and skilled \nself-employed workers; Class III: unskilled workers.\nThe level of education was classified as primary or \nelementary, secondary and university. We considered \nsmokers to be those who had consumed at least \none cigarette daily (or its equivalent in other types of \nconsumption) during the last month, or had quit smoking \nless than 12 months before. \nHeart-healthy eating habits are determined with the \n\u201cMediterranean diet adherence questionnaire\u201d used in \nthe PREDIMED study18. The questionnaire consists of 14 \nquestions that are scored with 0 and 1 point. Values of 9 \nor more indicate good adherence and therefore that the \ndiet is heart-healthy.\nPhysical activity is assessed with the International \nPhysical Activity Questionnaire (IPAQ), which evaluates \nthe physical activity performed in the last week19. \n19 To assess the metabolic syndrome (MS), we used \n3 different criteria, those of the National Cholesterol \nEducation Program Adult Treatment Panel III (NCEP/ATP-\nIII), the Joint Interim Statement (JIS) and the update of the \nInternational Diabetes Federation (IDF)20. \nStatistical analysis\nA descriptive analysis of the categorical variables was \nperformed, calculating the frequency and distribution of \nthe responses for each of them. For quantitative variables, \nthe mean and standard deviation were calculated \nfollowing a normal distribution.\nBivariate association analysis was performed using \nthe chi2 test (with correction for Fisher\u2019s exact statistic \nwhen conditions required it) and Student\u2019s t test for \nindependent samples (for comparison of means). \nMultivariate techniques were used to establish the \nvariables associated with the most significant risk \nfactors. Multinomial logistic regression was used for \nmultivariate analysis, with calculation of the odds ratio \nand the Hosmer-Lemeshow goodness-of-fit test. \nStatistical analysis was performed with the Statistical \nPackage for the Social Sciences (SPSS) version 28.0 \n(IBM Company, New York, NY, USA) for Windows, with \nan accepted statistical significance level of 0.05.\nEthical considerations and/or aspects\nThe research team undertook at all times to follow \nthe ethical principles of health sciences research \nestablished nationally and internationally (Declaration of \nHelsinki), paying special attention to the anonymity of the \nparticipants and the confidentiality of the data collected. Approval was requested from the Ethics and Research \nCommittee of the Balearic Islands (CEI-IB), which was \nobtained with indicator IB 4383/20. Participation in \nthe study was voluntary, so the participants gave their \nwritten and oral consent to participate in the study \nafter receiving sufficient information about the nature \nof the study. To this end, they were given an informed \nconsent form, as well as an information sheet explaining \nthe objective of the study. The data collected for the \nstudy were identified by a code and only the person \nresponsible for the study can relate these data to the \nparticipants. The identity of the participants will not be \ndisclosed in any report of this study. The investigators \nwill not disseminate any information that could identify \nthem. In any case, the research team undertakes \nto strictly comply with the Organic Law 3/2018, of \nDecember 5, on the protection of personal data and \nguarantee of digital rights, guaranteeing the participant \nin this study that he/she may exercise his/her rights of \naccess, rectification, cancellation and opposition of the \ndata collected.\nResults\nTable I shows the anthropometric and clinical \ncharacteristics of the 418.343 (246.061 men and \n172.282 women) persons included in the study. \nThe mean age of the sample was 40.2 \u00b1 11.0 years, \nthe largest group being between 30 and 49 years. \nAnthropometric, clinical and analytical values were more \nunfavorable in men. Most people belonged to social \nclass III and had primary education. More than half of \nthem do not engage in regular physical activity and do \nnot have a heart-healthy diet. One out of three workers \nsmoked.\nTable II shows the prevalence of metabolic syndrome, \napplying the three criteria, according to the different \nsociodemographic variables and healthy habits. The \nprevalence, applying any of the criteria, increases with \nage, as one descends in social class or level of education. \nSmokers, sedentary people or those with low adherence \nto the Mediterranean diet have higher prevalences of \nMS. In all cases, the prevalence of MS is higher in men.\nTable III shows the results of the multivariate analysis \nusing multinomial logistic regression. The risk of \npresenting metabolic syndrome with the three criteria is \ngreater in men, with increasing age, in people with a lower \nlevel of education, in sedentary people, in those with low \nadherence to the Mediterranean diet, and in smokers. \nThe variables that most increase the risk of presenting \nMS are sedentary lifestyle, followed by diet and age. It \nshould be noted that social class showed no effect on \nthe appearance of MS.132\n2023/38 (4): 129-135Andr\u00e9s Mart\u00ednez Jover et al. \nSBP systolic bllood pressure. DBP diastolic blood pressure.Table I: Characteristics of the population.\n  Women Men Total  \n n=172.282 n=246.061 n=418.343 \n Mean \u00b1 SD Mean \u00b1 SD Mean \u00b1 SD p-value\nAge 39.6 (10.8) 40.6 (11.1) 40.2 (11.0) <0.0001\nHeight 161.8 (6.5) 174.6 (7.0) 169.4 (9.3) <0.0001\nWeight 66.2 (14.0) 81.4 (14.7) 75.1 (16.2) <0.0001\nBMI 25.3 (5.2) 26.7 (4.5) 26.1 (4.8) <0.0001\nWaist 74.8 (10.6) 86.2 (11.1) 81.5 (12.2) <0.0001\nSBP 117.4 (15.7) 128.2 (15.5) 123.7 (16.5) <0.0001\nDBP 72.6 (10.4) 77.8 (11.0) 75.6 (11.0) <0.0001\nCholesterol 190.6 (35.8) 192.6 (38.9) 191.8 (37.7) <0.0001\nHDL-c 56.8 (8.7) 50.3 (8.5) 53.0 (9.1) <0.0001\nLDL-c 116.1 (34.8) 118.0 (36.7) 117.2 (35.9) <0.0001\nTriglycerides 89.1 (46.2) 123.7 (86.4) 109.5 (74.6) <0.0001\nGlycaemia  87.8 (15.1) 93.3 (21.3) 91.0 (19.2) <0.0001\n  % % % p-value\n18-29 years 20.7 18.8 19.6 <0.0001\n30-39 years 3.0 27.6 17.4 \n40-49 years 29.6 30.0 29.9 \n50-59 years 16.8 19.7 18.5 \n60-69 years 3.2 3.9 3.6 \nPrimary school 51.8 61.2 57.3 <0.0001\nSecondary school 40.7 34.0 36.8 \nUniversity 7.5 4.8 5.9 \nSocial class I 6.9 4.9 5.7 <0.0001\nSocial class II 23.4 14.9 18.4 \nSocial class III 69.7 80.3 75.9 \nNo physical activity 47.8 54.5 51.7 <0.0001\nYes physical activity 52.2 45.5 48.3 \nNo mediterranean diet 48.6 59.0 54.7 <0.0001\nYes mediterranean diet 51.4 41.0 45.3 \nNon-smokers 67.2 66.6 66.8 <0.0001\nSmokers 32.8 33.4 33.2  \nTable II: Prevalence of metabolic syndrome with different criteria according to sociodemographic variables and healthy habits.\n  Women ATPIII   IDF   JIS   Men ATPIII   IDF   JIS \n  n % p-value % p-value % p-value n % p-value % p-value % p-value\n18-29 years 35617 0.86 <0.0001 1.39 <0.0001 1.77 <0.0001 46215 2.79 <0.0001 4.08 <0.0001 3.79 <0.0001\n30-39 years 5115 1.99  2.69  3.13  67798 6.31  8.32  8.16 \n40-49 years 51017 4.19  5.40  7.01  73935 11.51  14.70  14.92 \n50-59 years 28951 9.15  7.93  13.13  48522 14.68  19.00  20.20 \n60-69 years 5582 12.63  9.98  18.33  9591 14.48  21.44  24.06 \nPrimary school 89221 4.63 <0.0001 5.16 <0.0001 7.40 <0.0001 150602 9.40 <0.0001 12.20 <0.0001 12.51 <0.0001\nSecondary school 70082 2.97  3.37  4.56  83734 8.09  10.86  10.88 \nUniversity 12979 2.27  2.34  3.10  11725 6.92  9.01  9.81 \nSocial class I 11894 2.46 <0.0001 2.38 <0.0001 3.20 <0.0001 11950 6.85 <0.0001 9.07 <0.0001 9.72 <0.0001\nSocial class II 40266 2.98  3.36  4.58  36590 7.97  10.90  10.77 \nSocial class III 120122 4.38  4.92  6.98  197521 9.17  11.92  12.21 \nNo physical activity 82373 7.71 <0.0001 8.63 <0.0001 11.99 <0.0001 134023 16.22 <0.0001 20.71 <0.0001 21.42 <0.0001\nYes physical activity 89909 0.68  0.71  0.78  112038 1.13  1.68  1.69 \nNo mediterranean diet 83651 7.57 <0.0001 8.48 <0.0001 11.76 <0.0001 145286 14.91 <0.0001 19.09 <0.0001 19.70 <0.0001\nYes mediterranean diet 88631 0.71  0.74  0.81  100775 1.92  2.04  1.89 \nNon-smokers 115727 3.77 <0.0001 4.15 <0.0001 5.76 <0.0001 163920 7.35 <0.0001 10.75 <0.0001 10.19 <0.0001\nSmokers 56555 3.81   4.38   6.23   82141 11.36   13.02   14.60  \nTotal 172282 3.78   4.22   5.92   246061 8.84   11.59   11.83  133\n2023/38 (4): 129-135Variables influencing the appearance of metabolic syndrome with three different definitions in 418.343 spanish workers \nTable III: Multinomial logistic regression.\n  NCEP-ATPIII IDF JIS\n  OR (95% CI) OR (95% CI) OR (95% CI)\nWomen 1 1 1\nMen 2.07 (1.98-2.17) 2.62 (2.51-2.73) 1.83 (1.76-1.90)\n18-29 years 1 1 1\n30-39 years 1.11 (1.02-1.21) 1.18 (1.09-1.28) 1.34 (1.25-1.45)\n40-49 years 1.43 (1.32-1.56) 1.39 (1.28-1.50) 1.81 (1.68-1.94)\n50-59 years 2.13 (1.95-2.33) 2.04 (1.88-2.21) 2.83 (2.62-3.05)\n60-69 years 3.50 (3.13-3.91) 3.01 (2.73-3.32) 4.32 (3.94-4.75)\nPrimary school 1 1 1\nSecondary school 1.17 (1.11-1.24) 1.16 (1.11-1.22) 1.19 (1.13-1.25)\nUniversity 1.43 (1.14-1.789) 1.45 (1.19-1.78) 1.46 (1.20-1.77)\nSocial class I 1 1 1\nSocial class II 46.44 (35.80-60.23) 13.83 (12.12-15.77) 18.45 (16.05-21.22)\nSocial class III 1 1 1\nNo physical activity 5.37 (4.38-6.58) 3.25 (2.86-3.70) 3.73 (3.27-4.24)\nYes physical activity 1 1 1\nNo mediterranean diet 1.73 (1.67-1.80) 1.39 (1.34-1.44) 1.69 (1.64-1.75)\nDiscussion\nAll the sociodemographic variables analyzed, with the \nexception of social class, influence the appearance of \nMS applying any of the three criteria. Smoking, level of \nphysical activity and adherence to the Mediterranean \ndiet also have an influence. Of these, the one that most \nincreases the risk of MS is sedentary lifestyle, followed by \nlow adherence to the Mediterranean diet and age.\nIn our study, the prevalence of MS is considerably higher in \nmen with the three scales and in all age groups, although \nthe differences become smaller as age increases. This \ndata partially coincide with those found in a review by \nPucci et al21, since in this study the prevalence in women \nexceeds that of men after the age of 50 years, that is, \nafter menopause. The explanation given by the authors \nis that this is due to several factors, some related to sex \nand others to gender. Those related to sex are due to \nhyperandrogenism, insulin resistance and the associated \nincrease in abdominal obesity and reduction of HDL \ncholesterol that appears after menopause. Those related \nto gender are sensitive to social and cultural behaviors, \ndietary habits and psychosocial factors. Women are \nmore likely than men to develop MS in response to work \nstress and low socioeconomic status. The negative \neffect of menopause on the prevalence of MS was also \nhighlighted in a meta-analysis by Pu et al22 in which the \nmain conclusion was that menopause negatively affects \nall components of MS. Similar results were found in \nanother meta-analysis by Hallajzadeh et al23.\nOur work shows the negative effect of more unfavorable \nsocioeconomic levels on the prevalence of MS. A study \ncarried out in a Mexican population by Bustamante-\nVillag\u00f3mez et al24 in which the influence of quality of \nlife and socioeconomic status on MS was assessed \nshowed that lower quality of life and low socioeconomic status increased the risk of MS; however, if quality of life \nwas improved, the negative effect of low socioeconomic \nstatus on MS could be diminished. A study by Zhan \net al25 in the Chinese population found an association \nbetween lower levels of income and education and a \nhigher prevalence of MS, although statistical significance \nwas only found in women. In the Iranian population, \nGharipour et al26 also found a higher prevalence of MS in \npersons with lower socioeconomic levels.\nOur study has shown the negative effect of smoking, \nsedentary lifestyle, and low adherence to the \nMediterranean diet on the prevalence of MS.\nThere is unanimity in considering the beneficial effect \nof physical activity on MS, and both observational and \ninterventional studies suggest this protective role. Each \nof the components of MS is, to some extent, favorably \ninfluenced by interventions that include physical activity27-29.\nThere is also unanimity on the beneficial effect of the \nMediterranean diet on MS. The Mediterranean diet \ncan be considered a therapy for MS as it prevents the \nformation of abnormal fat30-32.\nThe negative effect of smoking on MS observed \nin our study was also seen in a study in Palestinian \nadolescents by Damiri et al33. Another study by \nBermudez et al34 in more than 2000 Venezuelan adults \nof both sexes showed that smoking was associated \nwith lower HDL values, increased waist circumference \nand elevated triglycerides. \nStrengths and limitations\nThe strengths of the study include the large sample size \n(more than 400,000 workers) and the variety of metabolic 134\n2023/38 (4): 129-135Andr\u00e9s Mart\u00ednez Jover et al. \nsyndrome criteria, sociodemographic variables and \nhealthy habits used. Among the possible limitations, we \nwould point out that the study was carried out in the 18-\n67 age group (working population), which could prevent \nextrapolation of the results to the entire population. In \naddition, there may be a sample selection bias since the \nstudy included people who go for occupational medical \ncheck-ups, so that they could be people who are more \nconcerned about their health.Conclusions\nMale sex, age, educational level, physical activity, \nadherence to the Mediterranean diet, and tobacco \nconsumption influence the appearance of MS applying any \nof the three criteria. Social class has shown no influence.\nConflict of Interest\nThe authors declare that no competing interests exist.\nReferences\n1. Engin A. The Definition and Prevalence of Obesity and Metabolic \nSyndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-\n319-48382-5_1. \n2. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr \nHypertens Rep. 2018 Feb 26;20(2):12. doi: 10.1007/s11906-018-\n0812-z. \n3. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and \nhyperuricemia. Curr Opin Rheumatol. 2013 Mar;25(2):210-6. doi: \n10.1097/BOR.0b013e32835d951e.\n4. Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome \nPathophysiology and Predisposing Factors. Int J Sports Med. 2021 \nMar;42(3):199-214. doi: 10.1055/a-1263-0898.\n5. Xu H, Li X, Adams H, Kubena K, Guo S. Etiology of Metabolic \nSyndrome and Dietary Intervention. Int J Mol Sci. 2018 Dec \n31;20(1):128. doi: 10.3390/ijms20010128.\n6. Alberti G. Introduction to the metabolic s\u00edndrome.  European \nHeart Journal Supplements 2005; (7 suppl D) :D3\u2013D5, https://doi.\norg/10.1093/eurheartj/sui021\n7. Gundogan K, Bayram F, Gedik V, Kaya A, Karaman A, Demir O, et al. \nMetabolic syndrome prevalence according to ATP III and IDF criteria and \nrelated factors in Turkish adults. Arch Med Sci. 2013 Apr 20;9(2):243-\n53. doi: 10.5114/aoms.2013.34560. \n8. Assuncao N, Sudo FK, Drummond C, de Felice FG, Mattos P . \nMetabolic Syndrome and cognitive decline in the elderly: A systematic \nreview. PLoS One. 2018 Mar 26;13(3):e0194990. doi: 10.1371/\njournal.pone.0194990.\n9. Chen MS, Chiu CH, Chen SH. Risk assessment of metabolic \nsyndrome prevalence involving sedentary occupations and \nsocioeconomic status. BMJ Open. 2021 Dec 13;11(12):e042802. doi: \n10.1136/bmjopen-2020-042802. \n10. Yao F, Bo Y, Zhao L, Li Y, Ju L, Fang H, et al. Prevalence and \nInfluencing Factors of Metabolic Syndrome among Adults in China from \n2015 to 2017. Nutrients. 2021 Dec 15;13(12):4475. doi: 10.3390/\nnu13124475.\n11. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, \nBouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology \nand Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: \n10.3390/ijms23020786.12. Litwin M, Ku\u0142aga Z. Obesity, metabolic syndrome, and primary \nhypertension. Pediatr Nephrol. 2021 Apr;36(4):825-37. doi: 10.1007/\ns00467-020-04579-3. \n13. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, \nJoham AE, et al. Metabolic syndrome in polycystic ovary syndrome: \na systematic review, meta-analysis and meta-regression. Obes Rev. \n2019 Feb;20(2):339-52. doi: 10.1111/obr.12762. \n14. Hao Y, Zhu YJ, Zou S, Zhou P , Hu YW, Zhao QX, et al. Metabolic \nSyndrome and Psoriasis: Mechanisms and Future Directions. Front \nImmunol. 2021 Jul 23;12:711060. doi: 10.3389/fimmu.2021.711060.\n15. Smiley A, King D, Bidulescu A. The Association between Sleep \nDuration and Metabolic Syndrome: The NHANES 2013/2014. Nutrients. \n2019 Oct 26;11(11):2582. doi: 10.3390/nu11112582.\n16. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic \nSyndrome and Sarcopenia. Nutrients. 2021 Oct 7;13(10):3519. doi: \n10.3390/nu13103519\n17. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, \nFerrando J, Borrell C, et al. Propuestas de clase social neoweberiana \ny neomarxista a partir de la Clasificaci\u00f3n Nacional de Ocupaciones \n2011. Gac Sanit. 2013 May-Jun;27(3):263-72. doi: 10.1016/j.\ngaceta.2012.12.009.\n18. Ros E. The PREDIMED study. Endocrinol Diabetes Nutr. 2017 \nFeb;64(2):63-6.\n19. Sember V, Meh K, Sori\u0107 M, Starc G, Rocha P , Jurak G. Validity \nand Reliability of International Physical Activity Questionnaires for Adults \nacross EU Countries: Systematic Review and Meta Analysis. Int J \nEnviron Res Public Health. 2020 Sep 30;17(19):7161.\n20. Riutord-Sbert P , Riutord-Fe B, Riutord-Fe-N, Arroyo-Bote S, L\u00f3pez-\nGonz\u00e1lez AA, Ramirez-Manent JI. Relationship between physical activity \nand adherence to the mediterranean diet with metabolic syndrome, \nhypertriglyceridemic waist phenotype and hypertensive waist. Medicina \nBalear 2022;37(6):33-8. doi: 10.3306/AJHS.2022.37.06.33\n21. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. \nSex- and gender-related prevalence, cardiovascular risk and therapeutic \napproach in metabolic syndrome: A review of the literature. Pharmacol \nRes. 2017 Jun;120:34-42. doi: 10.1016/j.phrs.2017.03.008.\n22. Pu D, Tan R, Yu Q, Wu J. Metabolic syndrome in menopause and \nassociated factors: a meta-analysis. Climacteric. 2017 Dec;20(6):583-\n91. doi: 10.1080/13697137.2017.1386649.135\n2023/38 (4): 129-135Variables influencing the appearance of metabolic syndrome with three different definitions in 418.343 spanish workers \n23. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-\nHashiani A, Ayubi E, et al. Metabolic syndrome and its components \nin premenopausal and postmenopausal women: a comprehensive \nsystematic review and meta-analysis on observational studies. \nMenopause. 2018 Oct;25(10):1155-64. doi: 10.1097/\nGME.0000000000001136.\n24. Bustamante-Villag\u00f3mez SK, V\u00e1squez-Alvarez S, Gonzalez-Mejia \nME, Porchia LM, Herrera-Fomperosa O, Torres-Rasgado E, et al. \nAsociaci\u00f3n entre s\u00edndrome metab\u00f3lico, nivel socioecon\u00f3mico y calidad \nde vida en mexicanos. Rev Med Inst Mex Seguro Soc. 2021 Nov \n1;59(6):490-9.\n25. Zhan Y, Yu J, Chen R, Gao J, Ding R, Fu Y, et al. Socioeconomic \nstatus and metabolic syndrome in the general population of China: a \ncross-sectional study. BMC Public Health. 2012 Oct 30;12:921. doi: \n10.1186/1471-2458-12-921.\n26. Gharipour M, Sadeghi M, Nouri F, Nezafati P , Qader SS, Taheri M, \net al. Socioeconomic determinants and metabolic syndrome: Results \nfrom the Isfahan Healthy Heart Program. Acta Biomed. 2016 Jan \n16;87(3):191-8. \n27. Myers J, Kokkinos P , Nyelin E. Physical Activity, Cardiorespiratory \nFitness, and the Metabolic Syndrome. Nutrients. 2019 Jul \n19;11(7):1652. doi: 10.3390/nu11071652.\n28. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin \nresistance: underlying causes and modification by exercise training. \nCompr Physiol. 2013 Jan;3(1):1-58. doi: 10.1002/cphy.c110062.29. De Sousa SM Dr, Norman RJ Prof. Metabolic syndrome, diet and \nexercise. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:140-51. \ndoi: 10.1016/j.bpobgyn.2016.01.006.\n30. Di Daniele N, Noce A, Vidiri MF, Moriconi E, Marrone G, \nAnnicchiarico-Petruzzelli M, et al. Impact of Mediterranean diet on \nmetabolic syndrome, cancer and longevity. Oncotarget. 2017 Jan \n31;8(5):8947-79. doi: 10.18632/oncotarget.13553. \n31. Finicelli M, Squillaro T, Di Cristo F, Di Salle A, Melone MAB, Galderisi \nU, et al. Metabolic syndrome, Mediterranean diet, and polyphenols: \nEvidence and perspectives. J Cell Physiol. 2019 May;234(5):5807-26. \ndoi: 10.1002/jcp.27506. \n32. Say\u00f3n-Orea C, Razquin C, Bull\u00f3 M, Corella D, Fit\u00f3 M, Romaguera \nD, et al. Effect of a Nutritional and Behavioral Intervention on Energy-\nReduced Mediterranean Diet Adherence Among Patients With Metabolic \nSyndrome: Interim Analysis of the PREDIMED-Plus Randomized \nClinical Trial. JAMA. 2019 Oct 15;322(15):1486-1499. doi: 10.1001/\njama.2019.14630. \n33. Damiri B, Khatib O, Nazzal Z, Sanduka D, Igbaria S, Thabaleh \nA, et al. Metabolic Syndrome Associated with Tobacco and Caffeine \nProducts Use Among Refugee Adolescents: Risk of Dyslipidemia. \nDiabetes Metab Syndr Obes. 2021 Sep 29;14:4121-4133. doi: \n10.2147/DMSO.S329675.\n34. Bermudez V, Olivar LC, Torres W, Navarro C, Gonzalez R, Espinoza \nC, et al. Cigarette smoking and metabolic syndrome components: a \ncross-sectional study from Maracaibo City, Venezuela. F1000Res. \n2018 May 10;7:565. doi: 10.12688/f1000research.14571.3. 136\n2023/38 (4): 136-144ORIGINAL\nPrevalence of adverse drug effects of anti-retroviral drugs on \nhiv-positive patients receiving anti-retroviral treatment \nin General Hospital Onitsha, Anambra, Nigeria\nPrevalencia de los efectos adversos de los medicamentos antirretrovirales \nen pacientes seropositivos que reciben tratamiento antirretroviral \nen el Hospital General de Onitsha, Anambra, Nigeria  \nEmmanuella Chidimma Ofoelo1      , David Chinaecherem Innocent1      ,\nIfeoma Lucy Ofoelo2      , Advait Vasavada3      , Stanley Chinedu Eneh4\n1. Department of Public Health, Federal University of Technology Owerri, Imo State, Nigeria\n2. Anti-Retroviral Unit, General Hospital Onitsha, Anambra State, Nigeria\n3. MP Shah Medical College, Jamnagar, India\n4. Department of Community Health, Obafemi Awolowo University, Ile-Ife, Osun State, NigeriaeISSN 2255-0569\nReceived: 12 - II - 2023\nAccepted: 6 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.136Corresponding author\nDavid Chinaecherem Innocent \nE-mail: innocentdc1@gmail.com  \nAbstract \nBackground: The wide use and acceptability of antiretroviral treatment has really helped in fighting HIV and keeping infected \npatients healthy and reducing the risk of further transmission and because of that HIV has become less life threatening. The general \nobjective of this study was to determine the prevalence of adverse drug reactions of antiretroviral drugs on HIV patients receiving \ncare in General Hospital Onitsha. \nMethods: A descriptive cross sectional study was adopted to obtain findings on the Prevalence of Adverse Drug Reaction of Antiretroviral \nDrugs on HIV-positive patient in General Hospital Onitsha. A non-probability convenient sampling technique was used to determine a \nsample size of 310 respondents for the study and data was collected from all of them with the use of a detailed questionnaire. Data \nwas analyzed using the SPSS version 22 and Microsoft excel. Chi-square was used to test association between variables . \nResults: From the analysis, it showed that 65.8% of the respondents are female and adults in the age bracket of 29-48 years. \n51.9% were married and majority of the respondents (80%) are of the Igbo origin. Also a good number of them (n=200, 64.5%) are \nusing TDF+3TC+DTG. Only 37.1% of the respondents are found to have had an experience of adverse drug reactions in which \nskin rash, peripheral neuropathy and gastrointestinal problems are prevalent with percentages of 32.2, 23.5 and 22.6 respectively. \nConclusion: Adverse drug reactions associated with antiretroviral drugs in General Hospital Onitsha was found not to be prevalent \nand they occur mostly in people who are in the early years of treatment initiation. This study emphasized the need to monitor at \nrisk and vulnerable patients to know when they have developed an event as a result of treatment. It is highly recommended that \nintensive and close follow-up of patients, especially for those in their early years of treatment initiation for early detection and quick \nmanagement of adverse drug reaction.\nKeywords: Adverse Drug Effects, HIV, Anti-retroviral Drugs, HIV-Positive Patients, Prevalence. \nResumen\nAntecedentes: El amplio uso y la aceptaci\u00f3n del tratamiento antirretroviral han ayudado realmente a luchar contra el VIH y a man -\ntener sanos a los pacientes infectados y a reducir el riesgo de nuevas transmisiones, por lo que el VIH se ha convertido en una \namenaza para la vida. El objetivo general de este estudio fue determinar la prevalencia de las reacciones adversas a los medica -\nmentos antirretrovirales en los pacientes con VIH que reciben atenci\u00f3n en el Hospital General de Onitsha. \nM\u00e9todos: Se adopt\u00f3 un estudio transversal descriptivo para obtener resultados sobre la Prevalencia de Reacciones Adversas a \nlos Medicamentos Antirretrovirales en pacientes VIH positivos en el Hospital General de Onitsha. Se utiliz\u00f3 una t\u00e9cnica de muestreo \nconveniente no probabil\u00edstico para determinar un tama\u00f1o de muestra de 310 encuestados para el estudio y se recogieron datos de \ntodos ellos con el uso de un cuestionario detallado. Los datos se analizaron con el SPSS versi\u00f3n 22 y Microsoft Excel. Se utiliz\u00f3 \nel chi-cuadrado para probar la asociaci\u00f3n entre las variables. \nResultados: Del an\u00e1lisis se desprende que el 65,8% de los encuestados son mujeres y adultos en la franja de edad de 29 a 48 a\u00f1os. \nEl 51,9% estaban casados y la mayor\u00eda de los encuestados (80%) son de origen igbo. Adem\u00e1s, un buen n\u00famero de ellos (n=200, 64,5%) \nutiliza TDF+3TC+DTG. S\u00f3lo el 37,1% de los encuestados ha experimentado reacciones adversas al f\u00e1rmaco, en las que prevalecen las \nerupciones cut\u00e1neas, la neuropat\u00eda perif\u00e9rica y los problemas gastrointestinales, con porcentajes de 32,2, 23,5 y 22,6 respectivamente . \nConclusi\u00f3n: Se encontr\u00f3 que las reacciones adversas a los medicamentos antirretrovirales en el Hospital General de Onitsha no \nson prevalentes y ocurren principalmente en las personas que est\u00e1n en los primeros a\u00f1os de la iniciaci\u00f3n del tratamiento. Este \nestudio enfatiza la necesidad de monitorizar a los pacientes de riesgo y vulnerables para saber cu\u00e1ndo han desarrollado un evento \ncomo resultado del tratamiento. Se recomienda encarecidamente realizar un seguimiento intensivo y estrecho de los pacientes, \nespecialmente de los que se encuentran en los primeros a\u00f1os de inicio del tratamiento, para la detecci\u00f3n precoz y el manejo \nr\u00e1pido de las reacciones adversas a los medicamentos. \nPalabras clave: Efectos adversos de los medicamentos, VIH, medicamentos antirretrovirales, pacientes seropositivos, prevalencia.ID ID\nID ID137\n2023/38 (4): 136-144Prevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving anti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nIntroduction\nAnti-retroviral treatment is the most effective tool in \nhelping fight the Human Immunodeficiency Virus (HIV) by \nkeeping infected patients healthy and reducing the risk \nof further transmission. As countries implement the 2017 \nWorld Health Organization (WHO) treatment guidelines, \nwhich require all people living with HIV to be on long-term \ntreatment1,It is proven that effective treatment results in \na decrease in viral load, a boost in the number of CD4 \ncounts, and clinical improvement of the HIV-infected \npatient2. Therefore, ARV drugs have brought highly \nsignificant hope to people living with HIV as millions \nof eligible HIV-infected patients have access to life-\nprolonging ARV drugs, which has led to a reasonable \ndecrease in HIV-related morbidity and mortality3. As a \nresult, HIV has gone from a life-threatening to a chronic \ncondition as a result of the wide use and accessibility of \nanti-retroviral treatment (ART) among HIV patients4. It is \nestimated that out of the 35.3 million people living with \nHIV worldwide, only 10.6 million were receiving ART in \n2012, with nearly 6.6 million HIV/AIDS related deaths \nworldwide having been prevented using ART5. According \nto6, the sub-Saharan African region is most affected by \nHIV; more than 67% of the people were infected with HIV, \nand 72% of the patients have died since 2008 due to \nAcquired Immune Deficiency Syndrome (AIDS)7. At the \nsame time6, reports indicated that approximately 36.7 \nmillion people were living with HIV/AIDS, with only 18.2 \nmillion receiving anti-retroviral treatment globally.\nIn 2004, Nigeria received over 400 million dollars in \nfunding to scale up ART \u2014a funding that was partly \nimplemented by Family Health International under the \nGlobal HIV/AIDS Initiative Nigeria (GHAIN) project\u2014 \nand this resulted in the influx of ART into the country \nat an increased level3. The establishment of eligibility is \nattained using clinical staging and CD4 count (Stage I or \nII with a CD4 count less than 350 or stage IV irrespective \nof CD4 counts for adults; CD4 less than 25% for \nchildren less than 11 months and CD4 less than 20% \nfor children between the ages of 12-35 months) as a \ncriteria regarding Nigerian national guidelines8.\nDespite these gains, adverse reactions to these \nmedicines remain a highly significant public health \nconcern, which stands to contradict the effectiveness \nof anti-retroviral treatment2. Adverse drug reactions are a \ncritical component of HIV/AIDS care and treatment as they \nshould be evaluated for the prevalence and pathogenesis \nof ADRs to inform clinical management9. The occurrence \nof ADRs may negatively affect the quality of life of patients \nas well as adherence to the treatment, and the spectrum \nof ADRs is wide and varied, making it difficult to identify \nthe principal cause10. ADRs are highly significant in the \neffort to diminish toxicities that are most likely to increase \nthe prevalence of chronic diseases of ageing in the HIV-\npositive population4. A better understanding of the ADRs of ARV drugs among HIV patients could help specialists \nto optimize therapy and also improve the care given to \nHIV-positive patients9.\nAdverse drug reactions are the most common reason \nfor poor adherence to ART3. Non-adherence to anti-\nretroviral treatment regimens remains common, leading to \nconsiderable deterioration of the disease and enhanced \nHC expenditure11. Noncompliance is also thought to \nincrease viral load, drug resistance, and treatment \nfailure12. Chronic use of ARV drugs, multiple pills taken \nat once, exclusion from society and being lonely due to \nstigma and discrimination, and treatment failure are the \nmajor problems associated with highly active anti-retroviral \ntreatment13. Adverse drug reactions (ADRs) are regarded \nas the most prevailing cause of mortality among people \nliving with HIV/AIDS as they are significantly involved in \ntreatment interruptions, regimen changes, treatment \nfailure, and non-adherence among patients on ART13. \nADRs are brought about by many factors, including stock-\nout of drugs, poor health service quality, and treatment \ninterruptions, which limit the treatment options, increase \nthe cost of treatment programs, and might increase \nresistant viruses to the point of being transmissible if left \nuntreated14. ADRs are not exactly life-threatening but \ncan impact negatively on the quality of life as it impairs \nthe patients\u2019 willingness to adhere to their regimen and \ninfluences the decisions made about health care15.\nThe stock out of drugs interrupts the treatment and \nmay contribute to ARV drug resistance. That could urge \nregimen change to deter ARV drug resistance. The longer \na patient is on ART, the less likely they will experience \nADRs, possibly as a result of stability in the ARV regimen, \ncoming after many changes and eventually settling on \nan acceptable regimen16. Previous research has shown \nthat patients over the age of 38 years have a significantly \nhigher recurrence of ADRs than those under the age of \n30 years17,3. Also, gender differentials were also found \nwith females having higher risks of adverse drug effects \nthan males, as females experienced higher abnormal \nfat distribution and peripheral neuropathy that occurred \nat a significantly younger age compared to males16. \nIn a multisite trial in Africa, it was found that tenofovir \ntherapy was associated with a 1.3% rate of significant \nnephrotoxicity, which was comparable to other regimens, \nthereby showing no significant toxicity difference between \ntenofovir and other regimens3. This raises a sentinel sign \nthat perhaps drug response to TDF in this setting is not in \nconformity with the results from other studies where the \ndrug profile of TDF has been superior over AZT and d4T.\nThe problematic occurrence of widespread underreporting \nof ADRs and the importance of addressing shortcomings \neffectively in pharmacovigilance activities in the public \nhealthcare setting need to be appropriately addressed18. \nFurthermore, knowledge regarding antiretroviral (ARV) \ntoxicity in developing countries is limited. These toxicities 138\n2023/38 (4): 136-144Emmanuella Chidimma et al. \ncan result in unknown long-term effects and compromise \npatient confidence and adherence19. Poor adherence, \nparticularly at levels lower than 95%, has a negative \nimpact on HIV outcome20. Over the years, some adverse \ndrug reactions have been observed in every course of \nanti-retroviral therapy7. The occurrence of adverse drug \nreactions negatively affects the quality of life of patients as \nwell as adherence to the treatment, and the spectrum of \nadverse events is wide and varied, thereby making it difficult \nto identify the principal cause sometimes10. Different types \nof anti-retroviral adverse drug reactions occur commonly \namong patients. Because the ADRs vary in their severity, \na common cause of ADR is therefore poor adherence. \nAlso, monitoring safety and toxicity related to ART remains \na challenge facing the public health sector. Spontaneous \nreporting of ADRs is a very inefficient system for detecting \ndrug-related conditions, leading to an underestimation \nof the burden due to adverse drug reactions. Structured \nsurveillance tracks HIV positive patients who are on ART to \nassess drug-related morbidity and mortality over time. The \nobjective of this study was to determine the prevalence of \nadverse drug effects of anti-retroviral drugs on HIV-positive \nMethods\nDesign\nA descriptive cross-sectional design was adopted in the \nstudy on the prevalence of adverse drug effects of anti-\nretroviral drugs on HIV-positive patients who are receiving \nanti-retroviral treatment in General Hospital Onitsha.\nStudy Setting\nThis study was carried out at General Hospital Onitsha, \nOnitsha South Local Government Area, Anambra State. \nGeneral Hospital Onitsha is a government-owned tertiary \nhealthcare facility located in the cosmopolitan city of \nOnitsha in the southeastern zone of Nigeria. It has several \ndepartments, just like every other government hospital. \nServices at the ART unit are provided by a group of \ncompetent health and non-health professionals. The unit \nprovides comprehensive HIV-related services such as \nvoluntary counselling and testing (VCT), provider-initiated \ntesting and counselling (PITC), PMTCT, pediatric HIV \ncare, and treatment and support for PLWHAs. \nInclusion Criteria\nThe study recruited HIV-positive patients less than 18 years \nwho were receiving anti-retroviral treatment in General \nHospital Onitsha, at least for a minimum of 6 months.\nExclusion Criteria\nThe study excluded HIV-positive patients receiving \ntreatment in General Hospital Onitsha who refused to give \nin their consent for the study. The study also excluded \nHIV-positive patients who are absent at the time of study, \nthose who are below the age of 18, and those who \npicked up ARVs only once at the pharmacy.Sampling\nThe researcher made use of only three hundred and \nten HIV-infected patients receiving anti-retroviral care \nin General Hospital Onitsha. The respondents will be \ninterviewed in order to gather information for the progress \nof the study. \nSample Size determination\nThe sample size was determined using the Yamene \nformula (1967) for sample size determination. \nn = N \n1+Ne2  \nWhere;\nn is the desired sample size\nN is the population size (953)\ne is margin of error (0.05)\nn =  \n   \nn =\n   \n     \nTherefore,\nn = 281.74\nFurthermore, to account for Non Response Rate, the \nsample size was increased by 10% = 0.10 = 281.74 x \n0.10 = 28.1\nn =281.7+28.17 =309.9\nApproximately =310\nSampling Techniques\nA non-probability-based convenience sampling \ntechnique was employed for the study on the prevalence \nof adverse drug effects of anti-retroviral drugs on HIV-\n1 and HIV-2 patients who are receiving anti-retroviral \ntreatment in General Hospital Onitsha.\nData Collection\nA self-administered structured questionnaire was used \nfor the study on the prevalence of adverse drug effects \nof anti-retroviral drugs on HIV-positive patients who are \nreceiving anti-retroviral treatment in General Hospital \nOnitsha. Data was obtained using a self-administered, \nsemi-structured questionnaire. This was done with \nthe aid of two (2) field assistants who work in the ART \ndepartment unit of the hospital to aid the researcher in \nthe data collection process. Both the researcher and \nthe research assistants were involved in retrieving the \nadministered questionnaire for data analysis.\nValidity and Reliability of the Research Instrument\nThe questionnaire as the instrument of data collection \nwas developed by the researcher and submitted to the \nproject supervisor for face validity and proper scrutiny as 953\n9531+953(0.05)2\n1+953*0.0025139\n2023/38 (4): 136-144Prevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving anti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nwell as two other lecturers in order to ensure that the \nquestionnaire meets the objectives of study before the \ndistribution of questionnaires for reliability testing.\nThe reliability of the data instrument was determined \nusing the test retest method. The researcher gave copies \nof the questionnaire to some respondents outside the \narea of study by the researcher, thereby pre-testing \nthe questionnaire twice before administering it to the \nrespondents. This area shares similar characteristics \nwith General Hospital Onitsha, which was used for \nthis study. On reliability correlation testing using SPSS, \nthe Cronbach alpha value of 0.76 was obtained. The \ncloseness of this value to 1 indicates that the instrument \nof data collection is very reliable.\nMethod of Data Analysis\nThe data that was gathered from the questionnaire was \nanalyzed using the statistical package for social sciences \n(SPSS) version 22 and Microsoft Excel. Descriptive \nstatistics, which were expressed in frequency tables and \npercentages, were used to describe the characteristics \nin the study of the subjects. Inferential statistics were \nused with a confidence interval of 95% and a P-value of  \n0.05 for interpreting significance and correlation.\nEthics\nA letter of introduction was obtained from the ethics \ncommittee, department of public health, Federal \nUniversity of Technology Owerri (FUTO). The letter was \nhanded over to the Head of Department, Anti-retroviral Therapy (ART) unit, General Hospital Onitsha, in order \nto get his consent before carrying out the research in \nthe unit. The purpose of the research was explained to \neach respondent and verbally informed consent was \nobtained from them before inclusion in the study. Also, \nthe anonymity of the respondents was assured and \nensured. The confidentiality of the information they gave \nhad to be maintained.\nResults\nA total of 310 respondents were included in the final \nanalysis. 310 questionnaires were carefully distributed \nand collected by the researcher for the study. The \nquestionnaires were filled properly and cross-checked for \naccuracy. The flow diagram below (Figure 1) summarizes \nthe distribution of patients according to their antiretroviral \ntreatment regimen. This study final analysis includes only \nHIV-positive patients above the age of 18 who are receiving \nantiretroviral treatment in General Hospital Onitsha.\nThe flow diagram (Figure 1) summarizes the distribution \nof respondents according to their antiretroviral treatment \nregimen. As shown in the figure above, 66.5% (n=206) \nof the total population use combination of two nucleoside \nreverse transcriptase inhibitors (NRTI) and an integrase \ninhibitor (II); 29.6% (n=92) use combination of two NRTI \nand a non-nucleoside reverse transcriptase inhibitor \n(NNRTI); and the remaining 3.9% (n=12) use the \ncombination of two NRTI and a protease inhibitor (PI). \nFigure 1: Flow diagram of patients and ART regimen received at treatment initiation.\nTotal number of study participants (n=310)\nPatients on 2NRTI/\nNNRTI (n=92, 29.6%)Patients on 2NRTI/II \n(n=206, 66.5%)\nTDF+3TC+DTG\n(n=200, 64.5%)\nTDF+3TC+NVP \n(n=31, 10.0%)TDF+3TC+EFV \n(n=55, 17.7%)ABC+3TC+EFV \n(n=6, 1.9%)ABC+3TC+DTG \n(n=6, 1.9%)TDF+3TC+LPV/r \n(n=12, 3.9%)Patients on 2NRTI/PI \n(n=12, 3.9%)140\n2023/38 (4): 136-144Emmanuella Chidimma et al. \nTable I: Socio-demographic Characteristics of Study Participants. (N=310).\nSource: Field data, 2021.Variables Subgroup Frequency Percentage\n  (N=310) (100%)\nAge 18-28 59 19.0\n 29-38 71 22.9\n 39-48 115 37.1\n 49-58 35 11.3\n 58 and above 30 9.7\nGender Male 106 34.2\n Female 204 65.8\nMarital status  Single 66 21.3\n Married 161 51.9\n Divorced/Separated 31 10.0\n Widowed 52 16.8\nEthnicity Igbo 248 80\n Hausa 37 11.9\n Yoruba 17 5.5\n Others 8 2.6\nEducational level Primary 44 14.2\n Secondary 75 24.2\n Tertiary 104 33.5\n Uneducated 87 28.1\nOccupation Trader 137 44.2\n Farmer 95 30.6\n Civil servant 33 10.6\n Student 21 6.8\n Others 7 2.3\n Unemployed 17 5.5\nTable I above shows that a good number of the study \nparticipants were females (n=204, 65.8%) and adults in \nthe age bracket of 39-48 years. Many of the participants \n(n=104, 33.5%) have attained tertiary education, 87 \n(28.1%) are uneducated, 75 (24.2%) are recorded to \nhave achieved only secondary education and 44(14.2%) \nattained only primary education. Regarding marital status, \nmarried people are highest accounting for 51.9% of the \ntotal population, seconded by the singles (n=66, 21.3%), \nthen the widowed (n=52, 16.8%) and the divorced/\nseparated (n=31, 10%). Considering ethnicity, Igbos are leading amounting to 80% of the population, followed by \nthe Hausas (11.9%), then the Yorubas (5.5%) and then \nfew people from other tribes(2.6%). It is also shown in \nthe table above that most of the study participants are \ntraders with a percentage of 44.2, seconded by farmers \nwith a percentage of 30.6, then comes civil servants, \nstudents, people of other occupations not mentioned \nand unemployed people with a percentage of 10.6, 6.8, \n2.3, and 5.5 respectively.\nFigure 2 shows a diagrammatic representation of the \nage distribution of the respondents plotted against the \nfrequency of respondents found to be within these age \ngroups. As shown in the diagram, the leading age group \nis those within the ages of 39-48 years (n=115), while \nthe least one is found to be those who are 58 years and \nabove (n=30).\nTable II indicates that 139(44.8%) to have been on \ntreatment for the first 2 years, 57 are reported to fall \nwithin those receiving treatment for the past 2-6 years, \n98 have been on treatment for about 7-10 years and \nthe rest (n=16,5.2%) have been on treatment for over \nFigure 2: A bar chart representing the age distribution of respondents.\nAge distribution of respondents\nTable II: Ascertaining Type, Frequency and Dosage of ARV in Use.\nSource: Field data, 2021Characteristics Sub-group Frequency (n=310) Percent (100%)\nHow long the patient has been on treatment 6 months-2 years 139 44.8\n 2-6 years 57 18.4\n 7-10years 98 31.6\n Above 10 years 16 5.2\nThe ARV combination in use 2NRTI/II 206 66.5\n 2NRTI/NNRTI 92 29.6\n 2NRTI/PI 12 3.9\nThe exact drug combination in use TDF+3TC+DTG 200 64.5\n TDF+3TC+EFV 55 17.7\n TDF+3TC+LPV/r 12 3.9\n ABC+3TC+EFV 6 1.9\n TDF+3TC+NVP 31 10.0\n ABC+3TC+DTG 6 1.9\nPrescribed dosage of the drug 1 tab/daily 288 92.9\n 2 tabs/daily 22 7.1\nAdherence to everyday use of drug Yes 199 64.2\n No 35 11.3\n Sometimes 76 24.5\nAdherence of everyday use of drug with  respect to time and dosage Yes 178 57.4\n No 46 14.8\n Sometimes 86 27.7141\n2023/38 (4): 136-144Prevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving anti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nTable IV: Determining rate of occurrence and result on switching.\nSource: Field data, 2021.Variables Sub-group Frequency Percent\nRate of occurrence Weekly 0 0\n Monthly 21 18.3\n Yearly 40 34.8\n Rarely 54 46.9\nEver had a change Yes 73 63.5\nin regimen No 42 36.5\nResult of ADRs Disappeared 29 39.7\nafter drug switching Reduced/contained 44 60.3\nTable III: Ascertaining the incidence of ADRs resulting from ARV drugs.\nSource: Field data, 2021.Variables Sub-groups Frequency  Percent\nEver experienced any ADR Yes 115 37.1\n No 195 62.9\nWhat type of ADR experienced Neuropathy 27 23.5\n Skin rash/itching 37 32.2\n Insomnia 10 8.7\n Dizziness 15 13.0\n Gastro-intestinal 26 22.6\nPresence of severe Yes 26 22.6\ncondition as a result of ADR No 89 77.410 years. It also shows that all that study participants \nmake use of ARV drugs of which the common ones are \nTDF+3TC+DTG (66.5%), TDF+3TC+EFV (17.7%) and \nTDF+3TC+NVP (10.0%) while the least common ones \nareTDF+3TC+LPV/r (3.9%) and ABC+3TC+EFV and \nABC+3TC+DTG with percentages of 1.9% each. Almost \nall the respondents (92.9%) report their prescription to \nbe 1tab/day and the rest (7.1%) take theirs twice daily. \n64.2% of the study participants adhere to everyday \nuse of drug, 11.3% do not adhere while 24.5% adhere \nsometimes. 57.4% of the total population adhere to \neveryday use with respect to time and dosage, 14.8% \ndo not and the remaining 27.7% sometimes adhere to \neveryday use of drugs with respect to time and dosage.\nThe figure above (Figure 3) is a pie chart representing the \nhow long respondents have been on treatment, hence \nthe time treatment initiation. From the chart, it is seen that \n44.8% of the total population are within the first three years \nof treatment, 18.4% reported to have been on treatment \nfor about 3-6 years, 31.6% have been on treatment for \nabout 7-10 years, and the remaining 5.2% have been on \nantiretroviral treatment for more than 10 years.\nTable III shows that only 37.1% (n=115) adverse \ndrug reaction of antiretroviral drugs of which 22.6% \nexperience severe conditions as a result and 77.4% \nnever had such experience. The adverse events \nexperienced by the respondents include skin rash/\nitching, neuropathy, insomnia, dizziness and gastro-\nintestinal symptoms with percentages of 32.2, 23.5, \n22.6, 13.0 and 8.7 respectively.Table IV shows that of 115 patients that experience \nadverse events, 21 (18.3%) have them occur every \nmonth, 40 (34.8%) experience it yearly and 54 \n(46.9%) rarely have the experience. 63.5% of those \nthat experience adverse events have had a change \nin regimen, of which 39.7% had the adverse events \ndisappear after switching and 60.3% had their adverse \nevents reduced or contained.\nThe above figure (Figure 4) is another bar chart \nrepresenting the percentage distribution of the types \nof adverse drug reactions (ADRs) experienced by the \nrespondents. As shown above, the most prevalent \nADRs are skin rash, neuropathy and nausea/vomiting \nwith percentages of 32.2, 23.5 and 22.6 respectively. \nThe least occurring ones are dizziness and insomnia \nwith percentages of 13.0 and 8.7 respectively.\nTest of Hypothesis\nTable V shows that age, gender, educational level, the \ntime of treatment initiation and the patients\u2019 adherence \nto everyday use of drugs with respect to prescribed \ndosage and time all appear to have a correlation with \nthe patients\u2019 experience of adverse effect with p value \nof 0.0001 each. Marital status is not significant in \ndetermining the experience of adverse drug reaction of \nantiretroviral drugs.Figure 3: A pie chart representing how long a patient has been on treatment\nDistribution of how long respondents have been on ART\nFigure 4: A bar chart showing percentage distribution of ADR types.\nPercentage Distribution of ADR Types142\n2023/38 (4): 136-144Emmanuella Chidimma et al. \nTable V: Association of participants\u2019 demographic factors and adherence to prescribed dosage and frequency of drug use.\nSource: Field data, 2021Variables Sub-group Patients with ADR Patients without ADR Chi-square test value Df P value Decision\nAge 18 - 28 3 36    \n 29 - 38  20 51    \n 39 - 48 48 67 80.393 4 .0001 Sig\n 49 - 58 14 21    \n 59 and above 30 0    \nGender  Male  55 51 15.100 1 .0001 Sig\n Female  60 144    \nEducational Level  Primary  24 20    \n Secondary 20 55    \n Tertiary 28 76 19.517 3 .0001 Sig\n Uneducated 43 44    \nMarital Status  Single  28 38    \n Married 58 103 1.788 3 .618 Not Sig.\n Divorced 9 22    \n Windowed  20 32    \nHow long patient 6 mths - 3yrs 75 64    \nhas been on treatment 3 - 6 years 27 30 51.972 3 .0001 Sig\n 7 - 10 years  12 86    \n Above 10 years 1 15    \nAdherence to with Yes 36 142    \nrespect to dosage and time No 29 17 51.305 2 .0001 Sig\n Sometimes  50 36    \nDiscussion\nFrom the analysis, it is revealed that the majority of the \nrespondents (80%)of the study are of Igbo origin. This \nis because the study was conducted in the Southern \npart of Nigeria as the hospital is located in Onitsha, \nAnambra State. Considering the socio-demographic \ncharacteristics of the respondents, with regards to \ngender and age, a good number of respondents \n(65.8%) are females, and most respondents are within \nthe age range of 29-48 years old. This is in accordance \nwith the findings of21, that the majority of these patients \nare females and young adults in the age bracket of \n25-45 years old. This gender difference, though not \nstatistically significant, is found in much other related \nresearch carried out in African countries. It is also \nconsistent with other studies conducted in Nigeria that \nshow a feminization of the HIV epidemic22,23,21. Findings \nfrom the study show that 44.8% of the respondents \nare within their first three years of treatment, 18.4% \nreported to have been on treatment for about 3-6 years, \n31.6% have been on treatment for about 7-10 years, \nand the remaining 5.2% have been on antiretroviral \ntreatment for more than 10 years. A good percentage \nof the respondents (66.5%) use a combination of two \nnucleoside reverse transcriptase inhibitors (NRTI) and \nan integrase inhibitor (II). Following suit is the group \nusing the 2NRTI/NNRTI combination. People who make \nuse of the ABC+3TC+EFV and ABC+3TC+DTG are 6 \nand 6, respectively, which is a minority representative \nof the study participants. This is because the patients \nwho use these drugs are ones with special cases, for \ninstance, patients with kidney and liver diseases and \nchildren (which we didn\u2019t use for this study).Almost all the respondents (n = 200, 64.5%) make \nuse of TDF + 3TC + DTG. This is because it is the first \nline regimen and it is suitable for virtually every adult, \nincluding pregnant and lactating mothers, and also for \nadolescents. Meanwhile, TDF + 3TC + LPV is taken by \na small number of people (n = 12,3.9%) because it is a \nsecond-line regimen.\nConsidering the frequency and dosage, it is denoted here \nthat the majority of the study participants (n = 199, 64.2%) \nadhere to everyday use of their drugs, of which 89.4% \nadhere to everyday use of the drugs with respect to the \ntime and required dosage. 11% of the study participants \ndo not adhere at all, and 24.5% do not adhere all the \ntime as their answers to questions are sometimes. This \nargues the study conducted by24 that says this presents \nless than optimal adherence among HIV-positive \npatients. Almost all respondents (n = 288,92.9%) are \ntaking one tablet per day, while the remainder (n = \n22,7.1%) are taking two tablets per day because they are \non second-line therapy TDF + 3TC+LPV and abacavir-\nbased regimens. From the findings, 115 participants \nout of the 310 used for the study were reported to have \nexperienced or be experiencing adverse drug reactions \nas a result of the use of ARV drugs23. This represents \n37.1% of the total population and is in accordance with23. \nOf the people that have experienced ADRs, 26 (22.6%) \nhave experienced a chronic condition as a result of the \nADRs, while 89 (77.6%) haven\u2019t had such experience. \nThe prevalent ADRs are skin rash/itching, neuropathy \nand gastro-intestinal symptoms (which include vomiting, \nnausea, abdominal pain and diarrhea) with percentages 143\n2023/38 (4): 136-144Prevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving anti-retroviral treatment in General Hospital Onitsha, Anambra, Nigeria\nof 32.2%, 23.5% and 22.6%, respectively, which is \nthe same as reported by other Nigerian studies3,22,21. \nIn comparison to23, the study found a lower incidence \nof antiretroviral drug adverse drug reactions. Adverse \nevents are reported to be most prevalent among people \nwho are in the early years of treatment initiation, and this \nsupports the study3 that found ADRs are more likely to \noccur within the first 6 months of treatment. The study \nshows that the 54 respondents(46.9%) out of 115 that \nwere reported to have had an experience of ADR rarely \nhave the occurrence, 40 (34.8%) experience it yearly and \n21 (18.3%) experience it monthly. Also, 63.5% of those \nreported to be with ADR have had a change in regimen, \nof which 39.7% (n = 29) reported that the ADR had \ndisappeared and 60.3% (n = 44) reported ADRs to be \nreduced or contained. This is because most respondents \nare still adjusting to the treatment while few are allergic to \na combination of the regimen.\nConclusion\nAdverse drug reactions to antiretroviral treatment were \ncommon in this study and were reported to occur \nmostly within the early years of treatment initiation. The \nmost prevalent ADRs were skin rash/itching (n = 37, \n32.2%), neuropathy (n = 27, 23.5%) and gastro-intestinal \nsymptoms (n = 26, 22.6%). Other rarely occurring but \nserious cases of ADR include insomnia (n = 10,8.7%) \nand dizziness (n = 15,13%), which were also observed. \nAdverse Drug Reactions are significantly predicted by the \ntime of therapy initiation as people within the early years \nof initiation were reported to experience ADRs more \nthan others, with a percentage of 65.2%. This study \nemphasizes the need to monitor at-risk and vulnerable or \nlow-immune patients to know when they have developed \nan event as a result of treatment.Recommendations\nAs a result of this study, an intensive and close follow-\nup of patients, especially in the early years of treatment \ninitiation, is highly recommended for early detection of \nADR and quick management. These ADRs should be \nproperly documented in order to provide accurate data \nfor further studies or research. Patients who are not able \nto respond effectively to first-line therapies should be \nidentified and placed on effective second-line therapies. \nValuable information on patients\u2019 responsiveness to \ntreatment should be made available to physicians in-\ncharge and concerned NGOs like USAID when there is \na need to modify HAART regimens. Further study using \nlarger and more complete data is also recommended.\nLimitations of the Study\nWith regards to the study, there is a tendency that non-\nclinical ADRs were overlooked. There is a possibility of \nunder-reporting of ADRs by patients and caregivers. The \nresearcher was not able to relate the factors that caused \nthe ADRs, which would have played an important role in \nthe interpretation of the result.\nEthics Approval and consent to Participate\nNot Applicable.\nConsent to Publish\nNot applicable.\nAvailability of Data and Materials\nThe Data set from the study are available to the \ncorresponding author upon request.\nCompeting Interests\nAuthors have declared that they have no competing \ninterests.\nFunding\nNo funds were received for this study.\nAcknowledgements\nNot Applicable.144\n2023/38 (4): 136-144Prevalence of adverse drug effects of anti-retroviral drugs on hiv-positive patients receiving anti-retroviral treatment in General Hospital Onitsha, Anambra, NigeriaEmmanuella Chidimma et al. \nReferences\n1. World Health Organization. HIV Drug Resistance surveillance \nguideline-2015 Update. www.who.int\n2. WHO. Assuring safety of preventive chemotherapy interventions \nfor neglected tropical diseases. practical advice for national program \nmanagers on the prevention, detection and management of serious \nadverse effects 2010. Available at: http://whqlibdoc.who.int/\npublications/2011/9789241502191_eng.pdf \n3. Eluwa GI, Badru T. Akpoigbe KJ. Adverse drug reactions to \nantiretroviraltherapy (ARVs): incidence, type and risk factors in Nigeria. \nBMC Clinical Pharmacology 2012 12:7. doi:10.1186/1472-6904-12-7\n4. Hawkins T. Understanding and managing the adverse effects of \nantiretroviral therapy. Antiretroviral Resource 2010. 85: 201-9.\n5. Joint United Nations Program on HIV/AIDS. Global report: UNAIDS \nreports on the global AIDS Epidemic 2013. Geneva: Switzerland\n6. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic \nUNAIDS Geneva; 2010. \n7. Tatiparthi R, Mamo Y. Prevalence of ADRs and associated factors of \nantiretroviral treatment on HIV positive adults at Jush. Indian Journal of \nPharmacological Practice 2014;7(4):8-15\n8. Federal Ministry of Health, Nigeria. National guidelines for HIV/AIDS \ntreatment and care in adolescents and adults 2010.\n9. Takaki I, Quirelli L, Cuman R. Adverse drug reaction in HIV infected \npeople treated with HAART in Maringa, Southern Brazil. Tropical Journal \nof Pharmaceutical Research 2017; 16(4):939-45. http://www.tjpr.org\n10. Lartey M, Asante-Quashie A, Essex A, Kenu E, Gang V, Neequaye \nA. Adverse drug reaction to anti-retroviral therapy during the early ART \nperiod at Tertiary Hospital in Ghana. Pan African Medicine Journal 2014; \n18:25. Doi:10.11604/pamj.2014.18.25.3886\n11. Gelaw Y, Adugna B, Tsegave A, Melaku T, Kefale B. Coping \nstrategies for Adverse Effects of Antiretroviral Therapy among Adult HIV \npatients attending University of Gondar Hospital, Gondar, Northwest \nEthiopia: a cross-sectional study. AIDS Research and Treatment \n2018;18(7):91-8\n12. Rajesh R, Vidyasagar S, Nandakumar K. Highly active anti-retroviral \ntherapy induced adverse drug reactions in Indian human immuno-\ndeficiency virus positive patients. Pharmacy Practice 2011;9(1):48-55.\n13. Parchure R, Kulkami V, Darak T. Growth pattern of HIV infected \nIndian children in response to ART: a clinic based cohort study. Indian \nJournal of pediatricians 2015; 82(6):519-2414. WHO. Using early warning indicators to prevent HIV Drug resistance \n2010. www.who.int\n15. Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse drug reaction \nmonitoring in Ethiopia: Analysis of case reports, 2002-2007. Ethiopian \nJournal of Health Development 2011;25(2):168-73\n16. Dube M, Summers R, Tint K-S, Mayayise G. A pharmacovigilance \nstudy of adults on highly active anti-retroviral therapy, South Africa: \n2007-2011. Pan African Medical Journal 2012;11:39.\n17. Srikanth A, Babu S, Yadav H, Jain SK. Incidence of Adverse Drug \nReactions in human immunodeficiency virus positive patients using \nhigh active anti-retroviral therapy. Journal of advanced pharmacological \ntechnology resource 2012; 3:62-67.\n18. Ruud KW, Srinivas SC, Toverud EL. Addressing gaps in \npharmacovigilance practices in the antiretroviral therapy program in the \nEastern Cape Province, South Africa. Res Social Adm Pharm. 2010 \nDec;6(4):345-53. doi: 10.1016/j.sapharm.2009.11.006.\n19. Kyeyune R, Saathoff E, Ezeamama AE, L\u00f6scher T, Fawzi W, \nGuwatudde D. Prevalence and correlates of cytopenias in HIV-infected \nadults initiating highly active antiretroviral therapy in Uganda. BMC Infect \nDiseases 2014; 10;14:496. doi: 10.1186/1471-2334-14-496. \n20. Sweileh WM. Global research output on HIV/AIDS-related \nmedication adherence from 1980 to 2017. BMC Health Serv Res. \n2018 Oct 10;18(1):765. doi: 10.1186/s12913-018-3568-x.\n21. Abah IO. Adverse Drug Reaction to Antiretroviral Drugs: Effect on \nVirologic failure in a Nigerian Cohort of HIV-infected Adults on First Line \nAntiretroviral Therapy. Journal of International Association of Providers of \nAIDS care 2017; 2325957414589192.\n22. Agu KA, Oparah AC. Adverse Drug Reactions to Antiretroviral \nTherapy: Results on spontaneous reporting system in Nigeria. \nPerspectives in Clinical Research 2014;4(2): 117-24\n23. Masenyetse L, Manda S, Mwambi H. An assessment of adverse \ndrug reactions among HIV positive patients receiving antiretroviral \ntreatment in South Africa. AIDS research therapy 2015; 12(6):1-8\n24. Ndashimye E, Arts EJ. The urgent need for more potent antiretroviral \ntherapy in low-income countries to achieve UNAIDS 90-90-90 and \ncomplete eradication of AIDS by 2030. Infect Dis Poverty. 2019 Aug \n2;8(1):63. doi: 10.1186/s40249-019-0573-1.145\n2023/38 (4): 145-151ORIGINAL\nA Quantitative Assessment of Coping Strategies among \nJamaican Males 18+ years old: Post-COVID-19\nUna evaluaci\u00f3n cuantitativa de las estrategias de afrontamiento \nentre los varones jamaicanos mayores de 18 a\u00f1os: Post-COVID-19  \nPaul Andrew Bourne1      , Raveena Blake2, Serena Braham2, Betonia  Chisholm2,\nJaneil Deer2, Patrina Royal2, James Fallah3, Calvin Campbell4, Clifton Foster5, \nCaroline McLean2, Tabitha Muchee6, Advella L. Meikle2\n1. Department of Institutional Research, Northern Caribbean University, Mandeville, Manchester, Jamaica, WI\n2. Department of Nursing, Northern Caribbean University, Mandeville, Manchester, Jamaica, WI\n3. Department of Dental Hygiene, Northern Caribbean University, Mandeville, Manchester, Jamaica, WI\n4. Department of Mathematics and Engineering, Northern Caribbean University, Mandeville, Manchester, Jamaica, WI\n5. Department of Biology, Chemistry, and Environmental Sciences, Northern Caribbean University, Mandeville, Manchester, Jamaica, WI\n6. Department of Nutrition and Dietetics, Northern Caribbean University, Mandeville, Manchester, Jamaica, WIeISSN 2255-0569\nReceived: 15 - II - 2023\nAccepted: 10 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.145Corresponding author\nPaul Andrew Bourne \nE-mail:   \nAbstract \nIntroduction: The importance of a gendered perspective on men\u2019s unhealthy coping strategies for mental health is becoming more \nwidely recognized in the literature. There is no literature on Jamaican males and how they are coping and what coping strategies \nthey are engaged in during the post-COVID-19 period. \nObjectives: The aim is to examine the types of coping strategies used by Jamaican males who are 18 years and older used to \naddress problematic situations that arose in their life during the COVID-19 pandemic. \nMethods and materials: The study used cross-sectional web-based survey data on Jamaican men 18 years and older from \nthe fourteen parishes of Jamaica, the survey commenced on October 1, 2022, and ended on November 25, 2022. The \nSystematic Sampling Technique was utilized to draw a sample of 1088 respondents utilizing a randomized selection of every \nfifth male in the population. \nResults: Substance use has been strongly employed by Jamaican males to address the challenges of life post-COVID-19 (three in \nevery four Jamaican males have been using hard drugs). In addition, religion and denial have been strongly employed by sampled \nJamaicans to address the challenges of life post-COVID-19. Furthermore, self-blame and self-distraction have also been a part of \nthe strategies employed by Jamaican males to deal with life post-COVID-19. In addition to the aforementioned issues, Jamaican \nmales have been venting and acceptance of the challenges experienced in their lives post-COVID-19. \nConclusion: This research has provided insight into the stressors experienced by Jamaican males post-COVID-19 and is as such \nforwarding a need for social intervention programmes to assist them to deal with the new normal set by the pandemic..\nKeywords: Coping, coping strategies, stress. \nResumen\nIntroducci\u00f3n: La importancia de una perspectiva de g\u00e9nero en las estrategias de afrontamiento no saludables de los hombres \npara la salud mental es cada vez m\u00e1s reconocida en la literatura. No existe literatura sobre los hombres jamaicanos y c\u00f3mo est\u00e1n \nafrontando y qu\u00e9 estrategias de afrontamiento est\u00e1n llevando a cabo durante el per\u00edodo posterior a COVID-19. \nObjetivos: El objetivo es examinar los tipos de estrategias de afrontamiento utilizadas por los varones jamaicanos mayores de 18 \na\u00f1os para hacer frente a las situaciones problem\u00e1ticas que surgieron en su vida durante la pandemia COVID-19. \nM\u00e9todos y materiales: El estudio utiliz\u00f3 datos de encuestas transversales basadas en la web sobre hombres jamaicanos de 18 \na\u00f1os o m\u00e1s de las catorce parroquias de Jamaica, la encuesta comenz\u00f3 el 1 de octubre de 2022 y finaliz\u00f3 el 25 de noviembre \nde 2022. Se utiliz\u00f3 la t\u00e9cnica de muestreo sistem\u00e1tico para extraer una muestra de 1088 encuestados utilizando una selecci\u00f3n \naleatoria de uno de cada cinco varones de la poblaci\u00f3n. \nResultados: Los varones jamaicanos han recurrido en gran medida al consumo de sustancias para hacer frente a los retos de \nla vida tras el COVID-19 (tres de cada cuatro varones jamaicanos han consumido drogas duras). Adem\u00e1s, los jamaicanos de \nla muestra han recurrido en gran medida a la religi\u00f3n y a la negaci\u00f3n para hacer frente a los retos de la vida tras el COVID-19. \nAdem\u00e1s, la autoculpabilizaci\u00f3n y la autodistracci\u00f3n tambi\u00e9n han formado parte de las estrategias empleadas por los varones ja -\nmaicanos para hacer frente a la vida posterior a COVID-19. Adem\u00e1s de las cuestiones mencionadas, los varones jamaicanos se \nhan desahogado y han aceptado los retos experimentados en su vida tras el COVID-19. \nConclusiones: Esta investigaci\u00f3n ha proporcionado una visi\u00f3n de los factores de estr\u00e9s experimentados por los varones jamai -\ncanos despu\u00e9s del COVID-19 y, como tal, plantea la necesidad de programas de intervenci\u00f3n social para ayudarles a hacer frente \na la nueva normalidad establecida por la pandemia. \nPalabras clave: Afrontamiento, estrategias de afrontamiento, estr\u00e9s.ID146\n2023/38 (4): 145-151Paul Andrew Bourne et al. \nIntroduction\nThe importance of a gendered perspective on men\u2019s \nunhealthy coping strategies for mental health is becoming \nmore widely recognized in the literature. According to \nMental Health Foundation1, in 2017, nearly 6000 suicides \nwere recorded in Great Britain. Of these, 75% were men. \nIn a study by CBHS Health2, it was compared that more \nmen than women turn to negative coping strategies such \nas anger, alcohol, drugs, gambling, excessive use of \ntechnology and binge eating in an attempt to deal with \nmental health issues; on the other hand, there are several \npositive coping strategies that men may choose from when \ncoping with their problems such as eating healthy, keeping \nbusy, exercising, using humour, and helping someone. \nAccording to Lazarus and Folkman3, coping strategies \nare \u201cconstantly changing cognitive and behavioural efforts \nto manage specific external and/or internal demands that \nare appraised as taxing or exceeding the resources of \nthe person.\u201d The COPE Inventory created by Charles \nCarver has two main components namely problem-\nfocused coping and emotion-focused coping. Research \ndone by Endler and Parker as well Matud4,5, proved that \nmen are more likely to utilise problem-focused coping \nstrategies to deal with stressful situations, which involves \ntaking action to resolve stressful situations by addressing \nthe underlying cause. \nEmotion-focused coping involves directing one\u2019s \nfeelings and emotional response to the problem instead \nof addressing the problem6,7. Coping strategies are \ncognitive tactics that have been used to evaluate the \nconsequences of various stressful events. Using \nsuicides in Jamaica, the majority of the cases were \ncommitted by males and this speaks to the males\u2019 \ndifficulties to cope with life\u2019s challenges compared to \nfemales (Annexe). The question is \u2018what strategies did \nJamaican males employ post-COVID-19 (October 1 \n- November 25, 2022)? Hence, in this research, the \naim is to examine the types of coping strategies used \nby Jamaican males who are 18 years and older used \nto address problematic situations that arose in their life \nduring the COVID-19 pandemic.\nTheoretical Framework\nThe theoretical framework that will be utilized for this \nresearch is the cognitive theory of coping coined by \nFolkman and Lazarus3. This theory was selected as \nit correlates to the construct central to our study, \u2018An \nExamination of Coping Strategies among Males during \nCOVID-19\u2019. According to the theory, learning can be \npartially attributed to studying other people through \nsocial interactions, experiences, and external media \ninfluences. Folkman and Lazarus3 defined coping as a \nchange in cognitive and behavioural efforts to cope with \nspecific external and internal demands that are perceived \nas extreme. The theory posits three meta-theoretical assumptions: transaction, process, and context that \nclaim one\u2019s coping strategy are determined by their \nemotional experience and the context of the environment, \nrather than its effectiveness. This framework is consistent \nwith the topic of this study and allows a thorough \nexamination of survival techniques used by men in \nCOVID-19 in the context of human, environmental and \nsocial interactions8-10.\nLiterature Review \nCOVID-19 has impacted a lot of men negatively, and as \nsuch, it is key for them to seek help11-14. One way that \nmen had to cope was to seek assistance15-17. Coupled \nwith what we already highlighted, there are more ways \nthat men have used to cope during the pandemic. \n\u201cGetting informed about their current mental and \nphysical health conditions.\u201d \u201cPut that knowledge into \npractice by working on improving yourself to improve \nstress conditions.\u201d \u201cAsking your friends or even getting \nprofessionals to help you during times of duress is always \na good idea.\u201d \u201cConnecting with others on social media \nplatforms.\u201d \u201cOvercome the stigma and the negative \nattitudes when it comes to personal development.\u201d \n\u201cShifting your mind toward positive thoughts should be \na daily recurring activity18.\n\u201cDr Peter Bajic, a physician associated with the Cleveland \nClinic survey, notes that men are \u201cnot great about going \nto the doctor,\u201d and physicians need to stress to men \nthat taking care of themselves is important. \u201cMany \nmen see depression and anxiety as weakness, and by \nseeking mental or physical health treatment, they are \nvulnerable or weak\u201d10. The stress and the implications \nof the COVID-19 pandemic have left most men tight-\nlipped about their struggles and stress19-21. As a result, \nmen have opted to bottle their inner feelings as a means \nto cope with tough times, to them, they see this as a \nsign of strength. This accounts for the rise in alcohol \nconsumption and the use of other stimulants during the \nCOVID-19 pandemic22-24. According to Roberts et al.,22, \nthe proportion of people consuming other substances \nduring the pandemic ranged from 3.6% to 17.5% in the \ngeneral population.\u201d\nStress has always been an issue that affects men on a \nlarge scale, as men tend to have great difficulty dealing \nwith stress which causes their stress levels to be very \nhigh. Quote from Hans Selye \u201cAdopting the right attitude \ncan convert a negative stress into a positive one\u201d25. \nFrom Selye\u2019s statement, we can notice that focusing on \nnegative stress can only affect us negatively, whether \npsychical or mentally. Applying this to the additional \nstress brought on by the COVID-19 pandemic, one can \nargue that these additional stressors negatively impact \nan individual\u2019s health26. The World Health Organization \nfound that there has been a 25% increase in selected \nmental health conditions during the COVID-19 pandemic \n(i.e., anxiety and depression). 147\n2023/38 (4): 145-151A Quantitative Assessment of Coping Strategies among Jamaican Males 18+ years old: Post-COVID-19\nCOVID-19 has proven to be unpredictable and a \npandemic the world was not prepared for. The frequency \nof its transmission and how lethal it is causing the most \ndeveloped countries economic and healthcare systems \nto go under severe stress or near collapse causing \nstress on everyone. Jamaica recorded its first case \nof COVID-19 on March 10, 2020; COVID-19 affects \nindividuals differently based on social class, ethnicity \nand gender. As known males tend to have higher rates \nof mortality including suicides than females and this is \nowing to their risky behaviour, engagement in stressful \nactivities, healthcare hesitancy, and COVID-19 may have \nbrought with it a different state of stress on them. \nPre-COVID-19 studies indicate men\u2019s self-reported \ncoping strategies, avoidance-0riented strategies typified \nby excessive use of drugs or alcohol to cope with one\u2019s \ndistress28,29. Over-focusing at work as a distraction from \nissues, along with trying to hide or minimize symptoms \nby withdrawing and disengaging from relationships; are \navoidance-oriented strategies that typically exacerbate \ndistress in the long term. Many of these strategies are \nlinked to traditionally masculine norms, concealing and \navoiding negative emotions and partaking in risk-taking \nbehaviours; represent efforts of men to regain a feeling \nof control and power or discordant emotions when a \nsense of emasculation is noted. Men\u2019s mental health \nand other illnesses play a role in poverty, and unhealthy \ncoping mechanisms and make people more vulnerable \nto prolong mental health issues30,31. Hence, this study \nused a national probability study to examine the coping \nstrategies employed by Jamaican males post-COVID-19. \nMaterials and Methods\nThe study used cross-sectional web-based survey \ndata on Jamaican men 18 years and older from the \nfourteen parishes of Jamaica, the survey commenced \non October 1, 2022, and ended on November 25, 2022. \nThe Systematic Sampling Technique was utilized to draw \na sample of 1088 respondents utilizing a randomized \nselection of every fifth male in the population. The \nStatistical Institute of Jamaica (STATIN) reported that there \nare 1,350.633 males 18+ years in Jamaica as of the end \nof 201833 The sample size was calculated based on the \n2018 male population for Jamaica, which was 1,350, \n633. The researcher used the 2018 male population, a \n95% confidence level, and a 2.97% margin of error. \nThe survey was anonymous, so participants were not \nrequired to disclose any personal information. Informed \nconsent was implied based on the participants that \ncompleted the survey. Participants completed the \nsurvey voluntarily and were able to withdraw at any time \nwithout any form of liability. A 32-item questionnaire was \nused to collect the data. The 32-item questionnaire \nwas subdivided into 4 general demographic profiles of the sample and 28 items from the Brief Cope Scale \n(coping orientation to a problem experienced). The Brief \nCope Scale was divided into eight subscales namely, \nResting, Guarding, Relaxation, Asking for assistance, \nTask persistence, Seeking social support, Coping self-\nstatements and exercise/strength and each item was \nscored using the following statements; I haven\u2019t been \ndoing this at all, I\u2019ve been doing this a little bit, I\u2019ve been \ndoing this a medium amount and I\u2019ve been doing this \na lot8. The researcher sought and received permission \nfrom the late Dr Charles Carver\u2019s wife who was also a \ncollaborator in the development of the Brief Cope Scale8.  \nData were stored, retrieved and analyzed, using the \nStatistical Packages for the Social Sciences (SPSS) \nfor Windows, Version 28.0. The data were analyzed by \nway of descriptive statistics, reliability analysis, and per \ncents, and presented using tables and graphs. Evans\u2019 \ninterpretation of correlation coefficients was used to \nassess the reliability valuations34. Evans forwarded that a \nvery weak correlation ranges from 0 to 0.19; weak is 0.20 \nto 0.39; moderate is 0.40 to 0.59; strong is 0.60 to 0.79; \nand, a very strong correlation is 0.80 to 1.0034. Based on \nEvans\u2019 interpretation of statistical correlation coefficients, \n0.70 (or 70%) is used to indicate a good Cronbach alpha, \nand construct validity of Brief Coping strategies. \nResults\nTable I presents the sociodemographic characteristics \nof the sampled male respondents. Of the sampled male \nrespondents (n=1088), most of them were less than 28 \nyears old (29.0%, n=31%, lived in St. Catherine (18.85, \n204), where single people (43.1%, 469), and have tertiary \nlevel education (40.6%, 442).\nTable II presents the reliability testing of the subscales \nand overall Brief Coping Inventory using a sample of \n1088 Jamaican males 18 years and older. Using Evans\u2019 \ninterpretation of correlation coefficients [Evans, 1996], \nitems for the subscales and overall Brief Coping Inventory \nare very good to employ for assessing the construct of \ncoping among Jamaican males.\nTable III presents descriptive statistics for fourteen14 \npairs of double coping subscales. The fourteen14 pairs of \ndouble coping subscales provide insights into the various \ntypes of coping strategies employed by Jamaican males \npost-COVID-19 to deal with the hardship of life. Based \non the mean values for each of the pair double coping \nstrategies, Jamaican males have been employing all \nfourteen pairs of coping strategies post-COVID-19. The \nresults revealed that substance use has been strongly \nemployed by Jamaican males to address the challenges \nof life post-COVID-19. In addition, religion and denial \nhave been strongly employed by sampled Jamaicans \nto address the challenges of life post-COVID-19. 148\n2023/38 (4): 145-151Paul Andrew Bourne et al. \nTable I: Sociodemographic Characteristics of the Sampled Male Respondents, \nn=1088.\nDetails % (n)\nAge cohort \n     18 - 27 Years Old 29.0 (315)\n     28 - 38 Years Old 23.1 (251)\n     39 - 48 Years Old 15.3 (167)\n     49 - 58 Years Old 11.7 (127)\n     59 - 68 Years Old 8.6 (94)\n     69 - 78 Years Old 6.7 (73)\n     79+ Years Old 5.6 (61)\nParish of residence \n     Manchester 6.9 (75)\n     St. Elizabeth 5.4 (59)\n     Westmoreland 5.2 (57)\n     Trelawny 2.8 (30)\n     Hanover 2.5 (27)\n     Kingston 18.5 (201)\n     St. Catherine 18.8 (204)\n     Portland 3.2 (35)\n     St. Andrew 5.6 (61)\n     St. James 7.5 (82)\n     St. Mary 4.6 (50)\n     St. Ann 6.3 (68)\n     St. Thomas 3.4 (37)\n     Clarendon 9.4 (102)\nMarital status \n     Single 43.1 (469)\n     Divorced 8.4 (91)\n     Married 37.1 (404)\n     Widowed 11.4 (124)\nEducational level \n     None 3.3 (36)\n     Primary level 8.9 (97)\n     Secondary level 28.9 (314)\n     Vocational training 18.3 (199)\n     Tertiary level 40.6 (442)Table III: Descriptive Statistics for the 14 pairs of double coping subscales.\nNote: The maximum value for each subscale is eight8.Details Mean\u00b1SD, 95% CI\nSelf-distraction 4.9\u00b11.85, 4.8 - 5.1\nActive coping 5.1\u00b11.86, 5.0 - 5.2\nDenial 4.8\u00b11.91, 4.7 - 4.9\nSubstance use 4.8\u00b12.01, 4.7 - 4.9\nUse Emotional 4.8\u00b11.89, 4.7 - 5.0\nInstrumental Support 4.9\u00b11.87, 4.8 - 5.0 \nBehavioural Disengagement 4.8\u00b11.93, 4.7 - 5.0\nVenting 5.0\u00b11.85, 4.8 - 5.1\nPositive Reframing 5.1\u00b11.88, 4.9 - 5.2\nPlanning 5.1\u00b11.90, 5.0 - 5.2\nHumour 4.9\u00b11.91, 4.8 - 5.1\nAcceptance 5.1\u00b11.91, 5.0 - 5.3\nReligion 5.0\u00b11.91, 4.9 - 5.2\nSelf-blame 5.0\u00b11.89, 4.8 - 5.1\nTable II: Reliability Testing of Subscales and Overall Brief Coping Inventory.\nDetails Cronbach alpha\nProblem-focused Coping Inventory 0.935\nEmotion-focused Coping Inventory 0.947\nAvoidant Coping Inventory 0.929\nOverall Brief Coping Inventory 0.976Table IV: Descriptive Statistics of the 3 subscales.\nDetails Mean\u00b1SD, 95% CI\nProblem-focused Coping 20.1\u00b16.8, 19.7 - 20.5; maximum = 32\nEmotion-focused Coping 30.0\u00b19.8,  29.3 - 30.5; maximum = 48\nAvoidant Coping 19.3\u00b16.8, 18.9 - 19.8; maximum = 32\nOverall Brief Coping Index 69.3\u00b122.6, 68.0 - 70.7; maximum = 120\nTable V: Descriptive Statistics for Avoidant Coping Strategy.\nNotes: The maximum value is 4 for each item. Details Mean SD N\n1. I\u2019ve been turning to work or other activities to take my mind off things 2.46 0.998 1088\n3. I\u2019ve been saying to myself \u201cthis isn\u2019t real\u201d 2.44 1.069 1088\n4. I\u2019ve been using alcohol or other drugs to myself feel better 2.39 1.070 1088\n6. I\u2019ve been giving up trying to deal with it 2.40 1.046 1088\n8.  I\u2019ve been refusing to believe that it has happened 2.38 1.022 1088\n11. I\u2019ve been using alcohol or other drugs to help me get through it 2.41 1.068 1088\n16. I\u2019ve been giving up the attempt to cope 2.38 1.049 1088\n19. I\u2019ve been doing something to think about it less, such as going  2.48 1.024 1088\n      to movies, watching TV, reading, daydreaming, sleeping, or shopping Furthermore, self-blame and self-distraction have also \nbeen a part of the strategies employed by Jamaican \nmales to deal with life post-COVID-19. In addition to \nthe aforementioned issues, Jamaican males have been \nventing and acceptance of the challenges experienced in \ntheir lives post-COVID-19.Table IV presents descriptive statistics for the three \ngeneral subscales of coping strategies employed by \nJamaican males as well as the overall Brief Coping \nstrategies employed by them to deal with the hardship of \nlife post-COVID-19. Jamaican males have been moderately \nemploying various coping strategies to deal with the \nhardship of life post-COVID-19 (overall Brief Coping Index \n= 69.3\u00b122.6, maximum value = 120). On disaggregating \nthe various sub-components of coping strategies, the \nresults revealed that the sampled males have been \nstrongly employing problem-focus, emotion-focused, and \navoidant coping strategies to deal with life\u2019s difficulties \npost-COVID-19. Based on the results of the current study, \na potent deduction is that males are not effectively dealing \nwith the hardship of life post-COVID-19. This extrapolation \nfrom the findings is based on the widespread utilization of all \nthe established coping strategies as developed by Carver \n(1997), and Carver and colleagues (1989), particularly the \navoidant coping strategies. \nThe high utilization of avoidant coping strategies \nspeaks to delay behaviour, penned-up feelings, and \nchallenges that must be addressed in the future. Some \nof the avoidant coping strategies and their degree of \nemployment of these are presented in table V.149\n2023/38 (4): 145-151A Quantitative Assessment of Coping Strategies among Jamaican Males 18+ years old: Post-COVID-19\nTable V presents the descriptive statistics for the items \nin the avoidant coping strategies. On average, Jamaican \nmales have been turning to work or other activities to \ntake their minds off things (2.46\u00b10.998, out of 4), I\u2019ve \nbeen doing something to think about it less, such as \ngoing to movies, watching TV, reading, daydreaming, \nsleeping, or shopping (2.48\u00b11.024, out of 4), I\u2019ve been \nsaying to myself \u201cthis isn\u2019t real\u201d (2.44\u00b11.069, out of \n4), and so forth. A point of emphasis of this study is \nthe utilization of substances as a coping mechanism \n(2.41\u00b11.068, out of 4).\nFigure 1 depicts the prevalence of Jamaican males \nusing alcohol and hard drugs post-COVID-19. Of the \nsampled male respondents (n=1088), the response \nrate to the statement \u2018I\u2019ve been using alcohol or other \ndrugs to help me get through it.\u2019 The results revealed \nthat three in every four Jamaican males have been using \nhard drugs and consuming alcohol post-COVID-19. \nIn addition, one in every 5 Jamaican males has been \nutilizing hard drugs or consuming alcohol frequently \npost-COVID-19 as a coping mechanism.\nDiscussion\nThe COVID-19 pandemic has changed the population/\ndemographic composition of the world\u2019s human \npopulation. Many measures were implemented \nby governments across the globe to address \nthe COVID-19 pandemic, and the byproducts of \nthese measures include unemployment, low social \ninterventions, reduced living standards, increased \nfrustrations, and fright of the pandemic. The pandemic \nhas been lifted by the World Health Organization \nand the Centers for Disease Control and Prevention; \nbut, there are many challenges during this post-\nCOVID-19 period. In fact, \u201cExperiencing post-COVID \nconditions can be confusing and frustrating, and a \nperson who feels sick long-term may feel isolated. \nEveryone experiences these conditions differently \nand may want different types of support or even no \nsupport at all\u201d [35]. The current study revealed that the \npsychological/mental health status of Jamaican males has been exponentially compromised and has left them \nsearching for solutions, and as a result employing many \ncoping strategies in this post-COVID-19 era. 1) three in \nevery four Jamaican males have been using hard drugs \nand consuming alcohol post-COVID-19. In addition, \none in every 5 Jamaican males has been utilizing hard \ndrugs or consuming alcohol frequently post-COVID-19 \nas a coping mechanism, 2) on average, Jamaican \nmales have been turning to work or other activities to \ntake their minds off things (2.46\u00b10.998, out of 4), I\u2019ve \nbeen doing something to think about it less, such as \ngoing to movies, watching TV, reading, daydreaming, \nsleeping, or shopping (2.48\u00b11.024, out of 4), I\u2019ve \nbeen saying to myself \u201cthis isn\u2019t real\u201d (2.44\u00b11.069, \nout of 4), and so forth, 3) Jamaican males have been \nmoderately employing various coping strategies to deal \nwith the hardship of life post-COVID-19 (overall Brief \nCoping Index = 69.3\u00b122.6, maximum value = 120). On \ndisaggregating the various sub-components of coping \nstrategies, the results revealed that the sampled males \nhave been strongly employing problem-focus, emotion-\nfocused, and avoidant coping strategies to deal with \nlife\u2019s difficulties post-COVID-19.\nThe present study highlights that Jamaican males are \nengaged in various activities to address the challenges \nencountered as a result of the COVID-19 pandemic. \nThe reality is, they are engaging in different activities only \nbecause of wanting to cope with post-COVID-19. The \nCenters for Disease Control and Prevention provides \na rationale for men employing various measures to \nlive, post-COVID-19, which is aptly \u201cLearning to cope \nwith stress healthily will help you, the people you care \nabout, and those around you become more resilient\u201d36. \nJamaican males are in the process of dealing with the \nchallenges that emerged during COVID-19, which has \nbeen equally presented in the literature37-42. \nDuring this learning process, they have employed \nboth negative and positive measures to learn the right \nmeasures to deal with issues that emerged during the \npandemic. Hence, this accounts for the substance use \nthat has been strongly engaged by Jamaican males \nto address the challenges of life post-COVID-19. This \nstudy is not forwarding that a judgement should be \nascribed to Jamaican males, but the literature provides \na context for understanding the behaviour of people \npost-COVID-19. The Mount Sinai Hospital cited, \u201cIt \nmakes a lot of sense that people are feeling anxious \nand unsettled right now. Just when we were finally \nadjusting to a new normal with some predictability and \nflow, the world is preparing to change all over again. \nFuture uncertainty and a sense of not knowing what \nto expect can fuel anticipatory anxiety. There is even a \ndiagnosis for this feeling: adjustment disorder\u201d40. As a \nresult, they are engaged in destruction practices simply \nbecause of the anxiety, uncertainty, unsettled mental \nstate, unknown, and wanting to settle their experiences Figure 1: Using Alcohol and Hard drugs.Comsuming Alcohol and hard drugsI\u2019ve been doing this a lot 19,8%\n26,6%\n28,6%\n25,1%\n0% 10,0% 20,0% 30,0%I\u2019ve been doing this a medium amount\nI\u2019ve been doing this a little bit\nI haven\u2019t been doing this a all150\n2023/38 (4): 145-151Paul Andrew Bourne et al. \npost-COVID-19. The employment of the various coping \nstrategies by Jamaican males is simply in keeping with \nwhat Bhattacharjee and Ghosh43 referred to as \u2018Coping \nwith the new normal. \nConclusion\nThe current study revealed that 1) three in every four \nJamaican males have been using hard drugs and \nconsuming alcohol post-COVID-19, 2) Jamaican \nmales have been turning to work or other activities to \ntake their minds off things (2.46\u00b10.998, out of 4), I\u2019ve \nbeen doing something to think about it less, such as \ngoing to movies, watching TV, reading, daydreaming, \nsleeping, or shopping (2.48\u00b11.024, out of 4), I\u2019ve been \nsaying to myself \u201cthis isn\u2019t real\u201d (2.44\u00b11.069, out of \n4), Jamaican males have been moderately employing \nvarious coping strategies to deal with the hardship \nof life post-COVID-19 (overall Brief Coping Index = \n69.3\u00b122.6, maximum value = 120). On disaggregating \nthe various sub-components of coping strategies, the \nresults revealed that the sampled males have been \nstrongly employing problem-focus, emotion-focused, \nand avoidant coping strategies to deal with life\u2019s \ndifficulties post-COVID-19. This research has provided \ninsight into the stressors experienced by Jamaican \nmales post-COVID-19 and is as such forwarding a \nneed for social intervention programmes to assist them \nto deal with the new normal set by the pandemic. Annexe\nCompeting Interests\nAuthors have declared that they have no competing \ninterests.\nReferences\n1. Mental Health Foundation. Men and mental health. Mental Health \nFoundation: England and Wales, 2022. https://www.mentalhealth.org.\nuk/explore-mental-health/a-z-topics/men-and-mDo mental-health.\n2. CBHS Health. What coping mechanisms do men really use to stay \nmentally healthy? CBHS; 2019. https://www.cbhs.com.au/mind-\nand-body/blog/what-coping-mechanisms-do-men-really-use-to-stay-\nmentallyhealthy\n3. Lazarus RS, Folkman S. Stress, Appraisal and Coping. New York: \nSpringer; 1984. \n4. Endler NS, Parker JD. Multidimensional assessment of coping: A \ncritical evaluation. Journal of Personality and Social Psychology, 1990; \n58(5), 844\u201354. https://doi.org/10.1037/0022-3514.58.5.844\n5. Matud MP . Gender Differences in Stress and Coping Styles. Personality \nand Individual Differences, 2004; 37, 1401-15.\n6. http://dx.doi.org/10.1016/j.paid.2004.01.010\n7. Carver CS. You want to measure coping but your protocol is too long: \nConsider the brief cope. International journal of behavioural medicine, \n1997; 4(1), 92-100.\n8. Raypole C. 7 emotion-focused coping techniques for uncertain times. \nEvolve Health Center: Vancouver; 2022. https://evolvewellnessvancouver.\nca/2020/05/08/7-emotion-focused-coping-techniques-for-uncertain-times/9. Suratana S, Tamornpark R, Apidechkul T, Srichan P , Mulikaburt T, \nWongnuch P , et al. Impacts of and survival adaptations to the COVID-19 \npandemic among the hill tribe population of northern Thailand: A qualitative \nstudy. PLOS ONE, 2021; 16(6), e0252326. https://doi.org/10.1371/\njournal.pone.0252326\n10. Mofijur M, Fattah IMR, Alam MA, Islam ABMS, Ong HC, Rahman \nSMA, et al. Impact of COVID-19 on the social, economic, environmental \nand energy domains: Lessons learnt from a global pandemic. Sustain \nProd Consum. 2021 Apr;26:343-59. DOI: 10.1016/j.spc.2020.10.016. \nEpub 2020 Oct 14. PMID: 33072833; PMCID: PMC7556229.\n11. Woodruff Family Law Group. COVID and the mental and physical \neffects on men\u2019s health. North Carolina: Woodruff Family Law Group; \n2021. https://www.northcarolinadivorcelawyersblog.com/covid-and-the-\nmental-and-physical-effects-on-mens-health/\n12. White A. Men and COVID-19: the aftermath, Postgraduate Medicine, \n2020; 132:sup4, 18-27, DOI: 10.1080/00325481.2020.1823760\n13. Sousa AR, Santana TS, Moreira WC, Sousa AFL, Carvalho ESS, \nCraveiro I. Emotions and coping strategies of men to the COVID-19 \npandemic in Brazil. Texto Contexto Enferm [Internet]. 2020 [cited \nYEAR MONTH DAY]; 29:e20200248. Available from: https://doi.\norg/10.1590/1980-265X-TCE-2020-0248.\n14. Ellison JM, Semlow AR, Jaeger EC, Griffth DM. COVID-19 and \nMENtal Health: Addressing Men\u2019s Mental Health Needs in the Digital Table Number of Suicides by Gender and Male to Female Ratio.\n*This figure is for January 1 to November 28, 2022\n1Source: Jamaica Constabulary Force. (various years)\n2Computed by Paul Andrew BourneYear Male Female Total1 Male to Female2\n2000 66 11 77 6:1\n2001 62 13 75 5:1\n2002 51 6 57 9:1\n2003 55 9 64 6:1\n2004 6 4 10 2:1\n2005 48 10 58 5:1\n2006 42 5 47 8:1\n2007 46 4 50 12:1\n2008 41 6 47 7:1\n2009 51 3 54 17:1\n2010 29 6 35 5:1\n2011 47 5 52 9:1\n2012 45 8 53 6:1\n2013 45 10 55 5:1\n2014 46 6 52 8:1\n2015 51 8 59 6:1\n2016 50 5 55 10:1\n2017 42 5 47 8:1\n2018 56 5 61 11:1\n2019 51 7 58 7:1\n2020 37 6 43 6:1\n2021 44 7 51 6:1\n2022* 46 4 50 12:1151\n2023/38 (4): 145-151A Quantitative Assessment of Coping Strategies among Jamaican Males 18+ years old: Post-COVID-19\nWorld. Am J Mens Health. 2021 Jul-Aug;15(4):15579883211030021. \nDOI: 10.1177/15579883211030021. PMID: 34229530; PMCID: \nPMC8267042.\n15. Wilson MJ, Seidler ZE, Oliffe JL, Toogood N, Kealy D, Ogrodniczuk \nJS, Walther A, Rice SM. \u201cAppreciate the Little Things\u201d: A Qualitative \nSurvey of Men\u2019s Coping Strategies and Mental Health Impacts \nDuring the COVID-19 Pandemic. Am J Mens Health. 2022 May-\nJun;16(3):15579883221099794. doi: 10.1177/15579883221099794. \n16. National Center for Chronic Disease Prevention and Health Promotion, \nDivision of Population Health. Coping with stress. Atlanta; CDC: 2022. https://\nwww.cdc.gov/mentalhealth/stress-coping/cope-with-stress/index.html.\n17. Livingston JD, Youssef GJ, Francis LM, Greenwood CJ, Olsson \nCA, Macdonald JA. Hidden in Plain Sight? Men\u2019s Coping Patterns and \nPsychological Distress Before and During the COVID-19 Pandemic. Front \nPsychiatry. 2022 Jan 5;12:772942. doi: 10.3389/fpsyt.2021.772942. \nPMID: 35069282; PMCID: PMC8766713.\n18. Gottert A, Shattuck D, Pulerwitz J, Betron M, McLarnon C, Wilkins JD, \net al. Meeting men\u2019s mental health needs during COVID-19 and beyond: \na global health imperative. BMJ Glob Health. 2022 Apr;7(4):e008297. \ndoi: 10.1136/bmjgh-2021-008297. \n19. Ede H. The link between your body\u2019s physical and mental health is \nexplained. PACT: Bradford: 2020. https://physiciansallianceofconnecticut.\ncom/blog/link-between-physical-and-mental-health/\n20. Manchia M, Gathier AW, Yapici-Eser H, Schmidt MV, de Quervain \nD, van Amelsvoort T, et al. The impact of the prolonged COVID-19 \npandemic on stress resilience and mental health: A critical review across \nwaves. Eur Neuropsychopharmacol. 2022 Feb;55:22-83. doi: 10.1016/j.\neuroneuro.2021.10.864. Epub 2021 Oct 29. PMID: 34818601; PMCID: \nPMC8554139.\n21. Voltmer E, K\u00f6slich-Strumann S, Walther A, Kasem M, Obst K, K\u00f6tter \nT. The impact of the COVID-19 pandemic on stress, mental health and \ncoping behavior in German University students - a longitudinal study \nbefore and after the onset of the pandemic. BMC Public Health. 2021 Jul \n13;21(1):1385. doi: 10.1186/s12889-021-11295-6.  \n22. Cleveland Clinic. Coping with COVID Survey Illustrates the mental and \nphysical toll of pandemic is taking on men. Cleveland: Cleveland Clinic; \n2020. https://newsroom.clevelandclinic.org/2020/09/02/cleveland-\nclinic-coping-with-covid-survey-illustrates-the-mental-and-physical-toll-\nthe-pandemic-is-taking-on-men/\n23. Roberts A, Rogers J, Mason R, Siriwardena AN, Hogue T, Whitley GA, \net al. Alcohol and other substance use during the COVID-19 pandemic: A \nsystematic review. Drug Alcohol Depend. 2021 Dec 1;229(PtA):109150. \ndoi: 10.1016/j.drugalcdep.2021.109150. Epub 2021 Oct 29. PMID: \n34749198; PMCID: PMC8559994.\n24. Bourne PA, Reid, D-A,  Plummer S, Lewis T, Ferguson J, Foster C, et al. \nThe Influence of Alcohol Consumption on Sexual Promiscuity among Young \nJamaican Males during the COVID-19 Pandemic. International Journal of \nRecent Advances in Medical & Pharma Research, 2020; 3(1): 23-35.\n25. Bonsaksen T, Ekeberg \u00d8, Skogstad L, Heir T, Grimholt TK. Use \nof Alcohol and Addictive Drugs During the COVID-19 Outbreak in \nNorway: Associations With Mental Health and Pandemic-Related \nProblems. Frontiers in Public Health, 2020. https://doi.org/10.3389/\nfpubh.2021.667729.\n26. Magellan Health. Embracing lifelong wellness. https://www.bnl.gov/\nhr/occmed/hpp/files/pdf/lifelongwellness-newsletter.pdf\n27. World Health Organization (WHO). He believed stress was necessary to \nhave an exciting life but too much negative stress would lead to illness and \ndeath. Geneva: WHO; 2022. https://www.who.int/news-room/feature-stories/\ndetail/the-impact-of-covid-19-on-mental-health-cannot-be-made-light-of.\n28. World Health Organization. COVID-19 pandemic triggers 25% \nincrease in prevalence of anxiety and depression worldwide. Geneva: WHO; 2022. https://www.who.int/news/item/02-03-2022-covid-\n19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-\ndepression-worldwide.\n29. Wilson MJ, Seidler ZE, Oliffe JL, Toogood N, Kealy D, Ogrodniczuk JS, \net al. \u201cAppreciate the Little Things\u201d: A Qualitative Survey of Men\u2019s Coping \nStrategies and Mental Health Impacts During the COVID-19 Pandemic. \nAm J Mens Health. 2022 May-Jun;16(3):15579883221099794. \nDOI: 10.1177/15579883221099794. PMID: 35608377; PMCID: \nPMC9134443.\n30. Livingston JD, Youssef GJ, Francis LM, Greenwood CJ, Olsson \nCA, Macdonald JA. Hidden in Plain Sight? Men\u2019s Coping Patterns and \nPsychological Distress Before and During the COVID-19 Pandemic. \nFrontiers in Psychiatry . https://doi.org/10.3389/fpsyt.2021.772942\n31. Frech A, Damaske S. Men\u2019s Income Trajectories and Physical \nand Mental Health at Midlife. AJS. 2019 Mar;124(5):1372-1412. DOI: \n10.1086/702775. PMID: 34176948; PMCID: PMC8231310.\n32. World Health Organization. Mental health: strengthening our \nresponse. Geneva: WHO; 2022. https://www.who.int/news-room/fact-\nsheets/detail/mental-health-strengthening-our-response\n33. Statistical Institute of Jamaica. Mid-year population by age and \nsex. Kingston: SATTIN;2022. https://statinja.gov.jm/Demo_SocialStats/\nnewMidYearPopulationbyAgeandSex2008.aspx\n34. Evans JD. Straightforward Statistics for the Behavioral Sciences. \nBrooks/Cole Publishing; Pacific Grove, California; 1996.\n35. National Center for Immunization and Respiratory Diseases (NCIRD), \nDivision of Viral Diseases. Caring for People with Post-COVID Conditions. \nAtlanta: CDC; 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-\nterm-effects/care-post-covid.html#:~:text=Ways%20to%20Cope%20\nwith%20Stress&text=Take%20breaks%20from%20watching%2C%20\nreading,%2C%20meditate%2C%20or%20practice%20mindfulness.\n36. National Center for Immunization and Respiratory Diseases (NCIRD), \nDivision of Viral Diseases. Coping with Stress. Atlanta: CDC; 2022. https://\nwww.cdc.gov/mentalhealth/stress-coping/cope-with-stress/index.html.\n37. Fluharty M, Fancourt D. How have people been coping during the \nCOVID-19 pandemic? Patterns and predictors of coping strategies \namongst 26,016 UK adults. BMC Psychol 2021; 9, 107. https://doi.\norg/10.1186/s40359-021-00603-9\n38. Kavanagh BE, Ashton MM, Lotfaliany M, McCallum M, Wrobel \nAL, Croce S, et al. Saunders L, Lai J, Berk L. Coping with COVID-19: \nExploring coping strategies, distress, and post-traumatic growth during \nthe COVID-19 pandemic in Australia. Frontiers in Psychiatry , 2022; 13. \nhttps://doi.org/10.3389/fpsyt.2022.1025767.\n39. G\u00f6kalp Z\u015e, Ko\u00e7 H, Kozan H\u0130\u00d6. Coping and Post-traumatic \nGrowth Among COVID-19 Patients: A Qualitative Study. J Adult Dev. \n2022;29(3):228-39. doi: 10.1007/s10804-022-09398-4. Epub 2022 \nMar 15. PMID: 35308045; PMCID: PMC8921436.\n40. Mount Sinai. How to cope with post-pandemic anxiety. New York: \nMount Sinai; 2022. https://health.mountsinai.org/blog/how-to-cope-\nwith-post-pandemic-anxiety/\n41. World Health Organization (WHO). Coping with the unknown \u2013 a \nfamily\u2019s story of living with long COVID. Geneva: WHO; 2022. https://\nwww.who.int/europe/news-room/feature-stories/item/coping-with-the-\nunknown---a-family-s-story-of-living-with-long-covid\n42. Kira IA, Shuwiekh HAM, Ahmed SAE, Ebada EE, Tantawy SF, Waheep \nNN, Ashby JS. Coping with COVID-19 Prolonged and Cumulative \nStressors: the Case Example of Egypt. Int J Ment Health Addict. 2022 \nJan 8:1-22. doi: 10.1007/s11469-021-00712-x. \n43. Bhattacharjee A, Ghosh T. COVID-19 Pandemic and Stress: Coping \nwith the New Normal. Journal of Prevention and Health Promotion, \n2022;3(1):30-52. https://doi.org/10.1177/26320770211050058152\n2023/38 (4): 152-157ORIGINAL\nAssociation between different cardiometabolic risk scales \nand metabolic syndrome scales in 418.343 Spanish workers\nAsociaci\u00f3n entre diferentes escalas de riesgo cardiometab\u00f3lico \ny escalas de s\u00edndrome metab\u00f3lico en 418.343 trabajadores espa\u00f1oles  \nAndr\u00e9s Mart\u00ednez Jover1      , \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez1      , Pilar Tom\u00e1s Gil1      ,\nJosep Lluis Coll Villalonga1      , Pau Mart\u00ed Lliteras1      , Jos\u00e9 Ignacio Ram\u00edrez Manent1,2      \n1. Grupo ADEMA-SALUD IUNICS University of the Balearic Islands. Spain.\n2. Mallorca Primary Care eISSN 2255-0569\nReceived: 18 - II - 2023\nAccepted: 5 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.152Corresponding author\n\u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez \nE-mail: angarturo@gmail.com  \nAbstract \nIntroduction: Cardiometabolic diseases are currently a public health problem in all countries of the world due to their high \nprevalence and high morbidity and mortality. \nMaterial and methods: Descriptive, cross-sectional study to assess the association between various cardiometabolic risk scales \nand metabolic syndrome assessed with three different criteria. \nResults: Both the mean values and the prevalence of elevated values of the different cardiometabolic risk scales analyzed \n(atherogenic indices, vascular age, REGICOR and SCORE scales, atherogenic dyslipidemia, lipid triad, and diabesity) were higher \nin persons with metabolic syndrome with any of the criteria. The scales that most increase the risk of presenting metabolic \nsyndrome are the atherogenic indices, AD, LT and diabesity. \nConclusions: There is a good relationship between the cardiometabolic risk scales analyzed and metabolic syndrome with any of \nthe three criteria. The variables most associated with an increased risk of developing metabolic syndrome are atherogenic indices, \natherogenic dyslipidemia, lipid triad and diabesity.\nKeywords: Metabolic syndrome, atherogenic indices, diabesity, atherogenic dyslipidemia, cardiometabolic risk. \nResumen\nIntroducci\u00f3n: Las enfermedades cardiometab\u00f3licas son en la actualidad un problema de salud p\u00fablica en todos los pa\u00edses del \nmundo tanto por su elevada prevalencia como por su alta morbimortalidad. \nMaterial y m\u00e9todos: Estudio descriptivo y transversal para valorar la asociaci\u00f3n entre diversas escalas de riesgo cardiometab\u00f3-\nlico y el s\u00edndrome metab\u00f3lico valorado con tres criterios diferentes. \nResultados: Tanto los valores medios como la prevalencia de valores elevados de las diferentes escalas de riesgo cardiome-\ntab\u00f3lico analizadas (\u00edndices aterog\u00e9nicos, edad vascular, escalas REGICOR y SCORE, dislipemia aterog\u00e9nica, triada lip\u00eddica y \nDiabesity) presentan cifras superiores en las personas con s\u00edndrome metab\u00f3lico con cualquiera de los criterios. Las escalas que \nm\u00e1s incrementan el riesgo de presentar s\u00edndrome metab\u00f3lico son los \u00edndices aterog\u00e9nicos, DA, LT y Diabesity. \nConclusiones: Existe buena relaci\u00f3n entre las escalas de riesgo cardiometab\u00f3lico analizadas y el s\u00edndrome metab\u00f3lico con cual-\nquiera de los tres criterios. Las variables que m\u00e1s se relacionan con un aumento del riesgo de presentar s\u00edndrome metab\u00f3lico son \nlos \u00edndices aterog\u00e9nicos, dislipemia aterog\u00e9nica, triada lip\u00eddica y Diabesity.\nPalabras clave: S\u00edndrome metab\u00f3lico, actividad f\u00edsica, adherencia a la dieta mediterr\u00e1nea.ID\nID ID IDID ID153\n2023/38 (4): 152-157Association between different cardiometabolic risk scales and metabolic syndrome scales in 418.343 Spanish workers\nIntroduction\nCardiometabolic diseases, due to their high prevalence1 \nand the high morbimortality they cause2, are considered \none of the main public health problems in most countries, \nand not only in developed countries3.\nMetabolic syndrome (MS) is a pathological entity that has \nbeen known for more than a century and encompasses \ndifferent alterations such as obesity (mainly abdominal), \nelevated lipid profile, insulin resistance that results \nin elevated blood glucose levels and elevated blood \npressure4. \nThe similar pathophysiology of both pathological \nconditions suggests that there should be a close \nrelationship between them, so the aim of this study is to \nassess the association between the values of different \ncardiometabolic risk scales and MS determined with \ndifferent criteria in the Spanish working population.\nMaterial and methods\nA descriptive, cross-sectional study was carried out in \n418.343 Spanish workers from different regions and \nwork sectors and selected from occupational medical \nexaminations between the months of January 2017 and \nDecember 2019. The following inclusion criteria were \nestablished: age between 18 and 69 years, working in \none of the companies included in a study, not being in \na situation of temporary disability, signing the informed \nconsent to participate in the study and to use their data \nfor epidemiological purposes.\nFigure 1 shows the flow diagram of the study participants.Measurements and data collection\nAnthropometric (height, weight and waist circumference), \nclinical and analytical measurements were performed by \nthe health professionals of the companies participating \nin the study, after standardization of the measurement \ntechniques.\nWeight (in kg) and height (in cm) were obtained with a \nSECA 700 scale-measuring device. Waist circumference \n(WC) was measured with a SECA measuring tape with \nthe person standing, feet together, trunk erect and \nabdomen relaxed. The tape was placed parallel to the \nground at the height of the last floating rib.\nA calibrated OMRON M3 automatic sphygmomanometer \nwas used to determine blood pressure while the \nperson was seated and after a 10-minute rest. Three \ndeterminations were made one minute apart and the mean \nof the three was obtained. The analytical parameters were \nobtained after 12 h of fasting. Glycemia, total cholesterol \nand triglycerides were obtained by automated enzymatic \nmethods while HDL-c was obtained by a precipitation \nprocess with dextran sulfate-MgCl2. LDL-c was \ncalculated indirectly using the Friedewald formula (only \nvalid for triglycerides below 400 mg/dL). All analytical \nparameters were expressed in mg/dL.\nFriedewald formula: LDL = cholesterol - HDL - \ntriglycerides/5\nMetabolic syndrome (MS) was determined using three \ndifferent criteria: the National Cholesterol Education \nProgram Adult Treatment Panel III (NCEP/ATP-III), the Joint \nInterim Statement (JIS), and the International Diabetes \nFederation (IDF) update5.\nAs cardiometabolic risk scales, the following were \nassessed:\na. Cardiovascular risk scales\n- Years of life lost due to vascular age (ALLY) SCORE and \nFramingham6.\n- REGICOR and SCORE7 scales.\nb. Atherogenic indices\n- Cholesterol/HDL, triglycerides/HDL and LDL/HDL8.\nc. Other\n- Diabesity9.\n- Atherogenic dyslipidemia (AD) and lipid triad (LT)10.\nA smoker is defined as a person who has consumed at \nleast one cigarette a day (or its equivalent in other types \nof consumption) in the last 30 days or has quit smoking \nless than 1 year ago. \nBased on the profession and applying the proposal of \nthe social determinants group of the Spanish Society \nof Epidemiology11, the social class was obtained, \nestablishing three categories: Class I: directors/ Figure 1: Flow chart.\n421.625 workers start the study\n656 do not agree to participate\n1897 lack any variable \nto calculate the CVR\n418,343 (246,061 men and 172,282 \nwomen) finally entered the study729 are under 18 or over 67 years old154\n2023/38 (4): 152-157Andr\u00e9s Mart\u00ednez Jover et al. \nmanagers, university professionals, sportsmen and \nartists; Class II: intermediate occupations and skilled self-\nemployed workers; Class III: unskilled workers.\nThe level of education was classified as primary or \nelementary, secondary and university. We considered \nsmokers to be those who had consumed at least \none cigarette daily (or its equivalent in other types of \nconsumption) during the last month, or had quit smoking \nless than 12 months before. \nHeart-healthy eating habits are determined with the \n\u201cMediterranean diet adherence questionnaire\u201d used in \nthe PREDIMED study12. The questionnaire consists of 14 \nquestions that are scored with 0 and 1 point. Values of 9 \nor more indicate good adherence and therefore that the \ndiet is heart-healthy.\nPhysical activity is assessed with the International Physical \nActivity Questionnaire IPAQ (International Physical Activity \nQuestionnaire), which assesses physical activity in the \nlast week13.\nStatistical analysis\nA descriptive analysis of the categorical variables was \nperformed, calculating the frequency and distribution of \nthe responses for each of them. For quantitative variables, \nthe mean and standard deviation were calculated \nfollowing a normal distribution.\nBivariate association analysis was performed using the \nchi2 test (with correction for Fisher\u2019s exact statistic when \nconditions required it) and Student\u2019s t test for independent \nsamples (for comparison of means). Multivariate \ntechniques were used to establish the variables \nassociated with the most significant risk factors. For \nmultivariate analysis, logistic regression was used, with \ncalculation of the odds ratio and the Hosmer-Lemeshow \ngoodness-of-fit test. ROC curves were performed, and \nthe area under the curve \n(The statistical analysis was performed with the Statistical \nPackage for the Social Sciences (SPSS) version 28.0 \n(IBM Company, New York, NY, USA) for Windows, with \nan accepted statistical significance level of 0.05.\nEthical considerations and/or aspects\nThe research team undertook at all times to follow \nthe ethical principles of health sciences research \nestablished nationally and internationally (Declaration of \nHelsinki), paying special attention to the anonymity of the \nparticipants and the confidentiality of the data collected. \nApproval was requested from the Ethics and Research \nCommittee of the Balearic Islands (CEI-IB), which was \nobtained with indicator IB 4383/20. Participation in \nthe study was voluntary, so the participants gave their \nwritten and oral consent to participate in the study after \nreceiving sufficient information about the nature of the study. To this end, they were given an informed consent \nform, as well as an information sheet explaining the \nobjective of the study.\nThe data collected for the study were identified by a \ncode and only the person responsible for the study can \nrelate these data to the participants. The identity of the \nparticipants will not be disclosed in any report of this study. \nThe investigators will not disseminate any information \nthat could identify them. In any case, the research team \nundertakes to strictly comply with the Organic Law \n3/2018, of December 5, on the protection of personal \ndata and guarantee of digital rights, guaranteeing the \nparticipant in this study that he/she may exercise his/her \nrights of access, rectification, cancellation and opposition \nof the data collected\nResults\nTable I shows the anthropometric and clinical \ncharacteristics of the 418.343 workers (246.061 men \nand 172.282 women) who were included in the study. \nThe mean age of the sample was 40.2 \u00b1 11.0 years, the \nmajority being in the group between 30 and 49 years of \nage. All variables presented more unfavorable values in \nmen. Three out of four workers belonged to social class \nIII, one out of three smoked and slightly more than half \ndid not engage in regular physical activity or have high \nadherence to the Mediterranean diet.\nTable II shows the mean values of the different \ncardiometabolic risk scales analyzed according to the \npresence or absence of metabolic syndrome applying \nthe different criteria in men and women. The mean \nvalues of all the cardiometabolic risk scales were much \nhigher, in both sexes, in those who presented metabolic \nsyndrome applying any of the three criteria. In all cases, \nthe differences observed were statistically significant.\nTable III shows that the prevalence of high values of the \ndifferent cardiometabolic risk scales behaved similarly to \nthe mean values, that is, they were higher in workers with \nmetabolic syndrome, and the differences observed were \nstatistically significant.\nTable IV shows the results of the multinomial logistic \nregression, showing that the risk of presenting MS with the \ndifferent criteria increases in parallel with the increase in \nthe values of the cardiometabolic risk scales. The highest \nodds ratios were found for atherogenic dyslipidemia, lipid \ntriad and diabesity.155\n2023/38 (4): 152-157Association between different cardiometabolic risk scales and metabolic syndrome scales in 418.343 Spanish workers\nSBP systolic bllood pressure. DBP diastolic blood pressure.Table I: Characteristics of the population.\n  Women Men Total  \n n=172.282 n=246.061 n=418.343 \n Mean \u00b1 SD Mean \u00b1 SD Mean \u00b1 SD p-value\nAge 39.6 (10.8) 40.6 (11.1) 40.2 (11.0) <0.0001\nHeight 161.8 (6.5) 174.6 (7.0) 169.4 (9.3) <0.0001\nWeight 66.2 (14.0) 81.4 (14.7) 75.1 (16.2) <0.0001\nBMI 25.3 (5.2) 26.7 (4.5) 26.1 (4.8) <0.0001\nWaist 74.8 (10.6) 86.2 (11.1) 81.5 (12.2) <0.0001\nSBP 117.4 (15.7) 128.2 (15.5) 123.7 (16.5) <0.0001\nDBP 72.6 (10.4) 77.8 (11.0) 75.6 (11.0) <0.0001\nCholesterol 190.6 (35.8) 192.6 (38.9) 191.8 (37.7) <0.0001\nHDL-c 56.8 (8.7) 50.3 (8.5) 53.0 (9.1) <0.0001\nLDL-c 116.1 (34.8) 118.0 (36.7) 117.2 (35.9) <0.0001\nTriglycerides 89.1 (46.2) 123.7 (86.4) 109.5 (74.6) <0.0001\nGlycaemia  87.8 (15.1) 93.3 (21.3) 91.0 (19.2) <0.0001\n  % % % p-value\n18-29 years 20.7 18.8 19.6 <0.0001\n30-39 years 3.0 27.6 17.4 \n40-49 years 29.6 30.0 29.9 \n50-59 years 16.8 19.7 18.5 \n60-69 years 3.2 3.9 3.6 \nPrimary school 51.8 61.2 57.3 <0.0001\nSecondary school 40.7 34.0 36.8 \nUniversity 7.5 4.8 5.9 \nSocial class I 6.9 4.9 5.7 <0.0001\nSocial class II 23.4 14.9 18.4 \nSocial class III 69.7 80.3 75.9 \nNo physical activity 47.8 54.5 51.7 <0.0001\nYes physical activity 52.2 45.5 48.3 \nNo mediterranean diet 48.6 59.0 54.7 <0.0001\nYes mediterranean diet 51.4 41.0 45.3 \nNon-smokers 67.2 66.6 66.8 <0.0001\nSmokers 32.8 33.4 33.2  \nTable II: Mean values of different cardiometabolic risk scales according to the presence or absence of metabolic syndrome with the different criteria by sex.\n  No Yes   No Yes   No Yes  \n MS ATPIII MS ATPIII  MS IDF MS IDF  MS JIS MS JIS\nMen n=98425 n=33115 p-value n=107921 n=23619 p-value n=80890 n=50650 p-value\nALLY VA SCORE 6.7 (6.6) 10.7 (7.1) <0,001 7.2 (6.8) 9.9 (7.0) <0.001 6.1 (6.4) 10.1 (7.1) <0,001\nSCORE 1.5 (2.0) 2.6 (2.8) <0,001 1.7 (2.2) 2.2 (2.5) <0.001 1.3 (1.8) 2.5 (2.7) <0,001\nALLY VA Framingham 4.3 (8.9) 16.4 (10.7) <0,001 5.3 (9.8) 14.6 (10.7) <0.001 3.1 (8.2) 14.5 (10.7) <0,001\nREGICOR 3.2 (2.2) 3.9 (2.6) <0,001 3.2 (2.2) 3.7 (2.5) <0.001 3.1 (2.1) 3.7 (2.5) <0,001\nCholesterol/HDL 3.7 (1.0) 5.1 (1.3) <0,001 3.8 (1.0) 5.0 (1.3) <0.001 3.6 (0.9) 4.8 (1.2) <0,001\nTriglycerides/HDL 2.1 (1.4) 4.9 (3.2) <0,001 2.3 (1.8) 4.5 (3.0) <0.001 2.0 (1.2) 4.3 (2.9) <0,001\nLDL/HDL 2.3 (0.9) 3.1 (1.1) <0,001 2.3 (0.9) 3.1 (1.1) <0.001 2.2 (0.8) 3.0 (1.1) <0,001\nWomen n=72329 n=12967 p-value n=73270 n=12026 p-value n=70168 n=15128 p-value\nALLY VA SCORE 3.7 (5.0) 7.1 (5.4) <0,001 3.8 (5.0) 6.5 (5.4) <0.001 3.6 (4.9) 7.0 (5.4) <0,001\nSCORE 0.4 (0.8) 1.0 (1.4) <0,001 0.4 (0.9) 0.9 (1.3) <0.001 0.4 (0.8) 1.0 (1.4) <0,001\nALLY VA Framingham -1.2 (10.1) 16.5 (13.1) <0,001 -0.8 (10.6) 14.5 (13.1) <0.001 -1.4 (9.9) 15.8 (13.1) <0,001\nREGICOR 2.8 (2.2) 3.5 (2.3) <0,001 2.8 (2.2) 3.4 (2.3) <0.001 2.8 (2.2) 3.5 (2.3) <0,001\nCholesterol/HDL 3.3 (0.8) 4.3 (0.9) <0,001 3.4 (0.8) 4.3 (0.9) <0.001 3.3 (0.8) 4.3 (0.9) <0,001\nTriglycerides/HDL 1.5 (0.7) 3.0 (1.7) <0,001 1.5 (0.8) 2.8 (1.5) <0.001 1.5 (0.7) 2.9 (1.7) <0,001\nLDL/HDL 2.1 (0.8) 2.8 (0.8) <0,001 2.1 (0.8) 2.7 (0.8) <0.001 2.0 (0.7) 2.7 (0.8) <0,001\nALLY VA Years of life lost of vascular age. SCORE REGICOR Giron\u00ed heart registry. HDL High-density lipoproteins. LDL Low-density lipoproteins. MS ATPIII Metabolic \nsyndrome Adult Treatment Panel III. MS IDF Metabolic syndrome International Diabetes Federation. MS JIS Metabolic Syndrome Joint Interim Statement.156\n2023/38 (4): 152-157Andr\u00e9s Mart\u00ednez Jover et al. \nTable III: Prevalence of high values of different cardiometabolic risk scales according to the presence or absence of metabolic syndrome with the different criteria by sex.\n  No Yes   No Yes   No Yes  \n MS ATPIII MS ATPIII  MS IDF MS IDF  MS JIS MS JIS\nMen n=98425 n=33115 p-value n=107921 n=23619 p-value n=80890 n=50650 p-value\nSCORE high 8.1 20.8 <0.001 10.2 16.0 <0.001 6.7 18.7 <0,001\nREGICOR high-very high  1.7 3.5 <0.001 1.9 2.9 <0.001 1.6 3.0 <0,001\nCT/HDL moderate-high 10.1 49.5 <0.001 12.2 46.6 <0.001 7.7 40.4 <0,001\nTG/HDL high 16.4 77.5 <0.001 20.2 69.2 <0.001 12.2 64.6 <0,001\nLDL/HDL high 20.1 54.6 <0.001 21.7 53.4 <0.001 17.0 49.3 <0,001\nDiabesity 0.6 16.9 <0.001 1.1 17.6 <0.001 0.2 11.6 <0,001\nAtherogenic dyslipidemia  1.3 39.7 <0.001 3.8 33.4 <0.001 1.0 25.3 <0,001\nLipid triad 0.3 11.4 <0.001 1.1 9.2 <0.001 0.3 7.2 <0,001\nWomen n=72329 n=12967 p-value n=73270 n=12026 p-value n=70168 n=15128 p-value\nSCORE high 0.8 3.4 <0.001 1.0 2.5 <0.001 0.8 3.1 <0,001\nREGICOR high-very high  1.5 2.3 <0.001 1.5 2.2 <0.001 1.5 2.3 <0,001\nCT/HDL moderate-high 8.5 39.4 <0.001 9.0 35.8 <0.001 8.2 38.0 <0,001\nTG/HDL high 3.4 41.6 <0.001 4.3 33.6 <0.001 3.2 38.2 <0,001\nLDL/HDL high 10.5 35.9 <0.001 10.8 33.8 <0.001 10.2 35.2 <0,001\nDiabesity 0.2 14.8 <0.001 0.2 15.3 <0.001 0.2 13.6 <0,001\nAtherogenic dyslipidemia  1.0 31.8 <0.001 1.8 24.9 <0.001 1.0 27.9 <0,001\nLipid triad 0.3 7.9 <0.001 0.5 5.7 <0.001 0.2 7.0 <0,001\nSCORE Systematic Coronary Risk Estimation REGICOR Gironi Heart Registry. CT Total cholesterol. TG Triglycerides. HDL. High-density lipoproteins. LDL. Low-density \nlipoproteins. TG Triglycerides. MS ATPIII Metabolic syndrome Adult Treatment Panel III. MS IDF Metabolic syndrome International Diabetes Federation. MS JIS Metabolic \nsyndrome Joint Interim Statement.\nSCORE Systematic Coronary Risk Estimation REGICOR Gironi Heart Registry. CT Total cholesterol. HDL. High-density lipoproteins. LDL. Low-density lipoproteins. TG \nTriglycerides. MS ATPIII Metabolic syndrome Adult Treatment Panel III. MS IDF Metabolic syndrome International Diabetes Federation. MS JIS Metabolic syndrome Joint \nInterim Statement.Table IV: Multinomial logistic regression.\n  MS ATPIII MS IDF  MS IDF\n  OR (95% CI) OR (95% CI) OR (95% CI)\nSCORE low 1 1 1\nSCORE moderate 1.50 (1.44-1.56) 1.16 (1.11-1.22) 1.59 (1.53-1.66)\nSCORE high 4.14 (4.00-4.28) 2.00 (1.93-2.08) 5.08 (4.91-5.26)\nREGICOR low 1 1 1\nREGICOR moderate 1.41 (1.20-1.66) 1.38 (1.15-1.65) 1.44 (1.24-1.68)\nREGICOR high 1.76 (1.51-2.06) 1.51 (1.27-1.79) 1.69 (1.46-1.95)\nREGICOR very high 3.01 (2.58-3.50) 2.18 (1.89-2.59) 2.80 (2.42-3.24)\nCT/HDL low 1 1 1\nCT/HDL moderate 2.41 (2.05-2.84) 1.60 (1.37-1.87) 1.86 (1.57-2.20)\nCT/HDL high 20.11 (17.09-23.65) 9.88 (8.46-11.54) 14.26 (12.03-16.90)\nTG/HDL normal 1 1 1\nTG/HDL high 17.04 (16.70-17.39) 8.63 (8.45-8.80) 16.28 (15.99-16.58)\nLDL/HDL normal 1 1 1\nLDL/HDL high 5.12 (5.03-5.22) 4.28 (4.20-4.37) 5.34 (5.25-5.43)\nNo Atherogenic dyslipidemia 1 1 1\nYes Atherogenic dyslipidemia 50.86 (49.12-52.66) 14.37 (13.99-14.77) 34.31 (33.05-35.61)\nNo Lipid triad 1 1 1\nYes Lipid triad 39.66 (37.13-42.37) 9.97 (9.50-10.45) 29.73 (27.67-31.94)\nNo Diabesity 1 1 1\nYes Diabesity 45.42 (43.00-47.98) 26.34 (25.21-27.52) 83.36 (76.43-90.91)\nDiscussion\nThe mean values and prevalence of elevated values \nof the different cardiometabolic risk scales analyzed \n(atherogenic indices, vascular age, REGICOR and \nSCORE scales, atherogenic dyslipidemia, lipid triad, and \ndiabesity) show higher figures in persons with metabolic \nsyndrome with any of the criteria.\nThe scales that most increase the risk of presenting \nmetabolic syndrome are atherogenic indices, AD, LT \nand diabesity.We have not found articles that relate the metabolic \nsyndrome with most of the cardiometabolic scales \nanalyzed in this study, so we will focus on those that \nrelate the MS with cardiovascular risk scales.\nA cohort of persons aged between 20 and 75 years \n(mean age 59 years) with metabolic syndrome presented \na prevalence of high-risk values with the SCORE scale \nof 50% in men and 29.6% in women, higher figures than \nthose found in our study, perhaps due to the higher mean 157\n2023/38 (4): 152-157Association between different cardiometabolic risk scales and metabolic syndrome scales in 418.343 Spanish workers\nage of the sample14. A review of the literature15 concluded \nthat, based on prospective studies, the cardiovascular \nrisk in women with MS is equal to or somewhat higher \nthan that of men with MS; these data differ from those \nfound in our study. Another review conducted in Italy \nshowed that the metabolic syndrome seems to modestly \nincrease cardiovascular risk16.\nStrengths and limitations\nThe greatest strengths of the study are the large sample \nsize (more than 400 000 workers) and the large number \nof cardiometabolic risk and metabolic syndrome scales \nused. As limitations, we would highlight the fact that it \nwas carried out in the working population, which excludes \npeople under 18 and over 69 years of age, so we do \nnot know whether we can extrapolate our results to the \ngeneral population. Conclusions\nThe high values of all the cardiometabolic risk scales \nanalyzed have a very good relationship with the presence \nof MS with the three criteria. The variables that most \nincrease the risk of presenting MS with any of the \nthree criteria are high atherogenic cholesterol/HDL and \ntriglycerides/HDL indices, atherogenic dyslipidemia, lipid \ntriad, and diabesity.\nConflict of Interest\nThe authors declare that no competing interests exist.\nBibliography\n1. Sattar N, Gill JMR, Alazawi W. Improving prevention strategies for \ncardiometabolic disease. Nat Med. 2020 Mar;26(3):320-325. doi: \n10.1038/s41591-020-0786-7.\n2. Bedogni G, Gastaldelli A, Foschi FG. Fatty liver, cardiometabolic \ndisease and mortality. Curr Opin Lipidol. 2020 Feb;31(1):27-31. doi: \n10.1097/MOL.0000000000000652.\n3. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, \nBaddour LM, et al. GBD-NHLBI-JACC Global Burden of Cardiovascular \nDiseases Writing Group. Global Burden of Cardiovascular Diseases \nand Risk Factors, 1990-2019: Update From the GBD 2019 Study. \nJ Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.\njacc.2020.11.010.\n4. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr \nHypertens Rep. 2018 Feb 26;20(2):12. doi: 10.1007/s11906-018-\n0812-z.\n5. Riutord-Sbert P , Riutord-Fe B, Riutord-Fe-N, Arroyo-Bote S, L\u00f3pez-\nGonz\u00e1lez AA, Ramirez-Manent JI. Relationship between physical activity \nand adherence to the mediterranean diet with metabolic syndrome, \nhypertriglyceridemic waist phenotype and hypertensive waist. Medicina \nBalear 2022;37(6):33-8. doi: 10.3306/AJHS.2022.37.06.33\n6. Cuende JI. Vascular Age, RR, ALLY, RALLY and Vascular Speed, \nBased on SCORE: Relations Between New Concepts of Cardiovascular \nPrevention. Rev Esp Cardiol (Engl Ed). 2018 May;71(5):399-400. \nEnglish, Spanish. doi: 10.1016/j.rec.2017.02.043.\n7. G\u00f3mez-Vaquero C, Corrales A, Zacar\u00edas A, Rueda-Gotor J, Blanco \nR, Gonz\u00e1lez-Juanatey C, et al. SCORE and REGICOR function \ncharts underestimate the cardiovascular risk in Spanish patients with \nrheumatoid arthritis. Arthritis Res Ther. 2013 Aug 21;15(4):R91. doi: \n10.1186/ar4271.\n8. L\u00f3pez Gonz\u00e1lez \u00c1A, Rivero Ledo YI, Vicente Herrero MT, Gil Llin\u00e1s \nM, Tom\u00e1s Salv\u00e1 M, Riutord Fe B. \u00cdndices aterog\u00e9nicos en trabajadores \nde diferentes sectores laborales del \u00e1rea Mediterr\u00e1nea Espa\u00f1ola. \nClin Investig Arterioscler. 2015 May-Jun;27(3):118-28. Spanish. doi: \n10.1016/j.arteri.2014.10.004.9. Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined \nburden of obesity and diabetes on heart disease and the role of imaging. \nNat Rev Cardiol. 2021 Apr;18(4):291-304. doi: 10.1038/s41569-020-\n00465-5.\n10. Busquets-Cort\u00e9s C, L\u00f3pez C, Paublini H, Arroyo Bote S, L\u00f3pez-\nGonz\u00e1lez \u00c1A, Ram\u00edrez-Manent JI. Relationship between Atherogenic \nDyslipidaemia and Lipid Triad with Different Scales of Overweight \nand Obesity in 418,343 Spanish Workers. J Nutr Metab. 2022 Aug \n9;2022:9946255. doi: 10.1155/2022/9946255.\n11. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, \nFerrando J, Borrell C, et al. Propuestas de clase social neoweberiana \ny neomarxista a partir de la Clasificaci\u00f3n Nacional de Ocupaciones \n2011. Gac Sanit. 2013 May-Jun;27(3):263-72 doi: 10.1016/j.\ngaceta.2012.12.009.\n12. Ros E. The PREDIMED study. Endocrinol Diabetes Nutr. 2017 \nFeb;64(2):63-6.\n13. Sember V, Meh K, Sori\u0107 M, Starc G, Rocha P , Jurak G. Validity \nand Reliability of International Physical Activity Questionnaires for Adults \nacross EU Countries: Systematic Review and Meta Analysis. Int J \nEnviron Res Public Health. 2020 Sep 30;17(19):7161.\n14. Ruiz-Villaverde G, S\u00e1nchez-Cano D, Ruiz-Villaverde R, Abalos-\nMedina GM, Ram\u00edrez-Rodrigo J, Villaverde-Guti\u00e9rrez C. Agreement \nbetween Framingham-DORICA and SCORE scales in estimation of \ncardiovascular risk in the patients suffering from metabolic syndrome in \nGranada (Spain). Ir J Med Sci. 2011 Jun;180(2):351-4. doi: 10.1007/\ns11845-011-0673-9. \n15. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. \nSex- and gender-related prevalence, cardiovascular risk and therapeutic \napproach in metabolic syndrome: A review of the literature. Pharmacol \nRes. 2017 Jun;120:34-42. doi: 10.1016/j.phrs.2017.03.008. \n16. Vanuzzo D, Pilotto L, Mirolo R, Pirelli S. Cardiovascular risk and \ncardiometabolic risk: an epidemiological evaluation]. G Ital Cardiol \n(Rome). 2008 Apr;9(4 Suppl 1):6S-17S. 158\n2023/38 (4): 158-159ORIGINAL\nEfectos de una intervenci\u00f3n educativa m\u00e9dica personalizada \nsobre la percepci\u00f3n del riesgo de padecer un c\u00e1ncer \nginecol\u00f3gico y de las actitudes para controlarlo: \nun modelo de investigaci\u00f3n asistencial\nEffects of a personalized medical educational intervention on the perception \nof the risk of gynecological cancer and attitudes to control it:\na healthcare research model\nGabriel Ferret1, Gabriela Capllonch1, Javier Cort\u00e9s2\n1. Ginecolog\u00eda Policl\u00ednica Miramar. Palma. Islas Baleares.\n2. Real Academia de Medicina de las Islas BaleareseISSN 2255-0569\nReceived: 19 - II - 2023\nAccepted: 11 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.158Corresponding author\nJavier Cort\u00e9s  \nE-mail: cortes@ocea.es \n  \nResumen\nSe plantea a partir de la necesidad de aplicar criterios de Medicina Personalizada la conveniencia de averiguar cu\u00e1l es la percepci\u00f3n \ndel riesgo de sufrir un c\u00e1ncer ginecol\u00f3gico que siente una mujer y qu\u00e9 hace para prevenirlo, y se contrasta esta informaci\u00f3n con \nla evidencia disponible para su edad de cual es realmente el c\u00e1ncer ginecol\u00f3gico que m\u00e1s la amenaza y cu\u00e1l deber\u00eda ser su \nactitud preventiva, practic\u00e1ndose una intervenci\u00f3n educativa para corregir, si los hubiere, d\u00e9ficits en el concepto y en la actuaci\u00f3n \nderivada. \nPalabras clave: Educaci\u00f3n, c\u00e1ncer ginecol\u00f3gico, prevenci\u00f3n.\nAbstract \nBased on the need to apply Personalized Medicine criteria, the convenience of finding out what is the perception of the risk of \nsuffering a gynaecological cancer that a woman feels and what she does to prevent it is considered. This information is contrasted \nwith the evidence available for her age, which is really the gynaecological cancer that threatens the most and what should be its \npreventive attitude, practicing an educational intervention to correct, if any, deficits in the concept and in the derived action.\nKeywords: Education, gynecological cancer, prevention. ID\nLa Medicina se est\u00e1 dirigiendo hacia la aplicaci\u00f3n de \npautas personalizadas de atenci\u00f3n, incluyendo las de \nprevenci\u00f3n y tratamiento de los c\u00e1nceres ginecol\u00f3gicos, \nadaptadas a cada grupo de edad y al riesgo de cada \npaciente, la llamada Medicina de Precisi\u00f3n, bien \ndefinida en sus aspectos oncol\u00f3gicos por el National \nCancer Institute 1. Establecer pautas por un lado fieles \na las recomendaciones de los organismos nacionales e \ninternacionales que se ocupan del asunto y al mismo \ntiempo adaptar los procedimientos al perfil de la persona \nque consulta. En prevenci\u00f3n del c\u00e1ncer ginecol\u00f3gico, \nlos esquemas de aplicaci\u00f3n cl\u00ednica est\u00e1n recientemente publicados a nivel nacional e internacional y son \nabsolutamente coincidentes2,3.\nEntre las mujeres que acuden a la consulta ginecol\u00f3gica \npara revisiones de salud los autores han percibido un \ndesconocimiento de cu\u00e1l es el riesgo real personal \nde padecer un c\u00e1ncer ginecol\u00f3gico y, especialmente, \nqu\u00e9 tipo de c\u00e1ncer es el que por razones de edad \ne historia personal o familiar m\u00e1s les amenaza. Una \nestimaci\u00f3n inicial realizada por uno de los autores \ndemostr\u00f3 esta ignorancia y/o esta confusi\u00f3n4 hasta \nniveles que perjudican seriamente la acci\u00f3n preventiva 159\n2023/38 (4): 158-159Efectos de una intervenci\u00f3n educativa m\u00e9dica personalizada sobre la percepci\u00f3n del riesgo de padecer \nun c\u00e1ncer ginecol\u00f3gico y de las actitudes para controlarlo: un modelo de investigaci\u00f3n asistencial\nprimaria \u2013eliminar la causa identificada\u2013 o secundaria \n\u2013diagn\u00f3stico precoz\u2013 a realizar cuando son posibles, y \nlo son de manera muy relevante en todos los c\u00e1nceres \ndel \u00e1rea de preocupaci\u00f3n y acci\u00f3n ginecol\u00f3gicas, \nincluido el c\u00e1ncer de mama5.\nGracias al Registro de Tumores Poblacional operativo \nen la Isla de Mallorca, de cobertura poblacional y de \nalta calidad contrastada, sabemos con precisi\u00f3n cual \nes la incidencia en Mallorca por grupos de edad de los \nc\u00e1nceres ginecol\u00f3gicos6 y sabemos cu\u00e1les deber\u00edan ser \nlas pr\u00e1cticas preventivas primarias y secundarias para \ncada uno de ellos a aplicar en la consulta6.\nDesconocemos de manera clara y precisa cuales son \nlos h\u00e1bitos preventivos habituales desarrollados por las \nmujeres, y tambi\u00e9n el impacto real que una intervenci\u00f3n \neducativa personalizada seg\u00fan edad y antecedentes \npuede tener en la percepci\u00f3n del riesgo de sufrir \ndeterminados c\u00e1nceres y en la modificaci\u00f3n de las \nconductas preventivas relativas a ellos. \nEn este contexto, el proyecto de investigaci\u00f3n que aqu\u00ed \nse comenta plantea: \n1. Encuestar a las mujeres para conocer: \na. Su estimaci\u00f3n de riesgo de presentar alg\u00fan o \nalgunos de los c\u00e1nceres ginecol\u00f3gicos. \nb. Las pr\u00e1cticas preventivas que llevan a cabo frente \na ellos.\n2. Realizar una intervenci\u00f3n educacional personal para:  \na. Informar sobre su riesgo personal de sufrir estos \nc\u00e1nceres m\u00e1s incidentes. \nb. Educar en pr\u00e1cticas preventivas. 3. Estimar pasado un a\u00f1o cual ha sido el impacto de esta \nintervenci\u00f3n educativa sobre la percepci\u00f3n del riesgo de \npresentar un c\u00e1ncer ginecol\u00f3gico y sobre las conductas \npreventivas desarrolladas.\nSe plantea una metodolog\u00eda con un Grupo Control (GC) \ndividido en tres franjas de edad (30-39, 40-49, 50-\n59 a\u00f1os), con una \u201cN\u201d de 100 para cada franja, y un \nGrupo de Intervenci\u00f3n (GI) con los mismos subgrupos \ny el mismo tama\u00f1o muestral. A cada paciente se \nle pasar\u00e1 un cuestionario previo para situarle en su \ncontexto socioecon\u00f3mico y evaluar su percepci\u00f3n de \nriesgo de padecer c\u00e1ncer ginecol\u00f3gico. El GC recibir\u00e1 \nposteriormente una informaci\u00f3n generalizada est\u00e1ndar \nsobre pautas de prevenci\u00f3n y conductas de riesgo, \nmientras que el GI recibir\u00e1 una informaci\u00f3n educativa \npreventiva dirigida espec\u00edficamente a su perfil personal, \nincluyendo edad y antecedentes personales y familiares. \nUn a\u00f1o despu\u00e9s se pasar\u00e1 un nuevo cuestionario a \nambos grupos con el que se evaluar\u00e1 si se ha dado \nalg\u00fan cambio en la percepci\u00f3n del riesgo y en las \nconductas derivadas.  \nLos resultados de este estudio nos permitir\u00e1n conocer \nla utilidad de la intervenci\u00f3n educativa personalizada \nrealizada y, en caso de que se demuestre \u00fatil, sentar\u00edan \nlas bases para la implementaci\u00f3n de intervenciones \neducativas personalizadas en las consultas \nginecol\u00f3gicas. Es intenci\u00f3n del grupo realizar y publicar \nun an\u00e1lisis interino de procedimiento y resultados \nprovisionales cuando la intervenci\u00f3n se haya ya realizado \nen aproximadamente el 70% de la N planteada.\nConflicto de intereses\nLos autores declaran no incurrir para esta publicaci\u00f3n en \nning\u00fan conflicto de intereses.\nBibliograf\u00eda\n1. Disponible en https://www.cancer.gov/publications/dictionaries/\ncancer-terms/def/precision-medicine         Acceso 06.03.2023.\n2. Disponible en https://www.semnim.es/wp-content/\nuploads/2019/07/349.pdf      Acceso 06.03.2023.\n3. Disponible en https://www.cdc.gov/    Acceso 06.03.2023.\n4. Cort\u00e9s J.: Comunicaci\u00f3n a la Reuni\u00f3n Anual de la Sociedad Balear \nde Ginecolog\u00eda y Obstetricia. 2017.5. Cort\u00e9s J, Dexeus D, L\u00f3pez AC, Palacios S, Serrano L.: La prevenci\u00f3n \ndel c\u00e1ncer ginecol\u00f3gico en la asistencia privada. Prog Obstet Ginecol \n2017 ; 60: 160-75.\n6. Disponible en https://redecan.org/es/registros-de-cancer/15/\nregistre-de-cancer-de-mallorca      Acceso 06.03.2023.Gabriel Ferret et al. 160\n2023/38 (4): 160-162SPECIAL ARTICLE\nEliminaci\u00f3n del c\u00e1ncer de c\u00e9rvix\nElimination of cervical cancer\nJavier Cort\u00e9s1,2      , Ana Forteza2,3      , Jos\u00e9 Reyes4 \n1. Real Academia de Medicina de las Islas Baleares\n2. Laboratorio de Citolog\u00eda Dr. Cort\u00e9s. Palma.\n3. Servicio de Patolog\u00eda. Hospital Universitario Son Espases. Palma.\n4. Asociaci\u00f3n Espa\u00f1ola contra el C\u00e1ncer, Junta de Islas Baleares.eISSN 2255-0569\nReceived: 21 - II - 2023\nAccepted: 15 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.160Corresponding author\nJavier Cort\u00e9s \nE-mail: cortes@ocea.es \n  \nResumen\nA partir de la declaraci\u00f3n de la Organizaci\u00f3n Mundial de la Salud que identific\u00f3 al c\u00e1ncer de c\u00e9rvix como el primer c\u00e1ncer \nerradicable de nuestro mundo, se presentan las causas de esta propuesta y su situaci\u00f3n en Islas Baleares y Espa\u00f1a.\nPalabras clave: c\u00e1ncer, c\u00e9rvix, prevenci\u00f3n.\nAbstract \nBased on the declaration of the World Health Organization that identified cervical cancer as the first eradicable cancer in the world, \nthe causes of this proposal and its situation in the Balearic Islands and Spain are presented.\nKeywords: cancer, cervix, prevention. ID ID ID\nLa Organizaci\u00f3n Mundial de la Salud (OMS) ha \ndeclarado al c\u00e1ncer de c\u00e9rvix (CC) como el primer \nc\u00e1ncer eliminable, erradicable, de nuestro mundo1. \nEn esta declaraci\u00f3n se dice textualmente que \u201cha \nllegado el momento de poner en marcha una estrategia \nambiciosa e inclusiva para acelerar la eliminaci\u00f3n del \nc\u00e1ncer de c\u00e9rvix como problema de salud p\u00fablica. La \neliminaci\u00f3n est\u00e1 al alcance de todos los pa\u00edses. Todos \npodemos dejar un gran legado si aprovechamos las \noportunidades que est\u00e1n a nuestro alcance ahora, para \nque las ni\u00f1as que nazcan hoy vivan para ver un mundo \nlibre de esta enfermedad\u201d.\nLas razones que dan soporte a este posicionamiento \nson obvias:\n\u00b7 Conocemos la causa necesaria para el desarrollo \nde un CC, la infecci\u00f3n por virus papiloma humano \n(VPH)2,3.\n\u00b7 Disponemos de una prevenci\u00f3n primaria altamente \nsegura, eficaz y eficiente frente a la infecci\u00f3n por VPH, \nla vacunaci\u00f3n4.\n\u00b7 Tenemos muy bien identificadas a las lesiones pre-\ncancerosas del CC y somos capaces de detectarlas \ny de tratarlas de manera altamente c\u00f3moda y eficaz5.Las condiciones para lograr esta erradicaci\u00f3n se resumen \nseg\u00fan la OMS en tres cifras: 90-70-906, es decir:\n\u00b7 90% de cobertura de vacunaci\u00f3n frente al VPH.\n\u00b7 70% de cobertura en los programas de prevenci\u00f3n \nsecundaria del CC.\n\u00b7 90% de cobertura en los tratamientos de las lesiones \nprecancerosas detectadas.\n\u00bfCu\u00e1l es la situaci\u00f3n al respecto de estos tres objetivos \nen Islas Baleares y en Espa\u00f1a? La que se resume a \ncontinuaci\u00f3n:\n\u00b7 Cobertura de vacunaci\u00f3n frente al VPH en segunda \ndosis7:\n- Islas Baleares: No notificada y por tanto no incluida \nen la tabla facilitada por el Ministerio.\n- Espa\u00f1a: Cobertura media del 81,8%, con un rango \nque va desde el 33,3% de Asturias al 94,9 de La Rioja .\n\u00b7 Cobertura de los programas de prevenci\u00f3n secundaria \n(cribado) del CC 8:\n- 71% de las mujeres no se realiza un cribado de CC \nde forma regular.\n\u00b7 Cobertura en los tratamientos de las lesiones \nprecancerosas detectadas: No se dispone de datos, \naunque la accesibilidad a los equipos de tratamiento \n\u2013 en Sanidad P\u00fablica y Privada\u2013 parece correcta5,9.161\n2023/38 (4): 160-162Eliminaci\u00f3n del c\u00e1ncer de c\u00e9rvix\n\u00bfQu\u00e9 incidencia10 y qu\u00e9 mortalidad11 presenta el CC en \nIslas Baleares y en Espa\u00f1a, ahora y en los a\u00f1os pasados? \nPueden consultarse en las tablas I y II: se objetiva un \naumento apreciable en las cifras 2022 comparadas con \nlas de 2012 en las dos variables analizadas.\n\u00bfEs esta una situaci\u00f3n equiparable a la documentada \nen el resto del mundo? En una reciente publicaci\u00f3n \nde la OMS12 se dice textualmente que \u201cla carga del \nc\u00e1ncer de cuello uterino sigue siendo alta en muchas \npartes del mundo y, en la mayor\u00eda de los pa\u00edses, la \nincidencia y la mortalidad de la enfermedad siguen \nsiendo muy superiores al umbral establecido por la \niniciativa de la OMS sobre la eliminaci\u00f3n del c\u00e1ncer de \ncuello uterino. Identificamos desigualdades geogr\u00e1ficas \ny socioecon\u00f3micas sustanciales en el c\u00e1ncer de cuello \nuterino a nivel mundial, con un claro gradiente de tasas \ncrecientes para pa\u00edses con niveles m\u00e1s bajos de desarrollo \nhumano\u201d. Esta apreciaci\u00f3n coincide sustancialmente \ncon las conclusiones de un estudio global liderado por la \nUniversidad de Tianjin, en la Rep\u00fablica de China13, en el \nque se concluye que \u201clas pol\u00edticas de prevenci\u00f3n y control \ndel c\u00e1ncer en pa\u00edses con \u00edndices de desarrollo altos han \nlogrado efectos de implementaci\u00f3n relativamente ideales \nrelativos a la probable eliminaci\u00f3n del c\u00e1ncer de c\u00e9rvix. En \nlos pa\u00edses con un nivel de desarrollo social y econ\u00f3mico \nrelativamente atrasado, las pol\u00edticas de prevenci\u00f3n y \ncontrol del c\u00e1ncer tuvieron poco efecto, dada la menor \ncobertura de vacunaci\u00f3n contra el VPH, una asignaci\u00f3n \nregional deficiente de recursos de salud, incluyendo las \npr\u00e1cticas de prevenci\u00f3n secundaria y tratamiento de las \nlesiones pre-invasoras, y una escasa concienciaci\u00f3n de \nla educaci\u00f3n p\u00fablica\u201d.\n\u00bfQu\u00e9 ocurre en los pa\u00edses de nuestro entorno? Italia \nha publicado su situaci\u00f3n14, con esta conclusi\u00f3n: \u201cLa \nevaluaci\u00f3n del estado actual de la eliminaci\u00f3n de CC \ncomo objetivo general m\u00e1s all\u00e1 del logro de los objetivos \nde vacunaci\u00f3n, detecci\u00f3n y tratamiento representa el \nprimer paso para la identificaci\u00f3n de las intervenciones \nque se implementar\u00e1n para acelerar el camino hacia la \neliminaci\u00f3n de CC. En base a esto y siguiendo el llamado \nde la OMS, se propone un enfoque basado en valores \npara desentra\u00f1ar el beneficio total de las estrategias de eliminaci\u00f3n de los c\u00e1nceres relacionados con el VPH e \nidentificar las prioridades y las mejores pr\u00e1cticas\u201d.\nA\u00f1adamos que est\u00e1 documentada una alta inequidad \nespa\u00f1ola en el acceso a las tres variables preventivas, \nya denunciada en dos estudios que han devenido en \ncl\u00e1sicos15,16, con datos reproducidos recientemente 8: \n71% de las mujeres no se realiza en Espa\u00f1a un cribado \nde manera regular. En estas mujeres no controladas \nque b\u00e1sicamente viven en zonas no ciudadanas y \nque pertenecen a estratos sociales de nivel medio / \nbajo se concentra el 70% del CC incidente: 7 de cada \n10 mujeres con CC no tienen una historia previa de \ncribado. Puede concluirse que el trabajo preventivo \ndebe concentrarse en corregir estos d\u00e9ficits clamorosos \ny esto solamente podr\u00e1 hacerse reestructurando los \nprogramas ahora en aplicaci\u00f3n \u2013mayoritariamente \noportunistas\u2013 transform\u00e1ndolos en poblacionales que \ngaranticen m\u00e1ximas coberturas independientemente de \nnivel de riqueza, de educaci\u00f3n o de lugar de residencia. \nEste es, este debe ser el camino. Alcanzar este 90-70-\n90 es un objetivo alcanzable siempre que los esfuerzos \nse coordinen, desde todos los puntos de vista, desde \ntodas las instancias pol\u00edtico-sanitarias involucradas. \nTal como se reclama desde la Sociedad Espa\u00f1ola \nde Vacunolog\u00eda17 \u201cpara lograr el m\u00e1ximo impacto, las \nintervenciones encaminadas a alcanzar estos tres \nobjetivos deben realizarse de manera simult\u00e1nea y a \nla escala apropiada\u201d. Un esfuerzo de coordinaci\u00f3n es \nmandatorio, adaptando las decisiones a los protocolos \nestrat\u00e9gicos en vigor promulgados por los organismos \nsupranacionales y nacionales. \nComo dice el Dr. Fernando Moraga, Vice-Presidente \nprimero de la Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda,17 \n\u201cse estima que si se consigue implementar la triple \nestrategia 90-70-90 en 2030, para 2050 ya podr\u00eda haber \ndisminuido a la mitad la incidencia del c\u00e1ncer de cuello \nuterino, y en los pr\u00f3ximos 100 a\u00f1os se evitar\u00e1n m\u00e1s de \n74 millones de casos de este c\u00e1ncer y se salvar\u00e1n m\u00e1s \nde 62 millones de vidas de mujeres. Un gran triunfo de \nla vacunolog\u00eda y de la medicina preventiva\u201d. Un gran \ntriunfo factible si hacemos, entre todos, las cosas bien. \nUn gran triunfo que puede y debe ser extendido a la \naplicaci\u00f3n poblacional de programas de cribado de otros \ncuatro c\u00e1nceres, mama femenina, colon-recto, pulm\u00f3n y \npr\u00f3stata, tal como se recomienda en la \u00faltima propuesta \nejecutiva 14770/22 del Consejo de la Uni\u00f3n Europea18.\nConflicto de intereses\nNinguno para los tres autores.Tabla I: Incidencia del c\u00e1ncer de cuello de \u00fatero.\nFuente: Ref. 10. 2012 2022\nIslas Baleares 43 47\nEspa\u00f1a 1.883 1.965\nTabla II: Mortalidad por c\u00e1ncer de cuello de \u00fatero.\nFuente: Ref. 11. 2012 2022\nIslas Baleares 18 29\nEspa\u00f1a 666 684162\n2023/38 (4): 160-162Eliminaci\u00f3n del c\u00e1ncer de c\u00e9rvix Javier Cort\u00e9s et al. \nBibliograf\u00eda\n1. Disponible en https://www.who.int/es/news-room/events/\ndetail/2020/11/17/default-calendar/launch-of-the-global-strategy-to-\naccelerate-the-elimination-of-cervical-cancer    Acceso 27.12.2022.\n2. zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. Attempts to \ndetect virus-secific DNA in human tumors. I. Nucleic acid hybridizations \nwith complementary RNA of human wart virus. Int J Cancer. 1974 May \n15;13(5):650-6. doi: 10.1002/ijc.2910130509. \n3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, \nShah KV et al. Human papillomavirus is a necessary cause of invasive \ncervical cancer worldwide. J Pathol 1999; 189: 12 - 9.\n4. WHO Weekly Epidemiological Record N\u00ba 50, 2022, 97, 645\u2013672.\n5. https://www.aepcc.org/wp-content/uploads/2022/11/Guia-\nPrevencion-cancer-cervix-2022.pdf\n6. Disponible en https://www.who.int/     Acceso 27.12.2022.\n7. Disponible en https://www.sanidad.gob.es/profesionales/\nsaludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/\ncoberturas/docs/Todas_las_tablas2020.pdf      Acceso 28.12.22.\n8. Disponible en https://www.seap.es/c/document_library/get_\nfile?uuid=e0ecfbbc-9f49-4054-8ed6-9c7a40a40186&groupId=10157     \nAcceso 28.12.22.\n9. Disponible en https://seepidemiologia.es/wp-content/\nuploads/2022/03/S.E.Epidemiologia-NOTA-Webinar-Cervix-del-GT-\nde-Cribado-OK-.pdf   Acceso 28.12.2022.\n10. Disponible en https://observatorio.contraelcancer.es/informes/\ninforme-dinamico-incidencia   Acceso 28.12.2022.11. Disponible en https://observatorio.contraelcancer.es/informes/\ninforme-dinamico-mortalidad   Acceso 28.12.2022. \n12. Singh D , Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-\nSecretan B et al. Global estimates of incidence and mortality of cervical \ncancer in 2020: a baseline analysis of the WHO Global Cervical Cancer \nElimination Initiative. Lancet Glob Health.2022; S2214-109X (22) \n00501-0.\n13. Xu T, Yang X, He X, Wu J. The Study on Cervical Cancer Burden \nin 127 Countries and Its Socioeconomic Influence Factors. J Epidemiol \nGlob Health. 2022. doi: 10.1007/s44197-022-00081. \n14. Calabro GE, Riccardi MT, D\u2019Ambrosio F, Castagna C, Sapienza M, \nMillevolte R et al. Cervical cancer elimination in Italy: Current scenario \nand future endeavors for a value based prevention. Front Public Health. \n2022; 10: 1010237.\n15. Bosch FX, Castellsagu\u00e9 X, Cort\u00e9s J, Puig-Tintor\u00e9 LL, Roura E, \nde Sanjos\u00e9 S et al. Estudio AFRODITA: Cribado del c\u00e1ncer de cuello \nuterino en Espa\u00f1a y factores relacionados. GSK Eds. 2009. ISBN \n978-84-69I-8490-S.\n16. Castellsagu\u00e9 X, Iftner T, Roura E, Vidart JA,  Kjaer SK,  Bosch FX \net al. Prevalence and genotype distribution of human papillomavirus \ninfection of the cervix in Spain: the CLEOPATRE study. J Med Virol.2012; \n84(6): 947-56.\n17. Disponible en https://www.vacunas.org/un-mundo-sin-cancer-de-\ncuello-uterino-la-estrategia-90-70-90/   Acceso 04.01.23.\n18. Disponible en Cribado Uni\u00f3n Europea 11.22.pdf   Acceso 04.01.23.163\n2023/38 (4): 163-165CASE REPORT\nAcute pancreatitis due to diverticular compression of the gland\nPancreatitis aguda por compresi\u00f3n diverticular de la gl\u00e1ndula\nAlexey V. Shabunin1,2,3,4      , David D. Dolidze1,2,3, Serghei Covantsev1      , \nIvan N. Lebedinsky1,3      , Andrei I. Evsikov3      , Andrei A. Kolotilshchikov1,4\n1. Department of Clinical Research and Development, Botkin Hospital, Moscow, Russian Federation\n2.Department of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation\n3. Department of General Oncology n\u00ba 71, Botkin Hospital, Moscow, Russian Federation\n4. Department of Emergency Surgery n\u00ba 76, Botkin Hospital, Moscow, Russian FederationeISSN 2255-0569\nReceived: 23 - II - 2023\nAccepted: 18 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.163Corresponding author\nSerghei Covantsev \nE-mail: kovantsev.s.d@gmail.com \n  \nAbstract \nDiverticula are commonly located in the colon and are less frequent in other parts of the gastrointestinal tract. Diverticula of the \nduodenum are the most common in the small intestine and are usually asymptomatic. In rare cases they can lead to abdominal pain, \nbleeding and obstruction of the bowel or biliary system. In exceedingly rare cases they may be the cause for acute pancreatitis, \nusually when they are located near the major papilla. We present a rare case where the pancreas was compressed by a large 38 \nmm by 49.7 diverticulum of the horizontal part of the duodenum, and was managed conservatively.\nKeywords: pancreas, duodenal diverticulum, acute pancreatitis, diet. \nResumen\nLos divert\u00edculos suelen localizarse en el colon y son menos frecuentes en otras partes del tracto gastrointestinal. Los divert\u00edculos \ndel duodeno son los m\u00e1s frecuentes en el intestino delgado y suelen ser asintom\u00e1ticos. En raras ocasiones pueden provocar \ndolor abdominal, hemorragia y obstrucci\u00f3n intestinal o del sistema biliar. En casos extremadamente raros pueden ser la causa de \npancreatitis aguda, normalmente cuando se localizan cerca de la papila mayor. Presentamos un caso poco frecuente en el que \nel p\u00e1ncreas estaba comprimido por un gran divert\u00edculo de 38 mm por 49,7 de la parte horizontal del duodeno, y fue tratado de \nforma conservadora.\nPalabras clave: p\u00e1ncreas, divert\u00edculo duodenal, pancreatitis aguda, dieta.ID\nID ID IDID\nIntroduction\nDiverticula are commonly located in the colon and are \nless frequent in other parts of the gastrointestinal tract1,2. \nDiverticula of the duodenum are the most common in the \nsmall intestine. They are usually asymptomatic except for \ncases of pain, bleeding and obstruction of the bowel or \nbiliary system1.Pancreatitis due to duodenal diverticulum \nare rare and usually are caused by juxtapapillary \ndiverticula3. We report a rare case of a large diverticula \nlocated in the horizontal portion of duodenum that caused \nacute pancreatitis due to its compression of the pancreas.Case summary\nA 57-year-old male patient was admitted with complaints \nof pain in the upper abdomen with irradiation to the \nback, nausea, and vomiting. According to the patient, \nhe considers himself ill for about a year, when he began \nto notice epigastric pain and nausea after eating. During \nthe last year he lost 5 kg. At the time of examination, he \nhad pain in the epigastric region. Laboratory values were \nnormal, with the exception of an increased amylase \n(309 U/L, normal value 28-100 U/L). Ultrasound of \nthe abdominal cavity revealed an increase in the size 164\n2023/38 (4): 163-165of the pancreas with diffuse changes in its structure. \nFor the purpose of differential diagnosis, an upper \ngastrointestinal endoscopy was performed, which \nrevealed a diverticulum of the horizontal duodenal part \nwithout signs diverticulitis (Figure 1).\nContrast abdominal X-ray (Figure 2) and abdominal CT \nscan (Figures 3a, 3b, 3c) revealed a 38 mm by 49.7 mm \ndiverticulum, which exerted pressure on the pancreas \ncausing an inverted V shape lie (Figure 4). Against the \nbackground of conservative therapy, withhold of food \nand fluid there was an improvement in the condition. \nAmylase level decreased to 107 U/L when re-examined \nafter two days. The patient was discharged 9 days \nafter hospitalization with normal laboratory values and \nimproved overall condition. One year follow up revealed \nno exacerbation of his condition on diet of smaller but \nmore frequent meals with high amounts of fluid.\nDiscussion\nDuodenal diverticula are encountered in up to 23% of \ncases, depending on the mode of diagnosis. They \nFigure 1: Upper gastrointestinal endoscopy. DD \u2013 duodenal diverticulum, DL \u2013 \nduodenal lumen.Figure 2: Abdominal X-ray with oral contrasting.\nFigure 4: Abdominal CT demonstrating an inverted V shape of the pancreas (the \npancreas is marked in red).Figure 3: Abdominal CT showing large diverticulum that compresses the pancreas (arrow indicates the duodenal diverticulum). A \u2013 Axial plane, B \u2013 coronal plane, C \u2013 sagittal plane .\nAlexey V. Shabunin et al. 165\n2023/38 (4): 163-165Acute pancreatitis due to diverticular compression of the gland\ncan be congenital or acquired, while the last are more \nfrequent. The acquired type represents a protrusion \nof the mucosa, muscularis mucosa, or submucosa \nthrough a local weakness in the duodenal wall. They are \nsymptomatic in approximately 5-10% of cases. In the \nmajority of cases duodenal diverticula are small and are \nlocated in the periampullary region or in the medial aspect \nof the second and third portions of the duodenum. They \ncan mimic a variety of conditions of the duodenum and \npancreas including pancreatic pseudocyst or abscess3,4.\nGiant or large diverticula are rare and there are only a \nfew cases reported in the literature with measurements \nup to 11 cm, typically in the second or third part of the \nduodenum1,5,6. However, there is no measurement scale \nwhen a diverticulum is considered to be giant. None of these \ncases caused symptoms related to pancreatic diseases. \nPeriampullary diverticula are traditionally associated with \ndiseases of the biliary or pancreatic tree. Nevertheless, the \nassociation with acute pancreatitis is rare and there are only \nseveral cases reported in the literature. The pathogenetic \nmechanism is usually compression of the duodenal papilla, \ndiverticular inflammation or compression of the common \nbile duct7,8. The present case demonstrates a different \nmechanism when the size of the diverticula permitted \nconstant compression on the pancreatic parenchyma after \na heavy meal. Dietary modifications allowed to decrease \nthe symptoms of the disease. Conservative management \nis possible for cases where the duodenal neck is wide, \ntherefore allowing fast emptying of the diverticular content. \nThere are no commonly accepted guidelines on \nthe management of duodenal diverticula. However, \ncommonly accepted approach is to treat a duodenal diverticulum when it becomes symptomatic or causes \ncomplications6,9. The most common surgical treatment \nis open or laparoscopic resection, but there are several \nreports of successful conservative management6,9.\nAcute pancreatitis is a condition when the pancreas \nbecomes inflamed in a short period of time. The most \ncommon reasons for acute pancreatitis are alcohol use, \ngallstones, and hypertriglyceridemia cause. However, the \nlist of causes is extensive and includes other etiological \nfactors such as anomalies of development of the gland, \nviral infections, systemic conditions, medications, trauma \netc10,11,12. Acute pancreatitis due to external compression \nfrom adjacent anatomical structures is an exceedingly \nrare condition and there are only a few case reports in \nthe literature. The current case describes successful \nconservative management of such patients, however, \nsurgical management is possible in refractory cases or \nwhen complications occur.\nConflict of interest\nThe authors have no conflict of interest to declare\nFinancial support\nNone\nAuthor contribution\nSC - concept and design of the study, editing, analysis \nof the literature; INL - concept and design of the study, \nediting, collecting material, text writing; AIE - research \nconcept and design, editing, literature analysis, text \nwriting; AAK - collection and processing of material, \nediting, analysis of literature; DSB - collection and \nprocessing of material, text writing, editing.\nReferences\n1. Bierton C, Gupta A. Giant duodenal diverticulum-an incidental finding. \nJ Surg Case Rep. 2019(4):rjz120-rjz. https://doi.org/10.1093/jscr/rjz120\n2. Shabunin AV, Bedin VV, Yakomaskin VN, Grekov DN, Covantev \nS. Clinical Case of a Gastric Diverticulum Operated by Laparoscopic \nApproach. Online J Health Allied Scs. 2018;17(4):9. \n3. Barat M, Dohan A, Dautry R, Barral M, Boudiaf M, Hoeffel C, et al. \nMass-forming lesions of the duodenum: A pictorial review. Diagnostic \nand Interventional Imaging. 2017;98(10):663-75. https://doi.\norg/10.1016/j.diii.2017.01.004\n4. Dusunceli Atman E, Erden A, Ustuner E, Uzun C, Bektas M. MRI Findings \nof Intrinsic and Extrinsic Duodenal Abnormalities and Variations. Korean J \nRadiol. 2015;16(6):1240-52. https://doi.org/10.3348/kjr.2015.16.6.1240\n5. Millard JR, Ziter FM, Jr., Slover WP . Giant duodenal diverticula. \nThe American journal of roentgenology, radium therapy, and \nnuclear medicine. 1974;121(2):334-7. https://doi.org/ 10.2214/\najr.121.2.334\n6. Ter Horst M, Boer MC, Raber MH, Klaase JM. Giant Diverticulum of \nthe Duodenum. Gastroenterology research. 2011;4(6):289-93. https://\ndoi.org/10.4021/gr359w7. Rizwan MM, Singh H, Chandar V, Zulfiqar M, Singh V. Duodenal \ndiverticulum and associated pancreatitis: case report with brief review \nof literature. World J Gastrointest Endosc. 2011;3(3):62-3. https://doi.\norg/10.4253/wjge.v3.i3.62\n8. Yildirgan MI, Ba\u015fo\u011flu M, Yilmaz I, Atamanalp SS, Balik AA, Aydinli \nB, et al. Periampullary diverticula causing pancreaticobiliary disease. \nDigestive diseases and sciences. 2004;49(11-12):1943-5. https://doi.\norg/10.1007/s10620-004-9597-9\n9. Moysidis M, Paramythiotis D, Karakatsanis A, Amanatidou E, Psoma \nE, Mavropoulou X, Michalopoulos A. The challenging diagnosis and \ntreatment of duodenal diverticulum perforation: a report of two cases. BMC \nGastroenterol. 2020 Jan 8;20(1):5. doi: 10.1186/s12876-019-1154-2.\n10. Covantev S. Pancreas divisum: a reemerging risk factor for \npancreatic diseases. Rom J Intern Med. 2018;56(4):233-242. doi: \n10.2478/rjim-2018-0022. PMID: 30521477 \n11. Gapp J, Chandra S. Acute Pancreatitis. [Updated 2022 Jun 21]. In: \nStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. \nAvailable from: https://www.ncbi.nlm.nih.gov/books/NBK482468/\n12. Covantsev S, Chicu C, Mazuruc N, Belic O. Pancreatic ductal \nanatomy: more than meets the eye. Surg Radiol Anat. 2022;44(9):1231-\n1238. https://doi.org/10.1007/s00276-022-03002-w. 166\n2023/38 (4): 166-169CASE REPORT\nSurgical treatment of a patient with hemangiopericytoma \nand subsequent abdominoplasty: a clinical case\nTratamiento quir\u00fargico de una paciente con hemangiopericitoma \ny posterior abdominoplastia: un caso cl\u00ednico\nAlexey V. Shabunin1,2,3,      , David D. Dolidze1,2,3      , Ivan N. Lebedinsky1,3      , \nZurab A. Bagatelia1,2,3      , Anna S. Sukhotko3      , Maria V. Kovaleva2      , Serghei Covantsev1       \n1. Department of Clinical Research and Development, Botkin Hospital, Moscow, Russian Federation\n2. Department of Surgery, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation\n3. Department of General Oncology No 71, Botkin Hospital, Moscow, Russian FederationeISSN 2255-0569\nReceived: 25 - II - 2023\nAccepted: 20 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.166Corresponding author\nSerghei Covantsev \nE-mail: kovantsev.s.d@gmail.com \n  \nAbstract \nHemangiopericytoma is a rare neoplasm of mesenchymal tissue, which is mentioned in the literature mainly in the form of clinical \nobservations. The tumor usually occurs at the age of 20-70 years in the soft tissues of the neck, lower extremities, retroperitoneal \nspace and pelvis. There have been only 20 cases of hemangiopericytoma of the anterior abdominal wall. In rare cases they are \nassociated with paraneoplastic syndromes. In the presented clinical observation, the patient underwent a wide excision of soft \ntissue tumor, initially regarded as a desmoid, followed by abdominoplasty. The combination of wide excision with abdominoplasty \nleads an optimal cosmetic result while not violating oncological principles.\nKeywords: desmoid tumor, hemangiopericytoma, wide excision, abdominoplasty. \nResumen\nEl hemangiopericitoma es una neoplasia poco frecuente del tejido mesenquimal, que se menciona en la literatura principalmente \nen forma de observaciones cl\u00ednicas. El tumor suele aparecer entre los 20 y los 70 a\u00f1os de edad en los tejidos blandos del cuello, \nlas extremidades inferiores, el espacio retroperitoneal y la pelvis. S\u00f3lo se han registrado 20 casos de hemangiopericitoma de la \npared abdominal anterior. En raras ocasiones se asocian a s\u00edndromes paraneopl\u00e1sicos. En la observaci\u00f3n cl\u00ednica presentada, la \npaciente fue sometida a una escisi\u00f3n amplia del tumor de partes blandas, considerado inicialmente como un desmoide, seguida \nde abdominoplastia. La combinaci\u00f3n de escisi\u00f3n amplia con abdominoplastia conduce a un resultado cosm\u00e9tico \u00f3ptimo sin violar \nlos principios oncol\u00f3gicos.\nPalabras clave: tumor desmoide, hemangiopericitoma, escisi\u00f3n amplia, abdominoplastia.\nIntroduction\nHemangiopericytomas are abundantly vascularized \nmesenchymal tissue tumors that are currently classified as \nsolitary fibrous tumors. They were first described by Stout \nand Murray in 1942 as a group of vascular tumors derived \nfrom Zimmerman\u2019s pericytes1,2. Depending on the cellular \ncomposition, they are classified as hemangiopericytomas \nif the cellular component predominates and solitary \nfibrous tumors if the hyalinizing form of neoplasia \npredominates. Most commonly, this tumor occurs in the \nneck, meninges, pleura, retroperitoneum, pelvis, and \nlower extremities3. The incidence is 0.06 per 100,000 \nexamined, and localization within the abdominal wall has been described in only 20 cases3-5. There are \ntwo types of tumor: malignant and benign; in turn, the \nlatter can become malignant over time. Due to the rare \noccurrence of the disease and the diverse localization, \nthere are currently no precise recommendations on the \ntactics of treating these patients. Surgical intervention is \nconsidered optimal, which, if necessary, is supplemented \nby subsequent adjuvant chemotherapy or radiotherapy \nand active monitoring over time. In the presented clinical \nobservation, the patient underwent a wide excision of soft \ntissue tumor, initially regarded as a desmoid, followed by \nabdominoplasty.ID ID ID\nID ID ID ID167\n2023/38 (4): 166-169Surgical treatment of a patient with hemangiopericytoma and subsequent abdominoplasty: a clinical case\nClinical case\nIn 2019 a 43 years old woman drew attention to the \nappearance of a mass of the anterior abdominal wall \nin the umbilical region. She observed the mass until \nJune 2022 and due to the increase in size the patient \nconsulted a surgeon, then was referred for a consultation \nto an oncologist. On examination the entire anterior \nabdominal wall below the umbilicus was represented by \na voluminous multinodular mass measuring 18x15 cm \nwith clear, even contours, the skin over the tumor was \nhyperemic but without changes around the mass (Figure \n1A, 1C). On palpation, the tumor was painless, it was \ndisplaced along with the skin relative to the underlying \ntissues and the inguinal lymph nodes were not enlarged.\nOn July 25, 2022, the patient undergone a core-needle \nbiopsy of the lesion. The histological conclusion was \ndesmoid type fibromatosis. Immunohistochemical study \nrevealed that tumor cells were Actin- CD34+ Beta-\ncaternin+. She underwent computed tomography (CT) of \nthe abdominal cavity and pelvis with intravenous contrast \nenhancement. The CT scan revealed a solid multinodular \ntumor in the soft tissues of the anterior abdominal wall, 5 mm below the umbilical ring measuring 193x98x42 \nmm with clear, even contours, most likely originating \nfrom the left rectus abdominis muscle and accumulating \ncontrast (Figure 1B, 1D). Taking into account the size \nof the tumor and its location, we decided to perform a \nwide excision of the mass followed by abdominoplasty. \nThe preoperative marking of the anterior abdominal wall is \nindicated in figure 2A. The patient received preoperative \nantibiotic prophylaxis with 1 g of cefotaxime 30 minutes \nbefore surgery. Surgery was performed under combined \nendotracheal anesthesia. After preparing the skin with \nantiseptic solution, the skin and subcutaneous fat were \ndissected with two incisions. A skin flap with dimensions \nof 20.0 x 13.0 cm with the mass was isolated up to the \nfascia. Tumor invasion into the underlying muscles was \nnot detected intraoperatively. The navel was excised and \nskin flaps were dissected in the cranial direction to the \nedges of the costal arches and the xiphoid process. \nThe diastasis and the umbilical ring were sutured. The \nwound was sutured in layers with a cosmetic suture, \ntwo vacuum drainages were left, brought out through \ncounter-openings in the region of the inguinal folds. \nFigure 4: Preoperative picture of the mass. A - anterior projection of the mass B - CT image of the mass (axial section), C - anterior projection of the mass, D - CT \nimage of the mass (sagittal section).168\n2023/38 (4): 166-169Alexey V. Shabunin et al. \nUmbilicoplasty was performed using the petal method. \nThe patient received symptomatic therapy with NSAIDs in \nthe postoperative period (ketorolac 30 mg intravenously). \nOn the 2nd day after the operation, the drains were \nremoved. At the control ultrasound examination on the \n3rd day after the operation there was soft tissue edema \nin the area of intervention with no fluid accumulations. \nThe patient was discharged from the hospital on the \n3rd day after the operation. Histological examination \nrevealed an infiltrative tumor under the epidermis, \ncompletely germinating the subcutaneous fat, consisting \nof long bundles with elongated, thin, spindle-shaped \ncells of a homogeneous appearance, subcutaneous \nareas with minimal signs of cellular atypia, rare mitoses. \nIn the deep areas of the tumor there were noticeable \ncell atypia with mitoses (about 4 per 10 fields of view). \nImmunohistochemical examination revealed that tumor \ncells diffusely expressed vimentin, CD34. Ki67 was 2%, \nbeta-catenin and SMA were negative. According to the \nresults of histological and immunohistochemical studies, \nthe mass was classified as hemangiopericytoma. On \nthe 7th and 14th days after the operation, the patient \nunderwent seroma (60 ml) evacuation under ultrasound \nguidance (Figure 2A, B). During a control ultrasound of \nthe soft tissues of the anterior abdominal wall after 12 \nmonths there was no data for recurrence.\nDiscussions\nHemangiopericytoma is a rare neoplasm of mesenchymal \ntissue, which is mentioned in the literature mainly in the \nform of clinical observations. The tumor usually occurs \nat the age of 20-70 years in the soft tissues of the neck, \nlower extremities, retroperitoneal space and pelvis. To \nour knowledge, only 20 cases of hemangiopericytoma \nof the anterior abdominal wall have been described. \nAccording to the literature, most patients were over \n50 years old, the average size of the mass was 8 cm \n(from 1.9 to 16 cm)1,6,7. In most cases, patients did not \npresent any complaints, but in some cases they may be \nbothered by pain or a feeling of pressure in the area of the tumor1,8. In the presented clinical observation, the \npatient was younger and the tumor was 193 x 98 x 42 \nmm in size. To our knowledge this is the largest tumor \nreported in the literature.\nTwo paraneoplasty syndromes occur in patients with \nhemangiopericytoma: osteooarthropathy and Doege-\nPotter syndrome. Hypertrophic arthropathy predominantly \noccurs in 20% of cases in pleural hemangiopericytomas \nand is manifested by bone pain, finger clubbing, joint \nstiffness and swelling. Doege-Potter syndrome occurs \nin approximately 5% of patients, most often with large \ntumors localized in the pelvis or retroperitoneum, and \nmanifests itself with hypoglycemia, presumably due to \nthe secretion of IGF-29,10.\nAn analysis of 1.243 patients with hemangiopericytoma \nover 41 years indicates that surgery as the main \ntreatment method significantly increases patient survival. \nAt the same time, according to the results of the study, \nradiotherapy does not affect survival, and chemotherapy \nreduces it. The combination of various treatment options \nwith surgery, in general, does not improve the prognosis \nof the disease3. A major difficulty in surgery of tumors of \nthe abdominal wall is the surgical intervention, which often \nleaves an unpleasant and stigmatizing scar. An alternative \nto only direct excision is subsequent abdominoplasty, as a \nmeans to achieve aesthetic results and improve quality of \nlife, while maintaining the standards of surgical oncology.\nHistological verification has a number of difficulties and \nrequires immunohistochemical studies. Cells express \nCD34 antigens in 78-100% of cases, Bcl-2 in 96%, \nexpression of CD99 and vimentin is common. As a \nrule, cells do not express cytokeratin, actin, desmin, \nearly membrane antigen, c-kit and S100 protein on \nthe surface1,8,11.\nThe question of differential diagnosis of benign and \nmalignant forms of tumors also remains open. To \ndate, there are no precise criteria for malignancy. A \npresumably high mitosis index, large masses, invasion Figure 2: Comparison of preoperative and postoperative picture. A - preoperative marking; C - 14th day after the operation.\n169\n2023/38 (4): 166-169Surgical treatment of a patient with hemangiopericytoma and subsequent abdominoplasty: a clinical case\ninto surrounding tissues, the presence of immature cells \nin the biopsy, necrosis or hemorrhage loci are risk factors \nfor malignancy3,12. \nSurgical excision with reconstruction using local tissues \nis a common method for giant tumors13. However, he \ncosmetic results of such procedures is often far from \nideal. The current case demonstrates that wide surgical \nexcision of a large tumor with subsequent abdominoplasty \nis a valid alternative to standard wide excision for larger \ntumors located in the region of the abdominal wall.\nConclusion\nHemangiopericytomas are a group of mesenchymal \ntumors that are most often asymptomatic and difficult \nto recognize until they cause compression of adjacent \nstructures. In rare cases they are associated with paraneoplastic syndromes. In the literature, there are \nonly isolated cases of surgical treatment of patients with \nhemangiopericytomas of the anterior abdominal wall. The \ncombination of wide excision with abdominoplasty leads \nan optimal cosmetic result while not violating oncological \nprinciples.\nDisclosures \nEthics Committee Approval: No ethical approval required \nand the study was performed in accordance with the \nprinciples of the declaration of Helsinki. \nConflict of Interest\nThere is no conflict of interest.\nFinancial Support\nAuthors declare that they have not received funds for this \nstudy. \nReferences\n1. Migita K, Watanabe A, Nakagawa K, Ohyama T, Sekigawa S. Solitary \nfibrous tumor of the abdominal wall. International journal of clinical \noncology. 2009;14(6):555-9. \n2. Garcia-Bennett J, Oliv\u00e9 CS, Rivas A, Dom\u00ednguez-Oronoz R, Huguet \nP . Soft tissue solitary fibrous tumor. Imaging findings in a series of nine \ncases. Skeletal radiology. 2012;41(11):1427-33. \n3. Wang K, Mei F, Wu S, Tan Z. Hemangiopericytoma: Incidence, \nTreatment, and Prognosis Analysis Based on SEER Database. BioMed \nresearch international. 2020;2468320. \n4. Bi X, Zhai J, Chun CD. Solitary fibrous tumor of the abdominal wall re-\nsurfacing as unilateral pleural effusion and mass: A case report and review \nof the literature. Respiratory Medicine Case Reports. 2018;23:4-7.\n5. Testa DC, Selvaggi F, Andreano T, Mazzola L, Cortellese R. Solitary \nfibrous tumor of the anterior abdominal wall. A case report and review of \nthe literature. Annali italiani di chirurgia. 2019;13;8. \n6. Carnerero Herrera V, Dom\u00ednguez-P\u00e9rez A, Gonz\u00e1lez-Mart\u00edn R, \nNacarino-Mej\u00edas V, Alc\u00e1zar Iribarren-Mar\u00edn M. [Solitary fibrous tumor of \nthe abdomen. A rare neoplasm of vascular origin]. Gastroenterologia y \nhepatologia. 2010;33(8):578-81. 7. Penel N, Amela EY, Decanter G, Robin YM, Marec-Berard P . \nSolitary fibrous tumors and so-called hemangiopericytoma. Sarcoma. \n2012;2012:690251. \n8. Costa M, Oliva A, Velez A, Bento A, Garcia H, et al. (2014) Solitary \nFibrous Tumor of the Abdominal Wall. J Clin Case Rep 4: 363. \n9. Yuri T, Kanematsu S, Lei YC, Kuwata M, Oishi M, Tsubura A. Solitary \nfibrous tumor of soft tissue: a case report and immunohistochemical \nstudy. Medical molecular morphology. 2010;43(1):60-4. \n10. Ouazzani A, Delr\u00e9e P , De Saint Aubain N, Ceuterick M, Boudaka \nW. [Malignant solitary fibrous tumor of the abdominal wall in a man]. \nAnnales de chirurgie plastique et esthetique. 2008;53(6):517-20. \n11. Park MS, Araujo DM. New insights into the hemangiopericytoma/\nsolitary fibrous tumor spectrum of tumors. Current opinion in oncology. \n2009;21(4):327-31. \n12. Enzinger FM, Smith BH. Hemangiopericytoma: An analysis of 106 \ncases. Human Pathology. 1976;7(1):61-82.\n13. Shabunin AV, Lebedinsky IN, Dolidze DD, Bagatelia ZA, Covantsev \nS, Bocharnikov DS, et al. Giant bleeding post-traumatic thoracic \nsarcoma management: A case report. Front Surg. 2022;8;9:1044077.170\n2023/38 (4): 170-174Received: 27 - II - 2023\nAccepted: 24 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.170Corresponding author\nMarcos Fern\u00e1ndez-Cuadros \nE-mail: marcosefc@hotmail.com \nmarcosedgar.fernandez@salud.madrid.org\nAbstract \nThe knee is the second most common site of osteonecrosis (ON) after the hip. Three different entities are described: a) \nspontaneous ON; b) secondary ON; c) post-arthroscopy ON. In spontaneous ON the etiology is attributed to subchondral \ninsufficiency fractures and to avascular necrosis due to ischemic events. Diagnosis is based on clinical and radiological basis \n(radiography, bone scan scintigraphy and MRI). Koshino\u00b4s radiological classification grades severity and guides in the management. \nConservative management includes protected weight bearing, drugs (NSAIDs, bisphosphonates, D vitamin, calcium, prostaglandin \nI-2, corticosteroids, hyaluronic acid), physiotherapy (laser, pulsed electromagnetic fields), and hyperbaric oxygen therapy. Surgical \ntreatment is deserved for advanced stages or if conservative treatment failed. In pre-collapse Stage, joint preserving procedures \nare expected; on the contrary, in subchondral collapse stages, joint arthroplasty is required. We present for the first time in literature \nthe beneficial effect of intra articular ozone in the management of two cases of advanced ON of the knee.\nKeywords: ozone, osteonecrosis of the knee, treatment. \nResumen\nLa rodilla es la segunda localizaci\u00f3n m\u00e1s frecuente de la osteonecrosis (ON) despu\u00e9s de la cadera. Se describen tres entidades \ndiferentes: a) la ON espont\u00e1nea; b) la ON secundaria; c) la ON post-artroscopia. En la ON espont\u00e1nea la etiolog\u00eda se atribuye a las \nfracturas por insuficiencia subcondral y a la necrosis avascular debida a eventos isqu\u00e9micos. El diagn\u00f3stico se basa en la cl\u00ednica y \nla radiolog\u00eda (radiograf\u00eda, gammagraf\u00eda \u00f3sea y resonancia magn\u00e9tica). La clasificaci\u00f3n radiol\u00f3gica de Koshino califica la gravedad y \norienta el tratamiento. El tratamiento conservador incluye la protecci\u00f3n del peso, f\u00e1rmacos (AINE, bifosfonatos, vitamina D, calcio, \nprostaglandina I-2, corticosteroides, \u00e1cido hialur\u00f3nico), fisioterapia (l\u00e1ser, campos electromagn\u00e9ticos pulsados) y oxigenoterapia \nhiperb\u00e1rica. El tratamiento quir\u00fargico se merece para los estadios avanzados o si ha fracasado el tratamiento conservador. En el \nestadio precolapso, se esperan procedimientos de preservaci\u00f3n articular; por el contrario, en los estadios de colapso subcondral, \nse requiere una artroplastia articular. Presentamos por primera vez en la literatura el efecto beneficioso del ozono intraarticular en el \nmanejo de dos casos de ON avanzada de rodilla.\nPalabras clave: ozono, osteonecrosis de rodilla, tratamiento.\nIntroduction\nOsteonecrosis (ON) of the knee is a progressive disease \nthat leads to subchondral collapse and finally disabling \nknee osteoarthritis (OA)1. It was for the first time described \nin 1968 by Ahlb\u00e4ck et al2. The knee is the second most \naffected site after the hip3.Knee ON has been recently classified in three entities: \n1) spontaneous ON, the most common type with an \nincidence of 3.4% in people over 50 years and 9.4% in \nthose over 65; 2) secondary ON affects younger patients, \nin multiple and bilateral joints, and it is related to alcohol CASE REPORT\nPossible benefit of intra- articular ozone in advanced\nosteonecrosis of the knee: two case reports\nPosible beneficio del ozono intraarticular \nen la osteonecrosis avanzada de la rodilla: informe de dos casos  \nMarcos Edgar Fern\u00e1ndez-Cuadros1      , Olga Susana P\u00e9rez-Moro1,\nJavier Rodr\u00edguez de C\u00eda2, Mar\u00eda Jes\u00fas Albaladejo-Flor\u00edn1\n1. Servicio de Rehabilitaci\u00f3n y Medicina F\u00edsica, Hospital Universitario Santa Cristina, Madrid, Spain.\n2. Servicio de Laboratorio Cl\u00ednico, Hospital Universitario Santa Cristina, Madrid, SpainIDeISSN 2255-0569171\n2023/38 (4): 170-174Possible benefit of intra- articular ozone in advanced osteonecrosis of the knee: two case reports\nabuse, tobacco, corticosteroids, sickle cell disease and \nmyeloproliferative disorders; 3) post arthroscopy ON, a \nrare condition affecting 4% of all arthroscopies mainly \ndue to meniscopathies3.\nThe etiology of ON of the knee is unknown, although 2 \ntheories are postulated. The vascular insufficiency theory \nis based on the difference in blood supply between \nmedial and lateral condyles. The traumatic theory \nstates that ON is in reality the result of subchondral \ninsufficiency fractures4.\nKoshino in 1979 classified ON in four stages: Stage \nI is normal. Stage II shows radiolucent oval area in \nsubchondral region or flattening of medial femoral \ncondyle (MFC). Stage III depicts an sclerotic halo over \nradiolucent area and \u201ccrescent sign\u201d is observed. \nStage IV shows collapse of subchondral bone and \nosteophytes5.\nPrognostic factors for knee ON are based on Koshino\u00b4s \nclassification and on size of lesion. Lesions inferior to 3.5 \ncm2 tend to regress without surgical intervention. On the \ncontrary, lesions greater than 5 cm2 will lead to condyle \ncollapse6. Lotke states that lesions involving more than \n50% of condylar surface will require arthroplasty7.\nDi Caprio has stated an algorithm depending on the \nsize of lesion and where collapse is present or not \ninto three categories: a) Non-operative treatment \n(protected weight bearing, NSAIDs, bisphosphonates, \nhyperbaric oxygen therapy, pulsed electromagnetic \nfields); b) joint preserving techniques at pre-collapse \nstage (arthroscopic debridement, retrograde or  \nanterograde drilling, core decompression, bone \ngrafting, high tibial osteotomy); c) Replacement at \ncollapse stage (osteochondral autografts or allografts, \nunicompartimental knee arthroplasty [UKA] or total knee \narthroplasty [TKA]). This algorithm also applies for post \narthroscopy ON but the decision is made on early or \nlate diagnosis (more than 6 months)3. Lair et al also \nconsiders Laser, Vitamin D and Calcium, injections of \ncorticosteroids or hyaluronic acid and physiotherapy \nas conservative treatment8. Karim also suggests \nprostaglandin I2 as conservative treatment9.\nIn the case of ON of the femoral head, there are two \ncase reports (Iliakis et al and Yildizgorem et al)10,11 and \na case series of 71 patients (An et al) treated by intra \narticular ozone therapy12. However, to the best of author\u2019s \nknowledge, there is no report on the use of intra articular \nozone in the management of knee ON.\nRecently, our study group led by Fern\u00e1ndez-Cuadros \net al has observed symptomatic and disease modifying \neffect of ozone in osteoarthritis (OA) of the knee in a case \nreport13 and in a case series of 115 patients14, evaluating \nclinical, biochemical, and radiological variables. Moreover, in another series of 65 knee OA patients, an \nimprovement of anabolic IGF-1 and a decrease of anti-\ninflammatory cytokine IL-6 were observed after ozone \ntreatment confirming anabolic and anti-inflammatory \nproperties of ozone in knee OA13.\nThe objective of the present study is to postulate \nthe possible benefit of intra articular ozone in the \nmanagement of advanced ON of the knee (Koshino\u00b4s \nStage III-IV) in two females cases and to report for the \nfirst time in literature.\nCase report\nWe present two female cases with ON of the knee Stage \nIII on Koshino\u00b4s classification treated successfully by intra \narticular ozone, evaluated by clinical, biochemical and \nradiological variables.\nCase 1: Case 1 is an 83 years old female with ON \nof the medial femoral condyle (MFC) of the right knee, \nStage III. The patient was previously operated in the \nleft knee 10 months ago (TKA). Symptoms begun as \nacute onset of pain on the medial aspect of the knee. \nThe patient is independent for activities of daily life \nand is capable of walking only with the help of a cane. \nShe uses paracetamol on demand as a pain killer. \nPatient was referred to Rehabilitation Department for \nconservative treatment because she refused to get a \nTKA of the right knee.\nOn anamnesis, the patient referred pain (7/10), rigidity \n(5/8) and function impairment (55/68) as stated by \nWOMAC scale (Western Ontario and Mc master \nIndex for OA). We explained the properties of ozone \nhighlighting its symptomatic and disease modifying \neffects, and patient accepted and signed informed \nconsent. We performed clinical, biochemical and \nradiological evaluation before and after ozone treatment \n(evaluations at every cycle of ozone). Ozone treatment \nconsisted on 4 sessions of intra articular ozone, 20 mL \nof 5% ozone at a 20 \u03bcg/mL concentration on the lateral \naspect of suprapatellar knee.\nPatient was infiltrated in 6 cycles (4 sessions each \ncycle), on November 2019, February 2020, October \n2020, may 2021, November 2021 and May 2022. We \nregistered clinical and biochemical improvement on the \nfirst 4th cycles and radiographies from the beginning to \nthe end of treatment (Table I and figure 1). There is a \nclear benefit of ozone treatment in terms of clinical and \nbiochemical variables observed after each cycle; and a \nradiological improvement from the 1st to 6th cycle after \nozone intra articular infiltrations (Table I and Figure 1). \nPain has been reduced in each cycle and function has \nalso improved in the same way.172\n2023/38 (4): 170-174Marcos Edgar Fern\u00e1ndez-Cuadros et al. \nCase 2: Case 2 is a 70 years old female with ON of the \nMFC of the left knee, Stage III (Koshino\u00b4s classification). \nPatient reported acute onset of pain on medial aspect of \nthe knee and secondary pain on left trochanter because \nof antalgic walking. Patient was referred to Rehabilitation \nDepartment for conservative treatment. At that time, she \nwas candidate for UKA. \nAt Rehabilitation Department, patient was prescribed \npulsed electromagnetic fields (PEMFs) on the left knee and transcutaneous electrical nerve stimulation (TENS) \non left trochanter. After 10 sessions (5 sessions/week) \nand no improvement on pain and gait, she was offered \nintra articular ozone therapy because of its symptomatic \nand disease modifying effect on knee OA.\nAfter acceptance and signed informed consent, patient \nreceived 2 cycles (4 sessions each) of 20 mL of 5% \nozone at a 20 \u03bcg/mL concentration.  Clinical symptoms \n(pain, function and rigidity evaluated by WOMAC scale), Tabla I: Clinical, biochemical and radiological improvement before and after ozone therapy from cycle to cycle in both case reports.\nVAS, visual analogue scale. WOMAC, Western Ontario and Mc Master Index for Osteoarthritis. ESR, erythrocyte sedimentation rate. IL-6, Interleukin 6. IGF-1, Insulin \ngrowing factor 1. Variable Case 1 Case 2\n Pre-Ozone Post-ozone Pre-Ozone Post-ozone\nClinical\nVAS 1\u00ba (1-10) 7 5 8 4\nVAS 2\u00ba (1-10) 7 5 3 0\nVAS 3\u00ba (1-10) 7 3  \nVAS 4\u00ba (1-10) 5 3  \nWOMAC Rigidity 1\u00ba (0-8) 5 4 5 3\nWOMAC Rigidity 2\u00ba (0-8) 5 4 2 0\nWOMAC Rigidity 3\u00ba (0-8) 5 3  \nWOMAC Rigidity 4\u00ba (0-8) 4 3  \nWOMAC Function 1\u00ba (0-68) 55 50 60 40\nWOMAC Function 2\u00ba (0-68) 55 50 35 20\nWOMAC Function 3\u00ba (0-68) 55 40  \nWOMAC Function 4\u00ba (0-68) 40 30  \nBiochemical\nCRP 1\u00ba (mg/mL) 0.58 0.23 0.5 0.4\nCRP 2\u00ba (mg/mL) 0.2 0.1 1.82 0.52\nCRP 3\u00ba (mg/mL) 0.7 0.3  \nCRP 4\u00ba (mg/mL) 0.15 0.16  \nESR 1\u00ba (mL/hour) 17 17 27 13\nESR 2\u00ba (mL/hour) 14 13 28 20\nESR 3\u00ba (mL/hour) 24 24  \nESR 4\u00ba (mL/hour) 15 6  \nUric Acid 1\u00ba (mg/dL) 6.2 4.7 6.6 5.4\nUric Acid 2\u00ba (mg/dL) 5 4.7 5.4 5.3\nUric Acid 3\u00ba (mg/dL) 6.1 5.5  \nUric Acid 4\u00ba (mg/dL) 5.2 5.0  \nIL-6  1\u00ba (pg/mL) 8.41 6.01 1.15 0.83\nIL-6  2\u00ba (pg/mL) 2.09 2.07  \nIL-6  3\u00ba (pg/mL) 2.3 2.0  \nIGF-1 1\u00ba (ng/mL) 114.7 136.4 63.47 102.0\nIGF-1 2\u00ba (ng/mL) 109.9 138.6  \nRadiological \nSurface involvement 1\u00ba (%)  55.5  50\nSurface involvement 2\u00ba (%)  44.4  41.6\nSurface involvement 3\u00ba (%)  44.4  33.3\nSurface involvement 4\u00ba (%)  33.3  \nFigure 1: Case 1 after 6 cycles of intra articular ozone infiltrations. Radiographies were performed on October 2019; December 2020; November 2021 and May 2022. \nOn each radiography, surface involvement of osteonecrosis of the medial femoral condyle is expressed in percentage.173\n2023/38 (4): 170-174Possible benefit of intra- articular ozone in advanced osteonecrosis of the knee: two case reports\nbiochemical (PCRP , ESR, Uric Acid, IL-6 and IGF-1) and \nradiological variables were evaluated before and after each \ncycle (Table I and Figure 2). Patient was infiltrated on \nDiscussion\nTo the best of author\u2019s knowledge, these are the first \ntwo cases of severe ON of the MFC of the knee treated \nsuccessfully by intra articular ozone and evaluated by \nclinical, biochemical and radiological variables.\nAhlb\u00e4ck in 1968 was the first to describe spontaneous \nON of the knee. He described the entity as acute onset \nof pain typically presented in the MFC, affecting more \ncommonly females and older than 60 years2. This is in \naccordance with our two cases, females of 70 and 83 \nyears with acute onset of pain on the medial aspect of the \nknee. The presentation is usually in the medial condyle \nmore than lateral one. \nIn the case of secondary ON of the knee, the presentation \nis in people younger than 45 years, could be multilateral \nand is more frequent in hips than in knees1. Risk factors \ninclude alcohol abuse, coagulopathies, Caisson\u2019s \ndisease, chemotherapy, corticosteroids, Cushing\u2019s \nSyndrome, diabetes, familial thrombophilia, Gaucher\u2019s \ndisease, gout, hyperthyroidism, irritable bowel disease, \nliver disease, organ transplantation, pancreatitis, \npregnancy, radiation, renal disease, sickle cell disease \nand other hemoglobinopathies, smoking, systemic lupus \nerythematous and tumors3.\nAnother form is post arthroscopy ON of the knee. This is \nthe rarest form of ON of the knee with a prevalence of 4% \nof all arthroscopies. Meniscopathy is present in 87% of \ncases. Onset is usually after 6 weeks of the procedure3. \nNone of our cases were treated by arthroscopy \nprocedures before onset of pain. \nThe etiology of ON is thought to be vascular and is \ncharacterized by loss of blood bone circulation1. Since \nozone is believed to improve rheology of erythrocytes \nand to favor delivery of oxygen to tissues (by formation \nof 2,3 DPG which displaces the curve of dissociation \nof hemoglobin to the right)15. This fact would explain \nthe clinical and radiological improvement observed in our cases. Another theory for the explanation of ON \npresentation is that mechanical factors would lead to \nsubchondral insufficiency fractures3. Since we have \npreviously postulated and lately demonstrated that \nOzone could stimulate stem cells, chondrocytes and \ngrowth factors (TGF-\u03b2 and IGF-1) in knee OA13-14, and \nwe have observed improvement in minimal joint space \nin knee OA patients14, we believe that these properties \nhave been responsible for the radiological improvement \nin knee ON. In fact, case 1 reduced surface ON lesion \nfrom 55.5% to 33.3% and case 2 ameliorated ON lesion \nfrom 50% to 33.3%.\nPrognosis of ON of the knee is based on size of the \nlesion (3.5 cm2 vs 5 cm2), surface involvement of lesion \n(50%) and Kashino\u00b4s classification (Stage I-II vs III-IV). \nMost algorithms state conservative treatment in lesions \ninferior to 3.5 cm2, surface involvement lower than 50% \nor Kashino\u2019s Stage I-II. On the contrary, surgical treatment \nis proposed if lesion is greater than 5 cm2, superior than \n50% surface involvement or Stage III-IV. It depends of pre-\ncollapse to perform arthroscopic procedures or high tibial \nosteotomy; or collapse Stage to perform osteochondral \nautografts or UKA or TKA3.\nIntra articular infiltrations of hyaluronic acid, corticosteroids8, \nstem cells or platelet-rich plasma11 are considered as \nconservative treatment for the management of early \nStages (I-II) of knee ON. The importance of the study is \nthat for the first time in literature, we report the benefit \nof intra articular ozone in the management of advanced \nknee ON (Stages III-IV) where only surgical procedures \nare considered and it is supposed that intra articular \ninfiltrations have no place on such advanced stages.\nIn a very recent article, Spassim et al, in a rat model of knee \nOA, have demonstrated that 60 daily sessions of intra \narticular ozone (at 5 and 10 \u03bcg/mL concentration) could \ndelay the degeneration of the articular cartilage evidenced \nclinically, radiologically and histologically16. These findings \nwould explain the radiological improvement observed in \nour two case reports.October 2021 (first cycle) and on April 2022 (second cycle). \nSymptoms and gait improved to the point that a cane as no \nlonger used for walking, and pain disappeared at all.\nFigure 2: Case 2 after 2 cycles of intra articular ozone infiltrations. Radiographies were performed on April 2019; September 2020; May 2021 and April 2022. On each \nradiography, surface involvement of osteonecrosis of the medial femoral condyle is expressed in percentage.174\n2023/38 (4): 170-174Possible benefit of intra- articular ozone in advanced osteonecrosis of the knee: two case reports Marcos Edgar Fern\u00e1ndez-Cuadros et al. \nThere are only three publications on the benefit of intra \narticular ozone for the management of hip ON. Iliakis et al \nhave stated than in a 43 years old female with ON of the left \nhip, 7 sessions of intra articular ozone (5 mL at a 40 \u03bc\u03bcg/mL \nconcentration) improved clinical and radiological status10. \nYildizgoren reported that in a 45 years old male with bilateral \nhip ON secondary to corticosteroids use (for treatment of \nHodgkin\u2019s lymphoma), after 5 sessions (1/week) of intra \narticular ozone (15 mL at increasing doses of 15, 20 and \n25 \u03bcg/mL concentration) the patient ameliorated pain (VAS \nfrom 7 to 2) and improved walking distance (from 100 to \n1000 meters)11. An et al, in a series of 71 patients with hip \nON, observed that 3 cycles of 10 sessions of intra articular \nozone (5 sessions/week) every three months (30 mL at 30 \n\u03bcg/mL concentration) improved pain (VAS scale), Harris Hip \nScore and bone marrow edema. Ozone also delayed total \nhip arthroplasty at a 30-months follow-up period2.\nConclusion\nBased on two case reports, intra articular ozone could \nimprove clinical, biochemical and radiological variables in \npatients with advanced ON of the knee. It is necessary \nto perform a study with a greater sample to confirm the \npromising benefit observed in this report.Acknowledgments\nSaturnino D\u00edaz Trujillo, librarian at Hospital Universitario \nSanta Cristina, Madrid, is acknowledged for the \nbibliographic search to carry out this study.\nCompliance with ethical standards\nDr. Jose Gabriel Perez Karduss is acknowleged for the \nstatistical analysis.\nFunding\nFor the elaboration of the manuscript authors received no \nfinancial funding.\nConflicts of interest\nThe authors declare no conflict of interest.\nEthics approval\nThe case report has been approved by the Ethical \nCommittee of the Hospital. \nConsent to participate\nFor the application of this treatment, patients signed an \ninformed consent.\nConsent for publication\nFor case report publication, patients signed an informed \nconsent.\nReferences\n1. Mont MA, Marker DR, Zywiel MG, Carrino JA. Osteonecrosis of \nthe knee and related conditions. J Am Acad Orthop Surg. 2011 \nAug;19(8):482-94. doi: 10.5435/00124635-201108000-00004. \n2. Ahlb\u00e4ck S, Bauer GC, Bohne WH. Spontaneous osteonecrosis \nof the knee. Arthritis & Rheumatism: Official Journal of the American \nCollege of Rheumatology 1968; 11(6):705-33.\n3. Di Caprio F, Meringolo R, Navarra MA, Mosca M, Ponziani L. \nPostarthroscopy Osteonecrosis of the Knee: Current Concepts. Joints. \n2017 Nov 6;5(4):229-236. doi: 10.1055/s-0037-1608666. \n4. Alexa, O., Cionca, D., Albetar, S., & Veliceasa, B. (2015). Spontaneous \nOsteonecrosis of the Medial Femoral Condyle: Case Report. chirurgie, \n10(4), 291-3.\n5. Koshino T, Okamoto R, Takamura K, Tsuchiya K. Arthroscopy in \nspontaneous osteonecrosis of the knee. The Orthopedic Clinics of \nNorth America 1979; 10(3):609-18.\n6. Sibilska A, G\u00f3ralczyk A, Hermanowicz K, Malinowski K. Spontaneous \nosteonecrosis of the knee: what do we know so far? A literature review. \nInt Orthop. 2020 Jun;44(6):1063-1069. doi: 10.1007/s00264-020-\n04536-7.\n7. Lotke PA, Abend JA, Ecker ML. The treatment of osteonecrosis of the \nmedial femoral condyle. Clinical Orthopaedics and Related Research \n1982;171:109-16.\n8. Lair J, Fink C, Csapo R. Spontaneous Osteonecrosis of the Knee: a \nSystematic Review of Conservative Treatment Approaches. Research \nSquare, 2021. DOI: 10.21203/rs.3.rs-239294/v1.\n9. Karim AR, Cherian JJ, Jauregui JJ, Pierce T, Mont MA. Osteonecrosis \nof the knee: review. Ann Transl Med. 2015 Jan;3(1):6. doi: 10.3978/j.\nissn.2305-5839.2014.11.13.10. Iliakis E, Bonetti M, Iliakis A. Osteonecrosis of the femoral head: \nCould oxygen-ozone therapy became a treatment option?. Journal of \nOzone Therapy 2015; 1(1):3-7.\n11. Yildizg\u00f6ren MT, O\u011eUZ H. Ultrasound-Guided Intra-Articular \nOzone Injection as a Therapeutic Option for Hip Osteonecrosis. \nJournal of Physical Medicine & Rehabilitation Sciences/Fiziksel Tup ve \nRehabilitasyon Bilimleri Dergisi 2020; 23(3).\n12. An JX, Wu GP , Niu K, Wei YP , Liu H, Gao XY, Wu JP , Wang Y, Renz \nH, Williams JP . Treatment of Femoral Head Osteonecrosis with Ozone \nTherapy: Pilot Trial of a New Therapeutic Approach. Pain Physician. \n2022 Jan;25(1):E43-E54. \n13. Fern\u00e1ndez-Cuadros ME, P\u00e9rez-Moro OS, Albaladejo-Flor\u00edn MJ, \n\u00c1lava-Rabasa S. Symptomatic (Pain and Inflammation) and Disease-\nModifying Effect (Minimal Joint Space) of Intra-articular Ozone (O2-\nO3) in Osteoarthritis of the Knee: a Clinical Case. SN Comprehensive \nClinical Medicine 2019;1(10):817-21.\n14. Fern\u00e1ndez-Cuadros ME, P\u00e9rez-Moro O, Albaladejo-Flor\u00edn MJ, \u00c1lava-\nRabasa S. El ozono intra-articular modula la inflamaci\u00f3n, mejora el dolor, \nla rigidez, la funci\u00f3n y tiene un efecto anab\u00f3lico sobre la artrosis de \nrodilla: estudio cuasi-experimental prospectivo tipo antes-despu\u00e9s, 115 \npacientes. Revista de la Sociedad Espa\u00f1ola del Dolor 2020; 27(2):78-88.\n15. Fern\u00e1ndez-Cuadros ME, Albaladejo-Flor\u00edn MJ, Pe\u00f1a-Lora D, \n\u00c1lava-Rabasa S, P\u00e9rez-Moro OS. Ozone (O3) and SARS-CoV-2: \nphysiological bases and their therapeutic possibilities according to \nCOVID-19 evolutionary stage. SN Comprehensive Clinical Medicine \n2020; 2(8):1094-102.\n16. Spassim MR, Dos Santos RT, Rossato-Grando LG, Cardoso L, \nda Silva JS, de Souza SO, et al. Intra-articular ozone slows down the \nprocess of degeneration of articular cartilage in the knees of rats with \nosteoarthritis. The Knee 2022; 35: 114-23.175\n2023/38 (4): 175-177Received: 29 - II - 2023\nAccepted: 27 - IV - 2023\ndoi: 10.3306/AJHS.2023.38.04.175Corresponding author\nAhmed Muhammad Bashir  \nE-mail: ambashir@hotmail.com\nAbstract \nStevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a well-known severe cutaneous adverse reaction (SCAR) that \nbelongs to type IV hypersensitivity and is mediated by an immunological effect.\nHere, we report 4 cases of SJS presented to a tertiary hospital in Mogadishu, Somalia. Stevens-Johnson syndrome has a \nsignificant relationship to various drugs. Stevens-Johnson syndrome is a potential therapeutic complication, especially in Somalia, \nwhere antibiotics are used irrationally. Steroids are controversially used as treatment. SJS is more common in Somalia and other \nparts of Africa because antibiotics are available without a prescription. It\u2019s difficult to detect and manage; most patients die before \na firm diagnosis is obtained.\nKeywords: Stevens Johnson syndrome, Type IV Hypersensitivity, toxic epidermal necrolysis. \nResumen\nUna conocida reacci\u00f3n adversa cut\u00e1nea grave (RAC) de tipo IV, mediada por un impacto inmunitario, es el s\u00edndrome de Stevens-\nJohnson/necrolisis epid\u00e9rmica t\u00f3xica (SJS/TEN).\nEn este art\u00edculo se presentan 4 casos de SJS en un hospital de tercer nivel de Mogadiscio (Somalia). El s\u00edndrome de Stevens-\nJohnson tiene una importante relaci\u00f3n con diversos f\u00e1rmacos. El s\u00edndrome de Stevens-Johnson es una complicaci\u00f3n terap\u00e9utica \npotencial, especialmente en Somalia, donde los antibi\u00f3ticos se utilizan de forma irracional. Los esteroides se utilizan de forma \ncontrovertida como tratamiento. El s\u00edndrome de Stevens-Johnson es m\u00e1s com\u00fan en Somalia y otras partes de \u00c1frica porque los \nantibi\u00f3ticos est\u00e1n disponibles sin receta. Es dif\u00edcil de detectar y manejar; la mayor\u00eda de los pacientes mueren antes de obtener un \ndiagn\u00f3stico firme.\nPalabras clave: S\u00edndrome Stevens Johnson, hipersensibilidad de tipo IV, necrolisis epid\u00e9rmica t\u00f3xica.\nIntroduction\nStevens-Johnson syndrome/toxic epidermal necrolysis \n(SJS/TEN) is a well-known severe cutaneous adverse \nreaction (SCAR) that belongs to type IV hypersensitivity \nand is mediated by an immunological effect1. It has \nbeen determined that this hypersensitivity reaction is \na dysregulation of cellular immunity2 brought on by the \nproduction of cytotoxic signals such as granulysin3, \nperforin/granzyme B, and Fas/Fas ligand4, which were \ntriggered by cytotoxic T lymphocytes and natural killer \ncells. SJS/TEN is a spectrum disorder characterized by \nwidespread epidermal detachment and mucocutaneous \ninvolvement5. Stevens-Johnson syndrome (SJS), SJS/\nTEN overlap (SJS-TEN), and toxic epidermal necrolysis (TEN) are represented by different total body surface areas \n(TBSA) of detached or detachable skin lesions as 10%, \n10%-30%, and >30%6. SJS, SJS-TEN, and TEN mortality \nrates were 5-10%, 30%, and 50%, respectively2-5.\nIn this case series, we report 4 cases of SJS presented \nto a tertiary hospital in Mogadishu, Somalia. \nCase Report\nWe present four cases of Steven John\u2019s Syndrome \nadmitted in our ward.CASE REPORT\nDrug-Induced Stevens Johnson\u2019s Syndrome; \n4 case Series in Tertiary Hospital in Somalia\nS\u00edndrome de Stevens Johnson inducido por f\u00e1rmacos;\nserie de 4 casos en un hospital terciario de Somalia  \nOznur Sari1      , Ahmed Muhammad Bashir2\n1. Department of Internal Medicine, Department of Health Services, General Directorate of Public Hospitals, \nMinistry of Health, Ankara, Turkey  \n2. Department of Internal Medicine, Mogadishu Somalia Turkiye Training and Research Hospital, Mogadishu, SomaliaID IDeISSN 2255-0569176\n2023/38 (4): 175-177Case 1 \n71 years of female patient with no history of any chronic \ndisease presented in our emergency department with \ncomplain of macular rash extending from the trunk toward \nthe extremities, worsening lip swelling, mouth sores,  she \ngives a history of UTI for which she was treated with \nCiprofloxacin for her general practitioner. On examination, \nshe was ill looking old lady with rashes over all her body, \nthe mouth had stomatitis, with ulcers involving lips, tongue, \nand buccal mucosa and Nikolisky sign was positive.\nLaboratory investigation showed wbc 6 x1000mm3 Hg \n10.7g/dl Plt 101x1000mm3, Glucose 147mg/dl Urea \n75mg/dl Creatinine 1.59mg/dl Sodium 131mEq/l K \n4.76mEq/L CRP 92.5mg/l. She was admitted in the \nward, treated with IV fluids, methylprednisolone 90mg for \n5 days, daily dressing with normal saline and Bepanthen \ncream, Oral hygiene care. And patient is discharged after \n10 days with good recovery. \nCase 2 \n18 years old female patient presented to our emergency \ndepartment with complain of bullous formation all over \nher body for 4 days, initially it started with itching and \nsuddenly the bullous started becomes bigger and \nrupturing easily. She was treated Co-trimoxazole for \ntonsillitis few days ago. On examination, tense bullous \nthat contain clear fluids was noted in her torso, and \nruptured bullous all over her body. Oral and eye lesions \nwere less pronounced. Nikolisky sign was positive.\nLaboratory research showed wbc 6.15 x1000mm3 Hg \n13.1g/dl Plt 291x1000mm3, Glucose 112mg/dl Urea 20mg/dl Creatinine 0.58mg/dl Sodium 140mEq/l K \n4.25mEq/L CRP 96mg/l.\nCase 3 \n30 years female patient presented to our emergency with \nrash around her forehead, nose, chest and also lower \nextremity, and oral ulcers for 5 days. Patient reported \nshe was well before 10 days ago, then she developed \ngeneralized body ache, fever, and headache. Then she \nvisited her local doctor and he prescribed Acyclovir \ntablet, Ciprofloxacin, Artemether injection and Diclofenac \ntablet. She developed itching and rash after starting these \nmedications. On examination she had hyperpigmented \nskin, minute blisters around both the eyes and lips, all \nover the body.\nLaboratory research showed wbc 14.78 x1000mm3 \nHg 9.8g/dl Plt 473x1000mm3, Glucose 78mg/dl Urea \n27mg/dl Creatinine 1.91mg/dl Sodium 144mEq/l K \n3.4mEq/L  CRP 131.1mg/l.\nCase 4\n40 years old female patient presented to our emergency \nwith widespread erythema, necrosis, and bullous \ndetachment of the epidermis and mucous membranes \nfor 8 days, which she developed her body after 3 days \nof Ceftriaxone use, which her GP prescribed for urinary \ntract infection. On examination, she was disoriented, \nlooked dehydrated with sunken eyes, and also had \nbullous detachment of almost all of her body, Nikolisky \nsign was positive. \nLaboratory investigation showed wbc 1.54 \nx1000mm3 Hg 13.3g/dl Plt 546x1000mm3, Glucose \n68mg/dl Urea 73mg/dl Creatinine 1.17mg/dl Sodium \n158mEq/l K 4.05mEq/L  CRP 295.6mg/l. Ph 6.99 \npCO2 44.8 pO2 69 cNa 160 cK4.99 cHCO 7.6 \nWe admitted two of the patients in ICU and the other two \nin Medical Ward, we used plenty of IV fluids, Steroids \n90mg for 5 days, parenteral nutrition, oral hygiene care, \ndressing with normal saline, and covered with wet sterile \ngauze, we also used Dexpanthenol cream for open \nwounds in the evening.Figure 1: 71 years old with rashes all over her body, and some ruptured bullous. \nConsent was taken from the patient to use this photo.\nFigure 2: 18 years old female, bullous formation and some ruptured bullous on \nface and lips.\nFigure 3: 30 years female presented with rash and oral ulcers.\nOznur Sari et al. 177\n2023/38 (4): 175-177Drug-Induced Stevens Johnson\u2019s Syndrome \u2013 4 case Series in Tertiary Hospital in Somalia\neventually becomes necrotic \nand can separate from the \ndermis, a positive Nikolsky \nsign8. Drugs and infections, \nmost notably trimethoprim-\nsulfamethoxazole and \nMycoplasma, are frequently \ncited as causes of SJS in \nboth adults and children8. \nIn Somalia, a country where \nthere is indiscriminate prescription of antibiotics is \navailable, there is limited reports in the literature for SJS, \nthis, as far as we know, is the only documented case \nseries reported from Somalia. \nConclusion\nStevens-Johnson syndrome is a potentially fatal \nmultiorgan disease with a strong etiologic link to some \nmedications. Physicians must therefore consider \nStevens-Johnson syndrome as a potential complication \nof treatment, especially in a country like Somalia where \nthere is discriminate antibiotic use. Steroids were mostly \nused as treatment although its controversial yet. SJS \nis much higher in Somalia and other part of Africa due \nto availability of Antibiotics without prescription and it\u2019s \ndifficult to diagnose and manage, usually patients die \nbefore a definite diagnosis is made.\nConsent\nWritten and informed consent was taken from the patient \nfor possible publication of the cases.\nConflicts of interest\nThe authors declare no conflict of interest.\nFigure 4: patient presented with severe ruptured bullous all over her body.\nOne of our two patients admitted in ICU who presented late \nto the hospital died due to sepsis and multiorgan failure.\nWe didn\u2019t use antibiotics during the patients stay in the \nhospital and took extra care of the sterilization. After the \nlesions has improved, we discharged patients with oral \nsteroids and trapped off during their outpatient clinic visits.\nDiscussion\nIn this case series, we enrolled 4 cases diagnosed with \nSJS-TEN overlap, presented to a tertiary hospital in \nMogadishu, Somalia. All patients had drug relationship, \nand major contribution was antibiotics and antivirals. \nAccording to Li and Ma, antibiotics and anticonvulsants \nare the most commonly used single drugs in SJS and \ntraditional Chinese medicines in TEN7. Allopurinol, \naromatic anticonvulsants, sulfonamide antibiotics, \noxicam NSAIDs, and nevirapine have been linked to an \nincreased risk of induced severe cutaneous adverse \nreaction (SCARs)5.\nSJS begins with a viral-like prodrome lasting one to two \nweeks, followed by an acute onset of a widespread \nerythematous, macular rash with blisters or flat typical target \nlesions on the face, trunk, extremities, oral conjunctiva, \nand anogenital mucous membranes. The epidermis \nReferences\n1. Roujeau JC. Immune mechanisms in drug allergy. Allergol Int \n[Internet]. 2006;55(1):27-33. Available from: http://dx.doi.org/10.2332/\nallergolint.55.27\n2. Su SC, Mockenhaupt M, Wolkenstein P , Dunant A, Le Gouvello S, \nChen CB, et al. Interleukin-15 Is Associated with Severity and Mortality \nin Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest \nDermatol [Internet]. 2017;137(5):1065-73. Available from: http://dx.doi.\norg/10.1016/j.jid.2016.11.034\n3. Chung WH, Hung SI, Yang JY, Su SC, Huang SP , Wei CY, et al. \nGranulysin is a key mediator for disseminated keratinocyte death in \nStevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. \n2008;14(12):1343-50. \n4. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme \nB, and Fas-L to be related to disease severity. J Allergy Clin Immunol. \n2002;109(1):155-61. \n5. Su SC, Hung SI, Fan WL, Dao RL, Chung WH. Severe cutaneous \nadverse reactions: The pharmacogenomics from research to clinical \nimplementation. Vol. 17, International Journal of Molecular Sciences. \n2016. \n6. Jean Claude Roujeau RSS. Severe Adverse Cutaneous Reactions to \nDrugs. N Engl J Med. 1994;332(14):959-60. \n7. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug \nreactions in a city district of China. Clin Exp Dermatol. 2006;31(5):642-7.\n \n8. Peters J. Toxic epidermal necrolysis. Nurs Times. 2000;96(36):43-4. www.ramib.org \nJunta Directiva de la Reial Acad\u00e8mia de Medicina de les Illes Balears\n President  Excm. Sr. Joan Besalduch Vidal \n Vicepresident  \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez\n Secretari General  Javier Cort\u00e9s Bordoy\n Vicesecretari  Sebastian Cresp\u00ed Rotger \n Tresorer  Joan Benejam Gual \n Bibliotec\u00e0ria  Antonia Barcel\u00f3 Bennasar\nAcad\u00e8mics d\u2019honor\n 2007 - Excm. Sr. Ciril Rozman, Premi Jaime I\n2021 - Excm. Sr. Oriol Bonn\u00edn Gubianas, Doctor Honoris Causa per la UIB\nAcad\u00e8mics numeraris\nM. I. Sra. Juana M. Rom\u00e1n Pi\u00f1ana\nM. I. Sr. Josep Tom\u00e0s Monserrat\nM. I. Sr. Bartomeu Anguera Sans\u00f3\nM. I. Sr. Alfonso Ballesteros Fern\u00e1ndez\nM. I. Sr. Ferran Tolosa i Caban\u00ed\nM. I. Sr . Maci\u00e0 Tom\u00e0s Salv\u00e0\nM. I. Sra. Joana M. Sureda Trujillo\nM. I. Sr. Joan Buades Rein\u00e9s\nM. I. Sr. Jos\u00e9 L. Olea Vallejo\nM. I. Sr. Pere Riutord Sbert\nExcm. Sr . Joan Besalduch Vidal \nM. I. Sr. F\u00e8lix Grases Freixedas\nM. I. Sr. Antoni Ca\u00f1ellas Trobat\nM. I. Sr. Josep Francesc Forteza Albert\u00ed\nM. I. Sr. Jordi Ib\u00e1\u00f1ez Juv\u00e9\nM. I. Sr. Joan March Noguera\nM. I. Sr. \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez\nM. I. Sra. Pilar Roca Salom\nM. I. Sr. Javier Cort\u00e9s Bordoy\nM. I. Sr. Llu\u00eds Masmiquel Comas\nM. I. Sr. Sebasti\u00e0 Cresp\u00ed Rotger\nM. I. Sra. Ant\u00f2nia Barcel\u00f3 Bennassar\nM. I. Sr. Javier Garau Alemany\nM. I. Sr. Jordi Reina Prieto\nM. I. Sr. Joan M. Benejam Gual\nM. I. Sr. Claudio Rub\u00e9n Mirasso Santos\nM. I. Sr. Josep M\u00aa Vicens G\u00f3mez\nM. I. Sr. Rafael Morales Soriano\nAcad\u00e8mics supernumeraris\nM.I. Sr. \u00c0lvar Agust\u00ed Garc\u00eda-Navarro \nM.I. Sra. Marta Emma Couce Matovelle\nAcad\u00e8mics em\u00e8rits\nM.I. Sr. Arnau Casellas BernatProtectors de la Reial Acad\u00e8mia\nBanca March\nConselleria de Presid\u00e8ncia\nASISA\nConselleria de Salut\nCol\u00b7legi Oficial de Metges de les Illes Balears\nFundaci\u00f3 Patronat Cient\u00edfic del Col\u00b7legi de Metges de les Illes Balears\nBenefactors de la Reial Acad\u00e8mia  \nSalut i For\u00e7a\nPatrocinadors de la Reial Acad\u00e8mia\nCl\u00ednica Rotger\nMetges Rossell\u00f3\nGrup Hospitalari Quir\u00f3nsalud\nCol\u00b7legi Oficial d\u2019Infermeria de les Illes Balears\nAssociaci\u00f3 Espanyola contra el C\u00e0ncer a les Illes Balears\nCol\u00b7legi Oficial de Farmac\u00e8utics de Balears\nEscola Universit\u00e0ria ADEMAwww.ramib.org www.medicinabalear.orgMEDICINA BALEARACADEMIC  JOURNAL  \nOF HEALTH  SCIENCES", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}